[
  {
    "nct_id": "NCT02500043",
    "brief_title": "Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer",
    "status": "COMPLETED",
    "start_date": "2016-02-24",
    "completion_date": "2018-04-30",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Taiho Oncology, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT02500043",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "TAS-102+BSC",
        "value": 5.7,
        "unit": "months",
        "ci_lower": 4.8,
        "ci_upper": 6.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo+BSC",
        "value": 3.6,
        "unit": "months",
        "ci_lower": 3.1,
        "ci_upper": 4.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "TAS-102"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT02538666",
    "brief_title": "An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy",
    "status": "COMPLETED",
    "start_date": "2015-10-13",
    "completion_date": "2018-10-01",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT02538666",
    "cancer_types": [
      "SCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "MAINTENANCE",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Global Placebo",
        "value": 9.56,
        "unit": "Months",
        "ci_lower": 8.18,
        "ci_upper": 11.01,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Global Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg",
        "value": 9.17,
        "unit": "Months",
        "ci_lower": 8.15,
        "ci_upper": 10.25,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG001": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG003": [
        "Nivolumab"
      ],
      "OG004": [
        "Nivolumab"
      ],
      "OG005": [
        "Nivolumab",
        "Ipilimumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Placebo",
      "OG001": "IO",
      "OG002": "Placebo",
      "OG003": "IO",
      "OG004": "IO",
      "OG005": "IO"
    }
  },
  {
    "nct_id": "NCT02516241",
    "brief_title": "Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2015-11-02",
    "completion_date": "2020-01-27",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT02516241",
    "cancer_types": [
      "BLCA"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Tumor PD-L1 status must be known prior to randomization; IHC assay confirmed by a reference laboratory"
      }
    ],
    "cancer_stages": [
      "IV",
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Combination Therapy",
        "value": 15.1,
        "unit": "Months",
        "ci_lower": 13.1,
        "ci_upper": 18.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Standard of Care",
        "value": 12.1,
        "unit": "Months",
        "ci_lower": 10.9,
        "ci_upper": 14.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "MEDI4736 (Durvalumab)",
        "Tremelimumab"
      ],
      "OG001": [
        "Cisplatin",
        "Carboplatin",
        "Gemcitabine"
      ],
      "OG002": [
        "Cisplatin",
        "Carboplatin",
        "Gemcitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "Chemo",
      "OG002": "Chemo"
    }
  },
  {
    "nct_id": "NCT02549937",
    "brief_title": "A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2015-11",
    "completion_date": "2023-04-25",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hutchmed",
    "url": "https://clinicaltrials.gov/study/NCT02549937",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Dose-Expansion Phase: Arm A: BTC",
        "value": 50.1,
        "unit": "percentage of patients",
        "ci_lower": 27.8,
        "ci_upper": 68.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Dose-Expansion Phase: Arm D: STS",
        "value": 26.5,
        "unit": "percentage of patients",
        "ci_lower": 11.4,
        "ci_upper": 44.2,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "surufatinib"
      ],
      "OG001": [
        "surufatinib"
      ],
      "OG002": [
        "surufatinib"
      ],
      "OG003": [
        "surufatinib"
      ],
      "OG004": [
        "surufatinib"
      ],
      "OG005": [
        "surufatinib"
      ],
      "OG006": [
        "surufatinib"
      ],
      "OG007": [
        "surufatinib"
      ],
      "OG008": [
        "surufatinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI",
      "OG002": "TKI",
      "OG003": "TKI",
      "OG004": "TKI",
      "OG005": "TKI",
      "OG006": "TKI",
      "OG007": "TKI",
      "OG008": "TKI"
    }
  },
  {
    "nct_id": "NCT02536742",
    "brief_title": "Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2016-08-30",
    "completion_date": "2020-08-28",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "ETOP IBCSG Partners Foundation",
    "url": "https://clinicaltrials.gov/study/NCT02536742",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "ER positive tumor as assessed locally"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-negative tumor as assessed locally"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Experimental",
        "value": 92.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Experimental",
        "value": 30.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Palbociclib",
        "Fulvestrant"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02549209",
    "brief_title": "Pembro/Carbo/Taxol in Endometrial Cancer",
    "status": "COMPLETED",
    "start_date": "2017-08-22",
    "completion_date": "2019-12-12",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Daniela Matei, MD",
    "url": "https://clinicaltrials.gov/study/NCT02549209",
    "cancer_types": [
      "UCEC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "III",
      "IV",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Investigational Treatment",
        "value": 74.4,
        "unit": "percentage of participants",
        "ci_lower": 58.8,
        "ci_upper": 86.5,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Paclitaxel",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT02513563",
    "brief_title": "AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2015-10-13",
    "completion_date": "2022-11-27",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
    "url": "https://clinicaltrials.gov/study/NCT02513563",
    "cancer_types": [
      "LUSC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Carboplatin/Paclitaxel/AZD1775",
        "value": 4.8,
        "unit": "months",
        "ci_lower": 4.1,
        "ci_upper": 5.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Carboplatin/Paclitaxel/AZD1775",
        "value": 7.3,
        "unit": "months",
        "ci_lower": 6.4,
        "ci_upper": 8.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Carboplatin",
        "Paclitaxel",
        "AZD1775"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02500121",
    "brief_title": "Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer",
    "status": "COMPLETED",
    "start_date": "2015-11-11",
    "completion_date": "2019-07-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Matthew Galsky",
    "url": "https://clinicaltrials.gov/study/NCT02500121",
    "cancer_types": [
      "BLCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "MAINTENANCE",
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Control Arm A",
        "value": 3.0,
        "unit": "months",
        "ci_lower": 2.7,
        "ci_upper": 5.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Experimental Arm B",
        "value": 5.4,
        "unit": "months",
        "ci_lower": 3.1,
        "ci_upper": 7.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Control Arm A",
        "value": 18.7,
        "unit": "months",
        "ci_lower": 11.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Experimental Arm B",
        "value": 22.0,
        "unit": "months",
        "ci_lower": 12.9,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG001": [
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Placebo",
      "OG001": "IO"
    }
  },
  {
    "nct_id": "NCT02504372",
    "brief_title": "Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2015-11-06",
    "completion_date": "2023-01-24",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT02504372",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Available resection tumor sample for PD-L1 assessment by IHC"
      }
    ],
    "cancer_stages": [
      "IB",
      "II",
      "IIIA"
    ],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab",
        "value": 53.8,
        "unit": "Months",
        "ci_lower": 46.2,
        "ci_upper": 67.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 43.0,
        "unit": "Months",
        "ci_lower": 35.0,
        "ci_upper": 51.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab",
        "value": 67.0,
        "unit": "Months",
        "ci_lower": 47.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 47.6,
        "unit": "Months",
        "ci_lower": 36.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT02566993",
    "brief_title": "Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2016-08-30",
    "completion_date": "2020-02-24",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "PharmaMar",
    "url": "https://clinicaltrials.gov/study/NCT02566993",
    "cancer_types": [
      "SCLC"
    ],
    "biomarkers": [
      {
        "target": "KI67",
        "status": "HIGH",
        "details": ">50% tumor cells (Ki-67/MIB-1); required for small-cell carcinoma of unknown primary"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Lurbinectedin/Doxorubicin",
        "value": 8.6,
        "unit": "months",
        "ci_lower": 7.1,
        "ci_upper": 9.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Topotecan or Cyclophosphamide/Doxorubicin/Vincristine",
        "value": 7.6,
        "unit": "months",
        "ci_lower": 6.6,
        "ci_upper": 8.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Lurbinectedin (PM01183)",
        "Doxorubicin (DOX)"
      ],
      "OG001": [
        "Topotecan",
        "Cyclophosphamide (CTX)",
        "Doxorubicin (DOX)",
        "Vincristine (VCR)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT02513472",
    "brief_title": "Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)",
    "status": "COMPLETED",
    "start_date": "2015-08-28",
    "completion_date": "2019-07-31",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eisai Inc.",
    "url": "https://clinicaltrials.gov/study/NCT02513472",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "<1% tumor cells positive (ER negative defined as less than 1% staining)"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "<1% tumor cells positive (PR negative defined as less than 1% staining)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "IHC <2+ or FISH negative"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Stratum 1: Eribulin Mesylate + Pembrolizumab",
        "value": 25.8,
        "unit": "percentage of participant",
        "ci_lower": 15.8,
        "ci_upper": 38.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Stratum 2: Eribulin Mesylate + Pembrolizumab",
        "value": 21.8,
        "unit": "percentage of participant",
        "ci_lower": 14.2,
        "ci_upper": 31.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Overall: Eribulin Mesylate + Pembrolizumab",
        "value": 23.4,
        "unit": "percentage of participant",
        "ci_lower": 17.2,
        "ci_upper": 30.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Stratum 1: Eribulin Mesylate + Pembrolizumab",
        "value": 4.2,
        "unit": "months",
        "ci_lower": 3.5,
        "ci_upper": 5.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Stratum 2: Eribulin Mesylate + Pembrolizumab",
        "value": 4.1,
        "unit": "months",
        "ci_lower": 2.3,
        "ci_upper": 4.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Overall: Eribulin Mesylate + Pembrolizumab",
        "value": 4.1,
        "unit": "months",
        "ci_lower": 3.5,
        "ci_upper": 4.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Stratum 1: Eribulin Mesylate + Pembrolizumab",
        "value": 17.4,
        "unit": "months",
        "ci_lower": 13.2,
        "ci_upper": 21.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Stratum 2: Eribulin Mesylate + Pembrolizumab",
        "value": 15.5,
        "unit": "months",
        "ci_lower": 12.5,
        "ci_upper": 18.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Overall: Eribulin Mesylate + Pembrolizumab",
        "value": 16.1,
        "unit": "months",
        "ci_lower": 13.3,
        "ci_upper": 18.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG000",
        "arm_title": "Stratum 1: Eribulin Mesylate + Pembrolizumab",
        "value": 8.3,
        "unit": "months",
        "ci_lower": 3.2,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG001",
        "arm_title": "Stratum 2: Eribulin Mesylate + Pembrolizumab",
        "value": 8.2,
        "unit": "months",
        "ci_lower": 5.1,
        "ci_upper": 25.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG002",
        "arm_title": "Overall: Eribulin Mesylate + Pembrolizumab",
        "value": 8.2,
        "unit": "months",
        "ci_lower": 6.2,
        "ci_upper": 25.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Eribulin Mesylate",
        "Pembrolizumab"
      ],
      "OG001": [
        "Eribulin Mesylate",
        "Pembrolizumab"
      ],
      "OG002": [
        "Eribulin Mesylate",
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Combo_Chemo_IO",
      "OG002": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT02566304",
    "brief_title": "Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies",
    "status": "COMPLETED",
    "start_date": "2015-11-13",
    "completion_date": "2024-02-13",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sidney Kimmel Cancer Center at Thomas Jefferson University",
    "url": "https://clinicaltrials.gov/study/NCT02566304",
    "cancer_types": [
      "LAML",
      "DLBC",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "HLA",
        "status": "POSITIVE",
        "details": "Related donor mismatched at 2\u20134 antigens at HLA-A, HLA-B, HLA-C, HLA-DR loci in the graft-versus-host (GVHD) direction"
      },
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "HIV positive patients are excluded"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "RIC HSCT, GVHD Prophylaxis",
        "value": 74.0,
        "unit": "percentage of participants",
        "ci_lower": 54.0,
        "ci_upper": 86.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Fludarabine",
        "Cyclophosphamide",
        "T Cell-Depleted Donor Lymphocyte Infusion"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER"
    }
  },
  {
    "nct_id": "NCT02536794",
    "brief_title": "MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2016-01-14",
    "completion_date": "2020-02-06",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Northwestern University",
    "url": "https://clinicaltrials.gov/study/NCT02536794",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 non-overexpressing by IHC (0 or 1). If IHC 2 (equivocal), must be non-amplified by FISH (ratio < 2 and HER2 copy number < 4)."
      },
      {
        "target": "ER",
        "status": "ANY",
        "details": "Estrogen receptor (ER) status described and used to define prior-therapy requirements; ER positivity defined as \u22651%. (ER-negative and ER-positive patients both eligible but have different prior therapy requirements: ER-negative must have progressed through \u22651 prior chemotherapy regimen in the metastatic setting or within 12 months of last adjuvant systemic treatment; ER-positive must have progressed through standard hormone therapy options and have received \u22651 line of chemotherapy in the metastatic setting.)"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (MEDI4736, Tremelimumab)",
        "value": 4.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Treatment (MEDI4736, Tremelimumab)",
        "value": 11.3,
        "unit": "months",
        "ci_lower": 7.16,
        "ci_upper": 36.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment (MEDI4736, Tremelimumab)",
        "value": 4.86,
        "unit": "months",
        "ci_lower": 3.09,
        "ci_upper": 7.89,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "MEDI4736",
        "Tremelimumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO"
    }
  },
  {
    "nct_id": "NCT02499328",
    "brief_title": "Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck",
    "status": "COMPLETED",
    "start_date": "2015-08-06",
    "completion_date": "2020-02-28",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT02499328",
    "cancer_types": [
      "HNSC",
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT",
      "UNRESECTABLE",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Part B1:AZD9150+MEDI4736:PDL1 Pretreated",
        "value": 4.2,
        "unit": "percentage of participants",
        "ci_lower": 0.11,
        "ci_upper": 21.12,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Part B2:AZD5069+MEDI4736:PDL1 Pretreated",
        "value": 10.0,
        "unit": "percentage of participants",
        "ci_lower": 1.23,
        "ci_upper": 31.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Part B3: AZD9150+MED4736:Naiive 2L",
        "value": 22.6,
        "unit": "percentage of participants",
        "ci_lower": 12.28,
        "ci_upper": 36.21,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Part B4:AZD5069+MEDI4736:Naiive Patients",
        "value": 4.5,
        "unit": "percentage of participants",
        "ci_lower": 0.12,
        "ci_upper": 22.84,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Part B7: AZD9150+MEDI4736: Naiive 1L",
        "value": 21.8,
        "unit": "percentage of participants",
        "ci_lower": 11.81,
        "ci_upper": 35.01,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "Part B8: AZD9150 (Every Other Week)+MEDI4736: Naive 1L",
        "value": 26.0,
        "unit": "percentage of participants",
        "ci_lower": 14.63,
        "ci_upper": 40.34,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "AZD9150",
        "MEDI4736"
      ],
      "OG001": [
        "AZD9150",
        "MEDI4736"
      ],
      "OG002": [
        "AZD9150",
        "MEDI4736",
        "tremelimumab (treme)"
      ],
      "OG003": [
        "AZD9150",
        "MEDI4736",
        "tremelimumab (treme)"
      ],
      "OG004": [
        "AZD9150",
        "MEDI4736",
        "tremelimumab (treme)"
      ],
      "OG005": [
        "AZD9150",
        "MEDI4736"
      ],
      "OG006": [
        "AZD9150",
        "MEDI4736",
        "tremelimumab (treme)"
      ],
      "OG007": [
        "AZD9150",
        "MEDI4736",
        "tremelimumab (treme)"
      ],
      "OG008": [
        "AZD9150",
        "MEDI4736"
      ],
      "OG009": [
        "AZD9150",
        "MEDI4736"
      ],
      "OG010": [
        "AZD9150",
        "MEDI4736"
      ],
      "OG011": [
        "AZD9150",
        "MEDI4736"
      ],
      "OG012": [
        "AZD5069",
        "MEDI4736"
      ],
      "OG013": [
        "AZD9150",
        "MEDI4736"
      ],
      "OG014": [
        "AZD9150",
        "MEDI4736"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted",
      "OG002": "Combo_IO_Targeted",
      "OG003": "Combo_IO_Targeted",
      "OG004": "Combo_IO_Targeted",
      "OG005": "Combo_IO_Targeted",
      "OG006": "Combo_IO_Targeted",
      "OG007": "Combo_IO_Targeted",
      "OG008": "Combo_IO_Targeted",
      "OG009": "Combo_IO_Targeted",
      "OG010": "Combo_IO_Targeted",
      "OG011": "Combo_IO_Targeted",
      "OG012": "Combo_IO_Targeted",
      "OG013": "Combo_IO_Targeted",
      "OG014": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT02564900",
    "brief_title": "Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors",
    "status": "COMPLETED",
    "start_date": "2015-09-01",
    "completion_date": "2019-02-01",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Daiichi Sankyo Co., Ltd.",
    "url": "https://clinicaltrials.gov/study/NCT02564900",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER2 overexpression (breast; gastric/GEJ) \u2014 prior trastuzumab or T-DM1 required in specified cohorts"
      },
      {
        "target": "HER2",
        "status": "LOW",
        "details": "HER2 low expression (breast cancer, Part 2c)"
      },
      {
        "target": "HER2",
        "status": "ANY",
        "details": "HER2 expression in non-breast, non-gastric solid tumors (Part 2d)"
      },
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER2 mutation (any) (Part 2d)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Dose Escalation: Cohort 1, 0.8 mg/kg",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 70.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Dose Escalation: Cohort 2, 1.6 mg/kg",
        "value": 33.3,
        "unit": "percentage of participants",
        "ci_lower": 0.8,
        "ci_upper": 90.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Dose Escalation: Cohort 3, 3.2 mg/kg",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 70.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Dose Escalation: Cohort 4, 5.4 mg/kg",
        "value": 83.3,
        "unit": "percentage of participants",
        "ci_lower": 35.9,
        "ci_upper": 99.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Dose Escalation: Cohort 5, 6.4 mg/kg",
        "value": 33.3,
        "unit": "percentage of participants",
        "ci_lower": 4.3,
        "ci_upper": 77.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "Dose Escalation: Cohort 6, 8.0 mg/kg",
        "value": 50.0,
        "unit": "percentage of participants",
        "ci_lower": 11.8,
        "ci_upper": 88.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG006",
        "arm_title": "Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg",
        "value": 51.0,
        "unit": "percentage of participants",
        "ci_lower": 36.6,
        "ci_upper": 65.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG007",
        "arm_title": "Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg",
        "value": 53.7,
        "unit": "percentage of participants",
        "ci_lower": 41.1,
        "ci_upper": 66.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG008",
        "arm_title": "Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg",
        "value": 33.3,
        "unit": "percentage of participants",
        "ci_lower": 14.6,
        "ci_upper": 57.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG009",
        "arm_title": "Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg",
        "value": 39.4,
        "unit": "percentage of participants",
        "ci_lower": 22.9,
        "ci_upper": 57.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG010",
        "arm_title": "Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg",
        "value": 26.3,
        "unit": "percentage of participants",
        "ci_lower": 9.1,
        "ci_upper": 51.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG011",
        "arm_title": "Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg",
        "value": 32.0,
        "unit": "percentage of participants",
        "ci_lower": 14.9,
        "ci_upper": 53.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG012",
        "arm_title": "Dose Expansion: HER2-expressing NSCLC Tumors",
        "value": 55.6,
        "unit": "percentage of participants",
        "ci_lower": 30.8,
        "ci_upper": 78.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG013",
        "arm_title": "Dose Expansion: HER2-expressing Colorectal Tumors",
        "value": 5.0,
        "unit": "percentage of participants",
        "ci_lower": 0.1,
        "ci_upper": 24.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG014",
        "arm_title": "Dose Expansion: HER2-expressing Other Solid Tumors",
        "value": 30.4,
        "unit": "percentage of participants",
        "ci_lower": 13.2,
        "ci_upper": 52.9,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "DS-8201a (DP1)"
      ],
      "OG001": [
        "DS-8201a (DP1)"
      ],
      "OG002": [
        "DS-8201a (DP1)"
      ],
      "OG003": [
        "DS-8201a (DP1)"
      ],
      "OG004": [
        "DS-8201a (DP1)"
      ],
      "OG005": [
        "DS-8201a (DP1)"
      ],
      "OG006": [
        "DS-8201a (DP1)"
      ],
      "OG007": [
        "DS-8201a (DP1)"
      ],
      "OG008": [
        "DS-8201a (DP1)"
      ],
      "OG009": [
        "DS-8201a (DP1)"
      ],
      "OG010": [
        "DS-8201a (DP1)"
      ],
      "OG011": [
        "DS-8201a (DP1)"
      ],
      "OG012": [
        "DS-8201a (DP1)"
      ],
      "OG013": [
        "DS-8201a (DP1)"
      ],
      "OG014": [
        "DS-8201a (DP1)"
      ]
    },
    "treatment_class_map": {
      "OG000": "ADC",
      "OG001": "ADC",
      "OG002": "ADC",
      "OG003": "ADC",
      "OG004": "ADC",
      "OG005": "ADC",
      "OG006": "ADC",
      "OG007": "ADC",
      "OG008": "ADC",
      "OG009": "ADC",
      "OG010": "ADC",
      "OG011": "ADC",
      "OG012": "ADC",
      "OG013": "ADC",
      "OG014": "ADC"
    }
  },
  {
    "nct_id": "NCT02509507",
    "brief_title": "Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611",
    "status": "COMPLETED",
    "start_date": "2016-02-05",
    "completion_date": "2022-02-14",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Amgen",
    "url": "https://clinicaltrials.gov/study/NCT02509507",
    "cancer_types": [
      "LIHC",
      "SKCM"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "For Part 2 hormone receptor positive breast cancer arm: ER and/or PR positive required (either ER POSITIVE or PR POSITIVE)"
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": "For Part 2 hormone receptor positive breast cancer arm: ER and/or PR positive required (either ER POSITIVE or PR POSITIVE)"
      },
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "Triple negative breast cancer arm requires ER negative, PR negative, HER2 negative"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "Triple negative breast cancer arm requires ER negative, PR negative, HER2 negative"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "Triple negative breast cancer arm requires ER negative, PR negative, HER2 negative"
      },
      {
        "target": "HBV",
        "status": "LOW",
        "details": "For HCC with hepatitis B: on antiviral therapy \u22654 weeks prior to enrollment and HBV viral load by qPCR <100 IU/mL"
      },
      {
        "target": "HCV",
        "status": "LOW",
        "details": "For HCC with past or ongoing hepatitis C infection: completed treatment \u22651 month prior to enrollment and HCV viral load must be undetectable by qPCR"
      },
      {
        "target": "HBV",
        "status": "NEGATIVE",
        "details": "For non-HCC subjects: must have no acute or chronic HBV infection"
      },
      {
        "target": "HCV",
        "status": "NEGATIVE",
        "details": "For non-HCC subjects: must have no acute or chronic HCV infection"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Part 2: Hormone Receptor Positive Breast Cancer (HRBC)",
        "value": 10.0,
        "unit": "percentage of participants",
        "ci_lower": 0.3,
        "ci_upper": 44.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Part 2: Triple Negative Breast Cancer (TNBC)",
        "value": 16.7,
        "unit": "percentage of participants",
        "ci_lower": 3.6,
        "ci_upper": 41.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Part 2: Cutaneous Squamous Cell Carcinoma (CSCC)",
        "value": 10.0,
        "unit": "percentage of participants",
        "ci_lower": 0.3,
        "ci_upper": 44.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Part 2: Basal Cell Carcinoma (BCC)",
        "value": 20.0,
        "unit": "percentage of participants",
        "ci_lower": 0.5,
        "ci_upper": 71.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Part 2: Colorectal Adenocarcinoma (CRC)",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 30.8,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Talimogene Laherparepvec"
      ],
      "OG001": [
        "Talimogene Laherparepvec"
      ],
      "OG002": [
        "Talimogene Laherparepvec",
        "Pembrolizumab"
      ],
      "OG003": [
        "Talimogene Laherparepvec",
        "Pembrolizumab"
      ],
      "OG004": [
        "Talimogene Laherparepvec"
      ],
      "OG005": [
        "Talimogene Laherparepvec",
        "Pembrolizumab"
      ],
      "OG006": [
        "Talimogene Laherparepvec",
        "Pembrolizumab"
      ],
      "OG007": [
        "Talimogene Laherparepvec",
        "Pembrolizumab"
      ],
      "OG008": [
        "Talimogene Laherparepvec",
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO",
      "OG003": "IO",
      "OG004": "IO",
      "OG005": "IO",
      "OG006": "IO",
      "OG007": "IO",
      "OG008": "IO"
    }
  },
  {
    "nct_id": "NCT02573259",
    "brief_title": "A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2016-02-10",
    "completion_date": "2020-11-19",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT02573259",
    "cancer_types": [
      "SKCM",
      "HNSC",
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "EGFR mutation status is referenced; if tumor is known to have EGFR mutation, prior EGFR-targeted therapy is required"
      },
      {
        "target": "ALK",
        "status": "ANY",
        "details": "ALK mutation status is referenced; if tumor is known to have ALK mutation, prior ALK-targeted therapy is required"
      },
      {
        "target": "PD-L1",
        "status": "HIGH",
        "details": "Required for urothelial carcinoma patients who are treatment\u2011na\u00efve and refusing platinum-containing chemotherapy (documented previous PD-L1 high status)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Part 2: PF-06801591 300 mg (SC) for NSCLC",
        "value": 16.4,
        "unit": "Percentage",
        "ci_lower": 8.5,
        "ci_upper": 27.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Part 2: PF-06801591 300 mg (SC) for UC",
        "value": 18.4,
        "unit": "Percentage",
        "ci_lower": 7.7,
        "ci_upper": 34.3,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "PF-06801591"
      ],
      "OG001": [
        "PF-06801591"
      ],
      "OG002": [
        "PF-06801591"
      ],
      "OG003": [
        "PF-06801591"
      ],
      "OG004": [
        "PF-06801591"
      ],
      "OG005": [
        "PF-06801591"
      ],
      "OG006": [
        "PF-06801591"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER",
      "OG002": "OTHER",
      "OG003": "OTHER",
      "OG004": "OTHER",
      "OG005": "OTHER",
      "OG006": "OTHER"
    }
  },
  {
    "nct_id": "NCT02508532",
    "brief_title": "(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2015-08",
    "completion_date": "2020-03-06",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Blueprint Medicines Corporation",
    "url": "https://clinicaltrials.gov/study/NCT02508532",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "PDGFRA",
        "status": "POSITIVE",
        "details": "D842V mutation in PDGFRA (identified by local or central testing on archival tissue or new biopsy)"
      },
      {
        "target": "PDGFRA",
        "status": "NEGATIVE",
        "details": "Must NOT have D842V mutation in PDGFRA (Groups 1 and 3)"
      },
      {
        "target": "KIT",
        "status": "ANY",
        "details": "Known KIT wild type patients are excluded (Group 3 exclusion)"
      }
    ],
    "cancer_stages": [
      "UNRESECTABLE",
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Patients With a PDGFRA D842V Mutation",
        "value": 36.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "2L Patients Without a PDGFRA D842V Mutation",
        "value": 10.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "3L Patients Without a PDGFRA D842V Mutation",
        "value": 20.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Avapritinib"
      ],
      "OG001": [
        "Avapritinib"
      ],
      "OG002": [
        "Avapritinib"
      ],
      "OG003": [
        "Avapritinib"
      ],
      "OG004": [
        "Avapritinib"
      ],
      "OG005": [
        "Avapritinib"
      ],
      "OG006": [
        "Avapritinib"
      ],
      "OG007": [
        "Avapritinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI",
      "OG002": "TKI",
      "OG003": "TKI",
      "OG004": "TKI",
      "OG005": "TKI",
      "OG006": "TKI",
      "OG007": "TKI"
    }
  },
  {
    "nct_id": "NCT02563548",
    "brief_title": "A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2015-10-22",
    "completion_date": "2019-03-26",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Halozyme Therapeutics",
    "url": "https://clinicaltrials.gov/study/NCT02563548",
    "cancer_types": [
      "NSCLC",
      "STAD"
    ],
    "biomarkers": [
      {
        "target": "Hyaluronan",
        "status": "HIGH",
        "details": "Hyaluronan (HA) - must be determined to have HA-high levels from tumor biopsies for dose expansion"
      },
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Tissue must be available for PD-L1 testing (PD-L1 status is required to be tested but no specific status mandated)"
      },
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "If known to be EGFR-mutation positive, participant must have received an EGFR inhibitor prior to enrollment"
      },
      {
        "target": "ALK",
        "status": "POSITIVE",
        "details": "If known to be ALK-mutation positive, participant must have received an ALK inhibitor prior to enrollment"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV",
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Dose Expansion (GAC): PEGPH20 2.2 \u00b5g/kg + Pembrolizumab",
        "value": 9.5,
        "unit": "percentage of participants",
        "ci_lower": 2.6,
        "ci_upper": 23.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Dose Expansion (NSCLC): PEGPH20 2.2 \u00b5g/kg + Pembrolizumab",
        "value": 28.6,
        "unit": "percentage of participants",
        "ci_lower": 13.1,
        "ci_upper": 49.2,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "PEGPH20",
        "Pembrolizumab"
      ],
      "OG001": [
        "PEGPH20",
        "Pembrolizumab"
      ],
      "OG002": [
        "PEGPH20",
        "Pembrolizumab"
      ],
      "OG003": [
        "PEGPH20",
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted",
      "OG002": "Combo_IO_Targeted",
      "OG003": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT02501096",
    "brief_title": "A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2015-07-22",
    "completion_date": "2020-08-18",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eisai Inc.",
    "url": "https://clinicaltrials.gov/study/NCT02501096",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": true,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: EC",
        "value": 39.5,
        "unit": "percentage of participants",
        "ci_lower": 30.9,
        "ci_upper": 48.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCC",
        "value": 56.6,
        "unit": "percentage of participants",
        "ci_lower": 48.1,
        "ci_upper": 64.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: Melanoma",
        "value": 47.6,
        "unit": "percentage of participants",
        "ci_lower": 25.7,
        "ci_upper": 70.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLC",
        "value": 23.8,
        "unit": "percentage of participants",
        "ci_lower": 8.2,
        "ci_upper": 47.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Phase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCC",
        "value": 31.8,
        "unit": "percentage of participants",
        "ci_lower": 13.9,
        "ci_upper": 54.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UC",
        "value": 25.0,
        "unit": "percentage of participants",
        "ci_lower": 8.7,
        "ci_upper": 49.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG006",
        "arm_title": "Phase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: EC",
        "value": 7.5,
        "unit": "months",
        "ci_lower": 5.3,
        "ci_upper": 9.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCC",
        "value": 14.1,
        "unit": "months",
        "ci_lower": 11.6,
        "ci_upper": 18.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: Melanoma",
        "value": 5.5,
        "unit": "months",
        "ci_lower": 2.6,
        "ci_upper": 15.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLC",
        "value": 5.4,
        "unit": "months",
        "ci_lower": 2.3,
        "ci_upper": 7.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Phase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCC",
        "value": 4.4,
        "unit": "months",
        "ci_lower": 4.0,
        "ci_upper": 9.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG005",
        "arm_title": "Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UC",
        "value": 5.4,
        "unit": "months",
        "ci_lower": 1.3,
        "ci_upper": 42.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG006",
        "arm_title": "Phase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma",
        "value": 1.35,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: EC",
        "value": 19.9,
        "unit": "months",
        "ci_lower": 16.2,
        "ci_upper": 25.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCC",
        "value": 32.2,
        "unit": "months",
        "ci_lower": 29.8,
        "ci_upper": 55.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: Melanoma",
        "value": 25.4,
        "unit": "months",
        "ci_lower": 8.6,
        "ci_upper": 39.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLC",
        "value": 11.4,
        "unit": "months",
        "ci_lower": 3.6,
        "ci_upper": 23.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG004",
        "arm_title": "Phase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCC",
        "value": 16.2,
        "unit": "months",
        "ci_lower": 8.6,
        "ci_upper": 31.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG005",
        "arm_title": "Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UC",
        "value": 6.1,
        "unit": "months",
        "ci_lower": 2.4,
        "ci_upper": 30.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG006",
        "arm_title": "Phase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma",
        "value": 16.56,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Lenvatinib",
        "Pembrolizumab"
      ],
      "OG001": [
        "Lenvatinib",
        "Pembrolizumab"
      ],
      "OG002": [
        "Lenvatinib",
        "Pembrolizumab"
      ],
      "OG003": [
        "Lenvatinib",
        "Pembrolizumab"
      ],
      "OG004": [
        "Lenvatinib",
        "Pembrolizumab"
      ],
      "OG005": [
        "Lenvatinib",
        "Pembrolizumab"
      ],
      "OG006": [
        "Lenvatinib",
        "Pembrolizumab"
      ],
      "OG007": [
        "Lenvatinib",
        "Pembrolizumab"
      ],
      "OG008": [
        "Lenvatinib",
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_IO",
      "OG001": "Combo_TKI_IO",
      "OG002": "Combo_TKI_IO",
      "OG003": "Combo_TKI_IO",
      "OG004": "Combo_TKI_IO",
      "OG005": "Combo_TKI_IO",
      "OG006": "Combo_TKI_IO",
      "OG007": "Combo_TKI_IO",
      "OG008": "Combo_TKI_IO"
    }
  },
  {
    "nct_id": "NCT02584309",
    "brief_title": "Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma",
    "status": "COMPLETED",
    "start_date": "2016-02-22",
    "completion_date": "2022-07-17",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Washington University School of Medicine",
    "url": "https://clinicaltrials.gov/study/NCT02584309",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm 1: Doxorubicin and Upfront Dexrazoxane",
        "value": 5.48,
        "unit": "months",
        "ci_lower": 4.01,
        "ci_upper": 7.37,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm 2: Control (Doxorubicin and Standard of Care Dexrazoxane)",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Doxorubicin",
        "Dexrazoxane"
      ],
      "OG001": [
        "Doxorubicin",
        "Dexrazoxane"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT02611960",
    "brief_title": "Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)",
    "status": "COMPLETED",
    "start_date": "2016-04-18",
    "completion_date": "2020-11-30",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT02611960",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Tumor tissue must be available for PD-L1 testing"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab",
        "value": 17.2,
        "unit": "Months",
        "ci_lower": 11.7,
        "ci_upper": 22.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Standard Treatment",
        "value": 15.3,
        "unit": "Months",
        "ci_lower": 10.9,
        "ci_upper": 18.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab"
      ],
      "OG001": [
        "Capecitabine",
        "Gemcitabine",
        "Docetaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT02576574",
    "brief_title": "Avelumab in First-line NSCLC (JAVELIN Lung 100)",
    "status": "COMPLETED",
    "start_date": "2015-10-29",
    "completion_date": "2021-12-06",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "EMD Serono Research & Development Institute, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT02576574",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "Excludes tumors harboring EGFR activating mutations"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "Excludes tumors with ALK rearrangement"
      },
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Availability of tumor tissue suitable for PD-L1 expression assessment (FFPE biopsy preferably within 6 months or \u226510 unstained tumor slides cut within 1 week)"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Avelumab Biweekly",
        "value": 8.4,
        "unit": "months",
        "ci_lower": 5.4,
        "ci_upper": 12.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy",
        "value": 5.6,
        "unit": "months",
        "ci_lower": 5.4,
        "ci_upper": 6.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Avelumab Biweekly",
        "value": 20.1,
        "unit": "months",
        "ci_lower": 15.0,
        "ci_upper": 24.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy",
        "value": 14.9,
        "unit": "months",
        "ci_lower": 11.8,
        "ci_upper": 18.6,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Avelumab"
      ],
      "OG001": [
        "Pemetrexed",
        "Cisplatin"
      ],
      "OG002": [
        "Pemetrexed",
        "Cisplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "Chemo",
      "OG002": "Chemo"
    }
  },
  {
    "nct_id": "NCT02581215",
    "brief_title": "Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer",
    "status": "COMPLETED",
    "start_date": "2016-09-11",
    "completion_date": "2021-08-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Walid Shaib, MD",
    "url": "https://clinicaltrials.gov/study/NCT02581215",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A: Experimental Arm",
        "value": 25.1,
        "unit": "Percentage of participants",
        "ci_lower": 11.6,
        "ci_upper": 41.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Placebo Arm",
        "value": 35.0,
        "unit": "Percentage of participants",
        "ci_lower": 19.8,
        "ci_upper": 50.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A: Experimental Arm",
        "value": 10.3,
        "unit": "Months",
        "ci_lower": 6.0,
        "ci_upper": 11.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Placebo Arm",
        "value": 9.7,
        "unit": "Months",
        "ci_lower": 6.4,
        "ci_upper": 15.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "mFOLFIRINOX"
      ],
      "OG001": [
        "mFOLFIRINOX"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT02604342",
    "brief_title": "Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib",
    "status": "COMPLETED",
    "start_date": "2015-11-03",
    "completion_date": "2017-01-26",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT02604342",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "ALK",
        "status": "POSITIVE",
        "details": "ALK positivity by validated FISH (Vysis ALK Break-Apart Probe) or validated IHC (clone D5F3)"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV",
      "METASTATIC",
      "RECURRENT",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": true,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Experimental: Alectinib",
        "value": 10.9,
        "unit": "months",
        "ci_lower": 8.1,
        "ci_upper": 15.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Active Comparator: Premetrexed/Docetaxel",
        "value": 1.4,
        "unit": "months",
        "ci_lower": 1.2,
        "ci_upper": 1.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Experimental: Alectinib",
        "value": 27.8,
        "unit": "months",
        "ci_lower": 18.2,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Active Comparator: Premetrexed/Docetaxel",
        "value": null,
        "unit": "months",
        "ci_lower": 8.6,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Alectinib"
      ],
      "OG001": [
        "Docetaxel",
        "Pemetrexed"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT02613221",
    "brief_title": "A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2015-12-07",
    "completion_date": "2017-10-06",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Takeda",
    "url": "https://clinicaltrials.gov/study/NCT02613221",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "No mutation in KRAS codons: EXON2 (codon 12, 13), EXON3 (codon 59, 61), EXON4 (codon 117, 146)"
      },
      {
        "target": "NRAS",
        "status": "NEGATIVE",
        "details": "No mutation in NRAS codons: EXON2 (codon 12, 13), EXON3 (codon 59, 61), EXON4 (codon 117, 146)"
      },
      {
        "target": "BRAF",
        "status": "NEGATIVE",
        "details": "Known BRAF mutation excluded (any BRAF mutation)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE",
      "RECURRENT"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Panitumumab + TAS-102",
        "value": 33.3,
        "unit": "Percentage of Participants",
        "ci_lower": 22.77,
        "ci_upper": 45.32,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Panitumumab + TAS-102",
        "value": 14.1,
        "unit": "Months",
        "ci_lower": 12.18,
        "ci_upper": 19.29,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Panitumumab",
        "TAS-102"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02595892",
    "brief_title": "Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2016-08-25",
    "completion_date": "2020-06-15",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT02595892",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm I (Gemcitabine Hydrochloride)",
        "value": 14.7,
        "unit": "Weeks",
        "ci_lower": 9.7,
        "ci_upper": 36.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm II (Gemcitabine, ATR Kinase Inhibitor M6620)",
        "value": 22.9,
        "unit": "Weeks",
        "ci_lower": 17.9,
        "ci_upper": 72.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm I (Gemcitabine Hydrochloride)",
        "value": 43.0,
        "unit": "Weeks",
        "ci_lower": 34.4,
        "ci_upper": 67.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm II (Gemcitabine, ATR Kinase Inhibitor M6620)",
        "value": 59.4,
        "unit": "Weeks",
        "ci_lower": 33.7,
        "ci_upper": 86.6,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Gemcitabine Hydrochloride"
      ],
      "OG001": [
        "Gemcitabine Hydrochloride",
        "Berzosertib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02575300",
    "brief_title": "Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors",
    "status": "COMPLETED",
    "start_date": "2015-10-09",
    "completion_date": "2019-03-26",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
    "url": "https://clinicaltrials.gov/study/NCT02575300",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Ibrutinib Therapy",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ibrutinib Therapy",
        "value": 3.0,
        "unit": "months",
        "ci_lower": 2.8,
        "ci_upper": 5.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Ibrutinib Therapy",
        "value": 24.1,
        "unit": "months",
        "ci_lower": 16.5,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ibrutinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT02579616",
    "brief_title": "Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy",
    "status": "COMPLETED",
    "start_date": "2015-10-23",
    "completion_date": "2016-11-22",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eisai Co., Ltd.",
    "url": "https://clinicaltrials.gov/study/NCT02579616",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "UNRESECTABLE",
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Lenvatinib 24 mg",
        "value": 11.5,
        "unit": "Percent",
        "ci_lower": 2.4,
        "ci_upper": 30.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Lenvatinib 24 mg",
        "value": 72.2,
        "unit": "Percent",
        "ci_lower": 50.4,
        "ci_upper": 85.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Lenvatinib 24 mg",
        "value": 7.35,
        "unit": "Months",
        "ci_lower": 4.5,
        "ci_upper": 11.27,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Lenvatinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT02609737",
    "brief_title": "Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors",
    "status": "COMPLETED",
    "start_date": "2015-11-13",
    "completion_date": "2020-12-10",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Memorial Sloan Kettering Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT02609737",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "SSTR",
        "status": "POSITIVE",
        "details": "Uptake on 111In-DTPA-octreotide SPECT greater than physiologic liver uptake"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "68Ga-DOTA-JR11 and 177Lu-DOTA-JR11",
        "value": 9.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "68Ga-DOTA-JR11",
        "177Lu-DOTA-JR11"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER"
    }
  },
  {
    "nct_id": "NCT02603432",
    "brief_title": "A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)",
    "status": "COMPLETED",
    "start_date": "2016-04-25",
    "completion_date": "2019-10-21",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT02603432",
    "cancer_types": [
      "BLCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "IV",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "MAINTENANCE",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Avelumab + Best Supportive Care (BSC)",
        "value": 21.4,
        "unit": "months",
        "ci_lower": 18.9,
        "ci_upper": 26.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Best Supportive Care",
        "value": 14.3,
        "unit": "months",
        "ci_lower": 12.9,
        "ci_upper": 17.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Avelumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT02580058",
    "brief_title": "A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)",
    "status": "COMPLETED",
    "start_date": "2015-12-21",
    "completion_date": "2018-09-19",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT02580058",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Avelumab",
        "value": 11.8,
        "unit": "months",
        "ci_lower": 8.9,
        "ci_upper": 14.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Avelumab + PLD",
        "value": 15.7,
        "unit": "months",
        "ci_lower": 12.7,
        "ci_upper": 18.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Pegylated Liposomal Doxorubicin (PLD)",
        "value": 13.1,
        "unit": "months",
        "ci_lower": 11.8,
        "ci_upper": 15.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Avelumab",
        "value": 1.9,
        "unit": "months",
        "ci_lower": 1.8,
        "ci_upper": 1.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Avelumab + PLD",
        "value": 3.7,
        "unit": "months",
        "ci_lower": 3.3,
        "ci_upper": 5.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Pegylated Liposomal Doxorubicin (PLD)",
        "value": 3.5,
        "unit": "months",
        "ci_lower": 2.1,
        "ci_upper": 4.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "avelumab"
      ],
      "OG001": [
        "avelumab",
        "PLD"
      ],
      "OG002": [
        "PLD"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "Combo_Chemo_IO",
      "OG002": "Chemo"
    }
  },
  {
    "nct_id": "NCT02574455",
    "brief_title": "Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)",
    "status": "COMPLETED",
    "start_date": "2017-11-07",
    "completion_date": "2020-03-30",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Gilead Sciences",
    "url": "https://clinicaltrials.gov/study/NCT02574455",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "LOW",
        "details": "<1% expression"
      },
      {
        "target": "PR",
        "status": "LOW",
        "details": "<1% expression"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "negative by in-situ hybridization (ISH)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Sacituzumab Govitecan",
        "value": 4.8,
        "unit": "months",
        "ci_lower": 4.1,
        "ci_upper": 5.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Treatment of Physician's Choice (TPC)",
        "value": 1.7,
        "unit": "months",
        "ci_lower": 1.5,
        "ci_upper": 2.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Sacituzumab Govitecan",
        "value": 12.1,
        "unit": "months",
        "ci_lower": 10.7,
        "ci_upper": 14.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Treatment of Physician's Choice (TPC)",
        "value": 6.7,
        "unit": "months",
        "ci_lower": 5.8,
        "ci_upper": 7.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Sacituzumab govitecan"
      ],
      "OG001": [
        "Eribulin",
        "Capecitabine",
        "Gemcitabine",
        "Vinorelbine"
      ]
    },
    "treatment_class_map": {
      "OG000": "ADC",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT02601937",
    "brief_title": "EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma",
    "status": "COMPLETED",
    "start_date": "2016-01-07",
    "completion_date": "2021-06-19",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Epizyme, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT02601937",
    "cancer_types": [
      "OTHER",
      "OV"
    ],
    "biomarkers": [
      {
        "target": "SMARCB1",
        "status": "NEGATIVE",
        "details": "Loss of INI1 (SMARCB1) confirmed by IHC, or molecular confirmation of tumor bi-allelic SMARCB1 loss/mutation when IHC is equivocal or unavailable"
      },
      {
        "target": "SMARCA4",
        "status": "NEGATIVE",
        "details": "Loss of SMARCA4 confirmed by IHC, or molecular confirmation of tumor bi-allelic SMARCA4 loss/mutation when IHC is equivocal or unavailable"
      },
      {
        "target": "SS18",
        "status": "POSITIVE",
        "details": "SS18-SSX rearrangement (t(X;18)(p11;q11)) confirmed by cytogenetics, FISH and/or molecular testing"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Dose Expansion Cohort 1",
        "value": 26.3,
        "unit": "Percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Dose Expansion Cohort 2",
        "value": 0.0,
        "unit": "Percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Dose Expansion Cohort 3",
        "value": 16.7,
        "unit": "Percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Dose Expansion Cohort 4",
        "value": 16.7,
        "unit": "Percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Tazemetostat"
      ],
      "OG001": [
        "Tazemetostat"
      ],
      "OG002": [
        "Tazemetostat"
      ],
      "OG003": [
        "Tazemetostat"
      ],
      "OG004": [
        "Tazemetostat"
      ],
      "OG005": [
        "Tazemetostat"
      ],
      "OG006": [
        "Tazemetostat"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other",
      "OG004": "Targeted_Other",
      "OG005": "Targeted_Other",
      "OG006": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02591615",
    "brief_title": "Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC",
    "status": "COMPLETED",
    "start_date": "2016-03",
    "completion_date": "2019-01-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Alliance Foundation Trials, LLC.",
    "url": "https://clinicaltrials.gov/study/NCT02591615",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "Investigators must document EGFR mutation status; patients with sensitizing EGFR mutations must have progressed on an appropriate TKI"
      },
      {
        "target": "ALK",
        "status": "ANY",
        "details": "Investigators must document ALK translocation/rearrangement status; patients with ALK rearrangement must have progressed on an appropriate TKI"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Arm A (Both Squamous and Non-Squamous)",
        "value": 0.395,
        "unit": "proportion of participants",
        "ci_lower": 0.249,
        "ci_upper": 0.541,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Arm B (Both Squamous and Non-Squamous)",
        "value": 0.404,
        "unit": "proportion of participants",
        "ci_lower": 0.264,
        "ci_upper": 0.545,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A (Both Squamous and Non-Squamous)",
        "value": 5.8,
        "unit": "Months",
        "ci_lower": 4.4,
        "ci_upper": 10.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B (Both Squamous and Non-Squamous)",
        "value": 4.0,
        "unit": "Months",
        "ci_lower": 2.1,
        "ci_upper": 10.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Carboplatin",
        "Paclitaxel",
        "Pemetrexed"
      ],
      "OG001": [
        "MK-3475",
        "Carboplatin",
        "Paclitaxel",
        "Pemetrexed"
      ],
      "OG002": [
        "Pemetrexed"
      ],
      "OG003": [
        "Pemetrexed"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_IO",
      "OG002": "Chemo",
      "OG003": "Chemo"
    }
  },
  {
    "nct_id": "NCT02606305",
    "brief_title": "Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FR\u03b1) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer",
    "status": "COMPLETED",
    "start_date": "2016-03-02",
    "completion_date": "2021-03-12",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "ImmunoGen, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT02606305",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "FOLR1",
        "status": "POSITIVE",
        "details": "Folate receptor \u03b1 (FR\u03b1) positive tumor expression as defined in the protocol; archival tumor tissue or new biopsy required (new biopsy required for Regimen D)"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Regimen A Dose Expansion Cohort 1: Bevacizumab-na\nef",
        "value": 52.0,
        "unit": "percentage of participants",
        "ci_lower": 29.78,
        "ci_upper": 74.29,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Regimen A Dose Expansion Cohort 2: Bevacizumab Pre-treated",
        "value": 29.0,
        "unit": "percentage of participants",
        "ci_lower": 15.1,
        "ci_upper": 47.48,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Regimen A Dose Expansion Cohort 3: Pt-agnostic:",
        "value": 50.0,
        "unit": "percentage of participants",
        "ci_lower": 36.81,
        "ci_upper": 63.19,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Regimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg",
        "value": 27.0,
        "unit": "percentage of participants",
        "ci_lower": 14.6,
        "ci_upper": 41.94,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Regimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin",
        "value": 83.0,
        "unit": "percentage of participants",
        "ci_lower": 67.94,
        "ci_upper": 92.85,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Mirvetuximab soravtansine",
        "Bevacizumab"
      ],
      "OG001": [
        "Mirvetuximab soravtansine",
        "Bevacizumab"
      ],
      "OG002": [
        "Mirvetuximab soravtansine",
        "Carboplatin"
      ],
      "OG003": [
        "Mirvetuximab soravtansine",
        "Carboplatin"
      ],
      "OG004": [
        "Mirvetuximab soravtansine",
        "Carboplatin"
      ],
      "OG005": [
        "Mirvetuximab soravtansine",
        "Pegylated Liposomal Doxorubicin"
      ],
      "OG006": [
        "Mirvetuximab soravtansine",
        "Pegylated Liposomal Doxorubicin"
      ],
      "OG007": [
        "Mirvetuximab soravtansine",
        "Pegylated Liposomal Doxorubicin"
      ],
      "OG008": [
        "Mirvetuximab soravtansine",
        "Pembrolizumab"
      ],
      "OG009": [
        "Mirvetuximab soravtansine",
        "Pembrolizumab"
      ],
      "OG010": [
        "Mirvetuximab soravtansine",
        "Bevacizumab",
        "Carboplatin"
      ],
      "OG011": [
        "Mirvetuximab soravtansine",
        "Pembrolizumab"
      ],
      "OG012": [
        "Mirvetuximab soravtansine",
        "Pembrolizumab"
      ],
      "OG013": [
        "Mirvetuximab soravtansine",
        "Pembrolizumab"
      ],
      "OG014": [
        "Mirvetuximab soravtansine",
        "Bevacizumab",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER",
      "OG002": "OTHER",
      "OG003": "OTHER",
      "OG004": "OTHER",
      "OG005": "OTHER",
      "OG006": "OTHER",
      "OG007": "OTHER",
      "OG008": "OTHER",
      "OG009": "OTHER",
      "OG010": "Combo_Chemo_Targeted",
      "OG011": "OTHER",
      "OG012": "OTHER",
      "OG013": "OTHER",
      "OG014": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02574078",
    "brief_title": "A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)",
    "status": "COMPLETED",
    "start_date": "2015-11-23",
    "completion_date": "2020-04-15",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT02574078",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "IV"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Group A, Cohort A, Nivo",
        "value": 15.0,
        "unit": "Months",
        "ci_lower": 1.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Group A, Cohort A, Beva + Nivo",
        "value": 6.7,
        "unit": "Months",
        "ci_lower": 4.1,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Group A, Cohort A, Beva",
        "value": 6.0,
        "unit": "Months",
        "ci_lower": 3.3,
        "ci_upper": 19.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Group A, Cohort B, Nivo",
        "value": 5.9,
        "unit": "Months",
        "ci_lower": 2.6,
        "ci_upper": 12.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Group A, Cohort B, Peme + Nivo",
        "value": 8.1,
        "unit": "Months",
        "ci_lower": 4.0,
        "ci_upper": 12.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG005",
        "arm_title": "Group A, Cohort B, Peme",
        "value": 5.0,
        "unit": "Months",
        "ci_lower": 2.1,
        "ci_upper": 6.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG006",
        "arm_title": "Group B, Nivo",
        "value": 9.6,
        "unit": "Months",
        "ci_lower": 2.1,
        "ci_upper": 24.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG007",
        "arm_title": "Group B, BSC",
        "value": 2.3,
        "unit": "Months",
        "ci_lower": 1.0,
        "ci_upper": 4.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG008",
        "arm_title": "Group C, Nivo",
        "value": 2.7,
        "unit": "Months",
        "ci_lower": 1.2,
        "ci_upper": 4.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG009",
        "arm_title": "Group C, ICC",
        "value": 6.7,
        "unit": "Months",
        "ci_lower": 4.4,
        "ci_upper": 13.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG010",
        "arm_title": "Group D, Nivo + Erlo",
        "value": 11.0,
        "unit": "Months",
        "ci_lower": 9.3,
        "ci_upper": 17.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG011",
        "arm_title": "Group D, Erlo",
        "value": 11.0,
        "unit": "Months",
        "ci_lower": 7.6,
        "ci_upper": 13.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Group A, Cohort A, Nivo",
        "value": 20.0,
        "unit": "Months",
        "ci_lower": 2.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Group A, Cohort A, Beva + Nivo",
        "value": 30.8,
        "unit": "Months",
        "ci_lower": 8.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Group A, Cohort A, Beva",
        "value": 18.1,
        "unit": "Months",
        "ci_lower": 3.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Group A, Cohort B, Nivo",
        "value": 28.9,
        "unit": "Months",
        "ci_lower": 14.8,
        "ci_upper": 38.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG004",
        "arm_title": "Group A, Cohort B, Peme + Nivo",
        "value": 17.4,
        "unit": "Months",
        "ci_lower": 10.7,
        "ci_upper": 39.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG005",
        "arm_title": "Group A, Cohort B, Peme",
        "value": 18.4,
        "unit": "Months",
        "ci_lower": 6.7,
        "ci_upper": 30.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG006",
        "arm_title": "Group B, Nivo",
        "value": null,
        "unit": "Months",
        "ci_lower": 11.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG007",
        "arm_title": "Group B, BSC",
        "value": 13.6,
        "unit": "Months",
        "ci_lower": 2.0,
        "ci_upper": 36.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG008",
        "arm_title": "Group C, Nivo",
        "value": 3.9,
        "unit": "Months",
        "ci_lower": 1.5,
        "ci_upper": 12.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG009",
        "arm_title": "Group C, ICC",
        "value": 15.8,
        "unit": "Months",
        "ci_lower": 6.5,
        "ci_upper": 23.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab"
      ],
      "OG001": [
        "Bevacizumab",
        "Nivolumab"
      ],
      "OG002": [
        "Bevacizumab"
      ],
      "OG003": [
        "Nivolumab"
      ],
      "OG004": [
        "Pemetrexed",
        "Nivolumab"
      ],
      "OG005": [
        "Pemetrexed"
      ],
      "OG006": [
        "Nivolumab"
      ],
      "OG008": [
        "Nivolumab"
      ],
      "OG010": [
        "Nivolumab",
        "Erlotinib"
      ],
      "OG011": [
        "Erlotinib"
      ],
      "OG012": [
        "Nivolumab",
        "Crizotinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "Combo_IO_Targeted",
      "OG002": "Targeted_Other",
      "OG003": "IO",
      "OG004": "Combo_Chemo_IO",
      "OG005": "Chemo",
      "OG006": "IO",
      "OG007": "Placebo",
      "OG008": "IO",
      "OG009": "Chemo",
      "OG010": "Combo_TKI_IO",
      "OG011": "TKI",
      "OG012": "Combo_TKI_IO"
    }
  },
  {
    "nct_id": "NCT02608684",
    "brief_title": "A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer",
    "status": "COMPLETED",
    "start_date": "2016-02-08",
    "completion_date": "2019-05-17",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Cedars-Sinai Medical Center",
    "url": "https://clinicaltrials.gov/study/NCT02608684",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cisplatin+Gemcitabine+Pembrolizumab",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cisplatin+Gemcitabine+Pembrolizumab",
        "value": 10.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cisplatin+Gemcitabine+Pembrolizumab",
        "value": 5.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cisplatin+Gemcitabine+Pembrolizumab",
        "value": 2.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cisplatin+Gemcitabine+Pembrolizumab",
        "value": 50.0,
        "unit": "percentage of participants",
        "ci_lower": 25.93,
        "ci_upper": 70.05,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cisplatin+Gemcitabine+Pembrolizumab",
        "value": 5.56,
        "unit": "percentage of participants",
        "ci_lower": 0.37,
        "ci_upper": 22.42,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG000",
        "arm_title": "Cisplatin+Gemcitabine+Pembrolizumab",
        "value": 6.25,
        "unit": "months",
        "ci_lower": 3.78,
        "ci_upper": 7.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cisplatin+Gemcitabine+Pembrolizumab",
        "value": 17.75,
        "unit": "months",
        "ci_lower": 7.47,
        "ci_upper": 32.24,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cisplatin",
        "Gemcitabine",
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT02601950",
    "brief_title": "A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma",
    "status": "COMPLETED",
    "start_date": "2015-12-22",
    "completion_date": "2024-02-26",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Epizyme, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT02601950",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "SMARCB1",
        "status": "NEGATIVE",
        "details": "Loss of INI1 by IHC, or molecular confirmation of tumor bi-allelic SMARCB1 (INI1) loss or mutation when IHC is equivocal or unavailable"
      },
      {
        "target": "SMARCA4",
        "status": "NEGATIVE",
        "details": "Loss of SMARCA4 by IHC, or molecular confirmation of tumor bi-allelic SMARCA4 loss or mutation when IHC is equivocal or unavailable"
      },
      {
        "target": "SS18",
        "status": "POSITIVE",
        "details": "SS18 rearrangement t(X;18)(p11;q11) confirmed by cytogenetics, FISH, and/or molecular testing"
      },
      {
        "target": "EZH2",
        "status": "POSITIVE",
        "details": "Molecular evidence of EZH2 gain-of-function (GOF) mutation"
      },
      {
        "target": "CD34",
        "status": "ANY",
        "details": "Immunophenotypic marker (part of ES panel) consistent with epithelioid sarcoma"
      },
      {
        "target": "EMA",
        "status": "ANY",
        "details": "Immunophenotypic marker (part of ES panel) consistent with epithelioid sarcoma (EMA)"
      },
      {
        "target": "KERATIN",
        "status": "ANY",
        "details": "Immunophenotypic marker (part of ES panel) consistent with epithelioid sarcoma (Keratin)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Rhabdoid Tumors: Cohort 1",
        "value": 9.4,
        "unit": "Percentage of participants",
        "ci_lower": 2.0,
        "ci_upper": 25.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Other INI1-negative: Cohort 3",
        "value": 9.4,
        "unit": "Percentage of participants",
        "ci_lower": 2.0,
        "ci_upper": 25.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "RMC: Cohort 4",
        "value": 0.0,
        "unit": "Percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 23.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "ES: Cohort 5",
        "value": 16.1,
        "unit": "Percentage of participants",
        "ci_lower": 8.0,
        "ci_upper": 27.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "ES Paired Biopsy: Cohort 6",
        "value": 15.9,
        "unit": "Percentage of participants",
        "ci_lower": 8.2,
        "ci_upper": 26.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "Chordoma: Cohort 7",
        "value": 5.6,
        "unit": "Percentage of participants",
        "ci_lower": 0.1,
        "ci_upper": 27.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Synovial Sarcoma: Cohort 2",
        "value": 15.2,
        "unit": "Percentage of participants",
        "ci_lower": 5.1,
        "ci_upper": 31.9,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Tazemetostat"
      ],
      "OG001": [
        "Tazemetostat"
      ],
      "OG002": [
        "Tazemetostat"
      ],
      "OG003": [
        "Tazemetostat"
      ],
      "OG004": [
        "Tazemetostat"
      ],
      "OG005": [
        "Tazemetostat"
      ],
      "OG006": [
        "Tazemetostat"
      ],
      "OG007": [
        "Tazemetostat"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other",
      "OG004": "Targeted_Other",
      "OG005": "Targeted_Other",
      "OG006": "Targeted_Other",
      "OG007": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02581943",
    "brief_title": "Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2016-06-17",
    "completion_date": "2022-11-19",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Wake Forest University Health Sciences",
    "url": "https://clinicaltrials.gov/study/NCT02581943",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "If EGFR mutation present, patient must have received an approved EGFR-directed therapy and have documented disease progression prior to receiving pembrolizumab."
      },
      {
        "target": "ALK",
        "status": "ANY",
        "details": "If ALK gene rearrangement present, patient must have received an approved ALK-directed therapy and have documented disease progression prior to receiving pembrolizumab."
      },
      {
        "target": "ROS1",
        "status": "ANY",
        "details": "If ROS1 translocation present, patient must have received an approved ROS1-directed therapy and have documented disease progression prior to receiving pembrolizumab."
      },
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "PD-L1 staining required on newly obtained core or excisional biopsy (new specimen \u226412 weeks prior to consent). At least 4 mm of tumor tissue needed for PD-L1 staining."
      },
      {
        "target": "HBV",
        "status": "NEGATIVE",
        "details": "Known active HBV viremia excluded; HBV DNA must be undetectable. At-risk for HBV reactivation (HBsAg positive or anti-HBc positive) noted in criteria."
      },
      {
        "target": "HCV",
        "status": "NEGATIVE",
        "details": "HCV RNA must be undetectable (no active HCV viremia)."
      },
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "Known HIV infection is excluded."
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "DoR",
        "arm_id": "OG000",
        "arm_title": "Arm I (Pembrolizumab)",
        "value": 98.0,
        "unit": "days",
        "ci_lower": 0.0,
        "ci_upper": 326.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG001",
        "arm_title": "Arm II (Pembrolizumab, Paclitaxel, Carboplatin)",
        "value": 69.0,
        "unit": "days",
        "ci_lower": 0.0,
        "ci_upper": 252.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Arm I (Pembrolizumab)",
        "value": 6.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Arm II (Pembrolizumab, Paclitaxel, Carboplatin)",
        "value": 9.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm I (Pembrolizumab)",
        "value": 8.4,
        "unit": "months",
        "ci_lower": 5.0,
        "ci_upper": 29.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm II (Pembrolizumab, Paclitaxel, Carboplatin)",
        "value": 7.5,
        "unit": "months",
        "ci_lower": 3.9,
        "ci_upper": 25.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm I (Pembrolizumab)",
        "value": 4.3,
        "unit": "months",
        "ci_lower": 1.9,
        "ci_upper": 12.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm II (Pembrolizumab, Paclitaxel, Carboplatin)",
        "value": 5.0,
        "unit": "months",
        "ci_lower": 1.9,
        "ci_upper": 10.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab"
      ],
      "OG001": [
        "Pembrolizumab",
        "Paclitaxel",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "Combo_Chemo_IO",
      "OG002": "OTHER"
    }
  },
  {
    "nct_id": "NCT02614794",
    "brief_title": "A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2016-01-28",
    "completion_date": "2019-09-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Seagen Inc.",
    "url": "https://clinicaltrials.gov/study/NCT02614794",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER2+ defined by in situ hybridization (ISH), immunohistochemistry (IHC), or fluorescence in situ hybridization (FISH) methodology"
      },
      {
        "target": "DPYD",
        "status": "NEGATIVE",
        "details": "Known dihydropyrimidine dehydrogenase (DPD) deficiency excluded"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Tuc+Cap+Tra",
        "value": 7.8,
        "unit": "months",
        "ci_lower": 4.3,
        "ci_upper": 17.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Pbo+Cap+Tra",
        "value": 5.6,
        "unit": "months",
        "ci_lower": 3.0,
        "ci_upper": 9.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Tuc+Cap+Tra",
        "value": 21.9,
        "unit": "months",
        "ci_lower": 18.3,
        "ci_upper": 31.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Pbo+Cap+Tra",
        "value": 17.4,
        "unit": "months",
        "ci_lower": 13.6,
        "ci_upper": 19.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "tucatinib",
        "capecitabine",
        "trastuzumab"
      ],
      "OG001": [
        "capecitabine",
        "trastuzumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02638051",
    "brief_title": "Local mEHT + TCM Versus Intraperitoneal Chemoinfusion in Treatment of Malignant Ascites: Phase II RCT",
    "status": "COMPLETED",
    "start_date": "2014-01",
    "completion_date": "2014-12",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Galenic Research Institute Ltd",
    "url": "https://clinicaltrials.gov/study/NCT02638051",
    "cancer_types": [
      "OV",
      "CRC",
      "STAD"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Study Group",
        "value": 77.7,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Control Group",
        "value": 63.8,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG001": [
        "Cisplatin",
        "5-fluorouracil"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT02631590",
    "brief_title": "Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma",
    "status": "COMPLETED",
    "start_date": "2016-07-05",
    "completion_date": "2019-10-25",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
    "url": "https://clinicaltrials.gov/study/NCT02631590",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Combination Therapy",
        "value": 6.2,
        "unit": "months",
        "ci_lower": 2.9,
        "ci_upper": 10.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Combination Therapy",
        "value": 13.7,
        "unit": "months",
        "ci_lower": 6.8,
        "ci_upper": 18.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cisplatin",
        "Gemcitabine",
        "Copanlisib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02617589",
    "brief_title": "An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)",
    "status": "COMPLETED",
    "start_date": "2016-03-01",
    "completion_date": "2019-01-17",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT02617589",
    "cancer_types": [
      "GBM"
    ],
    "biomarkers": [
      {
        "target": "MGMT",
        "status": "NEGATIVE",
        "details": "MGMT promoter unmethylated"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Nivolumab + Radiation Therapy",
        "value": 13.4,
        "unit": "Months",
        "ci_lower": 12.62,
        "ci_upper": 14.29,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Temozolomide + Radiation Therapy",
        "value": 14.88,
        "unit": "Months",
        "ci_lower": 13.27,
        "ci_upper": 16.13,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab"
      ],
      "OG001": [
        "Temozolomide"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT02659059",
    "brief_title": "Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2016-02-15",
    "completion_date": "2018-06-22",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT02659059",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IV",
      "IIIB",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Nivolumab+Ipilimumab",
        "value": 41.3,
        "unit": "Percentage of participants",
        "ci_lower": 33.0,
        "ci_upper": 50.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Nivolumab+Ipilimumab",
        "value": 14.9,
        "unit": "Percentage of participants",
        "ci_lower": 8.9,
        "ci_upper": 22.8,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab",
        "Ipilimumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO"
    }
  },
  {
    "nct_id": "NCT02632409",
    "brief_title": "An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2016-03-22",
    "completion_date": "2020-07-17",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT02632409",
    "cancer_types": [
      "BLCA"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Placebo",
        "value": 10.84,
        "unit": "Months",
        "ci_lower": 8.25,
        "ci_upper": 13.86,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Nivolumab",
        "value": 20.76,
        "unit": "Months",
        "ci_lower": 16.49,
        "ci_upper": 27.63,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Placebo",
        "value": 8.41,
        "unit": "Months",
        "ci_lower": 5.59,
        "ci_upper": 21.19,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Nivolumab",
        "value": null,
        "unit": "Months",
        "ci_lower": 22.01,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG001": [
        "Nivolumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Placebo",
      "OG001": "IO"
    }
  },
  {
    "nct_id": "NCT02625623",
    "brief_title": "Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)",
    "status": "COMPLETED",
    "start_date": "2015-12-28",
    "completion_date": "2017-09-14",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "EMD Serono Research & Development Institute, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT02625623",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT",
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Physician Choice Chemotherapy + Best Supportive Care (BSC)",
        "value": 5.0,
        "unit": "months",
        "ci_lower": 4.5,
        "ci_upper": 6.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Avelumab + BSC",
        "value": 4.6,
        "unit": "months",
        "ci_lower": 3.6,
        "ci_upper": 5.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Physician Choice Chemotherapy + Best Supportive Care (BSC)",
        "value": 2.7,
        "unit": "months",
        "ci_lower": 1.81,
        "ci_upper": 2.83,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Avelumab + BSC",
        "value": 1.4,
        "unit": "months",
        "ci_lower": 1.38,
        "ci_upper": 1.45,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Paclitaxel"
      ],
      "OG001": [
        "Avelumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "IO"
    }
  },
  {
    "nct_id": "NCT02668666",
    "brief_title": "Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2017-02-01",
    "completion_date": "2023-07-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Oana Danciu, MD",
    "url": "https://clinicaltrials.gov/study/NCT02668666",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "ER >1% (by IHC)"
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": "PR >1% (by IHC)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-negative defined as IHC 0/1+ or IHC 2+ with negative in situ hybridization (e.g., FISH, CISH, SISH, DISH) on most recent biopsy"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Investigational Treatment",
        "value": 9.13,
        "unit": "Months",
        "ci_lower": 5.91,
        "ci_upper": 18.96,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Investigational Treatment",
        "value": 75.63,
        "unit": "Percentage of participants",
        "ci_lower": 60.28,
        "ci_upper": 85.72,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Palbociclib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02667587",
    "brief_title": "An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)",
    "status": "COMPLETED",
    "start_date": "2016-05-09",
    "completion_date": "2020-12-22",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT02667587",
    "cancer_types": [
      "GBM"
    ],
    "biomarkers": [
      {
        "target": "MGMT",
        "status": "POSITIVE",
        "details": "MGMT promoter methylation required; trial also allows indeterminate MGMT methylation results"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Radiotherapy, Temozolomide Plus Nivolumab",
        "value": 10.64,
        "unit": "Months",
        "ci_lower": 8.9,
        "ci_upper": 11.79,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Radiotherapy, Temozolomide Plus Placebo",
        "value": 10.32,
        "unit": "Months",
        "ci_lower": 9.69,
        "ci_upper": 12.45,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Radiotherapy, Temozolomide Plus Nivolumab",
        "value": 28.91,
        "unit": "Months",
        "ci_lower": 24.38,
        "ci_upper": 31.57,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Radiotherapy, Temozolomide Plus Placebo",
        "value": 32.07,
        "unit": "Months",
        "ci_lower": 29.37,
        "ci_upper": 33.77,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Radiotherapy, Temozolomide Plus Nivolumab",
        "value": 31.34,
        "unit": "Months",
        "ci_lower": 28.62,
        "ci_upper": 34.76,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Radiotherapy, Temozolomide Plus Placebo",
        "value": 32.99,
        "unit": "Months",
        "ci_lower": 31.01,
        "ci_upper": 35.09,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Temozolomide",
        "Nivolumab"
      ],
      "OG001": [
        "Temozolomide"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT02657434",
    "brief_title": "A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)",
    "status": "COMPLETED",
    "start_date": "2016-04-30",
    "completion_date": "2019-07-18",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT02657434",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "sensitizing EGFR mutation (no sensitizing EGFR mutations allowed); testing required if unknown"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "ALK fusion oncogene (no ALK fusions allowed); testing required if unknown"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm B (Carboplatin or Cisplatin + Pemetrexed)",
        "value": 5.2,
        "unit": "Months",
        "ci_lower": 4.3,
        "ci_upper": 5.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed",
        "value": 7.7,
        "unit": "Months",
        "ci_lower": 6.7,
        "ci_upper": 8.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm B (Carboplatin or Cisplatin + Pemetrexed)",
        "value": 13.6,
        "unit": "Months",
        "ci_lower": 11.0,
        "ci_upper": 15.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed",
        "value": 17.5,
        "unit": "Months",
        "ci_lower": 13.2,
        "ci_upper": 19.6,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Carboplatin",
        "Cisplatin",
        "Pemetrexed"
      ],
      "OG001": [
        "Atezolizumab",
        "Carboplatin",
        "Cisplatin",
        "Pemetrexed"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT02659514",
    "brief_title": "Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2016-02-22",
    "completion_date": "2020-03-11",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Spectrum Pharmaceuticals, Inc",
    "url": "https://clinicaltrials.gov/study/NCT02659514",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER2 overexpression or gene amplification"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "IV"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort 1: Poziotinib 24 mg",
        "value": 30.0,
        "unit": "percentage of participants",
        "ci_lower": 14.7,
        "ci_upper": 49.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Cohort 2: Poziotinib 16 mg",
        "value": 30.0,
        "unit": "percentage of participants",
        "ci_lower": 13.8,
        "ci_upper": 50.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1: Poziotinib 24 mg",
        "value": 4.1,
        "unit": "months",
        "ci_lower": 1.5,
        "ci_upper": 5.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort 2: Poziotinib 16 mg",
        "value": 4.9,
        "unit": "months",
        "ci_lower": 1.8,
        "ci_upper": 7.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Poziotinib"
      ],
      "OG001": [
        "Poziotinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT02651987",
    "brief_title": "Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel\u00ae 120 mg",
    "status": "COMPLETED",
    "start_date": "2015-12-15",
    "completion_date": "2019-10-16",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Ipsen",
    "url": "https://clinicaltrials.gov/study/NCT02651987",
    "cancer_types": [
      "PAAD",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "SSTR2",
        "status": "POSITIVE",
        "details": "Positive somatostatin receptor type 2 expression"
      },
      {
        "target": "Ki67",
        "status": "LOW",
        "details": "Proliferation index Ki67 \u226420% (grade 1 or 2)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "PanNET Cohort",
        "value": 5.6,
        "unit": "months",
        "ci_lower": 5.5,
        "ci_upper": 8.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Midgut NET Cohort",
        "value": 8.3,
        "unit": "months",
        "ci_lower": 5.6,
        "ci_upper": 11.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Lanreotide autogel 120 mg"
      ],
      "OG001": [
        "Lanreotide autogel 120 mg"
      ],
      "OG002": [
        "Lanreotide autogel 120 mg"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER",
      "OG002": "OTHER"
    }
  },
  {
    "nct_id": "NCT02631876",
    "brief_title": "A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer",
    "status": "COMPLETED",
    "start_date": "2016-03-02",
    "completion_date": "2019-01",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "ImmunoGen, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT02631876",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "FOLR1",
        "status": "POSITIVE",
        "details": "Folate receptor alpha (FR\u03b1) positive tumor expression per protocol"
      }
    ],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Mirvetuximab Soravtansine",
        "value": 4.14,
        "unit": "months",
        "ci_lower": 3.75,
        "ci_upper": 4.53,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Investigator's Choice (IC) Chemotherapy",
        "value": 4.44,
        "unit": "months",
        "ci_lower": 2.83,
        "ci_upper": 5.59,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Mirvetuximab Soravtansine",
        "value": 15.57,
        "unit": "months",
        "ci_lower": 12.85,
        "ci_upper": 18.04,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Investigator's Choice (IC) Chemotherapy",
        "value": 13.93,
        "unit": "months",
        "ci_lower": 11.4,
        "ci_upper": 18.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Mirvetuximab soravtansine"
      ],
      "OG001": [
        "Paclitaxel",
        "Topotecan",
        "Pegylated liposomal doxorubicin"
      ]
    },
    "treatment_class_map": {
      "OG000": "ADC",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT02639546",
    "brief_title": "Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2016-05-20",
    "completion_date": "2021-07-21",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT02639546",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "RAS",
        "status": "ANY",
        "details": "Known or expected involvement of the RAS/RAF/MEK/ERK signaling pathway (e.g., activating mutations or other alterations)"
      },
      {
        "target": "RAF",
        "status": "ANY",
        "details": "Known or expected involvement of the RAS/RAF/MEK/ERK signaling pathway (e.g., activating mutations or other alterations)"
      },
      {
        "target": "MEK",
        "status": "ANY",
        "details": "Known or expected involvement of the RAS/RAF/MEK/ERK signaling pathway (e.g., activating mutations or other alterations)"
      },
      {
        "target": "ERK",
        "status": "ANY",
        "details": "Known or expected involvement of the RAS/RAF/MEK/ERK signaling pathway (e.g., activating mutations or other alterations)"
      },
      {
        "target": "NF1",
        "status": "ANY",
        "details": "NF1-associated tumors (e.g., plexiform neurofibroma) or RASopathy-associated tumors qualify"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Neuroblastoma",
        "value": 1.3,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cobimetinib"
      ],
      "OG001": [
        "Cobimetinib"
      ],
      "OG002": [
        "Cobimetinib"
      ],
      "OG003": [
        "Cobimetinib"
      ],
      "OG004": [
        "Cobimetinib"
      ],
      "OG005": [
        "Cobimetinib"
      ],
      "OG006": [
        "Cobimetinib"
      ],
      "OG007": [
        "Cobimetinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other",
      "OG004": "Targeted_Other",
      "OG005": "Targeted_Other",
      "OG006": "Targeted_Other",
      "OG007": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02657889",
    "brief_title": "Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer",
    "status": "COMPLETED",
    "start_date": "2016-04-15",
    "completion_date": "2018-05-14",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Tesaro, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT02657889",
    "cancer_types": [
      "BRCA",
      "OV"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "Required for triple-negative breast cancer (breast cohort)"
      },
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "Required for triple-negative breast cancer (breast cohort)"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "Required for triple-negative breast cancer (breast cohort)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 2 OC: Niraparib 200mg + Pembrolizumab",
        "value": 15.1,
        "unit": "Percentage of participants",
        "ci_lower": 7.7,
        "ci_upper": 25.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Phase 2 TNBC: Niraparib 200mg + Pembrolizumab",
        "value": 18.2,
        "unit": "Percentage of participants",
        "ci_lower": 10.2,
        "ci_upper": 28.9,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "niraparib",
        "pembrolizumab"
      ],
      "OG001": [
        "niraparib",
        "pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT02616393",
    "brief_title": "Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases",
    "status": "COMPLETED",
    "start_date": "2015-11",
    "completion_date": "2018-04-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Kadmon Corporation, LLC",
    "url": "https://clinicaltrials.gov/study/NCT02616393",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "Activating EGFR mutation required (e.g., exon 19 deletion or L858R). T790M may be present/treated with osimertinib (allowed)."
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort A (BM)",
        "value": 15.4,
        "unit": "Percentage of participants (%)",
        "ci_lower": 2.0,
        "ci_upper": 45.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Cohort C (BM-IP)",
        "value": 100.0,
        "unit": "Percentage of participants (%)",
        "ci_lower": 29.0,
        "ci_upper": 100.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Overall BM",
        "value": 31.3,
        "unit": "Percentage of participants (%)",
        "ci_lower": 11.0,
        "ci_upper": 59.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort A (BM)",
        "value": 0.0,
        "unit": "Percentage of participants (%)",
        "ci_lower": 0.0,
        "ci_upper": 25.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Cohort C (BM-IP)",
        "value": 100.0,
        "unit": "Percentage of participants (%)",
        "ci_lower": 29.0,
        "ci_upper": 100.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Overall BM",
        "value": 18.8,
        "unit": "Percentage of participants (%)",
        "ci_lower": 4.0,
        "ci_upper": 46.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort A (BM)",
        "value": 15.4,
        "unit": "Percentage of participants (%)",
        "ci_lower": 2.0,
        "ci_upper": 45.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Cohort C (BM-IP)",
        "value": 100.0,
        "unit": "Percentage of participants (%)",
        "ci_lower": 29.0,
        "ci_upper": 100.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Overall BM",
        "value": 31.3,
        "unit": "Percentage of participants (%)",
        "ci_lower": 11.0,
        "ci_upper": 59.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Tesevatinib"
      ],
      "OG001": [
        "Tesevatinib"
      ],
      "OG002": [
        "Tesevatinib"
      ],
      "OG003": [
        "Tesevatinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI",
      "OG002": "TKI",
      "OG003": "TKI"
    }
  },
  {
    "nct_id": "NCT02674061",
    "brief_title": "Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)",
    "status": "COMPLETED",
    "start_date": "2016-02-25",
    "completion_date": "2019-09-18",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT02674061",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort A: Pembrolizumab",
        "value": 8.1,
        "unit": "Percentage of participants",
        "ci_lower": 5.2,
        "ci_upper": 11.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Cohort B: Pembrolizumab",
        "value": 9.9,
        "unit": "Percentage of participants",
        "ci_lower": 4.6,
        "ci_upper": 17.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort A: Pembrolizumab",
        "value": 2.1,
        "unit": "Months",
        "ci_lower": 2.1,
        "ci_upper": 2.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort B: Pembrolizumab",
        "value": 2.1,
        "unit": "Months",
        "ci_lower": 2.1,
        "ci_upper": 2.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cohort A: Pembrolizumab",
        "value": 18.7,
        "unit": "Months",
        "ci_lower": 17.0,
        "ci_upper": 22.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cohort B: Pembrolizumab",
        "value": 17.6,
        "unit": "Months",
        "ci_lower": 13.3,
        "ci_upper": 24.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab"
      ],
      "OG001": [
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO"
    }
  },
  {
    "nct_id": "NCT02632045",
    "brief_title": "Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2016-03",
    "completion_date": "2022-01-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Melissa K Accordino",
    "url": "https://clinicaltrials.gov/study/NCT02632045",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "IHC \u22651% per ASCO-CAP guidelines"
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": "IHC \u22651% per ASCO-CAP guidelines"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "Negative by ISH or IHC 0/1+; if IHC 2+ then require negative ISH per ASCO-CAP guidelines"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Placebo/Fulvestrant",
        "value": 2.76,
        "unit": "months",
        "ci_lower": 2.66,
        "ci_upper": 3.25,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Ribociclib (LEE-011)/Fulvestrant",
        "value": 5.29,
        "unit": "months",
        "ci_lower": 3.02,
        "ci_upper": 8.12,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Fulvestrant"
      ],
      "OG001": [
        "LEE-011",
        "Fulvestrant"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02671435",
    "brief_title": "A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2016-02-22",
    "completion_date": "2021-10-26",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "MedImmune LLC",
    "url": "https://clinicaltrials.gov/study/NCT02671435",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Exploration Cohort C1A: Monalizumab 750 mg Q2W + Durvalumab 1500 mg Q4W + Cetuximab Q2W",
        "value": 0.0,
        "unit": "Percentage of Participants",
        "ci_lower": 0.0,
        "ci_upper": 10.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Exploration Cohort C1B: Monalizumab 750 mg Q2W + Cetuximab Q2W",
        "value": 0.0,
        "unit": "Percentage of Participants",
        "ci_lower": 0.0,
        "ci_upper": 9.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Monalizumab",
        "Durvalumab"
      ],
      "OG001": [
        "Monalizumab",
        "Durvalumab"
      ],
      "OG002": [
        "Monalizumab",
        "Durvalumab"
      ],
      "OG003": [
        "Monalizumab",
        "Durvalumab"
      ],
      "OG004": [
        "Monalizumab",
        "Durvalumab"
      ],
      "OG005": [
        "Monalizumab",
        "Durvalumab"
      ],
      "OG006": [
        "Monalizumab",
        "Durvalumab"
      ],
      "OG007": [
        "Monalizumab",
        "Durvalumab"
      ],
      "OG008": [
        "Monalizumab",
        "Durvalumab"
      ],
      "OG009": [
        "Monalizumab",
        "Durvalumab",
        "mFOLFOX6",
        "Bevacizumab"
      ],
      "OG010": [
        "Monalizumab",
        "Durvalumab",
        "mFOLFOX6",
        "Cetuximab"
      ],
      "OG011": [
        "Monalizumab",
        "Durvalumab",
        "Cetuximab"
      ],
      "OG012": [
        "Monalizumab",
        "Cetuximab"
      ],
      "OG013": [
        "Monalizumab",
        "Durvalumab",
        "Cetuximab"
      ],
      "OG014": [
        "Monalizumab",
        "Cetuximab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO",
      "OG003": "IO",
      "OG004": "IO",
      "OG005": "IO",
      "OG006": "IO",
      "OG007": "IO",
      "OG008": "IO",
      "OG009": "Combo_Chemo_Targeted",
      "OG010": "Combo_Chemo_Targeted",
      "OG011": "Combo_IO_Targeted",
      "OG012": "Combo_IO_Targeted",
      "OG013": "Combo_IO_Targeted",
      "OG014": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT02661282",
    "brief_title": "Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma",
    "status": "COMPLETED",
    "start_date": "2016-06-01",
    "completion_date": "2022-02-23",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "M.D. Anderson Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT02661282",
    "cancer_types": [
      "GBM"
    ],
    "biomarkers": [
      {
        "target": "CMV",
        "status": "POSITIVE",
        "details": "CMV seropositive (CMV antibody positive)"
      },
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "No known HIV infection (HIV-1/2 antibody negative)"
      },
      {
        "target": "HTLV",
        "status": "NEGATIVE",
        "details": "HTLV1 and/or HTLV2 antibody negative (no HTLV infection)"
      },
      {
        "target": "HBV",
        "status": "NEGATIVE",
        "details": "No active hepatitis B (e.g., HBsAg negative); prior HBV vaccination (anti-HBs positive, HBsAg negative, anti-HBc negative) allowed"
      },
      {
        "target": "HCV",
        "status": "NEGATIVE",
        "details": "No active hepatitis C (HCV RNA not detected)"
      },
      {
        "target": "PREGNANCY",
        "status": "NEGATIVE",
        "details": "Negative urine or serum pregnancy test within 72 hours of enrollment (for females of childbearing potential)"
      }
    ],
    "cancer_stages": [
      "IV",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase II: Recurrent Glioblastoma Dose Level 1 x 10^8",
        "value": 2.5,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Phase II: Newly Diagnosed Dose Level 1 x 10^8",
        "value": 24.0,
        "unit": "weeks",
        "ci_lower": 13.0,
        "ci_upper": 24.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes",
        "Temozolomide"
      ],
      "OG001": [
        "Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes",
        "Temozolomide"
      ],
      "OG002": [
        "Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes",
        "Temozolomide"
      ],
      "OG003": [
        "Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes",
        "Temozolomide"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Combo_Chemo_IO",
      "OG002": "Combo_Chemo_IO",
      "OG003": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT02658890",
    "brief_title": "An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread",
    "status": "COMPLETED",
    "start_date": "2016-04-14",
    "completion_date": "2021-10-26",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT02658890",
    "cancer_types": [
      "SKCM",
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [],
    "arm_drugs": {
      "OG000": [
        "BMS-986205"
      ],
      "OG001": [
        "BMS-986205"
      ],
      "OG002": [
        "BMS-986205"
      ],
      "OG003": [
        "BMS-986205",
        "Nivolumab"
      ],
      "OG004": [
        "BMS-986205",
        "Nivolumab"
      ],
      "OG005": [
        "BMS-986205",
        "Nivolumab"
      ],
      "OG006": [
        "BMS-986205",
        "Nivolumab"
      ],
      "OG007": [
        "BMS-986205",
        "Nivolumab"
      ],
      "OG008": [
        "BMS-986205",
        "Nivolumab"
      ],
      "OG009": [
        "BMS-986205",
        "Nivolumab"
      ],
      "OG010": [
        "BMS-986205",
        "Nivolumab"
      ],
      "OG011": [
        "BMS-986205",
        "Nivolumab"
      ],
      "OG012": [
        "BMS-986205",
        "Nivolumab"
      ],
      "OG013": [
        "BMS-986205",
        "Nivolumab"
      ],
      "OG014": [
        "BMS-986205",
        "Nivolumab"
      ],
      "OG015": [
        "BMS-986205",
        "Nivolumab"
      ],
      "OG016": [
        "BMS-986205",
        "Nivolumab"
      ],
      "OG017": [
        "BMS-986205",
        "Nivolumab"
      ],
      "OG018": [
        "Nivolumab"
      ],
      "OG019": [
        "BMS-986205",
        "Nivolumab"
      ],
      "OG020": [
        "BMS-986205",
        "Nivolumab"
      ],
      "OG021": [
        "BMS-986205",
        "Nivolumab"
      ],
      "OG022": [
        "BMS-986205",
        "Nivolumab"
      ],
      "OG023": [
        "BMS-986205",
        "Nivolumab"
      ],
      "OG024": [
        "BMS-986205",
        "Nivolumab"
      ],
      "OG025": [
        "BMS-986205",
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG026": [
        "Nivolumab"
      ],
      "OG027": [
        "BMS-986205",
        "Nivolumab"
      ],
      "OG028": [
        "Nivolumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Combo_IO_Targeted",
      "OG004": "Combo_IO_Targeted",
      "OG005": "Combo_IO_Targeted",
      "OG006": "Combo_IO_Targeted",
      "OG007": "Combo_IO_Targeted",
      "OG008": "Combo_IO_Targeted",
      "OG009": "Combo_IO_Targeted",
      "OG010": "Combo_IO_Targeted",
      "OG011": "Combo_IO_Targeted",
      "OG012": "Combo_IO_Targeted",
      "OG013": "Combo_IO_Targeted",
      "OG014": "Combo_IO_Targeted",
      "OG015": "Combo_IO_Targeted",
      "OG016": "Combo_IO_Targeted",
      "OG017": "Combo_IO_Targeted",
      "OG018": "IO",
      "OG019": "Combo_IO_Targeted",
      "OG020": "Combo_IO_Targeted",
      "OG021": "Combo_IO_Targeted",
      "OG022": "Combo_IO_Targeted",
      "OG023": "Combo_IO_Targeted",
      "OG024": "Combo_IO_Targeted",
      "OG025": "Combo_IO_Targeted",
      "OG026": "IO",
      "OG027": "Combo_IO_Targeted",
      "OG028": "IO"
    }
  },
  {
    "nct_id": "NCT02660034",
    "brief_title": "The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2016-02-02",
    "completion_date": "2020-09-09",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "BeiGene",
    "url": "https://clinicaltrials.gov/study/NCT02660034",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "BRCA1",
        "status": "POSITIVE",
        "details": "Known deleterious or suspected deleterious germline or somatic BRCA1 mutation; archival or fresh tumor testing by validated diagnostic test"
      },
      {
        "target": "BRCA2",
        "status": "POSITIVE",
        "details": "Known deleterious or suspected deleterious germline or somatic BRCA2 mutation; archival or fresh tumor testing by validated diagnostic test"
      },
      {
        "target": "HRD",
        "status": "POSITIVE",
        "details": "Homologous recombination deficiency (HRD); may be defined by HR pathway mutations or HRD algorithms; archival or fresh tumor testing by validated diagnostic test"
      },
      {
        "target": "MMR",
        "status": "POSITIVE",
        "details": "Mismatch repair deficiency (dMMR) \u2014 tumors known to be mismatch repair deficient"
      },
      {
        "target": "MSI",
        "status": "HIGH",
        "details": "Microsatellite instability-high (MSI-H) (permitted e.g., MSI-H colorectal)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-negative required for gastric/gastroesophageal junction arm (and referenced in excluded tumor types)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [],
    "arm_drugs": {
      "OG000": [
        "Tislelizumab",
        "Pamiparib"
      ],
      "OG001": [
        "Tislelizumab",
        "Pamiparib"
      ],
      "OG002": [
        "Tislelizumab",
        "Pamiparib"
      ],
      "OG003": [
        "Tislelizumab",
        "Pamiparib"
      ],
      "OG004": [
        "Tislelizumab",
        "Pamiparib"
      ],
      "OG005": [
        "Tislelizumab",
        "Pamiparib"
      ],
      "OG006": [
        "Tislelizumab",
        "Pamiparib"
      ],
      "OG007": [
        "Tislelizumab",
        "Pamiparib"
      ],
      "OG008": [
        "Tislelizumab",
        "Pamiparib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted",
      "OG002": "Combo_IO_Targeted",
      "OG003": "Combo_IO_Targeted",
      "OG004": "Combo_IO_Targeted",
      "OG005": "Combo_IO_Targeted",
      "OG006": "Combo_IO_Targeted",
      "OG007": "Combo_IO_Targeted",
      "OG008": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT02743221",
    "brief_title": "A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy",
    "status": "COMPLETED",
    "start_date": "2016-04-29",
    "completion_date": "2018-01-15",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Institut de Recherches Internationales Servier",
    "url": "https://clinicaltrials.gov/study/NCT02743221",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "RAS",
        "status": "ANY",
        "details": "RAS status must be determined (mutant or wild)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Trifluridine/Tipiracil + Bevacizumab",
        "value": 9.2,
        "unit": "months",
        "ci_lower": 7.6,
        "ci_upper": 11.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Capecitabine + Bevacizumab",
        "value": 7.8,
        "unit": "months",
        "ci_lower": 5.5,
        "ci_upper": 10.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Trifluridine/Tipiracil + Bevacizumab",
        "value": 18.0,
        "unit": "months",
        "ci_lower": 15.18,
        "ci_upper": 19.48,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Capecitabine + Bevacizumab",
        "value": 16.2,
        "unit": "months",
        "ci_lower": 13.07,
        "ci_upper": 17.67,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Trifluridine/tipiracil",
        "Bevacizumab"
      ],
      "OG001": [
        "Capecitabine",
        "Bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02703714",
    "brief_title": "Pembrolizumab and GM-CSF in Biliary Cancer",
    "status": "COMPLETED",
    "start_date": "2016-05-06",
    "completion_date": "2020-12-31",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Robin Kate Kelley",
    "url": "https://clinicaltrials.gov/study/NCT02703714",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab and GM-CSF",
        "value": 0.12,
        "unit": "proportion of participants",
        "ci_lower": 0.04,
        "ci_upper": 0.26,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab and GM-CSF",
        "value": 0.26,
        "unit": "proportion of participants",
        "ci_lower": 0.14,
        "ci_upper": 0.42,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab and GM-CSF",
        "value": 393.0,
        "unit": "days",
        "ci_lower": 243.0,
        "ci_upper": 573.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Sargramostim"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO"
    }
  },
  {
    "nct_id": "NCT02711553",
    "brief_title": "A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2016-05-19",
    "completion_date": "2018-02-16",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT02711553",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT",
      "UNRESECTABLE",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "8 mg/kg Ramucirumab + 25 mg/m\u00178 Cisplatin + 1000 mg/m\u00178 Gemcitabine",
        "value": 6.47,
        "unit": "Months",
        "ci_lower": 3.68,
        "ci_upper": 8.51,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "80 mg Merestinib + 25 mg/m\u00178 Cisplatin + 1000 mg/m\u00178 Gemcitabine",
        "value": 6.97,
        "unit": "Months",
        "ci_lower": 4.34,
        "ci_upper": 9.79,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Pooled Placebo",
        "value": 6.64,
        "unit": "Months",
        "ci_lower": 4.11,
        "ci_upper": 9.72,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "8 mg/kg Ramucirumab + 25 mg/m\u00178 Cisplatin + 1000 mg/m\u00178 Gemcitabine",
        "value": 10.45,
        "unit": "Months",
        "ci_lower": 8.48,
        "ci_upper": 11.76,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "80 mg Merestinib + 25 mg/m\u00178 Cisplatin + 1000 mg/m\u00178 Gemcitabine",
        "value": 14.03,
        "unit": "Months",
        "ci_lower": 11.96,
        "ci_upper": 16.36,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Pooled Placebo",
        "value": 13.04,
        "unit": "Months",
        "ci_lower": 11.4,
        "ci_upper": 15.31,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ramucirumab",
        "Cisplatin",
        "Gemcitabine"
      ],
      "OG001": [
        "Merestinib",
        "Cisplatin",
        "Gemcitabine"
      ],
      "OG002": [
        "Cisplatin",
        "Gemcitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_TKI_Chemo",
      "OG002": "Chemo"
    }
  },
  {
    "nct_id": "NCT02713529",
    "brief_title": "Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer",
    "status": "COMPLETED",
    "start_date": "2016-04-14",
    "completion_date": "2019-01-02",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AmMax Bio, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT02713529",
    "cancer_types": [
      "PAAD",
      "CRC",
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Part 1: AMG 820 + Pem",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 0.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Part 2, Group 1: CRC MMR-proficient",
        "value": 4.9,
        "unit": "percentage of participants",
        "ci_lower": 0.6,
        "ci_upper": 16.53,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Part 2, Group 2: Pancreatic Cancer",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 0.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Part 2, Group 3: NSCLC PD-L1 Low, Na\u000efve",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 0.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Part 2, Group 4a: Refractory / Relapsing NSCLC PD-L1 Low",
        "value": 5.3,
        "unit": "percentage of participants",
        "ci_lower": 0.13,
        "ci_upper": 26.03,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "Part 2, Group 4b: Refractory/Relapsing NSCLC PD-L1 High",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 0.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "AMG 820",
        "pembrolizumab"
      ],
      "OG001": [
        "AMG 820",
        "pembrolizumab"
      ],
      "OG002": [
        "AMG 820",
        "pembrolizumab"
      ],
      "OG003": [
        "AMG 820",
        "pembrolizumab"
      ],
      "OG004": [
        "AMG 820",
        "pembrolizumab"
      ],
      "OG005": [
        "AMG 820",
        "pembrolizumab"
      ],
      "OG006": [
        "AMG 820",
        "pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted",
      "OG002": "Combo_IO_Targeted",
      "OG003": "Combo_IO_Targeted",
      "OG004": "Combo_IO_Targeted",
      "OG005": "Combo_IO_Targeted",
      "OG006": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT02737501",
    "brief_title": "ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants",
    "status": "COMPLETED",
    "start_date": "2016-05-26",
    "completion_date": "2020-07-28",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Ariad Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT02737501",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "ALK",
        "status": "POSITIVE",
        "details": "rearrangement"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Randomized Phase: Brigatinib 90 mg QD/180 QD",
        "value": 24.016,
        "unit": "Months",
        "ci_lower": 18.46,
        "ci_upper": 43.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Randomized Phase: Crizotinib 250 mg BID",
        "value": 11.072,
        "unit": "Months",
        "ci_lower": 9.13,
        "ci_upper": 13.01,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Crossover Phase: Brigatinib 90 mg QD/180 mg QD",
        "value": 16.821,
        "unit": "Months",
        "ci_lower": 10.12,
        "ci_upper": 23.85,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Randomized Phase: Brigatinib 90 mg QD/180 QD",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Randomized Phase: Crizotinib 250 mg BID",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Crossover Phase: Brigatinib 90 mg QD/180 mg QD",
        "value": 35.023,
        "unit": "Months",
        "ci_lower": 30.42,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Brigatinib"
      ],
      "OG001": [
        "Crizotinib"
      ],
      "OG002": [
        "Brigatinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI",
      "OG002": "TKI"
    }
  },
  {
    "nct_id": "NCT02684006",
    "brief_title": "A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)",
    "status": "COMPLETED",
    "start_date": "2016-03-23",
    "completion_date": "2023-08-31",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT02684006",
    "cancer_types": [
      "KIRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Avelumab + Axitinib",
        "value": 13.8,
        "unit": "Months",
        "ci_lower": 11.1,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Sunitinib",
        "value": 7.2,
        "unit": "Months",
        "ci_lower": 5.7,
        "ci_upper": 9.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Avelumab + Axitinib",
        "value": 43.2,
        "unit": "Months",
        "ci_lower": 36.5,
        "ci_upper": 51.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Sunitinib",
        "value": 36.2,
        "unit": "Months",
        "ci_lower": 29.8,
        "ci_upper": 44.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Avelumab (MSB0010718C)",
        "Axitinib (AG-013736)"
      ],
      "OG001": [
        "Sunitinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_IO",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT02735980",
    "brief_title": "A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2016-05-11",
    "completion_date": "2017-07-31",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT02735980",
    "cancer_types": [
      "SCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Prexasertib (Platinum Sensitive Disease)",
        "value": 5.2,
        "unit": "percentage of participants",
        "ci_lower": 0.7,
        "ci_upper": 9.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Prexasertib (Platinum Resistant Disease)",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 3.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Prexasertib Exploratory Addendum (Platinum Sensitive Disease)",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 14.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Prexasertib (Platinum Sensitive Disease)",
        "value": 1.41,
        "unit": "months",
        "ci_lower": 1.31,
        "ci_upper": 1.64,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Prexasertib (Platinum Resistant Disease)",
        "value": 1.36,
        "unit": "months",
        "ci_lower": 1.25,
        "ci_upper": 1.45,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Prexasertib Exploratory Addendum (Platinum Sensitive Disease)",
        "value": 1.58,
        "unit": "months",
        "ci_lower": 1.38,
        "ci_upper": 3.12,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1 Prexasertib (Platinum Sensitive Disease)",
        "value": 5.42,
        "unit": "months",
        "ci_lower": 3.75,
        "ci_upper": 8.51,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cohort 2 Prexasertib (Platinum Resistant Disease)",
        "value": 3.15,
        "unit": "months",
        "ci_lower": 2.27,
        "ci_upper": 5.52,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Cohort 3 Prexasertib Exploratory(Platinum Sensitive Disease)",
        "value": 7.26,
        "unit": "months",
        "ci_lower": 2.0,
        "ci_upper": 9.49,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Prexasertib"
      ],
      "OG001": [
        "Prexasertib"
      ],
      "OG002": [
        "Prexasertib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02753127",
    "brief_title": "A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2016-06",
    "completion_date": "2020-04-28",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sumitomo Pharma America, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT02753127",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Napabucasin + FOLFIRI \u00b1 Bevacizumab",
        "value": 14.29,
        "unit": "months",
        "ci_lower": 13.34,
        "ci_upper": 15.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "FOLFIRI \u00b1 Bevacizumab",
        "value": 13.83,
        "unit": "months",
        "ci_lower": 12.42,
        "ci_upper": 15.28,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Napabucasin + FOLFIRI \u00b1 Bevacizumab",
        "value": 13.17,
        "unit": "months",
        "ci_lower": 11.3,
        "ci_upper": 15.31,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "FOLFIRI \u00b1 Bevacizumab",
        "value": 12.12,
        "unit": "months",
        "ci_lower": 11.24,
        "ci_upper": 14.06,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Napabucasin",
        "Irinotecan",
        "Fluorouracil",
        "Leucovorin",
        "Bevacizumab"
      ],
      "OG001": [
        "Irinotecan",
        "Fluorouracil",
        "Leucovorin",
        "Bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02713386",
    "brief_title": "Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
    "status": "COMPLETED",
    "start_date": "2016-11-14",
    "completion_date": "2021-09-30",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "NRG Oncology",
    "url": "https://clinicaltrials.gov/study/NCT02713386",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "BRCA1",
        "status": "ANY",
        "details": "Comprehensive BRCA1 sequencing including assessment of gene rearrangements; germline testing reports accepted (positive, VUS, or negative)"
      },
      {
        "target": "BRCA2",
        "status": "ANY",
        "details": "Comprehensive BRCA2 sequencing including assessment of gene rearrangements; germline testing reports accepted (positive, VUS, or negative)"
      }
    ],
    "cancer_stages": [
      "III",
      "IV"
    ],
    "line_of_therapy": "NEOADJUVANT",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase 2 - Arm I (Paclitaxel and Carboplatin)",
        "value": 11.63,
        "unit": "months",
        "ci_lower": 10.32,
        "ci_upper": 14.39,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Phase 2 - Arm II (Ruxolitinib, Paclitaxel, and Carboplatin)",
        "value": 14.55,
        "unit": "months",
        "ci_lower": 11.89,
        "ci_upper": 16.92,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Carboplatin",
        "Paclitaxel",
        "Ruxolitinib Phosphate"
      ],
      "OG001": [
        "Carboplatin",
        "Paclitaxel",
        "Ruxolitinib Phosphate"
      ],
      "OG002": [
        "Carboplatin",
        "Paclitaxel",
        "Ruxolitinib Phosphate"
      ],
      "OG003": [
        "Carboplatin",
        "Paclitaxel",
        "Ruxolitinib Phosphate"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted",
      "OG003": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02743494",
    "brief_title": "An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer",
    "status": "COMPLETED",
    "start_date": "2016-07-14",
    "completion_date": "2020-05-12",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT02743494",
    "cancer_types": [
      "OTHER",
      "STAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "II",
      "III"
    ],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Nivolumab",
        "value": 22.41,
        "unit": "Months",
        "ci_lower": 16.62,
        "ci_upper": 34.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 11.04,
        "unit": "Months",
        "ci_lower": 8.34,
        "ci_upper": 14.32,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Nivolumab",
        "value": 51.71,
        "unit": "Months",
        "ci_lower": 41.03,
        "ci_upper": 61.63,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 35.25,
        "unit": "Months",
        "ci_lower": 30.72,
        "ci_upper": 48.76,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT02725268",
    "brief_title": "A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer",
    "status": "COMPLETED",
    "start_date": "2016-04-01",
    "completion_date": "2019-07-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Millennium Pharmaceuticals, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT02725268",
    "cancer_types": [
      "UCEC"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Exclusion: participants with endometrioid histology and histologically confirmed expression of estrogen receptor who have not received prior endocrine therapy and for whom endocrine therapy is currently indicated"
      },
      {
        "target": "PGR",
        "status": "POSITIVE",
        "details": "Exclusion: participants with endometrioid histology and histologically confirmed expression of progesterone receptor who have not received prior endocrine therapy and for whom endocrine therapy is currently indicated"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Paclitaxel 80 mg/m^2",
        "value": 3.7,
        "unit": "months",
        "ci_lower": 2.3,
        "ci_upper": 4.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg",
        "value": 5.6,
        "unit": "months",
        "ci_lower": 3.8,
        "ci_upper": 6.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Sapanisertib 30 mg",
        "value": 2.1,
        "unit": "months",
        "ci_lower": 1.9,
        "ci_upper": 3.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Sapanisertib 4 mg + MLN1117 200 mg",
        "value": 2.0,
        "unit": "months",
        "ci_lower": 1.5,
        "ci_upper": 3.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Paclitaxel 80 mg/m^2",
        "value": 12.7,
        "unit": "months",
        "ci_lower": 9.8,
        "ci_upper": 19.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg",
        "value": 13.8,
        "unit": "months",
        "ci_lower": 9.9,
        "ci_upper": 19.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Sapanisertib 30 mg",
        "value": 12.5,
        "unit": "months",
        "ci_lower": 9.0,
        "ci_upper": 15.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Sapanisertib 4 mg + MLN1117 200 mg",
        "value": 11.1,
        "unit": "months",
        "ci_lower": 2.7,
        "ci_upper": 17.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Paclitaxel"
      ],
      "OG001": [
        "Paclitaxel",
        "Sapanisertib"
      ],
      "OG002": [
        "Sapanisertib"
      ],
      "OG003": [
        "Sapanisertib",
        "MLN1117"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02675231",
    "brief_title": "A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2016-05-23",
    "completion_date": "2019-04-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT02675231",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HR",
        "status": "POSITIVE",
        "details": "Hormone receptor positive (ER and/or PR)"
      },
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": null
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant",
        "value": 8.3,
        "unit": "Months",
        "ci_lower": 5.9,
        "ci_upper": 12.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "150 mg Abemaciclib + 8 mg/kg Trastuzumab",
        "value": 5.7,
        "unit": "Months",
        "ci_lower": 4.2,
        "ci_upper": 7.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "8 mg/kg Trastuzumab + Standard of Care Chemotherapy",
        "value": 5.7,
        "unit": "Months",
        "ci_lower": 5.4,
        "ci_upper": 6.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Abemaciclib",
        "Trastuzumab",
        "Fulvestrant"
      ],
      "OG001": [
        "Abemaciclib",
        "Trastuzumab"
      ],
      "OG002": [
        "Trastuzumab",
        "Standard of Care Single Agent Chemotherapy"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02713373",
    "brief_title": "Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery",
    "status": "COMPLETED",
    "start_date": "2016-08-05",
    "completion_date": "2020-07-28",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Roswell Park Cancer Institute",
    "url": "https://clinicaltrials.gov/study/NCT02713373",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "RAS wild-type required; KRAS mutation must be absent. KRAS testing must be completed (conflicting results may be adjudicated by PI)."
      },
      {
        "target": "NRAS",
        "status": "NEGATIVE",
        "details": "RAS wild-type required; NRAS mutation must be absent. Full KRAS and NRAS testing strongly advised; presence of known NRAS mutation is exclusionary."
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm I (Cetuximab and Pembrolizumab)",
        "value": 31.0,
        "unit": "percentage of PFS at 6 months",
        "ci_lower": 20.0,
        "ci_upper": 43.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Arm I (Cetuximab and Pembrolizumab)",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cetuximab",
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT02741570",
    "brief_title": "Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",
    "status": "COMPLETED",
    "start_date": "2016-10-05",
    "completion_date": "2021-05-10",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT02741570",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Tumor tissue required for PD-L1 expression testing"
      },
      {
        "target": "p16",
        "status": "ANY",
        "details": "For oropharyngeal cancer: results from testing of HPV p16 status"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Nivolumab + Ipilimumab",
        "value": 17.58,
        "unit": "Months",
        "ci_lower": 13.77,
        "ci_upper": 21.98,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "EXTREME Regimen",
        "value": 14.59,
        "unit": "Months",
        "ci_lower": 12.32,
        "ci_upper": 15.97,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Nivolumab + Ipilimumab",
        "value": 3.29,
        "unit": "Months",
        "ci_lower": 2.83,
        "ci_upper": 4.17,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "EXTREME Regimen",
        "value": 6.77,
        "unit": "Months",
        "ci_lower": 5.78,
        "ci_upper": 7.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Nivolumab + Ipilimumab",
        "value": 5.39,
        "unit": "Months",
        "ci_lower": 3.09,
        "ci_upper": 6.93,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "EXTREME Regimen",
        "value": 6.97,
        "unit": "Months",
        "ci_lower": 5.78,
        "ci_upper": 8.67,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG001": [
        "Cetuximab/Erbitux",
        "Cisplatin/Platinol",
        "Carboplatin/Paraplatin",
        "Fluorouracil/Adrucil"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02747004",
    "brief_title": "A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2016-09-14",
    "completion_date": "2018-06-15",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT02747004",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HR",
        "status": "POSITIVE",
        "details": "Hormone receptor positive (ER and/or PR) \u2014 HR+"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": null
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "150mg Abemaciclib + 20mg Tamoxifen",
        "value": 9.07,
        "unit": "Months",
        "ci_lower": 6.9,
        "ci_upper": 10.95,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "150mg Abemaciclib",
        "value": 6.48,
        "unit": "Months",
        "ci_lower": 4.77,
        "ci_upper": 9.21,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "200mg Abemaciclib + 2mg Prophylactic Loperamide",
        "value": 7.43,
        "unit": "Months",
        "ci_lower": 5.42,
        "ci_upper": 9.17,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Abemaciclib",
        "Tamoxifen"
      ],
      "OG001": [
        "Abemaciclib"
      ],
      "OG002": [
        "Abemaciclib",
        "Prophylactic Loperamide"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02684058",
    "brief_title": "Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors",
    "status": "COMPLETED",
    "start_date": "2017-12-28",
    "completion_date": "2021-08-23",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT02684058",
    "cancer_types": [
      "LGG",
      "GBM"
    ],
    "biomarkers": [
      {
        "target": "BRAF",
        "status": "POSITIVE",
        "details": "V600 mutation"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "LGG Cohort: Dabrafenib and Trametinib",
        "value": 46.6,
        "unit": "Percentage of participants",
        "ci_lower": 34.8,
        "ci_upper": 58.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "LGG Cohort: Carboplatin and Vincristine",
        "value": 10.8,
        "unit": "Percentage of participants",
        "ci_lower": 3.0,
        "ci_upper": 25.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "LGG Cohort: Dabrafenib and Trametinib",
        "value": 20.1,
        "unit": "Months",
        "ci_lower": 12.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "LGG Cohort: Carboplatin and Vincristine",
        "value": 7.4,
        "unit": "Months",
        "ci_lower": 3.6,
        "ci_upper": 11.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "LGG Cohort: Dabrafenib and Trametinib",
        "value": 24.9,
        "unit": "Months",
        "ci_lower": 12.9,
        "ci_upper": 31.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "LGG Cohort: Carboplatin and Vincristine",
        "value": 7.2,
        "unit": "Months",
        "ci_lower": 2.8,
        "ci_upper": 11.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "LGG Cohort: Dabrafenib and Trametinib",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "LGG Cohort: Carboplatin and Vincristine",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Dabrafenib",
        "trametinib"
      ],
      "OG001": [
        "Carboplatin",
        "Vincristine"
      ],
      "OG002": [
        "Dabrafenib",
        "trametinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Targeted",
      "OG001": "Chemo",
      "OG002": "Combo_TKI_Targeted"
    }
  },
  {
    "nct_id": "NCT02708680",
    "brief_title": "Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In",
    "status": "COMPLETED",
    "start_date": "2016-05",
    "completion_date": "2021-03-31",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Syndax Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT02708680",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "Part of 'triple negative' (ER negative)"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "Part of 'triple negative' (PR negative)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "Part of 'triple negative' (HER2 negative)"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase 2 Expansion: Entinostat Plus Atezolizumab",
        "value": 1.68,
        "unit": "months",
        "ci_lower": 1.41,
        "ci_upper": 3.09,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Phase 2 Expansion: Placebo Plus Atezolizumab",
        "value": 1.51,
        "unit": "months",
        "ci_lower": 1.41,
        "ci_upper": 2.43,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Phase 2 Expansion: Entinostat Plus Atezolizumab",
        "value": 12.25,
        "unit": "months",
        "ci_lower": 5.49,
        "ci_upper": 21.16,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Phase 2 Expansion: Placebo Plus Atezolizumab",
        "value": 11.2,
        "unit": "months",
        "ci_lower": 7.43,
        "ci_upper": 15.77,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Entinostat",
        "Atezolizumab"
      ],
      "OG001": [
        "Atezolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "IO"
    }
  },
  {
    "nct_id": "NCT02734004",
    "brief_title": "A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2016-03-17",
    "completion_date": "2021-09-17",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT02734004",
    "cancer_types": [
      "OV",
      "BRCA",
      "SCLC"
    ],
    "biomarkers": [
      {
        "target": "BRCA",
        "status": "POSITIVE",
        "details": "germline BRCA mutation (gBRCAm); applies to metastatic breast cancer module and ovarian cancer modules 3 and 5"
      },
      {
        "target": "BRCA",
        "status": "NEGATIVE",
        "details": "germline BRCA mutation negative (gBRCAm negative); applies to ovarian cancer modules 6 and 7"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-negative metastatic breast cancer (concurrent requirement with gBRCAm for the breast cohort)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "DCR",
        "arm_id": "OG000",
        "arm_title": "Initial Stage: Small Cell Lung Cancer",
        "value": 28.9,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG001",
        "arm_title": "Initial Stage: Breast Cancer",
        "value": 80.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG002",
        "arm_title": "Initial Stage: Ovarian Cancer",
        "value": 81.3,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG003",
        "arm_title": "Initial Stage: Gastric Cancer",
        "value": 25.6,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Second Stage: Ovarian Cancer Expansion",
        "value": 92.2,
        "unit": "percentage of participants",
        "ci_lower": 81.12,
        "ci_upper": 97.82,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Initial Stage: Small Cell Lung Cancer",
        "value": 2.4,
        "unit": "months",
        "ci_lower": 0.9,
        "ci_upper": 3.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Initial Stage: Breast Cancer",
        "value": 8.2,
        "unit": "months",
        "ci_lower": 4.6,
        "ci_upper": 11.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Initial Stage: Ovarian Cancer",
        "value": 12.0,
        "unit": "months",
        "ci_lower": 8.2,
        "ci_upper": 15.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Initial Stage: Gastric Cancer",
        "value": 2.6,
        "unit": "months",
        "ci_lower": 1.4,
        "ci_upper": 2.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Second Stage: Ovarian Cancer Expansion",
        "value": 15.0,
        "unit": "months",
        "ci_lower": 12.9,
        "ci_upper": 24.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG005",
        "arm_title": "Second Stage: Ovarian Cancer Triplet",
        "value": 14.7,
        "unit": "months",
        "ci_lower": 9.2,
        "ci_upper": 18.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG006",
        "arm_title": "Second Stage: Ovarian Cancer Doublet",
        "value": 5.5,
        "unit": "months",
        "ci_lower": 3.6,
        "ci_upper": 7.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Initial Stage: Small Cell Lung Cancer",
        "value": 7.6,
        "unit": "months",
        "ci_lower": 5.6,
        "ci_upper": 8.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Initial Stage: Breast Cancer",
        "value": 20.5,
        "unit": "months",
        "ci_lower": 16.2,
        "ci_upper": 25.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Initial Stage: Ovarian Cancer",
        "value": 35.5,
        "unit": "months",
        "ci_lower": 27.2,
        "ci_upper": 50.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Initial Stage: Gastric Cancer",
        "value": 6.4,
        "unit": "months",
        "ci_lower": 4.3,
        "ci_upper": 9.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG004",
        "arm_title": "Second Stage: Ovarian Cancer Expansion",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG005",
        "arm_title": "Second Stage: Ovarian Cancer Triplet",
        "value": 31.9,
        "unit": "months",
        "ci_lower": 22.1,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG006",
        "arm_title": "Second Stage: Ovarian Cancer Doublet",
        "value": 26.1,
        "unit": "months",
        "ci_lower": 18.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Olaparib",
        "MEDI4736"
      ],
      "OG001": [
        "Olaparib",
        "MEDI4736"
      ],
      "OG002": [
        "Olaparib",
        "MEDI4736"
      ],
      "OG003": [
        "Olaparib",
        "MEDI4736"
      ],
      "OG004": [
        "Olaparib",
        "MEDI4736",
        "Bevacizumab"
      ],
      "OG005": [
        "Olaparib",
        "MEDI4736"
      ],
      "OG006": [
        "Olaparib",
        "MEDI4736"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted",
      "OG002": "Combo_IO_Targeted",
      "OG003": "Combo_IO_Targeted",
      "OG004": "Combo_IO_Targeted",
      "OG005": "Combo_IO_Targeted",
      "OG006": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT02678780",
    "brief_title": "Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors",
    "status": "COMPLETED",
    "start_date": "2015-10",
    "completion_date": "2017-12",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Grupo Espanol de Tumores Neuroendocrinos",
    "url": "https://clinicaltrials.gov/study/NCT02678780",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "Ki67",
        "status": "LOW",
        "details": "Ki67 <20% (WHO G1/G2)"
      },
      {
        "target": "MITOTIC_COUNT",
        "status": "LOW",
        "details": "\u2264 20 mitoses per 10 high power fields"
      },
      {
        "target": "WHO_GRADE",
        "status": "ANY",
        "details": "WHO Classification G1 or G2"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Neuroendocrine Tumors of the Pancreas",
        "value": 23.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Neuroendocrine Tumors of Gastrointestinal Tract",
        "value": 9.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG000",
        "arm_title": "Neuroendocrine Tumors of the Pancreas",
        "value": 50.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG001",
        "arm_title": "Neuroendocrine Tumors of Gastrointestinal Tract",
        "value": 51.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Lenvatinib"
      ],
      "OG001": [
        "Lenvatinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT02702388",
    "brief_title": "A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile",
    "status": "COMPLETED",
    "start_date": "2017-06-08",
    "completion_date": "2019-12-12",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eisai Inc.",
    "url": "https://clinicaltrials.gov/study/NCT02702388",
    "cancer_types": [
      "THCA"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Lenvatinib 24 mg",
        "value": 57.3,
        "unit": "percentage of participants",
        "ci_lower": 46.1,
        "ci_upper": 68.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Lenvatinib 18 mg",
        "value": 40.3,
        "unit": "percentage of participants",
        "ci_lower": 29.3,
        "ci_upper": 51.2,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Lenvatinib"
      ],
      "OG001": [
        "Lenvatinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT02775435",
    "brief_title": "A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)",
    "status": "COMPLETED",
    "start_date": "2016-06-09",
    "completion_date": "2018-04-03",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT02775435",
    "cancer_types": [
      "LUSC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + Chemotherapy Combo",
        "value": 6.4,
        "unit": "Months",
        "ci_lower": 6.2,
        "ci_upper": 8.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Chemotherapy",
        "value": 4.8,
        "unit": "Months",
        "ci_lower": 4.3,
        "ci_upper": 5.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + Chemotherapy Combo",
        "value": 15.9,
        "unit": "Months",
        "ci_lower": 13.2,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Chemotherapy",
        "value": 11.3,
        "unit": "Months",
        "ci_lower": 9.5,
        "ci_upper": 14.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Paclitaxel"
      ],
      "OG001": [
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT02795988",
    "brief_title": "A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer",
    "status": "COMPLETED",
    "start_date": "2017-08-30",
    "completion_date": "2024-03-20",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Imugene Limited",
    "url": "https://clinicaltrials.gov/study/NCT02795988",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER2/neu overexpression: IHC 3+ OR IHC 2+ confirmed by FISH or CISH. Phase 1b may include IHC 2+ without FISH/CISH confirmation with sponsor agreement."
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Phase 2: IMU-131 Plus Chemotherapy",
        "value": 13.9,
        "unit": "months",
        "ci_lower": 7.52,
        "ci_upper": 14.32,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Phase 2: Chemotherapy Only",
        "value": 8.31,
        "unit": "months",
        "ci_lower": 6.01,
        "ci_upper": 9.59,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "IMU-131",
        "Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine."
      ],
      "OG001": [
        "IMU-131",
        "Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine."
      ],
      "OG002": [
        "IMU-131",
        "Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine."
      ],
      "OG003": [
        "IMU-131",
        "Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine."
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Combo_Chemo_IO",
      "OG002": "Combo_Chemo_IO",
      "OG003": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT02799602",
    "brief_title": "Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer",
    "status": "COMPLETED",
    "start_date": "2016-11-30",
    "completion_date": "2021-10-25",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bayer",
    "url": "https://clinicaltrials.gov/study/NCT02799602",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Darolutamide (BAY1841788) + Docetaxel",
        "value": 229.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Docetaxel",
        "value": 304.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "BAY1841788 / darolutamide (ODM-201)",
        "Docetaxel",
        "Standard ADT (androgen deprivation therapy)"
      ],
      "OG001": [
        "Docetaxel",
        "Standard ADT (androgen deprivation therapy)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02795858",
    "brief_title": "A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors",
    "status": "COMPLETED",
    "start_date": "2016-06-14",
    "completion_date": "2022-12-31",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Dana-Farber Cancer Institute",
    "url": "https://clinicaltrials.gov/study/NCT02795858",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ramucirumab + Somatostatin Analog",
        "value": 14.2,
        "unit": "months",
        "ci_lower": 9.0,
        "ci_upper": 25.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Ramucirumab + Somatostatin Analog",
        "value": 24.9,
        "unit": "months",
        "ci_lower": 20.7,
        "ci_upper": 43.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ramucirumab",
        "Somatostatin Analog"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02766582",
    "brief_title": "Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer",
    "status": "COMPLETED",
    "start_date": "2016-10",
    "completion_date": "2022-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Medical College of Wisconsin",
    "url": "https://clinicaltrials.gov/study/NCT02766582",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "III",
      "IV"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Chemotherapy Combined With Pembrolizumab",
        "value": 13.2,
        "unit": "months",
        "ci_lower": 11.8,
        "ci_upper": 14.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Carboplatin",
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT02756364",
    "brief_title": "Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy",
    "status": "COMPLETED",
    "start_date": "2016-07-28",
    "completion_date": "2019-11-25",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Calithera Biosciences, Inc",
    "url": "https://clinicaltrials.gov/study/NCT02756364",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "ER-positive defined as \u22651% positive stained cells (histologically confirmed)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-negative by local laboratory testing per ASCO/CAP guidelines"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A: Fulvestrant 500 mg",
        "value": 3.5,
        "unit": "months",
        "ci_lower": 1.9,
        "ci_upper": 5.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Fulvestrant 500 mg + Sapanisertib 4 mg QD",
        "value": 7.2,
        "unit": "months",
        "ci_lower": 3.9,
        "ci_upper": 10.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Arm C: Fulvestrant 500 mg + Sapanisertib 30 mg QW",
        "value": 5.6,
        "unit": "months",
        "ci_lower": 4.1,
        "ci_upper": 9.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A: Fulvestrant 500 mg",
        "value": 30.5,
        "unit": "months",
        "ci_lower": 21.5,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Fulvestrant 500 mg + Sapanisertib 4 mg QD",
        "value": null,
        "unit": "months",
        "ci_lower": 29.9,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Arm C: Fulvestrant 500 mg + Sapanisertib 30 mg QW",
        "value": 34.2,
        "unit": "months",
        "ci_lower": 20.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Fulvestrant"
      ],
      "OG001": [
        "Fulvestrant",
        "Sapanisertib"
      ],
      "OG002": [
        "Fulvestrant",
        "Sapanisertib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02821754",
    "brief_title": "A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)",
    "status": "COMPLETED",
    "start_date": "2016-07-05",
    "completion_date": "2021-02-17",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT02821754",
    "cancer_types": [
      "LIHC",
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": true,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Radiofrequency Ablation/Trans-arterial Catheter Chemoembolization (RFA/TACE)",
        "value": 2.8,
        "unit": "Months",
        "ci_lower": 1.3,
        "ci_upper": 4.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Radiofrequency Ablation/Cryoablation (RFA/CA)",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Durvalumab",
        "Tremelimumab"
      ],
      "OG001": [
        "Durvalumab",
        "Tremelimumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO"
    }
  },
  {
    "nct_id": "NCT02787005",
    "brief_title": "Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)",
    "status": "COMPLETED",
    "start_date": "2016-07-01",
    "completion_date": "2022-02-28",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT02787005",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort 1: PD-L1 Positive With Measurable Disease",
        "value": 6.0,
        "unit": "Percentage of Participants",
        "ci_lower": 2.6,
        "ci_upper": 11.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Cohort 2: PD-L1 Negative With Measurable Disease",
        "value": 3.0,
        "unit": "Percentage of Participants",
        "ci_lower": 0.4,
        "ci_upper": 10.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Cohort 4: RECIST 1.1-measureable Disease",
        "value": 12.3,
        "unit": "Percentage of Participants",
        "ci_lower": 6.1,
        "ci_upper": 21.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Cohorts 1 and 2 Combined",
        "value": 5.0,
        "unit": "Percentage of Participants",
        "ci_lower": 2.4,
        "ci_upper": 9.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab"
      ],
      "OG001": [
        "Pembrolizumab"
      ],
      "OG002": [
        "Pembrolizumab"
      ],
      "OG003": [
        "Pembrolizumab"
      ],
      "OG004": [
        "Pembrolizumab"
      ],
      "OG005": [
        "Pembrolizumab"
      ],
      "OG006": [
        "Pembrolizumab"
      ],
      "OG007": [
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO",
      "OG003": "IO",
      "OG004": "IO",
      "OG005": "IO",
      "OG006": "IO",
      "OG007": "IO"
    }
  },
  {
    "nct_id": "NCT02768701",
    "brief_title": "Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2016-10-18",
    "completion_date": "2022-05-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "UNC Lineberger Comprehensive Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT02768701",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "< 1% staining by immunohistochemistry (IHC)"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "< 1% staining by immunohistochemistry (IHC)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "IHC 0-1+ or FISH ratio < 2.0"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Experimental: Single Arm",
        "value": 1.8,
        "unit": "months",
        "ci_lower": 1.4,
        "ci_upper": 2.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Experimental: Single Arm",
        "value": 6.3,
        "unit": "months",
        "ci_lower": 2.8,
        "ci_upper": 9.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Cyclophosphamide"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "OTHER",
      "OG002": "OTHER"
    }
  },
  {
    "nct_id": "NCT02761057",
    "brief_title": "Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed",
    "status": "COMPLETED",
    "start_date": "2016-07-25",
    "completion_date": "2023-10-19",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT02761057",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Sunitinib",
        "value": 5.6,
        "unit": "months",
        "ci_lower": 2.9,
        "ci_upper": 6.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cabozantinib",
        "value": 9.0,
        "unit": "months",
        "ci_lower": 5.6,
        "ci_upper": 12.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Crizotinib",
        "value": 2.8,
        "unit": "months",
        "ci_lower": 2.6,
        "ci_upper": 3.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Savolitinib",
        "value": 3.0,
        "unit": "months",
        "ci_lower": 2.8,
        "ci_upper": 7.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Sunitinib",
        "value": 16.4,
        "unit": "months",
        "ci_lower": 12.8,
        "ci_upper": 21.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cabozantinib",
        "value": 20.0,
        "unit": "months",
        "ci_lower": 11.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Crizotinib",
        "value": 19.9,
        "unit": "months",
        "ci_lower": 11.2,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Savolitinib",
        "value": 11.7,
        "unit": "months",
        "ci_lower": 6.7,
        "ci_upper": 28.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Sunitinib Malate"
      ],
      "OG001": [
        "Cabozantinib S-malate"
      ],
      "OG002": [
        "Crizotinib"
      ],
      "OG003": [
        "Savolitinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI",
      "OG002": "TKI",
      "OG003": "TKI"
    }
  },
  {
    "nct_id": "NCT02807844",
    "brief_title": "Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies",
    "status": "COMPLETED",
    "start_date": "2016-06-29",
    "completion_date": "2020-06-04",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT02807844",
    "cancer_types": [
      "BRCA",
      "SKCM",
      "PAAD"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC",
        "value": 5.0,
        "unit": "Percentage of participants",
        "ci_lower": 0.3,
        "ci_upper": 21.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC",
        "value": 0.0,
        "unit": "Percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 13.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC",
        "value": 9.5,
        "unit": "Percentage of participants",
        "ci_lower": 1.7,
        "ci_upper": 27.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME",
        "value": 0.0,
        "unit": "Percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 13.9,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "MCS110",
        "PDR001"
      ],
      "OG001": [
        "MCS110",
        "PDR001"
      ],
      "OG002": [
        "MCS110",
        "PDR001"
      ],
      "OG003": [
        "MCS110",
        "PDR001"
      ],
      "OG004": [
        "MCS110",
        "PDR001"
      ],
      "OG005": [
        "MCS110",
        "PDR001"
      ],
      "OG006": [
        "MCS110",
        "PDR001"
      ],
      "OG007": [
        "MCS110",
        "PDR001"
      ],
      "OG008": [
        "MCS110",
        "PDR001"
      ],
      "OG009": [
        "MCS110",
        "PDR001"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted",
      "OG002": "Combo_IO_Targeted",
      "OG003": "Combo_IO_Targeted",
      "OG004": "Combo_IO_Targeted",
      "OG005": "Combo_IO_Targeted",
      "OG006": "Combo_IO_Targeted",
      "OG007": "Combo_IO_Targeted",
      "OG008": "Combo_IO_Targeted",
      "OG009": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT02819518",
    "brief_title": "Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)",
    "status": "COMPLETED",
    "start_date": "2016-07-27",
    "completion_date": "2021-06-15",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT02819518",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "Estrogen receptor (ER) negative by central testing per ASCO/CAP guidelines (IHC)"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "Progesterone receptor (PR) negative by central testing per ASCO/CAP guidelines (IHC)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 negative by central testing per ASCO/CAP guidelines (IHC and/or ISH)"
      },
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "PD-L1 expression must be determined centrally from a recent or new biopsy; no specific positivity threshold required in inclusion criteria"
      }
    ],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Part 2: Pembrolizumab + Chemotherapy",
        "value": 7.5,
        "unit": "Months",
        "ci_lower": 6.3,
        "ci_upper": 7.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Part 2: Placebo + Chemotherapy",
        "value": 5.6,
        "unit": "Months",
        "ci_lower": 5.4,
        "ci_upper": 7.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Part 2: Pembrolizumab + Chemotherapy",
        "value": 17.2,
        "unit": "Months",
        "ci_lower": 15.3,
        "ci_upper": 19.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Part 2: Placebo + Chemotherapy",
        "value": 15.5,
        "unit": "Months",
        "ci_lower": 13.9,
        "ci_upper": 17.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Nab-paclitaxel"
      ],
      "OG001": [
        "Pembrolizumab",
        "Paclitaxel"
      ],
      "OG002": [
        "Pembrolizumab",
        "Gemcitabine",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Combo_Chemo_IO",
      "OG002": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT02763566",
    "brief_title": "A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2016-12-05",
    "completion_date": "2019-03-29",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT02763566",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "At least one hormone receptor (ER or PgR) must be positive by immunohistochemistry per ASCO/CAP guidelines; trial requires HR+ disease (i.e., \u22651 of ER or PgR positive)."
      },
      {
        "target": "PGR",
        "status": "POSITIVE",
        "details": "At least one hormone receptor (ER or PgR) must be positive by immunohistochemistry per ASCO/CAP guidelines; trial requires HR+ disease (i.e., \u22651 of ER or PgR positive)."
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "No HER2 overexpression by IHC or in-situ hybridization per ASCO/CAP guidelines (HER2- disease)."
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT",
      "UNRESECTABLE",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)",
        "value": null,
        "unit": "Months",
        "ci_lower": 22.32,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + NSAI",
        "value": 14.73,
        "unit": "Months",
        "ci_lower": 11.21,
        "ci_upper": 18.87,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Abemaciclib",
        "Anastrozole",
        "Letrozole"
      ],
      "OG001": [
        "Anastrozole",
        "Letrozole"
      ],
      "OG002": [
        "Abemaciclib",
        "Fulvestrant"
      ],
      "OG003": [
        "Fulvestrant"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "OTHER",
      "OG002": "Targeted_Other",
      "OG003": "OTHER"
    }
  },
  {
    "nct_id": "NCT02788981",
    "brief_title": "Abraxane\u00ae With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2017-03-28",
    "completion_date": "2022-12-21",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "University of Chicago",
    "url": "https://clinicaltrials.gov/study/NCT02788981",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "ER <10% positive by IHC"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "PR <10% positive by IHC"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 0-1+ by IHC or FISH ratio <2.0"
      },
      {
        "target": "GR",
        "status": "POSITIVE",
        "details": "GR >10% moderate to strong staining by central lab (IHC); tumor block/FFPE surgical or core needle biopsy required"
      }
    ],
    "cancer_stages": [
      "IV",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Nab-Paclitaxel+Mifepristone",
        "value": 3.0,
        "unit": "months",
        "ci_lower": 1.0,
        "ci_upper": 5.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Nab-Paclitaxel+Placebo",
        "value": 3.0,
        "unit": "months",
        "ci_lower": 1.0,
        "ci_upper": 6.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Nab-Paclitaxel+Mifepristone",
        "value": 9.0,
        "unit": "months",
        "ci_lower": 6.0,
        "ci_upper": 28.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Nab-Paclitaxel+Placebo",
        "value": 6.0,
        "unit": "months",
        "ci_lower": 2.0,
        "ci_upper": 15.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Mifepristone",
        "Nab-Paclitaxel"
      ],
      "OG001": [
        "Nab-Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT02788279",
    "brief_title": "A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)",
    "status": "COMPLETED",
    "start_date": "2016-07-05",
    "completion_date": "2018-03-09",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT02788279",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "MSI",
        "status": "ANY",
        "details": "MSI-high participants allowed up to a ~5% cap; after that only MSI-stable participants eligible."
      },
      {
        "target": "RAS",
        "status": "ANY",
        "details": "Study caps wild-type RAS enrollment at 50%; once cap reached, only extended RAS\u2011mutant (KRAS/NRAS) participants will be eligible."
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Regorafenib",
        "value": 8.51,
        "unit": "months",
        "ci_lower": 6.41,
        "ci_upper": 10.71,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cobimetinib + Atezolizumab",
        "value": 8.87,
        "unit": "months",
        "ci_lower": 7.0,
        "ci_upper": 10.61,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Atezolizumab",
        "value": 7.1,
        "unit": "months",
        "ci_lower": 6.05,
        "ci_upper": 10.05,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Regorafenib",
        "value": 2.0,
        "unit": "months",
        "ci_lower": 1.87,
        "ci_upper": 3.61,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cobimetinib + Atezolizumab",
        "value": 1.91,
        "unit": "months",
        "ci_lower": 1.87,
        "ci_upper": 1.97,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Atezolizumab",
        "value": 1.94,
        "unit": "months",
        "ci_lower": 1.91,
        "ci_upper": 2.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Regorafenib"
      ],
      "OG001": [
        "Cobimetinib",
        "Atezolizumab"
      ],
      "OG002": [
        "Atezolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Combo_IO_Targeted",
      "OG002": "IO"
    }
  },
  {
    "nct_id": "NCT02759835",
    "brief_title": "Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib",
    "status": "COMPLETED",
    "start_date": "2016-04-13",
    "completion_date": "2022-05-25",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT02759835",
    "cancer_types": [
      "LUAD",
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "EGFR-sensitizing somatic mutation detected by NGS or Cobas (CLIA or NCI lab) or via ctDNA"
      },
      {
        "target": "T790M",
        "status": "POSITIVE",
        "details": "T790M mutation (somatic T790M required for Cohort 2; germline T790M also permitted/mentioned)"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "All Participants in Cohort 1",
        "value": 14.7,
        "unit": "Months",
        "ci_lower": 5.6,
        "ci_upper": 22.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "All Participants in Cohort 2",
        "value": 11.0,
        "unit": "Months",
        "ci_lower": 5.5,
        "ci_upper": 25.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "osimertinib"
      ],
      "OG001": [
        "osimertinib"
      ],
      "OG002": [
        "osimertinib"
      ],
      "OG003": [
        "osimertinib"
      ],
      "OG004": [
        "osimertinib"
      ],
      "OG005": [
        "osimertinib"
      ],
      "OG006": [
        "osimertinib"
      ],
      "OG007": [
        "osimertinib"
      ],
      "OG008": [
        "osimertinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI",
      "OG002": "TKI",
      "OG003": "TKI",
      "OG004": "TKI",
      "OG005": "TKI",
      "OG006": "TKI",
      "OG007": "TKI",
      "OG008": "TKI"
    }
  },
  {
    "nct_id": "NCT02754882",
    "brief_title": "A Study Comparing SB8 and Avastin\u00ae in Patients With Advanced Non-squamous Non-small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2016-07-05",
    "completion_date": "2018-01-24",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Samsung Bioepis Co., Ltd.",
    "url": "https://clinicaltrials.gov/study/NCT02754882",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "sensitizing EGFR mutations"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "ALK rearrangements"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab (Avastin)",
        "value": 42.8,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "SB8 (A Proposed Bevacizumab Biosimilar)",
        "value": 47.6,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "SB8 (A Proposed Bevacizumab Biosimilar)",
        "value": 8.5,
        "unit": "months",
        "ci_lower": 7.4,
        "ci_upper": 9.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab (Avastin)",
        "value": 7.9,
        "unit": "months",
        "ci_lower": 7.4,
        "ci_upper": 9.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "SB8 (A Proposed Bevacizumab Biosimilar)",
        "value": 8.5,
        "unit": "months",
        "ci_lower": 7.2,
        "ci_upper": 9.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab (Avastin)",
        "value": 7.9,
        "unit": "months",
        "ci_lower": 7.3,
        "ci_upper": 9.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "SB8 (A Proposed Bevacizumab Biosimilar)",
        "value": 14.9,
        "unit": "months",
        "ci_lower": 13.3,
        "ci_upper": 17.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab (Avastin)",
        "value": 15.8,
        "unit": "months",
        "ci_lower": 13.6,
        "ci_upper": 17.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "SB8 (A Proposed Bevacizumab Biosimilar)",
        "value": 14.8,
        "unit": "months",
        "ci_lower": 13.0,
        "ci_upper": 17.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab (Avastin)",
        "value": 15.8,
        "unit": "months",
        "ci_lower": 13.8,
        "ci_upper": 17.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Bevacizumab",
        "Carboplatin",
        "Paclitaxel"
      ],
      "OG001": [
        "SB8",
        "Carboplatin",
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02799095",
    "brief_title": "A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2016-09-14",
    "completion_date": "2023-03-27",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Mural Oncology, Inc",
    "url": "https://clinicaltrials.gov/study/NCT02799095",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg",
        "value": 8.7,
        "unit": "percentage of participants",
        "ci_lower": 2.4,
        "ci_upper": 20.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg",
        "value": 13.6,
        "unit": "percentage of participants",
        "ci_lower": 2.9,
        "ci_upper": 34.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 70.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg +Pembrolizumab 200mg",
        "value": 13.9,
        "unit": "percentage of participants",
        "ci_lower": 4.7,
        "ci_upper": 29.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 15.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg",
        "value": 28.6,
        "unit": "percentage of participants",
        "ci_lower": 11.3,
        "ci_upper": 52.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG006",
        "arm_title": "Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg",
        "value": 7.7,
        "unit": "percentage of participants",
        "ci_lower": 1.6,
        "ci_upper": 20.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG007",
        "arm_title": "Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg",
        "value": 66.7,
        "unit": "percentage of participants",
        "ci_lower": 9.4,
        "ci_upper": 99.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG008",
        "arm_title": "Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg",
        "value": 11.1,
        "unit": "percentage of participants",
        "ci_lower": 1.4,
        "ci_upper": 34.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG009",
        "arm_title": "Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg",
        "value": 50.0,
        "unit": "percentage of participants",
        "ci_lower": 1.3,
        "ci_upper": 98.7,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nemvaleukin alfa"
      ],
      "OG001": [
        "Nemvaleukin alfa"
      ],
      "OG002": [
        "Nemvaleukin alfa"
      ],
      "OG003": [
        "Nemvaleukin alfa"
      ],
      "OG004": [
        "Nemvaleukin alfa"
      ],
      "OG005": [
        "Nemvaleukin alfa"
      ],
      "OG006": [
        "Nemvaleukin alfa"
      ],
      "OG007": [
        "Nemvaleukin alfa"
      ],
      "OG008": [
        "Nemvaleukin alfa"
      ],
      "OG009": [
        "Nemvaleukin alfa",
        "Pembrolizumab"
      ],
      "OG010": [
        "Nemvaleukin alfa",
        "Pembrolizumab"
      ],
      "OG011": [
        "Nemvaleukin alfa",
        "Pembrolizumab"
      ],
      "OG012": [
        "Nemvaleukin alfa",
        "Pembrolizumab"
      ],
      "OG013": [
        "Nemvaleukin alfa",
        "Pembrolizumab"
      ],
      "OG014": [
        "Nemvaleukin alfa",
        "Pembrolizumab"
      ],
      "OG015": [
        "Nemvaleukin alfa",
        "Pembrolizumab"
      ],
      "OG016": [
        "Nemvaleukin alfa",
        "Pembrolizumab"
      ],
      "OG017": [
        "Nemvaleukin alfa",
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO",
      "OG003": "IO",
      "OG004": "IO",
      "OG005": "IO",
      "OG006": "IO",
      "OG007": "IO",
      "OG008": "IO",
      "OG009": "IO",
      "OG010": "IO",
      "OG011": "IO",
      "OG012": "IO",
      "OG013": "IO",
      "OG014": "IO",
      "OG015": "IO",
      "OG016": "IO",
      "OG017": "IO"
    }
  },
  {
    "nct_id": "NCT02769962",
    "brief_title": "Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2016-05-09",
    "completion_date": "2023-04-19",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT02769962",
    "cancer_types": [
      "SCLC",
      "BLCA",
      "PRAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Small Cell Lung Cancer Dose Level 4R:EP0057(CLRX101) 12mg/m^2(Intravenous); Olaparib 250mg(by Mouth)",
        "value": 2.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Urothelial Carcinoma Dose Level 4R:EP0057(CLRX101) 12mg/m^2(Intravenous); Olaparib 250mg(by Mouth)",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "EP0057",
        "olaparib"
      ],
      "OG001": [
        "EP0057",
        "olaparib"
      ],
      "OG002": [
        "EP0057",
        "olaparib"
      ],
      "OG003": [
        "EP0057",
        "olaparib"
      ],
      "OG004": [
        "EP0057",
        "olaparib"
      ],
      "OG005": [
        "EP0057",
        "olaparib"
      ],
      "OG006": [
        "EP0057",
        "olaparib"
      ],
      "OG007": [
        "EP0057",
        "olaparib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted",
      "OG003": "Combo_Chemo_Targeted",
      "OG004": "Combo_Chemo_Targeted",
      "OG005": "Combo_Chemo_Targeted",
      "OG006": "Combo_Chemo_Targeted",
      "OG007": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02797964",
    "brief_title": "A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer",
    "status": "COMPLETED",
    "start_date": "2016-07",
    "completion_date": "2019-10-28",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sierra Oncology LLC - a GSK company",
    "url": "https://clinicaltrials.gov/study/NCT02797964",
    "cancer_types": [
      "OTHER",
      "DLBC"
    ],
    "biomarkers": [
      {
        "target": "MYC",
        "status": "POSITIVE",
        "details": "oncogenic driver"
      },
      {
        "target": "CCNE1",
        "status": "POSITIVE",
        "details": "oncogenic driver (cell cycle regulator)"
      },
      {
        "target": "RAD50",
        "status": "POSITIVE",
        "details": "tumor suppressor regulating G1 cell cycle progression/arrest"
      },
      {
        "target": "TP53",
        "status": "POSITIVE",
        "details": "tumor suppressor regulating G1 cell cycle progression/arrest"
      },
      {
        "target": "HPV",
        "status": "POSITIVE",
        "details": "positive HPV status considered for HNSCC or SCCA"
      },
      {
        "target": "BRCA1",
        "status": "POSITIVE",
        "details": null
      },
      {
        "target": "BRCA2",
        "status": "POSITIVE",
        "details": null
      },
      {
        "target": "FANC",
        "status": "POSITIVE",
        "details": "Fanconi pathway genes"
      },
      {
        "target": "MMR",
        "status": "POSITIVE",
        "details": "mismatch repair genetic alterations"
      },
      {
        "target": "MSI",
        "status": "HIGH",
        "details": "high microsatellite instability (MSI-H) considered for CRC"
      },
      {
        "target": "CHEK1",
        "status": "POSITIVE",
        "details": "gain of function or amplification"
      },
      {
        "target": "ATR",
        "status": "POSITIVE",
        "details": "gain of function or amplification"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "DCR",
        "arm_id": "OG000",
        "arm_title": "Colorectal Cancer",
        "value": 8.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG001",
        "arm_title": "High Grade Serous Ovarian Cancer",
        "value": 11.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG002",
        "arm_title": "Non Small Cell Lung Cancer",
        "value": 3.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG003",
        "arm_title": "Metastatic Other Tumor Type Castration Resistant Prostate Cancer",
        "value": 8.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG004",
        "arm_title": "Head and Neck Squamous Cell Carcinoma",
        "value": 3.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Colorectal Cancer",
        "value": 1.84,
        "unit": "months",
        "ci_lower": 1.68,
        "ci_upper": 1.87,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "High Grade Serous Ovarian Cancer",
        "value": 1.94,
        "unit": "months",
        "ci_lower": 1.81,
        "ci_upper": 3.68,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Non Small Cell Lung Cancer",
        "value": 1.76,
        "unit": "months",
        "ci_lower": 0.49,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Metastatic Other Tumor Type Castration Resistant Prostate Cancer",
        "value": 3.02,
        "unit": "months",
        "ci_lower": 1.64,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Head and Neck Squamous Cell Carcinoma",
        "value": 3.55,
        "unit": "months",
        "ci_lower": 1.64,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Colorectal Cancer",
        "value": 5.72,
        "unit": "months",
        "ci_lower": 4.14,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "High Grade Serous Ovarian Cancer",
        "value": 6.93,
        "unit": "months",
        "ci_lower": 4.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Non Small Cell Lung Cancer",
        "value": 6.08,
        "unit": "months",
        "ci_lower": 0.49,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Metastatic Castration Resistant Prostate Cancer",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG004",
        "arm_title": "Head and Neck Squamous Cell Carcinoma",
        "value": null,
        "unit": "months",
        "ci_lower": 3.55,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG005",
        "arm_title": "Other Tumor Type",
        "value": null,
        "unit": "months",
        "ci_lower": 1.64,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG006",
        "arm_title": "Overall",
        "value": 6.93,
        "unit": "months",
        "ci_lower": 5.72,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "SRA737"
      ],
      "OG001": [
        "SRA737"
      ],
      "OG002": [
        "SRA737"
      ],
      "OG003": [
        "SRA737"
      ],
      "OG004": [
        "SRA737"
      ],
      "OG005": [
        "SRA737"
      ],
      "OG006": [
        "SRA737"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other",
      "OG004": "Targeted_Other",
      "OG005": "Targeted_Other",
      "OG006": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02890355",
    "brief_title": "FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2016-09-01",
    "completion_date": "2019-05-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT02890355",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [
      {
        "target": "CA19-9",
        "status": "ANY",
        "details": "CA19-9 must be obtained within 14 days prior to registration"
      },
      {
        "target": "CEA",
        "status": "ANY",
        "details": "If CA19-9 is normal, a CEA must be tested within 14 days prior to registration"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm I (Veliparib and mFOLFIRI)",
        "value": 5.4,
        "unit": "months",
        "ci_lower": 3.7,
        "ci_upper": 7.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm II (FOLFIRI)",
        "value": 6.5,
        "unit": "months",
        "ci_lower": 5.6,
        "ci_upper": 7.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm I (Veliparib and mFOLFIRI)",
        "value": 2.1,
        "unit": "months",
        "ci_lower": 1.9,
        "ci_upper": 2.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm II (FOLFIRI)",
        "value": 2.9,
        "unit": "months",
        "ci_lower": 2.2,
        "ci_upper": 4.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Veliparib",
        "Irinotecan Hydrochloride",
        "Fluorouracil",
        "Leucovorin Calcium"
      ],
      "OG001": [
        "Irinotecan Hydrochloride",
        "Fluorouracil",
        "Leucovorin Calcium"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT02823574",
    "brief_title": "Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",
    "status": "COMPLETED",
    "start_date": "2016-11-08",
    "completion_date": "2019-01-23",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT02823574",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Tumor sample must be available for PD-L1 analysis"
      },
      {
        "target": "HPV",
        "status": "ANY",
        "details": "Tumor sample must be available for HPV testing (required for oropharyngeal primaries)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Treatment A",
        "value": 9.76,
        "unit": "Months",
        "ci_lower": 7.52,
        "ci_upper": 11.47,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Treatment B",
        "value": 11.3,
        "unit": "Months",
        "ci_lower": 8.48,
        "ci_upper": 14.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab"
      ],
      "OG001": [
        "Ipilimumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO"
    }
  },
  {
    "nct_id": "NCT02832167",
    "brief_title": "An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread",
    "status": "COMPLETED",
    "start_date": "2016-02-22",
    "completion_date": "2019-10-20",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT02832167",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Advanced Malignancies Cohort",
        "value": 7.9,
        "unit": "Percent of Participants",
        "ci_lower": 4.9,
        "ci_upper": 12.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Advanced Malignancies Cohort",
        "value": 56.1,
        "unit": "Percent of participants",
        "ci_lower": 49.1,
        "ci_upper": 62.5,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO"
    }
  },
  {
    "nct_id": "NCT02879617",
    "brief_title": "A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients",
    "status": "COMPLETED",
    "start_date": "2017-04-04",
    "completion_date": "2022-06-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Academic Thoracic Oncology Medical Investigators Consortium",
    "url": "https://clinicaltrials.gov/study/NCT02879617",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Tissue (archived or fresh tumor biopsy) required for PD-L1 assay"
      },
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "Sensitizing mutations (exclusion)"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "Rearrangements (exclusion)"
      },
      {
        "target": "ROS1",
        "status": "NEGATIVE",
        "details": "Rearrangements (exclusion)"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Durvalumab",
        "value": 6.0,
        "unit": "months",
        "ci_lower": 4.0,
        "ci_upper": 10.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Durvalumab",
        "value": 3.0,
        "unit": "months",
        "ci_lower": 1.0,
        "ci_upper": 4.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Durvalumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO"
    }
  },
  {
    "nct_id": "NCT02872116",
    "brief_title": "Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer",
    "status": "COMPLETED",
    "start_date": "2016-10-12",
    "completion_date": "2020-05-27",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT02872116",
    "cancer_types": [
      "STAD",
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm 1: Nivolumab + Chemotherapy (XELOX or FOLFOX)",
        "value": 14.39,
        "unit": "Months",
        "ci_lower": 13.11,
        "ci_upper": 16.23,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm 2a: Chemotherapy (XELOX or FOLFOX)",
        "value": 11.1,
        "unit": "Months",
        "ci_lower": 10.02,
        "ci_upper": 12.09,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm 1: Nivolumab + Chemotherapy (XELOX or FOLFOX)",
        "value": 7.69,
        "unit": "Months",
        "ci_lower": 7.03,
        "ci_upper": 9.17,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm 2a: Chemotherapy (XELOX or FOLFOX)",
        "value": 6.05,
        "unit": "Months",
        "ci_lower": 5.55,
        "ci_upper": 6.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab",
        "Oxaliplatin",
        "Capecitabine",
        "Fluorouracil",
        "Leucovorin"
      ],
      "OG001": [
        "Oxaliplatin",
        "Capecitabine",
        "Fluorouracil",
        "Leucovorin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT02889900",
    "brief_title": "Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer",
    "status": "COMPLETED",
    "start_date": "2017-01-17",
    "completion_date": "2019-08-27",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT02889900",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "BRCA1",
        "status": "NEGATIVE",
        "details": "No evidence of deleterious or suspected deleterious germline mutation"
      },
      {
        "target": "BRCA2",
        "status": "NEGATIVE",
        "details": "No evidence of deleterious or suspected deleterious germline mutation"
      }
    ],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cediranib + Olaparib",
        "value": 15.3,
        "unit": "percentage of patients",
        "ci_lower": 7.2,
        "ci_upper": 27.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cediranib + Olaparib",
        "value": 5.1,
        "unit": "months",
        "ci_lower": 3.5,
        "ci_upper": 5.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cediranib + Olaparib",
        "value": 3.8,
        "unit": "months",
        "ci_lower": 3.5,
        "ci_upper": 6.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cediranib + Olaparib",
        "value": 13.2,
        "unit": "months",
        "ci_lower": 9.4,
        "ci_upper": 16.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "cediranib",
        "olaparib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Targeted"
    }
  },
  {
    "nct_id": "NCT02844439",
    "brief_title": "Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma",
    "status": "COMPLETED",
    "start_date": "2016-06",
    "completion_date": "2020-04-30",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Kadmon Corporation, LLC",
    "url": "https://clinicaltrials.gov/study/NCT02844439",
    "cancer_types": [
      "GBM"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Total",
        "value": 22.5,
        "unit": "Percentage (%) of subjects",
        "ci_lower": 10.8,
        "ci_upper": 38.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Sub-population A",
        "value": 25.0,
        "unit": "Percentage (%) of subjects",
        "ci_lower": 9.8,
        "ci_upper": 46.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Sub-population B",
        "value": 18.2,
        "unit": "Percentage (%) of subjects",
        "ci_lower": 2.3,
        "ci_upper": 51.8,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Tesevatinib"
      ],
      "OG001": [
        "Tesevatinib"
      ],
      "OG002": [
        "Tesevatinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI",
      "OG002": "TKI"
    }
  },
  {
    "nct_id": "NCT02838420",
    "brief_title": "A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2016-08-03",
    "completion_date": "2018-05-31",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT02838420",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "ALK",
        "status": "POSITIVE",
        "details": "ALK positivity assessed by Ventana IHC; sufficient tumor tissue required; testing at designated central laboratory"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV",
      "METASTATIC",
      "RECURRENT",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Alectinib",
        "value": null,
        "unit": "Months",
        "ci_lower": 20.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Crizotinib",
        "value": 11.1,
        "unit": "Months",
        "ci_lower": 9.1,
        "ci_upper": 13.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Alectinib"
      ],
      "OG001": [
        "Crizotinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT02855125",
    "brief_title": "A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1",
    "status": "COMPLETED",
    "start_date": "2016-08-29",
    "completion_date": "2017-09-30",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Taiho Oncology, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT02855125",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "TAS-114 + S-1",
        "value": 3.65,
        "unit": "months",
        "ci_lower": 2.69,
        "ci_upper": 5.16,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "S-1 (Monotherapy)",
        "value": 4.17,
        "unit": "months",
        "ci_lower": 2.6,
        "ci_upper": 6.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "TAS-114 + S-1",
        "value": 7.92,
        "unit": "months",
        "ci_lower": 6.28,
        "ci_upper": 10.78,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "S-1 (Monotherapy)",
        "value": 9.82,
        "unit": "months",
        "ci_lower": 7.66,
        "ci_upper": 13.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "TAS-114",
        "S-1"
      ],
      "OG001": [
        "S-1"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT02879994",
    "brief_title": "Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2016-09-15",
    "completion_date": "2017-11-30",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Jonsson Comprehensive Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT02879994",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "Mutation present (sensitizing or non-sensitizing)"
      },
      {
        "target": "PD-L1",
        "status": "POSITIVE",
        "details": "IHC 22C3 pharmDx test; tumor PD-L1 positive (strongly or weakly); requires newly obtained formalin-fixed tumor biopsy (not previously irradiated); fine needle aspirates not acceptable"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (Pembrolizumab)",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Pembrolizumab)",
        "value": 119.0,
        "unit": "days",
        "ci_lower": 42.0,
        "ci_upper": 123.0,
        "dispersion_type": "MEAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Pembrolizumab)",
        "value": null,
        "unit": "days",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO"
    }
  },
  {
    "nct_id": "NCT02899793",
    "brief_title": "Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer",
    "status": "COMPLETED",
    "start_date": "2016-09",
    "completion_date": "2024-07-17",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Yale University",
    "url": "https://clinicaltrials.gov/study/NCT02899793",
    "cancer_types": [
      "UCEC"
    ],
    "biomarkers": [
      {
        "target": "POLE",
        "status": "POSITIVE",
        "details": "POLE mutation (ultramutation) detected by NGS/CGP"
      },
      {
        "target": "POLD1",
        "status": "POSITIVE",
        "details": "POLD1 mutation (ultramutation) detected by NGS/CGP"
      },
      {
        "target": "MMR",
        "status": "POSITIVE",
        "details": "Mismatch repair (MMR) gene defect / MMR-deficiency (eg, MLH1, MSH2, MSH6, PMS2) detected by NGS/CGP or IHC"
      },
      {
        "target": "MSI",
        "status": "POSITIVE",
        "details": "Microsatellite instability-high (MSI-H) by PCR-based DNA MSI testing"
      }
    ],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab",
        "value": 14.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab",
        "value": 27.4,
        "unit": "months",
        "ci_lower": 10.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab",
        "value": 71.5,
        "unit": "months",
        "ci_lower": 28.6,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO"
    }
  },
  {
    "nct_id": "NCT02829918",
    "brief_title": "Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers",
    "status": "COMPLETED",
    "start_date": "2016-10-05",
    "completion_date": "2019-03-27",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
    "url": "https://clinicaltrials.gov/study/NCT02829918",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "UNRESECTABLE",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Nivolumab Treatment",
        "value": 22.0,
        "unit": "Percent",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Nivolumab Treatment",
        "value": 8.9,
        "unit": "Months",
        "ci_lower": 5.2,
        "ci_upper": 17.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Nivolumab Treatment",
        "value": 3.68,
        "unit": "Months",
        "ci_lower": 2.3,
        "ci_upper": 5.69,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO"
    }
  },
  {
    "nct_id": "NCT02873195",
    "brief_title": "Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2017-07-07",
    "completion_date": "2023-03-06",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Academic and Community Cancer Research United",
    "url": "https://clinicaltrials.gov/study/NCT02873195",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "RAS",
        "status": "ANY",
        "details": "If tumor is RAS wild-type, prior anti-EGFR antibody therapy is expected/required (conditional requirement)"
      },
      {
        "target": "DPYD",
        "status": "NEGATIVE",
        "details": "Known dihydropyrimidine dehydrogenase (DPD) deficiency is excluded"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Atezolizumab, Bevacizumab, Capecitabine",
        "value": 4.37,
        "unit": "months",
        "ci_lower": 4.07,
        "ci_upper": 6.41,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo, Bevacizumab, Capecitabine",
        "value": 3.32,
        "unit": "months",
        "ci_lower": 2.14,
        "ci_upper": 6.21,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Atezolizumab, Bevacizumab, Capecitabine",
        "value": 10.55,
        "unit": "months",
        "ci_lower": 8.21,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo, Bevacizumab, Capecitabine",
        "value": 10.61,
        "unit": "months",
        "ci_lower": 8.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Atezolizumab",
        "Bevacizumab",
        "Capecitabine"
      ],
      "OG001": [
        "Bevacizumab",
        "Capecitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02899078",
    "brief_title": "Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer",
    "status": "COMPLETED",
    "start_date": "2016-11-15",
    "completion_date": "2020-08-05",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "University of California, Davis",
    "url": "https://clinicaltrials.gov/study/NCT02899078",
    "cancer_types": [
      "KIRC"
    ],
    "biomarkers": [
      {
        "target": "HBV",
        "status": "NEGATIVE",
        "details": "No active HBV infection; if anti-HBc or HBsAg positive must have negative HBV PCR prior to enrollment; PCR-positive excluded"
      },
      {
        "target": "HCV",
        "status": "NEGATIVE",
        "details": "No active HCV infection"
      },
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "Known history of HIV is excluded"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Ibrutinib, Nivolumab)",
        "value": 2.5,
        "unit": "months",
        "ci_lower": 1.9,
        "ci_upper": 4.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Ibrutinib, Nivolumab)",
        "value": 9.1,
        "unit": "months",
        "ci_lower": 6.6,
        "ci_upper": 19.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ibrutinib",
        "Nivolumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT02841579",
    "brief_title": "Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M",
    "status": "COMPLETED",
    "start_date": "2016-09-02",
    "completion_date": "2018-12",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "MedSIR",
    "url": "https://clinicaltrials.gov/study/NCT02841579",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "Activating EGFR mutation: exon 19 deletion or exon 21 (L858R, L861Q) or exon 18 (G719X); centrally confirmed prior to treatment"
      },
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "T790M mutation (concomitant with activating EGFR mutation); centrally confirmed prior to treatment"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "III"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Osimertinib",
        "value": 77.3,
        "unit": "percentage of patients",
        "ci_lower": 54.6,
        "ci_upper": 89.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Osimertinib",
        "value": 28.39,
        "unit": "months",
        "ci_lower": 25.62,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Osimertinib",
        "value": 23.1,
        "unit": "months",
        "ci_lower": 14.1,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Osimertinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT02854436",
    "brief_title": "An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies",
    "status": "COMPLETED",
    "start_date": "2016-08-31",
    "completion_date": "2021-01-26",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Janssen Research & Development, LLC",
    "url": "https://clinicaltrials.gov/study/NCT02854436",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [
      {
        "target": "DNA_REPAIR",
        "status": "POSITIVE",
        "details": "Biallelic DNA-repair anomaly by sponsor-validated blood or tissue assay"
      },
      {
        "target": "BRCA1",
        "status": "POSITIVE",
        "details": "Germline pathogenic BRCA1 (somatic local results must be confirmed by sponsor-validated assay before dosing)"
      },
      {
        "target": "BRCA2",
        "status": "POSITIVE",
        "details": "Germline pathogenic BRCA2 (somatic local results must be confirmed by sponsor-validated assay before dosing)"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Niraparib",
        "value": 34.2,
        "unit": "percentage of participants",
        "ci_lower": 23.7,
        "ci_upper": 46.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Niraparib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02861300",
    "brief_title": "CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2016-09-12",
    "completion_date": "2023-01-10",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "David Bajor, MD",
    "url": "https://clinicaltrials.gov/study/NCT02861300",
    "cancer_types": [
      "CRC",
      "COAD",
      "READ"
    ],
    "biomarkers": [
      {
        "target": "PIK3CA",
        "status": "POSITIVE",
        "details": "PIK3CA mutant; confirmed by tumor sequencing in a CLIA-certified laboratory"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase I Dose -1",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Phase I Dose 1",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Phase I Dose 2",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Phase I Dose 3",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Phase I Dose 3A",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG005",
        "arm_title": "Phase I Dose 4",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG006",
        "arm_title": "Phase II Dose",
        "value": 7.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "CB-839",
        "Capecitabine"
      ],
      "OG001": [
        "CB-839",
        "Capecitabine"
      ],
      "OG002": [
        "CB-839",
        "Capecitabine"
      ],
      "OG003": [
        "CB-839",
        "Capecitabine"
      ],
      "OG004": [
        "CB-839",
        "Capecitabine"
      ],
      "OG005": [
        "CB-839",
        "Capecitabine"
      ],
      "OG006": [
        "CB-839",
        "Capecitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted",
      "OG003": "Combo_Chemo_Targeted",
      "OG004": "Combo_Chemo_Targeted",
      "OG005": "Combo_Chemo_Targeted",
      "OG006": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02848651",
    "brief_title": "A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2016-09-23",
    "completion_date": "2019-05-14",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Genentech, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT02848651",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "any PD-L1 IHC result allowed or no test required"
      },
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "sensitizing mutations"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "rearrangements"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IIIC",
      "IVA",
      "IVB",
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Atezolizumab",
        "value": 17.1,
        "unit": "Percentage of Participants",
        "ci_lower": 11.62,
        "ci_upper": 23.86,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "bTMB Low (<16)",
        "value": 3.55,
        "unit": "Months",
        "ci_lower": 2.63,
        "ci_upper": 4.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "bTMB High (>=16)",
        "value": 4.98,
        "unit": "Months",
        "ci_lower": 1.58,
        "ci_upper": 10.81,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Atezolizumab",
        "value": 14.82,
        "unit": "Months",
        "ci_lower": 12.68,
        "ci_upper": 21.29,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Atezolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "OTHER",
      "OG002": "OTHER",
      "OG003": "OTHER",
      "OG004": "OTHER",
      "OG005": "OTHER"
    }
  },
  {
    "nct_id": "NCT02823990",
    "brief_title": "TG4010 and Nivolumab in Patients With Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2016-12-14",
    "completion_date": "2021-02-24",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Megan Daly, MD",
    "url": "https://clinicaltrials.gov/study/NCT02823990",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "Adenocarcinoma patients must have EGFR mutational testing; patients with actionable EGFR mutations are excluded"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "Adenocarcinoma patients must have ALK mutational testing; patients with actionable ALK rearrangements are excluded"
      }
    ],
    "cancer_stages": [
      "I",
      "IA",
      "IB",
      "II",
      "IIA",
      "IIB",
      "III",
      "IIIA",
      "IIIB",
      "IV",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment TG4010 + nivolumab",
        "value": 0.083,
        "unit": "Proportion of evaluable participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG000",
        "arm_title": "Treatment TG4010 + nivolumab",
        "value": 0.25,
        "unit": "Proportion of evaluable participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG000",
        "arm_title": "Treatment TG4010 + nivolumab",
        "value": 4.0,
        "unit": "years",
        "ci_lower": 4.0,
        "ci_upper": 4.0,
        "dispersion_type": "MEAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Treatment TG4010 + nivolumab",
        "value": 220.0,
        "unit": "days",
        "ci_lower": 171.0,
        "ci_upper": 341.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment TG4010 + nivolumab",
        "value": 41.0,
        "unit": "days",
        "ci_lower": 39.0,
        "ci_upper": 124.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "TG4010",
        "Nivolumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER"
    }
  },
  {
    "nct_id": "NCT02872714",
    "brief_title": "A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)",
    "status": "COMPLETED",
    "start_date": "2017-01-12",
    "completion_date": "2022-02-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Incyte Corporation",
    "url": "https://clinicaltrials.gov/study/NCT02872714",
    "cancer_types": [
      "BLCA"
    ],
    "biomarkers": [
      {
        "target": "FGFR",
        "status": "POSITIVE",
        "details": "Documented FGF/FGFR alteration"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort A-ID: FGFR3 Mutations or Fusions",
        "value": null,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Cohort B-ID: All Other FGF/FGFR Alterations",
        "value": null,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Other-ID",
        "value": null,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Cohort A-CD: FGFR3 Mutations or Fusions",
        "value": 17.8,
        "unit": "percentage of participants",
        "ci_lower": 10.92,
        "ci_upper": 26.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Other-CD",
        "value": null,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort A-ID: FGFR3 Mutations or Fusions",
        "value": 4.27,
        "unit": "months",
        "ci_lower": 3.91,
        "ci_upper": 6.05,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort B-ID: All Other FGF/FGFR Alterations",
        "value": 2.04,
        "unit": "months",
        "ci_lower": 1.87,
        "ci_upper": 2.17,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Other-ID",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Cohort A-CD: FGFR3 Mutations or Fusions",
        "value": 4.04,
        "unit": "months",
        "ci_lower": 3.45,
        "ci_upper": 4.17,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Other-CD",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cohort A-ID: FGFR3 Mutations or Fusions",
        "value": 8.9,
        "unit": "months",
        "ci_lower": 7.46,
        "ci_upper": 15.18,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cohort B-ID: All Other FGF/FGFR Alterations",
        "value": 9.13,
        "unit": "months",
        "ci_lower": 5.52,
        "ci_upper": 17.05,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Other-ID",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Cohort A-CD: FGFR3 Mutations or Fusions",
        "value": 6.8,
        "unit": "months",
        "ci_lower": 5.26,
        "ci_upper": 9.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG004",
        "arm_title": "Other-CD",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "pemigatinib"
      ],
      "OG001": [
        "pemigatinib"
      ],
      "OG002": [
        "pemigatinib"
      ],
      "OG003": [
        "pemigatinib"
      ],
      "OG004": [
        "pemigatinib"
      ],
      "OG005": [
        "pemigatinib"
      ],
      "OG006": [
        "pemigatinib"
      ],
      "OG007": [
        "pemigatinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI",
      "OG002": "TKI",
      "OG003": "TKI",
      "OG004": "TKI",
      "OG005": "TKI",
      "OG006": "TKI",
      "OG007": "TKI"
    }
  },
  {
    "nct_id": "NCT00143403",
    "brief_title": "Comparing Irinotecan and 5 FU/FA To 5-FU/FA After Resection Of Liver Metastases For Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2001-12",
    "completion_date": "2008-02",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT00143403",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [],
    "arm_drugs": {
      "OG000": [
        "Folinic Acid",
        "5 FU"
      ],
      "OG001": [
        "Irinotecan",
        "Folinic Acid",
        "5 FU"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00154102",
    "brief_title": "Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)",
    "status": "COMPLETED",
    "start_date": "2004-05",
    "completion_date": "2006-12",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck KGaA, Darmstadt, Germany",
    "url": "https://clinicaltrials.gov/study/NCT00154102",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "Immunohistochemical evidence of EGFR expression in tumor tissue"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cetuximab Plus FOLFIRI",
        "value": 8.9,
        "unit": "months",
        "ci_lower": 8.0,
        "ci_upper": 9.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "FOLFIRI Alone",
        "value": 8.0,
        "unit": "months",
        "ci_lower": 7.6,
        "ci_upper": 9.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cetuximab Plus FOLFIRI",
        "value": 19.9,
        "unit": "months",
        "ci_lower": 18.5,
        "ci_upper": 21.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "FOLFIRI Alone",
        "value": 18.6,
        "unit": "months",
        "ci_lower": 16.7,
        "ci_upper": 19.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cetuximab",
        "FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)"
      ],
      "OG001": [
        "FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00137839",
    "brief_title": "Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung",
    "status": "COMPLETED",
    "start_date": "2004-11",
    "completion_date": "2008-11",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pasi A. Janne, MD, PhD",
    "url": "https://clinicaltrials.gov/study/NCT00137839",
    "cancer_types": [
      "LUAD"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "Epidermal growth factor receptor (EGFR) mutation testing of tumor required"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Erlotinib",
        "value": 27.7,
        "unit": "percentage of participants",
        "ci_lower": 18.5,
        "ci_upper": 38.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Erlotinib",
        "value": 22.9,
        "unit": "months",
        "ci_lower": 15.7,
        "ci_upper": 26.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Erlotinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "OTHER",
      "OG002": "OTHER"
    }
  },
  {
    "nct_id": "NCT00113607",
    "brief_title": "An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer",
    "status": "COMPLETED",
    "start_date": "2005-04",
    "completion_date": "2010-11",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",
    "url": "https://clinicaltrials.gov/study/NCT00113607",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "DOXIL",
        "value": 5.8,
        "unit": "Months",
        "ci_lower": 5.5,
        "ci_upper": 7.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Trabectedin/DOXIL",
        "value": 7.3,
        "unit": "Months",
        "ci_lower": 5.9,
        "ci_upper": 7.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "DOXIL",
        "value": 18.9,
        "unit": "Months",
        "ci_lower": 17.1,
        "ci_upper": 21.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Trabectedin/DOXIL",
        "value": 22.2,
        "unit": "Months",
        "ci_lower": 19.3,
        "ci_upper": 25.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "DOXIL"
      ],
      "OG001": [
        "DOXIL",
        "Trabectedin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00177307",
    "brief_title": "Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2005-01",
    "completion_date": "2012-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "University of Pittsburgh",
    "url": "https://clinicaltrials.gov/study/NCT00177307",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Oxaliplatin, Capecitabine, and Bevacizumab",
        "value": 8.6,
        "unit": "Months",
        "ci_lower": 4.7,
        "ci_upper": 10.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Oxaliplatin, Capecitabine, and Bevacizumab",
        "value": 17.2,
        "unit": "Months",
        "ci_lower": 10.4,
        "ci_upper": 24.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Oxaliplatin",
        "Capecitabine",
        "Bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00129727",
    "brief_title": "Carboplatin Taxol Avastin in Ovarian Cancer (OVCA)",
    "status": "COMPLETED",
    "start_date": "2005-06",
    "completion_date": "2009-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Massachusetts General Hospital",
    "url": "https://clinicaltrials.gov/study/NCT00129727",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "I",
      "II",
      "III",
      "IV"
    ],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase II of Carboplatin, Pacitaxel, and Bevacizumab",
        "value": 29.8,
        "unit": "Months",
        "ci_lower": 17.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Carboplatin",
        "Paclitaxel",
        "Bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00130728",
    "brief_title": "A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2005-06-08",
    "completion_date": "2008-07-15",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Genentech, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT00130728",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Erlotinib HCl + Bevacizumab",
        "value": 9.3,
        "unit": "months",
        "ci_lower": 7.39,
        "ci_upper": 11.47,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Erlotinib HCl + Placebo",
        "value": 9.2,
        "unit": "months",
        "ci_lower": 7.85,
        "ci_upper": 11.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Erlotinib HCl + Bevacizumab",
        "value": 3.4,
        "unit": "months",
        "ci_lower": 2.79,
        "ci_upper": 4.27,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Erlotinib HCl + Placebo",
        "value": 1.7,
        "unit": "months",
        "ci_lower": 1.48,
        "ci_upper": 2.53,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "erlotinib HCl",
        "bevacizumab"
      ],
      "OG001": [
        "erlotinib HCl"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Targeted",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT00118755",
    "brief_title": "A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2005-07",
    "completion_date": "2009-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT00118755",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "XELOX Q3W + Bevacizumab",
        "value": 287.0,
        "unit": "Days",
        "ci_lower": 234.0,
        "ci_upper": 329.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "XELOX Q2W + Bevacizumab",
        "value": 273.0,
        "unit": "Days",
        "ci_lower": 231.0,
        "ci_upper": 313.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "XELOX Q3W + Bevacizumab",
        "value": 852.0,
        "unit": "Days",
        "ci_lower": 605.0,
        "ci_upper": 1052.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "XELOX Q2W + Bevacizumab",
        "value": 662.0,
        "unit": "Days",
        "ci_lower": 595.0,
        "ci_upper": 762.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "capecitabine",
        "Oxaliplatin",
        "bevacizumab"
      ],
      "OG001": [
        "capecitabine",
        "Oxaliplatin",
        "bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00122460",
    "brief_title": "Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)",
    "status": "COMPLETED",
    "start_date": "2004-12",
    "completion_date": "2007-03",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck KGaA, Darmstadt, Germany",
    "url": "https://clinicaltrials.gov/study/NCT00122460",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cetuximab Plus Chemotherapy",
        "value": 10.1,
        "unit": "months",
        "ci_lower": 8.6,
        "ci_upper": 11.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy Alone",
        "value": 7.4,
        "unit": "months",
        "ci_lower": 6.4,
        "ci_upper": 8.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cetuximab Plus Chemotherapy",
        "value": 5.6,
        "unit": "months",
        "ci_lower": 5.0,
        "ci_upper": 6.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy Alone",
        "value": 3.3,
        "unit": "months",
        "ci_lower": 2.9,
        "ci_upper": 4.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cetuximab",
        "Cisplatin",
        "Carboplatin",
        "5-Fluorouracil (5-FU)"
      ],
      "OG001": [
        "Cisplatin",
        "Carboplatin",
        "5-Fluorouracil (5-FU)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00148798",
    "brief_title": "Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)",
    "status": "COMPLETED",
    "start_date": "2004-10",
    "completion_date": "2007-07",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck KGaA, Darmstadt, Germany",
    "url": "https://clinicaltrials.gov/study/NCT00148798",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "Immunohistochemical (IHC) evidence of EGFR expression on tumor tissue"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cetuximab Plus Chemotherapy",
        "value": 11.3,
        "unit": "months",
        "ci_lower": 9.4,
        "ci_upper": 12.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy Alone",
        "value": 10.1,
        "unit": "months",
        "ci_lower": 9.1,
        "ci_upper": 10.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cetuximab Plus Chemotherapy",
        "value": 4.8,
        "unit": "months",
        "ci_lower": 4.2,
        "ci_upper": 5.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy Alone",
        "value": 4.8,
        "unit": "months",
        "ci_lower": 4.4,
        "ci_upper": 5.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "cetuximab",
        "cisplatin",
        "vinorelbine"
      ],
      "OG001": [
        "cisplatin",
        "vinorelbine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT02915523",
    "brief_title": "Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer",
    "status": "COMPLETED",
    "start_date": "2016-12-19",
    "completion_date": "2019-02-21",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Syndax Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT02915523",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase 2: Avelumab + Placebo",
        "value": 1.51,
        "unit": "months",
        "ci_lower": 1.45,
        "ci_upper": 2.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Phase 2: Avelumab + Entinostat",
        "value": 1.64,
        "unit": "months",
        "ci_lower": 1.41,
        "ci_upper": 2.69,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "avelumab"
      ],
      "OG001": [
        "avelumab",
        "entinostat"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT00126581",
    "brief_title": "Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2005-08-15",
    "completion_date": "2010-06-30",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT00126581",
    "cancer_types": [
      "NSCLC",
      "LUAD"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "Tissue (pathology block or unstained slides) must be available for sequencing; at least a core biopsy required"
      },
      {
        "target": "KRAS",
        "status": "ANY",
        "details": "Tissue (pathology block or unstained slides) must be available for sequencing; at least a core biopsy required"
      },
      {
        "target": "HER2",
        "status": "ANY",
        "details": "Tissue (pathology block or unstained slides) must be available for sequencing; at least a core biopsy required (listed as Erb-2)"
      },
      {
        "target": "BRAF",
        "status": "ANY",
        "details": "Tissue (pathology block or unstained slides) must be available for sequencing; at least a core biopsy required"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A: Erlotinib",
        "value": 52.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Erlotinib/Carboplatin/Paclitaxel",
        "value": 69.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A: Erlotinib",
        "value": 24.6,
        "unit": "months",
        "ci_lower": 18.4,
        "ci_upper": 33.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Erlotinib/Carboplatin/Paclitaxel",
        "value": 19.8,
        "unit": "months",
        "ci_lower": 14.4,
        "ci_upper": 27.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Erlotinib"
      ],
      "OG001": [
        "Erlotinib",
        "Carboplatin",
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT00121992",
    "brief_title": "Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment",
    "status": "COMPLETED",
    "start_date": "1999-07",
    "completion_date": "2010-12-02",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Spanish Breast Cancer Research Group",
    "url": "https://clinicaltrials.gov/study/NCT00121992",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "ANY",
        "details": "Estrogen receptor testing performed on the primary tumor prior to randomization (e.g., IHC)"
      },
      {
        "target": "PR",
        "status": "ANY",
        "details": "Progesterone receptor testing performed on the primary tumor prior to randomization (e.g., IHC)"
      }
    ],
    "cancer_stages": [
      "I",
      "II",
      "IA",
      "IB",
      "IIA",
      "IIB"
    ],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A: FAC",
        "value": 57.0,
        "unit": "Participants with mortality event",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B: TAC",
        "value": 53.0,
        "unit": "Participants with mortality event",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "5-fluorouracil",
        "Doxorubicin",
        "Cyclophosphamide"
      ],
      "OG001": [
        "Docetaxel",
        "Doxorubicin",
        "Cyclophosphamide"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00124657",
    "brief_title": "Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma",
    "status": "COMPLETED",
    "start_date": "2005-03",
    "completion_date": "2012-07",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "St. Jude Children's Research Hospital",
    "url": "https://clinicaltrials.gov/study/NCT00124657",
    "cancer_types": [
      "GBM",
      "LGG"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase I AA",
        "value": 0.75,
        "unit": "years",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Phase I GBM",
        "value": 0.33,
        "unit": "years",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Phase II AA",
        "value": 0.45,
        "unit": "years",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Phase II GBM",
        "value": 0.19,
        "unit": "years",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase I AA",
        "value": null,
        "unit": "years",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Phase I GBM",
        "value": null,
        "unit": "years",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Phase II AA",
        "value": 0.15,
        "unit": "years",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Phase II GBM",
        "value": 0.19,
        "unit": "years",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Erlotinib hydrochloride"
      ],
      "OG001": [
        "Erlotinib hydrochloride"
      ],
      "OG002": [
        "Erlotinib hydrochloride"
      ],
      "OG003": [
        "Erlotinib hydrochloride"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI",
      "OG002": "TKI",
      "OG003": "TKI"
    }
  },
  {
    "nct_id": "NCT00126594",
    "brief_title": "Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer",
    "status": "COMPLETED",
    "start_date": "2005-06",
    "completion_date": "2013-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT00126594",
    "cancer_types": [
      "KIRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Sorafenib Tosylate",
        "value": 30.0,
        "unit": "percentage of participants",
        "ci_lower": 16.56,
        "ci_upper": 46.53,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Sorafenib Tosylate, Recombinant Interferon Alfa-2b",
        "value": 25.0,
        "unit": "percentage of participants",
        "ci_lower": 12.69,
        "ci_upper": 41.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Sorafenib Tosylate",
        "value": 7.39,
        "unit": "Months",
        "ci_lower": 5.52,
        "ci_upper": 9.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Sorafenib Tosylate, Recombinant Interferon Alfa-2b",
        "value": 7.56,
        "unit": "Months",
        "ci_lower": 5.19,
        "ci_upper": 11.07,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Sorafenib Tosylate",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Sorafenib Tosylate, Recombinant Interferon Alfa-2b",
        "value": 27.04,
        "unit": "Months",
        "ci_lower": 22.31,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Sorafenib Tosylate"
      ],
      "OG001": [
        "Sorafenib Tosylate",
        "Recombinant Interferon Alfa-2b"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT00129389",
    "brief_title": "FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients",
    "status": "COMPLETED",
    "start_date": "2003-09-19",
    "completion_date": "2013-10-01",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Spanish Breast Cancer Research Group",
    "url": "https://clinicaltrials.gov/study/NCT00129389",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "IHC 0 or 1+ eligible; IHC 2+ requires FISH negative; IHC 3+ or positive FISH excluded"
      },
      {
        "target": "ER",
        "status": "ANY",
        "details": "Hormone receptor status must be available before end of adjuvant chemotherapy; ER-negative (with PR-negative) is one defined high\u2011risk criterion"
      },
      {
        "target": "PR",
        "status": "ANY",
        "details": "Hormone receptor status must be available before end of adjuvant chemotherapy; PR-negative (with ER-negative) is one defined high\u2011risk criterion"
      }
    ],
    "cancer_stages": [
      "I",
      "IA",
      "IB",
      "II",
      "IIA",
      "IIB"
    ],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A: FAC",
        "value": 98.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B: FAC-wP",
        "value": 71.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Fluorouracil",
        "Doxorubicin",
        "Cyclophosphamide"
      ],
      "OG001": [
        "Fluorouracil",
        "Doxorubicin",
        "Cyclophosphamide",
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00128102",
    "brief_title": "Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)",
    "status": "COMPLETED",
    "start_date": "2005-06-30",
    "completion_date": "2011-07-15",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT00128102",
    "cancer_types": [
      "MESO",
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Vorinostat",
        "value": 30.7,
        "unit": "Weeks",
        "ci_lower": 26.71,
        "ci_upper": 36.14,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 27.1,
        "unit": "Weeks",
        "ci_lower": 23.14,
        "ci_upper": 31.86,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Vorinostat",
        "value": 6.3,
        "unit": "Weeks",
        "ci_lower": 6.1,
        "ci_upper": 7.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 6.1,
        "unit": "Weeks",
        "ci_lower": 6.0,
        "ci_upper": 6.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Vorinostat"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT00129935",
    "brief_title": "EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2004-02",
    "completion_date": "2013-06",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Spanish Breast Cancer Research Group",
    "url": "https://clinicaltrials.gov/study/NCT00129935",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "IHC 0 or 1+ eligible; IHC 2+ requires negative FISH; IHC 3+ or positive FISH excluded"
      },
      {
        "target": "ER",
        "status": "ANY",
        "details": "Hormone receptor status must be available before the end of adjuvant chemotherapy"
      },
      {
        "target": "PR",
        "status": "ANY",
        "details": "Hormone receptor status must be available before the end of adjuvant chemotherapy"
      }
    ],
    "cancer_stages": [
      "IIA",
      "IIB",
      "IIIA",
      "IIIC"
    ],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A: EC-T",
        "value": 70.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B: ET-X",
        "value": 83.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Epirubicin",
        "Cyclophosphamide",
        "Docetaxel"
      ],
      "OG001": [
        "Epirubicin",
        "Docetaxel",
        "Capecitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT02913313",
    "brief_title": "A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2016-11-30",
    "completion_date": "2024-01-25",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT02913313",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "POSITIVE",
        "details": "tumor cell PD-L1 IHC \u22651% within 3 months of enrollment"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Part 2C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg",
        "value": 20.0,
        "unit": "percentage of participants",
        "ci_lower": 0.5,
        "ci_upper": 71.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG000",
        "arm_title": "Part 2C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Part 2C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg",
        "value": 80.0,
        "unit": "percentage of participants",
        "ci_lower": 20.4,
        "ci_upper": 96.9,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "BMS-986207"
      ],
      "OG001": [
        "BMS-986207"
      ],
      "OG002": [
        "BMS-986207"
      ],
      "OG003": [
        "BMS-986207"
      ],
      "OG004": [
        "BMS-986207"
      ],
      "OG005": [
        "BMS-986207"
      ],
      "OG006": [
        "BMS-986207"
      ],
      "OG007": [
        "BMS-986207",
        "Nivolumab"
      ],
      "OG008": [
        "BMS-986207",
        "Nivolumab"
      ],
      "OG009": [
        "BMS-986207",
        "Nivolumab"
      ],
      "OG010": [
        "BMS-986207",
        "Nivolumab"
      ],
      "OG011": [
        "BMS-986207",
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG012": [
        "BMS-986207",
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG013": [
        "BMS-986207",
        "Nivolumab",
        "Ipilimumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER",
      "OG002": "OTHER",
      "OG003": "OTHER",
      "OG004": "OTHER",
      "OG005": "OTHER",
      "OG006": "OTHER",
      "OG007": "IO",
      "OG008": "IO",
      "OG009": "IO",
      "OG010": "IO",
      "OG011": "IO",
      "OG012": "IO",
      "OG013": "IO"
    }
  },
  {
    "nct_id": "NCT00130533",
    "brief_title": "Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer Patients",
    "status": "COMPLETED",
    "start_date": "2006-01",
    "completion_date": "2017-02-17",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Spanish Breast Cancer Research Group",
    "url": "https://clinicaltrials.gov/study/NCT00130533",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 negative status in the primary tumor required; must be known before randomization."
      },
      {
        "target": "ER",
        "status": "ANY",
        "details": "Hormone receptor (estrogen receptor) status in the primary tumor must be assessed; results must be available (negative results must be available before end of adjuvant chemotherapy)."
      },
      {
        "target": "PR",
        "status": "ANY",
        "details": "Hormone receptor (progesterone receptor) status in the primary tumor must be assessed; results must be available (negative results must be available before end of adjuvant chemotherapy)."
      },
      {
        "target": "DPYD",
        "status": "NEGATIVE",
        "details": "History of dihydropyrimidine dehydrogenase (DPD) deficiency is an exclusion \u2014 DPYD deficiency must be absent."
      }
    ],
    "cancer_stages": [
      "I",
      "II",
      "III"
    ],
    "line_of_therapy": "MAINTENANCE",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Xeloda (Capecitabine)",
        "value": 71.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Observation",
        "value": 73.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Capecitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT00179309",
    "brief_title": "Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2005-09",
    "completion_date": "2013-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT00179309",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Estrogen receptor (ER) positive (patients whose tumors are ER-positive should have failed primary hormone therapy unless clinically indicated)"
      },
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER2 positive by FISH or IHC 3+ (patients who progressed or recurred following trastuzumab if HER2 FISH+ or IHC 3+)"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm I - PANVAC + Docetaxel",
        "value": 6.6,
        "unit": "Months",
        "ci_lower": 3.7,
        "ci_upper": 9.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm II - Docetaxel Alone",
        "value": 3.8,
        "unit": "Months",
        "ci_lower": 2.6,
        "ci_upper": 8.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Docetaxel",
        "PANVAC-V",
        "PANVAC-F",
        "Sargramostim"
      ],
      "OG001": [
        "Docetaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00193180",
    "brief_title": "Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2005-05",
    "completion_date": "2008-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SCRI Development Innovations, LLC",
    "url": "https://clinicaltrials.gov/study/NCT00193180",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Intervention",
        "value": 16.0,
        "unit": "percentage of participants",
        "ci_lower": 4.3,
        "ci_upper": 28.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Intervention",
        "value": 9.3,
        "unit": "Months",
        "ci_lower": 3.7,
        "ci_upper": 13.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Intervention",
        "value": 15.4,
        "unit": "months",
        "ci_lower": 9.6,
        "ci_upper": 26.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Docetaxel",
        "Imatinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT00193596",
    "brief_title": "Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site",
    "status": "COMPLETED",
    "start_date": "2003-09",
    "completion_date": "2008-09",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SCRI Development Innovations, LLC",
    "url": "https://clinicaltrials.gov/study/NCT00193596",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Paclitaxel/Carboplatin/Etoposide/Gefitinib",
        "value": 7.4,
        "unit": "months",
        "ci_lower": 4.67,
        "ci_upper": 10.28,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Irinotecan/Gemcitabine/Gefitinib",
        "value": 8.5,
        "unit": "months",
        "ci_lower": 6.64,
        "ci_upper": 10.58,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Paclitaxel/Carboplatin/Etoposide/Gefitinib",
        "value": 3.3,
        "unit": "months",
        "ci_lower": 2.2,
        "ci_upper": 4.86,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Irinotecan/Gemcitabine/Gefitinib",
        "value": 5.3,
        "unit": "months",
        "ci_lower": 3.88,
        "ci_upper": 6.21,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Paclitaxel",
        "Carboplatin",
        "Etoposide"
      ],
      "OG001": [
        "Irinotecan",
        "Gemcitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00193219",
    "brief_title": "Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2005-07",
    "completion_date": "2008-06",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SCRI Development Innovations, LLC",
    "url": "https://clinicaltrials.gov/study/NCT00193219",
    "cancer_types": [
      "COAD"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "Tumor tissue available for assessment of EGFR"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab/Cetuximab/FOLFOX",
        "value": 55.0,
        "unit": "percentage of patients",
        "ci_lower": 36.0,
        "ci_upper": 73.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab/Cetuximab/FOLFOX",
        "value": 9.0,
        "unit": "months",
        "ci_lower": 8.3,
        "ci_upper": 15.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab/Cetuximab/FOLFOX",
        "value": 25.7,
        "unit": "months",
        "ci_lower": 15.4,
        "ci_upper": 27.6,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Bevacizumab",
        "Cetuximab",
        "5-fluorouracil",
        "Leucovorin",
        "Oxaliplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00231465",
    "brief_title": "Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2003-07",
    "completion_date": "2012-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
    "url": "https://clinicaltrials.gov/study/NCT00231465",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Taxotere\u0000ae (Docetaxel) + ZD1839 (IRESSA\u0000ae)",
        "value": 40.0,
        "unit": "percentage of participants",
        "ci_lower": 26.0,
        "ci_upper": 57.0,
        "dispersion_type": "MEAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Taxotere\u0000ae (Docetaxel) + ZD1839 (IRESSA\u0000ae)",
        "value": 6.9,
        "unit": "Months",
        "ci_lower": 3.95,
        "ci_upper": 7.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Taxotere\u0000ae (Docetaxel) + ZD1839 (IRESSA\u0000ae)",
        "value": 9.59,
        "unit": "Months",
        "ci_lower": 4.6,
        "ci_upper": 16.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "docetaxel (Taxotere\u0000ae)",
        "ZD1839"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT00240071",
    "brief_title": "Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.",
    "status": "COMPLETED",
    "start_date": "2005-10",
    "completion_date": "2009-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "University of Alabama at Birmingham",
    "url": "https://clinicaltrials.gov/study/NCT00240071",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Estrogen receptor (hormone receptor) positive"
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": "Progesterone receptor (hormone receptor) positive"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Avastin (Bevacizumab) Plus Hormone",
        "value": 125.5,
        "unit": "days",
        "ci_lower": 90.0,
        "ci_upper": 256.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Avastin",
        "Hormonal therapy"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02928224",
    "brief_title": "Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2016-10-13",
    "completion_date": "2019-02-11",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT02928224",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "BRAF",
        "status": "POSITIVE",
        "details": "V600E mutation (BRAFV600E) detected by local or central assay"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Phase 3: Triplet Arm",
        "value": 9.03,
        "unit": "Months",
        "ci_lower": 8.02,
        "ci_upper": 11.43,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Phase 3: Control Arm",
        "value": 5.42,
        "unit": "Months",
        "ci_lower": 4.76,
        "ci_upper": 6.57,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 3: Triplet Arm",
        "value": 26.1,
        "unit": "Percentage of participants",
        "ci_lower": 18.2,
        "ci_upper": 35.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Phase 3:Control Arm",
        "value": 1.9,
        "unit": "Percentage of participants",
        "ci_lower": 0.2,
        "ci_upper": 6.6,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Encorafenib",
        "Binimetinib",
        "Cetuximab"
      ],
      "OG001": [
        "Cetuximab",
        "Irinotecan",
        "Folinic Acid",
        "5-Fluorouracil"
      ],
      "OG002": [
        "Cetuximab",
        "Irinotecan",
        "Folinic Acid",
        "5-Fluorouracil"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00244881",
    "brief_title": "A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)",
    "status": "COMPLETED",
    "start_date": "2005-09",
    "completion_date": "2007-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT00244881",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IV",
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (Cediranib Maleate)",
        "value": 8.0,
        "unit": "percentage of participants",
        "ci_lower": 1.0,
        "ci_upper": 25.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "cediranib maleate"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT00192114",
    "brief_title": "Enzastaurin for Patients With Metastatic Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2005-08",
    "completion_date": "2008-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00192114",
    "cancer_types": [
      "COAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Enzastaurin HCl",
        "value": 27.5,
        "unit": "percentage of participants",
        "ci_lower": 12.53,
        "ci_upper": 44.82,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Enzastaurin HCl",
        "value": 23.38,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Enzastaurin HCl"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00219557",
    "brief_title": "AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer",
    "status": "COMPLETED",
    "start_date": "2005-07-05",
    "completion_date": "2008-03-14",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT00219557",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Axitinib + Gemcitabine",
        "value": 210.0,
        "unit": "Days",
        "ci_lower": 162.0,
        "ci_upper": 308.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Gemcitabine",
        "value": 171.0,
        "unit": "Days",
        "ci_lower": 125.0,
        "ci_upper": 267.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Axitinib + Gemcitabine",
        "value": 116.0,
        "unit": "Days",
        "ci_lower": 109.0,
        "ci_upper": 160.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Gemcitabine",
        "value": 113.0,
        "unit": "Days",
        "ci_lower": 68.0,
        "ci_upper": 205.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Axitinib",
        "Gemcitabine"
      ],
      "OG001": [
        "Gemcitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00193063",
    "brief_title": "Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2001-07",
    "completion_date": "2009-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SCRI Development Innovations, LLC",
    "url": "https://clinicaltrials.gov/study/NCT00193063",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "confirmed by biopsy"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Gemcitabine/Trastuzumab",
        "value": 30.0,
        "unit": "percentage of participants",
        "ci_lower": 17.0,
        "ci_upper": 46.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Gemcitabine/Trastuzumab",
        "value": 4.0,
        "unit": "months",
        "ci_lower": 1.9,
        "ci_upper": 5.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Gemcitabine/Trastuzumab",
        "value": 21.0,
        "unit": "months",
        "ci_lower": 11.5,
        "ci_upper": 30.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Gemcitabine",
        "Trastuzumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00191646",
    "brief_title": "An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy",
    "status": "COMPLETED",
    "start_date": "2002-10",
    "completion_date": "2009-08",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00191646",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "I",
      "II",
      "III",
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Gemcitabine/Carboplatin",
        "value": 20.0,
        "unit": "Months",
        "ci_lower": 17.9,
        "ci_upper": 22.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Paclitaxel/Carboplatin",
        "value": 22.2,
        "unit": "Months",
        "ci_lower": 19.0,
        "ci_upper": 25.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Gemcitabine/Carboplatin",
        "value": 43.8,
        "unit": "months",
        "ci_lower": 38.8,
        "ci_upper": 48.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Paclitaxel/Carboplatin",
        "value": 57.3,
        "unit": "months",
        "ci_lower": 48.5,
        "ci_upper": 64.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Gemcitabine",
        "Carboplatin",
        "Paclitaxel"
      ],
      "OG001": [
        "Paclitaxel",
        "Carboplatin"
      ],
      "OG002": [
        "Gemcitabine"
      ],
      "OG003": [
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo",
      "OG002": "Chemo",
      "OG003": "Chemo"
    }
  },
  {
    "nct_id": "NCT00226239",
    "brief_title": "Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer",
    "status": "COMPLETED",
    "start_date": "2005-10",
    "completion_date": "2013-07",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "University of Pittsburgh",
    "url": "https://clinicaltrials.gov/study/NCT00226239",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "II",
      "III",
      "IVA",
      "IVB"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Head and Neck Cancer Patients",
        "value": 86.0,
        "unit": "percentage of participants",
        "ci_lower": 75.0,
        "ci_upper": 98.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Head and Neck Cancer Patients",
        "value": 70.0,
        "unit": "percentage of participants",
        "ci_lower": 53.0,
        "ci_upper": 82.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Head and Neck Cancer Patients",
        "value": 70.0,
        "unit": "percentage of participants",
        "ci_lower": 53.0,
        "ci_upper": 82.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Head and Neck Cancer Patients",
        "value": 84.0,
        "unit": "percentage of participants",
        "ci_lower": 68.0,
        "ci_upper": 93.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Docetaxel",
        "Cisplatin",
        "Cetuximab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02924883",
    "brief_title": "A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy",
    "status": "COMPLETED",
    "start_date": "2016-09-26",
    "completion_date": "2017-12-11",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT02924883",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "IHC score of 3+ OR gene amplification by in-situ hybridization defined as HER2/Chr17 ratio \u22652.0"
      },
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Able to submit tumor tissue evaluable for PD-L1 expression (no positivity threshold required)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "UNRESECTABLE",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Trastuzumab Emtansine + Placebo",
        "value": 6.8,
        "unit": "months",
        "ci_lower": 4.0,
        "ci_upper": 11.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Trastuzumab Emtansine + Atezolizumab",
        "value": 8.2,
        "unit": "months",
        "ci_lower": 5.8,
        "ci_upper": 10.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Trastuzumab Emtansine + Placebo",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Trastuzumab Emtansine + Atezolizumab",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Trastuzumab emtansine"
      ],
      "OG001": [
        "Atezolizumab",
        "Trastuzumab emtansine"
      ]
    },
    "treatment_class_map": {
      "OG000": "ADC",
      "OG001": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT00193037",
    "brief_title": "Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2001-02",
    "completion_date": "2008-12",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SCRI Development Innovations, LLC",
    "url": "https://clinicaltrials.gov/study/NCT00193037",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Arm A -Liposomal Doxorubicin Then Docetaxel",
        "value": 28.0,
        "unit": "percentage of patients",
        "ci_lower": 16.0,
        "ci_upper": 42.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Arm B - Docetaxel Then Liposomal Doxorubicin",
        "value": 31.0,
        "unit": "percentage of patients",
        "ci_lower": 18.0,
        "ci_upper": 45.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A -Liposomal Doxorubicin Then Docetaxel",
        "value": 6.5,
        "unit": "months",
        "ci_lower": 3.6,
        "ci_upper": 9.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B - Docetaxel Then Liposomal Doxorubicin",
        "value": 5.5,
        "unit": "months",
        "ci_lower": 4.9,
        "ci_upper": 9.6,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Liposomal Doxorubicin",
        "Docetaxel"
      ],
      "OG001": [
        "Docetaxel",
        "Liposomal Doxorubicin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00242502",
    "brief_title": "Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery",
    "status": "COMPLETED",
    "start_date": "2005-10",
    "completion_date": "2011-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "M.D. Anderson Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT00242502",
    "cancer_types": [
      "LIHC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab + Erlotinib",
        "value": 64.0,
        "unit": "percentage of participants",
        "ci_lower": 51.0,
        "ci_upper": 76.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Bevacizumab",
        "Erlotinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Targeted"
    }
  },
  {
    "nct_id": "NCT02921269",
    "brief_title": "Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer",
    "status": "COMPLETED",
    "start_date": "2017-03-10",
    "completion_date": "2020-10-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT02921269",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (Atezolizumab, Bevacizumab)",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Atezolizumab, Bevacizumab)",
        "value": 2.9,
        "unit": "months",
        "ci_lower": 1.8,
        "ci_upper": 6.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Atezolizumab, Bevacizumab)",
        "value": 8.9,
        "unit": "months",
        "ci_lower": 3.4,
        "ci_upper": 21.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Atezolizumab",
        "Bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT02915744",
    "brief_title": "A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine",
    "status": "COMPLETED",
    "start_date": "2016-11",
    "completion_date": "2020-07",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Nektar Therapeutics",
    "url": "https://clinicaltrials.gov/study/NCT02915744",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "NKTR-102",
        "value": 7.8,
        "unit": "months",
        "ci_lower": 6.1,
        "ci_upper": 10.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Treatment of Physician's Choice (TPC)",
        "value": 7.5,
        "unit": "months",
        "ci_lower": 5.8,
        "ci_upper": 10.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "NKTR-102"
      ],
      "OG001": [
        "Eribulin",
        "Ixabepilone",
        "Vinorelbine",
        "Gemcitabine",
        "Paclitaxel",
        "Docetaxel",
        "Nab-paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00246571",
    "brief_title": "Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2006-01",
    "completion_date": "2010-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT00246571",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "Estrogen receptor negative (ER)"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "Progesterone receptor negative (PR)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2/neu receptor negative (HER2)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Sunitinib",
        "value": 2.0,
        "unit": "Months",
        "ci_lower": 1.5,
        "ci_upper": 2.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Standard of Care",
        "value": 2.7,
        "unit": "Months",
        "ci_lower": 1.7,
        "ci_upper": 2.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Sunitinib",
        "value": 1.7,
        "unit": "Months",
        "ci_lower": 1.5,
        "ci_upper": 2.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Standard of Care",
        "value": 2.5,
        "unit": "Months",
        "ci_lower": 1.4,
        "ci_upper": 2.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Sunitinib",
        "value": 9.4,
        "unit": "months",
        "ci_lower": 5.8,
        "ci_upper": 11.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Standard of Care",
        "value": 10.5,
        "unit": "months",
        "ci_lower": 8.5,
        "ci_upper": 13.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "SU011248 (sunitinib)"
      ],
      "OG001": [
        "Capecitabine",
        "Vinorelbine"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00186121",
    "brief_title": "Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women",
    "status": "COMPLETED",
    "start_date": "2000-10",
    "completion_date": "2013-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Stanford University",
    "url": "https://clinicaltrials.gov/study/NCT00186121",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Estrogen receptor positive by IHC or competitive binding assay on metastatic disease, or positive on primary if metastatic not performed."
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": "Progesterone receptor positive by IHC or competitive binding assay on metastatic disease, or positive on primary if metastatic not performed."
      },
      {
        "target": "FSH",
        "status": "ANY",
        "details": "FSH in the premenopausal range (used to define premenopausal status if post-hysterectomy without bilateral oophorectomy)."
      },
      {
        "target": "Estradiol",
        "status": "ANY",
        "details": "Plasma estradiol in the premenopausal range (required if tamoxifen administered within the past 3 months to confirm premenopausal status)."
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Anastrozole + Goserelin",
        "value": 37.5,
        "unit": "percentage of participants",
        "ci_lower": 21.0,
        "ci_upper": 56.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Anastrozole + Goserelin",
        "value": null,
        "unit": "months",
        "ci_lower": 11.1,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Anastrozole (Arimidex)",
        "Goserelin (Zoladex)"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER"
    }
  },
  {
    "nct_id": "NCT00248287",
    "brief_title": "PhII ICb With/Without Erbitux in MBC Pts",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2005-07-28",
    "completion_date": "2025-12",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "US Oncology Research",
    "url": "https://clinicaltrials.gov/study/NCT00248287",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "ANY",
        "details": "Documented as either HER2-positive (3+ by IHC or FISH+) or HER2-negative; IHC 2+ requires FISH confirmation"
      },
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "Paraffin-embedded tissue available for analysis (required)"
      },
      {
        "target": "ER",
        "status": "ANY",
        "details": "ER status must be documented in eCRF"
      },
      {
        "target": "PR",
        "status": "ANY",
        "details": "PR status must be documented in eCRF"
      },
      {
        "target": "CYTOKERATIN",
        "status": "ANY",
        "details": "Paraffin-embedded tissue available for analysis (cytokeratin)"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Irinotecan+Carboplatin",
        "value": 36.4,
        "unit": "Percentage of Participants",
        "ci_lower": 24.9,
        "ci_upper": 49.1,
        "dispersion_type": "95% Confidence Interval"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Irinotecan+Carboplatin+Cetuximab",
        "value": 36.6,
        "unit": "Percentage of Participants",
        "ci_lower": 25.5,
        "ci_upper": 48.9,
        "dispersion_type": "95% Confidence Interval"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Irinotecan+Carboplatin",
        "value": 4.4,
        "unit": "months",
        "ci_lower": 3.2,
        "ci_upper": 5.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Irinotecan+Carboplatin+Cetuximab",
        "value": 4.6,
        "unit": "months",
        "ci_lower": 3.5,
        "ci_upper": 5.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Irinotecan+Carboplatin",
        "value": 12.5,
        "unit": "months",
        "ci_lower": 10.6,
        "ci_upper": 17.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Irinotecan+Carboplatin+Cetuximab",
        "value": 14.6,
        "unit": "months",
        "ci_lower": 10.4,
        "ci_upper": 16.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Irinotecan",
        "Carboplatin"
      ],
      "OG001": [
        "Irinotecan",
        "Carboplatin",
        "Cetuximab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00281658",
    "brief_title": "Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2",
    "status": "COMPLETED",
    "start_date": "2006-01-02",
    "completion_date": "2010-06-18",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT00281658",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "Amplification by FISH in primary or metastatic tumor tissue (central laboratory confirmation required for randomization)"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Lapatinib 1500 mg + Paclitaxel",
        "value": 27.8,
        "unit": "months",
        "ci_lower": 23.2,
        "ci_upper": 32.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Paclitaxel",
        "value": 20.5,
        "unit": "months",
        "ci_lower": 17.9,
        "ci_upper": 24.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Lapatinib",
        "Paclitaxel"
      ],
      "OG001": [
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00284154",
    "brief_title": "Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2006-01",
    "completion_date": "2009-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SCRI Development Innovations, LLC",
    "url": "https://clinicaltrials.gov/study/NCT00284154",
    "cancer_types": [
      "SCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Vinflunine",
        "value": 19.6,
        "unit": "percentage of participants",
        "ci_lower": 10.0,
        "ci_upper": 33.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Vinflunine",
        "value": 4.9,
        "unit": "Months",
        "ci_lower": 3.2,
        "ci_upper": 6.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Vinflunine",
        "value": 1.6,
        "unit": "Months",
        "ci_lower": 1.3,
        "ci_upper": 3.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Vinflunine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo"
    }
  },
  {
    "nct_id": "NCT00284180",
    "brief_title": "Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2006-01",
    "completion_date": "2008-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SCRI Development Innovations, LLC",
    "url": "https://clinicaltrials.gov/study/NCT00284180",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "ANY",
        "details": "HER2 assessed by FISH. HER2 FISH+ patients receive vinflunine + trastuzumab; HER2 FISH\u2011negative or unknown patients remain on study and receive vinflunine alone."
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Vinflunine",
        "value": 9.0,
        "unit": "percentage of participants",
        "ci_lower": 0.23,
        "ci_upper": 41.26,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Vinflunine/Trastuzumab",
        "value": 33.0,
        "unit": "percentage of participants",
        "ci_lower": 14.59,
        "ci_upper": 56.97,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Vinflunine"
      ],
      "OG001": [
        "Vinflunine",
        "Trastuzumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00283062",
    "brief_title": "Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy",
    "status": "COMPLETED",
    "start_date": "2005-12",
    "completion_date": "2010-12",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sanofi",
    "url": "https://clinicaltrials.gov/study/NCT00283062",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [
      {
        "target": "PSA",
        "status": "LOW",
        "details": "Post-operative PSA \u22640.2 ng/mL (measured at least 30 days after radical prostatectomy and within 7 days prior to randomization)"
      },
      {
        "target": "TESTOSTERONE",
        "status": "HIGH",
        "details": "Serum testosterone \u2265150 ng/dL within 6 months prior to randomization"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Docetaxel / Leuprolide Acetate - Immediate Treatment (I-CHT)",
        "value": 10.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Leuprolide Acetate - Immediate Treatment (I-HT)",
        "value": 14.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Docetaxel / Leuprolide Acetate - Deferred Treatment (D-CHT)",
        "value": 9.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Leuprolide Acetate - Deferred Treatment (D-HT)",
        "value": 8.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Docetaxel / Leuprolide Acetate - Immediate Treatment (I-CHT)",
        "value": 0.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Leuprolide Acetate - Immediate Treatment (I-HT)",
        "value": 2.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Docetaxel / Leuprolide Acetate - Deferred Treatment (D-CHT)",
        "value": 1.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Leuprolide Acetate - Deferred Treatment (D-HT)",
        "value": 1.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Docetaxel",
        "Leuprolide acetate"
      ],
      "OG001": [
        "Leuprolide acetate"
      ],
      "OG002": [
        "Docetaxel",
        "Leuprolide acetate"
      ],
      "OG003": [
        "Leuprolide acetate"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER",
      "OG002": "OTHER",
      "OG003": "OTHER"
    }
  },
  {
    "nct_id": "NCT00258960",
    "brief_title": "Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2006-02-15",
    "completion_date": "2008-07",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Spanish Breast Cancer Research Group",
    "url": "https://clinicaltrials.gov/study/NCT00258960",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "Overexpression of Her2neu (HER2)"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Caelyx,Cyclophosphamide,Trastuzumab",
        "value": 33.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Caelyx,Cyclophosphamide,Trastuzumab",
        "value": 34.2,
        "unit": "Months",
        "ci_lower": 27.2,
        "ci_upper": 41.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Liposomal Doxorubicin",
        "Cyclophosphamide",
        "Trastuzumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00257608",
    "brief_title": "A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)",
    "status": "COMPLETED",
    "start_date": "2006-01",
    "completion_date": "2014-11",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Genentech, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT00257608",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab + Placebo",
        "value": 3.7,
        "unit": "months",
        "ci_lower": 2.86,
        "ci_upper": 4.04,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab + Erlotinib",
        "value": 4.8,
        "unit": "months",
        "ci_lower": 4.14,
        "ci_upper": 5.52,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab + Placebo",
        "value": 13.3,
        "unit": "months",
        "ci_lower": 12.12,
        "ci_upper": 14.52,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab + Erlotinib",
        "value": 14.4,
        "unit": "months",
        "ci_lower": 12.29,
        "ci_upper": 18.6,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "bevacizumab"
      ],
      "OG001": [
        "bevacizumab",
        "erlotinib"
      ],
      "OG002": [
        "carboplatin",
        "docetaxel",
        "bevacizumab"
      ],
      "OG003": [
        "cisplatin",
        "gemcitabine",
        "bevacizumab"
      ],
      "OG004": [
        "cisplatin",
        "docetaxel",
        "vinorelbine",
        "bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Combo_TKI_Targeted",
      "OG002": "Combo_Chemo_Targeted",
      "OG003": "Combo_Chemo_Targeted",
      "OG004": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00252564",
    "brief_title": "Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2005-09",
    "completion_date": "2007-06",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "US Oncology Research",
    "url": "https://clinicaltrials.gov/study/NCT00252564",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "Paraffin tissue block(s) or unstained slides required for assessment of potential predictive markers related to the EGFR pathway"
      },
      {
        "target": "VEGF",
        "status": "ANY",
        "details": "Paraffin tissue block(s) or unstained slides required for assessment of potential predictive markers related to the VEGF pathway"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A",
        "value": 11.0,
        "unit": "months",
        "ci_lower": 9.2,
        "ci_upper": 13.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B",
        "value": 8.3,
        "unit": "months",
        "ci_lower": 6.7,
        "ci_upper": 9.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A",
        "value": 21.3,
        "unit": "Months",
        "ci_lower": 18.2,
        "ci_upper": 25.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B",
        "value": 19.5,
        "unit": "Months",
        "ci_lower": 16.5,
        "ci_upper": 21.6,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Bevacizumab",
        "Oxaliplatin",
        "Leucovorin",
        "Fluorouracil"
      ],
      "OG001": [
        "Cetuximab",
        "Bevacizumab",
        "Leucovorin",
        "Fluorouracil"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02963831",
    "brief_title": "A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies",
    "status": "COMPLETED",
    "start_date": "2017-09-07",
    "completion_date": "2022-06-25",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Ludwig Institute for Cancer Research",
    "url": "https://clinicaltrials.gov/study/NCT02963831",
    "cancer_types": [
      "CRC",
      "OV",
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort A: ONCOS-102 Dose Escalation",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort B: ONCOS-102 Dose Escalation",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Cohort 1: Epithelial Ovarian Cancer",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Cohort 2: Metastatic Colorectal Cancer",
        "value": 2.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "ONCOS-102",
        "Durvalumab",
        "Cyclophosphamide"
      ],
      "OG001": [
        "ONCOS-102",
        "Durvalumab",
        "Cyclophosphamide"
      ],
      "OG002": [
        "ONCOS-102",
        "Durvalumab",
        "Cyclophosphamide"
      ],
      "OG003": [
        "ONCOS-102",
        "Durvalumab",
        "Cyclophosphamide"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Combo_Chemo_IO",
      "OG002": "Combo_Chemo_IO",
      "OG003": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT02964078",
    "brief_title": "Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer",
    "status": "COMPLETED",
    "start_date": "2017-04-25",
    "completion_date": "2019-03-26",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
    "url": "https://clinicaltrials.gov/study/NCT02964078",
    "cancer_types": [
      "KIRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab and Interleukin-2",
        "value": 70.4,
        "unit": "percentage of participants",
        "ci_lower": 54.6,
        "ci_upper": 100.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab and Interleukin-2",
        "value": 1.0,
        "unit": "proportion of participants",
        "ci_lower": 0.871,
        "ci_upper": 1.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab and Interleukin-2",
        "value": 0.63,
        "unit": "proportion of participants",
        "ci_lower": 0.421,
        "ci_upper": 0.781,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Interleukin-2"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO"
    }
  },
  {
    "nct_id": "NCT00265941",
    "brief_title": "Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer",
    "status": "COMPLETED",
    "start_date": "2005-11",
    "completion_date": "2011-01",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Radiation Therapy Oncology Group",
    "url": "https://clinicaltrials.gov/study/NCT00265941",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "III",
      "IV",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "RT + Cisplatin",
        "value": 61.2,
        "unit": "percentage of participants",
        "ci_lower": 56.7,
        "ci_upper": 65.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "RT + Cisplatin + Cetuximab",
        "value": 58.9,
        "unit": "percentage of participants",
        "ci_lower": 54.2,
        "ci_upper": 63.6,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "cisplatin"
      ],
      "OG001": [
        "cisplatin",
        "cetuximab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "OTHER",
      "OG003": "OTHER"
    }
  },
  {
    "nct_id": "NCT02971956",
    "brief_title": "Pembrolizumab in Refractory Advanced Esophageal Cancer",
    "status": "COMPLETED",
    "start_date": "2017-01-18",
    "completion_date": "2019-07-23",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Dana-Farber Cancer Institute",
    "url": "https://clinicaltrials.gov/study/NCT02971956",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "UNRESECTABLE",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab",
        "value": 0.08,
        "unit": "proportion of participant",
        "ci_lower": 0.023,
        "ci_upper": 0.196,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab",
        "value": 1.8,
        "unit": "months",
        "ci_lower": 1.8,
        "ci_upper": 2.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab",
        "value": 5.8,
        "unit": "months",
        "ci_lower": 4.0,
        "ci_upper": 9.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO"
    }
  },
  {
    "nct_id": "NCT00271505",
    "brief_title": "Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2005-12-05",
    "completion_date": "2017-07-27",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "M.D. Anderson Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT00271505",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Carboplatin, Docetaxel, and Bevacizumab",
        "value": 7.9,
        "unit": "months",
        "ci_lower": 6.0,
        "ci_upper": 11.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Carboplatin,Docetaxel, and Bevacizumab",
        "value": 16.5,
        "unit": "months",
        "ci_lower": 13.6,
        "ci_upper": 31.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Carboplatin",
        "Docetaxel",
        "Bevacizumab (Avastin)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00267020",
    "brief_title": "Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic Cancer",
    "status": "COMPLETED",
    "start_date": "2005-12",
    "completion_date": "2008-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00267020",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Enzastaurin+Gemcitabine",
        "value": 5.6,
        "unit": "months",
        "ci_lower": 4.2,
        "ci_upper": 6.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Gemcitabine",
        "value": 5.1,
        "unit": "months",
        "ci_lower": 3.6,
        "ci_upper": 8.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Enzastaurin+Gemcitabine",
        "value": 3.4,
        "unit": "months",
        "ci_lower": 2.4,
        "ci_upper": 4.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Gemcitabine",
        "value": 3.0,
        "unit": "months",
        "ci_lower": 1.9,
        "ci_upper": 4.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "enzastaurin",
        "gemcitabine"
      ],
      "OG001": [
        "gemcitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT02981524",
    "brief_title": "Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2017-05-26",
    "completion_date": "2018-03-20",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
    "url": "https://clinicaltrials.gov/study/NCT02981524",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "MSI",
        "status": "NEGATIVE",
        "details": "Mismatch repair-proficient (pMMR) / microsatellite stable (MSS)"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "CY/GVAX With Pembrolizumab",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "CY/GVAX With Pembrolizumab",
        "value": 82.0,
        "unit": "days",
        "ci_lower": 48.0,
        "ci_upper": 97.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "CY/GVAX With Pembrolizumab",
        "value": 213.0,
        "unit": "days",
        "ci_lower": 179.0,
        "ci_upper": 441.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "CY",
        "GVAX",
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT02952534",
    "brief_title": "A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency",
    "status": "COMPLETED",
    "start_date": "2017-02-15",
    "completion_date": "2021-07-18",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "pharmaand GmbH",
    "url": "https://clinicaltrials.gov/study/NCT02952534",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [
      {
        "target": "BRCA1",
        "status": "POSITIVE",
        "details": "deleterious mutation"
      },
      {
        "target": "BRCA2",
        "status": "POSITIVE",
        "details": "deleterious mutation"
      },
      {
        "target": "ATM",
        "status": "POSITIVE",
        "details": "deleterious mutation"
      },
      {
        "target": "HRD",
        "status": "POSITIVE",
        "details": "molecular evidence of homologous recombination deficiency"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "BRCA Mutation",
        "value": 45.7,
        "unit": "percentage of participants",
        "ci_lower": 34.6,
        "ci_upper": 57.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "ATM Mutation",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 14.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "CDK12 Mutation",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 36.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "CHEK2 Mutation",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 60.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Other Gene Mutation",
        "value": 41.2,
        "unit": "percentage of participants",
        "ci_lower": 18.4,
        "ci_upper": 67.1,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Rucaparib"
      ],
      "OG001": [
        "Rucaparib"
      ],
      "OG002": [
        "Rucaparib"
      ],
      "OG003": [
        "Rucaparib"
      ],
      "OG004": [
        "Rucaparib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other",
      "OG004": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02953782",
    "brief_title": "Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2016-11-02",
    "completion_date": "2020-02-10",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Gilead Sciences",
    "url": "https://clinicaltrials.gov/study/NCT02953782",
    "cancer_types": [
      "CRC",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "POSITIVE",
        "details": "KRAS mutation (KRAS mutant colorectal cancer cohort)"
      },
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "KRAS wild-type (required for wild-type CRC cohort); cohort must be relapsed/refractory to at least 1 prior systemic therapy that included an anti-EGFR antibody"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "KRASwt CRC",
        "value": 6.3,
        "unit": "percentage of participants",
        "ci_lower": 0.8,
        "ci_upper": 20.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "KRASm CRC",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 8.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "KRASwt CRC",
        "value": 3.6,
        "unit": "months",
        "ci_lower": 1.8,
        "ci_upper": 5.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "KRASm CRC",
        "value": 1.9,
        "unit": "months",
        "ci_lower": 1.8,
        "ci_upper": 3.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "KRASwt CRC",
        "value": 9.5,
        "unit": "months",
        "ci_lower": 5.9,
        "ci_upper": 12.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "KRASm CRC",
        "value": 7.6,
        "unit": "months",
        "ci_lower": 5.4,
        "ci_upper": 11.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Magrolimab",
        "Cetuximab"
      ],
      "OG001": [
        "Magrolimab",
        "Cetuximab"
      ],
      "OG002": [
        "Magrolimab",
        "Cetuximab"
      ],
      "OG003": [
        "Magrolimab",
        "Cetuximab"
      ],
      "OG004": [
        "Magrolimab",
        "Cetuximab"
      ],
      "OG005": [
        "Magrolimab",
        "Cetuximab"
      ],
      "OG006": [
        "Magrolimab",
        "Cetuximab"
      ],
      "OG007": [
        "Magrolimab",
        "Cetuximab"
      ],
      "OG008": [
        "Magrolimab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted",
      "OG002": "Combo_IO_Targeted",
      "OG003": "Combo_IO_Targeted",
      "OG004": "Combo_IO_Targeted",
      "OG005": "Combo_IO_Targeted",
      "OG006": "Combo_IO_Targeted",
      "OG007": "Combo_IO_Targeted",
      "OG008": "IO"
    }
  },
  {
    "nct_id": "NCT02981303",
    "brief_title": "Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2017-02-22",
    "completion_date": "2020-12-31",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "HiberCell, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT02981303",
    "cancer_types": [
      "SKCM",
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Irrespective of PD-L1 status (mentioned for both melanoma and TNBC)"
      },
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "Defined by negative IHC for Estrogen Receptor"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "Defined by negative IHC for Progesterone Receptor"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 negative by IHC 0 or 1+, or 2+ by IHC confirmed negative by FISH"
      },
      {
        "target": "ABA",
        "status": "HIGH",
        "details": "IgG anti-\u03b2-glucan antibody (ABA) \u2265 20 mcg/mL as determined by ELISA within 28 days prior to treatment"
      }
    ],
    "cancer_stages": [
      "III",
      "IV",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": null,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Melanoma",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Triple Negative Breast Cancer",
        "value": 6.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Melanoma",
        "value": 1.76,
        "unit": "Months",
        "ci_lower": 1.31,
        "ci_upper": 2.79,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Triple Negative Breast Cancer",
        "value": 2.35,
        "unit": "Months",
        "ci_lower": 1.35,
        "ci_upper": 3.98,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Melanoma",
        "value": 8.8,
        "unit": "Months",
        "ci_lower": 3.61,
        "ci_upper": 15.67,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Triple Negative Breast Cancer",
        "value": 16.36,
        "unit": "Months",
        "ci_lower": 11.1,
        "ci_upper": 19.22,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Imprime PGG",
        "Pembrolizumab"
      ],
      "OG001": [
        "Imprime PGG",
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT02939651",
    "brief_title": "A Study of Pembrolizumab in Patients With Neuroendocrine Tumors",
    "status": "COMPLETED",
    "start_date": "2016-10-26",
    "completion_date": "2018-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Fox Chase Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT02939651",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "Ki67",
        "status": "HIGH",
        "details": ">20% (Ki67 proliferation index)"
      },
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "Known history of HIV excluded"
      },
      {
        "target": "HBV",
        "status": "NEGATIVE",
        "details": "Active hepatitis B excluded (e.g., HBsAg reactive)"
      },
      {
        "target": "HCV",
        "status": "NEGATIVE",
        "details": "Active hepatitis C excluded (e.g., HCV RNA qualitative)"
      },
      {
        "target": "Pregnancy",
        "status": "NEGATIVE",
        "details": "Negative serum pregnancy test within 72 hours prior to first dose; pregnant or breastfeeding excluded"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab",
        "value": 8.86,
        "unit": "weeks",
        "ci_lower": 6.0,
        "ci_upper": 9.43,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab",
        "value": 20.43,
        "unit": "weeks",
        "ci_lower": 12.86,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO"
    }
  },
  {
    "nct_id": "NCT02937116",
    "brief_title": "First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2016-10-19",
    "completion_date": "2020-09-30",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Innovent Biologics (Suzhou) Co. Ltd.",
    "url": "https://clinicaltrials.gov/study/NCT02937116",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "No known EGFR mutation"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "No known ALK rearrangement"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "No known HER2 amplification"
      },
      {
        "target": "KI67",
        "status": "HIGH",
        "details": "Ki-67 >20% (high grade G3 neuroendocrine tumor)"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV",
      "RECURRENT",
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1)",
        "value": null,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)",
        "value": null,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)",
        "value": null,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)",
        "value": null,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "MEL: Sintilimab 200mg Q3W (Cohort A)",
        "value": 4.5,
        "unit": "percentage of participants",
        "ci_lower": 0.1,
        "ci_upper": 22.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)",
        "value": 14.9,
        "unit": "percentage of participants",
        "ci_lower": 8.2,
        "ci_upper": 24.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG006",
        "arm_title": "NSCLC: Sintilimab 200mg Q3W (Cohort C)",
        "value": 13.5,
        "unit": "percentage of participants",
        "ci_lower": 4.5,
        "ci_upper": 28.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG007",
        "arm_title": "nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)",
        "value": 61.9,
        "unit": "percentage of participants",
        "ci_lower": 38.4,
        "ci_upper": 81.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG008",
        "arm_title": "scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)",
        "value": 55.0,
        "unit": "percentage of participants",
        "ci_lower": 31.5,
        "ci_upper": 76.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG009",
        "arm_title": "Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)",
        "value": 85.0,
        "unit": "percentage of participants",
        "ci_lower": 62.1,
        "ci_upper": 96.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG010",
        "arm_title": "Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)",
        "value": 42.9,
        "unit": "percentage of participants",
        "ci_lower": 9.9,
        "ci_upper": 81.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG011",
        "arm_title": "Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)",
        "value": 14.3,
        "unit": "percentage of participants",
        "ci_lower": 0.4,
        "ci_upper": 57.9,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Sintilimab"
      ],
      "OG001": [
        "Sintilimab"
      ],
      "OG002": [
        "Sintilimab"
      ],
      "OG003": [
        "Sintilimab"
      ],
      "OG004": [
        "Sintilimab"
      ],
      "OG005": [
        "Sintilimab"
      ],
      "OG006": [
        "Sintilimab"
      ],
      "OG007": [
        "Sintilimab",
        "Cisplatin",
        "Pemetrexed"
      ],
      "OG008": [
        "Sintilimab",
        "Cisplatin",
        "Gemcitabine"
      ],
      "OG009": [
        "Sintilimab",
        "Oxaliplatin",
        "Capecitabine"
      ],
      "OG010": [
        "Sintilimab",
        "Cisplatin",
        "Etoposide"
      ],
      "OG011": [
        "Sintilimab",
        "Irinotecan",
        "5-FU"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO",
      "OG003": "IO",
      "OG004": "IO",
      "OG005": "IO",
      "OG006": "IO",
      "OG007": "Combo_Chemo_IO",
      "OG008": "Combo_Chemo_IO",
      "OG009": "Combo_Chemo_IO",
      "OG010": "Combo_Chemo_IO",
      "OG011": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT02935634",
    "brief_title": "A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer",
    "status": "COMPLETED",
    "start_date": "2016-11-29",
    "completion_date": "2022-05-11",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT02935634",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "ANY",
        "details": "HER2-positive patients who are previously untreated with trastuzumab are excluded (i.e., HER2 status is assessed and prior trastuzumab treatment may affect eligibility)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Track 1: Nivolumab + Ipilimumab",
        "value": 4.3,
        "unit": "Percent of participants",
        "ci_lower": 0.1,
        "ci_upper": 21.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Track 1: Nivolumab + BMS-986016",
        "value": 5.0,
        "unit": "Percent of participants",
        "ci_lower": 0.1,
        "ci_upper": 24.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Track 1: Nivolumab + BMS-986205",
        "value": 13.2,
        "unit": "Percent of participants",
        "ci_lower": 4.4,
        "ci_upper": 28.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Track 1: Nivolumab + Rucaparib",
        "value": 0.0,
        "unit": "Percent of participants",
        "ci_lower": 0.0,
        "ci_upper": 41.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Track 1: Ipilimumab + Rucaparib",
        "value": 0.0,
        "unit": "Percent of participants",
        "ci_lower": 0.0,
        "ci_upper": 36.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "Track 1: Nivolumab + Ipilimumab + Rucaparib",
        "value": 16.7,
        "unit": "Percent of participants",
        "ci_lower": 0.4,
        "ci_upper": 64.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG006",
        "arm_title": "Track 2: Nivolumab + Ipilimumab",
        "value": 8.7,
        "unit": "Percent of participants",
        "ci_lower": 1.1,
        "ci_upper": 28.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG007",
        "arm_title": "Track 2: Nivolumab + BMS-986016",
        "value": 5.6,
        "unit": "Percent of participants",
        "ci_lower": 0.7,
        "ci_upper": 18.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG008",
        "arm_title": "Track 2: Nivolumab + BMS-986205",
        "value": 0.0,
        "unit": "Percent of participants",
        "ci_lower": 0.0,
        "ci_upper": 15.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG009",
        "arm_title": "Track 2: Nivolumab + Rucaparib",
        "value": 0.0,
        "unit": "Percent of participants",
        "ci_lower": 0.0,
        "ci_upper": 45.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG010",
        "arm_title": "Track 2: Ipilimumab + Rucaparib",
        "value": 0.0,
        "unit": "Percent of participants",
        "ci_lower": 0.0,
        "ci_upper": 84.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG011",
        "arm_title": "Track 2: Nivolumab + Ipilimumab + Rucaparib",
        "value": 0.0,
        "unit": "Percent of participants",
        "ci_lower": 0.0,
        "ci_upper": 60.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG000",
        "arm_title": "Track 1: Nivolumab + Ipilimumab",
        "value": 156.0,
        "unit": "Weeks",
        "ci_lower": 156.0,
        "ci_upper": 156.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG001",
        "arm_title": "Track 1: Nivolumab + BMS-986016",
        "value": null,
        "unit": "Weeks",
        "ci_lower": 113.4,
        "ci_upper": 113.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG002",
        "arm_title": "Track 1: Nivolumab + BMS-986205",
        "value": null,
        "unit": "Weeks",
        "ci_lower": 37.3,
        "ci_upper": 144.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG003",
        "arm_title": "Track 1: Nivolumab + Rucaparib",
        "value": null,
        "unit": "Weeks",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG004",
        "arm_title": "Track 1: Ipilimumab + Rucaparib",
        "value": null,
        "unit": "Weeks",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG005",
        "arm_title": "Track 1: Nivolumab + Ipilimumab + Rucaparib",
        "value": null,
        "unit": "Weeks",
        "ci_lower": 0.1,
        "ci_upper": 0.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG006",
        "arm_title": "Track 2: Nivolumab + Ipilimumab",
        "value": 14.71,
        "unit": "Weeks",
        "ci_lower": 0.1,
        "ci_upper": 14.71,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG007",
        "arm_title": "Track 2: Nivolumab + BMS-986016",
        "value": 16.86,
        "unit": "Weeks",
        "ci_lower": 8.1,
        "ci_upper": 25.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG008",
        "arm_title": "Track 2: Nivolumab + BMS-986205",
        "value": null,
        "unit": "Weeks",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG009",
        "arm_title": "Track 2: Nivolumab + Rucaparib",
        "value": null,
        "unit": "Weeks",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG010",
        "arm_title": "Track 2: Ipilimumab + Rucaparib",
        "value": null,
        "unit": "Weeks",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG011",
        "arm_title": "Track 2: Nivolumab + Ipilimumab + Rucaparib",
        "value": null,
        "unit": "Weeks",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Track 1: Nivolumab + Ipilimumab",
        "value": null,
        "unit": "Proportion of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Track 1: Nivolumab + BMS-986016",
        "value": null,
        "unit": "Proportion of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Track 1: Nivolumab + BMS-986205",
        "value": 0.24,
        "unit": "Proportion of participants",
        "ci_lower": 0.114,
        "ci_upper": 0.393,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Track 1: Nivolumab + Rucaparib",
        "value": null,
        "unit": "Proportion of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Track 1: Ipilimumab + Rucaparib",
        "value": null,
        "unit": "Proportion of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG005",
        "arm_title": "Track 1: Nivolumab + Ipilimumab + Rucaparib",
        "value": null,
        "unit": "Proportion of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG006",
        "arm_title": "Track 2: Nivolumab + Ipilimumab",
        "value": null,
        "unit": "Proportion of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG007",
        "arm_title": "Track 2: Nivolumab + BMS-986016",
        "value": 0.17,
        "unit": "Proportion of participants",
        "ci_lower": 0.063,
        "ci_upper": 0.322,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG008",
        "arm_title": "Track 2: Nivolumab + BMS-986205",
        "value": null,
        "unit": "Proportion of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG009",
        "arm_title": "Track 2: Nivolumab + Rucaparib",
        "value": null,
        "unit": "Proportion of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG010",
        "arm_title": "Track 2: Ipilimumab + Rucaparib",
        "value": null,
        "unit": "Proportion of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG011",
        "arm_title": "Track 2: Nivolumab + Ipilimumab + Rucaparib",
        "value": null,
        "unit": "Proportion of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG001": [
        "Nivolumab",
        "Relatlimab"
      ],
      "OG002": [
        "Nivolumab",
        "BMS-986205"
      ],
      "OG003": [
        "Nivolumab",
        "Rucaparib"
      ],
      "OG004": [
        "Ipilimumab",
        "Rucaparib"
      ],
      "OG005": [
        "Nivolumab",
        "Ipilimumab",
        "Rucaparib"
      ],
      "OG006": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG007": [
        "Nivolumab",
        "Relatlimab"
      ],
      "OG008": [
        "Nivolumab",
        "BMS-986205"
      ],
      "OG009": [
        "Nivolumab",
        "Rucaparib"
      ],
      "OG010": [
        "Ipilimumab",
        "Rucaparib"
      ],
      "OG011": [
        "Nivolumab",
        "Ipilimumab",
        "Rucaparib"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "Combo_IO_Targeted",
      "OG003": "Combo_IO_Targeted",
      "OG004": "Combo_IO_Targeted",
      "OG005": "Combo_IO_Targeted",
      "OG006": "IO",
      "OG007": "IO",
      "OG008": "Combo_IO_Targeted",
      "OG009": "Combo_IO_Targeted",
      "OG010": "Combo_IO_Targeted",
      "OG011": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT00305448",
    "brief_title": "A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg",
    "status": "COMPLETED",
    "start_date": "2006-03",
    "completion_date": "2008-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT00305448",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Fulvestrant 250 mg",
        "value": 11.1,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Fulvestrant 250 mg + Loading Dose",
        "value": 17.6,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Fulvestrant 500 mg",
        "value": 10.6,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Fulvestrant"
      ],
      "OG001": [
        "Fulvestrant"
      ],
      "OG002": [
        "Fulvestrant"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02988466",
    "brief_title": "Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT",
    "status": "COMPLETED",
    "start_date": "2017-01-24",
    "completion_date": "2023-05-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Masonic Cancer Center, University of Minnesota",
    "url": "https://clinicaltrials.gov/study/NCT02988466",
    "cancer_types": [
      "LAML",
      "DLBC"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [],
    "arm_drugs": {
      "OG000": [
        "Fludarabine (Flu)",
        "Cyclophosphamide (Cy)",
        "Melphalan (Mel)",
        "Total body irradiation (TBI)"
      ],
      "OG001": [
        "Fludarabine (Flu)",
        "Cyclophosphamide (Cy)",
        "Melphalan (Mel) (dose reduced)",
        "Total body irradiation (TBI)"
      ],
      "OG002": [
        "Fludarabine (Flu)",
        "Cyclophosphamide (Cy)",
        "Melphalan (Mel)",
        "Total body irradiation (TBI)"
      ],
      "OG003": [
        "Fludarabine (Flu)",
        "Cyclophosphamide (Cy)",
        "Total body irradiation (TBI)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo",
      "OG002": "Chemo",
      "OG003": "Chemo"
    }
  },
  {
    "nct_id": "NCT00312377",
    "brief_title": "ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2006-05",
    "completion_date": "2008-08",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Genzyme, a Sanofi Company",
    "url": "https://clinicaltrials.gov/study/NCT00312377",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV",
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Vandetanib 100 mg Plus Docetaxel",
        "value": 17.3,
        "unit": "Weeks",
        "ci_lower": 15.0,
        "ci_upper": 18.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo Plus Docetaxel",
        "value": 14.0,
        "unit": "Weeks",
        "ci_lower": 12.7,
        "ci_upper": 16.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Vandetanib 100 mg Plus Docetaxel",
        "value": 10.6,
        "unit": "Months",
        "ci_lower": 9.6,
        "ci_upper": 11.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo Plus Docetaxel",
        "value": 10.0,
        "unit": "Months",
        "ci_lower": 9.2,
        "ci_upper": 10.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Vandetanib",
        "Docetaxel"
      ],
      "OG001": [
        "Docetaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00313170",
    "brief_title": "A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg",
    "status": "COMPLETED",
    "start_date": "2006-05-30",
    "completion_date": "2008-06-13",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT00313170",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Fulvestrant 250 mg",
        "value": 8.5,
        "unit": "Percentage of patients",
        "ci_lower": 2.4,
        "ci_upper": 20.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Fulvestrant 250 mg + Loading Dose",
        "value": 5.9,
        "unit": "Percentage of patients",
        "ci_lower": 1.2,
        "ci_upper": 16.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Fulvestrant 500 mg",
        "value": 15.2,
        "unit": "Percentage of patients",
        "ci_lower": 6.3,
        "ci_upper": 28.9,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Fulvestrant"
      ],
      "OG001": [
        "Fulvestrant"
      ],
      "OG002": [
        "Fulvestrant"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER",
      "OG002": "OTHER"
    }
  },
  {
    "nct_id": "NCT00295646",
    "brief_title": "Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid",
    "status": "COMPLETED",
    "start_date": "1999-06",
    "completion_date": "2008-03-27",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Austrian Breast & Colorectal Cancer Study Group",
    "url": "https://clinicaltrials.gov/study/NCT00295646",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "hormone receptor-positive (ER and/or PR)"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [],
    "arm_drugs": {
      "OG000": [
        "anastrozole",
        "zoledronic acid"
      ],
      "OG001": [
        "tamoxifen",
        "zoledronic acid"
      ],
      "OG002": [
        "anastrozole"
      ],
      "OG003": [
        "tamoxifen"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER",
      "OG002": "OTHER",
      "OG003": "OTHER"
    }
  },
  {
    "nct_id": "NCT03001882",
    "brief_title": "An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)",
    "status": "COMPLETED",
    "start_date": "2017-03-29",
    "completion_date": "2022-02-17",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT03001882",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IV",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "PART 1: PD-L1+ Status",
        "value": 3.71,
        "unit": "Months",
        "ci_lower": 1.97,
        "ci_upper": 8.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "PART 1: PD-L1- Status",
        "value": 4.3,
        "unit": "Months",
        "ci_lower": 1.84,
        "ci_upper": 13.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "PART 1: Not Evaluable/Indeterminate PD-L1 Status",
        "value": 3.61,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "PART 2: PD-L1 Status Independent",
        "value": 6.28,
        "unit": "Months",
        "ci_lower": 5.09,
        "ci_upper": 7.56,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "PART 1: PD-L1+ Status",
        "value": 9.63,
        "unit": "Months",
        "ci_lower": 4.47,
        "ci_upper": 20.57,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "PART 1: PD-L1- Status",
        "value": 22.29,
        "unit": "Months",
        "ci_lower": 11.56,
        "ci_upper": 25.23,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "PART 1: Not Evaluable/Indeterminate PD-L1 Status",
        "value": 9.23,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "PART 2: PD-L1 Status Independent",
        "value": 14.78,
        "unit": "Months",
        "ci_lower": 11.99,
        "ci_upper": 20.6,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG001": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG002": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG003": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG004": [
        "Nivolumab",
        "Ipilimumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO",
      "OG003": "IO",
      "OG004": "IO"
    }
  },
  {
    "nct_id": "NCT03016312",
    "brief_title": "A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen",
    "status": "COMPLETED",
    "start_date": "2017-01-10",
    "completion_date": "2019-06-24",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT03016312",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Availability of a representative tumor specimen suitable for determination of PD-L1 status via central testing"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Atezolizumab + Enzalutamide",
        "value": 15.2,
        "unit": "Months",
        "ci_lower": 14.0,
        "ci_upper": 17.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Enzalutamide",
        "value": 16.6,
        "unit": "Months",
        "ci_lower": 14.7,
        "ci_upper": 18.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Atezolizumab",
        "Enzalutamide"
      ],
      "OG001": [
        "Enzalutamide"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03007407",
    "brief_title": "Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy",
    "status": "COMPLETED",
    "start_date": "2017-07-31",
    "completion_date": "2019-04-18",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "NSABP Foundation Inc",
    "url": "https://clinicaltrials.gov/study/NCT03007407",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "MSI",
        "status": "NEGATIVE",
        "details": "microsatellite stable (MSS)"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Durvalumab and Tremelimumab",
        "value": 9.52,
        "unit": "percentage of participants",
        "ci_lower": 1.17,
        "ci_upper": 30.38,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "durvalumab",
        "Tremelimumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO"
    }
  },
  {
    "nct_id": "NCT00319254",
    "brief_title": "Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2006-05",
    "completion_date": "2009-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT00319254",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IIIC",
      "IV"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Bosutinib",
        "value": 39.6,
        "unit": "percentage of participants",
        "ci_lower": 28.1,
        "ci_upper": 50.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Bosutinib",
        "value": 26.4,
        "unit": "percentage of participants",
        "ci_lower": 14.7,
        "ci_upper": 39.7,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Bosutinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT02997501",
    "brief_title": "T790M Plasma Testing Methodology Comparison and Clinical Validation",
    "status": "COMPLETED",
    "start_date": "2016-12-23",
    "completion_date": "2018-10-24",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT02997501",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV"
    ],
    "line_of_therapy": null,
    "prior_tki": true,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Experimental",
        "value": 9.7,
        "unit": "months",
        "ci_lower": 8.4,
        "ci_upper": 11.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Experimental",
        "value": 10.6,
        "unit": "months",
        "ci_lower": 8.5,
        "ci_upper": 13.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Experimental",
        "value": 10.6,
        "unit": "months",
        "ci_lower": 8.7,
        "ci_upper": 12.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Experimental",
        "value": 9.7,
        "unit": "months",
        "ci_lower": 8.3,
        "ci_upper": 11.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Experimental",
        "value": 11.0,
        "unit": "months",
        "ci_lower": 9.5,
        "ci_upper": 13.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Experimental",
        "value": 10.5,
        "unit": "months",
        "ci_lower": 8.3,
        "ci_upper": 12.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "AZD9291"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT00320385",
    "brief_title": "Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2005-11",
    "completion_date": "2007-06",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "GlaxoSmithKline",
    "url": "https://clinicaltrials.gov/study/NCT00320385",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "Documented IHC 3+ overexpression or FISH (ErbB2) amplification in primary or metastatic tumor tissue; archival tumor tissue required; local or central lab acceptable for randomization."
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Trastuzumab + Lapatinib",
        "value": 12.0,
        "unit": "weeks",
        "ci_lower": 8.1,
        "ci_upper": 16.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Lapatinib",
        "value": 8.1,
        "unit": "weeks",
        "ci_lower": 7.6,
        "ci_upper": 9.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Trastuzumab + Lapatinib",
        "value": 51.6,
        "unit": "weeks",
        "ci_lower": 42.9,
        "ci_upper": 57.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Lapatinib",
        "value": 39.0,
        "unit": "weeks",
        "ci_lower": 32.9,
        "ci_upper": 52.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Trastuzumab",
        "Lapatinib"
      ],
      "OG001": [
        "Lapatinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Targeted",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT00297596",
    "brief_title": "Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2006-02",
    "completion_date": "2008-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SCRI Development Innovations, LLC",
    "url": "https://clinicaltrials.gov/study/NCT00297596",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "3+ by IHC or FISH positive"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Oxaliplatin/Trastuzumab",
        "value": 20.0,
        "unit": "percentage of participants",
        "ci_lower": 4.3,
        "ci_upper": 35.7,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Oxaliplatin",
        "Trastuzumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02985957",
    "brief_title": "A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)",
    "status": "COMPLETED",
    "start_date": "2017-03-26",
    "completion_date": "2022-04-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT02985957",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort B: Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg",
        "value": 12.5,
        "unit": "Percent of Participants",
        "ci_lower": 3.5,
        "ci_upper": 29.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Cohort C: Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg",
        "value": 20.0,
        "unit": "Percent of Participants",
        "ci_lower": 7.7,
        "ci_upper": 38.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort B: Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg",
        "value": 7.59,
        "unit": "Months",
        "ci_lower": 3.65,
        "ci_upper": 10.22,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort C: Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg",
        "value": 5.36,
        "unit": "Months",
        "ci_lower": 2.92,
        "ci_upper": 7.66,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG001": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG002": [
        "Ipilimumab"
      ],
      "OG003": [
        "Cabazitaxel",
        "Prednisone"
      ],
      "OG004": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG005": [
        "Nivolumab",
        "Ipilimumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO",
      "OG003": "Chemo",
      "OG004": "IO",
      "OG005": "IO"
    }
  },
  {
    "nct_id": "NCT02983045",
    "brief_title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2016-12-19",
    "completion_date": "2022-04-28",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Nektar Therapeutics",
    "url": "https://clinicaltrials.gov/study/NCT02983045",
    "cancer_types": [
      "SKCM",
      "KIRC",
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Part 2 Dose Expansion: NKTR-214 (0.006 mg/kg) q3w + Nivolumab (360 mg) q3w",
        "value": 64.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Part 4 Dose Expansion of NKTR-214 + Nivolumab + Ipilimumab",
        "value": 3.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "NKTR-214",
        "nivolumab"
      ],
      "OG001": [
        "NKTR-214",
        "nivolumab"
      ],
      "OG002": [
        "NKTR-214",
        "nivolumab"
      ],
      "OG003": [
        "NKTR-214",
        "nivolumab"
      ],
      "OG004": [
        "NKTR-214",
        "nivolumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO",
      "OG003": "IO",
      "OG004": "IO"
    }
  },
  {
    "nct_id": "NCT00296816",
    "brief_title": "TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary",
    "status": "COMPLETED",
    "start_date": "2006-03",
    "completion_date": "2011-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sanofi",
    "url": "https://clinicaltrials.gov/study/NCT00296816",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "CA125",
        "status": "ANY",
        "details": "Baseline serologic measurement of CA-125 for subsequent determination of response using Rustin criteria"
      }
    ],
    "cancer_stages": [
      "IB",
      "II",
      "III",
      "IV"
    ],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Oxaliplatin/Docetaxel/Bevacizumab",
        "value": 65.7,
        "unit": "percentage of participants",
        "ci_lower": 53.4,
        "ci_upper": 76.7,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Oxaliplatin (Eloxatin\u0000AE)",
        "Docetaxel (Taxotere\u0000AE)",
        "Bevacizumab (Avastin\u0000AE)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00308516",
    "brief_title": "5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer",
    "status": "COMPLETED",
    "start_date": "2006-03",
    "completion_date": "2009-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SCRI Development Innovations, LLC",
    "url": "https://clinicaltrials.gov/study/NCT00308516",
    "cancer_types": [
      "READ",
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "I",
      "II"
    ],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Preoperative 5FU/Radiation/Bevacizumab",
        "value": 85.0,
        "unit": "percentage of participants",
        "ci_lower": 67.0,
        "ci_upper": 93.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Postoperative 5FU/Radiation/Bevacizumab",
        "value": 97.0,
        "unit": "percentage of participants",
        "ci_lower": 79.0,
        "ci_upper": 100.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Preoperative 5FU/Radiation/Bevacizumab",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Postoperative 5FU/Radiation/Bevacizumab",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "5-Fluorouracil",
        "Bevacizumab"
      ],
      "OG001": [
        "5-Fluorouracil",
        "Bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00303108",
    "brief_title": "Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2005-12",
    "completion_date": "2010-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "US Oncology Research",
    "url": "https://clinicaltrials.gov/study/NCT00303108",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "ANY",
        "details": "HER2-negative or HER2-positive allowed; HER2+ defined as IHC 3+ or FISH+"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "D+C and Taxane Naive",
        "value": 30.8,
        "unit": "percentage of participants",
        "ci_lower": 17.0,
        "ci_upper": 47.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "D+C and Taxane Pretreated",
        "value": 31.0,
        "unit": "percentage of participants",
        "ci_lower": 17.6,
        "ci_upper": 47.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "D+C+H",
        "value": 55.6,
        "unit": "percentage of participants",
        "ci_lower": 40.0,
        "ci_upper": 70.4,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pegylated liposomal doxorubicin",
        "Carboplatin"
      ],
      "OG001": [
        "Pegylated liposomal doxorubicin",
        "Carboplatin"
      ],
      "OG002": [
        "Pegylated liposomal doxorubicin",
        "Carboplatin",
        "trastuzumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo",
      "OG002": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02992743",
    "brief_title": "Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma",
    "status": "COMPLETED",
    "start_date": "2016-12-06",
    "completion_date": "2021-11-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "GlaxoSmithKline",
    "url": "https://clinicaltrials.gov/study/NCT02992743",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "NYESO1",
        "status": "POSITIVE",
        "details": "Tumor expression assessed on most recent archival specimen or fresh biopsy by a designated central laboratory"
      },
      {
        "target": "HLA-A",
        "status": "POSITIVE",
        "details": "Participant must be HLA-A*02:01, HLA-A*02:05 and/or HLA-A*02:06 positive"
      },
      {
        "target": "DDIT3",
        "status": "POSITIVE",
        "details": "Presence of reciprocal chromosomal translocation t(12;16)(q13;p11) or t(12;22)(q13;q12) confirming diagnosis of myxoid/round cell liposarcoma"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Reduced Lymphodepletion Dose Plus GSK3377794",
        "value": 20.0,
        "unit": "Percentage of participants",
        "ci_lower": 2.5,
        "ci_upper": 55.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Standard Lymphodepletion Dose Plus GSK3377794",
        "value": 40.0,
        "unit": "Percentage of participants",
        "ci_lower": 12.2,
        "ci_upper": 73.8,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "letetresgene autoleucel (GSK3377794)",
        "Cyclophosphamide",
        "Fludarabine"
      ],
      "OG001": [
        "letetresgene autoleucel (GSK3377794)",
        "Cyclophosphamide",
        "Fludarabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT03025035",
    "brief_title": "Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2017-09-10",
    "completion_date": "2024-10-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Yuan Yuan",
    "url": "https://clinicaltrials.gov/study/NCT03025035",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "BRCA",
        "status": "POSITIVE",
        "details": "Deleterious BRCA mutation (germline or somatic)"
      },
      {
        "target": "HRD",
        "status": "POSITIVE",
        "details": "HDR-defect (homologous recombination repair deficiency); eligibility may be met by BRCA mutation OR HRD/HDR-defect"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + Olaparib",
        "value": 7.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Olaparib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT00320541",
    "brief_title": "A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2006-05",
    "completion_date": "2009-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00320541",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Paclitaxel Plus Bevacizumab (PB)",
        "value": 0.489,
        "unit": "proportion of responders",
        "ci_lower": 0.385,
        "ci_upper": 0.595,
        "dispersion_type": "MEAN"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G)",
        "value": 0.587,
        "unit": "proportion of responders",
        "ci_lower": 0.479,
        "ci_upper": 0.689,
        "dispersion_type": "MEAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Paclitaxel Plus Bevacizumab (PB)",
        "value": 8.8,
        "unit": "months",
        "ci_lower": 0.1,
        "ci_upper": 27.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G)",
        "value": 11.3,
        "unit": "months",
        "ci_lower": 1.5,
        "ci_upper": 33.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Paclitaxel Plus Bevacizumab (PB)",
        "value": 25.0,
        "unit": "months",
        "ci_lower": 0.1,
        "ci_upper": 34.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G)",
        "value": 24.3,
        "unit": "months",
        "ci_lower": 1.5,
        "ci_upper": 33.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "paclitaxel",
        "bevacizumab"
      ],
      "OG001": [
        "paclitaxel",
        "gemcitabine",
        "bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02996110",
    "brief_title": "A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma",
    "status": "COMPLETED",
    "start_date": "2017-02-02",
    "completion_date": "2021-11-23",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT02996110",
    "cancer_types": [
      "KIRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Arm 1: Nivolumab Plus Ipilimumab (BMS-734016)",
        "value": 20.0,
        "unit": "Percent of participants",
        "ci_lower": 7.7,
        "ci_upper": 38.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Arm 1: Nivolumab Plus Ipilimumab (BMS-734016)",
        "value": 17.4,
        "unit": "Percent of participants",
        "ci_lower": 7.8,
        "ci_upper": 31.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Arm 2: Nivolumab Plus Relatlimab (BMS-986016)",
        "value": 30.0,
        "unit": "Percent of participants",
        "ci_lower": 14.7,
        "ci_upper": 49.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Arm 2: Nivolumab Plus Relatlimab (BMS-986016)",
        "value": 3.1,
        "unit": "Percent of participants",
        "ci_lower": 0.1,
        "ci_upper": 16.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Arm 3: Nivolumab Plus BMS-986205",
        "value": 3.2,
        "unit": "Percent of participants",
        "ci_lower": 0.1,
        "ci_upper": 16.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Arm 4: Nivolumab Plus BMS-813160 150 mg",
        "value": 9.5,
        "unit": "Percent of participants",
        "ci_lower": 1.2,
        "ci_upper": 30.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Arm 5: Nivolumab Plus BMS-813160 300mg",
        "value": 0.0,
        "unit": "Percent of participants",
        "ci_lower": 0.0,
        "ci_upper": 15.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG000",
        "arm_title": "Arm 1: Nivolumab Plus Ipilimumab (BMS-734016)",
        "value": null,
        "unit": "Weeks",
        "ci_lower": 33.4,
        "ci_upper": 139.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG000",
        "arm_title": "Arm 1: Nivolumab Plus Ipilimumab (BMS-734016)",
        "value": 68.0,
        "unit": "Weeks",
        "ci_lower": 0.1,
        "ci_upper": 117.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG001",
        "arm_title": "Arm 2: Nivolumab Plus Relatlimab (BMS-986016)",
        "value": 32.57,
        "unit": "Weeks",
        "ci_lower": 0.1,
        "ci_upper": 52.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG001",
        "arm_title": "Arm 2: Nivolumab Plus Relatlimab (BMS-986016)",
        "value": 99.4,
        "unit": "Weeks",
        "ci_lower": 99.4,
        "ci_upper": 99.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG002",
        "arm_title": "Arm 3: Nivolumab Plus BMS-986205",
        "value": null,
        "unit": "Weeks",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG003",
        "arm_title": "Arm 4: Nivolumab Plus BMS-813160 150 mg",
        "value": null,
        "unit": "Weeks",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG004",
        "arm_title": "Arm 5: Nivolumab Plus BMS-813160 300mg",
        "value": null,
        "unit": "Weeks",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm 1: Nivolumab Plus Ipilimumab (BMS-734016)",
        "value": 0.491,
        "unit": "Proportion of participants",
        "ci_lower": 0.294,
        "ci_upper": 0.661,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm 1: Nivolumab Plus Ipilimumab (BMS-734016)",
        "value": 0.432,
        "unit": "Proportion of participants",
        "ci_lower": 0.277,
        "ci_upper": 0.577,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm 2: Nivolumab Plus Relatlimab (BMS-986016)",
        "value": 0.429,
        "unit": "Proportion of participants",
        "ci_lower": 0.246,
        "ci_upper": 0.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm 2: Nivolumab Plus Relatlimab (BMS-986016)",
        "value": 0.194,
        "unit": "Proportion of participants",
        "ci_lower": 0.079,
        "ci_upper": 0.346,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Arm 3: Nivolumab Plus BMS-986205",
        "value": 0.278,
        "unit": "Proportion of participants",
        "ci_lower": 0.118,
        "ci_upper": 0.464,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Arm 4: Nivolumab Plus BMS-813160 150 mg",
        "value": 0.468,
        "unit": "Proportion of participants",
        "ci_lower": 0.237,
        "ci_upper": 0.67,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Arm 5: Nivolumab Plus BMS-813160 300mg",
        "value": null,
        "unit": "Proportion of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG001": [
        "Nivolumab",
        "Relatlimab"
      ],
      "OG002": [
        "Nivolumab",
        "BMS-986205"
      ],
      "OG003": [
        "Nivolumab",
        "BMS-813160"
      ],
      "OG004": [
        "Nivolumab",
        "BMS-813160"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "Combo_IO_Targeted",
      "OG003": "Combo_IO_Targeted",
      "OG004": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT00343291",
    "brief_title": "A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC",
    "status": "COMPLETED",
    "start_date": "2006-12",
    "completion_date": "2010-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00343291",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)",
        "value": 6.05,
        "unit": "months",
        "ci_lower": 5.65,
        "ci_upper": 7.03,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)",
        "value": 4.5,
        "unit": "months",
        "ci_lower": 4.01,
        "ci_upper": 5.42,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)",
        "value": 12.06,
        "unit": "months",
        "ci_lower": 9.4,
        "ci_upper": 19.25,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)",
        "value": 11.63,
        "unit": "months",
        "ci_lower": 6.64,
        "ci_upper": 17.61,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cetuximab",
        "Bevacizumab",
        "Paclitaxel",
        "Carboplatin"
      ],
      "OG001": [
        "Cetuximab",
        "Bevacizumab",
        "Paclitaxel",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03045653",
    "brief_title": "Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2017-09-01",
    "completion_date": "2019-02-21",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sun Yat-sen University",
    "url": "https://clinicaltrials.gov/study/NCT03045653",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "HIGH",
        "details": "IHC: ER \u226560% on primary tumor or metastatic biopsy"
      },
      {
        "target": "PR",
        "status": "HIGH",
        "details": "IHC: PR \u226560% on primary tumor or metastatic biopsy"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "Histological confirmation of HER2 negative on primary tumor or metastatic biopsy"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment Arm",
        "value": 5.0,
        "unit": "months",
        "ci_lower": 2.6,
        "ci_upper": 7.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Tamoxifen"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03036098",
    "brief_title": "Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2017-03-24",
    "completion_date": "2024-08-30",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT03036098",
    "cancer_types": [
      "BLCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Treatment 1",
        "value": 19.06,
        "unit": "Months",
        "ci_lower": 13.47,
        "ci_upper": 22.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Treatment 2",
        "value": 13.21,
        "unit": "Months",
        "ci_lower": 11.63,
        "ci_upper": 15.24,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab",
        "Ipilimumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT00323869",
    "brief_title": "Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2006-06",
    "completion_date": "2013-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Stanford University",
    "url": "https://clinicaltrials.gov/study/NCT00323869",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab + Carboplatin + Gemcitabine",
        "value": 8.7,
        "unit": "Months",
        "ci_lower": 7.8,
        "ci_upper": 17.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab + Carboplatin + Gemcitabine",
        "value": 12.8,
        "unit": "Months",
        "ci_lower": 10.0,
        "ci_upper": 16.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Bevacizumab",
        "Carboplatin",
        "Gemcitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03038100",
    "brief_title": "A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
    "status": "COMPLETED",
    "start_date": "2017-03-08",
    "completion_date": "2022-02-08",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT03038100",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "III",
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Placebo With Paclitaxel, Carboplatin and Bevacizumab",
        "value": 18.37,
        "unit": "Months",
        "ci_lower": 17.22,
        "ci_upper": 19.75,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab",
        "value": 19.48,
        "unit": "Months",
        "ci_lower": 18.14,
        "ci_upper": 20.76,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Placebo With Paclitaxel, Carboplatin and Bevacizumab",
        "value": 46.59,
        "unit": "Months",
        "ci_lower": 45.31,
        "ci_upper": 49.74,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab",
        "value": 50.53,
        "unit": "Months",
        "ci_lower": 46.26,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Paclitaxel",
        "Carboplatin",
        "Bevacizumab"
      ],
      "OG001": [
        "Paclitaxel",
        "Carboplatin",
        "Atezolizumab",
        "Bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT03042611",
    "brief_title": "A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer",
    "status": "COMPLETED",
    "start_date": "2017-03-14",
    "completion_date": "2019-02-15",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Elevar Therapeutics",
    "url": "https://clinicaltrials.gov/study/NCT03042611",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Rivoceranib Plus Best Supportive Care (BSC)",
        "value": 5.82,
        "unit": "Months",
        "ci_lower": 5.26,
        "ci_upper": 6.47,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo Plus BSC",
        "value": 5.13,
        "unit": "Months",
        "ci_lower": 4.47,
        "ci_upper": 6.24,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Rivoceranib Plus Best Supportive Care (BSC)",
        "value": 2.83,
        "unit": "Months",
        "ci_lower": 2.07,
        "ci_upper": 3.52,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo Plus BSC",
        "value": 1.77,
        "unit": "Months",
        "ci_lower": 1.71,
        "ci_upper": 1.84,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Rivoceranib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT03043599",
    "brief_title": "Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2017-02-13",
    "completion_date": "2018-10-26",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
    "url": "https://clinicaltrials.gov/study/NCT03043599",
    "cancer_types": [
      "SCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "MAINTENANCE",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Combination Therapy",
        "value": 4.5,
        "unit": "months",
        "ci_lower": 2.7,
        "ci_upper": 4.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Combination Therapy",
        "value": 11.7,
        "unit": "months",
        "ci_lower": 4.7,
        "ci_upper": 16.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ipilimumab",
        "Nivolumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO"
    }
  },
  {
    "nct_id": "NCT00323739",
    "brief_title": "Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma",
    "status": "COMPLETED",
    "start_date": "2006-05",
    "completion_date": "2008-11",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SCRI Development Innovations, LLC",
    "url": "https://clinicaltrials.gov/study/NCT00323739",
    "cancer_types": [
      "KIRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab and Everolimus",
        "value": 8.1,
        "unit": "Months",
        "ci_lower": 6.3,
        "ci_upper": 10.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab and Everolimus",
        "value": 18.5,
        "unit": "Months",
        "ci_lower": 14.52,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "bevacizumab",
        "everolimus"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00322348",
    "brief_title": "Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women",
    "status": "COMPLETED",
    "start_date": "2006-04",
    "completion_date": null,
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT00322348",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "oestrogen receptor positive (ER +ve)"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "ZOLADEX 10.8 mg",
        "value": 69.4,
        "unit": "Percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "ZOLADEX 3.6 mg",
        "value": 73.5,
        "unit": "Percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Goserelin acetate"
      ],
      "OG001": [
        "Goserelin acetate"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT00322452",
    "brief_title": "First Line IRESSA\u2122 Versus Carboplatin/Paclitaxel in Asia",
    "status": "COMPLETED",
    "start_date": "2006-03",
    "completion_date": "2008-04",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT00322452",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV",
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Gefitinib",
        "value": 5.7,
        "unit": "Months",
        "ci_lower": 5.4,
        "ci_upper": 6.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Carboplatin/Paclitaxel",
        "value": 5.8,
        "unit": "Months",
        "ci_lower": 5.6,
        "ci_upper": 6.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Gefitinib",
        "value": 18.8,
        "unit": "Months",
        "ci_lower": 17.3,
        "ci_upper": 20.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Carboplatin/Paclitaxel",
        "value": 17.4,
        "unit": "Months",
        "ci_lower": 16.2,
        "ci_upper": 18.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Gefitinib"
      ],
      "OG001": [
        "Carboplatin",
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00344773",
    "brief_title": "First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation",
    "status": "COMPLETED",
    "start_date": "2006-03",
    "completion_date": "2007-12",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT00344773",
    "cancer_types": [
      "LUAD"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "EGFR mutational analysis required; histological biopsy and paraffin block >5 mg from original tumor or metastatic site"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Gefitinib",
        "value": 0.0,
        "unit": "Percent of Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Gefitinib",
        "value": 86.25,
        "unit": "Percent of Participants",
        "ci_lower": 0.7191,
        "ci_upper": 0.9358,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Gefitinib",
        "value": 82.26,
        "unit": "Percent of Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Gefitinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT00339183",
    "brief_title": "Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone",
    "status": "COMPLETED",
    "start_date": "2006-06-30",
    "completion_date": "2009-04-01",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Amgen",
    "url": "https://clinicaltrials.gov/study/NCT00339183",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Wild-type KRAS - Panitumumab Plus FOLFIRI",
        "value": 5.9,
        "unit": "months",
        "ci_lower": 5.5,
        "ci_upper": 6.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Wild-type KRAS - FOLFIRI Alone",
        "value": 3.9,
        "unit": "months",
        "ci_lower": 3.7,
        "ci_upper": 5.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Mutant KRAS - Panitumumab Plus FOLFIRI",
        "value": 5.0,
        "unit": "months",
        "ci_lower": 3.8,
        "ci_upper": 5.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Mutant KRAS - FOLFIRI Alone",
        "value": 4.9,
        "unit": "months",
        "ci_lower": 3.6,
        "ci_upper": 5.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Wild-type KRAS - Panitumumab Plus FOLFIRI",
        "value": 14.5,
        "unit": "months",
        "ci_lower": 13.0,
        "ci_upper": 16.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Wild-type KRAS - FOLFIRI Alone",
        "value": 12.5,
        "unit": "months",
        "ci_lower": 11.2,
        "ci_upper": 14.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Mutant KRAS - Panitumumab Plus FOLFIRI",
        "value": 11.8,
        "unit": "months",
        "ci_lower": 10.4,
        "ci_upper": 13.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Mutant KRAS - FOLFIRI Alone",
        "value": 11.1,
        "unit": "months",
        "ci_lower": 10.3,
        "ci_upper": 12.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Panitumumab",
        "FOLFIRI"
      ],
      "OG001": [
        "FOLFIRI"
      ],
      "OG002": [
        "Panitumumab",
        "FOLFIRI"
      ],
      "OG003": [
        "FOLFIRI"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo",
      "OG002": "Combo_Chemo_Targeted",
      "OG003": "Chemo"
    }
  },
  {
    "nct_id": "NCT00337103",
    "brief_title": "E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes",
    "status": "COMPLETED",
    "start_date": "2006-09-20",
    "completion_date": "2012-03-12",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eisai Inc.",
    "url": "https://clinicaltrials.gov/study/NCT00337103",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "ANY",
        "details": "HER2/neu over-expressing tumors mentioned (may have been treated with trastuzumab)"
      },
      {
        "target": "ER",
        "status": "ANY",
        "details": "Estrogen receptor-expressing tumors mentioned (may have been treated with hormonal therapy)"
      },
      {
        "target": "PR",
        "status": "ANY",
        "details": "Progesterone receptor-expressing tumors mentioned (may have been treated with hormonal therapy)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Eribulin Mesylate 1.4 mg/m^2",
        "value": 484.0,
        "unit": "days",
        "ci_lower": 462.0,
        "ci_upper": 536.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Capecitabine 2.5 g/m^2/Day",
        "value": 440.0,
        "unit": "days",
        "ci_lower": 400.0,
        "ci_upper": 487.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Eribulin Mesylate 1.4 mg/m^2",
        "value": 126.0,
        "unit": "Days",
        "ci_lower": 106.0,
        "ci_upper": 131.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Capecitabine 2.5 g/m^2/Day",
        "value": 129.0,
        "unit": "Days",
        "ci_lower": 120.0,
        "ci_upper": 147.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Eribulin Mesylate"
      ],
      "OG001": [
        "Capecitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00326898",
    "brief_title": "Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery",
    "status": "COMPLETED",
    "start_date": "2006-04-24",
    "completion_date": "2015-08-27",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT00326898",
    "cancer_types": [
      "KIRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "I",
      "II",
      "III",
      "IV"
    ],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [],
    "arm_drugs": {
      "OG000": [
        "Sunitinib Malate"
      ],
      "OG001": [
        "Sorafenib Tosylate"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI",
      "OG002": "Placebo"
    }
  },
  {
    "nct_id": "NCT03051659",
    "brief_title": "A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2017-03-22",
    "completion_date": "2018-10-11",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Dana-Farber Cancer Institute",
    "url": "https://clinicaltrials.gov/study/NCT03051659",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "ER >1% (\u22651% by IHC)"
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": "PR >1% (\u22651% by IHC)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-negative per ASCO/CAP 2013 guidelines on primary tumor and/or metastatic lesion"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Eribulin Mesylate",
        "value": 4.2,
        "unit": "months",
        "ci_lower": 3.7,
        "ci_upper": 6.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Eribulin Mesylate Combine With Pembrolizumab",
        "value": 4.1,
        "unit": "months",
        "ci_lower": 3.5,
        "ci_upper": 6.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Eribulin Mesylate",
        "value": 12.5,
        "unit": "months",
        "ci_lower": 8.6,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Eribulin Mesylate Combine With Pembrolizumab",
        "value": 13.4,
        "unit": "months",
        "ci_lower": 10.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Eribulin Mesylate"
      ],
      "OG001": [
        "Pembrolizumab",
        "Eribulin Mesylate"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT03043664",
    "brief_title": "Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors",
    "status": "COMPLETED",
    "start_date": "2017-07-01",
    "completion_date": "2021-05-03",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Duke University",
    "url": "https://clinicaltrials.gov/study/NCT03043664",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "Ki67",
        "status": "LOW",
        "details": "Ki67 index \u226420% required (Ki67 >20% excluded)"
      },
      {
        "target": "MITOTIC_RATE",
        "status": "LOW",
        "details": "Tumor mitotic rate \u226420/10 hpf required (mitotic rate >20/10 hpf excluded)"
      },
      {
        "target": "HBV",
        "status": "NEGATIVE",
        "details": "No active Hepatitis B (e.g., HBsAg reactive)"
      },
      {
        "target": "HCV",
        "status": "NEGATIVE",
        "details": "No active Hepatitis C (e.g., HCV RNA undetected/qualitative negative)"
      },
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "No known history of HIV (HIV 1/2 antibodies negative)"
      },
      {
        "target": "PREGNANCY",
        "status": "NEGATIVE",
        "details": "Negative serum pregnancy test within \u22647 days prior to first dose for women of childbearing potential"
      }
    ],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Somatuline Depot and Keytruda",
        "value": 0.045,
        "unit": "proportion of participants",
        "ci_lower": 0.0,
        "ci_upper": 0.12,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Somatuline Depot and Keytruda",
        "value": 5.04,
        "unit": "months",
        "ci_lower": 2.7,
        "ci_upper": 11.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Somatuline Depot and Keytruda",
        "value": 28.6,
        "unit": "months",
        "ci_lower": 21.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Lanreotide",
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT03037385",
    "brief_title": "Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2017-03-17",
    "completion_date": "2024-03-21",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT03037385",
    "cancer_types": [
      "THCA",
      "NSCLC",
      "COAD"
    ],
    "biomarkers": [
      {
        "target": "RET",
        "status": "POSITIVE",
        "details": "Oncogenic RET rearrangement/fusion or mutation (excluding synonymous, frameshift, and nonsense); detection by local or central testing of tumor tissue or circulating tumor nucleic acid (ctDNA). For NSCLC groups a RET fusion is specifically required."
      },
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "No known primary driver alteration other than RET (examples: targetable EGFR mutation)."
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "No known primary driver alteration other than RET (examples: ALK fusion)."
      },
      {
        "target": "ROS1",
        "status": "NEGATIVE",
        "details": "No known primary driver alteration other than RET (examples: ROS1 fusion)."
      },
      {
        "target": "BRAF",
        "status": "NEGATIVE",
        "details": "No known primary driver alteration other than RET (examples: BRAF mutation)."
      },
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "No known primary driver alteration other than RET (examples: KRAS mutation)."
      },
      {
        "target": "NRAS",
        "status": "NEGATIVE",
        "details": "No known primary driver alteration other than RET (examples: NRAS mutation)."
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "UNRESECTABLE",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "RET- Fusion Positive NSCLC With Prior Platinum Treatment:",
        "value": 63.1,
        "unit": "percentage of participants",
        "ci_lower": 54.2,
        "ci_upper": 71.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "RET-fusion Positive NSCLC With Non-platinum Systemic Treatment",
        "value": 73.9,
        "unit": "percentage of participants",
        "ci_lower": 51.6,
        "ci_upper": 89.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "RET-fusion Positive NSCLC With No Prior Systemic or Platinum Treatment",
        "value": 78.3,
        "unit": "percentage of participants",
        "ci_lower": 69.2,
        "ci_upper": 85.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "RET-mutation MTC With Prior Cabozantinib and/or Vandetanib Treatment",
        "value": 56.7,
        "unit": "percentage of participants",
        "ci_lower": 43.2,
        "ci_upper": 69.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "RET-mutation MTC With No Prior Cabozantinib or Vandetanib Treatment",
        "value": 77.8,
        "unit": "percentage of participants",
        "ci_lower": 66.4,
        "ci_upper": 86.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "RET-fusion Positive TC",
        "value": 85.2,
        "unit": "percentage of participants",
        "ci_lower": 66.3,
        "ci_upper": 95.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG006",
        "arm_title": "RET-fusion Positive Solid Tumors Other Than NSCLC and TC",
        "value": 46.4,
        "unit": "percentage of participants",
        "ci_lower": 27.5,
        "ci_upper": 66.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG007",
        "arm_title": "RET-altered Solid Tumors Previously Treated With RET Inhibitor",
        "value": 19.0,
        "unit": "percentage of participants",
        "ci_lower": 5.4,
        "ci_upper": 41.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG008",
        "arm_title": "RET-mutation Positive Tumors Other Than MTC",
        "value": 7.7,
        "unit": "percentage of participants",
        "ci_lower": 0.99,
        "ci_upper": 36.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "pralsetinib (BLU-667)"
      ],
      "OG001": [
        "pralsetinib (BLU-667)"
      ],
      "OG002": [
        "pralsetinib (BLU-667)"
      ],
      "OG003": [
        "pralsetinib (BLU-667)"
      ],
      "OG004": [
        "pralsetinib (BLU-667)"
      ],
      "OG005": [
        "pralsetinib (BLU-667)"
      ],
      "OG006": [
        "pralsetinib (BLU-667)"
      ],
      "OG007": [
        "pralsetinib (BLU-667)"
      ],
      "OG008": [
        "pralsetinib (BLU-667)"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI",
      "OG002": "TKI",
      "OG003": "TKI",
      "OG004": "TKI",
      "OG005": "TKI",
      "OG006": "TKI",
      "OG007": "TKI",
      "OG008": "TKI"
    }
  },
  {
    "nct_id": "NCT03025880",
    "brief_title": "Trial to Evaluate Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABC",
    "status": "COMPLETED",
    "start_date": "2017-06-28",
    "completion_date": "2019-06-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Spanish Breast Cancer Research Group",
    "url": "https://clinicaltrials.gov/study/NCT03025880",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "IHQ score 0/1+ or negative by in situ hybridization defined as HER2/CEP17 ratio < 2 or for single probe assessment a HER2 copy number < 4"
      },
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": ">=1% of tumour cells with ER expression (required for Luminal A/B)"
      },
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "<1% of tumour cells with ER expression (defines triple negative disease)"
      },
      {
        "target": "PGR",
        "status": "HIGH",
        "details": "PgR >= 20% of tumour cells (defines Luminal A)"
      },
      {
        "target": "PGR",
        "status": "LOW",
        "details": "PgR < 20% of tumour cells (defines Luminal B)"
      },
      {
        "target": "PGR",
        "status": "NEGATIVE",
        "details": "PgR <1% (defines triple negative disease)"
      },
      {
        "target": "KI67",
        "status": "LOW",
        "details": "Ki67 < 14% (defines Luminal A)"
      },
      {
        "target": "KI67",
        "status": "HIGH",
        "details": "Ki67 >= 14% (defines Luminal B)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Run-in Phase Dose Level 0",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Phase II",
        "value": 5.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Run-in Phase Plus Phase II",
        "value": 5.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Run-in Phase Dose Level 0",
        "value": 3.1,
        "unit": "Months",
        "ci_lower": 0.9,
        "ci_upper": 5.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Phase II",
        "value": 2.6,
        "unit": "Months",
        "ci_lower": 1.9,
        "ci_upper": 6.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Run-in Phase Plus Phase II",
        "value": 3.1,
        "unit": "Months",
        "ci_lower": 2.0,
        "ci_upper": 4.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Run-in Phase Dose Level 0",
        "value": 6.1,
        "unit": "Months",
        "ci_lower": 1.3,
        "ci_upper": 11.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Phase II",
        "value": 10.1,
        "unit": "Months",
        "ci_lower": 7.3,
        "ci_upper": 17.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Run-in Phase Plus Phase II",
        "value": 8.7,
        "unit": "Months",
        "ci_lower": 6.5,
        "ci_upper": 11.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Gemcitabine"
      ],
      "OG001": [
        "Pembrolizumab",
        "Gemcitabine"
      ],
      "OG002": [
        "Pembrolizumab",
        "Gemcitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Combo_Chemo_IO",
      "OG002": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT00338728",
    "brief_title": "Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2003-10-03",
    "completion_date": "2018-11-27",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "M.D. Anderson Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT00338728",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Estrogen receptor positive by core biopsy immunohistochemistry with >10% positive malignant epithelial cells"
      },
      {
        "target": "PGR",
        "status": "POSITIVE",
        "details": "Progesterone receptor positive by core biopsy immunohistochemistry with >10% positive malignant epithelial cells"
      },
      {
        "target": "PDGFR",
        "status": "POSITIVE",
        "details": "Expression of PDGFR by immunohistochemistry (IHC) required"
      },
      {
        "target": "KIT",
        "status": "POSITIVE",
        "details": "Expression of KIT (CD117/c-kit) by immunohistochemistry (IHC) required"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Letrozole and Imatinib Mesylate",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Letrozole and Imatinib Mesylate",
        "value": 5.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Letrozole and Imatinib Mesylate",
        "value": 16.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Letrozole and Imatinib Mesylate",
        "value": 8.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Letrozole and Imatinib Mesylate",
        "value": 11.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Letrozole and Imatinib Mesylate",
        "value": 5.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Letrozole and Imatinib Mesylate",
        "value": 8.7,
        "unit": "months",
        "ci_lower": 3.8,
        "ci_upper": 11.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Letrozole and Imatinib Mesylate",
        "value": 44.3,
        "unit": "months",
        "ci_lower": 34.0,
        "ci_upper": 55.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Letrozole",
        "Imatinib Mesylate"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT03049618",
    "brief_title": "Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475",
    "status": "COMPLETED",
    "start_date": "2017-03-10",
    "completion_date": "2024-09-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "University of Southern California",
    "url": "https://clinicaltrials.gov/study/NCT03049618",
    "cancer_types": [
      "NSCLC",
      "HNSC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "If an actionable alteration in EGFR is present, patient must have progressed after an appropriate EGFR TKI"
      },
      {
        "target": "ALK",
        "status": "POSITIVE",
        "details": "If an actionable alteration in ALK is present, patient must have progressed after an appropriate ALK TKI"
      },
      {
        "target": "ROS1",
        "status": "POSITIVE",
        "details": "If an actionable alteration in ROS1 is present, patient must have progressed after an appropriate ROS1 TKI"
      },
      {
        "target": "BRAF",
        "status": "POSITIVE",
        "details": "If an actionable alteration in BRAF is present, patient must have progressed after an appropriate BRAF TKI"
      },
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "No known history of HIV (HIV 1/2 antibodies)"
      },
      {
        "target": "HBV",
        "status": "NEGATIVE",
        "details": "No active hepatitis B (e.g., HBsAg negative)"
      },
      {
        "target": "HCV",
        "status": "NEGATIVE",
        "details": "No active hepatitis C (e.g., HCV RNA not detected)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Head and Neck Cancer Cohort",
        "value": 6.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Non-Small Cell Lung Cancer Cohort",
        "value": 3.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Head and Neck Cancer Cohort",
        "value": 8.6,
        "unit": "Months",
        "ci_lower": 3.2,
        "ci_upper": 13.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Non-Small Cell Lung Cancer Cohort",
        "value": 11.8,
        "unit": "Months",
        "ci_lower": 4.2,
        "ci_upper": 30.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Head and Neck Cancer Cohort",
        "value": 2.6,
        "unit": "Months",
        "ci_lower": 1.3,
        "ci_upper": 4.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Non-Small Cell Lung Cancer Cohort",
        "value": 3.0,
        "unit": "Months",
        "ci_lower": 1.2,
        "ci_upper": 6.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Recombinant EphB4-HSA Fusion Protein"
      ],
      "OG001": [
        "Pembrolizumab",
        "Recombinant EphB4-HSA Fusion Protein"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT03066778",
    "brief_title": "A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)",
    "status": "COMPLETED",
    "start_date": "2017-05-02",
    "completion_date": "2019-12-02",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT03066778",
    "cancer_types": [
      "SCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab+EP",
        "value": 4.8,
        "unit": "Months",
        "ci_lower": 4.3,
        "ci_upper": 5.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo+EP",
        "value": 4.3,
        "unit": "Months",
        "ci_lower": 4.2,
        "ci_upper": 4.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab+EP",
        "value": 10.8,
        "unit": "Months",
        "ci_lower": 9.2,
        "ci_upper": 12.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo+EP",
        "value": 9.7,
        "unit": "Months",
        "ci_lower": 8.6,
        "ci_upper": 10.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Etoposide",
        "Carboplatin",
        "Cisplatin"
      ],
      "OG001": [
        "Etoposide",
        "Carboplatin",
        "Cisplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00354978",
    "brief_title": "Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients",
    "status": "COMPLETED",
    "start_date": "2005-01",
    "completion_date": "2011-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "M.D. Anderson Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT00354978",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "FOLFIRI Plus Bevacizumab",
        "value": 12.8,
        "unit": "Months",
        "ci_lower": 9.6,
        "ci_upper": 15.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "5-Fluorouracil",
        "Leucovorin",
        "Irinotecan",
        "Bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00353496",
    "brief_title": "Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours",
    "status": "COMPLETED",
    "start_date": "2006-06",
    "completion_date": "2013-04",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Ipsen",
    "url": "https://clinicaltrials.gov/study/NCT00353496",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Lanreotide (Autogel Formulation)",
        "value": null,
        "unit": "Weeks",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 72.0,
        "unit": "Weeks",
        "ci_lower": 48.6,
        "ci_upper": 96.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "lanreotide (Autogel formulation)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT03070301",
    "brief_title": "A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors",
    "status": "COMPLETED",
    "start_date": "2017-02-27",
    "completion_date": "2024-01-31",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Memorial Sloan Kettering Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT03070301",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "KI67",
        "status": "LOW",
        "details": "Ki67 \u2264 30%"
      }
    ],
    "cancer_stages": [
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "LEE011 and Everolimus",
        "value": 34.0,
        "unit": "% of participants with response",
        "ci_lower": 17.0,
        "ci_upper": 70.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "LEE011",
        "everolimus"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03061812",
    "brief_title": "Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)",
    "status": "COMPLETED",
    "start_date": "2017-04-11",
    "completion_date": "2020-02-12",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AbbVie",
    "url": "https://clinicaltrials.gov/study/NCT03061812",
    "cancer_types": [
      "SCLC"
    ],
    "biomarkers": [
      {
        "target": "DLL3",
        "status": "HIGH",
        "details": "\u226575% tumor cells staining positive by VENTANA DLL3 (SP347) IHC Assay"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Topotecan",
        "value": 8.57,
        "unit": "months",
        "ci_lower": 7.69,
        "ci_upper": 10.12,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Rovalpituzumab Tesirine",
        "value": 6.34,
        "unit": "months",
        "ci_lower": 5.55,
        "ci_upper": 7.33,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Topotecan",
        "value": 4.27,
        "unit": "months",
        "ci_lower": 3.75,
        "ci_upper": 5.42,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Rovalpituzumab Tesirine",
        "value": 3.02,
        "unit": "months",
        "ci_lower": 2.86,
        "ci_upper": 3.61,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Topotecan"
      ],
      "OG001": [
        "Rovalpituzumab tesirine",
        "Dexamethasone"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "ADC"
    }
  },
  {
    "nct_id": "NCT00356122",
    "brief_title": "Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)",
    "status": "COMPLETED",
    "start_date": "2006-07",
    "completion_date": "2010-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sanofi",
    "url": "https://clinicaltrials.gov/study/NCT00356122",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV",
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": null,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Docetaxel/Oxaliplatin/Bevacizumab",
        "value": 5.6,
        "unit": "Months",
        "ci_lower": 3.7,
        "ci_upper": 7.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Docetaxel/Oxaliplatin/Bevacizumab",
        "value": 14.0,
        "unit": "Months",
        "ci_lower": 9.9,
        "ci_upper": 16.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Docetaxel",
        "Oxaliplatin",
        "Bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03084237",
    "brief_title": "Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2016-11",
    "completion_date": "2018-11-23",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Shanghai Henlius Biotech",
    "url": "https://clinicaltrials.gov/study/NCT03084237",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "FISH amplification ratio \u22652.0 or IHC score 3+ (central confirmation on FFPE or fresh biopsy)"
      }
    ],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "HLX02+Docetaxel",
        "value": 71.1,
        "unit": "percentage of responders",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Herceptin\u00ae+Docetaxel",
        "value": 70.9,
        "unit": "percentage of responders",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "HLX02",
        "docetaxel"
      ],
      "OG001": [
        "Herceptin\u00ae",
        "docetaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00364351",
    "brief_title": "Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy",
    "status": "COMPLETED",
    "start_date": "2006-08",
    "completion_date": "2008-09",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Genzyme, a Sanofi Company",
    "url": "https://clinicaltrials.gov/study/NCT00364351",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Vandetanib",
        "value": 11.3,
        "unit": "Weeks",
        "ci_lower": 0.14,
        "ci_upper": 75.43,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Erlotinib",
        "value": 8.9,
        "unit": "Weeks",
        "ci_lower": 0.43,
        "ci_upper": 80.43,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Vandetanib",
        "value": 6.9,
        "unit": "Months",
        "ci_lower": 0.03,
        "ci_upper": 18.46,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Erlotinib",
        "value": 7.8,
        "unit": "Months",
        "ci_lower": 0.1,
        "ci_upper": 20.04,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Vandetanib"
      ],
      "OG001": [
        "Erlotinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT00358956",
    "brief_title": "A Study To Assess ZD6474 (ZACTIMA\u2122) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer",
    "status": "COMPLETED",
    "start_date": "2006-08",
    "completion_date": "2008-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Genzyme, a Sanofi Company",
    "url": "https://clinicaltrials.gov/study/NCT00358956",
    "cancer_types": [
      "THCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "ZD6474 (ZACTIMA\u00021) 100 mg",
        "value": 3.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "ZD6474 (ZACTIMA\u00021) 100 mg",
        "value": 16.2,
        "unit": "Months",
        "ci_lower": 6.8,
        "ci_upper": 38.6,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "ZD6474 (vandetanib)"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT03086369",
    "brief_title": "A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer",
    "status": "COMPLETED",
    "start_date": "2017-06-22",
    "completion_date": "2021-01-05",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT03086369",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IV",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Phase 2: Olaratumab + Nab-paclitaxel + Gemcitabine",
        "value": 9.1,
        "unit": "Months",
        "ci_lower": 7.49,
        "ci_upper": 14.09,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Phase 2: Placebo + Nab-paclitaxel + Gemcitabine",
        "value": 10.81,
        "unit": "Months",
        "ci_lower": 8.51,
        "ci_upper": 14.75,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Olaratumab",
        "Nab-paclitaxel",
        "Gemcitabine"
      ],
      "OG001": [
        "Olaratumab",
        "Nab-paclitaxel",
        "Gemcitabine"
      ],
      "OG002": [
        "Olaratumab",
        "Nab-paclitaxel",
        "Gemcitabine"
      ],
      "OG003": [
        "Olaratumab",
        "Nab-paclitaxel",
        "Gemcitabine"
      ],
      "OG004": [
        "Nab-paclitaxel",
        "Gemcitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted",
      "OG003": "Combo_Chemo_Targeted",
      "OG004": "Chemo"
    }
  },
  {
    "nct_id": "NCT00361842",
    "brief_title": "Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2006-07",
    "completion_date": "2008-12",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Jazz Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT00361842",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Irinotecan - Na\u00efve",
        "value": 2.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Irinotecan - Exposed",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Irinotecan - Na\u00efve",
        "value": 4.69,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Irinotecan - Exposed",
        "value": 3.48,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection",
        "Irinotecan",
        "Floxuridine"
      ],
      "OG001": [
        "CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection",
        "Irinotecan",
        "Floxuridine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00360360",
    "brief_title": "Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site",
    "status": "COMPLETED",
    "start_date": "2006-07",
    "completion_date": "2008-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SCRI Development Innovations, LLC",
    "url": "https://clinicaltrials.gov/study/NCT00360360",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab/Paclitaxel/Carboplatin/Erlotinib",
        "value": 12.6,
        "unit": "months",
        "ci_lower": 9.7,
        "ci_upper": 18.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab/Paclitaxel/Carboplatin/Erlotinib",
        "value": 8.0,
        "unit": "months",
        "ci_lower": 6.4,
        "ci_upper": 13.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "paclitaxel",
        "carboplatin",
        "bevacizumab",
        "erlotinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT03065179",
    "brief_title": "SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients",
    "status": "COMPLETED",
    "start_date": "2017-03-01",
    "completion_date": "2020-02-20",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "University of Texas Southwestern Medical Center",
    "url": "https://clinicaltrials.gov/study/NCT03065179",
    "cancer_types": [
      "KIRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Nivolumab/Ipilimumab Plus SBRT",
        "value": 56.0,
        "unit": "percentage of participants",
        "ci_lower": 38.7,
        "ci_upper": 78.9,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab",
        "Ipilimumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO"
    }
  },
  {
    "nct_id": "NCT03085914",
    "brief_title": "A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)",
    "status": "COMPLETED",
    "start_date": "2017-05-02",
    "completion_date": "2019-01-25",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Incyte Corporation",
    "url": "https://clinicaltrials.gov/study/NCT03085914",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Group A: Epa + Pembrolizumab + mFOLFOX6",
        "value": 5.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Group B: Epa + Pembrolizumab + Nab-Paclitaxel and Gemcitabine",
        "value": 3.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin",
        "value": 3.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent",
        "value": 2.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Group E: Epa + Pembrolizumab + Cyclophosphamide",
        "value": 3.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG006",
        "arm_title": "Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent",
        "value": 5.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Epacadostat",
        "Pembrolizumab",
        "Oxaliplatin",
        "Leucovorin",
        "5-Fluorouracil"
      ],
      "OG001": [
        "Epacadostat",
        "Pembrolizumab",
        "nab-Paclitaxel",
        "Gemcitabine"
      ],
      "OG002": [
        "Epacadostat",
        "Pembrolizumab",
        "Paclitaxel",
        "Carboplatin"
      ],
      "OG003": [
        "Epacadostat",
        "Pembrolizumab",
        "Pemetrexed",
        "Investigator's choice of platinum agent"
      ],
      "OG004": [
        "Epacadostat",
        "Pembrolizumab",
        "Cyclophosphamide"
      ],
      "OG005": [
        "Epacadostat",
        "Pembrolizumab",
        "Gemcitabine",
        "Investigator's choice of platinum agent"
      ],
      "OG006": [
        "Epacadostat",
        "Pembrolizumab",
        "5-Fluorouracil",
        "Investigator's choice of platinum agent"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Combo_Chemo_IO",
      "OG002": "Combo_Chemo_IO",
      "OG003": "Combo_Chemo_IO",
      "OG004": "Combo_Chemo_IO",
      "OG005": "Combo_Chemo_IO",
      "OG006": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT03077243",
    "brief_title": "P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC",
    "status": "COMPLETED",
    "start_date": "2016-12",
    "completion_date": "2022-12-14",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "UNC Lineberger Comprehensive Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT03077243",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [
      {
        "target": "HPV",
        "status": "POSITIVE",
        "details": "HPV positive (HPV-associated OPSCC)"
      },
      {
        "target": "p16",
        "status": "POSITIVE",
        "details": "p16 positive (surrogate marker for HPV)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Group A",
        "value": 3.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Group B",
        "value": 6.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Group C",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Group A",
        "value": 8.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Group B",
        "value": 45.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Group C",
        "value": 2.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cisplatin",
        "Cetuximab",
        "Carboplatin",
        "Paclitaxel"
      ],
      "OG001": [
        "Cisplatin",
        "Cetuximab",
        "Carboplatin",
        "Paclitaxel"
      ],
      "OG002": [
        "Cisplatin",
        "Cetuximab",
        "Carboplatin",
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo",
      "OG002": "Chemo"
    }
  },
  {
    "nct_id": "NCT00369317",
    "brief_title": "Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes",
    "status": "COMPLETED",
    "start_date": "2007-03",
    "completion_date": "2013-12-01",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Children's Oncology Group",
    "url": "https://clinicaltrials.gov/study/NCT00369317",
    "cancer_types": [
      "LAML",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "IMMUNOPHENOTYPE",
        "status": "ANY",
        "details": "Immunophenotype required for study entry (e.g., diagnostic immunophenotyping/flow cytometry)"
      },
      {
        "target": "PML-RARA",
        "status": "NEGATIVE",
        "details": "No promyelocytic leukemia (acute promyelocytic leukemia/APL)"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Combination Chemotherapy)",
        "value": 92.7,
        "unit": "percentage",
        "ci_lower": 88.0,
        "ci_upper": 95.6,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "cytarabine",
        "daunorubicin hydrochloride",
        "thioguanine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo"
    }
  },
  {
    "nct_id": "NCT00364611",
    "brief_title": "Pilot Study of Docetaxel & Bevacizumab +/- Trastuzumab in First-Line Treatment of Patients With Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2006-08",
    "completion_date": "2011-06",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sanofi",
    "url": "https://clinicaltrials.gov/study/NCT00364611",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "ANY",
        "details": "HER2/neu assessed by IHC 3+ or FISH positivity; protocol text also allows negative tumors"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Docetaxel and Bevacizumab",
        "value": 59.6,
        "unit": "percentage of participants",
        "ci_lower": 45.1,
        "ci_upper": 73.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Docetaxel, Bevacizumab and Trastuzumab",
        "value": 90.5,
        "unit": "percentage of participants",
        "ci_lower": 69.6,
        "ci_upper": 98.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Docetaxel and Bevacizumab",
        "value": 30.8,
        "unit": "percentage of participants",
        "ci_lower": 18.7,
        "ci_upper": 45.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Docetaxel, Bevacizumab and Trastuzumab",
        "value": 81.0,
        "unit": "percentage of participants",
        "ci_lower": 58.1,
        "ci_upper": 94.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Docetaxel and Bevacizumab",
        "value": 750.0,
        "unit": "days",
        "ci_lower": 362.0,
        "ci_upper": 1159.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Docetaxel, Bevacizumab and Trastuzumab",
        "value": 986.0,
        "unit": "days",
        "ci_lower": 619.0,
        "ci_upper": 1705.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Docetaxel",
        "Bevacizumab"
      ],
      "OG001": [
        "Docetaxel",
        "Bevacizumab",
        "Trastuzumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03083808",
    "brief_title": "Phase II Trial of Continuation Therapy in Advanced NSCLC",
    "status": "COMPLETED",
    "start_date": "2017-03-20",
    "completion_date": "2021-12-14",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Greg Durm, MD",
    "url": "https://clinicaltrials.gov/study/NCT03083808",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "exon 19 or 21 mutation"
      },
      {
        "target": "ALK",
        "status": "POSITIVE",
        "details": "gene rearrangement"
      },
      {
        "target": "ROS1",
        "status": "POSITIVE",
        "details": "gene rearrangement"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": true,
    "prior_io": true,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab 200mg IV Every 21 Days",
        "value": 5.1,
        "unit": "months",
        "ci_lower": 3.6,
        "ci_upper": 8.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab 200mg IV Every 21 Days",
        "value": 24.5,
        "unit": "months",
        "ci_lower": 15.6,
        "ci_upper": 30.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Docetaxel",
        "Pemetrexed",
        "Gemcitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT03057600",
    "brief_title": "Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)",
    "status": "COMPLETED",
    "start_date": "2017-05-01",
    "completion_date": "2019-11-25",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Calithera Biosciences, Inc",
    "url": "https://clinicaltrials.gov/study/NCT03057600",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "ER and PR by IHC <1%"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "ER and PR by IHC <1%"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 IHC 0-1+ or FISH negative"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort 1 - African Ancestry, 3rd Line+",
        "value": 22.2,
        "unit": "percentage of participants",
        "ci_lower": 2.8,
        "ci_upper": 60.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Cohort 2 - African Ancestry, 1st Line",
        "value": 10.0,
        "unit": "percentage of participants",
        "ci_lower": 0.3,
        "ci_upper": 44.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Cohort 3 - Non-African Ancestry, 3rd Line+",
        "value": 10.5,
        "unit": "percentage of participants",
        "ci_lower": 1.3,
        "ci_upper": 33.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Cohort 4 - Non-African Ancestry, 1st Line",
        "value": 53.8,
        "unit": "percentage of participants",
        "ci_lower": 25.1,
        "ci_upper": 80.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1 - African Ancestry, 3rd Line+",
        "value": 2.3,
        "unit": "months",
        "ci_lower": 1.74,
        "ci_upper": 3.48,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort 2 - African Ancestry, 1st Line",
        "value": 5.49,
        "unit": "months",
        "ci_lower": 1.84,
        "ci_upper": 5.72,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Cohort 3 - Non-African Ancestry, 3rd Line+",
        "value": 2.0,
        "unit": "months",
        "ci_lower": 1.64,
        "ci_upper": 3.38,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Cohort 4 - Non-African Ancestry, 1st Line",
        "value": 7.33,
        "unit": "months",
        "ci_lower": 3.71,
        "ci_upper": 16.46,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1 - African Ancestry, 3rd Line+",
        "value": 7.26,
        "unit": "months",
        "ci_lower": 5.09,
        "ci_upper": 16.95,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cohort 2 - African Ancestry, 1st Line",
        "value": 13.47,
        "unit": "months",
        "ci_lower": 6.97,
        "ci_upper": 14.69,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Cohort 3 - Non-African Ancestry, 3rd Line+",
        "value": 6.44,
        "unit": "months",
        "ci_lower": 2.73,
        "ci_upper": 8.84,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Cohort 4 - Non-African Ancestry, 1st Line",
        "value": 16.76,
        "unit": "months",
        "ci_lower": 12.88,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "CB-839"
      ],
      "OG001": [
        "CB-839"
      ],
      "OG002": [
        "CB-839"
      ],
      "OG003": [
        "CB-839"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00352534",
    "brief_title": "Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2006-11-06",
    "completion_date": "2014-12-31",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Children's Oncology Group",
    "url": "https://clinicaltrials.gov/study/NCT00352534",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "1p",
        "status": "ANY",
        "details": "Loss of heterozygosity (LOH) at chromosome 1p is used for risk stratification \u2014 presence (LOH at both 1p and 16q) or absence determines subgroup eligibility"
      },
      {
        "target": "16q",
        "status": "ANY",
        "details": "Loss of heterozygosity (LOH) at chromosome 16q is used for risk stratification \u2014 presence (LOH at both 1p and 16q) or absence determines subgroup eligibility"
      }
    ],
    "cancer_stages": [
      "I",
      "II",
      "III"
    ],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Very Low Risk",
        "value": 1.0,
        "unit": "Probability",
        "ci_lower": 1.0,
        "ci_upper": 1.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Standard Risk, Stage I or II, With LOH",
        "value": 1.0,
        "unit": "Probability",
        "ci_lower": 1.0,
        "ci_upper": 1.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Standard Risk, Stage III",
        "value": 0.97,
        "unit": "Probability",
        "ci_lower": 0.95,
        "ci_upper": 0.99,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {},
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER",
      "OG002": "OTHER"
    }
  },
  {
    "nct_id": "NCT00373425",
    "brief_title": "A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors",
    "status": "COMPLETED",
    "start_date": "2006-09",
    "completion_date": "2013-04",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "OSI Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT00373425",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "EGFR-positive on primary surgical tumor tissue (by local testing)"
      }
    ],
    "cancer_stages": [
      "IB",
      "IIA",
      "IIB",
      "IIIA"
    ],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Erlotinib",
        "value": 50.5,
        "unit": "months",
        "ci_lower": 44.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 48.2,
        "unit": "months",
        "ci_lower": 36.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Erlotinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT03098030",
    "brief_title": "Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2017-06-01",
    "completion_date": "2020-01-27",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "United Therapeutics",
    "url": "https://clinicaltrials.gov/study/NCT03098030",
    "cancer_types": [
      "SCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Part 2: Dinutuximab + Irinotecan",
        "value": 6.9,
        "unit": "months",
        "ci_lower": 6.0,
        "ci_upper": 7.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Part 2: Irinotecan",
        "value": 7.0,
        "unit": "months",
        "ci_lower": 5.6,
        "ci_upper": 8.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Part 2: Topotecan",
        "value": 7.4,
        "unit": "months",
        "ci_lower": 6.1,
        "ci_upper": 9.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Dinutuximab",
        "Irinotecan"
      ],
      "OG001": [
        "Irinotecan"
      ],
      "OG002": [
        "Topotecan"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Chemo",
      "OG002": "Chemo"
    }
  },
  {
    "nct_id": "NCT00375674",
    "brief_title": "A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer",
    "status": "COMPLETED",
    "start_date": "2007-08-01",
    "completion_date": "2016-04-07",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT00375674",
    "cancer_types": [
      "KIRC"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [],
    "arm_drugs": {
      "OG000": [
        "Sunitinib malate"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT00391092",
    "brief_title": "A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.",
    "status": "COMPLETED",
    "start_date": "2006-09",
    "completion_date": "2014-08",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT00391092",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": null
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Trastuzumab + Docetaxel",
        "value": 13.7,
        "unit": "months",
        "ci_lower": 11.4,
        "ci_upper": 16.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Trastuzumab + Bevacizumab + Docetaxel",
        "value": 16.5,
        "unit": "months",
        "ci_lower": 14.1,
        "ci_upper": 19.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Trastuzumab + Docetaxel",
        "value": 38.3,
        "unit": "months",
        "ci_lower": 34.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Trastuzumab + Bevacizumab + Docetaxel",
        "value": 38.5,
        "unit": "months",
        "ci_lower": 32.1,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Trastuzumab",
        "Docetaxel"
      ],
      "OG001": [
        "Trastuzumab",
        "Bevacizumab",
        "Docetaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03093155",
    "brief_title": "Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab",
    "status": "COMPLETED",
    "start_date": "2017-04-03",
    "completion_date": "2022-12-29",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Yale University",
    "url": "https://clinicaltrials.gov/study/NCT03093155",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "TUBB3",
        "status": "ANY",
        "details": "class III beta-tubulin by immunohistochemistry; recurrent tumor specimen preferred"
      }
    ],
    "cancer_stages": [
      "I",
      "II",
      "III",
      "IV",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ixabepilone",
        "value": 2.2,
        "unit": "months",
        "ci_lower": 1.61,
        "ci_upper": 4.96,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Ixabepilone + Bevacizumab",
        "value": 5.46,
        "unit": "months",
        "ci_lower": 3.98,
        "ci_upper": 11.47,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Ixabepilone",
        "value": 6.05,
        "unit": "months",
        "ci_lower": 2.83,
        "ci_upper": 16.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Ixabepilone + Bevacizumab",
        "value": 10.32,
        "unit": "months",
        "ci_lower": 7.92,
        "ci_upper": 28.14,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ixabepilone"
      ],
      "OG001": [
        "Ixabepilone",
        "Bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00372775",
    "brief_title": "Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases",
    "status": "COMPLETED",
    "start_date": "2007-03",
    "completion_date": "2009-12",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT00372775",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Sunitinib",
        "value": 9.4,
        "unit": "Weeks",
        "ci_lower": 7.5,
        "ci_upper": 13.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Sunitinib",
        "value": 5.8,
        "unit": "Months",
        "ci_lower": 3.1,
        "ci_upper": 8.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Sunitinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT03093870",
    "brief_title": "Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer",
    "status": "COMPLETED",
    "start_date": "2017-07-04",
    "completion_date": "2019-11-12",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "ASLAN Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT03093870",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Varlitinib and Capecitabine",
        "value": 6.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Placebo and Capecitabine",
        "value": 3.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Varlitinib and Capecitabine",
        "value": 2.83,
        "unit": "Months",
        "ci_lower": 1.48,
        "ci_upper": 5.62,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo and Capecitabine",
        "value": 2.79,
        "unit": "Months",
        "ci_lower": 1.41,
        "ci_upper": 4.24,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Varlitinib",
        "Capecitabine"
      ],
      "OG001": [
        "Capecitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00373256",
    "brief_title": "A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2006-11",
    "completion_date": "2009-06",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT00373256",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "ANY",
        "details": "HER2/neu-positive disease generally excluded unless trastuzumab was previously received or is contraindicated (i.e., HER2-positive allowed only if prior trastuzumab or contraindication)."
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Sunitinib + Paclitaxel",
        "value": 7.4,
        "unit": "Months",
        "ci_lower": 6.9,
        "ci_upper": 8.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab + Paclitaxel",
        "value": 9.2,
        "unit": "Months",
        "ci_lower": 7.7,
        "ci_upper": 13.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Sunitinib + Paclitaxel",
        "value": 17.6,
        "unit": "Months",
        "ci_lower": 16.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab + Paclitaxel",
        "value": null,
        "unit": "Months",
        "ci_lower": 22.1,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Sunitinib",
        "paclitaxel"
      ],
      "OG001": [
        "bevacizumab",
        "paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03092518",
    "brief_title": "Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology",
    "status": "COMPLETED",
    "start_date": "2017-06-05",
    "completion_date": "2024-04-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT03092518",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "ANY",
        "details": "Trastuzumab may be added for HER2-overexpressing cancers; HER2 overexpression is permitted but not required for eligibility"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": "NEOADJUVANT",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Heated Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer",
        "value": 11.96,
        "unit": "Months",
        "ci_lower": 5.42,
        "ci_upper": 19.71,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cisplatin",
        "Mitomycin C",
        "Sodium Thiosulfate"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT00380718",
    "brief_title": "Chemotherapy for Patients With Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2006-11",
    "completion_date": "2008-09",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00380718",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed",
        "value": 0.182,
        "unit": "proportion of responders",
        "ci_lower": 0.07,
        "ci_upper": 0.355,
        "dispersion_type": "MEAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed",
        "value": 20.2,
        "unit": "months",
        "ci_lower": 0.7,
        "ci_upper": 32.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed",
        "value": 6.9,
        "unit": "months",
        "ci_lower": 3.0,
        "ci_upper": 9.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed",
        "value": 6.9,
        "unit": "months",
        "ci_lower": 3.0,
        "ci_upper": 9.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "pemetrexed"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo"
    }
  },
  {
    "nct_id": "NCT00378703",
    "brief_title": "Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer",
    "status": "COMPLETED",
    "start_date": "2007-09-14",
    "completion_date": "2014-02-07",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT00378703",
    "cancer_types": [
      "KIRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A (Bevacizumab)",
        "value": 7.5,
        "unit": "Months",
        "ci_lower": 5.8,
        "ci_upper": 10.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B (Bevacizumab and Temsirolimus)",
        "value": 7.6,
        "unit": "Months",
        "ci_lower": 6.7,
        "ci_upper": 9.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Arm C (Bevacizumab and Sorafenib)",
        "value": 9.2,
        "unit": "Months",
        "ci_lower": 7.5,
        "ci_upper": 11.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Arm D (Sorafenib and Temsirolimus)",
        "value": 7.4,
        "unit": "Months",
        "ci_lower": 5.6,
        "ci_upper": 7.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A (Bevacizumab)",
        "value": 28.6,
        "unit": "Months",
        "ci_lower": 22.3,
        "ci_upper": 34.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B (Bevacizumab and Temsirolimus)",
        "value": 24.7,
        "unit": "Months",
        "ci_lower": 21.4,
        "ci_upper": 35.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Arm C (Bevacizumab and Sorafenib)",
        "value": 27.5,
        "unit": "Months",
        "ci_lower": 21.5,
        "ci_upper": 37.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Arm D (Sorafenib and Temsirolimus)",
        "value": 24.3,
        "unit": "Months",
        "ci_lower": 19.7,
        "ci_upper": 34.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Bevacizumab"
      ],
      "OG001": [
        "Temsirolimus",
        "Bevacizumab"
      ],
      "OG002": [
        "Bevacizumab",
        "Sorafenib Tosylate"
      ],
      "OG003": [
        "Sorafenib Tosylate",
        "Temsirolimus"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Combo_TKI_Targeted",
      "OG003": "Combo_TKI_Targeted"
    }
  },
  {
    "nct_id": "NCT00369590",
    "brief_title": "VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide",
    "status": "COMPLETED",
    "start_date": "2006-08",
    "completion_date": "2011-12",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT00369590",
    "cancer_types": [
      "GBM",
      "LGG"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm I - Anaplastic Glioma",
        "value": 25.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm 2 - Glioblastoma",
        "value": 7.7,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm I - Anaplastic Glioma",
        "value": 55.0,
        "unit": "weeks",
        "ci_lower": 16.0,
        "ci_upper": 128.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm 2 - Glioblastoma",
        "value": 39.0,
        "unit": "weeks",
        "ci_lower": 3.0,
        "ci_upper": 150.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "ziv-aflibercept"
      ],
      "OG001": [
        "ziv-aflibercept"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03091192",
    "brief_title": "Savolitinib vs. Sunitinib in MET-driven PRCC.",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2017-07-25",
    "completion_date": "2019-08-18",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT03091192",
    "cancer_types": [
      "KIRC"
    ],
    "biomarkers": [
      {
        "target": "MET",
        "status": "POSITIVE",
        "details": "Confirmation of MET-driven PRCC from an FFPE tumour sample using sponsor-designated central laboratory validated NGS assay"
      },
      {
        "target": "FH",
        "status": "NEGATIVE",
        "details": "No co\u2011occurring FH mutation detected by the sponsor-designated central laboratory validated NGS assay"
      },
      {
        "target": "VHL",
        "status": "NEGATIVE",
        "details": "No co\u2011occurring VHL mutation detected by the sponsor-designated central laboratory validated NGS assay"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Savolitinib QD",
        "value": 7.0,
        "unit": "Months",
        "ci_lower": 2.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Sunitinib QD",
        "value": 5.6,
        "unit": "Months",
        "ci_lower": 4.1,
        "ci_upper": 6.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Savolitinib QD",
        "value": 9.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Sunitinib QD",
        "value": 13.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Savolitinib QD",
        "value": 24.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Sunitinib QD",
        "value": 14.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Savolitinib"
      ],
      "OG001": [
        "Sunitinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT00374322",
    "brief_title": "Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2006-08",
    "completion_date": "2011-09",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "GlaxoSmithKline",
    "url": "https://clinicaltrials.gov/study/NCT00374322",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "ErbB2/HER2 overexpression defined as 3+ by IHC or c-erbB2 (HER2) gene amplification by FISH; documented prior to entry; tumor tissue sent for central re-analysis"
      },
      {
        "target": "ER",
        "status": "ANY",
        "details": "Analysis of estrogen receptor on primary tumor required prior to study entry; used for risk stratification (ER positive vs negative influences tumor size risk thresholds)"
      },
      {
        "target": "PR",
        "status": "ANY",
        "details": "Analysis of progesterone receptor on primary tumor required prior to study entry; used for risk stratification (PgR/PR positive vs negative influences tumor size risk thresholds)"
      }
    ],
    "cancer_stages": [
      "I",
      "IA",
      "IB",
      "II",
      "IIA",
      "IIB",
      "III",
      "IIIA",
      "IIIB",
      "IIIC"
    ],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Lapatinib 1500 mg",
        "value": 252.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 290.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "lapatinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT00390455",
    "brief_title": "Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive",
    "status": "COMPLETED",
    "start_date": "2006-09-15",
    "completion_date": "2014-07-01",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT00390455",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "IHC \u22651% cells considered positive"
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": "IHC \u22651% cells considered positive (PgR)"
      },
      {
        "target": "HER2",
        "status": "ANY",
        "details": "HER2 status must be documented by IHC (0,1+,2+,3+) or FISH (positive or negative)"
      }
    ],
    "cancer_stages": [
      "III",
      "IV",
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm I (Lapatinib)",
        "value": 4.7,
        "unit": "Months",
        "ci_lower": 3.7,
        "ci_upper": 5.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm II (Placebo)",
        "value": 3.8,
        "unit": "Months",
        "ci_lower": 3.8,
        "ci_upper": 5.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm I (Lapatinib)",
        "value": 29.9,
        "unit": "Months",
        "ci_lower": 24.8,
        "ci_upper": 34.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm II (Placebo)",
        "value": 26.4,
        "unit": "Months",
        "ci_lower": 23.9,
        "ci_upper": 39.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Arm I (Lapatinib)",
        "value": 38.0,
        "unit": "Percent",
        "ci_lower": 14.0,
        "ci_upper": 70.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Arm II (Placebo)",
        "value": 17.0,
        "unit": "Percent",
        "ci_lower": 5.0,
        "ci_upper": 45.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Lapatinib Ditosylate",
        "Fulvestrant"
      ],
      "OG001": [
        "Fulvestrant"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT03092934",
    "brief_title": "A Study of AK-01 (LY3295668) in Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2017-05-29",
    "completion_date": "2020-04-20",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT03092934",
    "cancer_types": [
      "BRCA",
      "SCLC",
      "HNSC"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Estrogen Receptor positive (breast cohort)"
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": "Progesterone Receptor positive (breast cohort)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 negative (breast cohort)"
      },
      {
        "target": "HPV",
        "status": "POSITIVE",
        "details": "HPV-associated squamous cell cancers of the head and neck (head & neck cohort)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "25 mg LY3295668 (Phase 2)",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "LY3295668"
      ],
      "OG001": [
        "LY3295668"
      ],
      "OG002": [
        "LY3295668"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER",
      "OG002": "OTHER"
    }
  },
  {
    "nct_id": "NCT03104699",
    "brief_title": "A Study of AGEN2034 in Advanced Tumors and Cervical Cancer",
    "status": "COMPLETED",
    "start_date": "2017-04-11",
    "completion_date": "2022-06-15",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Agenus Inc.",
    "url": "https://clinicaltrials.gov/study/NCT03104699",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 2: Balstilimab Recommended Phase 2 Dose",
        "value": 15.6,
        "unit": "percentage of participants",
        "ci_lower": 10.8,
        "ci_upper": 22.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase 2: Balstilimab Recommended Phase 2 Dose",
        "value": 2.8,
        "unit": "months",
        "ci_lower": 2.4,
        "ci_upper": 3.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase 2: Balstilimab Recommended Phase 2 Dose",
        "value": 3.6,
        "unit": "months",
        "ci_lower": 2.7,
        "ci_upper": 4.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Phase 2: Balstilimab Recommended Phase 2 Dose",
        "value": 11.2,
        "unit": "months",
        "ci_lower": 9.5,
        "ci_upper": 14.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "balstilimab"
      ],
      "OG001": [
        "balstilimab"
      ],
      "OG002": [
        "balstilimab"
      ],
      "OG003": [
        "balstilimab"
      ],
      "OG004": [
        "balstilimab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO",
      "OG003": "IO",
      "OG004": "IO"
    }
  },
  {
    "nct_id": "NCT03088813",
    "brief_title": "Study of Irinotecan Liposome Injection (ONIVYDE\u00ae) in Patients With Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2018-04-25",
    "completion_date": "2022-02-08",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Ipsen",
    "url": "https://clinicaltrials.gov/study/NCT03088813",
    "cancer_types": [
      "SCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Part 2: Irinotecan Liposome Injection 70 mg/m^2",
        "value": 7.92,
        "unit": "months",
        "ci_lower": 6.87,
        "ci_upper": 9.23,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Part 2: Topotecan 1.5 mg/m^2",
        "value": 8.31,
        "unit": "months",
        "ci_lower": 7.33,
        "ci_upper": 9.13,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Irinotecan liposome injection"
      ],
      "OG001": [
        "Irinotecan liposome injection"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT03098836",
    "brief_title": "Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer",
    "status": "COMPLETED",
    "start_date": "2017-07-10",
    "completion_date": "2024-07-09",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Daniel George, MD",
    "url": "https://clinicaltrials.gov/study/NCT03098836",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [
      {
        "target": "PSA",
        "status": "HIGH",
        "details": "PSA \u2265 2.0 ng/mL; note: evidence of castration resistance may be by PSA rise defined as absolute rise of 2.0 ng/mL or >25% from nadir with \u22652 consecutive rising PSA measurements \u22651 week apart"
      },
      {
        "target": "ANC",
        "status": "HIGH",
        "details": "Absolute neutrophil count \u2265 1.0 x 10^9/L"
      },
      {
        "target": "PLATELETS",
        "status": "HIGH",
        "details": "Platelets \u2265 100 x 10^9/L"
      },
      {
        "target": "HGB",
        "status": "HIGH",
        "details": "Hemoglobin \u2265 9 g/dL"
      },
      {
        "target": "POTASSIUM",
        "status": "HIGH",
        "details": "Serum potassium \u2265 3.5 mEq/L"
      },
      {
        "target": "ALBUMIN",
        "status": "HIGH",
        "details": "Serum albumin \u2265 3.0 g/dL"
      },
      {
        "target": "AST",
        "status": "LOW",
        "details": "AST/SGOT and ALT/SGPT < 2.5 \u00d7 institutional ULN"
      },
      {
        "target": "ALT",
        "status": "LOW",
        "details": "AST/SGOT and ALT/SGPT < 2.5 \u00d7 institutional ULN"
      },
      {
        "target": "BILIRUBIN",
        "status": "LOW",
        "details": "Total bilirubin \u2264 1.5 \u00d7 institutional ULN (Gilbert's syndrome: if total bilirubin >1.5 \u00d7 ULN, direct bilirubin \u22641.5 \u00d7 ULN permitted)"
      },
      {
        "target": "GFR",
        "status": "HIGH",
        "details": "GFR \u2265 45 mL/min"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Caucasian",
        "value": 38.0,
        "unit": "Percentage of participants",
        "ci_lower": 27.0,
        "ci_upper": 55.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "African American",
        "value": 61.0,
        "unit": "Percentage of participants",
        "ci_lower": 48.0,
        "ci_upper": 78.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Caucasian",
        "value": 36.0,
        "unit": "months",
        "ci_lower": 30.0,
        "ci_upper": 60.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "African American",
        "value": 72.0,
        "unit": "months",
        "ci_lower": 44.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "ARN-509",
        "Abiraterone Acetate",
        "Prednisone"
      ],
      "OG001": [
        "ARN-509",
        "Abiraterone Acetate",
        "Prednisone"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03099174",
    "brief_title": "This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2017-05-04",
    "completion_date": "2023-05-31",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Boehringer Ingelheim",
    "url": "https://clinicaltrials.gov/study/NCT03099174",
    "cancer_types": [
      "BRCA",
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Hormone receptor positive defined as ER or PR \u22651% positive tumour nuclei by IHC (ASCO/CAP); cohort eligibility requires HR+ (at least one of ER or PR positive)."
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": "Hormone receptor positive defined as ER or PR \u22651% positive tumour nuclei by IHC (ASCO/CAP); cohort eligibility requires HR+ (at least one of ER or PR positive)."
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 negative as defined by most recent ASCO/CAP guidelines (local lab results)."
      },
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "If tumour has an activating EGFR mutation, prior treatment with an EGFR-TKI is mandatory before enrolment."
      },
      {
        "target": "ALK",
        "status": "ANY",
        "details": "If tumour has an ALK translocation, prior treatment with an ALK inhibitor is mandatory before enrolment."
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": true,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort E: Xentuzumab 1000 mg & 150 mg Abemaciclib",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort D1: Xentuzumab 1000 mg & 150 mg Abemaciclib & 500 mg Fulvestrant",
        "value": 0.4143,
        "unit": "Probability of Survival at 18 months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort D2: Xentuzumab 1000 mg & 150 mg Abemaciclib & 500 mg Fulvestrant",
        "value": 0.7854,
        "unit": "Probability of Survival at 18 months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG000",
        "arm_title": "Cohort F: Xentuzumab 1000 mg & 150 mg Abemaciclib & 500 mg Fulvestrant",
        "value": 6.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Xentuzumab",
        "Abemaciclib"
      ],
      "OG001": [
        "Xentuzumab",
        "Abemaciclib",
        "Letrozole"
      ],
      "OG002": [
        "Xentuzumab",
        "Abemaciclib",
        "Anastrozole"
      ],
      "OG003": [
        "Xentuzumab",
        "Abemaciclib",
        "Fulvestrant"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00403403",
    "brief_title": "A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE)",
    "status": "COMPLETED",
    "start_date": "2007-03",
    "completion_date": "2009-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Genentech, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT00403403",
    "cancer_types": [
      "SCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Placebo+Chemotherapy",
        "value": 4.4,
        "unit": "Months",
        "ci_lower": 4.2,
        "ci_upper": 4.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab+Chemotherapy",
        "value": 5.5,
        "unit": "Months",
        "ci_lower": 4.5,
        "ci_upper": 6.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Placebo+Chemotherapy",
        "value": 10.9,
        "unit": "Months",
        "ci_lower": 8.1,
        "ci_upper": 14.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab+Chemotherapy",
        "value": 9.4,
        "unit": "Months",
        "ci_lower": 8.7,
        "ci_upper": 11.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Chemotherapy"
      ],
      "OG001": [
        "Bevacizumab",
        "Chemotherapy"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00392704",
    "brief_title": "Treatment of Head & Neck Cancer With Chemotherapy and Radiation",
    "status": "COMPLETED",
    "start_date": "2006-12",
    "completion_date": "2008-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SCRI Development Innovations, LLC",
    "url": "https://clinicaltrials.gov/study/NCT00392704",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Intervention",
        "value": 83.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Intervention",
        "value": 90.0,
        "unit": "percentage of patients",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Paclitaxel",
        "Carboplatin",
        "5-FU"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo"
    }
  },
  {
    "nct_id": "NCT03117049",
    "brief_title": "Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)",
    "status": "COMPLETED",
    "start_date": "2017-06-13",
    "completion_date": "2020-02-10",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Ono Pharmaceutical Co. Ltd",
    "url": "https://clinicaltrials.gov/study/NCT03117049",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "Known EGFR mutations (including exon 19 deletions and exon 21 L858R substitution)"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "Known ALK translocations"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "ONO-4538 Group",
        "value": 12.1,
        "unit": "months",
        "ci_lower": 9.8,
        "ci_upper": 14.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo Group",
        "value": 8.1,
        "unit": "months",
        "ci_lower": 7.0,
        "ci_upper": 8.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "ONO-4538 Group",
        "value": 25.4,
        "unit": "months",
        "ci_lower": 21.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo Group",
        "value": 24.7,
        "unit": "months",
        "ci_lower": 20.2,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "ONO-4538",
        "Carboplatin",
        "Paclitaxel"
      ],
      "OG001": [
        "Carboplatin",
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00392821",
    "brief_title": "Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer",
    "status": "COMPLETED",
    "start_date": "2006-12",
    "completion_date": "2013-10",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SCRI Development Innovations, LLC",
    "url": "https://clinicaltrials.gov/study/NCT00392821",
    "cancer_types": [
      "KIRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "RAD001 and Sorafenib",
        "value": 13.0,
        "unit": "percentage of evaluable patients",
        "ci_lower": 7.0,
        "ci_upper": 23.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "RAD001 and Sorafenib",
        "value": 5.45,
        "unit": "Months",
        "ci_lower": 3.9,
        "ci_upper": 7.6,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "RAD001",
        "Sorafenib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Targeted"
    }
  },
  {
    "nct_id": "NCT00391118",
    "brief_title": "Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo (\"Sugar Pill\")",
    "status": "COMPLETED",
    "start_date": "2006-11",
    "completion_date": "2010-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00391118",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIB",
      "IIB",
      "IIB",
      "IIB",
      "IIB",
      "IIB",
      "IIB",
      "IIB",
      "IIB",
      "IIB",
      "IIB",
      "IIB",
      "IIB",
      "IIB"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Part 2 - Regimen A",
        "value": 18.9,
        "unit": "months",
        "ci_lower": 13.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Part 2 - Regimen B",
        "value": 15.2,
        "unit": "months",
        "ci_lower": 11.0,
        "ci_upper": 18.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "enzastaurin",
        "carboplatin"
      ],
      "OG001": [
        "carboplatin",
        "paclitaxel"
      ],
      "OG002": [
        "carboplatin",
        "paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo",
      "OG002": "Chemo"
    }
  },
  {
    "nct_id": "NCT00398320",
    "brief_title": "Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors",
    "status": "COMPLETED",
    "start_date": "2006-11",
    "completion_date": "2012-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pamela L. Kunz",
    "url": "https://clinicaltrials.gov/study/NCT00398320",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Capecitabine / Oxaliplatin / Bevacizumab",
        "value": 64.7,
        "unit": "percentage of participants w/ 12 mo PFS",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Capecitabine / Oxaliplatin / Bevacizumab",
        "value": 42.2,
        "unit": "months",
        "ci_lower": 0.6,
        "ci_upper": 60.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Capecitabine",
        "Oxaliplatin",
        "Bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00402051",
    "brief_title": "Chemotherapy With Pemetrexed in Combination With Platinum for Advanced Non-Small Cell Lung Cancer (NSCLC)",
    "status": "COMPLETED",
    "start_date": "2006-11",
    "completion_date": "2008-12",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00402051",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed + Cisplatin",
        "value": 52.8,
        "unit": "percentage",
        "ci_lower": 40.3,
        "ci_upper": 65.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Pemetrexed + Carboplatin",
        "value": 39.3,
        "unit": "percentage",
        "ci_lower": 27.8,
        "ci_upper": 50.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed + Cisplatin",
        "value": 11.7,
        "unit": "months",
        "ci_lower": 9.2,
        "ci_upper": 14.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Pemetrexed + Carboplatin",
        "value": 8.9,
        "unit": "months",
        "ci_lower": 6.0,
        "ci_upper": 12.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pemetrexed",
        "Cisplatin"
      ],
      "OG001": [
        "Pemetrexed",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00407485",
    "brief_title": "VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium",
    "status": "COMPLETED",
    "start_date": "2006-11",
    "completion_date": "2010-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT00407485",
    "cancer_types": [
      "BLCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (Ziv-aflibercept)",
        "value": 4.5,
        "unit": "percentage of responders",
        "ci_lower": 0.1,
        "ci_upper": 22.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Ziv-aflibercept)",
        "value": 2.79,
        "unit": "Months",
        "ci_lower": 1.74,
        "ci_upper": 3.88,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "ziv-aflibercept"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03125902",
    "brief_title": "A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)",
    "status": "COMPLETED",
    "start_date": "2017-08-25",
    "completion_date": "2019-11-15",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT03125902",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "Absence of expression (triple negative)"
      },
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "Absence of expression (triple negative)"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "Absence of expression (triple negative)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Placebo and Paclitaxel",
        "value": 5.72,
        "unit": "Months",
        "ci_lower": 5.39,
        "ci_upper": 7.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Atezolizumab and Paclitaxel",
        "value": 5.95,
        "unit": "Months",
        "ci_lower": 5.62,
        "ci_upper": 7.43,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Placebo and Paclitaxel",
        "value": 28.29,
        "unit": "Months",
        "ci_lower": 19.06,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Atezolizumab and Paclitaxel",
        "value": 22.05,
        "unit": "Months",
        "ci_lower": 19.19,
        "ci_upper": 30.52,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Placebo and Paclitaxel",
        "value": 40.6,
        "unit": "Percentage of Participants",
        "ci_lower": 30.93,
        "ci_upper": 50.82,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Atezolizumab and Paclitaxel",
        "value": 49.2,
        "unit": "Percentage of Participants",
        "ci_lower": 41.92,
        "ci_upper": 56.53,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Paclitaxel"
      ],
      "OG001": [
        "Atezolizumab",
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT00398567",
    "brief_title": "A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2007-04-04",
    "completion_date": "2009-07-31",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Puma Biotechnology, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT00398567",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": null
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IIIC",
      "IV"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Part 2 - Expanded MTD Cohort",
        "value": 44.8,
        "unit": "percentage of population",
        "ci_lower": 25.9,
        "ci_upper": 62.1,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "HKI-272",
        "trastuzumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Targeted"
    }
  },
  {
    "nct_id": "NCT03108131",
    "brief_title": "Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors",
    "status": "COMPLETED",
    "start_date": "2017-04-07",
    "completion_date": "2024-04-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "M.D. Anderson Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT03108131",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Tumor PD-L1 expression testing required (FFPE tissue preferred; bone metastasis tissue not acceptable; biopsy during screening allowed if no adequate archival tissue)."
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Small Bowel Adenocarcinoma",
        "value": 2.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Small Bowel Adenocarcinoma",
        "value": 2.4,
        "unit": "months",
        "ci_lower": 1.3,
        "ci_upper": 3.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Small Bowel Adenocarcinoma",
        "value": 8.8,
        "unit": "months",
        "ci_lower": 5.6,
        "ci_upper": 12.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cobimetinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03130959",
    "brief_title": "A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies",
    "status": "COMPLETED",
    "start_date": "2017-06-12",
    "completion_date": "2020-03-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT03130959",
    "cancer_types": [
      "GBM",
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A1",
        "value": 11.66,
        "unit": "months",
        "ci_lower": 10.32,
        "ci_upper": 16.46,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B1",
        "value": 10.78,
        "unit": "months",
        "ci_lower": 9.13,
        "ci_upper": 15.77,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A2",
        "value": 1.74,
        "unit": "months",
        "ci_lower": 1.35,
        "ci_upper": 2.73,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B2",
        "value": 1.31,
        "unit": "months",
        "ci_lower": 1.18,
        "ci_upper": 1.45,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Arm A3",
        "value": 1.38,
        "unit": "months",
        "ci_lower": 1.22,
        "ci_upper": 1.38,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Arm B3",
        "value": 2.76,
        "unit": "months",
        "ci_lower": 1.48,
        "ci_upper": 4.53,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Arm A4",
        "value": 1.41,
        "unit": "months",
        "ci_lower": 1.41,
        "ci_upper": 2.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG005",
        "arm_title": "Arm B4",
        "value": 4.6,
        "unit": "months",
        "ci_lower": 1.41,
        "ci_upper": 5.39,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG003": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG004": [
        "Nivolumab"
      ],
      "OG005": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG006": [
        "Nivolumab"
      ],
      "OG007": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG008": [
        "Nivolumab"
      ],
      "OG009": [
        "Nivolumab",
        "Ipilimumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER",
      "OG002": "OTHER",
      "OG003": "IO",
      "OG004": "IO",
      "OG005": "IO",
      "OG006": "IO",
      "OG007": "IO",
      "OG008": "IO",
      "OG009": "IO"
    }
  },
  {
    "nct_id": "NCT00405938",
    "brief_title": "Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2006-11",
    "completion_date": "2010-06",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SCRI Development Innovations, LLC",
    "url": "https://clinicaltrials.gov/study/NCT00405938",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "ER+ and/or PR+ required; at least one hormone receptor (ER or PR) must be positive"
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": "ER+ and/or PR+ required; at least one hormone receptor (ER or PR) must be positive"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab/Anastrozole",
        "value": 21.0,
        "unit": "months",
        "ci_lower": 14.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab/Fulvestrant",
        "value": 9.0,
        "unit": "months",
        "ci_lower": 5.0,
        "ci_upper": 13.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Bevacizumab",
        "Anastrozole"
      ],
      "OG001": [
        "Bevacizumab",
        "Fulvestrant"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03121352",
    "brief_title": "Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2017-05-19",
    "completion_date": "2022-02-20",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Case Comprehensive Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT03121352",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "Part of triple-negative breast cancer definition (ER negative)"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "Part of triple-negative breast cancer definition (PR negative)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "Part of triple-negative breast cancer definition (HER2 negative)"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Carboplatin + Nab-paclitaxel + Pembrolizumab",
        "value": 2.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Carboplatin + Nab-paclitaxel + Pembrolizumab",
        "value": 11.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Carboplatin + Nab-paclitaxel + Pembrolizumab",
        "value": 6.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Carboplatin + Nab-paclitaxel + Pembrolizumab",
        "value": 8.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Carboplatin + Nab-paclitaxel + Pembrolizumab",
        "value": 5.8,
        "unit": "months",
        "ci_lower": 4.7,
        "ci_upper": 8.5,
        "dispersion_type": "MEAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Carboplatin",
        "Nab-paclitaxel",
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT03106987",
    "brief_title": "A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.",
    "status": "COMPLETED",
    "start_date": "2017-06-08",
    "completion_date": "2021-02-15",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT03106987",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "BRCA1",
        "status": "ANY",
        "details": "Documented BRCA1/2 status required. Cohorts defined as BRCA1/2 positive or negative with different minimum prior PARPi exposure durations (see below)."
      },
      {
        "target": "BRCA2",
        "status": "ANY",
        "details": "Documented BRCA1/2 status required. Cohorts defined as BRCA1/2 positive or negative with different minimum prior PARPi exposure durations (see below)."
      }
    ],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "MAINTENANCE",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Olaparib (BRCA1/2 +ve)",
        "value": 4.3,
        "unit": "Months",
        "ci_lower": 2.79,
        "ci_upper": 5.49,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo (BRCA1/2 +ve)",
        "value": 2.8,
        "unit": "Months",
        "ci_lower": 2.73,
        "ci_upper": 4.96,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Olaparib (BRCA1/2 -ve)",
        "value": 5.3,
        "unit": "Months",
        "ci_lower": 2.89,
        "ci_upper": 5.55,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Placebo (BRCA1/2 -ve)",
        "value": 2.8,
        "unit": "Months",
        "ci_lower": 2.79,
        "ci_upper": 2.89,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Olaparib (BRCA1/2 +ve)",
        "value": 20.1,
        "unit": "Months",
        "ci_lower": 16.39,
        "ci_upper": 25.43,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo (BRCA1/2 +ve)",
        "value": 20.9,
        "unit": "Months",
        "ci_lower": 15.21,
        "ci_upper": 23.92,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Olaparib (BRCA1/2 -ve)",
        "value": 23.2,
        "unit": "Months",
        "ci_lower": 15.15,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Placebo (BRCA1/2 -ve)",
        "value": 30.2,
        "unit": "Months",
        "ci_lower": 17.84,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Olaparib"
      ],
      "OG002": [
        "Olaparib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Placebo",
      "OG002": "Targeted_Other",
      "OG003": "Placebo"
    }
  },
  {
    "nct_id": "NCT03126110",
    "brief_title": "Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",
    "status": "COMPLETED",
    "start_date": "2017-04-25",
    "completion_date": "2021-11-09",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Incyte Biosciences International S\u00e0rl",
    "url": "https://clinicaltrials.gov/study/NCT03126110",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 2 Group C2 PD-1/PD-L1 RM: INCAGN01876 300 mg + Ipilimumab 1 mg/kg",
        "value": 0.0,
        "unit": "Percentage of Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Phase 2 Group F GC: INCAGN01876 300 mg + Nivolumab 240 mg",
        "value": 0.0,
        "unit": "Percentage of Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Phase 2 Group F SCCHN INCAGN01876 300 mg + Nivolumab 240 mg",
        "value": 23.9,
        "unit": "Percentage of Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Phase 2 Group F CC: INCAGN01876 300 mg + Nivolumab 240 mg",
        "value": 16.7,
        "unit": "Percentage of Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Phase 2 Group F PD-1/PD-L1 RM: INCAGN01876 300 mg + Nivolumab 240 mg",
        "value": 0.0,
        "unit": "Percentage of Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "Phase 2 Group F Biopsy: INCAGN01876 300 mg + Nivolumab 240 mg",
        "value": 0.0,
        "unit": "Percentage of Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "INCAGN01876",
        "Nivolumab"
      ],
      "OG001": [
        "INCAGN01876",
        "Nivolumab"
      ],
      "OG002": [
        "INCAGN01876",
        "Nivolumab"
      ],
      "OG003": [
        "INCAGN01876",
        "Nivolumab"
      ],
      "OG004": [
        "INCAGN01876",
        "Nivolumab"
      ],
      "OG005": [
        "INCAGN01876",
        "Nivolumab"
      ],
      "OG006": [
        "INCAGN01876",
        "Nivolumab"
      ],
      "OG007": [
        "INCAGN01876",
        "Ipilimumab"
      ],
      "OG008": [
        "INCAGN01876",
        "Ipilimumab"
      ],
      "OG009": [
        "INCAGN01876",
        "Ipilimumab"
      ],
      "OG010": [
        "INCAGN01876",
        "Nivolumab",
        "Ipilimumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO",
      "OG003": "IO",
      "OG004": "IO",
      "OG005": "IO",
      "OG006": "IO",
      "OG007": "IO",
      "OG008": "IO",
      "OG009": "IO",
      "OG010": "IO"
    }
  },
  {
    "nct_id": "NCT03106415",
    "brief_title": "Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2017-09-27",
    "completion_date": "2022-05-19",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Mayo Clinic",
    "url": "https://clinicaltrials.gov/study/NCT03106415",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "ER \u00003C=\u000010% staining by immunohistochemistry (IHC)"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "PR \u00003C=\u000010% staining by immunohistochemistry (IHC)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 negative by IHC (0 or 1+; or 2+ without gene amplification) OR ISH criteria: single-probe average HER2 copy number < 4.0 signals/cell OR dual-probe HER2/CEP17 ratio < 2.0 with average HER2 copy number < 4.0 signals/cell"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 2",
        "value": 0.304,
        "unit": "Proportion of participants",
        "ci_lower": 0.122,
        "ci_upper": 0.473,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "All Dose Level 0",
        "value": 2.43,
        "unit": "Months",
        "ci_lower": 0.49,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "All Dose Level -1",
        "value": 7.92,
        "unit": "Months",
        "ci_lower": 3.88,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "All Dose Level 0",
        "value": 7.03,
        "unit": "Months",
        "ci_lower": 0.49,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "All Dose Level -1",
        "value": 33.18,
        "unit": "Months",
        "ci_lower": 11.24,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Binimetinib",
        "Pembrolizumab"
      ],
      "OG001": [
        "Binimetinib",
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT00393939",
    "brief_title": "Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2007-02",
    "completion_date": "2010-02",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT00393939",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "Her-2 negative tumors"
      }
    ],
    "cancer_stages": [
      "RECURRENT",
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Docetaxel + Sunitinib",
        "value": 8.6,
        "unit": "months",
        "ci_lower": 8.2,
        "ci_upper": 10.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Docetaxel",
        "value": 8.3,
        "unit": "months",
        "ci_lower": 7.7,
        "ci_upper": 9.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Docetaxel + Sunitinib",
        "value": 8.2,
        "unit": "months",
        "ci_lower": 7.3,
        "ci_upper": 8.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Docetaxel",
        "value": 6.9,
        "unit": "months",
        "ci_lower": 6.5,
        "ci_upper": 7.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Docetaxel + Sunitinib",
        "value": 26.0,
        "unit": "months",
        "ci_lower": 22.5,
        "ci_upper": 32.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Docetaxel",
        "value": 28.9,
        "unit": "months",
        "ci_lower": 25.5,
        "ci_upper": 33.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Sunitinib malate",
        "Taxotere"
      ],
      "OG001": [
        "Taxotere"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT03111732",
    "brief_title": "Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)",
    "status": "COMPLETED",
    "start_date": "2017-06-14",
    "completion_date": "2020-07-22",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT03111732",
    "cancer_types": [
      "OTHER",
      "LIHC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "1/Arm 1 - Pembrolizumab Plus Oxaliplatin Plus Capecitabine",
        "value": 4.54,
        "unit": "Months",
        "ci_lower": 2.5,
        "ci_upper": 9.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "1/Arm 1 - Pembrolizumab Plus Oxaliplatin Plus Capecitabine",
        "value": 43.0,
        "unit": "Weeks",
        "ci_lower": 22.0,
        "ci_upper": 66.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab (MK-3475)",
        "Oxaliplatin",
        "Capecitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "OTHER",
      "OG002": "OTHER",
      "OG003": "OTHER",
      "OG004": "OTHER"
    }
  },
  {
    "nct_id": "NCT03132532",
    "brief_title": "Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery",
    "status": "COMPLETED",
    "start_date": "2017-07-31",
    "completion_date": "2023-12-23",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Mayo Clinic",
    "url": "https://clinicaltrials.gov/study/NCT03132532",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "II",
      "III",
      "RECURRENT",
      "UNRESECTABLE",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A (Platinum Doublet Chemotherapy, Lower Dose PBT)",
        "value": 0.6,
        "unit": "proportion of participants",
        "ci_lower": 0.362,
        "ci_upper": 0.995,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm C (Platinum Doublet Chemotherapy, Higher Dose PBT)",
        "value": 0.429,
        "unit": "proportion of participants",
        "ci_lower": 0.182,
        "ci_upper": 1.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A (Platinum Doublet Chemotherapy, Lower Dose PBT)",
        "value": 4.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A (Platinum Doublet Chemotherapy, Lower Dose PBT)",
        "value": 6.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm C (Platinum Doublet Chemotherapy, Higher Dose PBT)",
        "value": 2.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm C (Platinum Doublet Chemotherapy, Higher Dose PBT)",
        "value": 5.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Carboplatin",
        "Paclitaxel",
        "Etoposide",
        "Cisplatin",
        "Pemetrexed"
      ],
      "OG001": [
        "Carboplatin",
        "Paclitaxel",
        "Etoposide",
        "Cisplatin",
        "Pemetrexed"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT03123783",
    "brief_title": "CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab",
    "status": "COMPLETED",
    "start_date": "2017-07-10",
    "completion_date": "2020-11-16",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Apexigen America, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT03123783",
    "cancer_types": [
      "NSCLC",
      "SKCM"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "Documented activating mutation; if present must have received the appropriate targeted therapy and progressed"
      },
      {
        "target": "ALK",
        "status": "ANY",
        "details": "Documented activating mutation; if present must have received the appropriate targeted therapy and progressed"
      },
      {
        "target": "ROS1",
        "status": "ANY",
        "details": "Documented activating mutation; if present must have received the appropriate targeted therapy and progressed"
      },
      {
        "target": "BRAF",
        "status": "ANY",
        "details": "Mentioned for melanoma cohort: activating BRAF mutation (could have received BRAF and/or MEK inhibitor prior to anti-PD-1/PD-L1 therapy)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": true,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort 1 (Arm)/inNSCLC (Phase 2)",
        "value": 16.67,
        "unit": "Percentage of participants",
        "ci_lower": 8.57,
        "ci_upper": 28.07,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Cohort 2(Arm)/PD1-MM (Phase 2)",
        "value": 15.15,
        "unit": "Percentage of participants",
        "ci_lower": 6.17,
        "ci_upper": 29.25,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Cohort 3A(Arm)/PD1-NSCLC (Phase 2)",
        "value": 0.0,
        "unit": "Percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 22.09,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Cohort 3B(Arm)/PD1-NSCLC (Phase 2)",
        "value": 0.0,
        "unit": "Percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 11.29,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "APX005M",
        "Nivolumab"
      ],
      "OG001": [
        "APX005M",
        "Nivolumab"
      ],
      "OG002": [
        "APX005M",
        "Nivolumab"
      ],
      "OG003": [
        "APX005M",
        "Nivolumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted",
      "OG002": "Combo_IO_Targeted",
      "OG003": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT00410761",
    "brief_title": "An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer",
    "status": "COMPLETED",
    "start_date": "2006-11-23",
    "completion_date": "2009-07-31",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Genzyme, a Sanofi Company",
    "url": "https://clinicaltrials.gov/study/NCT00410761",
    "cancer_types": [
      "THCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "UNRESECTABLE",
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Vandetanib 300 mg",
        "value": 30.5,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 19.2,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Vandetanib 300 mg",
        "value": 81.6,
        "unit": "Months",
        "ci_lower": 64.6,
        "ci_upper": 98.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 80.4,
        "unit": "Months",
        "ci_lower": 52.5,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Vandetanib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT03143153",
    "brief_title": "A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin",
    "status": "COMPLETED",
    "start_date": "2017-06-29",
    "completion_date": "2021-01-18",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT03143153",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "UNRESECTABLE",
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A: Nivolumab + Ipilimumab",
        "value": 13.7,
        "unit": "Months",
        "ci_lower": 11.24,
        "ci_upper": 17.02,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Nivolumab + Chemotherapy",
        "value": 15.44,
        "unit": "Months",
        "ci_lower": 11.93,
        "ci_upper": 19.52,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Arm C: Chemotherapy",
        "value": 9.07,
        "unit": "Months",
        "ci_lower": 7.69,
        "ci_upper": 9.95,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A: Nivolumab + Ipilimumab",
        "value": 4.04,
        "unit": "Months",
        "ci_lower": 2.4,
        "ci_upper": 4.93,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Nivolumab + Chemotherapy",
        "value": 6.93,
        "unit": "Months",
        "ci_lower": 5.68,
        "ci_upper": 8.34,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Arm C: Chemotherapy",
        "value": 4.44,
        "unit": "Months",
        "ci_lower": 2.89,
        "ci_upper": 5.82,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG001": [
        "Nivolumab",
        "Fluorouracil"
      ],
      "OG002": [
        "Fluorouracil",
        "Cisplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "Combo_Chemo_IO",
      "OG002": "Chemo"
    }
  },
  {
    "nct_id": "NCT00415194",
    "brief_title": "A Study for Patients With Head and Neck Cancer",
    "status": "COMPLETED",
    "start_date": "2006-12",
    "completion_date": "2010-03",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00415194",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed/Cisplatin",
        "value": 7.33,
        "unit": "Months",
        "ci_lower": 6.34,
        "ci_upper": 8.38,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo/Cisplatin",
        "value": 6.28,
        "unit": "Months",
        "ci_lower": 5.52,
        "ci_upper": 7.06,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed/Cisplatin",
        "value": 3.61,
        "unit": "months",
        "ci_lower": 3.15,
        "ci_upper": 4.07,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo/Cisplatin",
        "value": 2.79,
        "unit": "months",
        "ci_lower": 2.69,
        "ci_upper": 3.22,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "pemetrexed",
        "cisplatin"
      ],
      "OG001": [
        "cisplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00409006",
    "brief_title": "Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers",
    "status": "COMPLETED",
    "start_date": "2007-02",
    "completion_date": "2009-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00409006",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed/Cisplatin/Gefitinib",
        "value": 9.95,
        "unit": "Months",
        "ci_lower": 5.85,
        "ci_upper": 16.49,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Pemetrexed/Cisplatin",
        "value": 6.83,
        "unit": "Months",
        "ci_lower": 5.78,
        "ci_upper": 7.98,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed/Cisplatin/Gefitinib",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Pemetrexed/Cisplatin",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pemetrexed",
        "Cisplatin",
        "Gefitinib"
      ],
      "OG001": [
        "Pemetrexed",
        "Cisplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00418886",
    "brief_title": "Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients",
    "status": "COMPLETED",
    "start_date": "2007-01",
    "completion_date": "2008-09",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Genzyme, a Sanofi Company",
    "url": "https://clinicaltrials.gov/study/NCT00418886",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV",
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Vandetanib Plus Pemetrexed",
        "value": 17.6,
        "unit": "weeks",
        "ci_lower": 13.4,
        "ci_upper": 18.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo Plus Pemetrexed",
        "value": 11.9,
        "unit": "weeks",
        "ci_lower": 11.4,
        "ci_upper": 15.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Vandetanib Plus Pemetrexed",
        "value": 10.5,
        "unit": "months",
        "ci_lower": 8.9,
        "ci_upper": 12.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo Plus Pemetrexed",
        "value": 9.2,
        "unit": "months",
        "ci_lower": 7.1,
        "ci_upper": 12.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Vandetanib",
        "Pemetrexed"
      ],
      "OG001": [
        "Pemetrexed"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT03164616",
    "brief_title": "Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2017-06-01",
    "completion_date": "2021-03-12",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT03164616",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Confirmed tumor PD-L1 status prior to randomization"
      },
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "No activating EGFR mutations"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "No ALK fusions"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "D + SoC",
        "value": 5.5,
        "unit": "months",
        "ci_lower": 4.7,
        "ci_upper": 6.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "SoC Alone",
        "value": 4.8,
        "unit": "months",
        "ci_lower": 4.6,
        "ci_upper": 5.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "D + SoC",
        "value": 13.3,
        "unit": "months",
        "ci_lower": 11.4,
        "ci_upper": 14.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "SoC Alone",
        "value": 11.7,
        "unit": "months",
        "ci_lower": 10.5,
        "ci_upper": 13.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Durvalumab",
        "Abraxane + carboplatin",
        "Gemcitabine + cisplatin",
        "Gemcitabine + carboplatin",
        "Pemetrexed + carboplatin",
        "Pemetrexed + cisplatin"
      ],
      "OG001": [
        "Abraxane + carboplatin",
        "Gemcitabine + cisplatin",
        "Gemcitabine + carboplatin",
        "Pemetrexed + carboplatin",
        "Pemetrexed + cisplatin"
      ],
      "OG002": [
        "Abraxane + carboplatin",
        "Gemcitabine + cisplatin",
        "Gemcitabine + carboplatin",
        "Pemetrexed + carboplatin",
        "Pemetrexed + cisplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Chemo",
      "OG002": "Chemo"
    }
  },
  {
    "nct_id": "NCT03150862",
    "brief_title": "A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma",
    "status": "COMPLETED",
    "start_date": "2017-07-24",
    "completion_date": "2021-03-17",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "BeiGene USA, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT03150862",
    "cancer_types": [
      "GBM"
    ],
    "biomarkers": [
      {
        "target": "MGMT",
        "status": "NEGATIVE",
        "details": "Unmethylated MGMT promoter required for enrollment in Arms A and B"
      },
      {
        "target": "MGMT",
        "status": "ANY",
        "details": "Documentation of MGMT promoter status required (Arms C escalation and expansion)"
      }
    ],
    "cancer_stages": [
      "IV",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "DCR",
        "arm_id": "OG000",
        "arm_title": "Arm A: Dose Expansion (E) - Pamiparib 6 Wks + RT 6 Wks",
        "value": 65.6,
        "unit": "Percentage of participants",
        "ci_lower": 46.8,
        "ci_upper": 81.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Arm C: E- Pamiparib + Temozolomide 60 mg",
        "value": 10.7,
        "unit": "Percentage of participants",
        "ci_lower": 2.3,
        "ci_upper": 28.2,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pamiparib"
      ],
      "OG001": [
        "Pamiparib"
      ],
      "OG002": [
        "Pamiparib"
      ],
      "OG003": [
        "Pamiparib",
        "TMZ"
      ],
      "OG004": [
        "Pamiparib",
        "TMZ"
      ],
      "OG005": [
        "Pamiparib",
        "TMZ"
      ],
      "OG006": [
        "Pamiparib",
        "TMZ"
      ],
      "OG007": [
        "Pamiparib",
        "TMZ"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Combo_Chemo_Targeted",
      "OG004": "Combo_Chemo_Targeted",
      "OG005": "Combo_Chemo_Targeted",
      "OG006": "Combo_Chemo_Targeted",
      "OG007": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00423917",
    "brief_title": "Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2007-08",
    "completion_date": "2009-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Alliance for Clinical Trials in Oncology",
    "url": "https://clinicaltrials.gov/study/NCT00423917",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Estrogen and/or progesterone receptor-positive tumor; at least one of ER or PR must be positive"
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": "Estrogen and/or progesterone receptor-positive tumor; at least one of ER or PR must be positive"
      },
      {
        "target": "HER2",
        "status": "ANY",
        "details": "If HER2 positive (IHC 3+ or FISH amplified), patient must have received \u22651 prior trastuzumab-containing regimen unless contraindicated"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Fulvestrant + Bevacizumab",
        "value": 39.0,
        "unit": "percentage of patients",
        "ci_lower": 23.0,
        "ci_upper": 58.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Fulvestrant + Bevacizumab",
        "value": 26.9,
        "unit": "months",
        "ci_lower": 12.5,
        "ci_upper": 36.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG000",
        "arm_title": "Fulvestrant + Bevacizumab",
        "value": 11.9,
        "unit": "months",
        "ci_lower": 3.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "fulvestrant",
        "bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER"
    }
  },
  {
    "nct_id": "NCT03167619",
    "brief_title": "Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)",
    "status": "COMPLETED",
    "start_date": "2018-10-04",
    "completion_date": "2021-06-30",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Duke University",
    "url": "https://clinicaltrials.gov/study/NCT03167619",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "ER negative defined as <1% tumor cells positive by IHC; subjects with ER low-expression (\u226410%) may be enrolled at investigator discretion"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "PR negative defined as <1% tumor cells positive by IHC; subjects with PR low-expression (\u226410%) may be enrolled at investigator discretion"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 negative defined as IHC 0 or 1+ per criteria (IHC 1+: incomplete faint/barely perceptible membrane staining in >10% of invasive tumor cells; IHC 0: no staining or incomplete faint staining in \u226410% of invasive tumor cells) or FISH negative (single-probe HER2 copy number <4.0 signals/cell or HER2/CEP17 ratio <2.0 with average HER2 copy number <4.0)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "A - Olaparib Alone",
        "value": 0.18,
        "unit": "events/month",
        "ci_lower": 0.11,
        "ci_upper": 0.27,
        "dispersion_type": "MEAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "A - Olaparib Alone",
        "value": 21.68,
        "unit": "months",
        "ci_lower": 7.69,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Olaparib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00420381",
    "brief_title": "Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer",
    "status": "COMPLETED",
    "start_date": "2007-01",
    "completion_date": "2008-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00420381",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Enzastaurin",
        "value": 10.0,
        "unit": "Percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 20.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Enzastaurin",
        "value": 15.1,
        "unit": "Months",
        "ci_lower": 9.5,
        "ci_upper": 33.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "enzastaurin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00409565",
    "brief_title": "A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer",
    "status": "COMPLETED",
    "start_date": "2006-09",
    "completion_date": "2012-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT00409565",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "Baseline tumor tissue required for EGFR determination (therapeutic target of cetuximab); repeat on-treatment biopsy optional 12\u201316 days post-initiation"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cetuximab Plus Bevacizumab",
        "value": 16.0,
        "unit": "percentage of participants",
        "ci_lower": 7.0,
        "ci_upper": 24.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cetuximab Plus Bevacizumab",
        "value": 2.8,
        "unit": "Months",
        "ci_lower": 2.7,
        "ci_upper": 4.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cetuximab Plus Bevacizumab",
        "value": 7.5,
        "unit": "months",
        "ci_lower": 5.7,
        "ci_upper": 9.6,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cetuximab",
        "Bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00418938",
    "brief_title": "SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial",
    "status": "COMPLETED",
    "start_date": "2006-11-01",
    "completion_date": "2012-05-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Amgen",
    "url": "https://clinicaltrials.gov/study/NCT00418938",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "wild-type KRAS (no KRAS mutation) from primary tumor or metastasis"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Panitumumab Plus FOLFIRI",
        "value": 7.7,
        "unit": "months",
        "ci_lower": 5.7,
        "ci_upper": 11.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab Plus FOLFIRI",
        "value": 9.2,
        "unit": "months",
        "ci_lower": 7.8,
        "ci_upper": 10.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Panitumumab Plus FOLFIRI",
        "value": 3.7,
        "unit": "months",
        "ci_lower": 2.7,
        "ci_upper": 5.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab Plus FOLFIRI",
        "value": 6.4,
        "unit": "months",
        "ci_lower": 3.5,
        "ci_upper": 17.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Panitumumab Plus FOLFIRI",
        "value": 18.0,
        "unit": "months",
        "ci_lower": 13.5,
        "ci_upper": 21.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab Plus FOLFIRI",
        "value": 21.4,
        "unit": "months",
        "ci_lower": 16.5,
        "ci_upper": 24.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Panitumumab Plus FOLFIRI",
        "value": 8.7,
        "unit": "months",
        "ci_lower": 6.1,
        "ci_upper": 14.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab Plus FOLFIRI",
        "value": 13.5,
        "unit": "months",
        "ci_lower": 9.1,
        "ci_upper": 14.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Panitumumab",
        "Leucovorin",
        "Irinotecan",
        "5-Fluorouracil"
      ],
      "OG001": [
        "Bevacizumab",
        "Leucovorin",
        "Irinotecan",
        "5-Fluorouracil"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03148795",
    "brief_title": "A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer",
    "status": "COMPLETED",
    "start_date": "2017-07-04",
    "completion_date": "2020-09-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT03148795",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [
      {
        "target": "DNA_REPAIR_DEFICIENCY",
        "status": "POSITIVE",
        "details": "DNA damage repair deficiency detected by central NGS gene panel (FoundationOne CDx) on tumor tissue or prior approved testing"
      },
      {
        "target": "TESTOSTERONE",
        "status": "LOW",
        "details": "Serum testosterone \u2264 1.73 nmol/L (50 ng/dL) at screening"
      },
      {
        "target": "PSA",
        "status": "HIGH",
        "details": "If qualifying solely by PSA progression: screening central laboratory PSA \u2265 2 \u03bcg/L (2 ng/mL); progression may be defined by \u22653 rising PSA values \u22651 week apart"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Talazoparib",
        "value": 29.8,
        "unit": "Percentage of participants",
        "ci_lower": 21.2,
        "ci_upper": 39.6,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Talazoparib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03133546",
    "brief_title": "Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER)",
    "status": "COMPLETED",
    "start_date": "2017-05-31",
    "completion_date": "2021-02-22",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "ETOP IBCSG Partners Foundation",
    "url": "https://clinicaltrials.gov/study/NCT03133546",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "exon 19 deletion or exon 21 L858R (sensitizing EGFR mutations)"
      },
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "T790M mutation (locally confirmed in tissue or detected in plasma/serum cfDNA after progression on prior EGFR TKI)"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IIIC",
      "IVA",
      "IVB",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": true,
    "prior_io": null,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Osimertinib Plus Bevacizumab",
        "value": 15.4,
        "unit": "months",
        "ci_lower": 9.2,
        "ci_upper": 18.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Osimertinib Alone",
        "value": 12.3,
        "unit": "months",
        "ci_lower": 6.2,
        "ci_upper": 17.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Osimertinib",
        "Bevacizumab"
      ],
      "OG001": [
        "Osimertinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Targeted",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT00412061",
    "brief_title": "Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor",
    "status": "COMPLETED",
    "start_date": "2006-12",
    "completion_date": "2010-04",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT00412061",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Octreotide+ Everolimus",
        "value": 16.43,
        "unit": "Months",
        "ci_lower": 13.67,
        "ci_upper": 21.19,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Octreotide+ Placebo",
        "value": 11.33,
        "unit": "Months",
        "ci_lower": 8.44,
        "ci_upper": 14.59,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Octreotide+ Everolimus",
        "value": 80.5,
        "unit": "Percentage of Participants",
        "ci_lower": 74.5,
        "ci_upper": 85.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Octreotide+ Placebo Followed by Open Label Arm",
        "value": 81.8,
        "unit": "Percentage of Participants",
        "ci_lower": 75.8,
        "ci_upper": 86.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Octreotide+ Everolimus",
        "value": 57.0,
        "unit": "Percentage of Participants",
        "ci_lower": 49.9,
        "ci_upper": 63.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Octreotide+ Placebo Followed by Open Label Arm",
        "value": 63.6,
        "unit": "Percentage of Participants",
        "ci_lower": 56.6,
        "ci_upper": 69.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Octreotide+ Everolimus",
        "value": 42.9,
        "unit": "Percentage of Participants",
        "ci_lower": 36.0,
        "ci_upper": 49.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Octreotide+ Placebo Followed by Open Label Arm",
        "value": 48.5,
        "unit": "Percentage of Participants",
        "ci_lower": 41.4,
        "ci_upper": 55.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Octreotide+ Everolimus",
        "value": 38.0,
        "unit": "Percentage of Participants",
        "ci_lower": 31.2,
        "ci_upper": 44.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Octreotide+ Placebo Followed by Open Label Arm",
        "value": 41.6,
        "unit": "Percentage of Participants",
        "ci_lower": 34.6,
        "ci_upper": 48.5,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Octreotide",
        "Everolimus"
      ],
      "OG001": [
        "Octreotide"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03147287",
    "brief_title": "Palbociclib After CDK and Endocrine Therapy (PACE)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2017-09-05",
    "completion_date": "2022-12-31",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Dana-Farber Cancer Institute",
    "url": "https://clinicaltrials.gov/study/NCT03147287",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HR",
        "status": "POSITIVE",
        "details": "Hormone receptor positive (ER and/or PR positive) per institutional ASCO/CAP guidelines; testing in CLIA-approved setting"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 negative per ASCO/CAP guidelines (IHC/FISH per institutional practice)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Fulvestrant",
        "value": 4.8,
        "unit": "months",
        "ci_lower": 2.1,
        "ci_upper": 8.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Fulvestrant With Palbociclib",
        "value": 4.6,
        "unit": "months",
        "ci_lower": 3.6,
        "ci_upper": 5.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Fulvestrant With Palbociclib and Avelumab",
        "value": 8.1,
        "unit": "months",
        "ci_lower": 3.2,
        "ci_upper": 10.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Fulvestrant"
      ],
      "OG001": [
        "Fulvestrant",
        "Palbociclib"
      ],
      "OG002": [
        "Fulvestrant",
        "Palbociclib",
        "Avelumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT03184571",
    "brief_title": "Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)",
    "status": "COMPLETED",
    "start_date": "2017-10-02",
    "completion_date": "2022-10-27",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "BerGenBio ASA",
    "url": "https://clinicaltrials.gov/study/NCT03184571",
    "cancer_types": [
      "NSCLC",
      "LUAD"
    ],
    "biomarkers": [
      {
        "target": "AXL",
        "status": "ANY",
        "details": "AXL kinase expression analysis required from tumor tissue (fresh FFPE or archival)"
      },
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "PD-L1 expression analysis required from tumor tissue (method/threshold not specified)"
      },
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "EGFR-mutant patients may be eligible for Cohort A if they have documented progression on \u22651 licensed therapy; EGFR-mutant patients are excluded from Cohorts B and C"
      },
      {
        "target": "ALK",
        "status": "ANY",
        "details": "ALK genomic rearrangement: patients with ALK rearrangements may be eligible for Cohort A if progressed on \u22651 licensed therapy; ALK-rearranged patients are excluded from Cohorts B and C"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort A",
        "value": 10.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Cohort B",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Cohort C",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Total Patients",
        "value": 10.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort A",
        "value": 35.7,
        "unit": "weeks",
        "ci_lower": 18.0,
        "ci_upper": 54.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort B",
        "value": 26.1,
        "unit": "weeks",
        "ci_lower": 9.6,
        "ci_upper": 36.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Cohort C",
        "value": 26.0,
        "unit": "weeks",
        "ci_lower": 9.7,
        "ci_upper": 64.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Total Patients",
        "value": 27.1,
        "unit": "weeks",
        "ci_lower": 19.0,
        "ci_upper": 38.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cohort A",
        "value": 61.0,
        "unit": "weeks",
        "ci_lower": 46.3,
        "ci_upper": 75.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cohort B",
        "value": 43.7,
        "unit": "weeks",
        "ci_lower": 29.1,
        "ci_upper": 70.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Cohort C",
        "value": 64.4,
        "unit": "weeks",
        "ci_lower": 27.9,
        "ci_upper": 110.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Total Patients",
        "value": 56.6,
        "unit": "weeks",
        "ci_lower": 43.7,
        "ci_upper": 66.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Bemcentinib",
        "Pemetrexed"
      ],
      "OG001": [
        "Bemcentinib",
        "Pembrolizumab"
      ],
      "OG002": [
        "Bemcentinib"
      ],
      "OG003": [
        "Bemcentinib",
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Combo_TKI_IO",
      "OG002": "TKI",
      "OG003": "Combo_TKI_IO"
    }
  },
  {
    "nct_id": "NCT00419159",
    "brief_title": "Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy",
    "status": "COMPLETED",
    "start_date": "2006-12",
    "completion_date": "2009-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT00419159",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "DCR",
        "arm_id": "OG000",
        "arm_title": "Everolimus (RAD001) 70 mg/Week",
        "value": 31.0,
        "unit": "Percentage of participants",
        "ci_lower": 20.5,
        "ci_upper": 43.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG001",
        "arm_title": "Everolimus (RAD001) 10 mg/Day",
        "value": 32.4,
        "unit": "Percentage of participants",
        "ci_lower": 21.8,
        "ci_upper": 44.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Everolimus (RAD001) 70 mg/Week",
        "value": 0.0,
        "unit": "Percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 0.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Everolimus (RAD001) 10 mg/Day",
        "value": 0.0,
        "unit": "Percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 0.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG000",
        "arm_title": "Everolimus (RAD001) 70 mg/Week",
        "value": 25.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG001",
        "arm_title": "Everolimus (RAD001) 10 mg/Day",
        "value": 26.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Everolimus (RAD001) 70 mg/Week",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Everolimus (RAD001) 10 mg/Day",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Everolimus (RAD001) 70 mg/Week",
        "value": 1.77,
        "unit": "Months",
        "ci_lower": 1.68,
        "ci_upper": 1.84,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Everolimus (RAD001) 10 mg/Day",
        "value": 1.77,
        "unit": "Months",
        "ci_lower": 1.68,
        "ci_upper": 1.87,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Everolimus (RAD001) 70 mg/Week",
        "value": 4.9,
        "unit": "Months",
        "ci_lower": 4.04,
        "ci_upper": 6.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Everolimus (RAD001) 10 mg/Day",
        "value": 5.88,
        "unit": "Months",
        "ci_lower": 4.7,
        "ci_upper": 7.06,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Everolimus (RAD001)"
      ],
      "OG001": [
        "Everolimus (RAD001)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03179436",
    "brief_title": "Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)",
    "status": "COMPLETED",
    "start_date": "2017-07-02",
    "completion_date": "2024-04-08",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT03179436",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "No activating EGFR mutation for which EGFR-directed therapy would be indicated (EGFR-directed therapy is not indicated as primary therapy)"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "No ALK translocation for which ALK-targeted therapy would be indicated (ALK translocation-directed therapy is not indicated as primary therapy)"
      },
      {
        "target": "BRAF",
        "status": "ANY",
        "details": "BRAF V600 mutation (including V600E) is specifically mentioned for melanoma cohorts; if BRAF V600-positive, participants should have received targeted therapy for advanced/metastatic disease prior to enrollment (exceptions described for certain V600E participants)"
      },
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "No known history of HIV infection (known HIV is an exclusion)"
      },
      {
        "target": "HBV",
        "status": "NEGATIVE",
        "details": "No active Hepatitis B infection; negative for HBsAg/HBV DNA (known active Hepatitis B is an exclusion)"
      },
      {
        "target": "HCV",
        "status": "NEGATIVE",
        "details": "No known active Hepatitis C infection (active Hepatitis C is an exclusion)"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "III",
      "IV",
      "METASTATIC",
      "UNRESECTABLE",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": true,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG008",
        "arm_title": "Arm F: MK-1308 25 mg Q6W + Pembro. 400 mg Q6W Co-admin",
        "value": 4.9,
        "unit": "Percentage of participants",
        "ci_lower": 0.6,
        "ci_upper": 16.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG009",
        "arm_title": "Arm G: MK-1308 25 mg Q6W",
        "value": 2.5,
        "unit": "Percentage of participants",
        "ci_lower": 0.1,
        "ci_upper": 13.2,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Quavonlimab",
        "Pembrolizumab"
      ],
      "OG001": [
        "Quavonlimab",
        "Pembrolizumab"
      ],
      "OG002": [
        "Quavonlimab",
        "Pembrolizumab"
      ],
      "OG003": [
        "Quavonlimab",
        "Pembrolizumab"
      ],
      "OG004": [
        "Quavonlimab",
        "Pembrolizumab"
      ],
      "OG005": [
        "Quavonlimab",
        "Pembrolizumab"
      ],
      "OG006": [
        "Quavonlimab",
        "Pembrolizumab"
      ],
      "OG007": [
        "Quavonlimab",
        "Pembrolizumab"
      ],
      "OG008": [
        "Quavonlimab",
        "Pembrolizumab"
      ],
      "OG009": [
        "Quavonlimab"
      ],
      "OG010": [
        "Pembrolizumab/Quavonlimab"
      ],
      "OG011": [
        "Pembrolizumab/Quavonlimab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO",
      "OG003": "IO",
      "OG004": "IO",
      "OG005": "IO",
      "OG006": "IO",
      "OG007": "IO",
      "OG008": "IO",
      "OG009": "IO",
      "OG010": "IO",
      "OG011": "IO"
    }
  },
  {
    "nct_id": "NCT03150810",
    "brief_title": "Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2017-06-28",
    "completion_date": "2023-05-04",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "BeiGene",
    "url": "https://clinicaltrials.gov/study/NCT03150810",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "HRD",
        "status": "POSITIVE",
        "details": "homologous recombination deficiency (HRD+)"
      },
      {
        "target": "BRCA",
        "status": "POSITIVE",
        "details": "known BRCA mutation (BRCA mutant)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [],
    "arm_drugs": {
      "OG000": [
        "Pamiparib",
        "Temozolomide"
      ],
      "OG001": [
        "Pamiparib",
        "Temozolomide"
      ],
      "OG002": [
        "Pamiparib",
        "Temozolomide"
      ],
      "OG003": [
        "Pamiparib",
        "Temozolomide"
      ],
      "OG004": [
        "Pamiparib",
        "Temozolomide"
      ],
      "OG005": [
        "Pamiparib",
        "Temozolomide"
      ],
      "OG006": [
        "Pamiparib",
        "Temozolomide"
      ],
      "OG007": [
        "Pamiparib",
        "Temozolomide"
      ],
      "OG008": [
        "Pamiparib",
        "Temozolomide"
      ],
      "OG009": [
        "Pamiparib",
        "Temozolomide"
      ],
      "OG010": [
        "Pamiparib",
        "Temozolomide"
      ],
      "OG011": [
        "Pamiparib",
        "Temozolomide"
      ],
      "OG012": [
        "Pamiparib",
        "Temozolomide"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted",
      "OG003": "Combo_Chemo_Targeted",
      "OG004": "Combo_Chemo_Targeted",
      "OG005": "Combo_Chemo_Targeted",
      "OG006": "Combo_Chemo_Targeted",
      "OG007": "Combo_Chemo_Targeted",
      "OG008": "Combo_Chemo_Targeted",
      "OG009": "Combo_Chemo_Targeted",
      "OG010": "Combo_Chemo_Targeted",
      "OG011": "Combo_Chemo_Targeted",
      "OG012": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03190265",
    "brief_title": "Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer",
    "status": "COMPLETED",
    "start_date": "2017-12-14",
    "completion_date": "2022-08-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
    "url": "https://clinicaltrials.gov/study/NCT03190265",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Arm A: CY, Nivolumab, Ipilimumab, Pancreas GVAX, CRS-207",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Arm B: Nivolumab, Ipilimumab, CRS-207",
        "value": 2.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cyclophosphamide",
        "Nivolumab",
        "Ipilimumab",
        "GVAX Pancreas Vaccine",
        "CRS-207"
      ],
      "OG001": [
        "Nivolumab",
        "Ipilimumab",
        "CRS-207"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "IO"
    }
  },
  {
    "nct_id": "NCT00428922",
    "brief_title": "Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients",
    "status": "COMPLETED",
    "start_date": "2007-06-14",
    "completion_date": "2012-11-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bhuvaneswari Ramaswamy",
    "url": "https://clinicaltrials.gov/study/NCT00428922",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "IHC 3+ or FISH positive"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Trastuzumab, Bevacizumab, and Docetaxel",
        "value": 14.3,
        "unit": "months",
        "ci_lower": 9.3,
        "ci_upper": 35.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Trastuzumab",
        "Bevacizumab",
        "Docetaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00432094",
    "brief_title": "Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors",
    "status": "COMPLETED",
    "start_date": "2006-12-19",
    "completion_date": "2021-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Masonic Cancer Center, University of Minnesota",
    "url": "https://clinicaltrials.gov/study/NCT00432094",
    "cancer_types": [
      "TGCT",
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "2 Transplants",
        "value": 86.0,
        "unit": "percentage of participants",
        "ci_lower": 54.0,
        "ci_upper": 96.0,
        "dispersion_type": "MEAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "1 Transplant",
        "value": 56.0,
        "unit": "percentage of participants",
        "ci_lower": 20.0,
        "ci_upper": 80.0,
        "dispersion_type": "MEAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "carboplatin"
      ],
      "OG001": [
        "ifosfamide",
        "paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00424255",
    "brief_title": "Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery",
    "status": "COMPLETED",
    "start_date": "2006-12",
    "completion_date": "2013-03",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "GlaxoSmithKline",
    "url": "https://clinicaltrials.gov/study/NCT00424255",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "ErbB1 (EGFR) expression assessed by IHC on archived or resected tumor tissue in a central laboratory"
      }
    ],
    "cancer_stages": [
      "II",
      "III",
      "IVA"
    ],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [],
    "arm_drugs": {
      "OG001": [
        "Lapatinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Placebo",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT03195478",
    "brief_title": "A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2017-08-02",
    "completion_date": "2024-01-05",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT03195478",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Part 2: Arm D",
        "value": 77.8,
        "unit": "Percentage of Participants",
        "ci_lower": 40.0,
        "ci_upper": 97.2,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG001": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG002": [
        "Nivolumab",
        "Ipilimumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO"
    }
  },
  {
    "nct_id": "NCT03189719",
    "brief_title": "First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)",
    "status": "COMPLETED",
    "start_date": "2017-07-25",
    "completion_date": "2020-07-02",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT03189719",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "PD-L1 by immunohistochemistry (IHC); newly obtained or archival tissue sample required"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + SOC",
        "value": 13.9,
        "unit": "Months",
        "ci_lower": 11.1,
        "ci_upper": 17.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + SOC",
        "value": 8.8,
        "unit": "Months",
        "ci_lower": 7.8,
        "ci_upper": 10.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + SOC",
        "value": 6.3,
        "unit": "Months",
        "ci_lower": 6.2,
        "ci_upper": 6.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + SOC",
        "value": 5.8,
        "unit": "Months",
        "ci_lower": 5.0,
        "ci_upper": 6.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Cisplatin",
        "5-FU"
      ],
      "OG001": [
        "Cisplatin",
        "5-FU"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00434642",
    "brief_title": "A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma",
    "status": "COMPLETED",
    "start_date": "2007-04",
    "completion_date": "2010-09",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Genentech, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT00434642",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Carboplatin and Gemcitabine + Bevacizumab",
        "value": 12.4,
        "unit": "Months",
        "ci_lower": 11.4,
        "ci_upper": 12.71,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Carboplatin and Gemcitabine + Placebo",
        "value": 8.4,
        "unit": "Months",
        "ci_lower": 8.31,
        "ci_upper": 9.66,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Carboplatin and Gemcitabine + Bevacizumab",
        "value": 33.6,
        "unit": "Months",
        "ci_lower": 30.32,
        "ci_upper": 35.84,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Carboplatin and Gemcitabine + Placebo",
        "value": 32.9,
        "unit": "Months",
        "ci_lower": 29.8,
        "ci_upper": 37.68,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Carboplatin",
        "Gemcitabine",
        "Bevacizumab"
      ],
      "OG001": [
        "Carboplatin",
        "Gemcitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT03215706",
    "brief_title": "A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC",
    "status": "COMPLETED",
    "start_date": "2017-08-24",
    "completion_date": "2019-08-16",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT03215706",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "deletions in exon 19 and exon 21 (L858R) and other EGFR sensitizing mutations"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "ALK translocations sensitive to available targeted inhibitor therapy"
      },
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "PD-L1 IHC testing with results performed by a central laboratory during screening"
      }
    ],
    "cancer_stages": [
      "IV",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Treatment A",
        "value": 14.13,
        "unit": "Months",
        "ci_lower": 13.24,
        "ci_upper": 16.16,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Treatment B",
        "value": 10.74,
        "unit": "Months",
        "ci_lower": 9.46,
        "ci_upper": 12.45,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment A",
        "value": 6.74,
        "unit": "Months",
        "ci_lower": 5.55,
        "ci_upper": 8.05,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Treatment B",
        "value": 5.26,
        "unit": "Months",
        "ci_lower": 4.37,
        "ci_upper": 5.59,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab",
        "Ipilimumab",
        "Chemotherapy"
      ],
      "OG001": [
        "Chemotherapy"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00434109",
    "brief_title": "Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization",
    "status": "COMPLETED",
    "start_date": "2006-11",
    "completion_date": "2012-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
    "url": "https://clinicaltrials.gov/study/NCT00434109",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Sunitinib Malate and Hepatic Artery Embolizations",
        "value": 66.0,
        "unit": "percentage of participants",
        "ci_lower": 51.0,
        "ci_upper": 81.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Sunitinib malate"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT00433381",
    "brief_title": "Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma",
    "status": "COMPLETED",
    "start_date": "2007-03-01",
    "completion_date": "2010-01-21",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT00433381",
    "cancer_types": [
      "GBM"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm II (Bevacizumab and Irinotecan Hydrochloride)",
        "value": 22.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Analyzable MRS Participants",
        "value": 7.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Bevacizumab",
        "Irinotecan Hydrochloride"
      ],
      "OG001": [
        "Bevacizumab",
        "Irinotecan Hydrochloride"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03189914",
    "brief_title": "RX-3117 in Combination With Abraxane\u00ae in Subjects With Metastatic Pancreatic Cancer",
    "status": "COMPLETED",
    "start_date": "2017-10-02",
    "completion_date": "2019-10-01",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Processa Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT03189914",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "RX-3117 + Abraxane Phase 2",
        "value": 17.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "RX-3117",
        "Abraxane"
      ],
      "OG001": [
        "RX-3117",
        "Abraxane"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT03213665",
    "brief_title": "Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)",
    "status": "COMPLETED",
    "start_date": "2017-11-13",
    "completion_date": "2022-03-31",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT03213665",
    "cancer_types": [
      "OTHER",
      "DLBC",
      "LGG"
    ],
    "biomarkers": [
      {
        "target": "EZH2",
        "status": "POSITIVE",
        "details": "Actionable gene mutation as determined by APEC1621SC MATCH assignment"
      },
      {
        "target": "SMARCB1",
        "status": "POSITIVE",
        "details": "Actionable gene mutation as determined by APEC1621SC MATCH assignment"
      },
      {
        "target": "SMARCA4",
        "status": "POSITIVE",
        "details": "Actionable gene mutation as determined by APEC1621SC MATCH assignment"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (Tazemetostat)",
        "value": 5.0,
        "unit": "Percentage of participants",
        "ci_lower": 1.0,
        "ci_upper": 20.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Tazemetostat)",
        "value": 35.0,
        "unit": "percentage of participants",
        "ci_lower": 15.7,
        "ci_upper": 55.2,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Tazemetostat"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03191786",
    "brief_title": "A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Na\u00efve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy",
    "status": "COMPLETED",
    "start_date": "2017-09-11",
    "completion_date": "2022-04-30",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT03191786",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "No sensitizing EGFR mutations: L858R or exon 19 deletions"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "No ALK fusion oncogene detected"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV",
      "RECURRENT",
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Atezolizumab",
        "value": 10.3,
        "unit": "Months",
        "ci_lower": 9.4,
        "ci_upper": 11.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Single Agent Chemotherapy (Vinorelbine or Gemcitabine)",
        "value": 9.2,
        "unit": "Months",
        "ci_lower": 5.9,
        "ci_upper": 11.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Atezolizumab",
        "value": 4.2,
        "unit": "Months",
        "ci_lower": 3.7,
        "ci_upper": 5.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Single Agent Chemotherapy (Vinorelbine or Gemcitabine)",
        "value": 4.0,
        "unit": "Months",
        "ci_lower": 2.9,
        "ci_upper": 5.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Atezolizumab"
      ],
      "OG001": [
        "Vinorelbine",
        "Gemcitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00430781",
    "brief_title": "Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer",
    "status": "COMPLETED",
    "start_date": "2006-11",
    "completion_date": "2008-07",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "GlaxoSmithKline",
    "url": "https://clinicaltrials.gov/study/NCT00430781",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IVB",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Combination Therapy: Lapatinib 1500 mg and Pazopanib 800 mg",
        "value": 12.6,
        "unit": "Weeks",
        "ci_lower": 11.7,
        "ci_upper": 14.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Lapatinib Monotherapy",
        "value": 12.6,
        "unit": "Weeks",
        "ci_lower": 11.6,
        "ci_upper": 18.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Pazopanib Monotherapy",
        "value": 17.9,
        "unit": "Weeks",
        "ci_lower": 12.1,
        "ci_upper": 23.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Lapatinib Monotherapy",
        "value": 44.1,
        "unit": "Weeks",
        "ci_lower": 35.6,
        "ci_upper": 48.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Pazopanib Monotherapy",
        "value": 49.7,
        "unit": "Weeks",
        "ci_lower": 42.0,
        "ci_upper": 55.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "lapatinib",
        "pazopanib"
      ],
      "OG001": [
        "lapatinib"
      ],
      "OG002": [
        "pazopanib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI",
      "OG002": "TKI"
    }
  },
  {
    "nct_id": "NCT03205761",
    "brief_title": "Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2017-10-23",
    "completion_date": "2022-12-15",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Spanish Breast Cancer Research Group",
    "url": "https://clinicaltrials.gov/study/NCT03205761",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "ER <1% by IHC (Estrogen Receptor) as part of triple\u2011negative definition"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "PR <1% by IHC (Progesterone Receptor) as part of triple\u2011negative definition"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 IHC 0/1+ or negative by ISH per local criteria (part of triple\u2011negative definition)"
      },
      {
        "target": "BRCA1",
        "status": "NEGATIVE",
        "details": "Absence of deleterious or suspected deleterious germline mutation; centrally assessed (Myriad)"
      },
      {
        "target": "BRCA2",
        "status": "NEGATIVE",
        "details": "Absence of deleterious or suspected deleterious germline mutation; centrally assessed (Myriad)"
      },
      {
        "target": "BRCA1",
        "status": "POSITIVE",
        "details": "Promoter methylation in tumour (BRCA1 promoter methylation) based on central testing on most recent metastatic lesion"
      },
      {
        "target": "BRCA2",
        "status": "POSITIVE",
        "details": "Promoter methylation in tumour (BRCA2 promoter methylation) based on central testing on most recent metastatic lesion"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Olaparib",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Olaparib",
        "value": 1.8,
        "unit": "months",
        "ci_lower": 1.2,
        "ci_upper": 3.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Olaparib",
        "value": 8.9,
        "unit": "months",
        "ci_lower": 1.2,
        "ci_upper": 13.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Olaparib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00435409",
    "brief_title": "A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2007-02",
    "completion_date": "2009-12",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT00435409",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Sunitinib + Capecitabine",
        "value": 5.5,
        "unit": "months",
        "ci_lower": 4.5,
        "ci_upper": 6.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Capecitabine",
        "value": 5.9,
        "unit": "months",
        "ci_lower": 5.4,
        "ci_upper": 7.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Sunitinib + Capecitabine",
        "value": 5.4,
        "unit": "months",
        "ci_lower": 4.4,
        "ci_upper": 5.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Capecitabine",
        "value": 5.5,
        "unit": "months",
        "ci_lower": 4.3,
        "ci_upper": 6.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Sunitinib + Capecitabine",
        "value": 16.5,
        "unit": "months",
        "ci_lower": 14.5,
        "ci_upper": 19.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Capecitabine",
        "value": 17.2,
        "unit": "months",
        "ci_lower": 15.5,
        "ci_upper": 19.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Sunitinib",
        "Capecitabine"
      ],
      "OG001": [
        "Capecitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00429793",
    "brief_title": "Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer",
    "status": "COMPLETED",
    "start_date": "2007-02",
    "completion_date": "2012-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT00429793",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Temsirolimus)",
        "value": 13.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (Temsirolimus)",
        "value": 5.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "temsirolimus"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "OTHER",
      "OG002": "OTHER",
      "OG003": "OTHER",
      "OG004": "OTHER"
    }
  },
  {
    "nct_id": "NCT03206203",
    "brief_title": "Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2017-08-29",
    "completion_date": "2022-11-30",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Vanderbilt-Ingram Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT03206203",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "ISH non-amplified (HER2/CEP17 ratio < 2.0 or average HER2 copy number < 4 signals/cell) or IHC 0 or IHC 1+ by local laboratory assessment"
      },
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "<= 5% of cells expressing estrogen receptor by IHC"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "<= 5% of cells expressing progesterone receptor by IHC"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm 1 (Atezolizumab, Carboplatin)",
        "value": 4.1,
        "unit": "months",
        "ci_lower": 2.4,
        "ci_upper": 7.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm 2 (Carboplatin)",
        "value": 2.2,
        "unit": "months",
        "ci_lower": 2.0,
        "ci_upper": 4.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm 1 (Atezolizumab, Carboplatin)",
        "value": 12.6,
        "unit": "months",
        "ci_lower": 10.9,
        "ci_upper": 19.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm 2 (Carboplatin)",
        "value": 7.0,
        "unit": "months",
        "ci_lower": 3.2,
        "ci_upper": 10.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Atezolizumab",
        "Carboplatin"
      ],
      "OG001": [
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00428714",
    "brief_title": "Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy",
    "status": "COMPLETED",
    "start_date": "2007-01",
    "completion_date": "2009-06",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00428714",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [
      {
        "target": "PSA",
        "status": "ANY",
        "details": "Cohort 1: rising PSA values of \u22645 ng/mL (at least 3 measurements 1 week apart) following antiandrogen withdrawal without evidence of metastases. Cohort 2: PSA progression defined as a 25% increase in PSA from the post-docetaxel value; PSA-only participants are not eligible for cohort 2."
      },
      {
        "target": "TESTOSTERONE",
        "status": "LOW",
        "details": "Castrate levels <50 ng/dL maintained by LHRH agonist or bilateral orchiectomy following anti-androgen withdrawal."
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Enzastaurin-Cohort 1",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Enzastaurin-Cohort 2",
        "value": 11.0,
        "unit": "Weeks",
        "ci_lower": 7.57,
        "ci_upper": 11.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "enzastaurin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03184870",
    "brief_title": "A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2017-08-08",
    "completion_date": "2023-04-06",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT03184870",
    "cancer_types": [
      "CRC",
      "PAAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [],
    "arm_drugs": {
      "OG000": [
        "BMS-813160",
        "5-fluorouracil (5-FU)",
        "Leucovorin",
        "Irinotecan"
      ],
      "OG001": [
        "BMS-813160",
        "5-fluorouracil (5-FU)",
        "Leucovorin",
        "Irinotecan"
      ],
      "OG002": [
        "BMS-813160",
        "Gemcitabine",
        "Nab-paclitaxel"
      ],
      "OG003": [
        "BMS-813160",
        "Gemcitabine",
        "Nab-paclitaxel"
      ],
      "OG004": [
        "BMS-813160",
        "Nivolumab"
      ],
      "OG005": [
        "BMS-813160",
        "Nivolumab"
      ],
      "OG006": [
        "BMS-813160",
        "Nivolumab"
      ],
      "OG007": [
        "BMS-813160",
        "Nivolumab"
      ],
      "OG008": [
        "BMS-813160",
        "Nivolumab"
      ],
      "OG009": [
        "BMS-813160",
        "Nivolumab"
      ],
      "OG010": [
        "BMS-813160",
        "5-fluorouracil (5-FU)",
        "Leucovorin",
        "Irinotecan"
      ],
      "OG011": [
        "BMS-813160",
        "5-fluorouracil (5-FU)",
        "Leucovorin",
        "Irinotecan"
      ],
      "OG012": [
        "5-fluorouracil (5-FU)",
        "Leucovorin",
        "Irinotecan"
      ],
      "OG013": [
        "BMS-813160",
        "Gemcitabine",
        "Nab-paclitaxel"
      ],
      "OG014": [
        "BMS-813160",
        "Gemcitabine",
        "Nab-paclitaxel",
        "Nivolumab"
      ],
      "OG015": [
        "Gemcitabine",
        "Nab-paclitaxel"
      ],
      "OG016": [
        "BMS-813160",
        "Nivolumab"
      ],
      "OG017": [
        "BMS-813160",
        "Nivolumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted",
      "OG003": "Combo_Chemo_Targeted",
      "OG004": "Combo_IO_Targeted",
      "OG005": "Combo_IO_Targeted",
      "OG006": "Combo_IO_Targeted",
      "OG007": "Combo_IO_Targeted",
      "OG008": "Combo_IO_Targeted",
      "OG009": "Combo_IO_Targeted",
      "OG010": "Combo_Chemo_Targeted",
      "OG011": "Combo_Chemo_Targeted",
      "OG012": "Chemo",
      "OG013": "Combo_Chemo_Targeted",
      "OG014": "Combo_Chemo_IO",
      "OG015": "Chemo",
      "OG016": "Combo_IO_Targeted",
      "OG017": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT00448279",
    "brief_title": "THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.",
    "status": "COMPLETED",
    "start_date": "2007-04",
    "completion_date": "2010-09",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT00448279",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "IHC 3+ and/or FISH positive"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Chemotherapy Alone",
        "value": 58.6,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy + Trastuzumab",
        "value": 58.6,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Chemotherapy Alone",
        "value": 55.2,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy + Trastuzumab",
        "value": 34.5,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Chemotherapy"
      ],
      "OG001": [
        "trastuzumab",
        "Chemotherapy"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00450866",
    "brief_title": "Epothilone B in Treating Patients With CNS Metastases From Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2007-01",
    "completion_date": "2011-06",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "David Peereboom, MD",
    "url": "https://clinicaltrials.gov/study/NCT00450866",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Epothilone B (Groups A and B)",
        "value": 12.7,
        "unit": "months",
        "ci_lower": 6.6,
        "ci_upper": 21.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "epothilone B"
      ],
      "OG001": [
        "epothilone B"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00439517",
    "brief_title": "Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab.",
    "status": "COMPLETED",
    "start_date": "2007-02",
    "completion_date": "2009-06",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck KGaA, Darmstadt, Germany",
    "url": "https://clinicaltrials.gov/study/NCT00439517",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IV",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "UFOX + Cetuximab",
        "value": 6.6,
        "unit": "months",
        "ci_lower": 5.6,
        "ci_upper": 7.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "FOLFOX4 + Cetuximab",
        "value": 8.2,
        "unit": "months",
        "ci_lower": 7.5,
        "ci_upper": 9.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "UFOX + Cetuximab",
        "value": 12.9,
        "unit": "months",
        "ci_lower": 11.5,
        "ci_upper": 15.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "FOLFOX4 + Cetuximab",
        "value": 15.5,
        "unit": "months",
        "ci_lower": 12.6,
        "ci_upper": 18.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "UFT (Tegafur + Uracil)",
        "Oxaliplatin",
        "Folinic acid (Leucovorin)",
        "Cetuximab"
      ],
      "OG001": [
        "5-Fluorouracil (5-FU)",
        "Oxaliplatin",
        "Folinic acid (Leucovorin)",
        "Cetuximab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00447330",
    "brief_title": "Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma",
    "status": "COMPLETED",
    "start_date": "2007-02",
    "completion_date": "2014-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Duke University",
    "url": "https://clinicaltrials.gov/study/NCT00447330",
    "cancer_types": [
      "OTHER",
      "STAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "1- Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avastin",
        "value": 6.97,
        "unit": "Months",
        "ci_lower": 6.41,
        "ci_upper": 8.15,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "capecitabine",
        "oxaliplatin",
        "bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00448136",
    "brief_title": "A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.",
    "status": "COMPLETED",
    "start_date": "2007-07",
    "completion_date": "2011-11",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT00448136",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab + 5-FU + Streptozocin",
        "value": 52.9,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab + Capecitabine",
        "value": 53.1,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab + 5-FU + Streptozocin",
        "value": 14.7,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab + Capecitabine",
        "value": 16.3,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "bevacizumab [Avastin]",
        "5 FU",
        "Streptozotocin"
      ],
      "OG001": [
        "bevacizumab [Avastin]",
        "Xeloda"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03245450",
    "brief_title": "Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2018-03-05",
    "completion_date": "2021-05-17",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eisai Inc.",
    "url": "https://clinicaltrials.gov/study/NCT03245450",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 2: RMS Cohort, Eribulin Mesilate 1.4 mg/m^2 + Irinotecan 40 mg/m^2",
        "value": 11.1,
        "unit": "percentage of participants",
        "ci_lower": 0.6,
        "ci_upper": 42.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Phase 2: NRSTS Cohort, Eribulin Mesilate 1.4 mg/m^2 + Irinotecan 40 mg/m^2",
        "value": 11.1,
        "unit": "percentage of participants",
        "ci_lower": 0.6,
        "ci_upper": 42.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Phase 2: EWS Cohort, Eribulin Mesilate 1.4 mg/m^2 + Irinotecan 40 mg/m^2",
        "value": 11.1,
        "unit": "percentage of participants",
        "ci_lower": 0.6,
        "ci_upper": 42.9,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Eribulin mesilate",
        "Irinotecan hydrochloride"
      ],
      "OG001": [
        "Eribulin mesilate",
        "Irinotecan hydrochloride"
      ],
      "OG002": [
        "Eribulin mesilate",
        "Irinotecan hydrochloride"
      ],
      "OG003": [
        "Eribulin mesilate",
        "Irinotecan hydrochloride"
      ],
      "OG004": [
        "Eribulin mesilate",
        "Irinotecan hydrochloride"
      ],
      "OG005": [
        "Eribulin mesilate",
        "Irinotecan hydrochloride"
      ],
      "OG006": [
        "Eribulin mesilate",
        "Irinotecan hydrochloride"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo",
      "OG002": "Chemo",
      "OG003": "Chemo",
      "OG004": "Chemo",
      "OG005": "Chemo",
      "OG006": "Chemo"
    }
  },
  {
    "nct_id": "NCT00436956",
    "brief_title": "AZD2171 to Treat Prostate Cancer",
    "status": "COMPLETED",
    "start_date": "2006-10-16",
    "completion_date": "2010-02-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT00436956",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "All Participants - AZD2171 & Prednisone",
        "value": 43.9,
        "unit": "percent probability",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "20 mg AZD2171 Daily",
        "value": 11.7,
        "unit": "Months",
        "ci_lower": 6.8,
        "ci_upper": 15.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "20 mg AZD2171 + 10mg Prednisone Daily",
        "value": 9.9,
        "unit": "Months",
        "ci_lower": 5.7,
        "ci_upper": 14.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "AZD2171",
        "Prednisone"
      ],
      "OG001": [
        "AZD2171",
        "Prednisone"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT03221426",
    "brief_title": "Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)",
    "status": "COMPLETED",
    "start_date": "2017-10-09",
    "completion_date": "2024-02-16",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT03221426",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "II",
      "III",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "NEOADJUVANT",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + XP/FP",
        "value": 71.8,
        "unit": "Months",
        "ci_lower": 52.5,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + XP/FP",
        "value": 55.7,
        "unit": "Months",
        "ci_lower": 41.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Cisplatin",
        "Capecitabine",
        "5-fluorouracil"
      ],
      "OG001": [
        "Cisplatin",
        "Capecitabine",
        "5-fluorouracil"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00437268",
    "brief_title": "A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2007-03",
    "completion_date": "2009-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00437268",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Enzastaurin+Irinotecan+Cetuximab",
        "value": 26.0,
        "unit": "percentage of participants",
        "ci_lower": 1.0,
        "ci_upper": 51.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Irinotecan+Cetuximab",
        "value": 23.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 49.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Enzastaurin+Irinotecan+Cetuximab",
        "value": 8.5,
        "unit": "months",
        "ci_lower": 5.5,
        "ci_upper": 16.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Irinotecan+Cetuximab",
        "value": 8.0,
        "unit": "months",
        "ci_lower": 4.5,
        "ci_upper": 21.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "enzastaurin",
        "irinotecan",
        "cetuximab"
      ],
      "OG001": [
        "irinotecan",
        "cetuximab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03250273",
    "brief_title": "A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma",
    "status": "COMPLETED",
    "start_date": "2017-11-06",
    "completion_date": "2020-11-20",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
    "url": "https://clinicaltrials.gov/study/NCT03250273",
    "cancer_types": [
      "PAAD",
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Arm A - Cholangiocarcinoma",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "ARM B - Pancreatic Cancer",
        "value": 3.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A - Cholangiocarcinoma",
        "value": 6.378,
        "unit": "months",
        "ci_lower": 3.748,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "ARM B - Pancreatic Cancer",
        "value": 2.729,
        "unit": "months",
        "ci_lower": 1.84,
        "ci_upper": 5.62,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A - Cholangiocarcinoma",
        "value": 0.0,
        "unit": "proportion of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "ARM B - Pancreatic Cancer",
        "value": 0.067,
        "unit": "proportion of participants",
        "ci_lower": 0.017,
        "ci_upper": 0.254,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Entinostat",
        "Nivolumab"
      ],
      "OG001": [
        "Entinostat",
        "Nivolumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT03253679",
    "brief_title": "AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification",
    "status": "COMPLETED",
    "start_date": "2019-01-16",
    "completion_date": "2022-10-31",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT03253679",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "CCNE1",
        "status": "POSITIVE",
        "details": "CCNE1 amplification >7 by targeted custom Ampliseq panel on Ion Torrent PGM; alternative CLIA platforms (e.g., FoundationOne, UW-OncoPlex, MSK-IMPACT) acceptable with PI approval; central NGS and FISH confirmatory testing performed"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (Adavosertib)",
        "value": 27.0,
        "unit": "percentage",
        "ci_lower": 12.0,
        "ci_upper": 46.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Adavosertib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03245151",
    "brief_title": "Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors",
    "status": "COMPLETED",
    "start_date": "2017-11-16",
    "completion_date": "2022-09-30",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eisai Inc.",
    "url": "https://clinicaltrials.gov/study/NCT03245151",
    "cancer_types": [
      "GBM",
      "LGG"
    ],
    "biomarkers": [
      {
        "target": "AFP",
        "status": "HIGH",
        "details": "Elevated alpha-fetoprotein may be used in lieu of histologic confirmation for diffuse intrinsic pontine glioma, optic pathway glioma, or pineal tumors"
      },
      {
        "target": "HCG",
        "status": "HIGH",
        "details": "Elevated beta\u2011hCG/hCG may be used in lieu of histologic confirmation for diffuse intrinsic pontine glioma, optic pathway glioma, or pineal tumors"
      }
    ],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 2: Cohort 1, Ewing Sarcoma",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 30.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Phase 2: Cohort 2, Rhabdomyosarcoma",
        "value": 10.0,
        "unit": "percentage of participants",
        "ci_lower": 1.2,
        "ci_upper": 31.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Phase 2: Cohort 3, HGG",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 30.8,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Lenvatinib",
        "Everolimus"
      ],
      "OG001": [
        "Lenvatinib",
        "Everolimus"
      ],
      "OG002": [
        "Lenvatinib",
        "Everolimus"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Targeted",
      "OG001": "Combo_TKI_Targeted",
      "OG002": "Combo_TKI_Targeted"
    }
  },
  {
    "nct_id": "NCT03219333",
    "brief_title": "A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer",
    "status": "COMPLETED",
    "start_date": "2017-10-08",
    "completion_date": "2020-10-27",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Astellas Pharma Inc",
    "url": "https://clinicaltrials.gov/study/NCT03219333",
    "cancer_types": [
      "BLCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": true,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Enfortumab Vedotin - Cohort 1",
        "value": 44.0,
        "unit": "Percentage of Participants",
        "ci_lower": 35.1,
        "ci_upper": 53.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Enfortumab Vedotin - Cohort 2",
        "value": 51.7,
        "unit": "Percentage of Participants",
        "ci_lower": 40.8,
        "ci_upper": 62.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Enfortumab Vedotin - Cohort 1",
        "value": 5.8,
        "unit": "Months",
        "ci_lower": 4.93,
        "ci_upper": 7.46,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Enfortumab Vedotin - Cohort 2",
        "value": 5.8,
        "unit": "Months",
        "ci_lower": 5.03,
        "ci_upper": 8.28,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Enfortumab Vedotin - Cohort 1",
        "value": 12.4,
        "unit": "Months",
        "ci_lower": 9.46,
        "ci_upper": 15.57,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Enfortumab Vedotin - Cohort 2",
        "value": 14.7,
        "unit": "Months",
        "ci_lower": 10.51,
        "ci_upper": 18.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Enfortumab vedotin"
      ],
      "OG001": [
        "Enfortumab vedotin"
      ]
    },
    "treatment_class_map": {
      "OG000": "ADC",
      "OG001": "ADC"
    }
  },
  {
    "nct_id": "NCT03250832",
    "brief_title": "Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2017-08-08",
    "completion_date": "2022-06-02",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Tesaro, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT03250832",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "MSI",
        "status": "NEGATIVE",
        "details": "MSS (microsatellite stable) as determined locally"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Part 2A - TSR-033 (720 mg) + Dostarlimab (1000 mg)",
        "value": 2.9,
        "unit": "Percentage of participants",
        "ci_lower": 0.1,
        "ci_upper": 15.3,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "TSR-033"
      ],
      "OG001": [
        "TSR-033"
      ],
      "OG002": [
        "TSR-033"
      ],
      "OG003": [
        "TSR-033"
      ],
      "OG004": [
        "TSR-033",
        "Dostarlimab"
      ],
      "OG005": [
        "TSR-033",
        "Dostarlimab"
      ],
      "OG006": [
        "TSR-033",
        "Dostarlimab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO",
      "OG003": "IO",
      "OG004": "IO",
      "OG005": "IO",
      "OG006": "IO"
    }
  },
  {
    "nct_id": "NCT00452413",
    "brief_title": "A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2007-05",
    "completion_date": "2009-07",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00452413",
    "cancer_types": [
      "NSCLC",
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase 2 (Enzastaurin 500 mg, Erlotinib 150 mg)",
        "value": 1.7,
        "unit": "months",
        "ci_lower": 1.5,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "enzastaurin",
        "erlotinib"
      ],
      "OG001": [
        "enzastaurin",
        "erlotinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT03241173",
    "brief_title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies",
    "status": "COMPLETED",
    "start_date": "2017-10-09",
    "completion_date": "2019-09-17",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Incyte Biosciences International S\u00e0rl",
    "url": "https://clinicaltrials.gov/study/NCT03241173",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": true,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 2, Part A: INCAGN01949 + Nivolumab",
        "value": null,
        "unit": null,
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Phase 2, Part B: INCAGN01949; INCAGN01949 + Nivolumab; INCAGN01949 + Nivolumab + Ipilimumab",
        "value": null,
        "unit": null,
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase 1, Dose Escalation: INCAGN01949 70 mg + Nivolumab 240 mg",
        "value": 1.8,
        "unit": "days",
        "ci_lower": 1.0,
        "ci_upper": 4.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Phase 1, Dose Escalation: INCAGN01949 200 mg + Nivolumab 240 mg",
        "value": 1.8,
        "unit": "days",
        "ci_lower": 1.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Phase 1, Dose Escalation: INCAGN01949 350 mg + Nivolumab 240 mg",
        "value": 2.7,
        "unit": "days",
        "ci_lower": 1.4,
        "ci_upper": 7.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Phase 1, Dose Escalation: INCAGN01949 700 mg + Nivolumab 240 mg",
        "value": 1.8,
        "unit": "days",
        "ci_lower": 0.8,
        "ci_upper": 2.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Phase 1, Dose Escalation: INCAGN01949 70 mg + Ipilimumab 1 mg/kg",
        "value": 3.5,
        "unit": "days",
        "ci_lower": 0.7,
        "ci_upper": 5.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG005",
        "arm_title": "Phase 1, Dose Escalation: INCAGN01949 200 mg + Ipilimumab 1 mg/kg",
        "value": 1.6,
        "unit": "days",
        "ci_lower": 1.2,
        "ci_upper": 1.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG006",
        "arm_title": "Phase 1, Dose Escalation: INCAGN01949 350 mg + Ipilimumab 1 mg/kg",
        "value": 4.6,
        "unit": "days",
        "ci_lower": 1.2,
        "ci_upper": 15.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG007",
        "arm_title": "Phase 1, Dose Escalation: INCAGN01949 700 mg + Ipilimumab 1 mg/kg",
        "value": 1.8,
        "unit": "days",
        "ci_lower": 1.7,
        "ci_upper": 5.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG008",
        "arm_title": "Phase 1, Safety Expansion: INCAGN01949 70 mg + Nivolumab 240 mg",
        "value": 1.6,
        "unit": "days",
        "ci_lower": 0.1,
        "ci_upper": 9.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG009",
        "arm_title": "Phase 1, Safety Expansion: INCAGN01949 200 mg + Nivolumab 240 mg",
        "value": 2.2,
        "unit": "days",
        "ci_lower": 1.8,
        "ci_upper": 6.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG010",
        "arm_title": "Phase 1, Safety Expansion: INCAGN01949 350 mg + Nivolumab 240 mg",
        "value": 4.6,
        "unit": "days",
        "ci_lower": 1.8,
        "ci_upper": 15.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "INCAGN01949",
        "Nivolumab"
      ],
      "OG001": [
        "INCAGN01949",
        "Nivolumab"
      ],
      "OG002": [
        "INCAGN01949",
        "Nivolumab"
      ],
      "OG003": [
        "INCAGN01949",
        "Nivolumab"
      ],
      "OG004": [
        "INCAGN01949",
        "Ipilimumab"
      ],
      "OG005": [
        "INCAGN01949",
        "Ipilimumab"
      ],
      "OG006": [
        "INCAGN01949",
        "Ipilimumab"
      ],
      "OG007": [
        "INCAGN01949",
        "Ipilimumab"
      ],
      "OG008": [
        "INCAGN01949",
        "Nivolumab"
      ],
      "OG009": [
        "INCAGN01949",
        "Nivolumab"
      ],
      "OG010": [
        "INCAGN01949",
        "Nivolumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted",
      "OG002": "Combo_IO_Targeted",
      "OG003": "Combo_IO_Targeted",
      "OG004": "Combo_IO_Targeted",
      "OG005": "Combo_IO_Targeted",
      "OG006": "Combo_IO_Targeted",
      "OG007": "Combo_IO_Targeted",
      "OG008": "Combo_IO_Targeted",
      "OG009": "Combo_IO_Targeted",
      "OG010": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT00450619",
    "brief_title": "153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer",
    "status": "COMPLETED",
    "start_date": "2007-02",
    "completion_date": "2012-11",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT00450619",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [
      {
        "target": "PSA",
        "status": "ANY",
        "details": "Progressive disease may be defined by 2 rising PSA values separated by \u22651 week, new/enlarging lesions, or clinical progression; study includes a PSA/TRICOM vaccine arm."
      },
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "HIV positivity is excluded."
      },
      {
        "target": "HEPATITIS_B",
        "status": "NEGATIVE",
        "details": "Hepatitis B positivity is excluded."
      },
      {
        "target": "HEPATITIS_C",
        "status": "NEGATIVE",
        "details": "Hepatitis C positivity is excluded."
      },
      {
        "target": "ANC",
        "status": "HIGH",
        "details": "Granulocyte count (absolute neutrophil count) \u2265 1,500/mm^3 (within 16 days of starting therapy)."
      },
      {
        "target": "PLATELETS",
        "status": "HIGH",
        "details": "Platelet count \u2265 100,000/mm^3 (within 16 days of starting therapy)."
      },
      {
        "target": "HEMOGLOBIN",
        "status": "HIGH",
        "details": "Hemoglobin \u2265 10 g/dL (transfusion allowed to meet this)."
      },
      {
        "target": "AST",
        "status": "LOW",
        "details": "AST < 2.5 \u00d7 upper limit of normal (within 16 days of starting therapy)."
      },
      {
        "target": "ALT",
        "status": "LOW",
        "details": "ALT < 2.5 \u00d7 upper limit of normal (within 16 days of starting therapy)."
      },
      {
        "target": "BILIRUBIN",
        "status": "LOW",
        "details": "Total bilirubin < 1.5 mg/dL (or \u2264 3.0 mg/dL for patients with Gilbert's syndrome)."
      },
      {
        "target": "CREATININE",
        "status": "LOW",
        "details": "Serum creatinine \u2264 1.5 \u00d7 upper limit of normal OR creatinine clearance (24-h urine) \u2265 60 mL/min."
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A - EDTMP Alone",
        "value": 1.7,
        "unit": "months",
        "ci_lower": 1.3,
        "ci_upper": 2.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B - 153Sm-EDTMP With Vaccine",
        "value": 3.7,
        "unit": "months",
        "ci_lower": 2.4,
        "ci_upper": 4.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Samarium Sm-153 lexidronam pentasodium (153Sm-EDTMP)"
      ],
      "OG001": [
        "153Sm-EDTMP (Samarium Sm-153 lexidronam pentasodium)",
        "Recombinant vaccinia-TRICOM vaccine",
        "Recombinant fowlpox-TRICOM vaccine",
        "Sargramostim"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT03251378",
    "brief_title": "A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers",
    "status": "COMPLETED",
    "start_date": "2017-12-11",
    "completion_date": "2022-12-13",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hutchison Medipharma Limited",
    "url": "https://clinicaltrials.gov/study/NCT03251378",
    "cancer_types": [
      "CRC",
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "Cohort D (Her2-negative required) and Cohort E (triple\u2011negative breast cancer includes HER2\u2011negative)"
      },
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Cohort D: hormone receptor positive (ER+ and/or PR+) \u2014 ER and/or PR required positive"
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": "Cohort D: hormone receptor positive (ER+ and/or PR+) \u2014 ER and/or PR required positive"
      },
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "Cohort E: triple\u2011negative breast cancer (ER\u2011, PR\u2011, HER2\u2011) \u2014 ER negative for TNBC cohort"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "Cohort E: triple\u2011negative breast cancer (ER\u2011, PR\u2011, HER2\u2011) \u2014 PR negative for TNBC cohort"
      },
      {
        "target": "RAS",
        "status": "NEGATIVE",
        "details": "Referenced as \u2018RAS wild\u2011type\u2019 \u2014 if RAS is wild\u2011type (no RAS mutation), patients must have received prior anti\u2011EGFR therapy (applies to Cohorts B and C)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Dose Expansion Phase, Cohort A: Fruquintinib 5 mg",
        "value": 53.33,
        "unit": "percentage of participants",
        "ci_lower": 4.68,
        "ci_upper": 100.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Dose Expansion Phase, Cohort B: Fruquintinib 5 mg",
        "value": 61.04,
        "unit": "percentage of participants",
        "ci_lower": 45.59,
        "ci_upper": 76.49,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Dose Expansion Phase, Cohort C: Fruquintinib 5 mg",
        "value": 55.64,
        "unit": "percentage of participants",
        "ci_lower": 39.87,
        "ci_upper": 71.41,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Dose Expansion Phase, Cohort D: Fruquintinib 5 mg",
        "value": 29.3,
        "unit": "percentage of participants",
        "ci_lower": 1.91,
        "ci_upper": 56.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Dose Expansion Phase, Cohort E: Fruquintinib 5 mg",
        "value": 38.46,
        "unit": "percentage of participants",
        "ci_lower": 12.02,
        "ci_upper": 64.91,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Fruquintinib (HMPL-013)"
      ],
      "OG001": [
        "Fruquintinib (HMPL-013)"
      ],
      "OG002": [
        "Fruquintinib (HMPL-013)"
      ],
      "OG003": [
        "Fruquintinib (HMPL-013)"
      ],
      "OG004": [
        "Fruquintinib (HMPL-013)"
      ],
      "OG005": [
        "Fruquintinib (HMPL-013)"
      ],
      "OG006": [
        "Fruquintinib (HMPL-013)"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI",
      "OG002": "TKI",
      "OG003": "TKI",
      "OG004": "TKI",
      "OG005": "TKI",
      "OG006": "TKI"
    }
  },
  {
    "nct_id": "NCT00436501",
    "brief_title": "VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",
    "status": "COMPLETED",
    "start_date": "2007-01",
    "completion_date": "2011-03",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT00436501",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase I VEGF Trap, Docetaxel",
        "value": 2.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Phase II: VEGF Trap, Docetaxel",
        "value": 25.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase II: VEGF Trap, Docetaxel",
        "value": 54.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Phase II: VEGF Trap, Docetaxel",
        "value": 26.6,
        "unit": "months",
        "ci_lower": 13.1,
        "ci_upper": 49.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase II: VEGF Trap, Docetaxel",
        "value": 6.4,
        "unit": "months",
        "ci_lower": 5.1,
        "ci_upper": 10.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "ziv-aflibercept",
        "docetaxel"
      ],
      "OG001": [
        "ziv-aflibercept",
        "docetaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03250676",
    "brief_title": "Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2017-08-23",
    "completion_date": "2023-10-26",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eisai Inc.",
    "url": "https://clinicaltrials.gov/study/NCT03250676",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Estrogen receptor positive (ER-positive)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-negative"
      },
      {
        "target": "ESR1",
        "status": "POSITIVE",
        "details": "ESR1 Y537S mutation required (central laboratory from nucleic acids whole blood sample)"
      },
      {
        "target": "ESR1",
        "status": "NEGATIVE",
        "details": "ESR1 D538G mutation must be absent (central laboratory)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [],
    "arm_drugs": {
      "OG000": [
        "H3B-6545"
      ],
      "OG001": [
        "H3B-6545"
      ],
      "OG002": [
        "H3B-6545"
      ],
      "OG003": [
        "H3B-6545"
      ],
      "OG004": [
        "H3B-6545"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other",
      "OG004": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00461851",
    "brief_title": "Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma",
    "status": "COMPLETED",
    "start_date": "2007-03",
    "completion_date": "2013-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Yale University",
    "url": "https://clinicaltrials.gov/study/NCT00461851",
    "cancer_types": [
      "BLCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Chemotherapy Plus Sorafenib",
        "value": 9.5,
        "unit": "months",
        "ci_lower": 5.6,
        "ci_upper": 16.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Gemcitabine",
        "Carboplatin",
        "Sorafenib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT00466505",
    "brief_title": "Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery",
    "status": "COMPLETED",
    "start_date": "2005-05",
    "completion_date": "2008-07",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Vanderbilt-Ingram Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT00466505",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Therapeutic Intervention",
        "value": 55.0,
        "unit": "Days",
        "ci_lower": 10.0,
        "ci_upper": 295.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "cetuximab",
        "celecoxib"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER"
    }
  },
  {
    "nct_id": "NCT00457691",
    "brief_title": "Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2007-06",
    "completion_date": "2010-03",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT00457691",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "FOLFIRI + Sunitinib",
        "value": 33.6,
        "unit": "Weeks",
        "ci_lower": 30.8,
        "ci_upper": 36.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "FOLFIRI + Placebo",
        "value": 36.6,
        "unit": "Weeks",
        "ci_lower": 32.9,
        "ci_upper": 40.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "FOLFIRI + Sunitinib",
        "value": 87.9,
        "unit": "Weeks",
        "ci_lower": 75.2,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "FOLFIRI + Placebo",
        "value": 85.9,
        "unit": "Weeks",
        "ci_lower": 81.1,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "5 fluorouracil",
        "irinotecan",
        "levo- leucovorin",
        "sunitinib"
      ],
      "OG001": [
        "5 fluorouracil",
        "irinotecan",
        "levo- leucovorin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT03278106",
    "brief_title": "TAS-102 in Treating Advanced Biliary Tract Cancers",
    "status": "COMPLETED",
    "start_date": "2017-10-20",
    "completion_date": "2018-11-30",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Mayo Clinic",
    "url": "https://clinicaltrials.gov/study/NCT03278106",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment (TAS-102)",
        "value": 32.0,
        "unit": "percentage of patients",
        "ci_lower": 14.9,
        "ci_upper": 53.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Treatment (TAS-102)",
        "value": 6.1,
        "unit": "months",
        "ci_lower": 4.4,
        "ci_upper": 11.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Trifluridine/Tipiracil (TAS-102)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo"
    }
  },
  {
    "nct_id": "NCT00483509",
    "brief_title": "Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma",
    "status": "COMPLETED",
    "start_date": "2007-02-14",
    "completion_date": "2010-09-22",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AGC Biologics S.p.A.",
    "url": "https://clinicaltrials.gov/study/NCT00483509",
    "cancer_types": [
      "SCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "A: NGR-hTNF + Doxorubicin",
        "value": 3.2,
        "unit": "months",
        "ci_lower": 1.8,
        "ci_upper": 4.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "A: NGR-hTNF + Doxorubicin",
        "value": 5.6,
        "unit": "months",
        "ci_lower": 5.3,
        "ci_upper": 5.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "NGR-hTNF",
        "Doxorubicin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo"
    }
  },
  {
    "nct_id": "NCT00468169",
    "brief_title": "Cetuximab (ERBITUX\u00ae) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer",
    "status": "COMPLETED",
    "start_date": "2006-07",
    "completion_date": "2012-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "University of Chicago",
    "url": "https://clinicaltrials.gov/study/NCT00468169",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "III",
      "IV",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "A: Cetuximab+FHX",
        "value": 87.7,
        "unit": "Probability (%)",
        "ci_lower": 76.0,
        "ci_upper": 94.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "B: Cetuximab + PX",
        "value": 92.5,
        "unit": "Probability (%)",
        "ci_lower": 81.1,
        "ci_upper": 97.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "A: Cetuximab+FHX",
        "value": 91.2,
        "unit": "Probability (%)",
        "ci_lower": 80.2,
        "ci_upper": 96.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "B: Cetuximab + PX",
        "value": 94.3,
        "unit": "Probability (%)",
        "ci_lower": 83.5,
        "ci_upper": 98.1,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cetuximab",
        "5-FU",
        "Hydroxyurea"
      ],
      "OG001": [
        "Cetuximab",
        "Cisplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00459342",
    "brief_title": "Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2007-03",
    "completion_date": "2012-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT00459342",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Dasatinib",
        "value": 1.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Dasatinib",
        "value": 1.36,
        "unit": "months",
        "ci_lower": 0.16,
        "ci_upper": 17.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "dasatinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT03264404",
    "brief_title": "Azacitidine and Pembrolizumab in Pancreatic Cancer",
    "status": "COMPLETED",
    "start_date": "2017-10-01",
    "completion_date": "2021-10-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Susan E. Bates",
    "url": "https://clinicaltrials.gov/study/NCT03264404",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab",
        "value": 1.58,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Azacitidine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT03268382",
    "brief_title": "p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246",
    "status": "COMPLETED",
    "start_date": "2017-07-31",
    "completion_date": "2019-07-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Aprea Therapeutics",
    "url": "https://clinicaltrials.gov/study/NCT03268382",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "TP53",
        "status": "POSITIVE",
        "details": "Positive nuclear immunohistochemical (IHC) staining for p53"
      }
    ],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "APR-246 (4.5g/6hr) + PLD",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "APR-246 (4.5g/3hr) + PLD",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "APR-246 (4.5g/4hr) + PLD",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "APR-246 (3.7g/4hr) + PLD",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "APR-246",
        "Pegylated Liposomal Doxorubicin Hydrochloride (PLD)"
      ],
      "OG001": [
        "APR-246",
        "Pegylated Liposomal Doxorubicin Hydrochloride (PLD)"
      ],
      "OG002": [
        "APR-246",
        "Pegylated Liposomal Doxorubicin Hydrochloride (PLD)"
      ],
      "OG003": [
        "APR-246",
        "Pegylated Liposomal Doxorubicin Hydrochloride (PLD)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted",
      "OG003": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03290079",
    "brief_title": "Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors",
    "status": "COMPLETED",
    "start_date": "2017-12-15",
    "completion_date": "2023-01-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
    "url": "https://clinicaltrials.gov/study/NCT03290079",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab & Lenvatinib Treatment",
        "value": 0.1,
        "unit": "proportion of participants",
        "ci_lower": 0.03,
        "ci_upper": 0.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab & Lenvatinib Treatment",
        "value": 8.0,
        "unit": "months",
        "ci_lower": 5.8,
        "ci_upper": 10.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab & Lenvatinib Treatment",
        "value": 70.0,
        "unit": "percentage of participants",
        "ci_lower": 48.1,
        "ci_upper": 84.4,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Lenvatinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_IO"
    }
  },
  {
    "nct_id": "NCT03288987",
    "brief_title": "Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2016-10-04",
    "completion_date": "2018-07-30",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AryoGen Pharmed Co.",
    "url": "https://clinicaltrials.gov/study/NCT03288987",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE",
      "RECURRENT",
      "IV"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab + FOLFIRI-3 (AryoGen Pharmed Bevacizumab)",
        "value": 232.0,
        "unit": "Day",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab + FOLFIRI-3 (Roche Bevacizumab)",
        "value": 210.0,
        "unit": "Day",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab + FOLFIRI-3 (AryoGen Pharmed Bevacizumab)",
        "value": 30.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab + FOLFIRI-3 (Roche Bevacizumab)",
        "value": 17.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Bevacizumab",
        "Irinotecan",
        "Leucovorin (calcium folinate)",
        "5-fluorouracil"
      ],
      "OG001": [
        "Bevacizumab",
        "Irinotecan",
        "Leucovorin (calcium folinate)",
        "5-fluorouracil"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03257267",
    "brief_title": "Study of Cemiplimab in Adults With Cervical Cancer",
    "status": "COMPLETED",
    "start_date": "2017-09-05",
    "completion_date": "2021-03-15",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Regeneron Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT03257267",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cemiplimab",
        "value": 11.7,
        "unit": "Months",
        "ci_lower": 9.6,
        "ci_upper": 13.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Investigator Choice (IC) Chemotherapy",
        "value": 8.5,
        "unit": "Months",
        "ci_lower": 7.5,
        "ci_upper": 9.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cemiplimab",
        "value": 2.8,
        "unit": "Months",
        "ci_lower": 2.6,
        "ci_upper": 3.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Investigator Choice (IC) Chemotherapy",
        "value": 2.9,
        "unit": "Months",
        "ci_lower": 2.7,
        "ci_upper": 3.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cemiplimab"
      ],
      "OG001": [
        "Pemetrexed",
        "Topotecan",
        "Irinotecan",
        "Gemcitabine",
        "Vinorelbine"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00461708",
    "brief_title": "A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and Survival",
    "status": "COMPLETED",
    "start_date": "2007-05",
    "completion_date": "2010-11",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT00461708",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "III",
      "IV",
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Erlotinib, Gemcitabine: Rash Grade < 2",
        "value": 4.468,
        "unit": "months",
        "ci_lower": 3.618,
        "ci_upper": 5.318,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Erlotinib, Gemcitabine: Rash Grade \u2265 2",
        "value": 10.546,
        "unit": "months",
        "ci_lower": 9.679,
        "ci_upper": 11.414,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Erlotinib, Gemcitabine: Rash Grade < 2",
        "value": 2.497,
        "unit": "months",
        "ci_lower": 2.13,
        "ci_upper": 2.864,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Erlotinib, Gemcitabine: Rash Grade \u2265 2",
        "value": 6.439,
        "unit": "months",
        "ci_lower": 4.919,
        "ci_upper": 7.96,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Erlotinib",
        "Gemcitabine"
      ],
      "OG001": [
        "Erlotinib",
        "Gemcitabine"
      ],
      "OG002": [
        "Erlotinib",
        "Gemcitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Combo_TKI_Chemo",
      "OG002": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT00453362",
    "brief_title": "A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib",
    "status": "COMPLETED",
    "start_date": "2006-12",
    "completion_date": "2010-04",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Genentech, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT00453362",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "Availability of archival paraffin-embedded tumor tissue and willingness to provide sufficient tissue for testing for EGFR levels in tumor by both immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Erlotinib_FDG Responders",
        "value": 28.1,
        "unit": "weeks",
        "ci_lower": 16.14,
        "ci_upper": 40.14,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Erlotinib_ FDG Non-Responders",
        "value": 12.1,
        "unit": "weeks",
        "ci_lower": 7.86,
        "ci_upper": 51.14,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Erlotinib_FDG Responders",
        "value": null,
        "unit": "months",
        "ci_lower": 4.99,
        "ci_upper": 23.98,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Erlotinib_ FDG Non-Responder",
        "value": 7.8,
        "unit": "months",
        "ci_lower": 1.94,
        "ci_upper": 24.51,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "erlotinib HCl"
      ],
      "OG001": [
        "erlotinib HCl"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT03285321",
    "brief_title": "Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)",
    "status": "COMPLETED",
    "start_date": "2017-09-15",
    "completion_date": "2023-10-13",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Greg Durm, MD",
    "url": "https://clinicaltrials.gov/study/NCT03285321",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIA",
      "IIIB",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "MAINTENANCE",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm 1: Nivolumab",
        "value": 65.5,
        "unit": "Percentage of participants",
        "ci_lower": 49.8,
        "ci_upper": 77.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm 2: Nivolumab Plus Ipilimumab",
        "value": 66.3,
        "unit": "Percentage of participants",
        "ci_lower": 56.3,
        "ci_upper": 74.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm 1: Nivolumab",
        "value": 32.0,
        "unit": "Months",
        "ci_lower": 32.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm 2: Nivolumab Plus Ipilimumab",
        "value": null,
        "unit": "Months",
        "ci_lower": 30.9,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab"
      ],
      "OG001": [
        "Nivolumab",
        "Ipilimumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO"
    }
  },
  {
    "nct_id": "NCT00471328",
    "brief_title": "Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib",
    "status": "COMPLETED",
    "start_date": "2007-03",
    "completion_date": "2008-08",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT00471328",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": "3L+",
    "prior_tki": true,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Nilotinib",
        "value": 109.0,
        "unit": "days",
        "ci_lower": 61.0,
        "ci_upper": 113.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Control/Cross Over to Nilotinib",
        "value": 111.0,
        "unit": "days",
        "ci_lower": 60.0,
        "ci_upper": 116.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Nilotinib",
        "value": 332.0,
        "unit": "days",
        "ci_lower": 246.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Control/Cross Over to Nilotinib",
        "value": 280.0,
        "unit": "days",
        "ci_lower": 240.0,
        "ci_upper": 372.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Control/Cross Over to Nilotinib",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": 0.0,
        "ci_upper": 8.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG000",
        "arm_title": "Control/Cross Over to Nilotinib",
        "value": 37.3,
        "unit": "Percentage of Participants",
        "ci_lower": 25.8,
        "ci_upper": 50.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG000",
        "arm_title": "Control/Cross Over to Nilotinib",
        "value": 7.5,
        "unit": "Percentage of Participants",
        "ci_lower": 2.5,
        "ci_upper": 16.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG000",
        "arm_title": "Control/Cross Over to Nilotinib",
        "value": 6.0,
        "unit": "Percentage of Participants",
        "ci_lower": 1.7,
        "ci_upper": 14.6,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nilotinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT00465179",
    "brief_title": "Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer",
    "status": "COMPLETED",
    "start_date": "2007-03",
    "completion_date": "2015-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "M.D. Anderson Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT00465179",
    "cancer_types": [
      "KIRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Sunitinib Malate",
        "value": 3.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG000",
        "arm_title": "Sunitinib Malate",
        "value": 32.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Sunitinib Malate",
        "value": 2.7,
        "unit": "months",
        "ci_lower": 1.4,
        "ci_upper": 5.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Sunitinib Malate"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT03286842",
    "brief_title": "To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.",
    "status": "COMPLETED",
    "start_date": "2018-01-17",
    "completion_date": "2021-10-08",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT03286842",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 negative by IHC 0 or 1+ or 2+ with in situ hybridization non-amplified (ratio <2.0)"
      },
      {
        "target": "BRCA1",
        "status": "POSITIVE",
        "details": "Deleterious or suspected deleterious BRCA1 mutation (germline or tumor); tumor BRCA (tBRCA) must be confirmed by validated method (e.g., CLIA-certified lab or CE-IVD device)"
      },
      {
        "target": "BRCA2",
        "status": "POSITIVE",
        "details": "Deleterious or suspected deleterious BRCA2 mutation (germline or tumor); tumor BRCA (tBRCA) must be confirmed by validated method (e.g., CLIA-certified lab or CE-IVD device)"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Olaparib gBRCAm Cohort",
        "value": 8.18,
        "unit": "months",
        "ci_lower": 6.97,
        "ci_upper": 9.17,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Olaparib gBRCAm Cohort",
        "value": 24.94,
        "unit": "months",
        "ci_lower": 21.06,
        "ci_upper": 28.91,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Olaparib"
      ],
      "OG001": [
        "Olaparib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03271047",
    "brief_title": "Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation",
    "status": "COMPLETED",
    "start_date": "2017-10-18",
    "completion_date": "2020-10-13",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT03271047",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "RAS",
        "status": "POSITIVE",
        "details": "RAS mutation by local assay at any time prior to Screening or by the central laboratory"
      },
      {
        "target": "MSI",
        "status": "NEGATIVE",
        "details": "Microsatellite stable (MSS) by PCR per local assay at any time prior to Screening or by the central laboratory"
      },
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "Known history of positive test for HIV or AIDS is exclusion; testing where locally mandated"
      },
      {
        "target": "HBV",
        "status": "NEGATIVE",
        "details": "Any positive test indicating acute or chronic infection and/or detectable virus is exclusion"
      },
      {
        "target": "HCV",
        "status": "NEGATIVE",
        "details": "Any positive test indicating acute or chronic infection and/or detectable virus is exclusion"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 2: Nivolumab+Binimetinib",
        "value": 0.0,
        "unit": "Percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Phase 2: Nivolumab+Ipilimumab+Binimetinib",
        "value": 7.4,
        "unit": "Percentage of participants",
        "ci_lower": 0.9,
        "ci_upper": 24.3,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "binimetinib",
        "nivolumab"
      ],
      "OG001": [
        "binimetinib",
        "nivolumab",
        "ipilimumab"
      ],
      "OG002": [
        "binimetinib",
        "nivolumab"
      ],
      "OG003": [
        "binimetinib",
        "nivolumab",
        "ipilimumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted",
      "OG002": "Combo_IO_Targeted",
      "OG003": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT03264066",
    "brief_title": "A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2017-11-23",
    "completion_date": "2020-06-25",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT03264066",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort 1 - SCCHN - Treatment Naive",
        "value": 20.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 40.03,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Cohort 2 - UC - Treatment Naive",
        "value": 30.0,
        "unit": "percentage of participants",
        "ci_lower": 7.42,
        "ci_upper": 52.58,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Cohort 3 - RCC - Treatment Naive",
        "value": 17.6,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 38.71,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Cohort 4 - SCCHN - Previous Treatment Exposure",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 2.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Cohort 5 - UC - Previous Treatment Exposure",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 7.14,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "Cohort 6 - RCC - Previous Treatment Exposure",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 16.67,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1 - SCCHN - Treatment Naive",
        "value": 16.8,
        "unit": "months",
        "ci_lower": 6.9,
        "ci_upper": 25.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cohort 2 - UC - Treatment Naive",
        "value": 18.7,
        "unit": "months",
        "ci_lower": 11.0,
        "ci_upper": 26.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Cohort 3 - RCC - Treatment Naive",
        "value": 21.7,
        "unit": "months",
        "ci_lower": 17.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Cohort 4 - SCCHN - Previous Treatment Exposure",
        "value": 7.7,
        "unit": "months",
        "ci_lower": 4.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG004",
        "arm_title": "Cohort 5 - UC - Previous Treatment Exposure",
        "value": 5.9,
        "unit": "months",
        "ci_lower": 3.1,
        "ci_upper": 12.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG005",
        "arm_title": "Cohort 6 - RCC - Previous Treatment Exposure",
        "value": null,
        "unit": "months",
        "ci_lower": 5.9,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1 - SCCHN - Treatment Naive",
        "value": 5.5,
        "unit": "months",
        "ci_lower": 2.0,
        "ci_upper": 26.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort 2 - UC - Treatment Naive",
        "value": 3.4,
        "unit": "months",
        "ci_lower": 2.0,
        "ci_upper": 26.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Cohort 3 - RCC - Treatment Naive",
        "value": 3.4,
        "unit": "months",
        "ci_lower": 1.0,
        "ci_upper": 28.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Cohort 4 - SCCHN - Previous Treatment Exposure",
        "value": 3.6,
        "unit": "months",
        "ci_lower": 0.0,
        "ci_upper": 9.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Cohort 5 - UC - Previous Treatment Exposure",
        "value": 2.1,
        "unit": "months",
        "ci_lower": 1.0,
        "ci_upper": 4.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG005",
        "arm_title": "Cohort 6 - RCC - Previous Treatment Exposure",
        "value": 2.7,
        "unit": "months",
        "ci_lower": 1.0,
        "ci_upper": 4.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cobimetinib"
      ],
      "OG001": [
        "Cobimetinib"
      ],
      "OG002": [
        "Cobimetinib"
      ],
      "OG003": [
        "Cobimetinib"
      ],
      "OG004": [
        "Cobimetinib"
      ],
      "OG005": [
        "Cobimetinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other",
      "OG004": "Targeted_Other",
      "OG005": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00498927",
    "brief_title": "Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma",
    "status": "COMPLETED",
    "start_date": "2007-06",
    "completion_date": "2013-12",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Memorial Sloan Kettering Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT00498927",
    "cancer_types": [
      "GBM",
      "LGG"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Temozolomide",
        "value": 19.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Temozolomide",
        "value": 7.0,
        "unit": "months",
        "ci_lower": 5.0,
        "ci_upper": 12.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "temozolomide"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo"
    }
  },
  {
    "nct_id": "NCT00496587",
    "brief_title": "Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma",
    "status": "COMPLETED",
    "start_date": "2007-07",
    "completion_date": "2016-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "M.D. Anderson Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT00496587",
    "cancer_types": [
      "KIRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Capecitabine + Gemcitabine + Bevacizumab",
        "value": 5.5,
        "unit": "Months",
        "ci_lower": 3.4,
        "ci_upper": 7.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Capecitabine",
        "Gemcitabine",
        "Bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00492206",
    "brief_title": "Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC",
    "status": "COMPLETED",
    "start_date": "2006-06",
    "completion_date": "2012-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "University of Pittsburgh",
    "url": "https://clinicaltrials.gov/study/NCT00492206",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "If available, tumor tissue should be submitted for EGFR status by IHC and correlative studies."
      }
    ],
    "cancer_stages": [
      "IIIA",
      "IIIB",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Received \u22651 Dose of Cetuximab",
        "value": 19.4,
        "unit": "months",
        "ci_lower": 15.4,
        "ci_upper": 26.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Received \u22651 Dose of Cetuximab",
        "value": 9.3,
        "unit": "months",
        "ci_lower": 8.5,
        "ci_upper": 17.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cetuximab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03314740",
    "brief_title": "Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib",
    "status": "COMPLETED",
    "start_date": "2017-06-12",
    "completion_date": "2021-04-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Mario Negri Institute for Pharmacological Research",
    "url": "https://clinicaltrials.gov/study/NCT03314740",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "BRCA1",
        "status": "ANY",
        "details": "BRCA1-2 mutation status must be known; testing required before randomization (or during study treatment if not feasible prior to randomization)"
      },
      {
        "target": "BRCA2",
        "status": "ANY",
        "details": "BRCA1-2 mutation status must be known; testing required before randomization (or during study treatment if not feasible prior to randomization)"
      }
    ],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A",
        "value": 3.1,
        "unit": "months",
        "ci_lower": 1.9,
        "ci_upper": 6.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B",
        "value": 5.6,
        "unit": "months",
        "ci_lower": 3.2,
        "ci_upper": 7.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Arm C",
        "value": 3.8,
        "unit": "months",
        "ci_lower": 2.0,
        "ci_upper": 5.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Paclitaxel"
      ],
      "OG001": [
        "Cediranib",
        "Olaparib"
      ],
      "OG002": [
        "Cediranib",
        "Olaparib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_TKI_Targeted",
      "OG002": "Combo_TKI_Targeted"
    }
  },
  {
    "nct_id": "NCT00486954",
    "brief_title": "Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer",
    "status": "COMPLETED",
    "start_date": "2007-07",
    "completion_date": "2012-01",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "GlaxoSmithKline",
    "url": "https://clinicaltrials.gov/study/NCT00486954",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "Amplification of ErbB2 (HER2) by fluorescence in situ hybridization (FISH) in primary or metastatic tumor tissue; archived or biopsy tissue available for central FISH testing per Wolff 2007"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Lapatinib Plus Paclitaxel",
        "value": 11.0,
        "unit": "months",
        "ci_lower": 9.5,
        "ci_upper": 14.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Paclitaxel Alone",
        "value": 8.9,
        "unit": "months",
        "ci_lower": 7.4,
        "ci_upper": 11.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Lapatinib",
        "Paclitaxel"
      ],
      "OG001": [
        "Lapatinib",
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT03312738",
    "brief_title": "A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor",
    "status": "COMPLETED",
    "start_date": "2017-09-15",
    "completion_date": "2022-04-25",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT03312738",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Estrogen receptor positive (ER+) by local histology/cytology"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-negative (HER2 overexpressing patients excluded: IHC 3+ or in situ hybridization positive on most recent test)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Everolimus + Exemestane",
        "value": 7.4,
        "unit": "Months",
        "ci_lower": 5.5,
        "ci_upper": 9.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Exemestane",
        "value": 2.0,
        "unit": "Months",
        "ci_lower": 1.9,
        "ci_upper": 3.6,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Everolimus",
        "Exemestane"
      ],
      "OG001": [
        "Exemestane"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00493649",
    "brief_title": "Adj TC + Herceptin Early Stage Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2007-06",
    "completion_date": "2013-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "US Oncology Research",
    "url": "https://clinicaltrials.gov/study/NCT00493649",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "IHC 3+ (uniform, intense membrane staining of >30% of invasive tumor cells) OR FISH HER2 gene copies per nucleus criteria or FISH ratio (HER2/CEP17) >2.2; equivocal FISH 1.8-2.2 eligible if IHC 3+"
      },
      {
        "target": "TOP2A",
        "status": "ANY",
        "details": "Adequate tumor specimen available for FISH analysis of TOP2A status"
      },
      {
        "target": "ER",
        "status": "ANY",
        "details": "Known estrogen receptor (ER) status must be available (positive or negative)"
      },
      {
        "target": "PR",
        "status": "ANY",
        "details": "Known progesterone receptor (PR) status must be available (positive or negative)"
      }
    ],
    "cancer_stages": [
      "I",
      "IIA",
      "IIB",
      "IIIA"
    ],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "TOP2A-amplified Group",
        "value": 0.978,
        "unit": "probability of disease-free survival",
        "ci_lower": 0.942,
        "ci_upper": 0.992,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "TOP2A-nonamplified Group",
        "value": 0.979,
        "unit": "probability of disease-free survival",
        "ci_lower": 0.949,
        "ci_upper": 0.991,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "docetaxel",
        "cyclophosphamide",
        "trastuzumab"
      ],
      "OG001": [
        "docetaxel",
        "cyclophosphamide",
        "trastuzumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00499109",
    "brief_title": "Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC",
    "status": "COMPLETED",
    "start_date": "2007-05",
    "completion_date": "2013-04",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
    "url": "https://clinicaltrials.gov/study/NCT00499109",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "E. Dual Agent Chemotherapy",
        "value": 52.0,
        "unit": "estimated percentage of participants",
        "ci_lower": 45.2,
        "ci_upper": 59.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "C. Standard of Care Control Arm",
        "value": 56.5,
        "unit": "estimated percentage of participants",
        "ci_lower": 47.2,
        "ci_upper": 67.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "E. Dual Agent Chemotherapy",
        "value": 46.1,
        "unit": "estimated percentage of participants",
        "ci_lower": 39.3,
        "ci_upper": 54.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "C. Standard of Care Control Arm",
        "value": 46.6,
        "unit": "estimated percentage of participants",
        "ci_lower": 37.5,
        "ci_upper": 58.1,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Gemcitabine",
        "Carboplatin",
        "Docetaxel",
        "Vinorelbine"
      ],
      "OG001": [
        "Gemcitabine",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT03296163",
    "brief_title": "A Study Comparing MB02 and Avastin\u00ae in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)",
    "status": "COMPLETED",
    "start_date": "2018-02-06",
    "completion_date": "2019-07-03",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "mAbxience Research S.L.",
    "url": "https://clinicaltrials.gov/study/NCT03296163",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "activating EGFR mutations (assessed locally)"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "ALK rearrangement/anaplastic lymphoma kinase (assessed locally)"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "MB02 (Bevacizumab Biosimilar Drug)",
        "value": 40.3,
        "unit": "Percentage of participants",
        "ci_lower": 34.9,
        "ci_upper": 46.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "EU-approved Avastin\u00ae",
        "value": 44.6,
        "unit": "Percentage of participants",
        "ci_lower": 39.0,
        "ci_upper": 50.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "MB02 (Bevacizumab Biosimilar Drug)",
        "value": 36.0,
        "unit": "weeks",
        "ci_lower": 33.0,
        "ci_upper": 36.43,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "EU-approved Avastin\u00ae",
        "value": 37.3,
        "unit": "weeks",
        "ci_lower": 36.14,
        "ci_upper": 45.14,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "MB02 (Bevacizumab Biosimilar Drug)",
        "value": null,
        "unit": "weeks",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "EU-approved Avastin\u00ae",
        "value": null,
        "unit": "weeks",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "MB02 (Bevacizumab Biosimilar Drug)",
        "Carboplatin",
        "Paclitaxel"
      ],
      "OG001": [
        "EU-approved Avastin\u00ae",
        "Carboplatin",
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00494234",
    "brief_title": "Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2007-06-15",
    "completion_date": "2009-02-27",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT00494234",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "BRCA1",
        "status": "POSITIVE",
        "details": "BRCA-positive (BRCA1 or BRCA2)"
      },
      {
        "target": "BRCA2",
        "status": "POSITIVE",
        "details": "BRCA-positive (BRCA1 or BRCA2)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Olaparib 100 mg",
        "value": 25.0,
        "unit": "Percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Olaparib 400 mg",
        "value": 42.3,
        "unit": "Percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Olaparib 100 mg",
        "value": 122.0,
        "unit": "Days",
        "ci_lower": 67.0,
        "ci_upper": 167.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Olaparib 400 mg",
        "value": 193.5,
        "unit": "Days",
        "ci_lower": 140.0,
        "ci_upper": 226.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Olaparib"
      ],
      "OG001": [
        "Olaparib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03314935",
    "brief_title": "A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2017-11-21",
    "completion_date": "2022-11-28",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Incyte Corporation",
    "url": "https://clinicaltrials.gov/study/NCT03314935",
    "cancer_types": [
      "CRC",
      "UCEC",
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 2: INCB001158 100 mg + mFOLFOX6: MSS-CRC (Cohort A1)",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 36.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Phase 2: INCB001158 100 mg + Gemcitabine + Cisplatin: BTC (Cohort B1)",
        "value": 24.2,
        "unit": "percentage of participants",
        "ci_lower": 11.1,
        "ci_upper": 42.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Phase 2: INCB001158 100 mg + Gemcitabine + Cisplatin: OC (Cohort B2)",
        "value": 22.2,
        "unit": "percentage of participants",
        "ci_lower": 2.8,
        "ci_upper": 60.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Phase 2: INCB001158 100 mg + Paclitaxel: GC (Cohort C1)",
        "value": 9.1,
        "unit": "percentage of participants",
        "ci_lower": 0.2,
        "ci_upper": 41.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Phase 2: INCB001158 100 mg + Paclitaxel: EC (Cohort C2)",
        "value": 30.0,
        "unit": "percentage of participants",
        "ci_lower": 6.7,
        "ci_upper": 65.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "Phase 2: INCB001158 100 mg + Paclitaxel: OC (Cohort C3)",
        "value": 16.7,
        "unit": "percentage of participants",
        "ci_lower": 4.7,
        "ci_upper": 37.4,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "INCB001158",
        "Oxaliplatin",
        "Leucovorin",
        "5-Fluorouracil"
      ],
      "OG001": [
        "INCB001158",
        "Oxaliplatin",
        "Leucovorin",
        "5-Fluorouracil"
      ],
      "OG002": [
        "INCB001158",
        "Oxaliplatin",
        "Leucovorin",
        "5-Fluorouracil"
      ],
      "OG003": [
        "INCB001158",
        "Gemcitabine",
        "Cisplatin"
      ],
      "OG004": [
        "INCB001158",
        "Gemcitabine",
        "Cisplatin"
      ],
      "OG005": [
        "INCB001158",
        "Gemcitabine",
        "Cisplatin"
      ],
      "OG006": [
        "INCB001158",
        "Paclitaxel"
      ],
      "OG007": [
        "INCB001158",
        "Paclitaxel"
      ],
      "OG008": [
        "INCB001158",
        "Paclitaxel"
      ],
      "OG009": [
        "INCB001158",
        "Oxaliplatin",
        "Leucovorin",
        "5-Fluorouracil"
      ],
      "OG010": [
        "INCB001158",
        "Gemcitabine",
        "Cisplatin"
      ],
      "OG011": [
        "INCB001158",
        "Gemcitabine",
        "Cisplatin"
      ],
      "OG012": [
        "INCB001158",
        "Paclitaxel"
      ],
      "OG013": [
        "INCB001158",
        "Paclitaxel"
      ],
      "OG014": [
        "INCB001158",
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted",
      "OG003": "Combo_Chemo_Targeted",
      "OG004": "Combo_Chemo_Targeted",
      "OG005": "Combo_Chemo_Targeted",
      "OG006": "Combo_Chemo_Targeted",
      "OG007": "Combo_Chemo_Targeted",
      "OG008": "Combo_Chemo_Targeted",
      "OG009": "Combo_Chemo_Targeted",
      "OG010": "Combo_Chemo_Targeted",
      "OG011": "Combo_Chemo_Targeted",
      "OG012": "Combo_Chemo_Targeted",
      "OG013": "Combo_Chemo_Targeted",
      "OG014": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03322566",
    "brief_title": "A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)",
    "status": "COMPLETED",
    "start_date": "2018-01-09",
    "completion_date": "2018-12-13",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Incyte Corporation",
    "url": "https://clinicaltrials.gov/study/NCT03322566",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "sensitizing mutation"
      },
      {
        "target": "ROS1",
        "status": "NEGATIVE",
        "details": "translocation"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "translocation"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + Chemotherapy + Epacadostat",
        "value": 26.4,
        "unit": "percentage of participants",
        "ci_lower": 17.7,
        "ci_upper": 36.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Pembrolizumab + Chemotherapy + Placebo",
        "value": 44.8,
        "unit": "percentage of participants",
        "ci_lower": 34.1,
        "ci_upper": 55.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + Chemotherapy + Epacadostat",
        "value": 8.0,
        "unit": "months",
        "ci_lower": 4.2,
        "ci_upper": 10.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Pembrolizumab + Chemotherapy + Placebo",
        "value": 8.2,
        "unit": "months",
        "ci_lower": 6.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + Chemotherapy + Epacadostat",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Pembrolizumab + Chemotherapy + Placebo",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + Chemotherapy + Epacadostat",
        "value": null,
        "unit": "months",
        "ci_lower": 1.1,
        "ci_upper": 7.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG001",
        "arm_title": "Pembrolizumab + Chemotherapy + Placebo",
        "value": 7.0,
        "unit": "months",
        "ci_lower": 1.2,
        "ci_upper": 8.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Epacadostat",
        "Platinum-based chemotherapy"
      ],
      "OG001": [
        "Pembrolizumab",
        "Platinum-based chemotherapy"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT00503685",
    "brief_title": "Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy",
    "status": "COMPLETED",
    "start_date": "2007-06",
    "completion_date": "2009-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00503685",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "Absence of mutations at codon 12 or 13 as determined by the DxS K-ras Mutation Kit (PCR-based analysis)"
      },
      {
        "target": "UGT1A1",
        "status": "POSITIVE",
        "details": "UGT1A1 promoter polymorphism (e.g., Gilbert syndrome) confirmed by genotyping or Invader UGT1A1 Molecular Assay; participants with this polymorphism must have total bilirubin \u2264 3 x ULN"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "IMC-A12",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 14.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "IMC-A12 + Cetuximab",
        "value": 4.8,
        "unit": "percentage of participants",
        "ci_lower": 0.1,
        "ci_upper": 23.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "IMC-A12 + Cetuximab (K-ras Wild-type)",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 16.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "IMC-A12",
        "value": 5.9,
        "unit": "weeks",
        "ci_lower": 5.6,
        "ci_upper": 5.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "IMC-A12 + Cetuximab",
        "value": 6.1,
        "unit": "weeks",
        "ci_lower": 5.6,
        "ci_upper": 6.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "IMC-A12 + Cetuximab (K-ras Wild-type)",
        "value": 9.4,
        "unit": "weeks",
        "ci_lower": 5.6,
        "ci_upper": 11.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "IMC-A12",
        "value": 5.7,
        "unit": "months",
        "ci_lower": 3.4,
        "ci_upper": 7.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "IMC-A12 + Cetuximab",
        "value": 4.5,
        "unit": "months",
        "ci_lower": 2.8,
        "ci_upper": 13.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "IMC-A12 + Cetuximab (K-ras Wild-type)",
        "value": 10.9,
        "unit": "months",
        "ci_lower": 5.5,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "IMC-A12"
      ],
      "OG001": [
        "IMC-A12",
        "cetuximab"
      ],
      "OG002": [
        "IMC-A12",
        "cetuximab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03321630",
    "brief_title": "A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies",
    "status": "COMPLETED",
    "start_date": "2017-10-24",
    "completion_date": "2023-03-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "NYU Langone Health",
    "url": "https://clinicaltrials.gov/study/NCT03321630",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "ANY",
        "details": "If HER2 positive, must have received and progressed on or been intolerant to trastuzumab for metastatic or recurrent disease."
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Lenvatinib & Pembrolizumab",
        "value": 25.0,
        "unit": "percentage of participants",
        "ci_lower": 8.7,
        "ci_upper": 49.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Lenvatinib & Pembrolizumab",
        "value": 21.4,
        "unit": "weeks",
        "ci_lower": 15.7,
        "ci_upper": 74.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Lenvatinib & Pembrolizumab",
        "value": 12.9,
        "unit": "weeks",
        "ci_lower": 8.6,
        "ci_upper": 41.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Lenvatinib",
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_IO"
    }
  },
  {
    "nct_id": "NCT03322540",
    "brief_title": "Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)",
    "status": "COMPLETED",
    "start_date": "2017-12-15",
    "completion_date": "2019-01-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Incyte Corporation",
    "url": "https://clinicaltrials.gov/study/NCT03322540",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "HIGH",
        "details": "TPS \u226550% by immunohistochemistry at a central laboratory"
      },
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "EGFR-sensitizing mutation (must be absent)"
      },
      {
        "target": "ROS1",
        "status": "NEGATIVE",
        "details": "ROS1 translocation (must be absent)"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "ALK translocation (must be absent)"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + Epacadostat",
        "value": 32.5,
        "unit": "percentage of participants",
        "ci_lower": 22.2,
        "ci_upper": 44.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Pembrolizumab + Placebo",
        "value": 39.0,
        "unit": "percentage of participants",
        "ci_lower": 28.0,
        "ci_upper": 50.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + Epacadostat",
        "value": 6.7,
        "unit": "months",
        "ci_lower": 4.3,
        "ci_upper": 8.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Pembrolizumab + Placebo",
        "value": 6.2,
        "unit": "months",
        "ci_lower": 4.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + Epacodostat",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Pembrolizumab + Placebo",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + Epacodostat",
        "value": 6.2,
        "unit": "Months",
        "ci_lower": 1.9,
        "ci_upper": 6.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG001",
        "arm_title": "Pembrolizumab + Placebo",
        "value": null,
        "unit": "Months",
        "ci_lower": 1.9,
        "ci_upper": 8.6,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Epacadostat"
      ],
      "OG001": [
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "IO"
    }
  },
  {
    "nct_id": "NCT00504257",
    "brief_title": "Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma",
    "status": "COMPLETED",
    "start_date": "2007-03",
    "completion_date": "2012-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
    "url": "https://clinicaltrials.gov/study/NCT00504257",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Avastin and Docetaxel",
        "value": 43.9,
        "unit": "percentage of participants",
        "ci_lower": 28.6,
        "ci_upper": 58.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Avastin and Docetaxel",
        "value": 12.4,
        "unit": "months",
        "ci_lower": 10.0,
        "ci_upper": 21.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Avastin",
        "Docetaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03311555",
    "brief_title": "A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)",
    "status": "COMPLETED",
    "start_date": "2018-03-28",
    "completion_date": "2022-12-22",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Andrew J. Armstrong, MD",
    "url": "https://clinicaltrials.gov/study/NCT03311555",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [
      {
        "target": "PSA",
        "status": "HIGH",
        "details": "PSA relapse within 4 years of prostatectomy; evidence of recurrence defined as PSA > 0.20 ng/mL OR two consecutive rises in PSA (\u22651 week apart). Note: protocol excludes PSA \u2265 4.0 ng/mL."
      },
      {
        "target": "GLEASON",
        "status": "ANY",
        "details": "Gleason sum 7 (with pT3 disease or positive margins or \u22644 positive nodes), 8, 9, or 10 on the radical prostatectomy specimen."
      },
      {
        "target": "TESTOSTERONE",
        "status": "HIGH",
        "details": "Testosterone must be >100 ng/dL (testosterone \u2264100 ng/dL is exclusionary)."
      }
    ],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Recurrent PSA-only Non-metastatic Prostate Cancer",
        "value": 69.2,
        "unit": "percentage of participants",
        "ci_lower": 56.5,
        "ci_upper": 86.5,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Apalutamide",
        "Androgen deprivation",
        "Docetaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER"
    }
  },
  {
    "nct_id": "NCT00490139",
    "brief_title": "ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D",
    "status": "COMPLETED",
    "start_date": "2007-05-16",
    "completion_date": "2013-12-06",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT00490139",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER2 overexpression/amplification: IHC 3+ and/or FISH positive"
      },
      {
        "target": "ER",
        "status": "ANY",
        "details": "Known hormone receptor status required (ER and/or PR)"
      },
      {
        "target": "PR",
        "status": "ANY",
        "details": "Known hormone receptor status required (ER and/or PR)"
      }
    ],
    "cancer_stages": [
      "I",
      "II",
      "III"
    ],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Lapatinib Plus Trastuzumab",
        "value": 1.9,
        "unit": "Years",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Trastuzumab Followed by Lapatinib",
        "value": 1.3,
        "unit": "Years",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Lapatinib",
        "value": 1.0,
        "unit": "Years",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Trastuzumab",
        "value": 1.5,
        "unit": "Years",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Lapatinib Plus Trastuzumab",
        "value": 1.7,
        "unit": "Years",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Trastuzumab Followed by Lapatinib",
        "value": 1.2,
        "unit": "Years",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Lapatinib",
        "value": null,
        "unit": "Years",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Trastuzumab",
        "value": 1.7,
        "unit": "Years",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Lapatinib",
        "Trastuzumab"
      ],
      "OG001": [
        "Trastuzumab",
        "Lapatinib"
      ],
      "OG002": [
        "Lapatinib"
      ],
      "OG003": [
        "Trastuzumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Targeted",
      "OG001": "Combo_TKI_Targeted",
      "OG002": "TKI",
      "OG003": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03308942",
    "brief_title": "Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants",
    "status": "COMPLETED",
    "start_date": "2017-09-29",
    "completion_date": "2020-05-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Tesaro, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT03308942",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "HIGH",
        "details": "TPS \u226550% per local assessment (Cohorts 1 and 1A require)"
      },
      {
        "target": "PD-L1",
        "status": "LOW",
        "details": "TPS 1%\u201349% per local assessment (Cohorts 2 and 2A require)"
      },
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "No known EGFR-sensitizing mutation (exon 19 or 21 sensitizing mutations referenced in exclusions)"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "No known ALK translocation"
      },
      {
        "target": "ROS1",
        "status": "NEGATIVE",
        "details": "No known ROS1 translocation"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV",
      "METASTATIC",
      "UNRESECTABLE",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Stage 1 (Cohort 1): Niraparib + Pembrolizumab",
        "value": 56.3,
        "unit": "Percentage of participants",
        "ci_lower": 29.9,
        "ci_upper": 80.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Stage 1 (Cohort 1): Niraparib + Pembrolizumab",
        "value": 8.4,
        "unit": "Months",
        "ci_lower": 3.9,
        "ci_upper": 36.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Stage 1 (Cohort 1): Niraparib + Pembrolizumab",
        "value": null,
        "unit": null,
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Niraparib",
        "Pembrolizumab"
      ],
      "OG001": [
        "Niraparib",
        "TSR-042 (Dostarlimab)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT03310957",
    "brief_title": "Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2018-02-27",
    "completion_date": "2024-09-30",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Seagen Inc.",
    "url": "https://clinicaltrials.gov/study/NCT03310957",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "Absence of HER2 expression (triple-negative definition)"
      },
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "Absence of estrogen receptor (ER) expression (triple-negative definition)"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "Absence of progesterone receptor (PR) expression (triple-negative definition)"
      },
      {
        "target": "PD-L1",
        "status": "LOW",
        "details": "Tumor tissue PD-L1 Combined Positive Score <10 (Part D only)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Part A, B: SGN-LIV 2.0 mg/kg (Q3WK) + Pembrolizumab",
        "value": 34.0,
        "unit": "Percentage of participants",
        "ci_lower": 18.6,
        "ci_upper": 53.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Part A, B: SGN-LIV 2.5 mg/kg (Q3WK) + Pembrolizumab",
        "value": 41.0,
        "unit": "Percentage of participants",
        "ci_lower": 28.1,
        "ci_upper": 54.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Part C: SGN-LIV 1.0 mg/kg (Q1WK) + Pembrolizumab",
        "value": 50.0,
        "unit": "Percentage of participants",
        "ci_lower": 1.3,
        "ci_upper": 98.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Part C: SGN-LIV 1.25 mg/kg (Q1WK) + Pembrolizumab",
        "value": 47.0,
        "unit": "Percentage of participants",
        "ci_lower": 33.3,
        "ci_upper": 61.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Part D: SGN-LIV 1.5 mg/kg (2Q3WK) + Pembrolizumab",
        "value": 39.0,
        "unit": "Percentage of participants",
        "ci_lower": 23.1,
        "ci_upper": 56.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Part A, B: SGN-LIV 2.0 mg/kg (Q3WK) + Pembrolizumab",
        "value": 3.5,
        "unit": "Months",
        "ci_lower": 1.7,
        "ci_upper": 4.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Part A, B: SGN-LIV 2.5 mg/kg (Q3WK) + Pembrolizumab",
        "value": 4.2,
        "unit": "Months",
        "ci_lower": 3.9,
        "ci_upper": 5.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Part C: SGN-LIV 1.0 mg/kg (Q1WK) + Pembrolizumab",
        "value": 3.3,
        "unit": "Months",
        "ci_lower": 1.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Part C: SGN-LIV 1.25 mg/kg (Q1WK) + Pembrolizumab",
        "value": 4.8,
        "unit": "Months",
        "ci_lower": 4.1,
        "ci_upper": 5.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Part D: SGN-LIV 1.5 mg/kg (2Q3WK) + Pembrolizumab",
        "value": 4.2,
        "unit": "Months",
        "ci_lower": 2.7,
        "ci_upper": 8.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Part A, B: SGN-LIV 2.0 mg/kg (Q3WK) + Pembrolizumab",
        "value": 14.6,
        "unit": "Months",
        "ci_lower": 8.1,
        "ci_upper": 26.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Part A, B: SGN-LIV 2.5 mg/kg (Q3WK) + Pembrolizumab",
        "value": 14.8,
        "unit": "Months",
        "ci_lower": 11.9,
        "ci_upper": 25.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Part C: SGN-LIV 1.0 mg/kg (Q1WK) + Pembrolizumab",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Part C: SGN-LIV 1.25 mg/kg (Q1WK) + Pembrolizumab",
        "value": 19.4,
        "unit": "Months",
        "ci_lower": 11.1,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG004",
        "arm_title": "Part D: SGN-LIV 1.5 mg/kg (2Q3WK) + Pembrolizumab",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "ladiratuzumab vedotin",
        "Pembrolizumab"
      ],
      "OG001": [
        "ladiratuzumab vedotin",
        "Pembrolizumab"
      ],
      "OG002": [
        "ladiratuzumab vedotin",
        "Pembrolizumab"
      ],
      "OG003": [
        "ladiratuzumab vedotin",
        "Pembrolizumab"
      ],
      "OG004": [
        "ladiratuzumab vedotin",
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted",
      "OG002": "Combo_IO_Targeted",
      "OG003": "Combo_IO_Targeted",
      "OG004": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT00513786",
    "brief_title": "Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma",
    "status": "COMPLETED",
    "start_date": "2007-08-01",
    "completion_date": "2017-01-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "David O'Malley",
    "url": "https://clinicaltrials.gov/study/NCT00513786",
    "cancer_types": [
      "UCEC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "III",
      "IV"
    ],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Carboplatin/Paclitaxel With Bevacizumab",
        "value": 26.0,
        "unit": "months",
        "ci_lower": 2.0,
        "ci_upper": 57.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Carboplatin",
        "Paclitaxel",
        "bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00515216",
    "brief_title": "Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors",
    "status": "COMPLETED",
    "start_date": "2007-08",
    "completion_date": "2011-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Vanderbilt University",
    "url": "https://clinicaltrials.gov/study/NCT00515216",
    "cancer_types": [
      "STAD",
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Oxaliplatin/Leucovorin/5-FU",
        "value": 39.1,
        "unit": "percentage of participants",
        "ci_lower": 22.2,
        "ci_upper": 59.2,
        "dispersion_type": "95% Confidence Interval"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Oxaliplatin/Leucovorin/5-FU",
        "value": 11.4,
        "unit": "months",
        "ci_lower": 6.3,
        "ci_upper": 16.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Oxaliplatin/Leucovorin/5-FU",
        "value": 6.2,
        "unit": "months",
        "ci_lower": 5.2,
        "ci_upper": 8.6,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Oxaliplatin",
        "Leucovorin",
        "5-fluorouracil"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo"
    }
  },
  {
    "nct_id": "NCT03342937",
    "brief_title": "KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer",
    "status": "COMPLETED",
    "start_date": "2018-01-11",
    "completion_date": "2023-02-06",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Duke University",
    "url": "https://clinicaltrials.gov/study/NCT03342937",
    "cancer_types": [
      "STAD",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "ANY",
        "details": "HER2-positive or negative allowed"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Oxaliplatin + Capecitabine + Pembrolizumab",
        "value": 7.6,
        "unit": "months",
        "ci_lower": 5.8,
        "ci_upper": 11.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Oxaliplatin + Capecitabine + Pembrolizumab",
        "value": 16.0,
        "unit": "months",
        "ci_lower": 11.6,
        "ci_upper": 24.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Oxaliplatin",
        "Capecitabine",
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT00510068",
    "brief_title": "Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors",
    "status": "COMPLETED",
    "start_date": "2007-07",
    "completion_date": "2010-02",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT00510068",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Everolimus 10 mg/Day",
        "value": 11.04,
        "unit": "Months",
        "ci_lower": 8.41,
        "ci_upper": 13.86,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 4.6,
        "unit": "Months",
        "ci_lower": 3.06,
        "ci_upper": 5.39,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Everolimus 10 mg/Day",
        "value": 44.02,
        "unit": "Months",
        "ci_lower": 35.61,
        "ci_upper": 51.75,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 37.68,
        "unit": "Months",
        "ci_lower": 29.14,
        "ci_upper": 45.77,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Everolimus"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT00517595",
    "brief_title": "Phase II Study Alimta and Gemzar + Avastin as First Line Chemotherapy for Elderly Patients With Stage IIIB/IV NSCLC",
    "status": "COMPLETED",
    "start_date": "2007-08",
    "completion_date": "2011-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Accelerated Community Oncology Research Network",
    "url": "https://clinicaltrials.gov/study/NCT00517595",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed, Gemcitabine, and Bevacizumab",
        "value": 4.9,
        "unit": "Months",
        "ci_lower": 3.82,
        "ci_upper": 5.76,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed, Gemcitabine, and Bevacizumab",
        "value": 8.78,
        "unit": "Months",
        "ci_lower": 6.71,
        "ci_upper": 19.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pemetrexed",
        "Gemcitabine",
        "Bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00520403",
    "brief_title": "A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.",
    "status": "COMPLETED",
    "start_date": "2007-09",
    "completion_date": "2010-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT00520403",
    "cancer_types": [
      "KIRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab + IFN/Vinblastine",
        "value": 274.0,
        "unit": "days",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Bevacizumab",
        "Interferon alfa-2a",
        "Vinblastine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00526669",
    "brief_title": "Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib",
    "status": "COMPLETED",
    "start_date": "2008-03",
    "completion_date": "2011-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "GlaxoSmithKline",
    "url": "https://clinicaltrials.gov/study/NCT00526669",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Lapatinib + Capecitabine",
        "value": 17.9,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Lapatinib + Capecitabine",
        "value": 29.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Lapatinib",
        "Capecitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT00528437",
    "brief_title": "Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors",
    "status": "COMPLETED",
    "start_date": "2005-10",
    "completion_date": "2017-06-30",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "NYU Langone Health",
    "url": "https://clinicaltrials.gov/study/NCT00528437",
    "cancer_types": [
      "GBM",
      "LGG"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Myeloablative Chemo-Temozolomide, Thiotepa, and Carboplatin.",
        "value": null,
        "unit": null,
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      }
    ],
    "arm_drugs": {
      "OG000": [
        "temozolomide",
        "thiotepa",
        "carboplatin",
        "13-cis-retinoic acid"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo"
    }
  },
  {
    "nct_id": "NCT03353675",
    "brief_title": "A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)",
    "status": "COMPLETED",
    "start_date": "2018-01-05",
    "completion_date": "2019-11-20",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Transgene",
    "url": "https://clinicaltrials.gov/study/NCT03353675",
    "cancer_types": [
      "NSCLC",
      "LUAD"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "LOW",
        "details": "PD-L1 expression by immunohistochemistry in <50% of tumor cells (IHC TPS <50%)"
      },
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "No EGFR activating mutations allowed; testing mandatory"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "No ALK rearrangements allowed; testing mandatory"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV",
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "TG4010/Chemotherapy/Nivolumab",
        "value": 32.5,
        "unit": "percentage of participants",
        "ci_lower": 20.4,
        "ci_upper": 46.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "TG4010/Chemotherapy/Nivolumab",
        "value": 5.7,
        "unit": "Months",
        "ci_lower": 1.5,
        "ci_upper": 11.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "TG4010/Chemotherapy/Nivolumab",
        "value": 14.9,
        "unit": "Months",
        "ci_lower": 8.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "TG4010",
        "Pemetrexed",
        "Cisplatin",
        "Carboplatin",
        "Nivolumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT03336216",
    "brief_title": "A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer",
    "status": "COMPLETED",
    "start_date": "2017-12-18",
    "completion_date": "2023-06-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT03336216",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A: Investigator Choice",
        "value": 3.52,
        "unit": "Months",
        "ci_lower": 2.53,
        "ci_upper": 4.21,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Cabiralizumab + Nivolumab",
        "value": 1.92,
        "unit": "Months",
        "ci_lower": 1.77,
        "ci_upper": 2.14,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Arm C: Cabiralizumab + Nivolumab + Gemcitabine-Based Chemotherapy",
        "value": 3.68,
        "unit": "Months",
        "ci_lower": 1.94,
        "ci_upper": 4.83,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Arm D: Cabiralizumab + Nivolumab + 5-FU-Based Chemotherapy",
        "value": 3.22,
        "unit": "Months",
        "ci_lower": 2.04,
        "ci_upper": 3.94,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A: Investigator Choice",
        "value": 6.28,
        "unit": "Months",
        "ci_lower": 4.53,
        "ci_upper": 8.11,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Cabiralizumab + Nivolumab",
        "value": 4.44,
        "unit": "Months",
        "ci_lower": 3.19,
        "ci_upper": 7.26,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Arm C: Cabiralizumab + Nivolumab + Gemcitabine-Based Chemotherapy",
        "value": 6.72,
        "unit": "Months",
        "ci_lower": 4.96,
        "ci_upper": 8.54,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Arm D: Cabiralizumab + Nivolumab + 5-FU-Based Chemotherapy",
        "value": 5.68,
        "unit": "Months",
        "ci_lower": 4.57,
        "ci_upper": 7.33,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Gemcitabine",
        "Nab-paclitaxel",
        "Fluorouracil",
        "Leucovorin",
        "Onivyde"
      ],
      "OG001": [
        "Cabiralizumab",
        "Nivolumab"
      ],
      "OG002": [
        "Cabiralizumab",
        "Nivolumab",
        "Gemcitabine",
        "Nab-paclitaxel"
      ],
      "OG003": [
        "Cabiralizumab",
        "Nivolumab",
        "Oxaliplatin",
        "Fluorouracil",
        "Leucovorin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_IO_Targeted",
      "OG002": "Combo_Chemo_IO",
      "OG003": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT00530621",
    "brief_title": "Study of Enzastaurin Versus Placebo With Pemetrexed for Participants With Advanced or Metastatic Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2007-09",
    "completion_date": "2008-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00530621",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed + Enzastaurin",
        "value": 2.96,
        "unit": "months",
        "ci_lower": 1.87,
        "ci_upper": 3.58,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Pemetrexed + Placebo",
        "value": 3.02,
        "unit": "months",
        "ci_lower": 1.74,
        "ci_upper": 3.98,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed + Enzastaurin",
        "value": 9.63,
        "unit": "months",
        "ci_lower": 8.18,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Pemetrexed + Placebo",
        "value": 7.39,
        "unit": "months",
        "ci_lower": 6.41,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "pemetrexed",
        "enzastaurin"
      ],
      "OG001": [
        "pemetrexed"
      ],
      "OG002": [
        "pemetrexed",
        "enzastaurin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo",
      "OG002": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03353753",
    "brief_title": "Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies",
    "status": "COMPLETED",
    "start_date": "2018-02-27",
    "completion_date": "2019-05-31",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Deciphera Pharmaceuticals, LLC",
    "url": "https://clinicaltrials.gov/study/NCT03353753",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": true,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ripretinib",
        "value": 27.6,
        "unit": "Weeks",
        "ci_lower": 20.0,
        "ci_upper": 29.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 4.1,
        "unit": "Weeks",
        "ci_lower": 4.0,
        "ci_upper": 7.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG000",
        "arm_title": "Ripretinib",
        "value": 28.0,
        "unit": "Weeks",
        "ci_lower": 20.0,
        "ci_upper": 36.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 4.1,
        "unit": "Weeks",
        "ci_lower": 4.0,
        "ci_upper": 7.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Ripretinib",
        "value": 65.6,
        "unit": "weeks",
        "ci_lower": 53.6,
        "ci_upper": 65.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 28.6,
        "unit": "weeks",
        "ci_lower": 17.9,
        "ci_upper": 50.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ripretinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT00529100",
    "brief_title": "Concurrent Pemetrexed, Cisplatin and Radiation Therapy in Patients With Stage IIIA/B Non Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2005-12",
    "completion_date": "2010-08",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00529100",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIA",
      "IIIB"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed/Cisplatin/Radiation Phase 2",
        "value": 79.0,
        "unit": "percentage of participants",
        "ci_lower": 66.1,
        "ci_upper": 92.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pemetrexed",
        "Cisplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo"
    }
  },
  {
    "nct_id": "NCT00510653",
    "brief_title": "Gleevec Study for Patients With Ovarian Cancer",
    "status": "COMPLETED",
    "start_date": "2002-03",
    "completion_date": "2012-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "M.D. Anderson Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT00510653",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "KIT",
        "status": "POSITIVE",
        "details": "Tumor tissue expression by immunohistochemistry; positivity defined as 2+ or 3+"
      },
      {
        "target": "PDGFR",
        "status": "POSITIVE",
        "details": "Tumor tissue expression by immunohistochemistry; positivity defined as 2+ or 3+"
      },
      {
        "target": "ABL",
        "status": "POSITIVE",
        "details": "Tumor tissue expression by immunohistochemistry; positivity defined as 2+ or 3+"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Imatinib Mesylate",
        "value": 0.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Imatinib Mesylate",
        "value": 0.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Imatinib Mesylate"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT00515411",
    "brief_title": "Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma",
    "status": "COMPLETED",
    "start_date": "2006-10-23",
    "completion_date": "2018-10-26",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Memorial Sloan Kettering Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT00515411",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER2 positive by FISH or IHC 3+; FISH+ defined as HER2:CEP17 ratio \u22652.0 (text also references >2); cohesive IHC3+ or FISH+ clones considered positive irrespective of clone size (<10%)."
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A, - Modified DCF",
        "value": 63.0,
        "unit": "percentage of paticipants",
        "ci_lower": 48.0,
        "ci_upper": 75.0,
        "dispersion_type": "MEAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "ARM B - Parent DCF With G-CSF",
        "value": 53.0,
        "unit": "percentage of paticipants",
        "ci_lower": 34.0,
        "ci_upper": 69.0,
        "dispersion_type": "MEAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Arm C - Modified DCF+ Trastuzumab",
        "value": 73.0,
        "unit": "percentage of paticipants",
        "ci_lower": 51.0,
        "ci_upper": 86.0,
        "dispersion_type": "MEAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A, - Modified DCF",
        "value": 18.8,
        "unit": "months",
        "ci_lower": 14.9,
        "ci_upper": 24.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "ARM B - Parent DCF With G-CSF",
        "value": 12.6,
        "unit": "months",
        "ci_lower": 6.7,
        "ci_upper": 16.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Arm C - Modified DCF+ Trastuzumab",
        "value": 24.9,
        "unit": "months",
        "ci_lower": 14.4,
        "ci_upper": 42.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Docetaxel",
        "Leucovorin",
        "Fluorouracil",
        "Cisplatin"
      ],
      "OG001": [
        "Docetaxel",
        "Cisplatin",
        "Fluorouracil",
        "Neulasta",
        "Neupogen"
      ],
      "OG002": [
        "Docetaxel",
        "Leucovorin",
        "Fluorouracil",
        "Cisplatin",
        "Trastuzumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo",
      "OG002": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03358472",
    "brief_title": "Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)",
    "status": "COMPLETED",
    "start_date": "2017-12-01",
    "completion_date": "2018-07-19",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Incyte Corporation",
    "url": "https://clinicaltrials.gov/study/NCT03358472",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [
      {
        "target": "HPV",
        "status": "ANY",
        "details": "Documentation of HPV testing results for oropharyngeal cancer required"
      },
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "Known history of HIV infection excluded; testing not required unless locally mandated"
      },
      {
        "target": "HBV",
        "status": "NEGATIVE",
        "details": "Active hepatitis B (HBsAg reactive) excluded \u2014 must be HBsAg negative"
      },
      {
        "target": "HCV",
        "status": "NEGATIVE",
        "details": "Active hepatitis C (HCV RNA qualitative detected) excluded \u2014 must be HCV RNA negative"
      }
    ],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + Epacadostat",
        "value": 31.4,
        "unit": "percentage of participants",
        "ci_lower": 16.9,
        "ci_upper": 49.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Pembrolizumab",
        "value": 21.1,
        "unit": "percentage of participants",
        "ci_lower": 6.1,
        "ci_upper": 45.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "EXTREME",
        "value": 34.3,
        "unit": "percentage of participants",
        "ci_lower": 19.1,
        "ci_upper": 52.2,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Epacadostat"
      ],
      "OG001": [
        "Pembrolizumab"
      ],
      "OG002": [
        "Cetuximab",
        "Cisplatin",
        "Carboplatin",
        "5-Fluorouracil"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "IO",
      "OG002": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03338790",
    "brief_title": "An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer",
    "status": "COMPLETED",
    "start_date": "2017-12-19",
    "completion_date": "2021-01-13",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT03338790",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Arm A1",
        "value": 10.3,
        "unit": "Percentage of participants",
        "ci_lower": 3.9,
        "ci_upper": 21.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Arm A2",
        "value": 15.4,
        "unit": "Percentage of participants",
        "ci_lower": 5.9,
        "ci_upper": 30.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Arm B",
        "value": 40.0,
        "unit": "Percentage of participants",
        "ci_lower": 25.7,
        "ci_upper": 55.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Arm C",
        "value": 11.1,
        "unit": "Percentage of participants",
        "ci_lower": 1.4,
        "ci_upper": 34.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Arm A1",
        "value": 17.2,
        "unit": "Percentage of participants",
        "ci_lower": 5.8,
        "ci_upper": 35.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Arm A2",
        "value": 25.0,
        "unit": "Percentage of participants",
        "ci_lower": 8.7,
        "ci_upper": 49.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Arm B",
        "value": 36.8,
        "unit": "Percentage of participants",
        "ci_lower": 16.3,
        "ci_upper": 61.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Arm C",
        "value": 20.0,
        "unit": "Percentage of participants",
        "ci_lower": 0.5,
        "ci_upper": 71.6,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "nivolumab",
        "rucaparib"
      ],
      "OG001": [
        "nivolumab",
        "rucaparib"
      ],
      "OG002": [
        "nivolumab",
        "docetaxel",
        "prednisone"
      ],
      "OG003": [
        "nivolumab",
        "enzalutamide"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted",
      "OG002": "Combo_Chemo_IO",
      "OG003": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT03337724",
    "brief_title": "A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2018-01-06",
    "completion_date": "2023-01-04",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT03337724",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "PIK3CA",
        "status": "POSITIVE",
        "details": "PIK3CA-altered status required (alteration detected by an appropriately validated molecular assay on tumor tissue or blood; CLIA or equivalent)."
      },
      {
        "target": "AKT1",
        "status": "POSITIVE",
        "details": "AKT1-altered status required (alteration detected by an appropriately validated molecular assay on tumor tissue or blood; CLIA or equivalent)."
      },
      {
        "target": "PTEN",
        "status": "POSITIVE",
        "details": "PTEN-altered status required (alteration or loss detected by an appropriately validated molecular assay on tumor tissue or blood; CLIA or equivalent)."
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-negative required (cohorts: triple-negative breast cancer or HR+/HER2-)."
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "UNRESECTABLE",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort A: Placebo + Paclitaxel",
        "value": 6.1,
        "unit": "months",
        "ci_lower": 5.5,
        "ci_upper": 9.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort A: Ipatasertib + Paclitaxel",
        "value": 7.4,
        "unit": "months",
        "ci_lower": 5.6,
        "ci_upper": 8.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cohort A: Placebo + Paclitaxel",
        "value": 24.9,
        "unit": "months",
        "ci_lower": 16.9,
        "ci_upper": 40.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cohort A: Ipatasertib + Paclitaxel",
        "value": 24.2,
        "unit": "months",
        "ci_lower": 19.2,
        "ci_upper": 29.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Cohort B: Placebo + Paclitaxel",
        "value": 28.4,
        "unit": "months",
        "ci_lower": 20.6,
        "ci_upper": 37.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Cohort B: Ipatasertib + Paclitaxel",
        "value": 29.0,
        "unit": "months",
        "ci_lower": 22.4,
        "ci_upper": 34.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG004",
        "arm_title": "Cohort C: Ipatasertib + Atezolizumab + Paclitaxel",
        "value": 22.8,
        "unit": "months",
        "ci_lower": 17.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Paclitaxel"
      ],
      "OG001": [
        "Ipatasertib",
        "Paclitaxel"
      ],
      "OG002": [
        "Paclitaxel"
      ],
      "OG003": [
        "Ipatasertib",
        "Paclitaxel"
      ],
      "OG004": [
        "Ipatasertib",
        "Atezolizumab",
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Chemo",
      "OG003": "Combo_Chemo_Targeted",
      "OG004": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT03333915",
    "brief_title": "Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2016-12-21",
    "completion_date": "2020-08-24",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "BeiGene",
    "url": "https://clinicaltrials.gov/study/NCT03333915",
    "cancer_types": [
      "OV",
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "BRCA1",
        "status": "POSITIVE",
        "details": "germline BRCA1 mutation (phase 2 inclusion)"
      },
      {
        "target": "BRCA2",
        "status": "POSITIVE",
        "details": "germline BRCA2 mutation (phase 2 inclusion)"
      },
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "triple-negative breast cancer (ER-, PR-, HER2-; phase 1 inclusion)"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "triple-negative breast cancer (ER-, PR-, HER2-; phase 1 inclusion)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "triple-negative breast cancer (ER-, PR-, HER2-; phase 1 inclusion)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 2: 60 mg Pamiparib in PSOC",
        "value": 68.3,
        "unit": "Percentage of participants",
        "ci_lower": 57.1,
        "ci_upper": 78.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Phase 2: 60 mg Pamiparib in PROC",
        "value": 31.6,
        "unit": "Percentage of participants",
        "ci_lower": 12.6,
        "ci_upper": 56.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase 1: 20 mg Pamiparib",
        "value": 2.2,
        "unit": "Months",
        "ci_lower": 1.48,
        "ci_upper": 34.53,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Phase 1: 40 mg Pamiparib",
        "value": null,
        "unit": "Months",
        "ci_lower": 1.45,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Phase 1: 60 mg Pamiparib",
        "value": 5.6,
        "unit": "Months",
        "ci_lower": 1.48,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Phase 2: 60 mg Pamiparib in PSOC",
        "value": 34.1,
        "unit": "Months",
        "ci_lower": 29.08,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Phase 2: 60 mg Pamiparib in PROC",
        "value": 13.6,
        "unit": "Months",
        "ci_lower": 7.13,
        "ci_upper": 19.75,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pamiparib"
      ],
      "OG001": [
        "Pamiparib"
      ],
      "OG002": [
        "Pamiparib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03326193",
    "brief_title": "A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy",
    "status": "COMPLETED",
    "start_date": "2017-12-12",
    "completion_date": "2020-12-24",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Tesaro, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT03326193",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "HRD",
        "status": "ANY",
        "details": "Tumor homologous recombination deficiency (HRD) testing required at screening; archival tissue or fresh biopsy acceptable; enrollment may proceed before result"
      },
      {
        "target": "CA-125",
        "status": "LOW",
        "details": "CA-125 must be in normal range OR decreased by >90% during front-line therapy and stable for \u22657 days (no increase >15% from nadir)"
      },
      {
        "target": "Proteinuria",
        "status": "LOW",
        "details": "Urine protein:creatinine ratio must be <1.0 at screening (dipstick <2); if dipstick \u22652 then 24\u2011hour urine protein must be <2 g"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IIIC",
      "IV"
    ],
    "line_of_therapy": "MAINTENANCE",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Niraparib + Bevacizumab",
        "value": 62.0,
        "unit": "Percentage of participants",
        "ci_lower": 51.9,
        "ci_upper": 71.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Niraparib + Bevacizumab",
        "value": 61.1,
        "unit": "Months",
        "ci_lower": 44.88,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Niraparib",
        "Bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00561470",
    "brief_title": "Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen",
    "status": "COMPLETED",
    "start_date": "2007-11",
    "completion_date": "2011-02",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sanofi",
    "url": "https://clinicaltrials.gov/study/NCT00561470",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Placebo/FOLFIRI",
        "value": 12.06,
        "unit": "months",
        "ci_lower": 6.83,
        "ci_upper": 21.03,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Aflibercept/FOLFIRI",
        "value": 13.5,
        "unit": "months",
        "ci_lower": 7.62,
        "ci_upper": 25.59,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)"
      ],
      "OG001": [
        "Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP\u0000ae)",
        "FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00570713",
    "brief_title": "An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer",
    "status": "COMPLETED",
    "start_date": "2007-12",
    "completion_date": "2009-12",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Morphotek",
    "url": "https://clinicaltrials.gov/study/NCT00570713",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "MORAb-009 Plus Gemcitabine ('MORAb-009')",
        "value": 6.5,
        "unit": "Months",
        "ci_lower": 4.5,
        "ci_upper": 8.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo Plus Gemcitabine ('Placebo')",
        "value": 6.9,
        "unit": "Months",
        "ci_lower": 5.4,
        "ci_upper": 8.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "MORAb-009",
        "Gemcitabine"
      ],
      "OG001": [
        "Gemcitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00588770",
    "brief_title": "Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2008-08-08",
    "completion_date": "2018-06-05",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT00588770",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Chemotherapy Arm (Arm A)",
        "value": 11.0,
        "unit": "months",
        "ci_lower": 9.5,
        "ci_upper": 13.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy+Bevacizumab (Arm B)",
        "value": 12.6,
        "unit": "months",
        "ci_lower": 10.3,
        "ci_upper": 15.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Chemotherapy Arm (Arm A)",
        "value": 4.3,
        "unit": "months",
        "ci_lower": 3.8,
        "ci_upper": 5.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy+Bevacizumab (Arm B)",
        "value": 6.0,
        "unit": "months",
        "ci_lower": 4.9,
        "ci_upper": 6.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Docetaxel",
        "Cisplatin"
      ],
      "OG001": [
        "Bevacizumab",
        "Docetaxel",
        "Cisplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00567190",
    "brief_title": "A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2008-02-12",
    "completion_date": "2011-05-13",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Genentech, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT00567190",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER2-positive metastatic breast cancer (testing method/threshold not specified)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT",
      "IV",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pertuzumab + Trastuzumab + Docetaxel",
        "value": 18.5,
        "unit": "Months",
        "ci_lower": 15.0,
        "ci_upper": 23.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Trastuzumab + Docetaxel",
        "value": 12.4,
        "unit": "Months",
        "ci_lower": 10.0,
        "ci_upper": 13.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pertuzumab",
        "Trastuzumab",
        "Docetaxel"
      ],
      "OG001": [
        "Trastuzumab",
        "Docetaxel"
      ],
      "OG002": [
        "Pertuzumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00553410",
    "brief_title": "Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2007-08",
    "completion_date": "2018-04",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "ETOP IBCSG Partners Foundation",
    "url": "https://clinicaltrials.gov/study/NCT00553410",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "estrogen receptor positive by immunohistochemistry (determined after primary surgery and before commencement of prior endocrine therapy)"
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": "progesterone receptor positive by immunohistochemistry (determined after primary surgery and before commencement of prior endocrine therapy)"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [],
    "arm_drugs": {
      "OG000": [
        "Letrozole"
      ],
      "OG001": [
        "Letrozole"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT00537381",
    "brief_title": "An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer",
    "status": "COMPLETED",
    "start_date": "2007-05",
    "completion_date": "2009-11",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Centocor, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT00537381",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Docetaxel + Prednisone + Placebo",
        "value": 336.0,
        "unit": "Days",
        "ci_lower": 266.0,
        "ci_upper": 477.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Docetaxel + Prednisone + Intetumumab",
        "value": 232.0,
        "unit": "Days",
        "ci_lower": 155.0,
        "ci_upper": 320.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Docetaxel + Prednisone + Placebo",
        "value": 626.0,
        "unit": "Days",
        "ci_lower": 532.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Docetaxel + Prednisone + Intetumumab",
        "value": 522.0,
        "unit": "Days",
        "ci_lower": 418.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Docetaxel",
        "Prednisone"
      ],
      "OG001": [
        "Docetaxel",
        "Prednisone",
        "Intetumumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00560235",
    "brief_title": "Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors",
    "status": "COMPLETED",
    "start_date": "2008-03",
    "completion_date": "2010-03",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT00560235",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Figitumumab 30 mg/kg (Phase 2)",
        "value": 14.2,
        "unit": "percentage of participants",
        "ci_lower": 8.1,
        "ci_upper": 22.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Figitumumab 30 mg/kg (Phase 2)",
        "value": 1.9,
        "unit": "months",
        "ci_lower": 1.8,
        "ci_upper": 2.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Figitumumab 30 mg/kg (Phase 2)",
        "value": 8.9,
        "unit": "months",
        "ci_lower": 7.2,
        "ci_upper": 10.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Figitumumab (CP-751,871)",
        "Rapamycin"
      ],
      "OG001": [
        "Figitumumab (CP-751,871)"
      ],
      "OG002": [
        "Figitumumab (CP-751,871)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00550173",
    "brief_title": "A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2007-11",
    "completion_date": "2012-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00550173",
    "cancer_types": [
      "NSCLC",
      "LUAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed + Erlotinib",
        "value": 7.4,
        "unit": "months",
        "ci_lower": 4.4,
        "ci_upper": 12.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Erlotinib",
        "value": 3.8,
        "unit": "months",
        "ci_lower": 2.7,
        "ci_upper": 6.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Pemetrexed",
        "value": 4.4,
        "unit": "months",
        "ci_lower": 3.0,
        "ci_upper": 6.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed + Erlotinib",
        "value": 20.5,
        "unit": "months",
        "ci_lower": 17.1,
        "ci_upper": 25.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Erlotinib",
        "value": 22.8,
        "unit": "months",
        "ci_lower": 18.2,
        "ci_upper": 29.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Pemetrexed",
        "value": 17.7,
        "unit": "months",
        "ci_lower": 11.8,
        "ci_upper": 25.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "pemetrexed",
        "erlotinib"
      ],
      "OG001": [
        "erlotinib"
      ],
      "OG002": [
        "pemetrexed"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "TKI",
      "OG002": "Chemo"
    }
  },
  {
    "nct_id": "NCT00577031",
    "brief_title": "OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.",
    "status": "COMPLETED",
    "start_date": "2008-02",
    "completion_date": "2011-08",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT00577031",
    "cancer_types": [
      "COAD",
      "READ"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab",
        "value": 50.25,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab",
        "value": 58.79,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG000",
        "arm_title": "Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab",
        "value": 8.52,
        "unit": "months",
        "ci_lower": 7.28,
        "ci_upper": 10.33,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab",
        "value": 50.76,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "bevacizumab [Avastin]",
        "Oxaliplatin",
        "Xeloda"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00533429",
    "brief_title": "Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy",
    "status": "COMPLETED",
    "start_date": "2007-10",
    "completion_date": "2009-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00533429",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin",
        "value": 3.5,
        "unit": "months",
        "ci_lower": 2.0,
        "ci_upper": 5.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Pemetrexed + Carboplatin + Bevacizumab + Placebo",
        "value": 4.3,
        "unit": "months",
        "ci_lower": 2.5,
        "ci_upper": 5.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin",
        "value": 9.1,
        "unit": "months",
        "ci_lower": 7.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Pemetrexed + Carboplatin + Bevacizumab + Placebo",
        "value": 7.6,
        "unit": "months",
        "ci_lower": 4.2,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "enzastaurin",
        "pemetrexed",
        "carboplatin",
        "bevacizumab"
      ],
      "OG001": [
        "pemetrexed",
        "carboplatin",
        "bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00542451",
    "brief_title": "Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2007-10",
    "completion_date": "2014-04-21",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Dana-Farber Cancer Institute",
    "url": "https://clinicaltrials.gov/study/NCT00542451",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "IHC 3+ or FISH >2"
      },
      {
        "target": "ER",
        "status": "ANY",
        "details": "ER assay required by immunohistochemistry (IHC)"
      },
      {
        "target": "PR",
        "status": "ANY",
        "details": "PR assay required by immunohistochemistry (IHC)"
      }
    ],
    "cancer_stages": [
      "I",
      "IIA"
    ],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer",
        "value": 0.987,
        "unit": "proportion of participant",
        "ci_lower": 0.976,
        "ci_upper": 0.998,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Paclitaxel",
        "Trastuzumab"
      ],
      "OG001": [
        "Paclitaxel",
        "Trastuzumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00531960",
    "brief_title": "A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.",
    "status": "COMPLETED",
    "start_date": "2008-01",
    "completion_date": "2010-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT00531960",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab + Chemotherapy",
        "value": 34.6,
        "unit": "weeks",
        "ci_lower": 25.0,
        "ci_upper": 42.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab + Erlotinib",
        "value": 23.4,
        "unit": "weeks",
        "ci_lower": 17.4,
        "ci_upper": 45.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab + Chemotherapy",
        "value": null,
        "unit": "months",
        "ci_lower": 12.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab + Erlotinib",
        "value": 16.4,
        "unit": "months",
        "ci_lower": 11.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Bevacizumab",
        "Standard platinum-based chemotherapy"
      ],
      "OG001": [
        "Bevacizumab",
        "Erlotinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_TKI_Targeted"
    }
  },
  {
    "nct_id": "NCT00545077",
    "brief_title": "Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women",
    "status": "COMPLETED",
    "start_date": "2007-11-06",
    "completion_date": "2013-12",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Spanish Breast Cancer Research Group",
    "url": "https://clinicaltrials.gov/study/NCT00545077",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 negative by IHC and FISH/CISH: IHC 0 or 1+, or IHC 2+ with negative FISH/CISH; IHC 3+ or positive FISH/CISH (>2 amplifications) are excluded"
      },
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Estrogen receptor (ER) positive by local or central laboratory criteria; at least one hormone receptor (ER and/or PGR) must be positive"
      },
      {
        "target": "PGR",
        "status": "POSITIVE",
        "details": "Progesterone receptor (PGR) positive by local or central laboratory criteria; at least one hormone receptor (ER and/or PGR) must be positive"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A: Endocrine Therapy (ET)",
        "value": 14.4,
        "unit": "Months",
        "ci_lower": 11.4,
        "ci_upper": 17.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B: ET With Bevacizumab (ET-B)",
        "value": 19.3,
        "unit": "Months",
        "ci_lower": 16.5,
        "ci_upper": 22.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A: Endocrine Therapy (ET)",
        "value": 51.8,
        "unit": "Months",
        "ci_lower": 38.82,
        "ci_upper": 64.75,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B: ET With Bevacizumab (ET-B)",
        "value": 52.1,
        "unit": "Months",
        "ci_lower": 35.79,
        "ci_upper": 68.49,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Letrozole",
        "Fulvestrant"
      ],
      "OG001": [
        "Bevacizumab",
        "Letrozole",
        "Fulvestrant"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00578942",
    "brief_title": "Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath",
    "status": "COMPLETED",
    "start_date": "2005-05",
    "completion_date": "2013-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "David Rizzieri, MD",
    "url": "https://clinicaltrials.gov/study/NCT00578942",
    "cancer_types": [
      "LAML",
      "DLBC",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "HIV antibody negative"
      },
      {
        "target": "HCG",
        "status": "NEGATIVE",
        "details": "serum beta-human chorionic gonadotropin (pregnancy) negative; patient must agree to use adequate contraception during chemotherapy and related post-chemotherapy medications"
      },
      {
        "target": "HLA",
        "status": "ANY",
        "details": "Requires a 6/6 HLA-matched related donor able to provide peripheral blood progenitor cells and/or marrow"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Campath Purged Non-myeloablative ASCT",
        "value": 32.0,
        "unit": "months alive post-infusion",
        "ci_lower": 2.0,
        "ci_upper": 123.0,
        "dispersion_type": "MEAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "fludarabine",
        "cyclophosphamide",
        "Campath-1H (alemtuzumab)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00542308",
    "brief_title": "Zalutumumab in Non-curable Patients With SCCHN",
    "status": "COMPLETED",
    "start_date": "2008-01",
    "completion_date": "2011-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Genmab",
    "url": "https://clinicaltrials.gov/study/NCT00542308",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Zalutumumab 4-16 mg/kg",
        "value": 5.3,
        "unit": "months",
        "ci_lower": 4.1,
        "ci_upper": 7.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Zalutumumab 4-16 mg/kg",
        "value": 8.6,
        "unit": "months",
        "ci_lower": 8.0,
        "ci_upper": 10.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Zalutumumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00556712",
    "brief_title": "A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)",
    "status": "COMPLETED",
    "start_date": "2006-01",
    "completion_date": "2010-11",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT00556712",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "MAINTENANCE",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Placebo",
        "value": 89.5,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Erlotinib, 150 mg/Day",
        "value": 79.9,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Placebo",
        "value": 11.1,
        "unit": "weeks",
        "ci_lower": 8.1,
        "ci_upper": 11.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Erlotinib, 150 mg/Day",
        "value": 12.3,
        "unit": "weeks",
        "ci_lower": 12.0,
        "ci_upper": 13.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Placebo",
        "value": 15.0,
        "unit": "percentage of participants",
        "ci_lower": 12.0,
        "ci_upper": 19.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Erlotinib, 150 mg/Day",
        "value": 25.0,
        "unit": "percentage of participants",
        "ci_lower": 21.0,
        "ci_upper": 29.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Placebo",
        "value": 89.4,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Erlotinib, 150 mg/Day",
        "value": 79.5,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG001": [
        "erlotinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Placebo",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT00580034",
    "brief_title": "Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath",
    "status": "COMPLETED",
    "start_date": "2003-02",
    "completion_date": "2013-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "David Rizzieri, MD",
    "url": "https://clinicaltrials.gov/study/NCT00580034",
    "cancer_types": [
      "LAML",
      "DLBC",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "HIV antibody test must be negative"
      },
      {
        "target": "hCG",
        "status": "NEGATIVE",
        "details": "Serum beta-hCG (pregnancy test) must be negative; patients must agree to use contraception during therapy"
      },
      {
        "target": "HLA",
        "status": "ANY",
        "details": "Require a 3-5/6 HLA-matched related donor (related donor match of 3\u20135 out of 6) able to provide PBPCs and/or marrow"
      },
      {
        "target": "CYTOGENETICS",
        "status": "NEGATIVE",
        "details": "Excludes leukemia patients in first remission with good-risk cytogenetics (t(15;17); t(8,22))"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Campath Purged Non-myeloablative ASCT",
        "value": 20.0,
        "unit": "months",
        "ci_lower": 0.03,
        "ci_upper": 101.0,
        "dispersion_type": "MEAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Fludarabine",
        "Cyclophosphamide",
        "Campath-1H (Alemtuzumab)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00534417",
    "brief_title": "Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2007-10",
    "completion_date": "2011-09",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Accelerated Community Oncology Research Network",
    "url": "https://clinicaltrials.gov/study/NCT00534417",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "Primary tumor HER-2 negative at study entry; IHC 2+ handled at investigator discretion"
      },
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Primary tumor and/or metastatic lesion positive by immunohistochemistry (IHC)"
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": "Primary tumor and/or metastatic lesion positive by immunohistochemistry (IHC)"
      },
      {
        "target": "DPYD",
        "status": "NEGATIVE",
        "details": "Known dihydropyrimidine dehydrogenase (DPD) deficiency is excluded (no known DPYD/DPD deficiency)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Capecitabine and Fulvestrant",
        "value": 14.98,
        "unit": "Months",
        "ci_lower": 7.26,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Capecitabine and Fulvestrant",
        "value": 28.65,
        "unit": "Months",
        "ci_lower": 23.95,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "capecitabine",
        "fulvestrant"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER"
    }
  },
  {
    "nct_id": "NCT00536601",
    "brief_title": "High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2006-06-29",
    "completion_date": "2018-07-09",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Roswell Park Cancer Institute",
    "url": "https://clinicaltrials.gov/study/NCT00536601",
    "cancer_types": [
      "LAML",
      "LLBC",
      "DLBC"
    ],
    "biomarkers": [
      {
        "target": "DLCO",
        "status": "HIGH",
        "details": ">= 50% predicted; DLCO to be corrected for hemoglobin and/or alveolar ventilation"
      },
      {
        "target": "DLVA",
        "status": "HIGH",
        "details": ">= 50% predicted (alternative measure: DLVA)"
      },
      {
        "target": "PULMONARY_FUNCTION",
        "status": "HIGH",
        "details": ">= 50% predicted (pulmonary function requirement)"
      },
      {
        "target": "EJECTION_FRACTION",
        "status": "HIGH",
        "details": ">= 50% by radionuclide ventriculogram or echocardiogram"
      },
      {
        "target": "BILIRUBIN",
        "status": "LOW",
        "details": "Bilirubin must be less than 3 x normal"
      },
      {
        "target": "ALKALINE_PHOSPHATASE",
        "status": "LOW",
        "details": "Alkaline phosphatase and SGOT (AST) must be less than 3 x normal"
      },
      {
        "target": "SGOT",
        "status": "LOW",
        "details": "Alkaline phosphatase and SGOT (AST) must be less than 3 x normal"
      },
      {
        "target": "CREATININE_CLEARANCE",
        "status": "LOW",
        "details": "Calculated creatinine clearance < 40 cc/min by Cockcroft-Gault (adult) or Schwartz (pediatric) \u2014 stated in criteria"
      },
      {
        "target": "GFR",
        "status": "ANY",
        "details": "Glomerular filtration rate by renal scan for neuroblastoma patients to determine dosing parameters"
      },
      {
        "target": "PMN",
        "status": "HIGH",
        "details": "Peripheral blood polymorphonuclear neutrophil (PMN) count > 1500/\u00b5L"
      },
      {
        "target": "PLATELET",
        "status": "HIGH",
        "details": "Platelet count > 75,000/\u00b5L"
      },
      {
        "target": "CD34",
        "status": "HIGH",
        "details": "Total CD34+ \u2265 2 x 10^6/kg required for blood stem cell product"
      },
      {
        "target": "CMV",
        "status": "POSITIVE",
        "details": "Positive CMV IgM requires Infectious Disease consult and clearance (allowed with clearance)"
      },
      {
        "target": "HEPATITIS",
        "status": "POSITIVE",
        "details": "Positive hepatitis serologies require Infectious Disease consult and clearance (allowed with clearance)"
      },
      {
        "target": "HIV",
        "status": "POSITIVE",
        "details": "HIV-positive hematologic malignancy patients may be eligible if on anti-retroviral therapy with CD4+ > 75 cells/\u00b5L and HIV copy number < 100,000/\u00b5L and with Infectious Disease clearance"
      },
      {
        "target": "CD4",
        "status": "HIGH",
        "details": "CD4+ cell count > 75 cells/\u00b5L (eligibility requirement for HIV-positive patients on ART)"
      },
      {
        "target": "HIV_VIRAL_LOAD",
        "status": "LOW",
        "details": "HIV copy number < 100,000 per \u00b5L (eligibility requirement for HIV-positive patients on ART)"
      }
    ],
    "cancer_stages": [
      "RECURRENT",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Acute Leukemia",
        "value": 33.0,
        "unit": "Proportion of participants",
        "ci_lower": 0.0,
        "ci_upper": 71.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Hodgkin Lymphoma",
        "value": 14.0,
        "unit": "Proportion of participants",
        "ci_lower": 0.0,
        "ci_upper": 40.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Non-Hodgkin Lymphoma",
        "value": 22.0,
        "unit": "Proportion of participants",
        "ci_lower": 7.0,
        "ci_upper": 38.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Hodgkin Lymphoma",
        "value": 43.0,
        "unit": "Proportion of participants",
        "ci_lower": 17.0,
        "ci_upper": 69.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Non-Hodgkin Lymphoma",
        "value": 37.0,
        "unit": "Proportion of participants",
        "ci_lower": 23.0,
        "ci_upper": 52.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Non-Hodgkin Lymphoma",
        "value": 0.0,
        "unit": "Proportion of participants",
        "ci_lower": 0.0,
        "ci_upper": 0.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Solid Tumors",
        "value": 43.0,
        "unit": "Proportion of participants",
        "ci_lower": 6.0,
        "ci_upper": 80.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "MM/Amyloid",
        "value": 22.0,
        "unit": "Proportion of participants",
        "ci_lower": 2.0,
        "ci_upper": 41.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "MM/Amyloid",
        "value": 13.0,
        "unit": "Proportion of participants",
        "ci_lower": 3.0,
        "ci_upper": 22.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Solid Tumors",
        "value": 0.0,
        "unit": "Proportion of participants",
        "ci_lower": 0.0,
        "ci_upper": 0.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Solid Tumors",
        "value": 50.0,
        "unit": "Proportion of participants",
        "ci_lower": 0.0,
        "ci_upper": 100.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Acute Leukemia",
        "value": 33.0,
        "unit": "Proportion of participants",
        "ci_lower": 0.0,
        "ci_upper": 71.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Hodgkin Lymphoma",
        "value": 61.0,
        "unit": "Proportion of participants",
        "ci_lower": 40.0,
        "ci_upper": 82.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Non-Hodgkin Lymphoma",
        "value": 45.0,
        "unit": "Proportion of participants",
        "ci_lower": 33.0,
        "ci_upper": 57.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "MM/Amyloid",
        "value": 39.0,
        "unit": "Proportion of participants",
        "ci_lower": 27.0,
        "ci_upper": 51.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG004",
        "arm_title": "Solid Tumors",
        "value": 46.0,
        "unit": "Proportion of participants",
        "ci_lower": 16.0,
        "ci_upper": 75.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {},
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER",
      "OG002": "OTHER",
      "OG003": "OTHER",
      "OG004": "OTHER"
    }
  },
  {
    "nct_id": "NCT00585195",
    "brief_title": "A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer",
    "status": "COMPLETED",
    "start_date": "2006-04-19",
    "completion_date": "2020-07-30",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT00585195",
    "cancer_types": [
      "NSCLC",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "ALK",
        "status": "POSITIVE",
        "details": "Alteration making tumor sensitive to PF-02341066 inhibition (e.g., ALK fusion)"
      },
      {
        "target": "MET",
        "status": "POSITIVE",
        "details": "c-Met alterations making tumor sensitive to PF-02341066 inhibition (e.g., overexpression or amplification)"
      },
      {
        "target": "ROS1",
        "status": "POSITIVE",
        "details": "Alteration making tumor sensitive to PF-02341066 inhibition (e.g., ROS1 fusion)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg",
        "value": 71.7,
        "unit": "percentage of participants",
        "ci_lower": 57.7,
        "ci_upper": 83.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg",
        "value": 32.3,
        "unit": "percentage of participants",
        "ci_lower": 21.2,
        "ci_upper": 45.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg",
        "value": 31.6,
        "unit": "percentage of participants",
        "ci_lower": 17.5,
        "ci_upper": 48.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "RP2D Cohort: ALK-Negative Cohort 2, NSCLC: Crizotinib 250 mg",
        "value": 19.0,
        "unit": "percentage of participants",
        "ci_lower": 5.4,
        "ci_upper": 41.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg",
        "value": 61.2,
        "unit": "percentage of participants",
        "ci_lower": 51.7,
        "ci_upper": 70.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "RP2D Cohort: Enriched Other: Crizotinib 250 mg",
        "value": 8.3,
        "unit": "percentage of participants",
        "ci_lower": 0.2,
        "ci_upper": 38.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG000",
        "arm_title": "RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg",
        "value": 14.5,
        "unit": "Weeks",
        "ci_lower": 2.8,
        "ci_upper": 45.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG001",
        "arm_title": "RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg",
        "value": 6.8,
        "unit": "Weeks",
        "ci_lower": 2.8,
        "ci_upper": 13.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG002",
        "arm_title": "RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg",
        "value": 5.2,
        "unit": "Weeks",
        "ci_lower": 3.8,
        "ci_upper": 12.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG003",
        "arm_title": "RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg",
        "value": 26.2,
        "unit": "Weeks",
        "ci_lower": 8.1,
        "ci_upper": 72.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG000",
        "arm_title": "RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg",
        "value": 7.9,
        "unit": "Weeks",
        "ci_lower": 4.3,
        "ci_upper": 103.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG001",
        "arm_title": "RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg",
        "value": 7.6,
        "unit": "Weeks",
        "ci_lower": 3.7,
        "ci_upper": 47.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG002",
        "arm_title": "RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg",
        "value": 8.0,
        "unit": "Weeks",
        "ci_lower": 7.1,
        "ci_upper": 23.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG003",
        "arm_title": "RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg",
        "value": 7.7,
        "unit": "Weeks",
        "ci_lower": 4.3,
        "ci_upper": 39.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG000",
        "arm_title": "RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg",
        "value": 86.8,
        "unit": "percentage of participants",
        "ci_lower": 74.7,
        "ci_upper": 94.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG001",
        "arm_title": "RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg",
        "value": 71.8,
        "unit": "percentage of participants",
        "ci_lower": 61.0,
        "ci_upper": 81.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG002",
        "arm_title": "RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg",
        "value": 79.3,
        "unit": "percentage of participants",
        "ci_lower": 70.8,
        "ci_upper": 86.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG003",
        "arm_title": "RP2D Cohort: ALK-Negative Cohort 2, NSCLC: Crizotinib 250 mg",
        "value": 47.6,
        "unit": "percentage of participants",
        "ci_lower": 25.7,
        "ci_upper": 70.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg",
        "value": 19.3,
        "unit": "Months",
        "ci_lower": 15.2,
        "ci_upper": 39.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg",
        "value": 7.6,
        "unit": "Months",
        "ci_lower": 5.6,
        "ci_upper": 9.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg",
        "value": 4.0,
        "unit": "Months",
        "ci_lower": 1.9,
        "ci_upper": 6.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg",
        "value": 10.0,
        "unit": "Months",
        "ci_lower": 8.2,
        "ci_upper": 14.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg",
        "value": 51.4,
        "unit": "Months",
        "ci_lower": 29.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg",
        "value": 20.0,
        "unit": "Months",
        "ci_lower": 13.2,
        "ci_upper": 25.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg",
        "value": 10.1,
        "unit": "Months",
        "ci_lower": 7.1,
        "ci_upper": 12.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Crizotinib"
      ],
      "OG001": [
        "Crizotinib",
        "Midazolam"
      ],
      "OG002": [
        "Crizotinib"
      ],
      "OG003": [
        "Crizotinib"
      ],
      "OG004": [
        "Crizotinib"
      ],
      "OG005": [
        "Crizotinib",
        "Midazolam"
      ],
      "OG006": [
        "Crizotinib"
      ],
      "OG007": [
        "Crizotinib"
      ],
      "OG008": [
        "Crizotinib"
      ],
      "OG009": [
        "Crizotinib"
      ],
      "OG010": [
        "Crizotinib"
      ],
      "OG011": [
        "Crizotinib"
      ],
      "OG012": [
        "Crizotinib"
      ],
      "OG013": [
        "Crizotinib"
      ],
      "OG014": [
        "Crizotinib"
      ],
      "OG015": [
        "Crizotinib"
      ],
      "OG016": [
        "Crizotinib"
      ],
      "OG017": [
        "Crizotinib"
      ],
      "OG018": [
        "Crizotinib",
        "Itraconazole"
      ],
      "OG019": [
        "Crizotinib",
        "Rifampin"
      ],
      "OG020": [
        "Crizotinib",
        "Midazolam"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI",
      "OG002": "TKI",
      "OG003": "TKI",
      "OG004": "TKI",
      "OG005": "TKI",
      "OG006": "TKI",
      "OG007": "TKI",
      "OG008": "TKI",
      "OG009": "TKI",
      "OG010": "TKI",
      "OG011": "TKI",
      "OG012": "TKI",
      "OG013": "TKI",
      "OG014": "TKI",
      "OG015": "TKI",
      "OG016": "TKI",
      "OG017": "TKI",
      "OG018": "TKI",
      "OG019": "TKI",
      "OG020": "TKI"
    }
  },
  {
    "nct_id": "NCT00590954",
    "brief_title": "Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas",
    "status": "COMPLETED",
    "start_date": "2006-05",
    "completion_date": "2019-11-11",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Memorial Sloan Kettering Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT00590954",
    "cancer_types": [
      "GBM",
      "LGG"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Glioblastoma",
        "value": 1.58,
        "unit": "months",
        "ci_lower": 1.08,
        "ci_upper": 1.84,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Anaplastic Glioma",
        "value": 2.12,
        "unit": "months",
        "ci_lower": 1.84,
        "ci_upper": 12.79,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Perifosine"
      ],
      "OG001": [
        "Perifosine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00615056",
    "brief_title": "A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen",
    "status": "COMPLETED",
    "start_date": "2008-03",
    "completion_date": "2011-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT00615056",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Axitinib + FOLFIRI",
        "value": 5.72,
        "unit": "Months",
        "ci_lower": 4.5,
        "ci_upper": 7.42,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab + FOLFIRI",
        "value": 6.87,
        "unit": "Months",
        "ci_lower": 4.96,
        "ci_upper": 9.13,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Axitinib + FOLFOX",
        "value": 7.59,
        "unit": "Months",
        "ci_lower": 5.62,
        "ci_upper": 11.07,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Bevacizumab + FOLFOX",
        "value": 6.44,
        "unit": "Months",
        "ci_lower": 5.52,
        "ci_upper": 13.11,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Axitinib + FOLFIRI",
        "value": 12.9,
        "unit": "Months",
        "ci_lower": 10.2,
        "ci_upper": 16.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab + FOLFIRI",
        "value": 15.7,
        "unit": "Months",
        "ci_lower": 12.1,
        "ci_upper": 23.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Axitinib + FOLFOX",
        "value": 17.1,
        "unit": "Months",
        "ci_lower": 10.1,
        "ci_upper": 23.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Bevacizumab + FOLFOX",
        "value": 14.1,
        "unit": "Months",
        "ci_lower": 9.0,
        "ci_upper": 16.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "AG-013736 (axitinib)",
        "FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU])"
      ],
      "OG001": [
        "Bevacizumab (avastin)",
        "FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU])"
      ],
      "OG002": [
        "AG-013736 (axitinib)",
        "FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])"
      ],
      "OG003": [
        "Bevacizumab (avastin)",
        "FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_TKI_Chemo",
      "OG003": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00605722",
    "brief_title": "A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.",
    "status": "COMPLETED",
    "start_date": "2008-03",
    "completion_date": "2010-09",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT00605722",
    "cancer_types": [
      "LIHC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab + Erlotinib",
        "value": 35.3,
        "unit": "percentage of participants",
        "ci_lower": 22.4,
        "ci_upper": 49.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab + Erlotinib",
        "value": 2.9,
        "unit": "Months",
        "ci_lower": 1.8,
        "ci_upper": 5.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab + Erlotinib",
        "value": 10.7,
        "unit": "months",
        "ci_lower": 7.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "bevacizumab (Avastin)",
        "erlotinib (Tarceva)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Targeted"
    }
  },
  {
    "nct_id": "NCT00612586",
    "brief_title": "Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer",
    "status": "COMPLETED",
    "start_date": "2008-02",
    "completion_date": "2010-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00612586",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "MAINTENANCE",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Enzastaurin + 5-FU/LV + Bev",
        "value": 5.8,
        "unit": "months",
        "ci_lower": 4.4,
        "ci_upper": 7.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + 5FU/LV + Bev",
        "value": 8.1,
        "unit": "months",
        "ci_lower": 6.8,
        "ci_upper": 12.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Enzastaurin + 5-FU/LV + Bev",
        "value": null,
        "unit": "months",
        "ci_lower": 13.1,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + 5FU/LV + Bev",
        "value": null,
        "unit": "months",
        "ci_lower": 15.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Enzastaurin",
        "5-fluorouracil (5-FU)",
        "Leucovorin (LV)",
        "Bevacizumab (Bev)"
      ],
      "OG001": [
        "5-fluorouracil (5-FU)",
        "Leucovorin (LV)",
        "Bevacizumab (Bev)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00608972",
    "brief_title": "Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2008-05-16",
    "completion_date": "2015-07-12",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Rutgers, The State University of New Jersey",
    "url": "https://clinicaltrials.gov/study/NCT00608972",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "Estrogen receptor (ER) negative"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "Progesterone receptor (PR) negative"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2/neu negative"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Doxil, Carboplatin and Bevacizumab",
        "value": 6.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Doxil",
        "Carboplatin",
        "Bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00602667",
    "brief_title": "Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2007-12-17",
    "completion_date": "2017-09-27",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "St. Jude Children's Research Hospital",
    "url": "https://clinicaltrials.gov/study/NCT00602667",
    "cancer_types": [
      "GBM",
      "LGG"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Low-Risk Group",
        "value": 73.9,
        "unit": "Percent Probability",
        "ci_lower": 56.5,
        "ci_upper": 91.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Intermediate-Risk Group",
        "value": 46.9,
        "unit": "Percent Probability",
        "ci_lower": 30.2,
        "ci_upper": 63.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "High-Risk Group",
        "value": 30.8,
        "unit": "Percent Probability",
        "ci_lower": 14.1,
        "ci_upper": 47.5,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "methotrexate",
        "vincristine",
        "cisplatin",
        "cyclophosphamide",
        "carboplatin",
        "etoposide",
        "topotecan",
        "erlotinib"
      ],
      "OG001": [
        "methotrexate",
        "vincristine",
        "cisplatin",
        "cyclophosphamide",
        "topotecan",
        "erlotinib",
        "etoposide"
      ],
      "OG002": [
        "methotrexate",
        "vincristine",
        "cisplatin",
        "cyclophosphamide",
        "vinblastine",
        "topotecan",
        "erlotinib",
        "etoposide"
      ],
      "OG003": [
        "methotrexate",
        "vincristine",
        "cisplatin",
        "cyclophosphamide",
        "carboplatin",
        "etoposide",
        "topotecan",
        "erlotinib"
      ],
      "OG004": [
        "methotrexate",
        "vincristine",
        "cisplatin",
        "cyclophosphamide",
        "topotecan",
        "erlotinib",
        "etoposide"
      ],
      "OG005": [
        "methotrexate",
        "vincristine",
        "cisplatin",
        "cyclophosphamide",
        "vinblastine",
        "topotecan",
        "erlotinib",
        "etoposide"
      ],
      "OG006": [
        "methotrexate",
        "vincristine",
        "cisplatin",
        "cyclophosphamide",
        "carboplatin",
        "etoposide",
        "topotecan",
        "erlotinib"
      ],
      "OG007": [
        "methotrexate",
        "vincristine",
        "cisplatin",
        "cyclophosphamide",
        "topotecan",
        "erlotinib",
        "etoposide"
      ],
      "OG008": [
        "methotrexate",
        "vincristine",
        "cisplatin",
        "cyclophosphamide",
        "vinblastine",
        "topotecan",
        "erlotinib",
        "etoposide"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Combo_TKI_Chemo",
      "OG002": "Combo_TKI_Chemo",
      "OG003": "Combo_TKI_Chemo",
      "OG004": "Combo_TKI_Chemo",
      "OG005": "Combo_TKI_Chemo",
      "OG006": "Combo_TKI_Chemo",
      "OG007": "Combo_TKI_Chemo",
      "OG008": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT00610129",
    "brief_title": "Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)",
    "status": "COMPLETED",
    "start_date": "2008-01",
    "completion_date": "2010-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Memorial Sloan Kettering Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT00610129",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Patients With Metastatic Neuroendocrine Tumors",
        "value": 13.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Patients With Metastatic Neuroendocrine Tumors",
        "value": 12.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "MK-0646"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00593827",
    "brief_title": "Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2008-05",
    "completion_date": "2010-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "R-Pharm",
    "url": "https://clinicaltrials.gov/study/NCT00593827",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": null
      },
      {
        "target": "CA27.29",
        "status": "HIGH",
        "details": "Serum CA27.29 \u2265 50 required if disease is non-measurable (alternative: CA15.3 \u2265 50)"
      },
      {
        "target": "CA15.3",
        "status": "HIGH",
        "details": "Serum CA15.3 \u2265 50 required if disease is non-measurable (alternative: CA27.29 \u2265 50)"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ixabepilone 16 mg/m^2",
        "value": 28.6,
        "unit": "Percentage of Participants",
        "ci_lower": 18.9,
        "ci_upper": 38.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Ixabepilone 40 mg/m^2",
        "value": 42.7,
        "unit": "Percentage of Participants",
        "ci_lower": 31.5,
        "ci_upper": 53.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Ixabepilone 16 mg/m^2",
        "value": 13.9,
        "unit": "Months",
        "ci_lower": 12.1,
        "ci_upper": 15.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Ixabepilone 40 mg/m^2",
        "value": 16.1,
        "unit": "Months",
        "ci_lower": 10.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ixabepilone"
      ],
      "OG001": [
        "Ixabepilone"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00614393",
    "brief_title": "Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)",
    "status": "COMPLETED",
    "start_date": "2007-12-24",
    "completion_date": "2010-06-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT00614393",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "wild-type KRAS (wtKRAS) \u2014 no activating KRAS mutation"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Dalotuzumab 10 mg/kg Q1W (DB)",
        "value": 10.8,
        "unit": "Months",
        "ci_lower": 7.9,
        "ci_upper": 12.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Dalotuzumab 15 mg/kg/7.5 mg/kg Q2W (OL)",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Dalotuzumab 10 mg/kg Q1W (OL)",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Dalotuzumab 15 mg/kg/7.5 mg/kg Q2W (DB)",
        "value": 11.6,
        "unit": "Months",
        "ci_lower": 9.6,
        "ci_upper": 14.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG004",
        "arm_title": "Placebo + Cetuximab + Irinotecan (DB)",
        "value": 14.0,
        "unit": "Months",
        "ci_lower": 10.7,
        "ci_upper": 16.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Dalotuzumab 10 mg/kg Q1W (DB)",
        "value": 3.9,
        "unit": "Months",
        "ci_lower": 2.7,
        "ci_upper": 5.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Dalotuzumab 15 mg/kg/7.5 mg/kg Q2W (OL)",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Dalotuzumab 10 mg/kg Q1W (OL)",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Dalotuzumab 15 mg/kg/7.5 mg/kg Q2W (DB)",
        "value": 5.4,
        "unit": "Months",
        "ci_lower": 3.9,
        "ci_upper": 6.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Placebo + Cetuximab + Irinotecan (DB)",
        "value": 5.6,
        "unit": "Months",
        "ci_lower": 4.1,
        "ci_upper": 6.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "dalotuzumab",
        "cetuximab",
        "irinotecan hydrochloride"
      ],
      "OG001": [
        "dalotuzumab",
        "cetuximab",
        "irinotecan hydrochloride"
      ],
      "OG002": [
        "dalotuzumab",
        "cetuximab",
        "irinotecan hydrochloride"
      ],
      "OG003": [
        "dalotuzumab",
        "cetuximab",
        "irinotecan hydrochloride"
      ],
      "OG004": [
        "cetuximab",
        "irinotecan hydrochloride"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted",
      "OG003": "Combo_Chemo_Targeted",
      "OG004": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00597402",
    "brief_title": "Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas",
    "status": "COMPLETED",
    "start_date": "2007-07",
    "completion_date": "2011-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Duke University",
    "url": "https://clinicaltrials.gov/study/NCT00597402",
    "cancer_types": [
      "GBM"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Avastin, Radiation, Temozolomide, and Irinotecan",
        "value": 64.8,
        "unit": "percentage of participants",
        "ci_lower": 55.7,
        "ci_upper": 72.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Avastin, Radiation, Temozolomide, and Irinotecan",
        "value": 63.2,
        "unit": "percentage of participants",
        "ci_lower": 54.1,
        "ci_upper": 71.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Avastin",
        "Temozolomide",
        "Irinotecan"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00605566",
    "brief_title": "Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors",
    "status": "COMPLETED",
    "start_date": "2008-01",
    "completion_date": "2015-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "University Health Network, Toronto",
    "url": "https://clinicaltrials.gov/study/NCT00605566",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Sorafenib and Cyclophosphamide",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Sorafenib and Cyclophosphamide",
        "value": 2.8,
        "unit": "months",
        "ci_lower": 1.8,
        "ci_upper": 6.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Sorafenib and Cyclophosphamide",
        "value": 14.9,
        "unit": "months",
        "ci_lower": 3.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Sorafenib and Cyclophosphamide",
        "value": 6.4,
        "unit": "months",
        "ci_lower": 2.8,
        "ci_upper": 6.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Sorafenib and Cyclophosphamide",
        "value": 21.3,
        "unit": "months",
        "ci_lower": 7.9,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Sorafenib",
        "Cyclophosphamide"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT03370276",
    "brief_title": "Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2017-12-20",
    "completion_date": "2021-09-04",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
    "url": "https://clinicaltrials.gov/study/NCT03370276",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [
      {
        "target": "P16",
        "status": "POSITIVE",
        "details": "Required for squamous cell carcinoma of unknown primary in cervical lymph node (p16 positive)"
      }
    ],
    "cancer_stages": [
      "III",
      "IV",
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Phase I Lead in + Phase II: Cohort A",
        "value": 11.4,
        "unit": "months",
        "ci_lower": 9.4,
        "ci_upper": 14.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Phase II - Cohort B",
        "value": 20.2,
        "unit": "months",
        "ci_lower": 15.7,
        "ci_upper": 24.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase I Lead in + Phase II: Cohort A",
        "value": 3.35,
        "unit": "months",
        "ci_lower": 2.56,
        "ci_upper": 7.13,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Phase II - Cohort B",
        "value": 6.15,
        "unit": "months",
        "ci_lower": 3.06,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab",
        "Cetuximab"
      ],
      "OG001": [
        "Nivolumab",
        "Cetuximab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT03361865",
    "brief_title": "Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)",
    "status": "COMPLETED",
    "start_date": "2017-12-04",
    "completion_date": "2018-08-09",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Incyte Corporation",
    "url": "https://clinicaltrials.gov/study/NCT03361865",
    "cancer_types": [
      "BLCA"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Provision of tissue for PD-L1 analysis from an archival sample or newly obtained core/excisional biopsy of a tumor lesion not previously irradiated"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab 200 mg + Epacadostat 100 mg BID",
        "value": 31.8,
        "unit": "percentage of participants",
        "ci_lower": 22.46,
        "ci_upper": 55.24,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Pembrolizumab 200 mg + Placebo BID",
        "value": 24.5,
        "unit": "percentage of participants",
        "ci_lower": 15.33,
        "ci_upper": 43.67,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Epacadostat"
      ],
      "OG001": [
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "IO"
    }
  },
  {
    "nct_id": "NCT00599313",
    "brief_title": "Phase II Sunitinib Prog Met AIPC",
    "status": "COMPLETED",
    "start_date": "2007-03",
    "completion_date": "2009-06",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "US Oncology Research",
    "url": "https://clinicaltrials.gov/study/NCT00599313",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [
      {
        "target": "PSA",
        "status": "HIGH",
        "details": "Elevated and progressive PSA required for patients progressing by PSA criteria; PSA progression defined as baseline increase followed by any serial increase after 2 weeks"
      },
      {
        "target": "TESTOSTERONE",
        "status": "LOW",
        "details": "On androgen ablation with testosterone <50 ng/dL (LHRH agonist or orchiectomy)"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Sunitinib Malate",
        "value": 19.4,
        "unit": "weeks",
        "ci_lower": 2.6,
        "ci_upper": 48.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Sunitinib Malate",
        "value": 0.42,
        "unit": "Probability of Survival at 1-year",
        "ci_lower": 0.23,
        "ci_upper": 0.6,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Sunitinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT00609804",
    "brief_title": "Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib",
    "status": "COMPLETED",
    "start_date": "2008-03",
    "completion_date": "2012-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SCRI Development Innovations, LLC",
    "url": "https://clinicaltrials.gov/study/NCT00609804",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": true,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Sorafenib+Erlotinib",
        "value": 3.1,
        "unit": "months",
        "ci_lower": 1.7,
        "ci_upper": 3.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Sorafenib",
        "value": 1.9,
        "unit": "months",
        "ci_lower": 1.7,
        "ci_upper": 3.6,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Sorafenib",
        "Erlotinib"
      ],
      "OG001": [
        "Sorafenib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT03358875",
    "brief_title": "Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)",
    "status": "COMPLETED",
    "start_date": "2017-11-30",
    "completion_date": "2021-07-15",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "BeiGene",
    "url": "https://clinicaltrials.gov/study/NCT03358875",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "No sensitizing EGFR mutation required (non-squamous histology must provide evidence by a histology-based method)"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "No ALK gene translocation"
      },
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Fresh or archival tumor tissue required for central assessment of PD-L1 expression in tumor cells"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV",
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Tislelizumab",
        "value": 17.2,
        "unit": "months",
        "ci_lower": 15.28,
        "ci_upper": 20.04,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Docetaxel",
        "value": 11.9,
        "unit": "months",
        "ci_lower": 10.18,
        "ci_upper": 13.93,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Tislelizumab"
      ],
      "OG001": [
        "Docetaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00600015",
    "brief_title": "Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)",
    "status": "COMPLETED",
    "start_date": "2008-02",
    "completion_date": "2009-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SCRI Development Innovations, LLC",
    "url": "https://clinicaltrials.gov/study/NCT00600015",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV",
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Combination Therapy",
        "value": 8.1,
        "unit": "percentage of participants",
        "ci_lower": 3.77,
        "ci_upper": 14.83,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 10.9,
        "unit": "percentage of participants",
        "ci_lower": 4.11,
        "ci_upper": 22.25,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Combination Therapy",
        "value": 3.38,
        "unit": "Months",
        "ci_lower": 2.3,
        "ci_upper": 3.81,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 1.94,
        "unit": "Months",
        "ci_lower": 1.77,
        "ci_upper": 3.65,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG000",
        "arm_title": "Combination Therapy",
        "value": 54.0,
        "unit": "percentage of participants",
        "ci_lower": 44.0,
        "ci_upper": 64.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 38.0,
        "unit": "percentage of participants",
        "ci_lower": 25.0,
        "ci_upper": 52.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Erlotinib",
        "Sorafenib"
      ],
      "OG001": [
        "Erlotinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT00606502",
    "brief_title": "Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment",
    "status": "COMPLETED",
    "start_date": "2008-01",
    "completion_date": "2010-06-24",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Spectrum Pharmaceuticals, Inc",
    "url": "https://clinicaltrials.gov/study/NCT00606502",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pralatrexate",
        "value": 6.7,
        "unit": "Months Survival",
        "ci_lower": 5.3,
        "ci_upper": 9.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Erlotinib",
        "value": 7.0,
        "unit": "Months Survival",
        "ci_lower": 3.9,
        "ci_upper": 7.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pralatrexate",
        "value": 3.4,
        "unit": "months",
        "ci_lower": 2.1,
        "ci_upper": 4.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Erlotinib",
        "value": 2.8,
        "unit": "months",
        "ci_lower": 2.1,
        "ci_upper": 3.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pralatrexate"
      ],
      "OG001": [
        "Erlotinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT03371017",
    "brief_title": "A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2018-01-11",
    "completion_date": "2024-10-23",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT03371017",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "POSITIVE",
        "details": "PD-L1 expression on tumour-infiltrating immune cells (IC) of \u22651% assessed centrally prior to randomisation; required for patients enrolled after all-comers recruitment is complete"
      },
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "Part of definition of triple-negative breast cancer (ER-, PR-, HER2-)"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "Part of definition of triple-negative breast cancer (ER-, PR-, HER2-)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "Part of definition of triple-negative breast cancer (ER-, PR-, HER2-); per standard IHC/ISH testing"
      },
      {
        "target": "DPYD",
        "status": "NEGATIVE",
        "details": "No known dihydropyrimidine dehydrogenase (DPD) deficiency in patients selected to receive capecitabine"
      },
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "Negative HIV test at screening"
      },
      {
        "target": "HBsAg",
        "status": "NEGATIVE",
        "details": "Negative hepatitis B surface antigen (HBsAg) test at screening"
      },
      {
        "target": "HBcAb",
        "status": "ANY",
        "details": "Negative total hepatitis B core antibody (HBcAb) at screening, or if HBcAb positive then must have a negative HBV DNA test at screening"
      },
      {
        "target": "HBV DNA",
        "status": "NEGATIVE",
        "details": "HBV DNA must be negative if HBcAb is positive (HBV DNA testing performed only if HBsAg negative and HBcAb positive)"
      },
      {
        "target": "HCV antibody",
        "status": "ANY",
        "details": "Negative hepatitis C virus (HCV) antibody test at screening, or if HCV antibody positive then must have a negative HCV RNA test at screening"
      },
      {
        "target": "HCV RNA",
        "status": "NEGATIVE",
        "details": "HCV RNA must be negative if HCV antibody is positive"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Placebo + Chemotherapy",
        "value": 11.24,
        "unit": "months",
        "ci_lower": 9.0,
        "ci_upper": 13.31,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Atezolizumab + Chemotherapy",
        "value": 12.09,
        "unit": "months",
        "ci_lower": 10.12,
        "ci_upper": 15.08,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Gemcitabine",
        "Carboplatin"
      ],
      "OG001": [
        "Atezolizumab",
        "Gemcitabine",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT03369223",
    "brief_title": "A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2017-12-06",
    "completion_date": "2024-11-07",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT03369223",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Part 2A: Melanoma Arm C: BMS-986249 1200 mg Q8W + Nivolumab 480 mg Q4W",
        "value": 36.2,
        "unit": "Percentage of participants",
        "ci_lower": 24.0,
        "ci_upper": 49.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Part 2A: Melanoma Arm F: BMS-986249 600 mg Q4W + Nivolumab 480 mg Q4W",
        "value": 52.8,
        "unit": "Percentage of participants",
        "ci_lower": 35.5,
        "ci_upper": 69.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Part 1A: BMS-986249 240 mg Monotherapy",
        "value": 1.74,
        "unit": "Months",
        "ci_lower": 1.41,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Part 1A: BMS-986249 800 mg Monotherapy",
        "value": 1.77,
        "unit": "Months",
        "ci_lower": 1.15,
        "ci_upper": 1.84,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Part 1A: BMS-986249 1600 mg Monotherapy",
        "value": 1.69,
        "unit": "Months",
        "ci_lower": 0.53,
        "ci_upper": 3.25,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Part 1A: BMS-986249 2400 mg Monotherapy",
        "value": 3.55,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Part 1A: BMS-986249 1600 mg Q8W Monotherapy",
        "value": 1.68,
        "unit": "Months",
        "ci_lower": 1.05,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG005",
        "arm_title": "Part 1B: BMS-986249 240 mg Q4W + Nivolumab Combination",
        "value": 2.33,
        "unit": "Months",
        "ci_lower": 1.68,
        "ci_upper": 3.32,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG006",
        "arm_title": "Part 1B: BMS-986249 800 mg Q4W+ Nivolumab Combination",
        "value": 1.71,
        "unit": "Months",
        "ci_lower": 0.85,
        "ci_upper": 14.23,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG007",
        "arm_title": "Part 1B: BMS-986249 1200 mg Q4W + Nivolumab Combination",
        "value": 3.32,
        "unit": "Months",
        "ci_lower": 1.22,
        "ci_upper": 4.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG008",
        "arm_title": "Part 1B: BMS-986249 800 mg Q8W + Nivolumab Combination",
        "value": 1.92,
        "unit": "Months",
        "ci_lower": 0.59,
        "ci_upper": 7.13,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG009",
        "arm_title": "Part 1B: BMS-986249 1200 mg Q8W+ Nivolumab Combination",
        "value": 1.91,
        "unit": "Months",
        "ci_lower": 1.02,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG010",
        "arm_title": "Part 1B: BMS-986249 1600 mg Q8W+ Nivolumab Combination",
        "value": 4.35,
        "unit": "Months",
        "ci_lower": 0.92,
        "ci_upper": 12.45,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG011",
        "arm_title": "Part 2A: Melanoma Arm C: BMS-986249 1200 mg Q8W + Nivolumab 480 mg Q4W",
        "value": 6.51,
        "unit": "Months",
        "ci_lower": 4.9,
        "ci_upper": 12.52,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG012",
        "arm_title": "Part 2A: Melanoma Arm D: Ipilimumab 3 mg/kg Q3W + Nivolumab 1 mg/kg Q3W",
        "value": 4.73,
        "unit": "Months",
        "ci_lower": 2.89,
        "ci_upper": 9.76,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG013",
        "arm_title": "Part 2A: Melanoma Arm F: BMS-986249 600 mg Q4W + Nivolumab 480 mg Q4W",
        "value": 10.38,
        "unit": "Months",
        "ci_lower": 6.74,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG014",
        "arm_title": "Part 2B: Cohort 1 (Advanced or Intermediate HCC): BMS-986249 1200 mg Q8W + Nivolumab 480 mg IV Q4W",
        "value": 2.99,
        "unit": "Months",
        "ci_lower": 1.77,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG015",
        "arm_title": "Part 2B: Cohort 2 (Metastatic CRPC): BMS-986249 1200 mg Q8W + Nivolumab 480 mg IV Q4W",
        "value": 5.62,
        "unit": "Months",
        "ci_lower": 3.68,
        "ci_upper": 8.28,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG016",
        "arm_title": "Part 2B: Cohort 3 (Unresectable TNBC): BMS-986249 1200 mg Q8W + Nivolumab 480 mg IV Q4W",
        "value": 3.35,
        "unit": "Months",
        "ci_lower": 1.84,
        "ci_upper": 5.36,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "BMS-986249"
      ],
      "OG001": [
        "BMS-986249"
      ],
      "OG002": [
        "BMS-986249"
      ],
      "OG003": [
        "BMS-986249"
      ],
      "OG004": [
        "BMS-986249"
      ],
      "OG005": [
        "BMS-986249",
        "Nivolumab"
      ],
      "OG006": [
        "BMS-986249",
        "Nivolumab"
      ],
      "OG007": [
        "BMS-986249",
        "Nivolumab"
      ],
      "OG008": [
        "BMS-986249",
        "Nivolumab"
      ],
      "OG009": [
        "BMS-986249",
        "Nivolumab"
      ],
      "OG010": [
        "BMS-986249",
        "Nivolumab"
      ],
      "OG011": [
        "BMS-986249",
        "Nivolumab"
      ],
      "OG012": [
        "Ipilimumab",
        "Nivolumab"
      ],
      "OG013": [
        "BMS-986249",
        "Nivolumab"
      ],
      "OG014": [
        "BMS-986249",
        "Nivolumab"
      ],
      "OG015": [
        "BMS-986249",
        "Nivolumab"
      ],
      "OG016": [
        "BMS-986249",
        "Nivolumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER",
      "OG002": "OTHER",
      "OG003": "OTHER",
      "OG004": "OTHER",
      "OG005": "OTHER",
      "OG006": "OTHER",
      "OG007": "OTHER",
      "OG008": "OTHER",
      "OG009": "OTHER",
      "OG010": "OTHER",
      "OG011": "OTHER",
      "OG012": "IO",
      "OG013": "OTHER",
      "OG014": "OTHER",
      "OG015": "OTHER",
      "OG016": "OTHER"
    }
  },
  {
    "nct_id": "NCT03365882",
    "brief_title": "S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2017-11-27",
    "completion_date": "2022-11-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SWOG Cancer Research Network",
    "url": "https://clinicaltrials.gov/study/NCT03365882",
    "cancer_types": [
      "COAD",
      "READ"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "IHC 3+ or 2+ and HER2 gene amplification by in situ hybridization (HER2/CEP17 ratio >= 2.0)"
      },
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "No activating mutations in exon 2 (codons 12,13), exon 3 (codons 59,61) or exon 4 (codons 117,146)"
      },
      {
        "target": "NRAS",
        "status": "NEGATIVE",
        "details": "No activating mutations in exon 2 (codons 12,13), exon 3 (codons 59,61) or exon 4 (codons 117,146)"
      },
      {
        "target": "BRAF",
        "status": "NEGATIVE",
        "details": "No V600E mutation (BRAF exon 15)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Trastuzumab + Pertuzumab",
        "value": 4.7,
        "unit": "Months",
        "ci_lower": 1.9,
        "ci_upper": 7.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cetuximab + Irinotecan",
        "value": 3.7,
        "unit": "Months",
        "ci_lower": 1.6,
        "ci_upper": 6.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Trastuzumab",
        "Pertuzumab"
      ],
      "OG001": [
        "Cetuximab",
        "Irinotecan Hydrochloride"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00636610",
    "brief_title": "A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2008-05",
    "completion_date": "2010-12",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Genentech, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT00636610",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Vismodegib 150 mg",
        "value": 9.3,
        "unit": "Months",
        "ci_lower": 7.98,
        "ci_upper": 10.51,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo to Vismodegib",
        "value": 10.1,
        "unit": "Months",
        "ci_lower": 9.43,
        "ci_upper": 11.33,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Vismodegib 150 mg",
        "Modified FOLFOX"
      ],
      "OG001": [
        "Modified FOLFOX"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00643097",
    "brief_title": "Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",
    "status": "COMPLETED",
    "start_date": "2007-09",
    "completion_date": "2012-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "John Sampson",
    "url": "https://clinicaltrials.gov/study/NCT00643097",
    "cancer_types": [
      "GBM"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "EGFRvIII (EGFR variant III) detected by immunohistochemistry, PCR, or related molecular techniques"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm I (ACTIVATE)",
        "value": 14.2,
        "unit": "months",
        "ci_lower": 9.9,
        "ci_upper": 17.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm II (ACT II STD)",
        "value": 12.1,
        "unit": "months",
        "ci_lower": 10.5,
        "ci_upper": 23.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Arm III (ACT II DI)",
        "value": 11.6,
        "unit": "months",
        "ci_lower": 8.1,
        "ci_upper": 12.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "PEP-3 vaccine",
        "sargramostim"
      ],
      "OG001": [
        "PEP-3 vaccine",
        "sargramostim"
      ],
      "OG002": [
        "PEP-3 vaccine",
        "sargramostim"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER",
      "OG002": "OTHER"
    }
  },
  {
    "nct_id": "NCT03374488",
    "brief_title": "Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma",
    "status": "COMPLETED",
    "start_date": "2017-12-22",
    "completion_date": "2018-07-27",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Incyte Corporation",
    "url": "https://clinicaltrials.gov/study/NCT03374488",
    "cancer_types": [
      "BLCA"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Archival tumor tissue or newly obtained core/excisional biopsy for PD-L1 analysis (no threshold specified)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab 200 mg + Epacadostat 100 mg BID",
        "value": 21.4,
        "unit": "percentage of participants",
        "ci_lower": 12.49,
        "ci_upper": 43.26,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Pembrolizumab 200 mg + Placebo BID",
        "value": 9.5,
        "unit": "percentage of participants",
        "ci_lower": 3.11,
        "ci_upper": 26.06,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Epacadostat"
      ],
      "OG001": [
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "IO"
    }
  },
  {
    "nct_id": "NCT03400332",
    "brief_title": "A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2018-02-12",
    "completion_date": "2024-04-26",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT03400332",
    "cancer_types": [
      "SKCM",
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Part 2 Arm A: BMS+Nivo+Ipi",
        "value": 14.5,
        "unit": "Percentage of Participants",
        "ci_lower": 6.9,
        "ci_upper": 25.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Part 2 Arm B: Placebo+Nivo+Ipi",
        "value": 11.7,
        "unit": "Percentage of Participants",
        "ci_lower": 4.8,
        "ci_upper": 22.6,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "BMS-986253",
        "Nivolumab"
      ],
      "OG001": [
        "BMS-986253",
        "Nivolumab"
      ],
      "OG002": [
        "BMS-986253",
        "Nivolumab"
      ],
      "OG003": [
        "BMS-986253",
        "Nivolumab"
      ],
      "OG004": [
        "BMS-986253",
        "Nivolumab"
      ],
      "OG005": [
        "BMS-986253",
        "Nivolumab"
      ],
      "OG006": [
        "BMS-986253",
        "Nivolumab",
        "Ipilimumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted",
      "OG002": "Combo_IO_Targeted",
      "OG003": "Combo_IO_Targeted",
      "OG004": "Combo_IO_Targeted",
      "OG005": "Combo_IO_Targeted",
      "OG006": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT00639509",
    "brief_title": "IMC-A12 in Treating Patients With Advanced Liver Cancer",
    "status": "COMPLETED",
    "start_date": "2008-03",
    "completion_date": "2011-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT00639509",
    "cancer_types": [
      "LIHC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Monoclonal Antibody Therapy)",
        "value": 30.0,
        "unit": "percentage of participants",
        "ci_lower": 13.0,
        "ci_upper": 48.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (Monoclonal Antibody Therapy)",
        "value": 0.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "cixutumumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00617734",
    "brief_title": "Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck",
    "status": "COMPLETED",
    "start_date": "2008-03",
    "completion_date": "2012-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00617734",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "IMC-A12 (Cixutumumab)",
        "value": 1.9,
        "unit": "months",
        "ci_lower": 1.6,
        "ci_upper": 1.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "IMC-A12 (Cixutumumab) + Cetuximab",
        "value": 2.0,
        "unit": "months",
        "ci_lower": 1.8,
        "ci_upper": 3.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "IMC-A12 (Cixutumumab)",
        "value": 5.3,
        "unit": "months",
        "ci_lower": 4.3,
        "ci_upper": 8.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "IMC-A12 (Cixutumumab) + Cetuximab",
        "value": 5.5,
        "unit": "months",
        "ci_lower": 4.3,
        "ci_upper": 7.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "IMC-A12 (cixutumumab)"
      ],
      "OG001": [
        "IMC-A12 (cixutumumab)",
        "cetuximab (Erbitux \u00ae)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00628251",
    "brief_title": "Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer",
    "status": "COMPLETED",
    "start_date": "2008-07-30",
    "completion_date": "2009-09-15",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT00628251",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "BRCA1",
        "status": "POSITIVE",
        "details": "Positive BRCA1 status required"
      },
      {
        "target": "BRCA2",
        "status": "POSITIVE",
        "details": "Positive BRCA2 status required"
      }
    ],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Olaparib 200 mg bd",
        "value": 19.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Olaparib 400 mg bd",
        "value": 20.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Liposomal Doxorubicin",
        "value": 20.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Olaparib 200 mg bd",
        "value": 9.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Olaparib 400 mg bd",
        "value": 11.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Liposomal Doxorubicin",
        "value": 13.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Olaparib"
      ],
      "OG001": [
        "Olaparib"
      ],
      "OG002": [
        "Liposomal Doxorubicin"
      ],
      "OG003": [
        "Liposomal Doxorubicin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Chemo",
      "OG003": "Chemo"
    }
  },
  {
    "nct_id": "NCT00642018",
    "brief_title": "A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer",
    "status": "COMPLETED",
    "start_date": "2008-03",
    "completion_date": "2011-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00642018",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [
      {
        "target": "PSA",
        "status": "ANY",
        "details": "Documented two sequential increases in Prostate Specific Antigen (PSA) over a prior reference value to define hormone-refractory disease."
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Docetaxel",
        "value": 9.0,
        "unit": "months",
        "ci_lower": 7.0,
        "ci_upper": 10.09,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "LY2181308 + Docetaxel",
        "value": 8.64,
        "unit": "months",
        "ci_lower": 7.39,
        "ci_upper": 10.45,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "docetaxel",
        "Prednisone"
      ],
      "OG001": [
        "LY2181308 sodium",
        "docetaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT00623233",
    "brief_title": "Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2008-03",
    "completion_date": "2011-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00623233",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 gene amplification/overexpression"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Gemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg",
        "value": 4.8,
        "unit": "months",
        "ci_lower": 3.42,
        "ci_upper": 7.56,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Gemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg",
        "value": 68.68,
        "unit": "percentage of participants",
        "ci_lower": 54.05,
        "ci_upper": 79.5,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Gemcitabine",
        "Bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03382600",
    "brief_title": "Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659)",
    "status": "COMPLETED",
    "start_date": "2018-03-26",
    "completion_date": "2021-05-30",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT03382600",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "POSITIVE",
        "details": "PD-L1 positive by immunohistochemistry (IHC) at a central laboratory"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-positive patients are excluded (must not be HER2-positive)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1)",
        "value": 72.2,
        "unit": "Percentage of participants",
        "ci_lower": 58.4,
        "ci_upper": 83.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Pembrolizumab + Cisplatin +TS-1 (Cohort 2)",
        "value": 80.4,
        "unit": "Percentage of participants",
        "ci_lower": 66.1,
        "ci_upper": 90.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1)",
        "value": 9.4,
        "unit": "months",
        "ci_lower": 6.6,
        "ci_upper": 12.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Pembrolizumab + Cisplatin +TS-1 (Cohort 2)",
        "value": 8.3,
        "unit": "months",
        "ci_lower": 5.8,
        "ci_upper": 15.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1)",
        "value": 16.9,
        "unit": "months",
        "ci_lower": 13.4,
        "ci_upper": 20.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Pembrolizumab + Cisplatin +TS-1 (Cohort 2)",
        "value": 17.1,
        "unit": "months",
        "ci_lower": 12.6,
        "ci_upper": 23.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Oxaliplatin",
        "TS-1"
      ],
      "OG001": [
        "Pembrolizumab",
        "Cisplatin",
        "TS-1"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT03375320",
    "brief_title": "Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2018-10-26",
    "completion_date": "2023-08-23",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT03375320",
    "cancer_types": [
      "PAAD",
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm Ia (Cabozantinib S-malate, Extra-pancreatic NET Cohort [epNET])",
        "value": 8.4,
        "unit": "months",
        "ci_lower": 7.6,
        "ci_upper": 12.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm IIa (Placebo, Extra-pancreatic NET Cohort [epNET])",
        "value": 3.9,
        "unit": "months",
        "ci_lower": 3.0,
        "ci_upper": 5.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Arm Ib (Cabozantinib S-malate, Pancreatic NET Cohort [pNET])",
        "value": 13.8,
        "unit": "months",
        "ci_lower": 9.2,
        "ci_upper": 18.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Arm IIb (Placebo, Pancreatic NET Cohort [pNET])",
        "value": 4.4,
        "unit": "months",
        "ci_lower": 3.0,
        "ci_upper": 5.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm Ia (Cabozantinib S-malate, Extra-pancreatic NET Cohort [epNET])",
        "value": 21.9,
        "unit": "months",
        "ci_lower": 18.8,
        "ci_upper": 30.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm IIa (Placebo, Extra-pancreatic NET Cohort [epNET])",
        "value": 19.7,
        "unit": "months",
        "ci_lower": 14.2,
        "ci_upper": 30.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Arm Ib (Cabozantinib S-malate, Pancreatic NET Cohort [pNET])",
        "value": 40.0,
        "unit": "months",
        "ci_lower": 31.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Arm IIb (Placebo, Pancreatic NET Cohort [pNET])",
        "value": 31.1,
        "unit": "months",
        "ci_lower": 23.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cabozantinib S-malate"
      ],
      "OG002": [
        "Cabozantinib S-malate"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Placebo",
      "OG002": "TKI",
      "OG003": "Placebo"
    }
  },
  {
    "nct_id": "NCT00652366",
    "brief_title": "A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer",
    "status": "COMPLETED",
    "start_date": "2008-05",
    "completion_date": "2012-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT00652366",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "G+E Standard Dose: Rash Grade < 2",
        "value": 8.4,
        "unit": "months",
        "ci_lower": 6.4,
        "ci_upper": 10.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "G+E Escalating Dose: Rash Grade < 2",
        "value": 7.0,
        "unit": "months",
        "ci_lower": 5.8,
        "ci_upper": 8.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Gemcitabine",
        "Erlotinib, standard dose"
      ],
      "OG001": [
        "Gemcitabine",
        "Erlotinib, escalating dose"
      ],
      "OG002": [
        "Gemcitabine",
        "Erlotinib, escalating dose"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Combo_TKI_Chemo",
      "OG002": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT00651742",
    "brief_title": "Phase 2 Study of S-1 in Advanced or Metastatic Pancreatic Cancer",
    "status": "COMPLETED",
    "start_date": "2006-01-09",
    "completion_date": "2008-07-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Taiho Oncology, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT00651742",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "S-1 30 mg/m^2",
        "value": 4.0,
        "unit": "percentage of participants",
        "ci_lower": 0.1,
        "ci_upper": 20.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "S-1 30 mg/m^2",
        "value": 9.5,
        "unit": "percentage of participants",
        "ci_lower": 1.2,
        "ci_upper": 30.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "S-1 30 mg/m^2",
        "value": 3.5,
        "unit": "months",
        "ci_lower": 1.6,
        "ci_upper": 5.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "S-1 30 mg/m^2",
        "value": 3.5,
        "unit": "months",
        "ci_lower": 2.5,
        "ci_upper": 5.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "S-1 30 mg/m^2",
        "value": 9.1,
        "unit": "months",
        "ci_lower": 4.7,
        "ci_upper": 11.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "S-1"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo"
    }
  },
  {
    "nct_id": "NCT00626106",
    "brief_title": "QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2008-03-27",
    "completion_date": "2010-05-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "NantCell, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT00626106",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HR",
        "status": "POSITIVE",
        "details": "hormone receptor positive (ER and/or PR)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A: AMG 479 12 mg/kg IV Q2W + Endocrine Therapy",
        "value": 3.9,
        "unit": "Months",
        "ci_lower": 3.6,
        "ci_upper": 5.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Placebo IV Q2W + Endocrine Therapy",
        "value": 5.7,
        "unit": "Months",
        "ci_lower": 4.4,
        "ci_upper": 7.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG000",
        "arm_title": "Arm A: AMG 479 12 mg/kg IV Q2W + Endocrine Therapy",
        "value": 17.0,
        "unit": "Weeks",
        "ci_lower": 15.9,
        "ci_upper": 23.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG001",
        "arm_title": "Arm B: Placebo IV Q2W + Endocrine Therapy",
        "value": 24.6,
        "unit": "Weeks",
        "ci_lower": 19.0,
        "ci_upper": 32.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG000",
        "arm_title": "Arm A: AMG 479 12 mg/kg IV Q2W + Endocrine Therapy",
        "value": 15.8,
        "unit": "Weeks",
        "ci_lower": 14.0,
        "ci_upper": 20.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG001",
        "arm_title": "Arm B: Placebo IV Q2W + Endocrine Therapy",
        "value": 21.6,
        "unit": "Weeks",
        "ci_lower": 18.6,
        "ci_upper": 31.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A: AMG 479 12 mg/kg IV Q2W + Endocrine Therapy",
        "value": 96.6,
        "unit": "Weeks",
        "ci_lower": 82.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Placebo IV Q2W + Endocrine Therapy",
        "value": null,
        "unit": "Weeks",
        "ci_lower": 82.6,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "AMG 479"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT03377023",
    "brief_title": "Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2018-02-02",
    "completion_date": "2023-11-28",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
    "url": "https://clinicaltrials.gov/study/NCT03377023",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "non-resistant EGFR mutations (allowed if patient received prior FDA\u2011approved targeted therapy)"
      },
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "T790M mutation (EGFR T790M)"
      },
      {
        "target": "ALK",
        "status": "ANY",
        "details": "ALK rearrangement (allowed if patient received prior FDA\u2011approved targeted therapy)"
      },
      {
        "target": "ROS1",
        "status": "ANY",
        "details": "ROS rearrangement (ROS1) (allowed if patient received prior FDA\u2011approved targeted therapy)"
      },
      {
        "target": "BRAF",
        "status": "ANY",
        "details": "BRAF V600E mutation (allowed if patient received prior FDA\u2011approved targeted therapy)"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 2 - Arm A",
        "value": 40.9,
        "unit": "percentage of participants",
        "ci_lower": 21.5,
        "ci_upper": 63.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Phase 2 - Arm B",
        "value": 21.4,
        "unit": "percentage of participants",
        "ci_lower": 9.03,
        "ci_upper": 41.5,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab",
        "Ipilimumab",
        "Nintedanib"
      ],
      "OG001": [
        "Nivolumab",
        "Ipilimumab",
        "Nintedanib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_IO",
      "OG001": "Combo_TKI_IO"
    }
  },
  {
    "nct_id": "NCT03396926",
    "brief_title": "Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2018-04-18",
    "completion_date": "2024-01-30",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "University of California, San Francisco",
    "url": "https://clinicaltrials.gov/study/NCT03396926",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "MSI",
        "status": "NEGATIVE",
        "details": "MSS defined as 0-1 allelic shifts among 3-5 tumor microsatellite loci using a PCR-based assay"
      },
      {
        "target": "MMR",
        "status": "POSITIVE",
        "details": "pMMR defined as presence of MLH1, MSH2, MSH6, and PMS2 protein expression by immunohistochemistry"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "ASaT Population (Pembrolizumab, Bevacizumab, Capecitabine)",
        "value": 5.0,
        "unit": "percentage of participants",
        "ci_lower": 0.6,
        "ci_upper": 16.9,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Bevacizumab",
        "Capecitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT03394027",
    "brief_title": "ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma",
    "status": "COMPLETED",
    "start_date": "2018-01-17",
    "completion_date": "2021-03-18",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT03394027",
    "cancer_types": [
      "BRCA",
      "UCEC"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": ">=10% by IHC (HR+ cohort requirement)"
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": ">=10% by IHC (HR+ cohort requirement)"
      },
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "<10% by IHC (TNBC cohort requirement)"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "<10% by IHC (TNBC cohort requirement)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "Per ASCO-CAP guidelines: IHC 0 or 1+ or ISH negative (single\u2011probe avg HER2 <4.0 signals/cell OR HER2/CEP17 ratio <2.0 with avg HER2 <4.0); required for HR+ and TNBC cohorts"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1-Hormone Receptor (HR) + Breast Cancer (Male and Female)",
        "value": 1.9,
        "unit": "Months",
        "ci_lower": 0.6,
        "ci_upper": 4.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort 2-Triple Negative Breast Cancer (Male and Female)",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "ONC201"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER",
      "OG002": "OTHER",
      "OG003": "OTHER",
      "OG004": "OTHER",
      "OG005": "OTHER",
      "OG006": "OTHER",
      "OG007": "OTHER",
      "OG008": "OTHER",
      "OG009": "OTHER",
      "OG010": "OTHER",
      "OG011": "OTHER",
      "OG012": "OTHER",
      "OG013": "OTHER",
      "OG014": "OTHER"
    }
  },
  {
    "nct_id": "NCT03402841",
    "brief_title": "Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients",
    "status": "COMPLETED",
    "start_date": "2018-01-30",
    "completion_date": "2020-10-02",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT03402841",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "BRCA",
        "status": "NEGATIVE",
        "details": "germline BRCA1/2 \u2014 no deleterious or suspected deleterious mutation (non-gBRCAm)"
      }
    ],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "MAINTENANCE",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Olaparib",
        "value": 9.2,
        "unit": "months",
        "ci_lower": 7.6,
        "ci_upper": 10.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Olaparib",
        "value": 32.7,
        "unit": "months",
        "ci_lower": 29.5,
        "ci_upper": 35.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Olaparib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03390504",
    "brief_title": "A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2018-03-23",
    "completion_date": "2024-04-15",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Janssen Research & Development, LLC",
    "url": "https://clinicaltrials.gov/study/NCT03390504",
    "cancer_types": [
      "BLCA"
    ],
    "biomarkers": [
      {
        "target": "FGFR",
        "status": "POSITIVE",
        "details": "Selected fibroblast growth factor receptor (FGFR) gene aberrations; participants must meet molecular eligibility criteria. Prior FGFR inhibitor exposure is excluded."
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1: Arm 1A: Erdafitinib 8 mg/9 mg",
        "value": 12.06,
        "unit": "Months",
        "ci_lower": 10.25,
        "ci_upper": 16.36,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cohort 1: Arm 1B: Chemotherapy (Vinflunine 320 mg/m^2 or Docetaxel 75 mg/m^2)",
        "value": 8.74,
        "unit": "Months",
        "ci_lower": 6.67,
        "ci_upper": 10.71,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Cohort 2: Arm 2A: Erdafitinib 8 mg/ 9 mg",
        "value": 10.91,
        "unit": "Months",
        "ci_lower": 9.23,
        "ci_upper": 12.58,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Cohort 2: Arm 2B: Pembrolizumab 200 mg",
        "value": 11.07,
        "unit": "Months",
        "ci_lower": 9.72,
        "ci_upper": 13.63,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1: Arm 1A: Erdafitinib 8 mg/9 mg",
        "value": 5.39,
        "unit": "Months",
        "ci_lower": 4.37,
        "ci_upper": 5.62,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort 1: Arm 1B: Chemotherapy (Vinflunine 320 mg/m^2 or Docetaxel 75 mg/m^2)",
        "value": 2.73,
        "unit": "Months",
        "ci_lower": 2.1,
        "ci_upper": 4.17,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Cohort 2: Arm 2A: Erdafitinib 8 mg/ 9 mg",
        "value": 4.44,
        "unit": "Months",
        "ci_lower": 4.07,
        "ci_upper": 5.49,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Cohort 2: Arm 2B: Pembrolizumab 200 mg",
        "value": 2.69,
        "unit": "Months",
        "ci_lower": 1.64,
        "ci_upper": 3.02,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Erdafitinib"
      ],
      "OG001": [
        "Vinflunine",
        "Docetaxel"
      ],
      "OG002": [
        "Erdafitinib"
      ],
      "OG003": [
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Chemo",
      "OG002": "TKI",
      "OG003": "IO"
    }
  },
  {
    "nct_id": "NCT00630032",
    "brief_title": "Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2007-09",
    "completion_date": "2017-06",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "UNICANCER",
    "url": "https://clinicaltrials.gov/study/NCT00630032",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 negativity defined as IHC 0-1+ OR IHC 2+ with FISH or CISH negative. HER2 overexpression (IHC 3+ OR IHC 2+ with FISH/CISH positive) is excluded."
      },
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "ER <10% by IHC required for triple-negative tumors (required for node-negative patients; one eligible option for node-positive patients is triple-negative)."
      },
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Allowed alternative for node-positive patients in the \u2018double-negative\u2019 profile (HER2 negative, PR negative, ER positive)."
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "PR <10% by IHC required for triple-negative tumors and required in the 'double-negative' (node-positive) profile (HER2 negative, PR negative, ER positive)."
      }
    ],
    "cancer_stages": [
      "II",
      "III"
    ],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Docetaxel",
        "value": 78.97,
        "unit": "Percentage of participants",
        "ci_lower": 74.53,
        "ci_upper": 82.73,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Ixabepilone",
        "value": 83.37,
        "unit": "Percentage of participants",
        "ci_lower": 79.06,
        "ci_upper": 86.87,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "fluorouracil",
        "epirubicin hydrochloride",
        "cyclophosphamide",
        "Docetaxel"
      ],
      "OG001": [
        "fluorouracil",
        "epirubicin hydrochloride",
        "cyclophosphamide",
        "ixabepilone"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT03395080",
    "brief_title": "A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma",
    "status": "COMPLETED",
    "start_date": "2018-03-05",
    "completion_date": "2020-09-09",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Leap Therapeutics, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT03395080",
    "cancer_types": [
      "UCEC",
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "DKN-01 Monotherapy in Recurrent EEC",
        "value": 2.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "DKN-01 + Paclitaxel in Recurrent EEC",
        "value": 0.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "DKN-01 Monotherapy in Recurrent EOC",
        "value": 0.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "DKN-01 + Paclitaxel in Recurrent EOC",
        "value": 0.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG000",
        "arm_title": "DKN-01 Monotherapy in Recurrent EEC",
        "value": 11.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG001",
        "arm_title": "DKN-01 + Paclitaxel in Recurrent EEC",
        "value": 12.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG002",
        "arm_title": "DKN-01 Monotherapy in Recurrent EOC",
        "value": 6.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG003",
        "arm_title": "DKN-01 + Paclitaxel in Recurrent EOC",
        "value": 13.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG004",
        "arm_title": "DKN-01 300mg Monotherapy in Carcinosarcoma",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG005",
        "arm_title": "DKN-01 600mg Monotherapy in Carcinosarcoma",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG006",
        "arm_title": "DKN-01 300mg + Paclitaxel in Carcinosarcoma",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG007",
        "arm_title": "DKN-01 600mg + Paclitaxel in Carcinosarcoma",
        "value": 5.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "DKN-01 Monotherapy in Recurrent EEC",
        "value": 12.2,
        "unit": "months",
        "ci_lower": 4.6,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "DKN-01 + Paclitaxel in Recurrent EEC",
        "value": 10.1,
        "unit": "months",
        "ci_lower": 6.5,
        "ci_upper": 13.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "DKN-01 Monotherapy in Recurrent EOC",
        "value": 10.8,
        "unit": "months",
        "ci_lower": 5.7,
        "ci_upper": 17.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "DKN-01 + Paclitaxel in Recurrent EOC",
        "value": 11.9,
        "unit": "months",
        "ci_lower": 6.6,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG004",
        "arm_title": "DKN-01 300mg Monotherapy in Carcinosarcoma",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG005",
        "arm_title": "DKN-01 600mg Monotherapy in Carcinosarcoma",
        "value": 8.4,
        "unit": "months",
        "ci_lower": 1.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG006",
        "arm_title": "DKN-01 300mg + Paclitaxel in Carcinosarcoma",
        "value": 7.3,
        "unit": "months",
        "ci_lower": 5.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG007",
        "arm_title": "DKN-01 600mg + Paclitaxel in Carcinosarcoma",
        "value": 5.7,
        "unit": "months",
        "ci_lower": 1.6,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "DKN-01 Monotherapy in Recurrent EEC",
        "value": 1.8,
        "unit": "months",
        "ci_lower": 1.7,
        "ci_upper": 5.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "DKN-01 + Paclitaxel in Recurrent EEC",
        "value": 3.8,
        "unit": "months",
        "ci_lower": 1.8,
        "ci_upper": 5.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "DKN-01 Monotherapy in Recurrent EOC",
        "value": 2.1,
        "unit": "months",
        "ci_lower": 1.6,
        "ci_upper": 3.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "DKN-01 + Paclitaxel in Recurrent EOC",
        "value": 3.6,
        "unit": "months",
        "ci_lower": 1.8,
        "ci_upper": 7.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "DKN-01 300mg Monotherapy in Carcinosarcoma",
        "value": 11.6,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG005",
        "arm_title": "DKN-01 600mg Monotherapy in Carcinosarcoma",
        "value": 1.6,
        "unit": "months",
        "ci_lower": 0.5,
        "ci_upper": 7.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG006",
        "arm_title": "DKN-01 300mg + Paclitaxel in Carcinosarcoma",
        "value": 2.0,
        "unit": "months",
        "ci_lower": 1.8,
        "ci_upper": 5.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG007",
        "arm_title": "DKN-01 600mg + Paclitaxel in Carcinosarcoma",
        "value": 1.9,
        "unit": "months",
        "ci_lower": 0.9,
        "ci_upper": 4.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG000",
        "arm_title": "DKN-01 Monotherapy in Recurrent EEC",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG006",
        "arm_title": "DKN-01 300mg + Paclitaxel in Carcinosarcoma",
        "value": 3.7,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG007",
        "arm_title": "DKN-01 600mg + Paclitaxel in Carcinosarcoma",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "300mg DKN-01"
      ],
      "OG001": [
        "300mg DKN-01",
        "Paclitaxel"
      ],
      "OG002": [
        "300mg DKN-01"
      ],
      "OG003": [
        "300mg DKN-01",
        "Paclitaxel"
      ],
      "OG004": [
        "300mg DKN-01"
      ],
      "OG005": [
        "600mg DKN-01"
      ],
      "OG006": [
        "300mg DKN-01",
        "Paclitaxel"
      ],
      "OG007": [
        "600mg DKN-01",
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Targeted_Other",
      "OG003": "Combo_Chemo_Targeted",
      "OG004": "Targeted_Other",
      "OG005": "Targeted_Other",
      "OG006": "Combo_Chemo_Targeted",
      "OG007": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03427814",
    "brief_title": "Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer",
    "status": "COMPLETED",
    "start_date": "2018-07-03",
    "completion_date": "2020-06-18",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "BeiGene",
    "url": "https://clinicaltrials.gov/study/NCT03427814",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "MAINTENANCE",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pamiparib",
        "value": 3.7,
        "unit": "Months",
        "ci_lower": 1.94,
        "ci_upper": 5.26,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 2.1,
        "unit": "Months",
        "ci_lower": 1.87,
        "ci_upper": 3.75,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pamiparib",
        "value": 10.2,
        "unit": "Months",
        "ci_lower": 8.71,
        "ci_upper": 16.33,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 12.0,
        "unit": "Months",
        "ci_lower": 8.21,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pamiparib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT00653939",
    "brief_title": "A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2008-03",
    "completion_date": "2011-07",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Mateon Therapeutics",
    "url": "https://clinicaltrials.gov/study/NCT00653939",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm 1: Chemotherapy+Bevacizumab",
        "value": 9.3,
        "unit": "months",
        "ci_lower": 4.4,
        "ci_upper": 11.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm 2: Active Comparator+Fosbretabulin",
        "value": 8.6,
        "unit": "months",
        "ci_lower": 5.0,
        "ci_upper": 10.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Carboplatin",
        "Paclitaxel",
        "Bevacizumab"
      ],
      "OG001": [
        "Carboplatin",
        "Paclitaxel",
        "Bevacizumab",
        "Fosbretabulin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00668863",
    "brief_title": "Study Of Sunitinib With FOLFIRI In Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2008-05",
    "completion_date": "2010-09",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT00668863",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI",
        "value": 28.9,
        "unit": "weeks",
        "ci_lower": 20.3,
        "ci_upper": 40.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI",
        "value": null,
        "unit": "weeks",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Sunitinib",
        "FOLFIRI"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT03431350",
    "brief_title": "A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2018-03-02",
    "completion_date": "2021-08-31",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Janssen Research & Development, LLC",
    "url": "https://clinicaltrials.gov/study/NCT03431350",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Combination 1: Part 2 (Dose Expansion): Cohort 1A: BM+: Niraparib 200 mg + Cetrelimab 480 mg",
        "value": 23.8,
        "unit": "Percentage of participants",
        "ci_lower": 9.9,
        "ci_upper": 43.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Combination 1: Part 2 (Dose Expansion): Cohort 1B: BM-: Niraparib 200 mg + Cetrelimab 480 mg",
        "value": 9.1,
        "unit": "Percentage of participants",
        "ci_lower": 0.5,
        "ci_upper": 36.4,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Niraparib 200 mg",
        "Cetrelimab 240 mg"
      ],
      "OG001": [
        "Niraparib 200 mg",
        "Cetrelimab 480 mg"
      ],
      "OG002": [
        "Niraparib 200 mg",
        "Abiraterone acetate 1000 mg",
        "Prednisone 5 mg"
      ],
      "OG003": [
        "Niraparib 200 mg",
        "Abiraterone acetate 1000 mg",
        "Prednisone 5 mg"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03444376",
    "brief_title": "The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer",
    "status": "COMPLETED",
    "start_date": "2018-06-19",
    "completion_date": "2022-04-29",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Genexine, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT03444376",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "HPV",
        "status": "POSITIVE",
        "details": "HPV-16 or HPV-18 positive (HPV-positive cervical cancer)"
      },
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Baseline tumor tissue required for PD-L1 staining; PD-L1 positivity not required for eligibility"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "GX-188E, KEYTRUDA\u00ae",
        "value": 41.4,
        "unit": "percentage of responders",
        "ci_lower": 25.89,
        "ci_upper": 100.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "GX-188E, KEYTRUDA\u00ae",
        "value": 35.0,
        "unit": "percentage of responders",
        "ci_lower": 22.93,
        "ci_upper": 47.07,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "GX-188E",
        "KEYTRUDA\u00ae"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO"
    }
  },
  {
    "nct_id": "NCT03425643",
    "brief_title": "Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2018-04-24",
    "completion_date": "2023-07-10",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT03425643",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "FFPE tumor tissue sample (or unstained slides) required for central PD-L1 testing"
      }
    ],
    "cancer_stages": [
      "II",
      "IIIA",
      "IIIB"
    ],
    "line_of_therapy": "NEOADJUVANT",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "NAC + Neoadjuvant/Adjuvant Pembrolizumab",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "NAC + Neoadjuvant/Adjuvant Placebo",
        "value": 52.4,
        "unit": "Months",
        "ci_lower": 45.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Cisplatin",
        "Gemcitabine",
        "Pemetrexed"
      ],
      "OG001": [
        "Cisplatin",
        "Gemcitabine",
        "Pemetrexed"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00662129",
    "brief_title": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2008-11",
    "completion_date": "2010-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Alliance for Clinical Trials in Oncology",
    "url": "https://clinicaltrials.gov/study/NCT00662129",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER-2/neu positive tumors must have received prior treatment with trastuzumab or have a contraindication to trastuzumab"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Paclitaxel + Gemcitabine + Bevacizumab",
        "value": 0.792,
        "unit": "proportion of patients progression-free",
        "ci_lower": 0.647,
        "ci_upper": 0.882,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Paclitaxel + Gemcitabine + Bevacizumab",
        "value": 24.4,
        "unit": "months",
        "ci_lower": 18.2,
        "ci_upper": 29.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "paclitaxel albumin-stabilized nanoparticle formulation",
        "gemcitabine hydrochloride",
        "bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03417895",
    "brief_title": "SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy",
    "status": "COMPLETED",
    "start_date": "2018-04-20",
    "completion_date": "2021-08-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Jiangsu HengRui Medicine Co., Ltd.",
    "url": "https://clinicaltrials.gov/study/NCT03417895",
    "cancer_types": [
      "SCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "A(SHR-1210+Apatinib)",
        "value": 34.0,
        "unit": "percentage of number of people in FAS",
        "ci_lower": 20.9,
        "ci_upper": 49.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "B(SHR-1210+Apatinib)",
        "value": 33.3,
        "unit": "percentage of number of people in FAS",
        "ci_lower": 4.3,
        "ci_upper": 77.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "C(SHR-1210+Apatinib)",
        "value": 33.3,
        "unit": "percentage of number of people in FAS",
        "ci_lower": 4.3,
        "ci_upper": 77.7,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "SHR-1210",
        "Apatinib"
      ],
      "OG001": [
        "SHR-1210",
        "Apatinib"
      ],
      "OG002": [
        "SHR-1210",
        "Apatinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_IO",
      "OG001": "Combo_TKI_IO",
      "OG002": "Combo_TKI_IO"
    }
  },
  {
    "nct_id": "NCT00667862",
    "brief_title": "Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer",
    "status": "COMPLETED",
    "start_date": "2008-03-18",
    "completion_date": "2010-11-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT00667862",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [
      {
        "target": "PSA",
        "status": "ANY",
        "details": "Two documented increases in prostate-specific antigen (PSA) consistent with disease progression"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Panobinostat",
        "value": 11.4,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Panobinostat"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00653068",
    "brief_title": "Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System",
    "status": "COMPLETED",
    "start_date": "2009-02-10",
    "completion_date": "2016-09-27",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Children's Oncology Group",
    "url": "https://clinicaltrials.gov/study/NCT00653068",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "SMARCB1",
        "status": "POSITIVE",
        "details": "INI1 (SMARCB1) gene mutation \u2014 patients with tumors harboring INI1/SMARCB1 mutation are eligible even without typical AT/RT histology"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Stratum I",
        "value": 0.3401,
        "unit": "Estimated probability",
        "ci_lower": 0.2174,
        "ci_upper": 0.4666,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Stratum III",
        "value": 0.45,
        "unit": "Estimated probability",
        "ci_lower": 0.1267,
        "ci_upper": 0.7345,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Stratum I",
        "value": 0.3888,
        "unit": "Estimated Probability",
        "ci_lower": 0.2582,
        "ci_upper": 0.5173,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Stratum III",
        "value": 0.5486,
        "unit": "Estimated Probability",
        "ci_lower": 0.1873,
        "ci_upper": 0.8064,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {},
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT00655499",
    "brief_title": "Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2008-06",
    "completion_date": "2012-06",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "GERCOR - Multidisciplinary Oncology Cooperative Group",
    "url": "https://clinicaltrials.gov/study/NCT00655499",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "wild-type (no mutation) by allelic discrimination on tumor DNA"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Panitumumab Combined With Irinotecan",
        "value": 29.2,
        "unit": "percentage of patients",
        "ci_lower": 18.2,
        "ci_upper": 40.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Panitumumab Combined With Irinotecan",
        "value": 5.5,
        "unit": "percentage of participants",
        "ci_lower": 3.7,
        "ci_upper": 7.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Panitumumab Combined With Irinotecan",
        "value": 9.7,
        "unit": "percentage of participant",
        "ci_lower": 6.6,
        "ci_upper": 15.8,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Panitumumab",
        "Irinotecan hydrochloride"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00661609",
    "brief_title": "A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer",
    "status": "COMPLETED",
    "start_date": "2008-05",
    "completion_date": "2009-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT00661609",
    "cancer_types": [
      "BLCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IV",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "AZD4877",
        "value": 2.6,
        "unit": "Percengate of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "AZD4877",
        "value": 7.3,
        "unit": "Weeks",
        "ci_lower": 0.0,
        "ci_upper": 44.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "AZD4877",
        "value": 23.1,
        "unit": "Weeks",
        "ci_lower": 1.3,
        "ci_upper": 48.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "AZD4877"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00655850",
    "brief_title": "Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2008-03",
    "completion_date": "2015-09",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "University of Alabama at Birmingham",
    "url": "https://clinicaltrials.gov/study/NCT00655850",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Paclitaxel and Gemcitabine + Avastin",
        "value": 8.5,
        "unit": "months",
        "ci_lower": 5.0,
        "ci_upper": 10.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Paclitaxel and Gemcitabine + Avastin",
        "value": 25.5,
        "unit": "months",
        "ci_lower": 15.0,
        "ci_upper": 35.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Paclitaxel",
        "Gemcitabine",
        "Avastin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03414047",
    "brief_title": "A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer",
    "status": "COMPLETED",
    "start_date": "2018-04-10",
    "completion_date": "2019-06-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT03414047",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "BRCA1",
        "status": "ANY",
        "details": "Documented testing of BRCA1 required prior to treatment. Cohorts 1\u20132 require BRCA-negative; cohort 3 requires BRCA-positive (and prior PARP exposure)."
      },
      {
        "target": "BRCA2",
        "status": "ANY",
        "details": "Documented testing of BRCA2 required prior to treatment. Cohorts 1\u20132 require BRCA-negative; cohort 3 requires BRCA-positive (and prior PARP exposure)."
      }
    ],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Prexasertib Cohort 1",
        "value": 11.3,
        "unit": "Percentage of Participants",
        "ci_lower": 4.3,
        "ci_upper": 23.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Prexasertib Cohort 2",
        "value": 13.0,
        "unit": "Percentage of Participants",
        "ci_lower": 4.9,
        "ci_upper": 26.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Prexasertib Cohort 3",
        "value": 12.2,
        "unit": "Percentage of Participants",
        "ci_lower": 4.1,
        "ci_upper": 26.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Prexasertib Cohort 4",
        "value": 6.9,
        "unit": "Percentage of Participants",
        "ci_lower": 0.8,
        "ci_upper": 22.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Prexasertib Cohort 1",
        "value": 3.91,
        "unit": "Months",
        "ci_lower": 3.68,
        "ci_upper": 5.68,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Prexasertib Cohort 2",
        "value": 3.71,
        "unit": "Months",
        "ci_lower": 3.12,
        "ci_upper": 4.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Prexasertib Cohort 3",
        "value": 3.58,
        "unit": "Months",
        "ci_lower": 1.87,
        "ci_upper": 3.91,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Prexasertib Cohort 4",
        "value": 3.71,
        "unit": "Months",
        "ci_lower": 1.77,
        "ci_upper": 4.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Prexasertib Cohort 1",
        "value": 13.04,
        "unit": "Months",
        "ci_lower": 7.46,
        "ci_upper": 19.25,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Prexasertib Cohort 2",
        "value": 14.32,
        "unit": "Months",
        "ci_lower": 11.76,
        "ci_upper": 16.46,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Prexasertib Cohort 3",
        "value": 11.14,
        "unit": "Months",
        "ci_lower": 7.23,
        "ci_upper": 16.43,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Prexasertib Cohort 4",
        "value": 8.18,
        "unit": "Months",
        "ci_lower": 6.18,
        "ci_upper": 11.93,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Prexasertib"
      ],
      "OG001": [
        "Prexasertib"
      ],
      "OG002": [
        "Prexasertib"
      ],
      "OG003": [
        "Prexasertib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03414983",
    "brief_title": "An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread",
    "status": "COMPLETED",
    "start_date": "2018-02-20",
    "completion_date": "2021-02-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT03414983",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "HBV",
        "status": "NEGATIVE",
        "details": "Any positive test result indicating presence of virus is excluded"
      },
      {
        "target": "HCV",
        "status": "NEGATIVE",
        "details": "Any positive test result indicating presence of virus is excluded"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A: NIV+mFOLFOX+BEV",
        "value": 11.86,
        "unit": "Months",
        "ci_lower": 8.94,
        "ci_upper": 15.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B: mFOLFOX+BEV",
        "value": 11.93,
        "unit": "Months",
        "ci_lower": 10.09,
        "ci_upper": 12.19,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A: NIV+mFOLFOX+BEV",
        "value": 30.52,
        "unit": "Months",
        "ci_lower": 25.2,
        "ci_upper": 39.39,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B: mFOLFOX+BEV",
        "value": 31.77,
        "unit": "Months",
        "ci_lower": 24.38,
        "ci_upper": 38.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab",
        "Oxaliplatin",
        "Leucovorin",
        "Fluorouracil",
        "Bevacizumab"
      ],
      "OG001": [
        "Oxaliplatin",
        "Leucovorin",
        "Fluorouracil",
        "Bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00667251",
    "brief_title": "Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2008-10-07",
    "completion_date": "2012-08-01",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT00667251",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER2 overexpression by IHC 3+ (>30% invasive tumor cells), or IHC 2+ with FISH/CISH demonstrating HER2 gene amplification, or HER2 amplification by FISH/CISH (>6 copies per nucleus or HER2/Chr17 ratio >=2.2)"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Lapatinib (LTax/L)",
        "value": 8.97,
        "unit": "Months",
        "ci_lower": 0.3,
        "ci_upper": 32.69,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Trastuzumab (TTax/T)",
        "value": 11.3,
        "unit": "Months",
        "ci_lower": 0.3,
        "ci_upper": 38.54,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Lapatinib (LTax/L)",
        "value": 30.0,
        "unit": "Months",
        "ci_lower": 24.2,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Trastuzumab (TTax/T)",
        "value": 38.3,
        "unit": "Months",
        "ci_lower": 31.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "lapatinib ditosylate",
        "paclitaxel",
        "docetaxel"
      ],
      "OG001": [
        "trastuzumab",
        "paclitaxel"
      ],
      "OG002": [
        "trastuzumab"
      ],
      "OG003": [
        "trastuzumab",
        "paclitaxel",
        "docetaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Targeted_Other",
      "OG003": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00668148",
    "brief_title": "A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma",
    "status": "COMPLETED",
    "start_date": "2008-07",
    "completion_date": "2010-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00668148",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ewing's Sarcoma/PNET",
        "value": 27.3,
        "unit": "percentage of participants",
        "ci_lower": 8.5,
        "ci_upper": 50.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Rhabdomyosarcoma",
        "value": 12.5,
        "unit": "percentage of participants",
        "ci_lower": 2.1,
        "ci_upper": 32.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Leiomyosarcoma",
        "value": 25.4,
        "unit": "percentage of participants",
        "ci_lower": 8.4,
        "ci_upper": 46.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Adipocytic Sarcoma",
        "value": 50.0,
        "unit": "percentage of participants",
        "ci_lower": 32.9,
        "ci_upper": 64.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Synovial Sarcoma",
        "value": 21.4,
        "unit": "percentage of participants",
        "ci_lower": 5.2,
        "ci_upper": 44.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG005",
        "arm_title": "Total",
        "value": 31.9,
        "unit": "percentage of participants",
        "ci_lower": 23.0,
        "ci_upper": 41.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Ewing's Sarcoma/PNET",
        "value": 24.1,
        "unit": "weeks",
        "ci_lower": 12.6,
        "ci_upper": 37.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Rhabdomyosarcoma",
        "value": 23.6,
        "unit": "weeks",
        "ci_lower": 8.9,
        "ci_upper": 52.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Leiomyosarcoma",
        "value": null,
        "unit": "weeks",
        "ci_lower": 25.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Adipocytic Sarcoma",
        "value": 46.4,
        "unit": "weeks",
        "ci_lower": 31.3,
        "ci_upper": 61.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG004",
        "arm_title": "Synovial Sarcoma",
        "value": 56.3,
        "unit": "weeks",
        "ci_lower": 22.3,
        "ci_upper": 71.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG005",
        "arm_title": "Total",
        "value": 38.4,
        "unit": "weeks",
        "ci_lower": 31.1,
        "ci_upper": 52.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "IMC-A12 (cixutumumab)"
      ],
      "OG001": [
        "IMC-A12 (cixutumumab)"
      ],
      "OG002": [
        "IMC-A12 (cixutumumab)"
      ],
      "OG003": [
        "IMC-A12 (cixutumumab)"
      ],
      "OG004": [
        "IMC-A12 (cixutumumab)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other",
      "OG004": "Targeted_Other",
      "OG005": "OTHER"
    }
  },
  {
    "nct_id": "NCT03422536",
    "brief_title": "Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma",
    "status": "COMPLETED",
    "start_date": "2017-12-05",
    "completion_date": "2022-03-29",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "University of Arizona",
    "url": "https://clinicaltrials.gov/study/NCT03422536",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [
      {
        "target": "p16",
        "status": "ANY",
        "details": "Known tumoral HPV status required for oropharyngeal primary or unknown primary. Acceptable: p16 immunohistochemistry (p16-positive defined as diffuse nuclear and cytoplasmic staining in \u226570% of tumor cells) and/or HPV DNA assessment. Documentation must be submitted."
      },
      {
        "target": "EBV",
        "status": "NEGATIVE",
        "details": "Nasopharyngeal WHO Type III (non-keratinizing and EBV-positive) are excluded; eligible nasopharyngeal histologies are WHO Type I and II (keratinizing, non-EBV positive)."
      }
    ],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": true,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm I (Ficlatuzumab)",
        "value": 1.8,
        "unit": "months",
        "ci_lower": 1.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm II (Ficlatuzumab, Cetuximab)",
        "value": 3.7,
        "unit": "months",
        "ci_lower": 2.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm I (Ficlatuzumab)",
        "value": 6.4,
        "unit": "months",
        "ci_lower": 3.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm II (Ficlatuzumab, Cetuximab)",
        "value": 7.4,
        "unit": "months",
        "ci_lower": 4.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ficlatuzumab"
      ],
      "OG001": [
        "Cetuximab",
        "Ficlatuzumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03428958",
    "brief_title": "A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment",
    "status": "COMPLETED",
    "start_date": "2018-10-05",
    "completion_date": "2024-03-19",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "NuCana plc",
    "url": "https://clinicaltrials.gov/study/NCT03428958",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "RAS",
        "status": "ANY",
        "details": "Known RAS status (e.g., KRAS/NRAS) required"
      },
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "Wild-type KRAS required for enrollment to cohorts that do not contain an EGFR pathway inhibitor (Arms 2a,2b,2c,2d,3a,3b,3c,3d,3e)"
      },
      {
        "target": "BRAF",
        "status": "ANY",
        "details": "Known BRAF status required"
      },
      {
        "target": "BRAF",
        "status": "POSITIVE",
        "details": "V600E mutation; patients with BRAF V600E mutant tumours should have received prior encorafenib in combination with an EGFR inhibitor unless not standard of care"
      },
      {
        "target": "DPD",
        "status": "NEGATIVE",
        "details": "Known DPD mutations associated with fluoropyrimidine toxicity are exclusionary"
      },
      {
        "target": "TYMP",
        "status": "NEGATIVE",
        "details": "Known TYMP mutations associated with fluoropyrimidine toxicity are exclusionary"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "DCR",
        "arm_id": "OG000",
        "arm_title": "NUC-3373 + Leucovorin (LV) Every Other Week",
        "value": 0.0,
        "unit": "percentage of patients",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG001",
        "arm_title": "NUC-3373 Every Other Week",
        "value": 42.9,
        "unit": "percentage of patients",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG002",
        "arm_title": "NUC-3373 (1500 mg/m2) + Leucovorin (LV) Weekly",
        "value": 62.5,
        "unit": "percentage of patients",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG003",
        "arm_title": "NUC-3373 (2500 mg/m2) + Leucovorin (LV) Weekly",
        "value": 50.0,
        "unit": "percentage of patients",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG004",
        "arm_title": "NUC-3373 + Oxaliplatin Weekly",
        "value": 46.7,
        "unit": "percentage of patients",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG005",
        "arm_title": "NUC-3373 + Irinotecan Weekly",
        "value": 42.9,
        "unit": "percentage of patients",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG006",
        "arm_title": "NUC-3373 + Irinotecan Weekly (PK Sub-study)",
        "value": 33.3,
        "unit": "percentage of patients",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG007",
        "arm_title": "NUFOX + Bevacizumab Weekly",
        "value": 80.0,
        "unit": "percentage of patients",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG008",
        "arm_title": "NUFIRI + Bevacizumab Weekly",
        "value": 88.9,
        "unit": "percentage of patients",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "NUC-3373 + Leucovorin (LV) Every Other Week",
        "value": 1.7,
        "unit": "months",
        "ci_lower": 0.03,
        "ci_upper": 2.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "NUC-3373 Every Other Week",
        "value": 2.3,
        "unit": "months",
        "ci_lower": 0.03,
        "ci_upper": 4.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "NUC-3373 (1500 mg/m2) + Leucovorin (LV) Weekly",
        "value": 2.9,
        "unit": "months",
        "ci_lower": 0.03,
        "ci_upper": 5.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "NUC-3373 (2500 mg/m2) + Leucovorin (LV) Weekly",
        "value": 1.8,
        "unit": "months",
        "ci_lower": 0.03,
        "ci_upper": 3.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "NUC-3373 + Oxaliplatin Weekly",
        "value": 2.5,
        "unit": "months",
        "ci_lower": 0.03,
        "ci_upper": 6.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG005",
        "arm_title": "NUC-3373 + Irinotecan Weekly",
        "value": 3.6,
        "unit": "months",
        "ci_lower": 0.03,
        "ci_upper": 6.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG006",
        "arm_title": "NUC-3373 + Irinotecan Weekly (PK Sub-study)",
        "value": 2.0,
        "unit": "months",
        "ci_lower": 0.03,
        "ci_upper": 4.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG007",
        "arm_title": "NUFOX + Bevacizumab Weekly",
        "value": 7.7,
        "unit": "months",
        "ci_lower": 2.3,
        "ci_upper": 9.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG008",
        "arm_title": "NUFIRI + Bevacizumab Weekly",
        "value": 5.5,
        "unit": "months",
        "ci_lower": 1.9,
        "ci_upper": 15.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "NUC-3373 + Leucovorin (LV) Every Other Week",
        "value": 1.9,
        "unit": "months",
        "ci_lower": 0.9,
        "ci_upper": 3.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "NUC-3373 Every Other Week",
        "value": 3.0,
        "unit": "months",
        "ci_lower": 1.5,
        "ci_upper": 7.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "NUC-3373 (1500 mg/m2) + Leucovorin (LV) Weekly",
        "value": 3.6,
        "unit": "months",
        "ci_lower": 0.8,
        "ci_upper": 8.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "NUC-3373 (2500 mg/m2) + Leucovorin (LV) Weekly",
        "value": 3.6,
        "unit": "months",
        "ci_lower": 1.3,
        "ci_upper": 5.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG004",
        "arm_title": "NUC-3373 + Oxaliplatin Weekly",
        "value": 3.4,
        "unit": "months",
        "ci_lower": 0.4,
        "ci_upper": 24.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG005",
        "arm_title": "NUC-3373 + Irinotecan Weekly",
        "value": 3.2,
        "unit": "months",
        "ci_lower": 0.5,
        "ci_upper": 19.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG006",
        "arm_title": "NUC-3373 + Irinotecan Weekly (PK Sub-study)",
        "value": 7.3,
        "unit": "months",
        "ci_lower": 1.4,
        "ci_upper": 13.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG007",
        "arm_title": "NUFOX + Bevacizumab Weekly",
        "value": 14.2,
        "unit": "months",
        "ci_lower": 9.4,
        "ci_upper": 16.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG008",
        "arm_title": "NUFIRI + Bevacizumab Weekly",
        "value": 12.8,
        "unit": "months",
        "ci_lower": 3.2,
        "ci_upper": 18.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "NUC-3373",
        "leucovorin"
      ],
      "OG001": [
        "NUC-3373"
      ],
      "OG002": [
        "NUC-3373",
        "leucovorin"
      ],
      "OG003": [
        "NUC-3373",
        "leucovorin"
      ],
      "OG004": [
        "NUC-3373",
        "oxaliplatin"
      ],
      "OG005": [
        "NUC-3373",
        "irinotecan"
      ],
      "OG006": [
        "NUC-3373",
        "irinotecan"
      ],
      "OG007": [
        "NUC-3373",
        "oxaliplatin",
        "bevacizumab"
      ],
      "OG008": [
        "NUC-3373",
        "irinotecan",
        "bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo",
      "OG002": "Chemo",
      "OG003": "Chemo",
      "OG004": "Chemo",
      "OG005": "Chemo",
      "OG006": "Chemo",
      "OG007": "Combo_Chemo_Targeted",
      "OG008": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03448718",
    "brief_title": "Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations",
    "status": "COMPLETED",
    "start_date": "2018-04-17",
    "completion_date": "2021-07-14",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Matthew Galsky",
    "url": "https://clinicaltrials.gov/study/NCT03448718",
    "cancer_types": [
      "BLCA"
    ],
    "biomarkers": [
      {
        "target": "ERCC2",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing. Germline alterations considered on a case-by-case basis."
      },
      {
        "target": "ERCC3",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing. Germline alterations considered on a case-by-case basis."
      },
      {
        "target": "ERCC4",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing. Germline alterations considered on a case-by-case basis."
      },
      {
        "target": "ERCC5",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing. Germline alterations considered on a case-by-case basis."
      },
      {
        "target": "ERCC6",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing. Germline alterations considered on a case-by-case basis."
      },
      {
        "target": "BRCA1",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing. At least 6 subjects must have BRCA or ATM alterations. Germline alterations considered on a case-by-case basis."
      },
      {
        "target": "BRCA2",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing. At least 6 subjects must have BRCA or ATM alterations. Germline alterations considered on a case-by-case basis."
      },
      {
        "target": "RAD52",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing. Germline alterations considered on a case-by-case basis."
      },
      {
        "target": "RAD54L",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing. Germline alterations considered on a case-by-case basis."
      },
      {
        "target": "RAD50",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing. Germline alterations considered on a case-by-case basis."
      },
      {
        "target": "NBN",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing. Germline alterations considered on a case-by-case basis."
      },
      {
        "target": "RAD51",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing. Germline alterations considered on a case-by-case basis."
      },
      {
        "target": "MRE11A",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing. Germline alterations considered on a case-by-case basis."
      },
      {
        "target": "RAD51B",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing. Germline alterations considered on a case-by-case basis."
      },
      {
        "target": "RAD51D",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing. Germline alterations considered on a case-by-case basis."
      },
      {
        "target": "RAD51C",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing. Germline alterations considered on a case-by-case basis."
      },
      {
        "target": "CTIP",
        "status": "POSITIVE",
        "details": "Listed as CTIP in protocol; pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing. Germline alterations considered on a case-by-case basis."
      },
      {
        "target": "ATM",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing. Germline alterations considered on a case-by-case basis."
      },
      {
        "target": "ATR",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing."
      },
      {
        "target": "MDC1",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing."
      },
      {
        "target": "ATRX",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing."
      },
      {
        "target": "CHEK1",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing."
      },
      {
        "target": "CHEK2",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing."
      },
      {
        "target": "PALB2",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing."
      },
      {
        "target": "FANCE",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing."
      },
      {
        "target": "BRIP1",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing."
      },
      {
        "target": "FANCF",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing."
      },
      {
        "target": "FANCA",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing."
      },
      {
        "target": "FANCG",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing."
      },
      {
        "target": "FANCB",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing."
      },
      {
        "target": "BLM",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing."
      },
      {
        "target": "FANCC",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing."
      },
      {
        "target": "FANCD2",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing."
      },
      {
        "target": "XRCC2",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing."
      },
      {
        "target": "XRCC3",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing."
      },
      {
        "target": "XRCC4",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing."
      },
      {
        "target": "XRCC5",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing."
      },
      {
        "target": "XRCC6",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing."
      },
      {
        "target": "MUTYH",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing."
      },
      {
        "target": "RECQL4",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing."
      },
      {
        "target": "POLQ",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing."
      },
      {
        "target": "POLE",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing."
      },
      {
        "target": "WRN",
        "status": "POSITIVE",
        "details": "Pathogenic/likely pathogenic somatic alteration (nonsense, frameshift, splice-site, missense, or homozygous deletion) identified by CLIA-certified genomic sequencing."
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Olaparib Monotherapy",
        "value": 0.0,
        "unit": "Percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Olaparib Monotherapy",
        "value": 1.9,
        "unit": "Months",
        "ci_lower": 0.8,
        "ci_upper": 16.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Olaparib Monotherapy",
        "value": 9.5,
        "unit": "Months",
        "ci_lower": 1.5,
        "ci_upper": 22.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Olaparib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00698516",
    "brief_title": "Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2008-07",
    "completion_date": "2010-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "GlaxoSmithKline",
    "url": "https://clinicaltrials.gov/study/NCT00698516",
    "cancer_types": [
      "SCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Topotecan and Bevacizumab",
        "value": 65.0,
        "unit": "percentageof participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      }
    ],
    "arm_drugs": {
      "OG000": [
        "topotecan",
        "bevacizumab"
      ],
      "OG001": [
        "topotecan",
        "bevacizumab"
      ],
      "OG002": [
        "topotecan",
        "bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00673738",
    "brief_title": "Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC)",
    "status": "COMPLETED",
    "start_date": "2008-04",
    "completion_date": "2013-12",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
    "url": "https://clinicaltrials.gov/study/NCT00673738",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIA",
      "IIB",
      "IIIA",
      "IIIB",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cetuximab Plus Radiotherapy",
        "value": 7.5,
        "unit": "Months",
        "ci_lower": 4.0,
        "ci_upper": 10.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cetuximab Plus Radiotherapy",
        "value": 10.5,
        "unit": "Months",
        "ci_lower": 4.3,
        "ci_upper": 20.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cetuximab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00696696",
    "brief_title": "Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer",
    "status": "COMPLETED",
    "start_date": "2007-09",
    "completion_date": "2010-11",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "NYU Langone Health",
    "url": "https://clinicaltrials.gov/study/NCT00696696",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Combination GES",
        "value": 49.0,
        "unit": "percentage of patients",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Combination GES",
        "value": 195.0,
        "unit": "days",
        "ci_lower": 144.0,
        "ci_upper": 290.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Gemcitabine",
        "Erlotinib",
        "Sorafenib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT00693992",
    "brief_title": "Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy",
    "status": "COMPLETED",
    "start_date": "2008-06-15",
    "completion_date": "2013-11-08",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT00693992",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV"
    ],
    "line_of_therapy": "MAINTENANCE",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm I (Sunitinib Malate)",
        "value": 4.3,
        "unit": "months",
        "ci_lower": 3.2,
        "ci_upper": 4.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm II (Placebo)",
        "value": 2.6,
        "unit": "months",
        "ci_lower": 1.8,
        "ci_upper": 3.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Sunitinib Malate"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT00679341",
    "brief_title": "A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin\u00ae) and Docetaxel (Taxotere\u00ae) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease",
    "status": "COMPLETED",
    "start_date": "2008-09",
    "completion_date": "2010-11",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT00679341",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "Human epidermal growth factor receptor 2 (HER2)-positive"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Trastuzumab Emtansine",
        "value": 14.2,
        "unit": "Months",
        "ci_lower": 10.6,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Trastuzumab + Docetaxel",
        "value": 9.2,
        "unit": "Months",
        "ci_lower": 8.2,
        "ci_upper": 11.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Trastuzumab emtansine [Kadcyla]"
      ],
      "OG001": [
        "Trastuzumab",
        "Docetaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "ADC",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03472365",
    "brief_title": "A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer",
    "status": "COMPLETED",
    "start_date": "2018-04-02",
    "completion_date": "2020-11-25",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Jiangsu HengRui Medicine Co., Ltd.",
    "url": "https://clinicaltrials.gov/study/NCT03472365",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "Known HER2-positive status excluded"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort 1",
        "value": 58.3,
        "unit": "Percent",
        "ci_lower": 43.2,
        "ci_upper": 72.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Cohort 2",
        "value": 10.5,
        "unit": "Percent",
        "ci_lower": 1.3,
        "ci_upper": 33.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1",
        "value": 6.768,
        "unit": "Months",
        "ci_lower": 5.552,
        "ci_upper": 9.495,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort 2",
        "value": 2.793,
        "unit": "Months",
        "ci_lower": 1.38,
        "ci_upper": 4.764,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "SHR-1210",
        "Capecitabine"
      ],
      "OG001": [
        "SHR-1210",
        "Apatinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Combo_TKI_IO"
    }
  },
  {
    "nct_id": "NCT03504423",
    "brief_title": "Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas",
    "status": "COMPLETED",
    "start_date": "2018-11-09",
    "completion_date": "2021-08-16",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Cornerstone Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT03504423",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "CPI-613, mFolfirinox",
        "value": 11.1,
        "unit": "months",
        "ci_lower": 10.22,
        "ci_upper": 12.94,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Folfirinox",
        "value": 11.73,
        "unit": "months",
        "ci_lower": 10.12,
        "ci_upper": 13.24,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "CPI-613, mFolfirinox",
        "value": 7.82,
        "unit": "months",
        "ci_lower": 6.97,
        "ci_upper": 10.91,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Folfirinox",
        "value": 7.98,
        "unit": "months",
        "ci_lower": 7.23,
        "ci_upper": 11.14,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "CPI-613",
        "Oxaliplatin",
        "Folinic acid",
        "Irinotecan",
        "Fluorouracil"
      ],
      "OG001": [
        "Oxaliplatin",
        "Folinic acid",
        "Irinotecan",
        "Fluorouracil"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00678392",
    "brief_title": "Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer",
    "status": "COMPLETED",
    "start_date": "2008-09-03",
    "completion_date": "2010-08-31",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT00678392",
    "cancer_types": [
      "KIRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Axitinib 5 mg",
        "value": 6.7,
        "unit": "Months",
        "ci_lower": 6.3,
        "ci_upper": 8.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Sorafenib 400 mg",
        "value": 4.7,
        "unit": "Months",
        "ci_lower": 4.6,
        "ci_upper": 5.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Axitinib 5 mg",
        "value": 20.1,
        "unit": "Months",
        "ci_lower": 16.7,
        "ci_upper": 23.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Sorafenib 400 mg",
        "value": 19.2,
        "unit": "Months",
        "ci_lower": 17.5,
        "ci_upper": 22.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Axitinib (AG-013736)"
      ],
      "OG001": [
        "Sorafenib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT03451331",
    "brief_title": "Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer",
    "status": "COMPLETED",
    "start_date": "2018-05-10",
    "completion_date": "2023-06-07",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Matthew Galsky",
    "url": "https://clinicaltrials.gov/study/NCT03451331",
    "cancer_types": [
      "BLCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "IV",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Arm A",
        "value": 69.6,
        "unit": "Percentage of participants",
        "ci_lower": 47.0,
        "ci_upper": 87.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Arm B",
        "value": 33.3,
        "unit": "Percentage of participants",
        "ci_lower": 15.0,
        "ci_upper": 57.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A",
        "value": 9.4,
        "unit": "Months",
        "ci_lower": 5.62,
        "ci_upper": 12.88,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B",
        "value": 8.57,
        "unit": "Months",
        "ci_lower": 2.56,
        "ci_upper": 10.38,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A",
        "value": 24.74,
        "unit": "Months",
        "ci_lower": 17.45,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B",
        "value": 16.43,
        "unit": "Months",
        "ci_lower": 7.66,
        "ci_upper": 28.68,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Gemcitabine",
        "Carboplatin",
        "Nivolumab"
      ],
      "OG001": [
        "Gemcitabine",
        "Oxaliplatin",
        "Nivolumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT00684983",
    "brief_title": "Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2008-07-30",
    "completion_date": "2014-01-07",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT00684983",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "IHC 3+ (uniform, intense staining of >30% of invasive tumor cells) OR average HER2 gene copy number >6 OR HER2:D17Z1 ratio >2.20 (gene amplification)"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IIIC",
      "IV",
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A",
        "value": 6.0,
        "unit": "Median survival and CI in months",
        "ci_lower": 4.3,
        "ci_upper": 8.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B",
        "value": 4.9,
        "unit": "Median survival and CI in months",
        "ci_lower": 2.9,
        "ci_upper": 8.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A",
        "value": 16.8,
        "unit": "Months",
        "ci_lower": 1.7,
        "ci_upper": 37.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B",
        "value": 14.7,
        "unit": "Months",
        "ci_lower": 3.1,
        "ci_upper": 47.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Capecitabine",
        "Lapatinib Ditosylate"
      ],
      "OG001": [
        "Capecitabine",
        "Lapatinib Ditosylate",
        "Cixutumumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT03511664",
    "brief_title": "Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer",
    "status": "COMPLETED",
    "start_date": "2018-05-29",
    "completion_date": "2021-01-27",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Endocyte",
    "url": "https://clinicaltrials.gov/study/NCT03511664",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [
      {
        "target": "PSMA",
        "status": "POSITIVE",
        "details": "68Ga-PSMA-11 PET/CT positive as determined by sponsor's central reader"
      },
      {
        "target": "TESTOSTERONE",
        "status": "LOW",
        "details": "Castrate level of serum/plasma testosterone: <50 ng/dL or <1.7 nmol/L"
      },
      {
        "target": "PSA",
        "status": "HIGH",
        "details": "Option for documented progressive disease: 2 consecutive increases in PSA over a previous reference value measured at least 1 week apart; minimal start value 2.0 ng/mL"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)",
        "value": 8.7,
        "unit": "Months",
        "ci_lower": 7.9,
        "ci_upper": 10.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone",
        "value": 3.4,
        "unit": "Months",
        "ci_lower": 2.4,
        "ci_upper": 4.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)",
        "value": 15.3,
        "unit": "Months",
        "ci_lower": 14.2,
        "ci_upper": 16.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone",
        "value": 11.3,
        "unit": "Months",
        "ci_lower": 9.8,
        "ci_upper": 13.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "177Lu-PSMA-617"
      ],
      "OG002": [
        "177Lu-PSMA-617"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "Placebo",
      "OG002": "OTHER"
    }
  },
  {
    "nct_id": "NCT03474107",
    "brief_title": "A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2018-06-27",
    "completion_date": "2020-07-15",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Astellas Pharma Global Development, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT03474107",
    "cancer_types": [
      "BLCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": true,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Enfortumab Vedotin 1.25 mg/kg",
        "value": 12.88,
        "unit": "months",
        "ci_lower": 10.58,
        "ci_upper": 15.21,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy",
        "value": 8.97,
        "unit": "months",
        "ci_lower": 8.05,
        "ci_upper": 10.74,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Enfortumab Vedotin"
      ],
      "OG001": [
        "Docetaxel",
        "Vinflunine",
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "ADC",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT03498521",
    "brief_title": "A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site",
    "status": "COMPLETED",
    "start_date": "2018-07-10",
    "completion_date": "2023-02-14",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT03498521",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Molecularly-Guided Therapy (MGT) Category 1",
        "value": 6.14,
        "unit": "Months",
        "ci_lower": 4.7,
        "ci_upper": 6.47,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy Category 1",
        "value": 4.4,
        "unit": "Months",
        "ci_lower": 4.17,
        "ci_upper": 6.37,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG001": [
        "Cisplatin",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00679783",
    "brief_title": "Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2008-07-08",
    "completion_date": "2010-03-26",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT00679783",
    "cancer_types": [
      "OV",
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "BRCA",
        "status": "POSITIVE",
        "details": "Known BRCA mutation positive (breast or ovarian cancer); may refer to BRCA1/BRCA2; subgroup excludes high\u2011grade serous/undifferentiated tubo-ovarian carcinoma."
      },
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "Oestrogen receptor negative (part of triple-negative breast cancer)"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "Progesterone receptor negative (part of triple-negative breast cancer)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 negative (part of triple-negative breast cancer)"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "BRCA Positive Non-serous Ovarian",
        "value": 75.0,
        "unit": "Percentage of participants",
        "ci_lower": 30.06,
        "ci_upper": 95.44,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "BRCA Positive Serous Ovarian",
        "value": 30.77,
        "unit": "Percentage of participants",
        "ci_lower": 12.68,
        "ci_upper": 57.63,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "BRCA Negative Non-serous Ovarian",
        "value": 0.0,
        "unit": "Percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 56.15,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "BRCA Negative Serous Ovarian",
        "value": 25.58,
        "unit": "Percentage of participants",
        "ci_lower": 14.93,
        "ci_upper": 40.24,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "BRCA Positive Non-triple Negative Breast",
        "value": 0.0,
        "unit": "Percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 48.99,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "BRCA Positive Triple Negative Breast",
        "value": 0.0,
        "unit": "Percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 48.99,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG006",
        "arm_title": "BRCA Negative Triple Negative Breast",
        "value": 0.0,
        "unit": "Percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 20.39,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "BRCA Positive Non-serous Ovarian",
        "value": 346.5,
        "unit": "Days",
        "ci_lower": 51.0,
        "ci_upper": 553.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "BRCA Positive Serous Ovarian",
        "value": 219.0,
        "unit": "Days",
        "ci_lower": 1.0,
        "ci_upper": 503.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "BRCA Negative Non-serous Ovarian",
        "value": 79.5,
        "unit": "Days",
        "ci_lower": 1.0,
        "ci_upper": 109.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "BRCA Negative Serous Ovarian",
        "value": 192.0,
        "unit": "Days",
        "ci_lower": 1.0,
        "ci_upper": 559.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "BRCA Positive Non-triple Negative Breast",
        "value": 165.0,
        "unit": "Days",
        "ci_lower": 53.0,
        "ci_upper": 168.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG005",
        "arm_title": "BRCA Positive Triple Negative Breast",
        "value": 106.0,
        "unit": "Days",
        "ci_lower": 37.0,
        "ci_upper": 277.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG006",
        "arm_title": "BRCA Negative Triple Negative Breast",
        "value": 54.0,
        "unit": "Days",
        "ci_lower": 1.0,
        "ci_upper": 111.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Olaparib"
      ],
      "OG001": [
        "Olaparib"
      ],
      "OG002": [
        "Olaparib"
      ],
      "OG003": [
        "Olaparib"
      ],
      "OG004": [
        "Olaparib"
      ],
      "OG005": [
        "Olaparib"
      ],
      "OG006": [
        "Olaparib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other",
      "OG004": "Targeted_Other",
      "OG005": "Targeted_Other",
      "OG006": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00678535",
    "brief_title": "Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer",
    "status": "COMPLETED",
    "start_date": "2008-06",
    "completion_date": "2012-03",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck KGaA, Darmstadt, Germany",
    "url": "https://clinicaltrials.gov/study/NCT00678535",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "Archived tumor material for standardized EGFR expression assessment"
      },
      {
        "target": "DPYD",
        "status": "NEGATIVE",
        "details": "Known dihydropyrimidine dehydrogenase (DPD) deficiency excluded"
      },
      {
        "target": "HBV",
        "status": "NEGATIVE",
        "details": "Active Hepatitis B infection excluded"
      },
      {
        "target": "HCV",
        "status": "NEGATIVE",
        "details": "Active Hepatitis C infection excluded"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cetuximab Plus Capecitabine Plus Cisplatin",
        "value": 4.4,
        "unit": "months",
        "ci_lower": 4.2,
        "ci_upper": 5.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Capecitabine Plus Cisplatin",
        "value": 5.6,
        "unit": "months",
        "ci_lower": 5.1,
        "ci_upper": 5.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cetuximab Plus Capecitabine Plus Cisplatin",
        "value": 9.4,
        "unit": "months",
        "ci_lower": 8.3,
        "ci_upper": 10.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Capecitabine Plus Cisplatin",
        "value": 10.7,
        "unit": "months",
        "ci_lower": 9.4,
        "ci_upper": 11.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cetuximab",
        "Capecitabine",
        "Cisplatin"
      ],
      "OG001": [
        "Capecitabine",
        "Cisplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00676663",
    "brief_title": "Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2008-06-13",
    "completion_date": "2011-01-29",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Syndax Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT00676663",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "estrogen receptor positive (ER+)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Exemestane 25 mg + Placebo",
        "value": 2.27,
        "unit": "months",
        "ci_lower": 1.81,
        "ci_upper": 3.68,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Exemestane 25 mg + Entinostat 5 mg",
        "value": 4.28,
        "unit": "months",
        "ci_lower": 3.26,
        "ci_upper": 5.36,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Exemestane 25 mg + Placebo (EP)",
        "value": 19.84,
        "unit": "months",
        "ci_lower": 17.04,
        "ci_upper": 26.71,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Exemestane 25 mg + Entinostat 5 mg (EE)",
        "value": 28.13,
        "unit": "months",
        "ci_lower": 21.15,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "exemestane"
      ],
      "OG001": [
        "exemestane",
        "entinostat"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03459846",
    "brief_title": "A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2018-03-16",
    "completion_date": "2020-10-15",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT03459846",
    "cancer_types": [
      "BLCA"
    ],
    "biomarkers": [
      {
        "target": "HRR",
        "status": "ANY",
        "details": "Known tumor homologous recombination repair (HRR) mutation status required prior to randomization"
      }
    ],
    "cancer_stages": [
      "IV",
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Durva + Olaparib",
        "value": 4.2,
        "unit": "Months",
        "ci_lower": 3.6,
        "ci_upper": 5.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Durva + Placebo",
        "value": 3.5,
        "unit": "Months",
        "ci_lower": 1.9,
        "ci_upper": 5.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Durva + Olaparib",
        "value": 52.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Durva + Placebo",
        "value": 46.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Durva + Olaparib",
        "value": 26.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Durva + Placebo",
        "value": 30.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Durvalumab",
        "Olaparib"
      ],
      "OG001": [
        "Durvalumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "IO"
    }
  },
  {
    "nct_id": "NCT03499899",
    "brief_title": "A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2018-07-02",
    "completion_date": "2020-02-27",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT03499899",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "negative in situ hybridization test or IHC 0 or 1+"
      },
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "<1% by IHC"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "<1% by IHC"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "LAG525 + PDR001",
        "value": 5.0,
        "unit": "Percentage of participants",
        "ci_lower": 0.1,
        "ci_upper": 24.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "LAG525+ PDR001+ Carboplatin",
        "value": 32.4,
        "unit": "Percentage of participants",
        "ci_lower": 17.4,
        "ci_upper": 50.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "LAG525 + Carboplatin",
        "value": 17.6,
        "unit": "Percentage of participants",
        "ci_lower": 6.8,
        "ci_upper": 34.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "LAG525 + PDR001",
        "value": 1.4,
        "unit": "Months",
        "ci_lower": 1.2,
        "ci_upper": 1.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "LAG525+ PDR001+ Carboplatin",
        "value": 4.3,
        "unit": "Months",
        "ci_lower": 2.8,
        "ci_upper": 5.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "LAG525 + Carboplatin",
        "value": 3.0,
        "unit": "Months",
        "ci_lower": 2.2,
        "ci_upper": 5.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "LAG525 + PDR001",
        "value": 6.1,
        "unit": "Months",
        "ci_lower": 4.6,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "LAG525+ PDR001+ Carboplatin",
        "value": 11.6,
        "unit": "Months",
        "ci_lower": 7.5,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "LAG525 + Carboplatin",
        "value": 8.0,
        "unit": "Months",
        "ci_lower": 6.2,
        "ci_upper": 9.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "LAG525",
        "PDR001"
      ],
      "OG001": [
        "LAG525",
        "PDR001",
        "Carboplatin"
      ],
      "OG002": [
        "LAG525",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "Combo_Chemo_IO",
      "OG002": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT03504397",
    "brief_title": "A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2018-06-21",
    "completion_date": "2022-09-09",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Astellas Pharma Global Development, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT03504397",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [
      {
        "target": "CLDN18.2",
        "status": "HIGH",
        "details": "\u226575% of tumor cells with moderate to strong membranous staining by central IHC"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-negative as determined by local or central testing on a gastric or GEJ tumor specimen"
      },
      {
        "target": "DPYD",
        "status": "NEGATIVE",
        "details": "No known dihydropyrimidine dehydrogenase deficiency (DPD)"
      },
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "No known positive HIV test (subjects with known history of HIV infection are excluded)"
      },
      {
        "target": "HBsAg",
        "status": "NEGATIVE",
        "details": "No active hepatitis B (HBsAg positive). If HBsAg negative but anti-HBc positive, HBV DNA must be negative"
      },
      {
        "target": "HBV DNA",
        "status": "NEGATIVE",
        "details": "If hepatitis B core antibody (anti-HBc) positive, HBV DNA must be negative"
      },
      {
        "target": "HCV RNA",
        "status": "NEGATIVE",
        "details": "HCV RNA must be negative (subjects with positive HCV serology but negative HCV RNA are eligible; treated HCV with undetectable viral load are eligible)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "mFOLFOX6 + Zolbetuximab",
        "value": 11.04,
        "unit": "Months",
        "ci_lower": 9.69,
        "ci_upper": 12.52,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "mFOLFOX6+ Placebo",
        "value": 8.94,
        "unit": "Months",
        "ci_lower": 8.21,
        "ci_upper": 10.41,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "mFOLFOX6 + Zolbetuximab",
        "value": 18.23,
        "unit": "Months",
        "ci_lower": 16.13,
        "ci_upper": 20.63,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "mFOLFOX6+ Placebo",
        "value": 15.57,
        "unit": "Months",
        "ci_lower": 13.67,
        "ci_upper": 16.92,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "zolbetuximab",
        "oxaliplatin",
        "folinic acid",
        "fluorouracil"
      ],
      "OG001": [
        "oxaliplatin",
        "folinic acid",
        "fluorouracil"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT03473925",
    "brief_title": "Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)",
    "status": "COMPLETED",
    "start_date": "2018-04-10",
    "completion_date": "2021-05-19",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT03473925",
    "cancer_types": [
      "NSCLC",
      "CRC",
      "PRAD"
    ],
    "biomarkers": [
      {
        "target": "MSI",
        "status": "NEGATIVE",
        "details": "Must be microsatellite stable (MSS); MSI\u2011H or microsatellite unstable CRC are excluded"
      },
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Prior treatment with an anti\u2011PD\u2011L1 monoclonal antibody required for NSCLC cohort with documented progression after \u22652 doses per RECIST 1.1 within 12 weeks of last dose"
      }
    ],
    "cancer_stages": [
      "III",
      "IV",
      "METASTATIC",
      "UNRESECTABLE",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Navarixin 30 mg + Pembrolizumab 200 mg",
        "value": 3.9,
        "unit": "Percentage of participants",
        "ci_lower": 0.5,
        "ci_upper": 13.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Navarixin 100 mg + Pembrolizumab 200 mg",
        "value": 1.9,
        "unit": "Percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 9.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Navarixin 30 mg + Pembrolizumab 200 mg",
        "value": 1.8,
        "unit": "Months",
        "ci_lower": 1.0,
        "ci_upper": 2.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Navarixin 100 mg + Pembrolizumab 200 mg",
        "value": 1.9,
        "unit": "Months",
        "ci_lower": 1.6,
        "ci_upper": 2.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Navarixin 30 mg + Pembrolizumab 200 mg",
        "value": 2.1,
        "unit": "Months",
        "ci_lower": 1.9,
        "ci_upper": 4.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Navarixin 100 mg + Pembrolizumab 200 mg",
        "value": 2.1,
        "unit": "Months",
        "ci_lower": 1.9,
        "ci_upper": 4.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Navarixin 30 mg + Pembrolizumab 200 mg",
        "value": 2.4,
        "unit": "Months",
        "ci_lower": 1.6,
        "ci_upper": 10.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Navarixin 100 mg + Pembrolizumab 200 mg",
        "value": 2.1,
        "unit": "Months",
        "ci_lower": 1.9,
        "ci_upper": 2.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Navarixin 30 mg + Pembrolizumab 200 mg",
        "value": 6.5,
        "unit": "Months",
        "ci_lower": 3.0,
        "ci_upper": 9.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Navarixin 100 mg + Pembrolizumab 200 mg",
        "value": 8.0,
        "unit": "Months",
        "ci_lower": 5.7,
        "ci_upper": 14.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Navarixin 30 mg + Pembrolizumab 200 mg",
        "value": 10.8,
        "unit": "Months",
        "ci_lower": 7.9,
        "ci_upper": 13.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Navarixin 100 mg + Pembrolizumab 200 mg",
        "value": 11.2,
        "unit": "Months",
        "ci_lower": 3.7,
        "ci_upper": 23.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Navarixin 30 mg + Pembrolizumab 200 mg",
        "value": 13.0,
        "unit": "Months",
        "ci_lower": 3.2,
        "ci_upper": 18.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Navarixin 100 mg + Pembrolizumab 200 mg",
        "value": 12.0,
        "unit": "Months",
        "ci_lower": 2.4,
        "ci_upper": 19.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Navarixin",
        "Pembrolizumab"
      ],
      "OG001": [
        "Navarixin",
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT00719212",
    "brief_title": "Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer",
    "status": "COMPLETED",
    "start_date": "2009-01",
    "completion_date": "2013-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Translational Research in Oncology",
    "url": "https://clinicaltrials.gov/study/NCT00719212",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "AMG 479",
        "value": 1.6,
        "unit": "percentage of patients",
        "ci_lower": 0.0,
        "ci_upper": 8.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "AMG 479",
        "value": 20.994,
        "unit": "months",
        "ci_lower": 19.45,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "AMG 479",
        "value": 1.938,
        "unit": "months",
        "ci_lower": 1.446,
        "ci_upper": 2.103,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "AMG 479"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00710762",
    "brief_title": "A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer",
    "status": "COMPLETED",
    "start_date": "2006-03",
    "completion_date": "2008-09",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Boehringer Ingelheim",
    "url": "https://clinicaltrials.gov/study/NCT00710762",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "MAINTENANCE",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Nintedanib",
        "value": 15.6,
        "unit": "percent probability of PFS",
        "ci_lower": 3.8,
        "ci_upper": 27.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 2.9,
        "unit": "percent probability of PFS",
        "ci_lower": 0.0,
        "ci_upper": 8.4,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "BIBF1120"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT00703326",
    "brief_title": "Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2008-08-06",
    "completion_date": "2013-03-31",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00703326",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-negative by FISH or CISH, or 0\u20131+ by IHC"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ramucirumab (IMC-1121B) + Docetaxel",
        "value": 9.5,
        "unit": "months",
        "ci_lower": 8.3,
        "ci_upper": 9.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Docetaxel",
        "value": 8.2,
        "unit": "months",
        "ci_lower": 7.1,
        "ci_upper": 8.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Ramucirumab (IMC-1121B) + Docetaxel",
        "value": 30.3,
        "unit": "months",
        "ci_lower": 27.5,
        "ci_upper": 33.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Docetaxel",
        "value": 28.7,
        "unit": "months",
        "ci_lower": 25.6,
        "ci_upper": 32.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "ramucirumab (IMC-1121B)",
        "docetaxel"
      ],
      "OG001": [
        "docetaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00705016",
    "brief_title": "Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)",
    "status": "COMPLETED",
    "start_date": "2008-10",
    "completion_date": "2011-09",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck KGaA, Darmstadt, Germany",
    "url": "https://clinicaltrials.gov/study/NCT00705016",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin",
        "value": 6.4,
        "unit": "months",
        "ci_lower": 5.4,
        "ci_upper": 8.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin",
        "value": 5.6,
        "unit": "months",
        "ci_lower": 4.0,
        "ci_upper": 6.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Cetuximab+5-FU+Cisplatin",
        "value": 5.7,
        "unit": "months",
        "ci_lower": 4.2,
        "ci_upper": 9.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin",
        "value": 12.4,
        "unit": "months",
        "ci_lower": 9.4,
        "ci_upper": 14.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin",
        "value": 10.6,
        "unit": "months",
        "ci_lower": 9.0,
        "ci_upper": 14.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Cetuximab+5-FU+Cisplatin",
        "value": 11.6,
        "unit": "months",
        "ci_lower": 7.1,
        "ci_upper": 16.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cilengitide 2000 mg once weekly",
        "Cetuximab",
        "5-fluorouracil (5-FU)",
        "Cisplatin"
      ],
      "OG001": [
        "Cilengitide 2000 mg twice weekly",
        "Cetuximab",
        "5-fluorouracil (5-FU)",
        "Cisplatin"
      ],
      "OG002": [
        "Cetuximab",
        "5-fluorouracil (5-FU)",
        "Cisplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03522246",
    "brief_title": "A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2018-05-14",
    "completion_date": "2024-05-20",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "pharmaand GmbH",
    "url": "https://clinicaltrials.gov/study/NCT03522246",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "III",
      "IV"
    ],
    "line_of_therapy": "MAINTENANCE",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm B: Rucaparib + Placebo",
        "value": 28.7,
        "unit": "months",
        "ci_lower": 23.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm D: Placebo + Placebo",
        "value": 11.3,
        "unit": "months",
        "ci_lower": 9.1,
        "ci_upper": 22.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm B: Rucaparib + Placebo",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm D: Placebo + Placebo",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Rucaparib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT00720304",
    "brief_title": "Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck",
    "status": "COMPLETED",
    "start_date": "2007-11-19",
    "completion_date": "2015-11-13",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Case Comprehensive Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT00720304",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "III",
      "IV",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Oral Erlotinib Hydrochloride",
        "value": 69.5,
        "unit": "Percent",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG000",
        "arm_title": "Oral Erlotinib Hydrochloride",
        "value": null,
        "unit": null,
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      }
    ],
    "arm_drugs": {
      "OG000": [
        "erlotinib hydrochloride",
        "docetaxel"
      ],
      "OG001": [
        "docetaxel"
      ],
      "OG002": [
        "docetaxel"
      ],
      "OG003": [
        "docetaxel"
      ],
      "OG004": [
        "docetaxel"
      ],
      "OG005": [
        "docetaxel"
      ],
      "OG006": [
        "docetaxel"
      ],
      "OG007": [
        "docetaxel"
      ],
      "OG008": [
        "docetaxel"
      ],
      "OG009": [
        "docetaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Chemo",
      "OG002": "Chemo",
      "OG003": "Chemo",
      "OG004": "Chemo",
      "OG005": "Chemo",
      "OG006": "Chemo",
      "OG007": "Chemo",
      "OG008": "Chemo",
      "OG009": "Chemo"
    }
  },
  {
    "nct_id": "NCT00704730",
    "brief_title": "Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer",
    "status": "COMPLETED",
    "start_date": "2008-06",
    "completion_date": "2011-10",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Exelixis",
    "url": "https://clinicaltrials.gov/study/NCT00704730",
    "cancer_types": [
      "THCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "XL184 (Cabozantinib)",
        "value": 11.2,
        "unit": "months",
        "ci_lower": 9.3,
        "ci_upper": 13.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 4.0,
        "unit": "months",
        "ci_lower": 3.0,
        "ci_upper": 5.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "XL184 (Cabozantinib)",
        "value": 21.1,
        "unit": "months",
        "ci_lower": 16.59,
        "ci_upper": 28.52,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": null,
        "unit": "months",
        "ci_lower": 17.41,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "XL184"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT03520842",
    "brief_title": "Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2018-08-14",
    "completion_date": "2022-06-15",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Stanford University",
    "url": "https://clinicaltrials.gov/study/NCT03520842",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "POSITIVE",
        "details": "pathogenic KRAS mutation"
      }
    ],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Regorafenib, Methotrexate)",
        "value": 3.7,
        "unit": "months",
        "ci_lower": 1.8,
        "ci_upper": 8.6,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Regorafenib",
        "Methotrexate"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT00700336",
    "brief_title": "Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)",
    "status": "COMPLETED",
    "start_date": "2008-05",
    "completion_date": "2012-07",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "CanBas Co. Ltd.",
    "url": "https://clinicaltrials.gov/study/NCT00700336",
    "cancer_types": [
      "MESO",
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed, Cisplatin, and CBP501",
        "value": 25.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Pemetrexed and Cisplatin",
        "value": 9.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed, Cisplatin, and CBP501",
        "value": 27.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Pemetrexed and Cisplatin",
        "value": 13.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "CBP501",
        "Pemetrexed",
        "Cisplatin"
      ],
      "OG001": [
        "Pemetrexed",
        "Cisplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT03523572",
    "brief_title": "Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer",
    "status": "COMPLETED",
    "start_date": "2018-08-02",
    "completion_date": "2021-07-22",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Daiichi Sankyo",
    "url": "https://clinicaltrials.gov/study/NCT03523572",
    "cancer_types": [
      "BRCA",
      "BLCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Dose Escalation (3.2 mg/kg)",
        "value": 25.0,
        "unit": "Percentage of Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Dose Escalation (5.4 mg/kg) + Dose Expansion Cohort 1 (5.4 mg/kg): HER2 Positive BC",
        "value": 65.6,
        "unit": "Percentage of Participants",
        "ci_lower": 46.8,
        "ci_upper": 81.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Dose Expansion Cohort 2 (5.4 mg/kg): HER2 Low BC",
        "value": 50.0,
        "unit": "Percentage of Participants",
        "ci_lower": 24.7,
        "ci_upper": 75.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Dose Expansion Cohort 3 (5.4 mg/kg): HER2 High Expressing (IHC 2+/3+) UC",
        "value": 36.7,
        "unit": "Percentage of Participants",
        "ci_lower": 19.9,
        "ci_upper": 56.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Dose Expansion Cohort 4 (5.4 mg/kg): HER2 Low Expressing (IHC 1+) UC",
        "value": 50.0,
        "unit": "Percentage of Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Trastuzumab deruxtecan",
        "Nivolumab"
      ],
      "OG001": [
        "Trastuzumab deruxtecan",
        "Nivolumab"
      ],
      "OG002": [
        "Trastuzumab deruxtecan",
        "Nivolumab"
      ],
      "OG003": [
        "Trastuzumab deruxtecan",
        "Nivolumab"
      ],
      "OG004": [
        "Trastuzumab deruxtecan",
        "Nivolumab"
      ],
      "OG005": [
        "Trastuzumab deruxtecan",
        "Nivolumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted",
      "OG002": "Combo_IO_Targeted",
      "OG003": "Combo_IO_Targeted",
      "OG004": "Combo_IO_Targeted",
      "OG005": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT00698815",
    "brief_title": "Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2008-04-15",
    "completion_date": "2011-12-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT00698815",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm I (Pemetrexed)",
        "value": 54.0,
        "unit": "percentage of participants",
        "ci_lower": 40.0,
        "ci_upper": 71.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm II (Sunitinib)",
        "value": 37.0,
        "unit": "percentage of participants",
        "ci_lower": 25.0,
        "ci_upper": 54.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Arm III (Pemetrexed and Sunitinib)",
        "value": 48.0,
        "unit": "percentage of participants",
        "ci_lower": 35.0,
        "ci_upper": 66.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm I (Pemetrexed)",
        "value": 10.5,
        "unit": "months",
        "ci_lower": 8.3,
        "ci_upper": 20.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm II (Sunitinib)",
        "value": 8.0,
        "unit": "months",
        "ci_lower": 6.8,
        "ci_upper": 13.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Arm III (Pemetrexed and Sunitinib)",
        "value": 6.7,
        "unit": "months",
        "ci_lower": 4.1,
        "ci_upper": 10.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pemetrexed Disodium"
      ],
      "OG001": [
        "Sunitinib Malate"
      ],
      "OG002": [
        "Pemetrexed Disodium",
        "Sunitinib Malate"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "TKI",
      "OG002": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT03521154",
    "brief_title": "A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2018-07-19",
    "completion_date": "2024-01-05",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT03521154",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "Exon 19 deletion (Ex19del) or L858R (either alone or in combination with other EGFR mutations); assessed by cobas\u00ae EGFR Mutation Test v2 or FoundationOne in CLIA/accredited/local lab or by central testing (cobas v2)"
      }
    ],
    "cancer_stages": [
      "III",
      "UNRESECTABLE",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "MAINTENANCE",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Osimertinib",
        "value": 39.13,
        "unit": "Months",
        "ci_lower": 31.51,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 5.55,
        "unit": "Months",
        "ci_lower": 3.71,
        "ci_upper": 7.43,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Osimertinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT03519971",
    "brief_title": "Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2018-03-29",
    "completion_date": "2023-09-07",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT03519971",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "III",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Durvalumab + SoC CRT",
        "value": 13.8,
        "unit": "months",
        "ci_lower": 9.5,
        "ci_upper": 16.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + SoC CRT",
        "value": 9.4,
        "unit": "months",
        "ci_lower": 7.5,
        "ci_upper": 16.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Durvalumab + SoC CRT",
        "value": 36.4,
        "unit": "months",
        "ci_lower": 26.2,
        "ci_upper": 45.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + SoC CRT",
        "value": 29.5,
        "unit": "months",
        "ci_lower": 23.2,
        "ci_upper": 45.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Durvalumab",
        "Cisplatin/ Etoposide",
        "Carboplatin/ Paclitaxel",
        "Pemetrexed/ Cisplatin",
        "Pemetrexed/ Carboplatin"
      ],
      "OG001": [
        "Cisplatin/ Etoposide",
        "Carboplatin/ Paclitaxel",
        "Pemetrexed/ Cisplatin",
        "Pemetrexed/ Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00701558",
    "brief_title": "A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2008-08",
    "completion_date": "2010-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT00701558",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Erlotinib + Gemcitabine",
        "value": 15.0,
        "unit": "weeks",
        "ci_lower": 7.0,
        "ci_upper": 36.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Erlotinib + Gemcitabine",
        "value": 15.8,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Erlotinib",
        "Gemcitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT03515837",
    "brief_title": "Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)",
    "status": "COMPLETED",
    "start_date": "2018-06-29",
    "completion_date": "2023-01-17",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT03515837",
    "cancer_types": [
      "LUAD"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "Activating EGFR mutation: exon 19 deletion (DEL19) or L858R"
      },
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "T790M mutation absent required for participants previously treated with 1st/2nd generation EGFR TKIs"
      },
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "Acquired T790M mutation (if present after 1st/2nd generation EGFR TKIs) \u2014 such participants must have had osimertinib TKI treatment failure prior to enrollment"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": true,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembro + Pemetrexed + Chemo",
        "value": 5.6,
        "unit": "Months",
        "ci_lower": 5.5,
        "ci_upper": 5.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Pemetrexed + Chemo",
        "value": 5.5,
        "unit": "Months",
        "ci_lower": 5.4,
        "ci_upper": 5.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembro + Pemetrexed + Chemo",
        "value": 15.9,
        "unit": "Months",
        "ci_lower": 13.7,
        "ci_upper": 18.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Pemetrexed + Chemo",
        "value": 14.7,
        "unit": "Months",
        "ci_lower": 12.7,
        "ci_upper": 17.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "pembrolizumab",
        "pemetrexed"
      ],
      "OG001": [
        "pemetrexed"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00703976",
    "brief_title": "Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer",
    "status": "COMPLETED",
    "start_date": "2008-10",
    "completion_date": "2014-09",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "University of Pittsburgh",
    "url": "https://clinicaltrials.gov/study/NCT00703976",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "III",
      "IV",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cetuximab, Pemetrexed and Radiation Therapy",
        "value": 79.0,
        "unit": "percentage of participants",
        "ci_lower": 69.0,
        "ci_upper": 92.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cetuximab, Pemetrexed, Radiation Therapy Plus Bevacizumab",
        "value": 75.0,
        "unit": "percentage of participants",
        "ci_lower": 64.0,
        "ci_upper": 88.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "All Participants (Overall Study)",
        "value": 88.0,
        "unit": "percentage of participants",
        "ci_lower": 81.0,
        "ci_upper": 96.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cetuximab, Pemetrexed and Radiation Therapy",
        "value": 91.0,
        "unit": "percentage of participants",
        "ci_lower": 82.0,
        "ci_upper": 100.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Cetuximab, Pemetrexed, Radiation Therapy Plus Bevacizumab",
        "value": 87.0,
        "unit": "percentage of participants",
        "ci_lower": 77.0,
        "ci_upper": 98.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cetuximab",
        "Pemetrexed"
      ],
      "OG001": [
        "Cetuximab",
        "Pemetrexed",
        "Bevacizumab"
      ],
      "OG002": [
        "Cetuximab",
        "Pemetrexed",
        "Bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03517449",
    "brief_title": "Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])",
    "status": "COMPLETED",
    "start_date": "2018-06-11",
    "completion_date": "2020-10-26",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eisai Inc.",
    "url": "https://clinicaltrials.gov/study/NCT03517449",
    "cancer_types": [
      "UCEC"
    ],
    "biomarkers": [
      {
        "target": "MMR",
        "status": "ANY",
        "details": "Mismatch repair (MMR) status; historical or fresh tumor biopsy required for determination"
      },
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "Participants who are HIV-positive are excluded (must be HIV negative)"
      },
      {
        "target": "HBV",
        "status": "NEGATIVE",
        "details": "No active Hepatitis B (active HBV excluded)"
      },
      {
        "target": "HCV",
        "status": "NEGATIVE",
        "details": "No active Hepatitis C (active HCV excluded)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Lenvatinib 20 mg + Pembrolizumab 200 mg",
        "value": 7.2,
        "unit": "Months",
        "ci_lower": 5.7,
        "ci_upper": 7.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Treatment of Physician's Choice (TPC): Doxorubicin or Paclitaxel",
        "value": 3.8,
        "unit": "Months",
        "ci_lower": 3.6,
        "ci_upper": 4.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Lenvatinib 20 mg + Pembrolizumab 200 mg",
        "value": 18.3,
        "unit": "Months",
        "ci_lower": 15.2,
        "ci_upper": 20.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Treatment of Physician's Choice (TPC): Doxorubicin or Paclitaxel",
        "value": 11.4,
        "unit": "Months",
        "ci_lower": 10.5,
        "ci_upper": 12.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Lenvatinib",
        "Pembrolizumab"
      ],
      "OG001": [
        "Doxorubicin",
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT03523585",
    "brief_title": "DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2018-08-01",
    "completion_date": "2022-06-30",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Daiichi Sankyo",
    "url": "https://clinicaltrials.gov/study/NCT03523585",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER2-positive per ASCO-CAP guidelines, confirmed by central laboratory on most recent tumor tissue sample; fresh biopsy required if archived tissue unavailable"
      }
    ],
    "cancer_stages": [
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Trastuzumab Deruxtecan (T-DXd)",
        "value": 17.8,
        "unit": "months",
        "ci_lower": 14.3,
        "ci_upper": 20.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Treatment of Investigator's/Physician's Choice (TPC)",
        "value": 6.9,
        "unit": "months",
        "ci_lower": 5.5,
        "ci_upper": 8.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Trastuzumab Deruxtecan (T-DXd)",
        "value": 39.2,
        "unit": "months",
        "ci_lower": 32.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Treatment of Investigator's/Physician's Choice (TPC)",
        "value": 26.5,
        "unit": "months",
        "ci_lower": 21.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Trastuzumab Deruxtecan (T-DXd)",
        "value": 69.7,
        "unit": "Percentage of Participants",
        "ci_lower": 65.0,
        "ci_upper": 74.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Treatment of Investigator's/Physician's Choice (TPC)",
        "value": 29.2,
        "unit": "Percentage of Participants",
        "ci_lower": 23.0,
        "ci_upper": 36.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Trastuzumab Deruxtecan (T-DXd)",
        "value": 74.1,
        "unit": "Percentage of Participants",
        "ci_lower": 69.6,
        "ci_upper": 78.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Treatment of Investigator's/Physician's Choice (TPC)",
        "value": 26.7,
        "unit": "Percentage of Participants",
        "ci_lower": 20.8,
        "ci_upper": 33.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG000",
        "arm_title": "Trastuzumab Deruxtecan (T-DXd)",
        "value": 19.6,
        "unit": "months",
        "ci_lower": 15.9,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG001",
        "arm_title": "Treatment of Investigator's/Physician's Choice (TPC)",
        "value": 8.3,
        "unit": "months",
        "ci_lower": 5.8,
        "ci_upper": 9.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Trastuzumab deruxtecan"
      ],
      "OG001": [
        "Capecitabine",
        "Lapatinib",
        "Trastuzumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "ADC",
      "OG001": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT03513952",
    "brief_title": "Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma",
    "status": "COMPLETED",
    "start_date": "2019-06-05",
    "completion_date": "2023-09-30",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT03513952",
    "cancer_types": [
      "BLCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Group 1 (CYT107, Atezolizumab)",
        "value": 5.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Group 2 (Atezolizumab)",
        "value": 5.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Safety Run in Phase",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Group 1 (CYT107, Atezolizumab)",
        "value": 2.1,
        "unit": "months",
        "ci_lower": 1.2,
        "ci_upper": 6.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Group 2 (Atezolizumab)",
        "value": 2.2,
        "unit": "months",
        "ci_lower": 1.8,
        "ci_upper": 4.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Safety Run in Phase",
        "value": 2.1,
        "unit": "months",
        "ci_lower": 1.1,
        "ci_upper": 4.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Group 1 (CYT107, Atezolizumab)",
        "value": 9.1,
        "unit": "months",
        "ci_lower": 2.6,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Group 2 (Atezolizumab)",
        "value": 10.4,
        "unit": "months",
        "ci_lower": 4.7,
        "ci_upper": 20.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Safety Run in Phase",
        "value": 4.5,
        "unit": "months",
        "ci_lower": 1.1,
        "ci_upper": 9.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Glycosylated Recombinant Human Interleukin-7",
        "Atezolizumab"
      ],
      "OG001": [
        "Atezolizumab"
      ],
      "OG002": [
        "Glycosylated Recombinant Human Interleukin-7",
        "Atezolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "IO",
      "OG002": "OTHER"
    }
  },
  {
    "nct_id": "NCT03520075",
    "brief_title": "Study of ASTX029 in Subjects With Advanced Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2018-05-07",
    "completion_date": "2024-08-01",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Taiho Oncology, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT03520075",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "MAPK",
        "status": "POSITIVE",
        "details": "Documented gene alterations in the MAPK pathway (required in Phase 1 Part B and in the Phase 2 portion)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 2: Cohort A",
        "value": 12.5,
        "unit": "percentage of participants",
        "ci_lower": 4.4,
        "ci_upper": 26.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Phase 2: Cohort B",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 18.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Phase 2: Cohort C",
        "value": 8.3,
        "unit": "percentage of participants",
        "ci_lower": 0.4,
        "ci_upper": 33.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Phase 2: Cohort D",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 28.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Phase 2: Cohort E",
        "value": 12.5,
        "unit": "percentage of participants",
        "ci_lower": 4.4,
        "ci_upper": 26.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "Phase 2: Cohort F",
        "value": 7.1,
        "unit": "percentage of participants",
        "ci_lower": 0.4,
        "ci_upper": 29.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase 1A: Cohort 1 Dose Escalation",
        "value": 1.3,
        "unit": "months",
        "ci_lower": 1.2,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Phase 1A: Cohort 2 Dose Escalation",
        "value": 1.2,
        "unit": "months",
        "ci_lower": 1.2,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Phase 1A: Cohort 3 Dose Escalation",
        "value": 8.1,
        "unit": "months",
        "ci_lower": 2.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Phase 1A: Cohort 4 Dose Escalation",
        "value": 2.0,
        "unit": "months",
        "ci_lower": 1.1,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Phase 1A: Cohort 5 Dose Escalation",
        "value": 1.2,
        "unit": "months",
        "ci_lower": 0.2,
        "ci_upper": 4.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG005",
        "arm_title": "Phase 1A: Cohort 6 Dose Escalation",
        "value": 1.3,
        "unit": "months",
        "ci_lower": 0.9,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG006",
        "arm_title": "Phase 1A: Cohort 7 Dose Escalation",
        "value": 3.0,
        "unit": "months",
        "ci_lower": 1.2,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG007",
        "arm_title": "Phase 1A: Cohort 8 Dose Escalation",
        "value": 1.1,
        "unit": "months",
        "ci_lower": 1.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG008",
        "arm_title": "Phase 1A: Cohort 9 Dose Escalation",
        "value": 1.3,
        "unit": "months",
        "ci_lower": 1.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG009",
        "arm_title": "Phase 1A: Cohort 10 Dose Escalation",
        "value": 2.3,
        "unit": "months",
        "ci_lower": 1.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG010",
        "arm_title": "Phase 1A: Cohort 11 Dose Escalation",
        "value": 3.0,
        "unit": "months",
        "ci_lower": 0.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG011",
        "arm_title": "Phase 1A: Cohort 12 Dose Escalation",
        "value": 2.5,
        "unit": "months",
        "ci_lower": 0.4,
        "ci_upper": 4.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG012",
        "arm_title": "Phase 1B Dose Expansion",
        "value": 1.4,
        "unit": "months",
        "ci_lower": 1.2,
        "ci_upper": 4.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Phase 1A: Cohort 1 Dose Escalation",
        "value": 13.5,
        "unit": "months",
        "ci_lower": 4.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Phase 1A: Cohort 2 Dose Escalation",
        "value": 4.5,
        "unit": "months",
        "ci_lower": 3.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Phase 1A: Cohort 3 Dose Escalation",
        "value": 10.2,
        "unit": "months",
        "ci_lower": 4.1,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Phase 1A: Cohort 4 Dose Escalation",
        "value": 3.8,
        "unit": "months",
        "ci_lower": 2.1,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG004",
        "arm_title": "Phase 1A: Cohort 5 Dose Escalation",
        "value": 2.1,
        "unit": "months",
        "ci_lower": 0.5,
        "ci_upper": 25.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG005",
        "arm_title": "Phase 1A: Cohort 6 Dose Escalation",
        "value": 11.3,
        "unit": "months",
        "ci_lower": 4.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG006",
        "arm_title": "Phase 1A: Cohort 7 Dose Escalation",
        "value": 8.7,
        "unit": "months",
        "ci_lower": 2.6,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG007",
        "arm_title": "Phase 1A: Cohort 8 Dose Escalation",
        "value": 2.0,
        "unit": "months",
        "ci_lower": 1.1,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG008",
        "arm_title": "Phase 1A: Cohort 9 Dose Escalation",
        "value": 10.9,
        "unit": "months",
        "ci_lower": 1.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG009",
        "arm_title": "Phase 1A: Cohort 10 Dose Escalation",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG010",
        "arm_title": "Phase 1A: Cohort 11 Dose Escalation",
        "value": 14.8,
        "unit": "months",
        "ci_lower": 2.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG011",
        "arm_title": "Phase 1A: Cohort 12 Dose Escalation",
        "value": 2.5,
        "unit": "months",
        "ci_lower": 1.2,
        "ci_upper": 13.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG012",
        "arm_title": "Phase 1B Dose Expansion",
        "value": 15.1,
        "unit": "months",
        "ci_lower": 2.7,
        "ci_upper": 26.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "ASTX029"
      ],
      "OG001": [
        "ASTX029"
      ],
      "OG002": [
        "ASTX029"
      ],
      "OG003": [
        "ASTX029"
      ],
      "OG004": [
        "ASTX029"
      ],
      "OG005": [
        "ASTX029"
      ],
      "OG006": [
        "ASTX029"
      ],
      "OG007": [
        "ASTX029"
      ],
      "OG008": [
        "ASTX029"
      ],
      "OG009": [
        "ASTX029"
      ],
      "OG010": [
        "ASTX029"
      ],
      "OG011": [
        "ASTX029"
      ],
      "OG012": [
        "ASTX029"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER",
      "OG002": "OTHER",
      "OG003": "OTHER",
      "OG004": "OTHER",
      "OG005": "OTHER",
      "OG006": "OTHER",
      "OG007": "OTHER",
      "OG008": "OTHER",
      "OG009": "OTHER",
      "OG010": "OTHER",
      "OG011": "OTHER",
      "OG012": "OTHER"
    }
  },
  {
    "nct_id": "NCT00721799",
    "brief_title": "F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients",
    "status": "COMPLETED",
    "start_date": "2008-03-01",
    "completion_date": "2014-12-31",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "University of Iowa",
    "url": "https://clinicaltrials.gov/study/NCT00721799",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "FLT PET Scan",
        "value": 4.23,
        "unit": "standardized uptake value (SUV)",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "FLT PET Scan",
        "value": 4.23,
        "unit": "standardized uptake value (SUV)",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "18F-Fluorothymidine (FLT) PET scan"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER"
    }
  },
  {
    "nct_id": "NCT03526900",
    "brief_title": "Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-na\u00efve Patients With Asymptomatic Brain Metastasis",
    "status": "COMPLETED",
    "start_date": "2018-07-07",
    "completion_date": "2022-03-31",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Spanish Lung Cancer Group",
    "url": "https://clinicaltrials.gov/study/NCT03526900",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "EGFR mutation"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "ALK fusion"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Atezolizumab",
        "value": 62.2,
        "unit": "percentage of participants",
        "ci_lower": 47.1,
        "ci_upper": 76.2,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Atezolizumab",
        "Carboplatin",
        "Pemetrexed"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT03535727",
    "brief_title": "A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer",
    "status": "COMPLETED",
    "start_date": "2018-06-21",
    "completion_date": "2022-10-03",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
    "url": "https://clinicaltrials.gov/study/NCT03535727",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase 1 MTD/ Phase 2",
        "value": 5.92,
        "unit": "months",
        "ci_lower": 5.52,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Gemcitabine",
        "Nab-paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo"
    }
  },
  {
    "nct_id": "NCT00724503",
    "brief_title": "FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2006-08",
    "completion_date": "2015-05",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sirtex Medical",
    "url": "https://clinicaltrials.gov/study/NCT00724503",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "mFOLFOX6 Plus SIRT",
        "value": 10.7,
        "unit": "Months",
        "ci_lower": 9.9,
        "ci_upper": 11.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "mFOLFOX6 Alone",
        "value": 10.2,
        "unit": "Months",
        "ci_lower": 9.4,
        "ci_upper": 11.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Oxaliplatin",
        "Leucovorin",
        "5-Fluorouracil"
      ],
      "OG001": [
        "Oxaliplatin",
        "Leucovorin",
        "5-Fluorouracil"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT03563716",
    "brief_title": "A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Na\u00efve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2018-08-10",
    "completion_date": "2019-06-30",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Genentech, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT03563716",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Tumor PD-L1 expression required; method/threshold not specified"
      },
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "Sensitizing EGFR mutation excluded"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "ALK fusion oncogene excluded"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Placebo + Atezolizumab",
        "value": 16.2,
        "unit": "percentage of participants",
        "ci_lower": 6.69,
        "ci_upper": 25.66,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Tiragolumab + Atezolizumab",
        "value": 31.3,
        "unit": "percentage of participants",
        "ci_lower": 19.49,
        "ci_upper": 43.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Placebo + Atezolizumab",
        "value": 3.58,
        "unit": "months",
        "ci_lower": 2.73,
        "ci_upper": 4.44,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Tiragolumab + Atezolizumab",
        "value": 5.42,
        "unit": "months",
        "ci_lower": 4.21,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Atezolizumab"
      ],
      "OG001": [
        "Tiragolumab",
        "Atezolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO"
    }
  },
  {
    "nct_id": "NCT00721162",
    "brief_title": "Study of Ramucirumab in Ovarian Cancer",
    "status": "COMPLETED",
    "start_date": "2008-08",
    "completion_date": "2012-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00721162",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ramucirumab",
        "value": 25.0,
        "unit": "percentage of participants",
        "ci_lower": 14.7,
        "ci_upper": 37.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Ramucirumab",
        "value": 5.0,
        "unit": "percentage of participants",
        "ci_lower": 1.0,
        "ci_upper": 13.9,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ramucirumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00735696",
    "brief_title": "A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2009-01",
    "completion_date": "2011-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00735696",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV",
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ramucirumab + Paclitaxel + Carboplatin",
        "value": 59.0,
        "unit": "percentage of participants",
        "ci_lower": 41.3,
        "ci_upper": 72.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Ramucirumab + Paclitaxel + Carboplatin",
        "value": 74.6,
        "unit": "percentage of participants",
        "ci_lower": 57.9,
        "ci_upper": 85.4,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ramucirumab",
        "Paclitaxel",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00728949",
    "brief_title": "A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2008-08",
    "completion_date": "2012-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00728949",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "\u226510% nuclear staining of infiltrating cancer cells for ER; positive biochemical test acceptable"
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": "\u226510% nuclear staining of infiltrating cancer cells for PR (PgR); positive biochemical test acceptable"
      }
    ],
    "cancer_stages": [
      "III",
      "IV",
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "IMC-A12 (Cixutumumab) + Antiestrogen Therapy",
        "value": 2.0,
        "unit": "Months",
        "ci_lower": 1.9,
        "ci_upper": 3.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "IMC-A12 (Cixutumumab)",
        "value": 3.1,
        "unit": "Months",
        "ci_lower": 1.9,
        "ci_upper": 4.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "IMC-A12 (Cixutumumab) + Antiestrogen Therapy",
        "value": 20.3,
        "unit": "Months",
        "ci_lower": 11.5,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "IMC-A12 (Cixutumumab)",
        "value": null,
        "unit": "Months",
        "ci_lower": 17.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "IMC-A12 (cixutumumab)",
        "tamoxifen",
        "Anastrozole",
        "Letrozole",
        "Exemestane",
        "Fulvestrant"
      ],
      "OG001": [
        "IMC-A12 (cixutumumab)"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00725764",
    "brief_title": "Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck",
    "status": "COMPLETED",
    "start_date": "2007-08-27",
    "completion_date": "2009-05-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "GlaxoSmithKline",
    "url": "https://clinicaltrials.gov/study/NCT00725764",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Foretinib 240 mg",
        "value": 0.0,
        "unit": "Percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 23.2,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "GSK1363089 (foretinib)"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT00722553",
    "brief_title": "Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder",
    "status": "COMPLETED",
    "start_date": "2008-07",
    "completion_date": "2011-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Acrotech Biopharma Inc.",
    "url": "https://clinicaltrials.gov/study/NCT00722553",
    "cancer_types": [
      "BLCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Evaluable Population",
        "value": 1.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": 17.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Evaluable Population",
        "value": 4.0,
        "unit": "Months",
        "ci_lower": 2.1,
        "ci_upper": 4.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Evaluable Population",
        "value": 9.3,
        "unit": "Months",
        "ci_lower": 5.6,
        "ci_upper": 13.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pralatrexate Injection"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo"
    }
  },
  {
    "nct_id": "NCT03523702",
    "brief_title": "The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial",
    "status": "COMPLETED",
    "start_date": "2018-08-30",
    "completion_date": "2022-11-18",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Albert Einstein College of Medicine",
    "url": "https://clinicaltrials.gov/study/NCT03523702",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "II",
      "III",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "PembroRT Cohort",
        "value": 19.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "PembroRT Cohort",
        "value": 23.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "PembroRT Cohort",
        "value": 19.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO"
    }
  },
  {
    "nct_id": "NCT03526679",
    "brief_title": "Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma",
    "status": "COMPLETED",
    "start_date": "2018-07-12",
    "completion_date": "2021-06-30",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Taiwan University Hospital",
    "url": "https://clinicaltrials.gov/study/NCT03526679",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Experimental arm",
        "value": 6.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Lenvatinib",
        "Eribulin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT03575793",
    "brief_title": "A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2018-09-06",
    "completion_date": "2023-09-25",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Salma Sabbour",
    "url": "https://clinicaltrials.gov/study/NCT03575793",
    "cancer_types": [
      "SCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Plinabulin 30mg/m^2 With Nivolumab and Ipilimumab",
        "value": 1.6,
        "unit": "Months",
        "ci_lower": 1.2,
        "ci_upper": 2.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab",
        "Ipilimumab",
        "Plinabulin"
      ],
      "OG001": [
        "Nivolumab",
        "Ipilimumab",
        "Plinabulin"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO"
    }
  },
  {
    "nct_id": "NCT00721409",
    "brief_title": "Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2008-09-15",
    "completion_date": "2013-11-29",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT00721409",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "estrogen receptor positive"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 negative"
      },
      {
        "target": "CCND1",
        "status": "POSITIVE",
        "details": "CCND1 amplification (Phase 2 Part 2; central laboratory)"
      },
      {
        "target": "CDKN2A",
        "status": "NEGATIVE",
        "details": "loss of p16 (assessed by central laboratory)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase 2 (Palbociclib + Letrozole)",
        "value": 20.2,
        "unit": "Months",
        "ci_lower": 13.8,
        "ci_upper": 27.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Phase 2 (Letrozole)",
        "value": 10.2,
        "unit": "Months",
        "ci_lower": 5.7,
        "ci_upper": 12.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Ph2P1 (Palbociclib + Letrozole)",
        "value": 26.1,
        "unit": "Months",
        "ci_lower": 11.2,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Ph2P1 (Letrozole)",
        "value": 5.7,
        "unit": "Months",
        "ci_lower": 2.6,
        "ci_upper": 10.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Ph2P2 (Palbociclib + Letrozole)",
        "value": 18.1,
        "unit": "Months",
        "ci_lower": 13.1,
        "ci_upper": 27.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG005",
        "arm_title": "Ph2P2 (Letrozole)",
        "value": 11.1,
        "unit": "Months",
        "ci_lower": 7.1,
        "ci_upper": 16.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "palbociclib",
        "letrozole"
      ],
      "OG001": [
        "letrozole"
      ],
      "OG002": [
        "palbociclib",
        "letrozole"
      ],
      "OG003": [
        "letrozole"
      ],
      "OG004": [
        "palbociclib",
        "letrozole"
      ],
      "OG005": [
        "letrozole"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other",
      "OG004": "Targeted_Other",
      "OG005": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03573947",
    "brief_title": "Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC",
    "status": "COMPLETED",
    "start_date": "2018-10-02",
    "completion_date": "2023-03-12",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Jeffrey Clarke",
    "url": "https://clinicaltrials.gov/study/NCT03573947",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "If positive, must have received \u22651 prior TKI; mutations sensitive to available targeted inhibitors"
      },
      {
        "target": "ALK",
        "status": "POSITIVE",
        "details": "If positive (ALK translocation), must have received \u22651 prior TKI; translocation sensitive to available targeted inhibitors"
      },
      {
        "target": "ROS1",
        "status": "POSITIVE",
        "details": "If positive (ROS1 translocation), must have received \u22651 prior TKI; translocation sensitive to available targeted inhibitors"
      }
    ],
    "cancer_stages": [
      "IV",
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "nivolumab, ipilimumab and paclitaxel",
        "value": 9.4,
        "unit": "months",
        "ci_lower": 5.9,
        "ci_upper": 16.6,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab",
        "Ipilimumab",
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT00725712",
    "brief_title": "Study of GSK1363089 in Metastatic Gastric Cancer",
    "status": "COMPLETED",
    "start_date": "2007-03-31",
    "completion_date": "2009-11-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "GlaxoSmithKline",
    "url": "https://clinicaltrials.gov/study/NCT00725712",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "GSK1363089, Intermittent 5 and 9 Dosing",
        "value": 0.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "GSK136308, Daily Dosing",
        "value": 0.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "GSK1363089, Intermittent 5 and 9 Dosing",
        "value": 1.64,
        "unit": "months",
        "ci_lower": 1.61,
        "ci_upper": 1.81,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "GSK136308, Daily Dosing",
        "value": 1.77,
        "unit": "months",
        "ci_lower": 1.64,
        "ci_upper": 1.84,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "GSK1363089, Intermittent 5 and 9 Dosing",
        "value": 7.36,
        "unit": "months",
        "ci_lower": 0.66,
        "ci_upper": 15.61,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "GSK136308, Daily Dosing",
        "value": 4.34,
        "unit": "months",
        "ci_lower": 0.79,
        "ci_upper": 9.23,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "GSK1363089 (foretinib)"
      ],
      "OG001": [
        "GSK1363089 (foretinib)"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT03558139",
    "brief_title": "Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy",
    "status": "COMPLETED",
    "start_date": "2018-05-23",
    "completion_date": "2020-12-03",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Gilead Sciences",
    "url": "https://clinicaltrials.gov/study/NCT03558139",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Availability of pre-treatment tumor tissue to evaluate PD-L1 expression"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Magrolimab 45 mg/kg + Avelumab 800 mg (Ovarian Cancer Participants)",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 16.8,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Magrolimab",
        "Avelumab"
      ],
      "OG001": [
        "Magrolimab",
        "Avelumab"
      ],
      "OG002": [
        "Magrolimab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted",
      "OG002": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03575065",
    "brief_title": "Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China",
    "status": "COMPLETED",
    "start_date": "2018-06-22",
    "completion_date": "2020-10-09",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "BeiGene",
    "url": "https://clinicaltrials.gov/study/NCT03575065",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "BRCA1",
        "status": "POSITIVE",
        "details": "Deleterious or suspected deleterious germline BRCA1 mutation"
      },
      {
        "target": "BRCA2",
        "status": "POSITIVE",
        "details": "Deleterious or suspected deleterious germline BRCA2 mutation"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "Histologically or cytologically confirmed HER2(-) breast cancer"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "TNBC",
        "value": 38.2,
        "unit": "Percentage of participants",
        "ci_lower": 25.4,
        "ci_upper": 52.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "HR(+) /HER2(-) Breast Cancer",
        "value": 61.9,
        "unit": "Percentage of participants",
        "ci_lower": 38.4,
        "ci_upper": 81.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "TNBC (IRC)",
        "value": 5.49,
        "unit": "Months",
        "ci_lower": 3.65,
        "ci_upper": 7.33,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "HR(+) /HER2(-) Breast Cancer (IRC)",
        "value": 9.2,
        "unit": "Months",
        "ci_lower": 7.39,
        "ci_upper": 11.93,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "TNBC (Investigator)",
        "value": 3.78,
        "unit": "Months",
        "ci_lower": 3.68,
        "ci_upper": 6.41,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "HR(+) /HER2(-) Breast Cancer (Investigator)",
        "value": 9.69,
        "unit": "Months",
        "ci_lower": 5.55,
        "ci_upper": 12.85,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "TNBC",
        "value": 17.08,
        "unit": "Months",
        "ci_lower": 15.57,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "HR(+) /HER2(-) Breast Cancer",
        "value": 27.89,
        "unit": "Months",
        "ci_lower": 18.1,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pamiparib"
      ],
      "OG001": [
        "Pamiparib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00733408",
    "brief_title": "Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2008-04-23",
    "completion_date": "2017-07-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "University of Washington",
    "url": "https://clinicaltrials.gov/study/NCT00733408",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "\u226410% by immunohistochemistry (IHC)"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "\u226410% by immunohistochemistry (IHC)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "Normal (\u226410% of cells) by IHC or by FISH"
      },
      {
        "target": "CA15-3",
        "status": "HIGH",
        "details": "Rising by two consecutive measurements \u226514 days apart with the second \u226520% increase over the first and CA15-3 \u226540 units/mL; most recent measurement within 42 days prior to registration"
      },
      {
        "target": "CA27.29",
        "status": "HIGH",
        "details": "Rising by two consecutive measurements \u226514 days apart with the second \u226520% increase over the first and CA27.29 \u226540 units/mL; most recent measurement within 42 days prior to registration"
      },
      {
        "target": "CEA",
        "status": "HIGH",
        "details": "Rising by two consecutive measurements \u226514 days apart with the second \u226520% increase over the first and CEA \u22654 ng/mL; most recent measurement within 42 days prior to registration"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Tx (Chemo, MoAb, and Enzyme Inhibitor)",
        "value": 9.1,
        "unit": "Months",
        "ci_lower": 7.2,
        "ci_upper": 11.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Tx (Chemo, MoAb, and Enzyme Inhibitor)",
        "value": 18.1,
        "unit": "Months",
        "ci_lower": 15.6,
        "ci_upper": 21.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "paclitaxel albumin-stabilized nanoparticle formulation",
        "bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03529110",
    "brief_title": "DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2018-08-09",
    "completion_date": "2021-05-21",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Daiichi Sankyo",
    "url": "https://clinicaltrials.gov/study/NCT03529110",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "Confirmed HER2-positive per ASCO-CAP guidelines by central laboratory assessment of most recent tumor tissue; fresh biopsy required if archived tissue unavailable"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Trastuzumab Deruxtecan (T-DXd)",
        "value": null,
        "unit": "months",
        "ci_lower": 18.5,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Ado-trastuzumab Emtansine (T-DM1)",
        "value": 6.8,
        "unit": "months",
        "ci_lower": 5.6,
        "ci_upper": 8.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Trastuzumab Deruxtecan (T-DXd)",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Ado-trastuzumab Emtansine (T-DM1)",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Trastuzumab Deruxtecan (T-DXd)",
        "value": 79.7,
        "unit": "Percentage of Participants",
        "ci_lower": 74.3,
        "ci_upper": 84.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Ado-trastuzumab Emtansine (T-DM1)",
        "value": 34.2,
        "unit": "Percentage of Participants",
        "ci_lower": 28.5,
        "ci_upper": 40.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Trastuzumab Deruxtecan (T-DXd)",
        "value": 77.0,
        "unit": "Percentage of Participants",
        "ci_lower": 71.2,
        "ci_upper": 82.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Ado-trastuzumab Emtansine (T-DM1)",
        "value": 36.9,
        "unit": "Percentage of Participants",
        "ci_lower": 31.0,
        "ci_upper": 43.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG000",
        "arm_title": "Trastuzumab Deruxtecan (T-DXd)",
        "value": null,
        "unit": "months",
        "ci_lower": 20.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG001",
        "arm_title": "Ado-trastuzumab Emtansine (T-DM1)",
        "value": null,
        "unit": "months",
        "ci_lower": 12.6,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG000",
        "arm_title": "Trastuzumab Deruxtecan (T-DXd)",
        "value": null,
        "unit": "months",
        "ci_lower": 20.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG001",
        "arm_title": "Ado-trastuzumab Emtansine (T-DM1)",
        "value": null,
        "unit": "months",
        "ci_lower": 14.1,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Trastuzumab deruxtecan (T-DXd)"
      ],
      "OG001": [
        "Ado-trastuzumab emtansine (T-DM1)"
      ]
    },
    "treatment_class_map": {
      "OG000": "ADC",
      "OG001": "ADC"
    }
  },
  {
    "nct_id": "NCT00753545",
    "brief_title": "Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer",
    "status": "COMPLETED",
    "start_date": "2008-08-28",
    "completion_date": "2010-06-30",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT00753545",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Olaparib 400 mg bd",
        "value": 8.4,
        "unit": "Months",
        "ci_lower": 7.4,
        "ci_upper": 11.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo bd",
        "value": 4.8,
        "unit": "Months",
        "ci_lower": 4.0,
        "ci_upper": 5.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "AZD2281"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT00739661",
    "brief_title": "A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission",
    "status": "COMPLETED",
    "start_date": "2008-12",
    "completion_date": "2010-11",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Genentech, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT00739661",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "MAINTENANCE",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Vismodegib 150 mg",
        "value": 7.5,
        "unit": "Months",
        "ci_lower": 5.59,
        "ci_upper": 11.24,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo to Vismodegib",
        "value": 5.8,
        "unit": "Months",
        "ci_lower": 4.14,
        "ci_upper": 7.49,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Vismodegib 150 mg",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo to Vismodegib",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Vismodegib 150 mg"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT00738530",
    "brief_title": "A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy",
    "status": "COMPLETED",
    "start_date": "2004-06",
    "completion_date": "2008-09",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT00738530",
    "cancer_types": [
      "KIRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab + IFN-Alfa-2A",
        "value": 23.3,
        "unit": "Months",
        "ci_lower": 20.4,
        "ci_upper": 27.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + IFN-Alfa-2A",
        "value": 21.3,
        "unit": "Months",
        "ci_lower": 18.4,
        "ci_upper": 24.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Bevacizumab [Avastin]",
        "Interferon alfa 2a [Roferon]"
      ],
      "OG001": [
        "Interferon alfa 2a [Roferon]"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "IO"
    }
  },
  {
    "nct_id": "NCT03617679",
    "brief_title": "Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2019-03-06",
    "completion_date": "2023-10-31",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "University of Colorado, Denver",
    "url": "https://clinicaltrials.gov/study/NCT03617679",
    "cancer_types": [
      "UCEC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "III",
      "IV",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "MAINTENANCE",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Active Ingredient",
        "value": 28.1,
        "unit": "Months",
        "ci_lower": 12.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 8.7,
        "unit": "Months",
        "ci_lower": 5.4,
        "ci_upper": 16.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Active Ingredient",
        "value": null,
        "unit": "Months",
        "ci_lower": 34.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 28.4,
        "unit": "Months",
        "ci_lower": 19.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Rucaparib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT03607539",
    "brief_title": "Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC",
    "status": "COMPLETED",
    "start_date": "2018-08-23",
    "completion_date": "2023-02-13",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Innovent Biologics (Suzhou) Co. Ltd.",
    "url": "https://clinicaltrials.gov/study/NCT03607539",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "no tumor EGFR-sensitive mutations"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "no ALK gene rearrangement"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IIIC",
      "IV",
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Sintilimab Combination",
        "value": 8.9,
        "unit": "Months",
        "ci_lower": 7.1,
        "ci_upper": 11.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo Combination",
        "value": 5.0,
        "unit": "Months",
        "ci_lower": 4.8,
        "ci_upper": 6.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Sintilimab Combination",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo Combination",
        "value": null,
        "unit": "Months",
        "ci_lower": 11.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Sintilimab",
        "Pemetrexed",
        "Platinum"
      ],
      "OG001": [
        "Pemetrexed",
        "Platinum"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT03631199",
    "brief_title": "Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2018-12-21",
    "completion_date": "2021-08-09",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT03631199",
    "cancer_types": [
      "NSCLC",
      "LUAD",
      "LUSC"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Known PD-L1 status required prior to randomization (tissue biopsy or archival); PD-L1 IHC 22C3 pharmDx assay"
      },
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "No EGFR sensitizing mutations (identified in exons 19, 20, or 21)"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "No ALK rearrangement by locally approved laboratory testing"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV",
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Part 2: Canakinumab+Pembro+CTx",
        "value": 6.77,
        "unit": "months",
        "ci_lower": 5.62,
        "ci_upper": 7.75,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Part 2: Placebo+Pembro+CTx",
        "value": 6.77,
        "unit": "months",
        "ci_lower": 5.52,
        "ci_upper": 6.93,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Part 2: Canakinumab+Pembro+CTx",
        "value": 20.83,
        "unit": "months",
        "ci_lower": 16.26,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Part 2: Placebo+Pembro+CTx",
        "value": 20.17,
        "unit": "months",
        "ci_lower": 16.23,
        "ci_upper": 22.37,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "canakinumab",
        "pembrolizumab",
        "carboplatin",
        "pemetrexed"
      ],
      "OG001": [
        "canakinumab",
        "pembrolizumab",
        "cisplatin",
        "pemetrexed"
      ],
      "OG002": [
        "canakinumab",
        "pembrolizumab",
        "carboplatin",
        "paclitaxel"
      ],
      "OG003": [
        "canakinumab",
        "pembrolizumab",
        "carboplatin",
        "cisplatin",
        "pemetrexed",
        "paclitaxel"
      ],
      "OG004": [
        "pembrolizumab",
        "carboplatin",
        "cisplatin",
        "pemetrexed",
        "paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Combo_Chemo_IO",
      "OG002": "Combo_Chemo_IO",
      "OG003": "Combo_Chemo_IO",
      "OG004": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT00748553",
    "brief_title": "A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2008-09",
    "completion_date": "2015-10",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "University of Utah",
    "url": "https://clinicaltrials.gov/study/NCT00748553",
    "cancer_types": [
      "BRCA",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 (Her-2/neu) negative required for Phase II"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 1",
        "value": 61.5,
        "unit": "percent of participants with response",
        "ci_lower": 35.0,
        "ci_upper": 87.95,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase II",
        "value": 53.8,
        "unit": "percentage of participants",
        "ci_lower": 26.7,
        "ci_upper": 80.9,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Azacitidine (Vidaza)",
        "Nab-paclitaxel (Abraxane)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo"
    }
  },
  {
    "nct_id": "NCT00770588",
    "brief_title": "Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa\u00ae 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)",
    "status": "COMPLETED",
    "start_date": "2008-09",
    "completion_date": "2011-01",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT00770588",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "Tumour EGFR gene copy number; tumour EGFR gene mutation status; tumour EGFR protein expression"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV",
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "MAINTENANCE",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Gefitinib",
        "value": 4.8,
        "unit": "Months",
        "ci_lower": 3.19,
        "ci_upper": 8.54,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 2.6,
        "unit": "Months",
        "ci_lower": 1.61,
        "ci_upper": 2.76,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Gefitinib",
        "value": 18.7,
        "unit": "Months",
        "ci_lower": 15.6,
        "ci_upper": 22.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 16.9,
        "unit": "Months",
        "ci_lower": 14.5,
        "ci_upper": 19.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Gefitinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT03594747",
    "brief_title": "A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2018-07-30",
    "completion_date": "2020-09-30",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "BeiGene",
    "url": "https://clinicaltrials.gov/study/NCT03594747",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "sensitizing mutation"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "gene translocation"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Tislelizumab + Paclitaxel + Carboplatin",
        "value": 7.6,
        "unit": "Months",
        "ci_lower": 5.95,
        "ci_upper": 9.79,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Tislelizumab + Nab-paclitaxel + Carboplatin",
        "value": 7.6,
        "unit": "Months",
        "ci_lower": 5.75,
        "ci_upper": 11.01,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Paclitaxel + Carboplatin",
        "value": 5.5,
        "unit": "Months",
        "ci_lower": 4.21,
        "ci_upper": 5.65,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Tislelizumab + Paclitaxel + Carboplatin",
        "value": 26.1,
        "unit": "Months",
        "ci_lower": 18.99,
        "ci_upper": 33.81,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Tislelizumab + Nab-paclitaxel + Carboplatin",
        "value": 23.3,
        "unit": "Months",
        "ci_lower": 18.76,
        "ci_upper": 26.38,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Paclitaxel + Carboplatin",
        "value": 19.4,
        "unit": "Months",
        "ci_lower": 15.97,
        "ci_upper": 23.43,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Tislelizumab",
        "Paclitaxel",
        "Carboplatin"
      ],
      "OG001": [
        "Tislelizumab",
        "Nab-paclitaxel",
        "Carboplatin"
      ],
      "OG002": [
        "Paclitaxel",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Combo_Chemo_IO",
      "OG002": "Chemo"
    }
  },
  {
    "nct_id": "NCT00769067",
    "brief_title": "A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen",
    "status": "COMPLETED",
    "start_date": "2008-11",
    "completion_date": "2010-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT00769067",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "ANY",
        "details": "tissue available for future KRAS/EGFR testing"
      },
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "tissue available for future KRAS/EGFR testing"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Erlotinib",
        "value": 8.3,
        "unit": "weeks",
        "ci_lower": 7.9,
        "ci_upper": 11.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Dacomitinib",
        "value": 12.4,
        "unit": "weeks",
        "ci_lower": 8.1,
        "ci_upper": 16.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Erlotinib",
        "value": 32.3,
        "unit": "weeks",
        "ci_lower": 24.0,
        "ci_upper": 40.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Dacomitinib",
        "value": 41.4,
        "unit": "weeks",
        "ci_lower": 30.4,
        "ci_upper": 48.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Erlotinib"
      ],
      "OG001": [
        "Dacomitinib",
        "PF-00299804"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT03615326",
    "brief_title": "Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)",
    "status": "COMPLETED",
    "start_date": "2018-10-05",
    "completion_date": "2024-03-20",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT03615326",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "IHC 3+ OR IHC 2+ with in-situ hybridization positive (ISH+) / FISH, assessed by central review on primary or metastatic tumor"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Global Pembrolizumab + Standard of Care First Course",
        "value": 10.0,
        "unit": "Months",
        "ci_lower": 8.6,
        "ci_upper": 12.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Global Standard of Care",
        "value": 8.1,
        "unit": "Months",
        "ci_lower": 7.0,
        "ci_upper": 8.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Global Pembrolizumab + Standard of Care First Course",
        "value": 20.0,
        "unit": "Months",
        "ci_lower": 17.8,
        "ci_upper": 22.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Global Standard of Care First Course",
        "value": 16.8,
        "unit": "Months",
        "ci_lower": 14.9,
        "ci_upper": 18.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Trastuzumab",
        "Cisplatin",
        "5-FU",
        "Oxaliplatin",
        "Capecitabine"
      ],
      "OG001": [
        "Trastuzumab",
        "Cisplatin",
        "5-FU",
        "Oxaliplatin",
        "Capecitabine"
      ],
      "OG002": [
        "Pembrolizumab",
        "Trastuzumab",
        "S-1",
        "Oxaliplatin"
      ],
      "OG003": [
        "Trastuzumab",
        "S-1",
        "Oxaliplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_IO",
      "OG003": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03595124",
    "brief_title": "A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2019-01-08",
    "completion_date": "2024-09-30",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT03595124",
    "cancer_types": [
      "KIRC"
    ],
    "biomarkers": [
      {
        "target": "TFE3",
        "status": "POSITIVE",
        "details": "TFE3 nuclear protein expression by immunohistochemistry (any nuclear positivity considered positive) or evidence of TFE3 translocation by FISH or RT-PCR; testing at a CLIA-certified laboratory"
      },
      {
        "target": "TFEB",
        "status": "POSITIVE",
        "details": "Evidence of TFEB translocation by FISH or RT-PCR at a CLIA-certified laboratory"
      }
    ],
    "cancer_stages": [
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A (Axitinib, Nivolumab)",
        "value": 33.0,
        "unit": "percentage of participants",
        "ci_lower": 18.32,
        "ci_upper": 60.64,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm C (Nivolumab)",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A (Axitinib, Nivolumab)",
        "value": 100.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm C (Nivolumab)",
        "value": 80.0,
        "unit": "percentage of participants",
        "ci_lower": 63.45,
        "ci_upper": 100.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Axitinib",
        "Nivolumab"
      ],
      "OG001": [
        "Nivolumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_IO",
      "OG001": "IO"
    }
  },
  {
    "nct_id": "NCT03609359",
    "brief_title": "Lenvatinib and Pembrolizumab Simultaneous Combination Study",
    "status": "COMPLETED",
    "start_date": "2018-10-03",
    "completion_date": "2021-04-30",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Center Hospital East",
    "url": "https://clinicaltrials.gov/study/NCT03609359",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Lenvatinib + Pembrolizumab",
        "value": 20.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Lenvatinib + Pembrolizumab",
        "value": 7.1,
        "unit": "months",
        "ci_lower": 5.4,
        "ci_upper": 13.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Lenvatinib + Pembrolizumab",
        "value": 24.5,
        "unit": "months",
        "ci_lower": 11.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Lenvatinib",
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_IO"
    }
  },
  {
    "nct_id": "NCT00741988",
    "brief_title": "Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2008-09",
    "completion_date": "2010-09",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SCRI Development Innovations, LLC",
    "url": "https://clinicaltrials.gov/study/NCT00741988",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "III",
      "IV",
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Ixabepilone/Carboplatin",
        "value": 29.0,
        "unit": "percentage of participants",
        "ci_lower": 16.0,
        "ci_upper": 45.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Ixabepilone/Carboplatin/Bevacizumab",
        "value": 50.0,
        "unit": "percentage of participants",
        "ci_lower": 34.0,
        "ci_upper": 66.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ixabepilone/Carboplatin",
        "value": 5.3,
        "unit": "months",
        "ci_lower": 2.8,
        "ci_upper": 8.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Ixabepilone/Carboplatin/Bevacizumab",
        "value": 6.7,
        "unit": "months",
        "ci_lower": 5.1,
        "ci_upper": 8.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Ixabepilone/Carboplatin",
        "value": 9.3,
        "unit": "months",
        "ci_lower": 6.4,
        "ci_upper": 16.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Ixabepilone/Carboplatin/Bevacizumab",
        "value": 13.2,
        "unit": "months",
        "ci_lower": 8.9,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ixabepilone",
        "Carboplatin"
      ],
      "OG001": [
        "Ixabepilone",
        "Carboplatin",
        "Bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00754845",
    "brief_title": "Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy",
    "status": "COMPLETED",
    "start_date": "2004-11-23",
    "completion_date": "2015-12-21",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Canadian Cancer Trials Group",
    "url": "https://clinicaltrials.gov/study/NCT00754845",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Estrogen receptor positive (ER+) primary tumor at diagnosis; defined as receptor content >10 fmol/mg protein or positive by immunocytochemical assay. (Patients previously enrolled on CAN\u2011NCIC\u2011MA17 may have unknown hormone receptor status.)"
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": "Progesterone receptor positive (PR+) primary tumor at diagnosis; defined as receptor content >10 fmol/mg protein or positive by immunocytochemical assay. (Patients previously enrolled on CAN\u2011NCIC\u2011MA17 may have unknown hormone receptor status.)"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Letrozole",
        "value": 0.95,
        "unit": "probability of DFS at 5 years",
        "ci_lower": 0.93,
        "ci_upper": 0.96,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 0.91,
        "unit": "probability of DFS at 5 years",
        "ci_lower": 0.89,
        "ci_upper": 0.93,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "letrozole"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT03631407",
    "brief_title": "Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)",
    "status": "COMPLETED",
    "start_date": "2018-09-24",
    "completion_date": "2021-06-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT03631407",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "MSI",
        "status": "NEGATIVE",
        "details": "Microsatellite stable (MSS)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Vicriviroc QD at Dose Level 1 (150 mg) + Pembrolizumab (200 mg)",
        "value": 5.0,
        "unit": "Percentage of Participants",
        "ci_lower": 0.1,
        "ci_upper": 24.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Vicriviroc QD at Dose Level 2 (250 mg) + Pembrolizumab (200 mg)",
        "value": 5.0,
        "unit": "Percentage of Participants",
        "ci_lower": 0.1,
        "ci_upper": 24.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Vicriviroc QD at Dose Level 1 (150 mg) + Pembrolizumab (200 mg)",
        "value": 2.1,
        "unit": "Months",
        "ci_lower": 1.8,
        "ci_upper": 3.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Vicriviroc QD at Dose Level 2 (250 mg) + Pembrolizumab (200 mg)",
        "value": 2.1,
        "unit": "Months",
        "ci_lower": 1.6,
        "ci_upper": 3.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Vicriviroc QD at Dose Level 1 (150 mg) + Pembrolizumab (200 mg)",
        "value": 4.6,
        "unit": "Months",
        "ci_lower": 2.7,
        "ci_upper": 12.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Vicriviroc QD at Dose Level 2 (250 mg) + Pembrolizumab (200 mg)",
        "value": 5.3,
        "unit": "Months",
        "ci_lower": 3.2,
        "ci_upper": 8.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Vicriviroc",
        "Pembrolizumab"
      ],
      "OG001": [
        "Vicriviroc",
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT00767520",
    "brief_title": "Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2009-02",
    "completion_date": "2011-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT00767520",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Histologically-documented invasive estrogen receptor positive breast cancer; tumor tissue available for analysis"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Exemestane + Dasatinib",
        "value": 18.1,
        "unit": "weeks",
        "ci_lower": 15.1,
        "ci_upper": 24.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Exemestane + Placebo",
        "value": 16.1,
        "unit": "weeks",
        "ci_lower": 12.1,
        "ci_upper": 18.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Exemestane",
        "Dasatinib"
      ],
      "OG001": [
        "Exemestane"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT03628716",
    "brief_title": "CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer",
    "status": "COMPLETED",
    "start_date": "2018-09-18",
    "completion_date": "2020-11-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bavarian Nordic",
    "url": "https://clinicaltrials.gov/study/NCT03628716",
    "cancer_types": [
      "BLCA"
    ],
    "biomarkers": [
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "Active HIV infection excluded (positive HIV test is exclusion)"
      },
      {
        "target": "HBV",
        "status": "NEGATIVE",
        "details": "Active HBV excluded (positive HBsAg = active HBV). Resolved HBV (HBcAb+/HBsAg-) allowed but HBV DNA PCR required prior to Day 1"
      },
      {
        "target": "HCV",
        "status": "NEGATIVE",
        "details": "HCV antibody-positive patients eligible only if HCV RNA (PCR) is negative prior to enrollment"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT",
      "IV",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "CV301 + Atezolizumab (Cohort 1)",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "CV301 + Atezolizumab (Cohort 2)",
        "value": 2.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "CV301 + Atezolizumab (Cohort 1)",
        "value": 2.0,
        "unit": "Months",
        "ci_lower": 1.68,
        "ci_upper": 2.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "CV301 + Atezolizumab (Cohort 2)",
        "value": 1.95,
        "unit": "Months",
        "ci_lower": 1.87,
        "ci_upper": 2.07,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "CV301 + Atezolizumab (Cohort 1)",
        "value": 13.8,
        "unit": "Months",
        "ci_lower": 2.37,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "CV301 + Atezolizumab (Cohort 2)",
        "value": 8.13,
        "unit": "Months",
        "ci_lower": 4.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "CV301",
        "Atezolizumab"
      ],
      "OG001": [
        "CV301",
        "Atezolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO"
    }
  },
  {
    "nct_id": "NCT03582475",
    "brief_title": "Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2019-01-11",
    "completion_date": "2025-12-01",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Jonsson Comprehensive Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT03582475",
    "cancer_types": [
      "BLCA",
      "PRAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort 1: Metastatic or Locally Advanced Naive Small Cell Bladder Cancer",
        "value": 100.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Cohort 2: Small Cell or Neuroendocrine Prostate Cancer",
        "value": 66.7,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG000",
        "arm_title": "Cohort 1: Metastatic or Locally Advanced Naive Small Cell Bladder Cancer",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG001",
        "arm_title": "Cohort 2: Small Cell or Neuroendocrine Prostate Cancer",
        "value": 12.6,
        "unit": "Months",
        "ci_lower": 3.15,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1: Metastatic or Locally Advanced Naive Small Cell Bladder Cancer",
        "value": 0.86,
        "unit": "Proportion of patients (12 months)",
        "ci_lower": 0.63,
        "ci_upper": 1.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort 2: Small Cell or Neuroendocrine Prostate Cancer",
        "value": 0.43,
        "unit": "Proportion of patients (12 months)",
        "ci_lower": 0.18,
        "ci_upper": 1.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1: Metastatic or Locally Advanced Naive Small Cell Bladder Cancer",
        "value": 0.86,
        "unit": "Proportion of patients (24 months)",
        "ci_lower": 0.63,
        "ci_upper": 1.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort 2: Small Cell or Neuroendocrine Prostate Cancer",
        "value": 0.14,
        "unit": "Proportion of patients (24 months)",
        "ci_lower": 0.02,
        "ci_upper": 0.88,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1: Metastatic or Locally Advanced Naive Small Cell Bladder Cancer",
        "value": 0.86,
        "unit": "Proportion of patients (12 months)",
        "ci_lower": 0.63,
        "ci_upper": 1.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cohort 2: Small Cell or Neuroendocrine Prostate Cancer",
        "value": 0.71,
        "unit": "Proportion of patients (12 months)",
        "ci_lower": 0.45,
        "ci_upper": 1.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1: Metastatic or Locally Advanced Naive Small Cell Bladder Cancer",
        "value": 0.86,
        "unit": "Proportion of patients (24 months)",
        "ci_lower": 0.63,
        "ci_upper": 1.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cohort 2: Small Cell or Neuroendocrine Prostate Cancer",
        "value": 0.57,
        "unit": "Proportion of patients (24 months)",
        "ci_lower": 0.3,
        "ci_upper": 1.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab"
      ],
      "OG001": [
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO"
    }
  },
  {
    "nct_id": "NCT00742560",
    "brief_title": "A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma",
    "status": "COMPLETED",
    "start_date": "2008-08",
    "completion_date": "2016-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AbbVie (prior sponsor, Abbott)",
    "url": "https://clinicaltrials.gov/study/NCT00742560",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "M-protein",
        "status": "ANY",
        "details": "Measurable monoclonal (M-) protein in serum \u22650.5 g/dL and/or urine \u22650.2 g excreted in 24 h; subjects with free light chain only disease are excluded."
      },
      {
        "target": "Pregnancy",
        "status": "NEGATIVE",
        "details": "Negative urine pregnancy test in women of childbearing potential at screening and prior to prescribing lenalidomide; contraception requirements specified."
      },
      {
        "target": "Creatinine clearance",
        "status": "ANY",
        "details": "Creatinine clearance \u226550 mL/min measured by Cockcroft-Gault."
      },
      {
        "target": "ANC",
        "status": "ANY",
        "details": "Absolute neutrophil count >1000 cells/mm^3 without growth factors for 7 days."
      },
      {
        "target": "Platelets",
        "status": "ANY",
        "details": "Platelets \u226575,000 cells/mm^3 (75 \u00d710^9/L) without platelet transfusion within 72 hours of screening."
      },
      {
        "target": "Hemoglobin",
        "status": "ANY",
        "details": "Hemoglobin \u22658 g/dL without red blood cell transfusion within 72 hours of screening."
      },
      {
        "target": "ALT",
        "status": "ANY",
        "details": "Alanine aminotransferase (ALT) <3\u00d7 upper limit of normal."
      },
      {
        "target": "AST",
        "status": "ANY",
        "details": "Aspartate aminotransferase (AST) <3\u00d7 upper limit of normal."
      },
      {
        "target": "Total bilirubin",
        "status": "ANY",
        "details": "Total bilirubin <2\u00d7 upper limit of normal; direct bilirubin <2.0 mg/dL."
      },
      {
        "target": "Calcium",
        "status": "ANY",
        "details": "Serum calcium (corrected for albumin) <12 mg/dL (subjects with \u226512 mg/dL are excluded)."
      },
      {
        "target": "ECOG",
        "status": "ANY",
        "details": "Eastern Cooperative Oncology Group (ECOG) performance status 0\u20132."
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 2)",
        "value": 91.7,
        "unit": "percentage of participants",
        "ci_lower": 77.5,
        "ci_upper": 98.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 2)",
        "value": 75.7,
        "unit": "percentage of participants",
        "ci_lower": 58.8,
        "ci_upper": 88.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Total (Phase 2)",
        "value": 83.6,
        "unit": "percentage of participants",
        "ci_lower": 73.0,
        "ci_upper": 91.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Elotuzumab 5 mg/kg + Lenalidomide and Dexamethasone (Phase 1)",
        "value": 6.08,
        "unit": "months",
        "ci_lower": 6.05,
        "ci_upper": 6.08,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 1)",
        "value": 11.53,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 1)",
        "value": 52.93,
        "unit": "months",
        "ci_lower": 7.43,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Total (Phase 1)",
        "value": 52.93,
        "unit": "months",
        "ci_lower": 7.43,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 2)",
        "value": 32.49,
        "unit": "months",
        "ci_lower": 14.9,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG005",
        "arm_title": "Elotuzumab 10 mg/kg Administered as an IV Infusion in Combinat",
        "value": 19.94,
        "unit": "months",
        "ci_lower": 12.9,
        "ci_upper": 35.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG006",
        "arm_title": "Total (Phase 2)",
        "value": 28.16,
        "unit": "months",
        "ci_lower": 16.6,
        "ci_upper": 43.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "elotuzumab",
        "lenalidomide",
        "dexamethasone oral"
      ],
      "OG001": [
        "elotuzumab",
        "lenalidomide",
        "dexamethasone oral"
      ],
      "OG002": [
        "elotuzumab",
        "lenalidomide",
        "dexamethasone oral"
      ],
      "OG003": [
        "elotuzumab",
        "lenalidomide",
        "dexamethasone oral"
      ],
      "OG004": [
        "elotuzumab",
        "lenalidomide",
        "dexamethasone oral"
      ],
      "OG005": [
        "elotuzumab",
        "lenalidomide",
        "dexamethasone oral"
      ],
      "OG006": [
        "elotuzumab",
        "lenalidomide",
        "dexamethasone oral"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other",
      "OG004": "Targeted_Other",
      "OG005": "Targeted_Other",
      "OG006": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00793871",
    "brief_title": "Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor",
    "status": "COMPLETED",
    "start_date": "2008-11",
    "completion_date": "2014-04",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT00793871",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": "2L",
    "prior_tki": true,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Sutent (Sunitinib Malate)",
        "value": 46.4,
        "unit": "weeks",
        "ci_lower": 33.6,
        "ci_upper": 53.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Sunitinib Malate"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT00791778",
    "brief_title": "Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer",
    "status": "COMPLETED",
    "start_date": "2008-11",
    "completion_date": "2011-07",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bayer",
    "url": "https://clinicaltrials.gov/study/NCT00791778",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "CA125",
        "status": "LOW",
        "details": "Normal serum CA125 within 7 days of first dose of sorafenib"
      }
    ],
    "cancer_stages": [
      "III",
      "IV"
    ],
    "line_of_therapy": "MAINTENANCE",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Sorafenib (Nexavar, BAY43-9006)",
        "value": 386.0,
        "unit": "Days",
        "ci_lower": 230.0,
        "ci_upper": 691.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 478.0,
        "unit": "Days",
        "ci_lower": 337.0,
        "ci_upper": 567.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Sorafenib (Nexavar, BAY43-9006)",
        "value": null,
        "unit": "Days",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": null,
        "unit": "Days",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Sorafenib (Nexavar, BAY43-9006)"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT00798655",
    "brief_title": "Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer",
    "status": "COMPLETED",
    "start_date": "2007-11",
    "completion_date": "2015-06",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Robert Ferris",
    "url": "https://clinicaltrials.gov/study/NCT00798655",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "Tumor tissue should be submitted for assessment of EGFR and related biomarkers after consent; testing requested but no specific status required."
      }
    ],
    "cancer_stages": [
      "III",
      "IVA"
    ],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Radiation Therapy+Cisplatin+Panitumumab",
        "value": 70.0,
        "unit": "Percent",
        "ci_lower": 58.0,
        "ci_upper": 85.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cisplatin",
        "Panitumumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00785785",
    "brief_title": "A Study of Nilotinib Versus Imatinib in GIST Patients",
    "status": "COMPLETED",
    "start_date": "2009-03",
    "completion_date": "2014-10",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT00785785",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "UNRESECTABLE",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Nilotinib",
        "value": 25.9,
        "unit": "months",
        "ci_lower": 0.0,
        "ci_upper": 32.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Imatinib",
        "value": 29.7,
        "unit": "months",
        "ci_lower": 0.0,
        "ci_upper": 36.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nilotinib (AMN107)"
      ],
      "OG001": [
        "imatinib (STI571)"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT03663205",
    "brief_title": "A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2018-07-23",
    "completion_date": "2020-01-23",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "BeiGene",
    "url": "https://clinicaltrials.gov/study/NCT03663205",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "EGFR-sensitizing mutation"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "ALK gene translocation"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Tislelizumab + Platinum + Pemetrexed",
        "value": 9.7,
        "unit": "Months",
        "ci_lower": 7.72,
        "ci_upper": 11.53,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Platinum + Pemetrexed",
        "value": 7.6,
        "unit": "Months",
        "ci_lower": 5.55,
        "ci_upper": 8.02,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Tislelizumab + Platinum + Pemetrexed",
        "value": 21.4,
        "unit": "Months",
        "ci_lower": 17.91,
        "ci_upper": 25.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Platinum + Pemetrexed",
        "value": 20.1,
        "unit": "Months",
        "ci_lower": 14.88,
        "ci_upper": 28.12,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Tislelizumab",
        "Cisplatin",
        "Carboplatin",
        "Pemetrexed"
      ],
      "OG001": [
        "Cisplatin",
        "Carboplatin",
        "Pemetrexed"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT03653507",
    "brief_title": "A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2018-11-28",
    "completion_date": "2022-10-25",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Astellas Pharma Global Development, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT03653507",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [
      {
        "target": "CLDN18.2",
        "status": "POSITIVE",
        "details": "\u226575% of tumor cells demonstrating moderate to strong membranous staining by central IHC"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-negative as determined by local or central testing on a gastric or GEJ tumor specimen"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "CAPOX+ Zolbetuximab",
        "value": 8.21,
        "unit": "Months",
        "ci_lower": 7.26,
        "ci_upper": 8.84,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "CAPOX+ Placebo",
        "value": 6.8,
        "unit": "Months",
        "ci_lower": 6.14,
        "ci_upper": 8.08,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "CAPOX+ Zolbetuximab",
        "value": 14.32,
        "unit": "Months",
        "ci_lower": 12.09,
        "ci_upper": 16.39,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "CAPOX+ Placebo",
        "value": 12.16,
        "unit": "Months",
        "ci_lower": 10.28,
        "ci_upper": 13.67,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "zolbetuximab",
        "oxaliplatin",
        "capecitabine"
      ],
      "OG001": [
        "oxaliplatin",
        "capecitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT03631706",
    "brief_title": "M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)",
    "status": "COMPLETED",
    "start_date": "2018-10-01",
    "completion_date": "2021-06-07",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "EMD Serono Research & Development Institute, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT03631706",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "HIGH",
        "details": "Determined by central testing; tumor tissue <6 months required"
      },
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "Sensitizing (activating) EGFR mutations excluded"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "ALK translocation excluded"
      },
      {
        "target": "ROS1",
        "status": "NEGATIVE",
        "details": "ROS1 rearrangement excluded"
      },
      {
        "target": "BRAF",
        "status": "NEGATIVE",
        "details": "BRAF V600E mutation excluded"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "M7824",
        "value": 7.0,
        "unit": "Months",
        "ci_lower": 0.0,
        "ci_upper": 19.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Pembrolizumab",
        "value": 11.1,
        "unit": "Months",
        "ci_lower": 0.0,
        "ci_upper": 18.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "M7824",
        "value": 21.1,
        "unit": "Months",
        "ci_lower": 0.2,
        "ci_upper": 22.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Pembrolizumab",
        "value": 22.1,
        "unit": "Months",
        "ci_lower": 0.1,
        "ci_upper": 26.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "M7824"
      ],
      "OG001": [
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO"
    }
  },
  {
    "nct_id": "NCT00789373",
    "brief_title": "A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2008-11",
    "completion_date": "2010-06",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00789373",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed",
        "value": 4.11,
        "unit": "months",
        "ci_lower": 3.15,
        "ci_upper": 4.57,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Pemetrexed + Cisplatin Followed by Placebo",
        "value": 2.83,
        "unit": "months",
        "ci_lower": 2.6,
        "ci_upper": 3.12,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed",
        "value": 13.86,
        "unit": "months",
        "ci_lower": 12.75,
        "ci_upper": 16.03,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Pemetrexed + Cisplatin Followed by Placebo",
        "value": 11.01,
        "unit": "months",
        "ci_lower": 9.95,
        "ci_upper": 12.52,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pemetrexed",
        "Cisplatin"
      ],
      "OG001": [
        "Pemetrexed",
        "Cisplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT03635489",
    "brief_title": "A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
    "status": "COMPLETED",
    "start_date": "2018-08-15",
    "completion_date": "2021-05-26",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT03635489",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "III",
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Placebo + Paclitaxel + Carboplatin",
        "value": 12.32,
        "unit": "months",
        "ci_lower": 9.53,
        "ci_upper": 15.05,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab + Paclitaxel + Carboplatin",
        "value": 22.57,
        "unit": "months",
        "ci_lower": 18.6,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Placebo + Paclitaxel + Carboplatin",
        "value": 48.89,
        "unit": "months",
        "ci_lower": 40.31,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab + Paclitaxel + Carboplatin",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Paclitaxel",
        "Carboplatin"
      ],
      "OG001": [
        "Bevacizumab",
        "Paclitaxel",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03659136",
    "brief_title": "The XENERA\u2122 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread",
    "status": "COMPLETED",
    "start_date": "2018-11-28",
    "completion_date": "2021-08-30",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Boehringer Ingelheim",
    "url": "https://clinicaltrials.gov/study/NCT03659136",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "ER and/or PGR positive (hormone receptor\u2013positive disease)"
      },
      {
        "target": "PGR",
        "status": "POSITIVE",
        "details": "ER and/or PGR positive (hormone receptor\u2013positive disease)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-negative status"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "1000 mg Xentuzumab + 10 mg Everolimus + 25 mg Exemestane",
        "value": 12.7,
        "unit": "Months",
        "ci_lower": 6.8,
        "ci_upper": 29.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + 10 mg Everolimus + 25 mg Exemestane",
        "value": 11.0,
        "unit": "Months",
        "ci_lower": 7.7,
        "ci_upper": 19.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "1000 mg Xentuzumab + 10 mg Everolimus + 25 mg Exemestane",
        "value": null,
        "unit": "Months",
        "ci_lower": 22.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + 10 mg Everolimus + 25 mg Exemestane",
        "value": null,
        "unit": "Months",
        "ci_lower": 22.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Xentuzumab",
        "Everolimus",
        "Exemestane"
      ],
      "OG001": [
        "Everolimus",
        "Exemestane"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03641313",
    "brief_title": "Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2020-11-16",
    "completion_date": "2024-07-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT03641313",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [
      {
        "target": "TP53",
        "status": "POSITIVE",
        "details": "Hot-spot TP53 mutation within exon 2 or exons 4-11 determined by NGS (e.g., FoundationOne/FoundationOneCDx) performed in a CLIA-certified laboratory"
      },
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER2-positive gastric/GEJ tumors: if HER2-positive, patient must have progressed on trastuzumab plus chemotherapy in the first-line setting"
      },
      {
        "target": "MSI",
        "status": "POSITIVE",
        "details": "MSI-H (microsatellite instability-high); MSI-H tumors must have received prior immunotherapy with pembrolizumab"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (Irinotecan and M6620)",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Irinotecan and M6620)",
        "value": 4.01,
        "unit": "months",
        "ci_lower": 2.07,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Irinotecan and M6620)",
        "value": 6.21,
        "unit": "months",
        "ci_lower": 4.83,
        "ci_upper": 8.61,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Irinotecan",
        "Berzosertib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT00796757",
    "brief_title": "A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).",
    "status": "COMPLETED",
    "start_date": "2008-12",
    "completion_date": "2012-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT00796757",
    "cancer_types": [
      "KIRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab + Interferon",
        "value": 58.2,
        "unit": "percentage of participants",
        "ci_lower": 49.9,
        "ci_upper": 66.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab + Interferon",
        "value": 28.9,
        "unit": "percentage of participants",
        "ci_lower": 20.8,
        "ci_upper": 36.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab + Interferon",
        "value": 84.1,
        "unit": "percentage of participants",
        "ci_lower": 78.0,
        "ci_upper": 90.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab + Interferon",
        "value": 59.6,
        "unit": "percentage of participants",
        "ci_lower": 51.0,
        "ci_upper": 68.2,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "bevacizumab [Avastin]",
        "interferon alfa-2a"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT03635567",
    "brief_title": "Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)",
    "status": "COMPLETED",
    "start_date": "2018-10-25",
    "completion_date": "2022-10-03",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT03635567",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Archival tumor tissue or newly obtained core/excisional biopsy required for prospective determination of PD-L1 status prior to randomization"
      }
    ],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab+Chemotherapy",
        "value": 10.5,
        "unit": "Months",
        "ci_lower": 9.7,
        "ci_upper": 12.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo+Chemotherapy",
        "value": 8.2,
        "unit": "Months",
        "ci_lower": 6.3,
        "ci_upper": 8.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab+Chemotherapy",
        "value": 28.6,
        "unit": "Months",
        "ci_lower": 22.1,
        "ci_upper": 38.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo+Chemotherapy",
        "value": 16.5,
        "unit": "Months",
        "ci_lower": 14.5,
        "ci_upper": 20.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Paclitaxel",
        "Cisplatin",
        "Carboplatin"
      ],
      "OG001": [
        "Paclitaxel",
        "Cisplatin",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00784303",
    "brief_title": "Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology",
    "status": "COMPLETED",
    "start_date": "2008-11-06",
    "completion_date": "2011-04-11",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eisai Inc.",
    "url": "https://clinicaltrials.gov/study/NCT00784303",
    "cancer_types": [
      "THCA"
    ],
    "biomarkers": [
      {
        "target": "I131",
        "status": "ANY",
        "details": "I-131 (radioiodine) refractory/resistant: never demonstrated I-131 uptake, progression despite I-131 uptake, or cumulative I-131 dose >600 mCi (last dose given \u22656 months prior to study entry)."
      }
    ],
    "cancer_stages": [
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "DTC Cohort",
        "value": 50.0,
        "unit": "Percentage of participants",
        "ci_lower": 36.6,
        "ci_upper": 63.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "MTC Cohort",
        "value": 35.6,
        "unit": "Percentage of participants",
        "ci_lower": 23.6,
        "ci_upper": 49.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "DTC Cohort",
        "value": 12.6,
        "unit": "Months",
        "ci_lower": 9.9,
        "ci_upper": 16.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "MTC Cohort",
        "value": 9.0,
        "unit": "Months",
        "ci_lower": 7.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "DTC Cohort",
        "value": 27.7,
        "unit": "Months",
        "ci_lower": 27.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "MTC Cohort",
        "value": 16.6,
        "unit": "Months",
        "ci_lower": 16.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Lenvatinib"
      ],
      "OG001": [
        "Lenvatinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT03631784",
    "brief_title": "A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)",
    "status": "COMPLETED",
    "start_date": "2018-10-19",
    "completion_date": "2021-10-18",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT03631784",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIA",
      "IIIB",
      "IIIC",
      "UNRESECTABLE",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + cCRT + Paclitaxel + Carboplatin",
        "value": 71.4,
        "unit": "Percentage of Participants",
        "ci_lower": 62.1,
        "ci_upper": 79.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Pembrolizumab + cCRT + Pemetrexed + Cisplatin",
        "value": 75.5,
        "unit": "Percentage of Participants",
        "ci_lower": 66.0,
        "ci_upper": 83.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + cCRT + Paclitaxel + Carboplatin",
        "value": 29.0,
        "unit": "Months",
        "ci_lower": 16.6,
        "ci_upper": 48.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Pembrolizumab + cCRT + Pemetrexed + Cisplatin",
        "value": 45.3,
        "unit": "Months",
        "ci_lower": 17.9,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + cCRT + Paclitaxel + Carboplatin",
        "value": 35.6,
        "unit": "Months",
        "ci_lower": 26.1,
        "ci_upper": 44.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Pembrolizumab + cCRT + Pemetrexed + Cisplatin",
        "value": 56.7,
        "unit": "Months",
        "ci_lower": 41.1,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Paclitaxel",
        "Carboplatin"
      ],
      "OG001": [
        "Pembrolizumab",
        "Pemetrexed",
        "Cisplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT03662659",
    "brief_title": "An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers",
    "status": "COMPLETED",
    "start_date": "2018-10-16",
    "completion_date": "2020-08-27",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT03662659",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "Participants with HER2 positive status are excluded"
      }
    ],
    "cancer_stages": [
      "UNRESECTABLE",
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "BMS986213 + Chemotherapy",
        "value": 48.5,
        "unit": "Percentage of Participants",
        "ci_lower": 38.2,
        "ci_upper": 58.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Nivolumab + Chemotherapy",
        "value": 61.2,
        "unit": "Percentage of Participants",
        "ci_lower": 50.8,
        "ci_upper": 70.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "BMS986213 + Chemotherapy",
        "value": 12.65,
        "unit": "Months",
        "ci_lower": 10.91,
        "ci_upper": 14.49,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Nivolumab + Chemotherapy",
        "value": 15.15,
        "unit": "Months",
        "ci_lower": 11.5,
        "ci_upper": 17.61,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "BMS986213 + Chemotherapy",
        "value": 7.13,
        "unit": "Months",
        "ci_lower": 6.74,
        "ci_upper": 9.82,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Nivolumab + Chemotherapy",
        "value": 10.45,
        "unit": "Months",
        "ci_lower": 7.13,
        "ci_upper": 12.65,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "BMS-986213",
        "XELOX",
        "FOLFOX",
        "SOX"
      ],
      "OG001": [
        "Nivolumab",
        "XELOX",
        "FOLFOX",
        "SOX"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT03657043",
    "brief_title": "A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)",
    "status": "COMPLETED",
    "start_date": "2019-03-20",
    "completion_date": "2022-02-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Seagen Inc.",
    "url": "https://clinicaltrials.gov/study/NCT03657043",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Part B Expansion",
        "value": 7.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Part B Expansion",
        "value": 2.73,
        "unit": "Months",
        "ci_lower": 1.64,
        "ci_upper": 2.99,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Part B Expansion",
        "value": 10.68,
        "unit": "Months",
        "ci_lower": 7.75,
        "ci_upper": 12.81,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "tisotumab vedotin"
      ],
      "OG001": [
        "tisotumab vedotin"
      ]
    },
    "treatment_class_map": {
      "OG000": "ADC",
      "OG001": "ADC"
    }
  },
  {
    "nct_id": "NCT00780494",
    "brief_title": "Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma",
    "status": "COMPLETED",
    "start_date": "2009-02",
    "completion_date": "2017-12-31",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Stanford University",
    "url": "https://clinicaltrials.gov/study/NCT00780494",
    "cancer_types": [
      "STAD",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "DPYD",
        "status": "NEGATIVE",
        "details": "dihydropyrimidine dehydrogenase (DPYD) deficiency is excluded"
      },
      {
        "target": "HBV",
        "status": "NEGATIVE",
        "details": "no chronic or active hepatitis B infection"
      },
      {
        "target": "HCV",
        "status": "NEGATIVE",
        "details": "no chronic or active hepatitis C infection"
      },
      {
        "target": "PROTEINURIA",
        "status": "LOW",
        "details": "urine protein <2+ on dipstick and <1.0 g/24h required (proteinuria exclusion threshold)"
      },
      {
        "target": "PREGNANCY",
        "status": "NEGATIVE",
        "details": "negative serum pregnancy test within 72 hours prior to randomization; not breastfeeding"
      }
    ],
    "cancer_stages": [
      "UNRESECTABLE",
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT",
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab+ Carboplatin +Capecitabine",
        "value": 9.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab+ Carboplatin +Capecitabine",
        "value": 458.0,
        "unit": "Days",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "bevacizumab",
        "carboplatin",
        "capecitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00772915",
    "brief_title": "Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma",
    "status": "COMPLETED",
    "start_date": "2008-12-03",
    "completion_date": "2011-03-22",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Mayo Clinic",
    "url": "https://clinicaltrials.gov/study/NCT00772915",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "MONOCLONAL_PROTEIN",
        "status": "HIGH",
        "details": "Serum monoclonal protein \u2265 1.0 g/dL"
      },
      {
        "target": "URINE_MONOCLONAL_PROTEIN",
        "status": "HIGH",
        "details": "Monoclonal protein > 200 mg by 24-hour urine electrophoresis"
      },
      {
        "target": "FREE_LIGHT_CHAIN",
        "status": "HIGH",
        "details": "Serum immunoglobulin free light chain \u2265 10 mg/dL AND abnormal kappa:lambda free light chain ratio"
      },
      {
        "target": "BONE_MARROW_PLASMACYTOSIS",
        "status": "HIGH",
        "details": "Monoclonal bone marrow plasmacytosis \u2265 30% (evaluable disease)"
      },
      {
        "target": "PLASMACYTOMA",
        "status": "POSITIVE",
        "details": "Measurable soft tissue plasmacytoma, not previously radiated"
      },
      {
        "target": "MGUS",
        "status": "NEGATIVE",
        "details": "No monoclonal gammopathy of unknown significance or asymptomatic myeloma"
      },
      {
        "target": "ANC",
        "status": "HIGH",
        "details": "Absolute neutrophil count (ANC) \u2265 1,500/\u03bcL"
      },
      {
        "target": "PLATELETS",
        "status": "HIGH",
        "details": "Platelet count \u2265 75,000/\u03bcL"
      },
      {
        "target": "CREATININE",
        "status": "LOW",
        "details": "Creatinine \u2264 2.0 mg/dL"
      },
      {
        "target": "TOTAL_BILIRUBIN",
        "status": "LOW",
        "details": "Total bilirubin \u2264 1.5 mg/dL"
      },
      {
        "target": "PREGNANCY_TEST",
        "status": "NEGATIVE",
        "details": "Negative pregnancy test; not pregnant or nursing; fertile patients must use contraception"
      },
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "No known HIV positivity"
      },
      {
        "target": "HEPATITIS_B",
        "status": "NEGATIVE",
        "details": "No known hepatitis B infection"
      },
      {
        "target": "HEPATITIS_C",
        "status": "NEGATIVE",
        "details": "No known hepatitis C infection"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Lenalidomide With On-Demand Dexamethasone",
        "value": 79.0,
        "unit": "percentage of participants",
        "ci_lower": 65.0,
        "ci_upper": 96.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Lenalidomide With On-Demand Dexamethasone",
        "value": 61.1,
        "unit": "months",
        "ci_lower": 26.0,
        "ci_upper": 75.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "lenalidomide",
        "dexamethasone"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER"
    }
  },
  {
    "nct_id": "NCT00781911",
    "brief_title": "A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer",
    "status": "COMPLETED",
    "start_date": "2009-02",
    "completion_date": "2011-07",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00781911",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "MKI67",
        "status": "LOW",
        "details": "Ki-67 expression \u2264 20%"
      },
      {
        "target": "5HIAA",
        "status": "ANY",
        "details": "24-hour urine 5-HIAA may be used for measurability"
      },
      {
        "target": "CHROMOGRANIN_A",
        "status": "ANY",
        "details": "Chromogranin A may be used for measurability"
      },
      {
        "target": "ACTH",
        "status": "ANY",
        "details": "Adrenocorticotropin hormone (ACTH) may be used for measurability"
      },
      {
        "target": "GASTRIN",
        "status": "ANY",
        "details": "Gastrin may be used for measurability"
      },
      {
        "target": "ANC",
        "status": "HIGH",
        "details": "Absolute neutrophil count \u2265 1500/\u00b5L"
      },
      {
        "target": "HEMOGLOBIN",
        "status": "HIGH",
        "details": "Hemoglobin \u2265 9 g/dL"
      },
      {
        "target": "PLATELETS",
        "status": "HIGH",
        "details": "Platelet count \u2265 100,000/\u00b5L"
      },
      {
        "target": "BILIRUBIN",
        "status": "LOW",
        "details": "Total bilirubin \u2264 1.5 x ULN"
      },
      {
        "target": "AST",
        "status": "LOW",
        "details": "AST \u2264 3 x ULN (\u2264 5 x ULN in presence of known liver metastases)"
      },
      {
        "target": "ALT",
        "status": "LOW",
        "details": "ALT \u2264 3 x ULN (\u2264 5 x ULN in presence of known liver metastases)"
      },
      {
        "target": "INR",
        "status": "LOW",
        "details": "INR \u2264 1.5 (or on stable anticoagulant)"
      },
      {
        "target": "PTT",
        "status": "LOW",
        "details": "PTT no more than 5 seconds above ULN (or on stable anticoagulant)"
      },
      {
        "target": "CREATININE",
        "status": "LOW",
        "details": "Serum creatinine \u2264 1.5 x ULN"
      },
      {
        "target": "CREATININE_CLEARANCE",
        "status": "HIGH",
        "details": "Or creatinine clearance \u2265 60 mL/min (alternative to serum creatinine criteria)"
      },
      {
        "target": "GLUCOSE",
        "status": "LOW",
        "details": "Fasting serum glucose < 160 mg/dL (nonfasting <160 mg/dL acceptable at baseline)"
      },
      {
        "target": "HBA1C",
        "status": "LOW",
        "details": "Hemoglobin A1c \u2264 7%"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Carcinoid Tumor",
        "value": 45.2,
        "unit": "percentage of participants",
        "ci_lower": 27.3,
        "ci_upper": 64.0,
        "dispersion_type": "95% Confidence Interval"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Islet Cell Carcinoma",
        "value": 41.7,
        "unit": "percentage of participants",
        "ci_lower": 15.2,
        "ci_upper": 72.3,
        "dispersion_type": "95% Confidence Interval"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Carcinoid Tumor",
        "value": 54.1,
        "unit": "percentage of participants",
        "ci_lower": 34.2,
        "ci_upper": 70.3,
        "dispersion_type": "95% Confidence Interval"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Islet Cell Carcinoma",
        "value": 61.4,
        "unit": "percentage of participants",
        "ci_lower": 26.6,
        "ci_upper": 83.5,
        "dispersion_type": "95% Confidence Interval"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cixutumumab",
        "depot octreotide"
      ],
      "OG001": [
        "Cixutumumab",
        "depot octreotide"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03690388",
    "brief_title": "A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2018-10-05",
    "completion_date": "2020-08-19",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Exelixis",
    "url": "https://clinicaltrials.gov/study/NCT03690388",
    "cancer_types": [
      "THCA"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": true,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cabozantinib",
        "value": null,
        "unit": "months",
        "ci_lower": 5.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 1.9,
        "unit": "months",
        "ci_lower": 1.8,
        "ci_upper": 3.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cabozantinib",
        "value": 15.0,
        "unit": "percentage of participants",
        "ci_lower": 5.8,
        "ci_upper": 29.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 14.8,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cabozantinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT03694262",
    "brief_title": "The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2019-07-19",
    "completion_date": "2023-03-30",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Medical College of Wisconsin",
    "url": "https://clinicaltrials.gov/study/NCT03694262",
    "cancer_types": [
      "UCEC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment",
        "value": 30.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Rucaparib",
        "Bevacizumab",
        "Atezolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT00820248",
    "brief_title": "Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer",
    "status": "COMPLETED",
    "start_date": "2008-12-30",
    "completion_date": "2015-05-16",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "NCIC Clinical Trials Group",
    "url": "https://clinicaltrials.gov/study/NCT00820248",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "III",
      "IV",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cisplatin",
        "value": 50.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Panitumumab",
        "value": 43.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "cisplatin"
      ],
      "OG001": [
        "panitumumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03694522",
    "brief_title": "A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer",
    "status": "COMPLETED",
    "start_date": "2018-09-14",
    "completion_date": "2020-09-23",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Five Prime Therapeutics, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT03694522",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [
      {
        "target": "FGFR2",
        "status": "POSITIVE",
        "details": "FGFR2b overexpression by centrally performed IHC and/or FGFR2 gene amplification by centrally performed ctDNA assay"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "Known HER2 positivity is an exclusion criterion (must not be HER2 positive)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Bemarituzumab + mFOLFOX6",
        "value": 9.5,
        "unit": "Months",
        "ci_lower": 7.3,
        "ci_upper": 12.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + mFOLFOX6",
        "value": 7.4,
        "unit": "Months",
        "ci_lower": 5.8,
        "ci_upper": 8.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Bemarituzumab + mFOLFOX6",
        "value": null,
        "unit": "Months",
        "ci_lower": 13.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + mFOLFOX6",
        "value": 12.9,
        "unit": "Months",
        "ci_lower": 9.1,
        "ci_upper": 15.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Bemarituzumab",
        "Modified FOLFOX6"
      ],
      "OG001": [
        "Modified FOLFOX6"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT03673501",
    "brief_title": "A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2019-02-08",
    "completion_date": "2021-09-01",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Deciphera Pharmaceuticals, LLC",
    "url": "https://clinicaltrials.gov/study/NCT03673501",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": true,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ripretinib",
        "value": 8.3,
        "unit": "months",
        "ci_lower": 6.8,
        "ci_upper": 13.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Sunitinib",
        "value": 7.0,
        "unit": "months",
        "ci_lower": 5.6,
        "ci_upper": 10.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Ripretinib",
        "value": 34.0,
        "unit": "months",
        "ci_lower": 29.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Sunitinib",
        "value": 31.5,
        "unit": "months",
        "ci_lower": 29.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ripretinib"
      ],
      "OG001": [
        "Sunitinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT00806156",
    "brief_title": "Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer",
    "status": "COMPLETED",
    "start_date": "2008-10",
    "completion_date": "2012-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Nektar Therapeutics",
    "url": "https://clinicaltrials.gov/study/NCT00806156",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "NKTR-102 q21d",
        "value": 14.4,
        "unit": "Percentage of Patients",
        "ci_lower": 8.3,
        "ci_upper": 22.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Primary Efficacy Population",
        "value": 14.4,
        "unit": "Percentage of Patients",
        "ci_lower": 8.3,
        "ci_upper": 22.7,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "NKTR-102 q21d"
      ],
      "OG001": [
        "NKTR-102 q21d"
      ],
      "OG002": [
        "NKTR-102 q14d",
        "NKTR-102 q21d"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo",
      "OG002": "Chemo"
    }
  },
  {
    "nct_id": "NCT00802945",
    "brief_title": "Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2008-10",
    "completion_date": "2011-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Nektar Therapeutics",
    "url": "https://clinicaltrials.gov/study/NCT00802945",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "NKTR-102 14 Day",
        "value": 28.6,
        "unit": "percentage of subjects",
        "ci_lower": 14.6,
        "ci_upper": 46.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "NKTR-102 21 Days",
        "value": 35.0,
        "unit": "percentage of subjects",
        "ci_lower": 14.6,
        "ci_upper": 46.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "NKTR-102 14 Day",
        "value": 3.3,
        "unit": "Months",
        "ci_lower": 2.6,
        "ci_upper": 5.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "NKTR-102 21 Days",
        "value": 5.6,
        "unit": "Months",
        "ci_lower": 1.8,
        "ci_upper": 6.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "NKTR-102 14 Day",
        "value": 8.8,
        "unit": "Months",
        "ci_lower": 5.4,
        "ci_upper": 15.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "NKTR-102 21 Days",
        "value": 13.1,
        "unit": "Months",
        "ci_lower": 9.2,
        "ci_upper": 19.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "NKTR-102"
      ],
      "OG001": [
        "NKTR-102"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00823797",
    "brief_title": "Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma",
    "status": "COMPLETED",
    "start_date": "2008-10",
    "completion_date": "2015-12",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "University of Washington",
    "url": "https://clinicaltrials.gov/study/NCT00823797",
    "cancer_types": [
      "GBM",
      "LGG"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Bendamustine Hydrochloride) for Glioblastoma",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Treatment (Bendamustine Hydrochloride) for Anaplastic Glioma",
        "value": 8.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Bendamustine Hydrochloride) for Glioblastoma",
        "value": 18.3,
        "unit": "months",
        "ci_lower": 8.2,
        "ci_upper": 28.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Treatment (Bendamustine Hydrochloride) for Anaplastic Glioma",
        "value": 45.6,
        "unit": "months",
        "ci_lower": 33.6,
        "ci_upper": 57.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Bendamustine Hydrochloride"
      ],
      "OG001": [
        "Bendamustine Hydrochloride"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00819780",
    "brief_title": "PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors",
    "status": "COMPLETED",
    "start_date": "2009-04-24",
    "completion_date": "2012-05-30",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Amgen",
    "url": "https://clinicaltrials.gov/study/NCT00819780",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "Wild-type KRAS (no KRAS mutation); confirmed by Amgen-approved central laboratory or validated local laboratory per local regulatory guidelines"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "IV",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Panitumumab Plus mFOLFOX6",
        "value": 10.9,
        "unit": "months",
        "ci_lower": 9.4,
        "ci_upper": 13.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab Plus mFOLFOX6",
        "value": 10.1,
        "unit": "months",
        "ci_lower": 9.0,
        "ci_upper": 12.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Panitumumab Plus mFOLFOX6",
        "value": null,
        "unit": "months",
        "ci_lower": 28.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab Plus mFOLFOX6",
        "value": 25.4,
        "unit": "months",
        "ci_lower": 22.9,
        "ci_upper": 29.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Panitumumab",
        "mFOLFOX6"
      ],
      "OG001": [
        "Bevacizumab",
        "mFOLFOX6"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00821327",
    "brief_title": "Gemzar, Cisp, Sunitinib Urothelial Ca",
    "status": "COMPLETED",
    "start_date": "2008-08",
    "completion_date": "2012-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "US Oncology Research",
    "url": "https://clinicaltrials.gov/study/NCT00821327",
    "cancer_types": [
      "BLCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Study Arm: Advanced/Metastatic UC",
        "value": 48.5,
        "unit": "Percentage of participants",
        "ci_lower": 30.8,
        "ci_upper": 66.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Study Arm: Advanced/Metastatic UC",
        "value": 8.0,
        "unit": "Month",
        "ci_lower": 7.0,
        "ci_upper": 14.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Study Arm: Advanced/Metastatic UC",
        "value": 13.8,
        "unit": "months",
        "ci_lower": 10.1,
        "ci_upper": 22.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Gemcitabine",
        "Cisplatin",
        "Sunitinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT03675737",
    "brief_title": "Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)",
    "status": "COMPLETED",
    "start_date": "2018-11-08",
    "completion_date": "2022-10-03",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT03675737",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Known PD-L1 expression status required; tumor tissue adequate for PD-L1 biomarker analysis"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 negative cancer required"
      },
      {
        "target": "MSI",
        "status": "ANY",
        "details": "Tumor tissue sample provided for microsatellite instability (MSI) biomarker analysis"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + Chemotherapy (FP or CAPOX Regimen)",
        "value": 12.9,
        "unit": "Months",
        "ci_lower": 11.9,
        "ci_upper": 14.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Chemotherapy (FP or CAPOX Regimen)",
        "value": 11.5,
        "unit": "Months",
        "ci_lower": 10.6,
        "ci_upper": 12.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Cisplatin",
        "5-fluorouracil",
        "oxaliplatin",
        "capecitabine"
      ],
      "OG001": [
        "Cisplatin",
        "5-fluorouracil",
        "oxaliplatin",
        "capecitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00800202",
    "brief_title": "A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis",
    "status": "COMPLETED",
    "start_date": "2009-04",
    "completion_date": "2012-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT00800202",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab+Paclitaxel+Carboplatin",
        "value": 56.5,
        "unit": "percentage of participants",
        "ci_lower": 43.8,
        "ci_upper": 67.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab+Erlotinib",
        "value": 57.2,
        "unit": "percentage of participants",
        "ci_lower": 37.0,
        "ci_upper": 76.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab+Paclitaxel+Carboplatin",
        "value": 6.7,
        "unit": "months",
        "ci_lower": 5.7,
        "ci_upper": 7.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab+Erlotinib",
        "value": 6.3,
        "unit": "months",
        "ci_lower": 3.0,
        "ci_upper": 8.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "bevacizumab",
        "paclitaxel",
        "carboplatin"
      ],
      "OG001": [
        "bevacizumab",
        "erlotinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_TKI_Targeted"
    }
  },
  {
    "nct_id": "NCT00820170",
    "brief_title": "Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194",
    "status": "COMPLETED",
    "start_date": "2009-01",
    "completion_date": "2018-08",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Memorial Sloan Kettering Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT00820170",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "IHC 0-1+ or FISH/CISH negative (required for phase II)"
      },
      {
        "target": "ER",
        "status": "ANY",
        "details": "Any ER disease status allowed (phase I and phase II)"
      },
      {
        "target": "PR",
        "status": "ANY",
        "details": "Any PR disease status allowed (phase I and phase II)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 100 mg",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 150 mg",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 70 mg",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Phase 2: Paclitaxel 80 mg/m2 + Dasatinib 120 mg",
        "value": 11.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "No Arm Selected",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Dasatinib",
        "Paclitaxel"
      ],
      "OG001": [
        "Paclitaxel",
        "Dasatinib"
      ],
      "OG002": [
        "Paclitaxel",
        "Dasatinib"
      ],
      "OG003": [
        "Paclitaxel",
        "Dasatinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Combo_TKI_Chemo",
      "OG002": "Combo_TKI_Chemo",
      "OG003": "Combo_TKI_Chemo",
      "OG004": "OTHER"
    }
  },
  {
    "nct_id": "NCT03698994",
    "brief_title": "Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2018-11-14",
    "completion_date": "2022-03-31",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT03698994",
    "cancer_types": [
      "LGG",
      "OTHER",
      "DLBC"
    ],
    "biomarkers": [
      {
        "target": "MAPK",
        "status": "POSITIVE",
        "details": "Actionable MAPK pathway mutation as determined by Pediatric MATCH assignment (APEC1621SC \u2192 APEC1621J)."
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (Ulixertinib)",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 0.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ulixertinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00820755",
    "brief_title": "Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC)",
    "status": "COMPLETED",
    "start_date": "2009-01",
    "completion_date": "2011-12",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck KGaA, Darmstadt, Germany",
    "url": "https://clinicaltrials.gov/study/NCT00820755",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV"
    ],
    "line_of_therapy": "MAINTENANCE",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cetuximab 500 mg/m^2 Every 2 Weeks",
        "value": 16.1,
        "unit": "months",
        "ci_lower": 13.6,
        "ci_upper": 18.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cetuximab 250 mg/m^2 Weekly",
        "value": 15.5,
        "unit": "months",
        "ci_lower": 13.2,
        "ci_upper": 19.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cetuximab 500 mg/m^2"
      ],
      "OG001": [
        "Cetuximab 250 mg/m^2"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03689855",
    "brief_title": "Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC",
    "status": "COMPLETED",
    "start_date": "2019-06-05",
    "completion_date": "2021-07-16",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Washington University School of Medicine",
    "url": "https://clinicaltrials.gov/study/NCT03689855",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "If known EGFR mutation, patient is eligible only if they have received at least one line of targeted therapy for the mutation."
      },
      {
        "target": "ALK",
        "status": "ANY",
        "details": "If known ALK mutation, patient is eligible only if they have received at least one line of targeted therapy for the mutation."
      },
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Baseline/archival biopsy required for biomarker analysis including PD-L1 by IHC; PD-L1 test results are not required for enrollment."
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": true,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Ramucirumab + Atezolizumab",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Ramucirumab + Atezolizumab",
        "value": 16.3,
        "unit": "months",
        "ci_lower": 7.1,
        "ci_upper": 20.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ramucirumab + Atezolizumab",
        "value": 1.0,
        "unit": "months",
        "ci_lower": 1.0,
        "ci_upper": 2.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ramucirumab",
        "Atezolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT03668119",
    "brief_title": "A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)",
    "status": "COMPLETED",
    "start_date": "2018-10-31",
    "completion_date": "2022-05-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT03668119",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "TMB",
        "status": "HIGH",
        "details": "Must be tumor mutational burden-high (TMB-H); tissue and blood TMB-H testing results required"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Arm A: Nivolumab+Ipilimumab",
        "value": 22.5,
        "unit": "Precentage of participants",
        "ci_lower": 13.9,
        "ci_upper": 33.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Arm A: Nivolumab+Ipilimumab",
        "value": 38.6,
        "unit": "Precentage of participants",
        "ci_lower": 28.4,
        "ci_upper": 49.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A: Nivolumab+Ipilimumab",
        "value": 2.99,
        "unit": "Months",
        "ci_lower": 2.66,
        "ci_upper": 4.34,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Nivolumab",
        "value": 3.04,
        "unit": "Months",
        "ci_lower": 2.79,
        "ci_upper": 5.36,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A: Nivolumab+Ipilimumab",
        "value": 8.15,
        "unit": "Months",
        "ci_lower": 4.83,
        "ci_upper": 12.94,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Nivolumab",
        "value": 3.06,
        "unit": "Months",
        "ci_lower": 2.79,
        "ci_upper": 10.91,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A: Nivolumab+Ipilimumab",
        "value": 8.07,
        "unit": "Months",
        "ci_lower": 5.82,
        "ci_upper": 10.45,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Nivolumab",
        "value": 11.24,
        "unit": "Months",
        "ci_lower": 5.26,
        "ci_upper": 18.99,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A: Nivolumab+Ipilimumab",
        "value": 16.48,
        "unit": "Months",
        "ci_lower": 10.18,
        "ci_upper": 30.52,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Nivolumab",
        "value": 14.59,
        "unit": "Months",
        "ci_lower": 7.69,
        "ci_upper": 18.23,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG001": [
        "Nivolumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO"
    }
  },
  {
    "nct_id": "NCT03679767",
    "brief_title": "A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)",
    "status": "COMPLETED",
    "start_date": "2019-01-09",
    "completion_date": "2021-04-15",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Incyte Corporation",
    "url": "https://clinicaltrials.gov/study/NCT03679767",
    "cancer_types": [
      "NSCLC",
      "BLCA",
      "KIRC"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "HIGH",
        "details": "TPS \u2265 50% (treatment\u2011na\u00efve metastatic NSCLC) or CPS \u2265 10 (cisplatin\u2011ineligible urothelial carcinoma)"
      },
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "No EGFR activating genomic tumor aberrations"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "No ALK activating genomic tumor aberrations"
      },
      {
        "target": "ROS1",
        "status": "NEGATIVE",
        "details": "No ROS1 activating genomic tumor aberrations"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Melanoma",
        "value": 40.0,
        "unit": "percentage of participants",
        "ci_lower": 23.9,
        "ci_upper": 57.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Non-small Cell Lung Cancer",
        "value": 34.8,
        "unit": "percentage of participants",
        "ci_lower": 16.4,
        "ci_upper": 57.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Urethelial Carcinoma",
        "value": 37.9,
        "unit": "percentage of participants",
        "ci_lower": 20.7,
        "ci_upper": 57.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Renal Cell Carcinoma",
        "value": 23.5,
        "unit": "percentage of participants",
        "ci_lower": 10.7,
        "ci_upper": 41.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Melanoma",
        "value": 3.6,
        "unit": "months",
        "ci_lower": 1.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Non-small Cell Lung Cancer",
        "value": 4.4,
        "unit": "months",
        "ci_lower": 1.8,
        "ci_upper": 21.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Urethelial Carcinoma",
        "value": 5.7,
        "unit": "months",
        "ci_lower": 1.8,
        "ci_upper": 13.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Renal Cell Carcinoma",
        "value": 5.4,
        "unit": "months",
        "ci_lower": 2.3,
        "ci_upper": 11.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Melanoma",
        "value": null,
        "unit": "months",
        "ci_lower": 8.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Non-small Cell Lung Cancer",
        "value": 21.9,
        "unit": "months",
        "ci_lower": 5.2,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Urethelial Carcinoma",
        "value": 15.2,
        "unit": "months",
        "ci_lower": 7.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Renal Cell Carcinoma",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Retifanlimab"
      ],
      "OG001": [
        "Retifanlimab"
      ],
      "OG002": [
        "Retifanlimab"
      ],
      "OG003": [
        "Retifanlimab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO",
      "OG003": "IO"
    }
  },
  {
    "nct_id": "NCT00804908",
    "brief_title": "A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma",
    "status": "COMPLETED",
    "start_date": "2009-02",
    "completion_date": "2016-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AbbVie (prior sponsor, Abbott)",
    "url": "https://clinicaltrials.gov/study/NCT00804908",
    "cancer_types": [
      "SKCM"
    ],
    "biomarkers": [
      {
        "target": "LDH",
        "status": "LOW",
        "details": "LDH must be \u22642\u00d7ULN (LDH >2\u00d7ULN excluded)"
      },
      {
        "target": "PTT",
        "status": "LOW",
        "details": "PTT \u22641.5\u00d7 institution upper normal limit"
      },
      {
        "target": "INR",
        "status": "LOW",
        "details": "INR <1.5"
      }
    ],
    "cancer_stages": [
      "III",
      "IV",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Placebo for ABT-888 BID + TMZ QD",
        "value": 60.0,
        "unit": "days",
        "ci_lower": 57.0,
        "ci_upper": 111.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "ABT-888 20 mg BID + TMZ QD",
        "value": 113.0,
        "unit": "days",
        "ci_lower": 92.0,
        "ci_upper": 168.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "ABT-888 40 mg BID + TMZ QD",
        "value": 110.0,
        "unit": "days",
        "ci_lower": 57.0,
        "ci_upper": 125.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Placebo for ABT-888 BID + TMZ QD",
        "value": 390.0,
        "unit": "days",
        "ci_lower": 299.0,
        "ci_upper": 436.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "ABT-888 20 mg BID + TMZ QD",
        "value": 327.0,
        "unit": "days",
        "ci_lower": 274.0,
        "ci_upper": 399.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "ABT-888 40 mg BID + TMZ QD",
        "value": 412.0,
        "unit": "days",
        "ci_lower": 346.0,
        "ci_upper": 483.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "temozolomide"
      ],
      "OG001": [
        "ABT-888",
        "temozolomide"
      ],
      "OG002": [
        "ABT-888",
        "temozolomide"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03684811",
    "brief_title": "A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation",
    "status": "COMPLETED",
    "start_date": "2018-11-01",
    "completion_date": "2021-05-24",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Forma Therapeutics, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT03684811",
    "cancer_types": [
      "GBM",
      "LIHC",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "IDH1",
        "status": "POSITIVE",
        "details": "IDH1 R132 mutation (documented IDH1-R132 gene-mutated disease)"
      }
    ],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort 1A",
        "value": 2.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Cohort 1B",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Cohort 2A",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Cohort 3A",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Cohort 4A",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "Cohort 5A",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Olutasidenib"
      ],
      "OG001": [
        "Olutasidenib",
        "Azacitidine"
      ],
      "OG002": [
        "Olutasidenib"
      ],
      "OG003": [
        "Olutasidenib"
      ],
      "OG004": [
        "Olutasidenib"
      ],
      "OG005": [
        "Olutasidenib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "OTHER",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other",
      "OG004": "Targeted_Other",
      "OG005": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00844649",
    "brief_title": "Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas",
    "status": "COMPLETED",
    "start_date": "2009-03-01",
    "completion_date": "2012-09-17",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Celgene",
    "url": "https://clinicaltrials.gov/study/NCT00844649",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Albumin-bound Paclitaxel (ABI-007)/Gemcitabine",
        "value": 8.5,
        "unit": "months",
        "ci_lower": 7.89,
        "ci_upper": 9.53,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Gemcitabine",
        "value": 6.7,
        "unit": "months",
        "ci_lower": 6.01,
        "ci_upper": 7.23,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Albumin-bound paclitaxel (ABI-007)",
        "Gemcitabine"
      ],
      "OG001": [
        "Gemcitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00839332",
    "brief_title": "A Study for Participants With Pancreatic Cancer",
    "status": "COMPLETED",
    "start_date": "2009-02",
    "completion_date": "2013-02",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00839332",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Phase 2: LY2603618 + Gemcitabine",
        "value": 7.8,
        "unit": "months",
        "ci_lower": 5.0,
        "ci_upper": 11.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Phase 2: Gemcitabine",
        "value": 8.3,
        "unit": "months",
        "ci_lower": 5.1,
        "ci_upper": 14.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "LY2603618",
        "Gemcitabine"
      ],
      "OG001": [
        "Gemcitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT03703297",
    "brief_title": "Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2018-09-27",
    "completion_date": "2024-01-15",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT03703297",
    "cancer_types": [
      "SCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "I",
      "II",
      "III"
    ],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Durvalumab",
        "value": 16.6,
        "unit": "months",
        "ci_lower": 10.2,
        "ci_upper": 28.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 9.2,
        "unit": "months",
        "ci_lower": 7.4,
        "ci_upper": 12.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Durvalumab",
        "value": 55.9,
        "unit": "months",
        "ci_lower": 37.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 33.4,
        "unit": "months",
        "ci_lower": 25.5,
        "ci_upper": 39.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Durvalumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT00825734",
    "brief_title": "Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2009-03",
    "completion_date": "2013-06",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SCRI Development Innovations, LLC",
    "url": "https://clinicaltrials.gov/study/NCT00825734",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "IHC 0 or IHC 1+ OR FISH ratio <2.2 OR SISH ratio <2.2; IHC 2+ must be validated as HER2-negative by FISH"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Sorafenib and Ixabepilone",
        "value": 4.8,
        "unit": "months",
        "ci_lower": 3.5,
        "ci_upper": 6.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Sorafenib and Ixabepilone",
        "value": 15.5,
        "unit": "months",
        "ci_lower": 11.0,
        "ci_upper": 20.6,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Sorafenib",
        "Ixabepilone"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT00851084",
    "brief_title": "Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2009-02",
    "completion_date": "2011-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sanofi",
    "url": "https://clinicaltrials.gov/study/NCT00851084",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "mFOLFOX6 Only",
        "value": 21.2,
        "unit": "percentage of participants",
        "ci_lower": 12.2,
        "ci_upper": 30.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "mFOLFOX6 + Aflibercept",
        "value": 25.8,
        "unit": "percentage of participants",
        "ci_lower": 17.2,
        "ci_upper": 34.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "mFOLFOX6 Only",
        "value": 22.31,
        "unit": "months",
        "ci_lower": 15.57,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "mFOLFOX6 + Aflibercept",
        "value": 19.45,
        "unit": "months",
        "ci_lower": 15.64,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "oxaliplatin",
        "5-FU",
        "Folinic Acid"
      ],
      "OG001": [
        "oxaliplatin",
        "5-FU",
        "Folinic Acid",
        "aflibercept"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00833261",
    "brief_title": "Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer",
    "status": "COMPLETED",
    "start_date": "2008-12",
    "completion_date": "2013-09",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "University of Texas Southwestern Medical Center",
    "url": "https://clinicaltrials.gov/study/NCT00833261",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Single Arm: Chemotherapy With Concurrent Radiation Therapy",
        "value": 60.0,
        "unit": "percentage of participants",
        "ci_lower": 42.0,
        "ci_upper": 78.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nab-Paclitaxel",
        "cetuximab",
        "cisplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03734692",
    "brief_title": "Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2019-01-28",
    "completion_date": "2024-07-01",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Robert Edwards",
    "url": "https://clinicaltrials.gov/study/NCT03734692",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cisplatin + Rintatolimod + Pembrolizumab",
        "value": 50.0,
        "unit": "percentage of patients",
        "ci_lower": 31.0,
        "ci_upper": 69.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cisplatin",
        "Rintatolimod",
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT00856375",
    "brief_title": "NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Na\u00efve, KRAS Mutant, Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2008-12",
    "completion_date": "2014-07",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Nektar Therapeutics",
    "url": "https://clinicaltrials.gov/study/NCT00856375",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "POSITIVE",
        "details": "k-ras mutation"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "NKTR-102",
        "value": 4.0,
        "unit": "months",
        "ci_lower": 2.7,
        "ci_upper": 5.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Irinotecan",
        "value": 2.8,
        "unit": "months",
        "ci_lower": 1.4,
        "ci_upper": 4.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "NKTR-102",
        "value": 9.6,
        "unit": "months",
        "ci_lower": 7.3,
        "ci_upper": 13.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Irinotecan",
        "value": 8.4,
        "unit": "months",
        "ci_lower": 4.4,
        "ci_upper": 13.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "NKTR-102"
      ],
      "OG001": [
        "irinotecan"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00837031",
    "brief_title": "Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas",
    "status": "COMPLETED",
    "start_date": "2009-02",
    "completion_date": "2010-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SCRI Development Innovations, LLC",
    "url": "https://clinicaltrials.gov/study/NCT00837031",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Lenalidomide/Gemcitabine",
        "value": 37.0,
        "unit": "percentage of participants",
        "ci_lower": 26.0,
        "ci_upper": 48.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Lenalidomide/Gemcitabine",
        "value": 2.3,
        "unit": "months",
        "ci_lower": 1.9,
        "ci_upper": 3.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Lenalidomide",
        "Gemcitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00829166",
    "brief_title": "A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2009-02",
    "completion_date": "2012-07",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT00829166",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "Prospectively centrally tested; HER2-positive based on central laboratory assay results"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Trastuzumab Emtansine",
        "value": 9.6,
        "unit": "Months",
        "ci_lower": 8.25,
        "ci_upper": 10.64,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Lapatinib + Capecitabine",
        "value": 6.4,
        "unit": "Months",
        "ci_lower": 5.68,
        "ci_upper": 7.06,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Trastuzumab Emtansine",
        "value": 30.9,
        "unit": "Months",
        "ci_lower": 26.81,
        "ci_upper": 34.27,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Lapatinib + Capecitabine",
        "value": 25.1,
        "unit": "Months",
        "ci_lower": 22.74,
        "ci_upper": 27.96,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Trastuzumab emtansine"
      ],
      "OG001": [
        "Lapatinib",
        "Capecitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "ADC",
      "OG001": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT03759600",
    "brief_title": "Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer",
    "status": "COMPLETED",
    "start_date": "2018-12-26",
    "completion_date": "2022-12-28",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Takeda",
    "url": "https://clinicaltrials.gov/study/NCT03759600",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "HRD",
        "status": "POSITIVE",
        "details": "Homologous recombination deficiency (HRD) positive by central lab; defined as presence of a deleterious or suspected deleterious BRCA mutation or positive genomic instability"
      },
      {
        "target": "BRCA",
        "status": "POSITIVE",
        "details": "Deleterious or suspected deleterious BRCA mutation (germline or tumor). Historic germline BRCA mutation (gBRCAmut) accepted prior to enrollment but tumor HRD testing still required"
      }
    ],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Niraparib 300 mg",
        "value": 60.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Niraparib 300 mg",
        "value": 8.3,
        "unit": "months",
        "ci_lower": 5.6,
        "ci_upper": 13.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Niraparib 300 mg",
        "value": 24.9,
        "unit": "months",
        "ci_lower": 14.9,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Niraparib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00828139",
    "brief_title": "S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2009-05",
    "completion_date": "2012-09",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT00828139",
    "cancer_types": [
      "SCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Platinum-Sensitive Treated With Topotecan and Ziv-aflibercept",
        "value": 1.8,
        "unit": "Months",
        "ci_lower": 1.5,
        "ci_upper": 2.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Platinum Sensitivity Treated With Topotecan Alone",
        "value": 1.3,
        "unit": "Months",
        "ci_lower": 1.2,
        "ci_upper": 1.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Platinum Refractory Treated With Topotecan + Ziv-aflibercept",
        "value": 1.4,
        "unit": "Months",
        "ci_lower": 1.3,
        "ci_upper": 1.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Platinum Refractory Treated With Topotecan Aloine",
        "value": 1.4,
        "unit": "Months",
        "ci_lower": 1.3,
        "ci_upper": 1.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Platinum-Sensitive Treated With Topotecan and Ziv-aflibercept",
        "value": 6.0,
        "unit": "months",
        "ci_lower": 4.8,
        "ci_upper": 10.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Platinum Sensitivity Treated With Topotecan Alone",
        "value": 4.6,
        "unit": "months",
        "ci_lower": 2.9,
        "ci_upper": 5.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Platinum Refractory Treated With Topotecan + Ziv-aflibercept",
        "value": 4.6,
        "unit": "months",
        "ci_lower": 4.0,
        "ci_upper": 5.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Platinum Refractory Treated With Topotecan Aloine",
        "value": 4.2,
        "unit": "months",
        "ci_lower": 2.7,
        "ci_upper": 5.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "topotecan hydrochloride",
        "ziv-aflibercept"
      ],
      "OG001": [
        "topotecan hydrochloride"
      ],
      "OG002": [
        "topotecan hydrochloride",
        "ziv-aflibercept"
      ],
      "OG003": [
        "topotecan hydrochloride"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo",
      "OG002": "Combo_Chemo_Targeted",
      "OG003": "Chemo"
    }
  },
  {
    "nct_id": "NCT03733990",
    "brief_title": "A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)",
    "status": "COMPLETED",
    "start_date": "2018-12-03",
    "completion_date": "2023-09-06",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Faron Pharmaceuticals Ltd",
    "url": "https://clinicaltrials.gov/study/NCT03733990",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": true,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "FP-1305 (Bexmarilimab) 0.3 mg/kg",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "FP-1305 (Bexmarilimab) 1 mg/kg",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "FP-1305 (Bexmarilimab) 3 mg/kg",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "FP-1305 (Bexmarilimab) 10 mg/kg",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "FP-1305 (Bexmarilimab) 0.1 mg/kg",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "FP-1305 (Bexmarilimab) 30 mg/kg",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG000",
        "arm_title": "FP-1305 (Bexmarilimab) 0.3 mg/kg",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG001",
        "arm_title": "FP-1305 (Bexmarilimab) 1 mg/kg",
        "value": 20.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG002",
        "arm_title": "FP-1305 (Bexmarilimab) 3 mg/kg",
        "value": 4.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG003",
        "arm_title": "FP-1305 (Bexmarilimab) 10 mg/kg",
        "value": 2.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG004",
        "arm_title": "FP-1305 (Bexmarilimab) 0.1 mg/kg",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG005",
        "arm_title": "FP-1305 (Bexmarilimab) 30 mg/kg",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "FP-1305 (bexmarilimab)"
      ],
      "OG001": [
        "FP-1305 (bexmarilimab)"
      ],
      "OG002": [
        "FP-1305 (bexmarilimab)"
      ],
      "OG003": [
        "FP-1305 (bexmarilimab)"
      ],
      "OG004": [
        "FP-1305 (bexmarilimab)"
      ],
      "OG005": [
        "FP-1305 (bexmarilimab)"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO",
      "OG003": "IO",
      "OG004": "IO",
      "OG005": "IO"
    }
  },
  {
    "nct_id": "NCT03740165",
    "brief_title": "Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2018-12-18",
    "completion_date": "2024-08-26",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT03740165",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "BRCA1",
        "status": "NEGATIVE",
        "details": "No known or suspected deleterious (germline or somatic) mutation in BRCA1"
      },
      {
        "target": "BRCA2",
        "status": "NEGATIVE",
        "details": "No known or suspected deleterious (germline or somatic) mutation in BRCA2"
      },
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Prospective testing required prior to randomization"
      },
      {
        "target": "CA125",
        "status": "ANY",
        "details": "CA-125:CEA ratio \u226525 required for candidates for neoadjuvant chemotherapy (requires CEA measurement)"
      }
    ],
    "cancer_stages": [
      "III",
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Carboplatin + Paclitaxel + Pembrolizumab + Olaparib",
        "value": 23.9,
        "unit": "Months",
        "ci_lower": 21.0,
        "ci_upper": 30.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Carboplatin + Paclitaxel + Pembrolizumab",
        "value": 17.3,
        "unit": "Months",
        "ci_lower": 15.2,
        "ci_upper": 19.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Carboplatin + Paclitaxel",
        "value": 15.2,
        "unit": "Months",
        "ci_lower": 12.5,
        "ci_upper": 17.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Carboplatin",
        "Paclitaxel",
        "Pembrolizumab",
        "Olaparib"
      ],
      "OG001": [
        "Carboplatin",
        "Paclitaxel",
        "Pembrolizumab"
      ],
      "OG002": [
        "Carboplatin",
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Combo_Chemo_IO",
      "OG002": "Chemo"
    }
  },
  {
    "nct_id": "NCT03711058",
    "brief_title": "Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2019-01-17",
    "completion_date": "2022-06-14",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
    "url": "https://clinicaltrials.gov/study/NCT03711058",
    "cancer_types": [
      "COAD",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "wildtype (no activating mutation); if wildtype must have received or refused anti-EGFR therapy"
      },
      {
        "target": "NRAS",
        "status": "NEGATIVE",
        "details": "wildtype (no activating mutation); if wildtype must have received or refused anti-EGFR therapy"
      },
      {
        "target": "BRAF",
        "status": "NEGATIVE",
        "details": "wildtype (no activating mutation); if wildtype must have received or refused anti-EGFR therapy"
      },
      {
        "target": "MSI",
        "status": "NEGATIVE",
        "details": "MSS (mismatch-repair proficient) colorectal cancer (microsatellite stable) \u2014 expansion cohort per study title"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Phase II /Cohort A- PI3K Mutation",
        "value": 2.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Phase II /Cohort B- PI3K Wild Type",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase I - Dose Finding (Dose Level 1)",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase I - Dose Finding (Dose Level 1)",
        "value": 1.64,
        "unit": "months",
        "ci_lower": 1.38,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Phase II /Cohort A- PI3K Mutation",
        "value": 1.68,
        "unit": "months",
        "ci_lower": 1.64,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Phase II /Cohort B- PI3K Wild Type",
        "value": 1.82,
        "unit": "months",
        "ci_lower": 1.68,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Phase I - Dose Finding (Dose Level 1)",
        "value": 5.61,
        "unit": "months",
        "ci_lower": 2.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Phase II /Cohort A- PI3K Mutation",
        "value": 6.77,
        "unit": "months",
        "ci_lower": 4.21,
        "ci_upper": 16.04,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Phase II /Cohort B- PI3K Wild Type",
        "value": 10.26,
        "unit": "months",
        "ci_lower": 4.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Copanlisib",
        "Nivolumab"
      ],
      "OG001": [
        "Copanlisib",
        "Nivolumab"
      ],
      "OG002": [
        "Copanlisib",
        "Nivolumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted",
      "OG002": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT03734029",
    "brief_title": "Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2018-12-27",
    "completion_date": "2022-01-11",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Daiichi Sankyo",
    "url": "https://clinicaltrials.gov/study/NCT03734029",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "LOW",
        "details": "IHC 2+/ISH- or IHC 1+ (ISH- or untested)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "Was never previously HER2-positive (IHC 3+ or ISH+) per ASCO-CAP guidelines"
      },
      {
        "target": "HR",
        "status": "ANY",
        "details": "Hormone receptor status may be positive or negative; progressed on endocrine therapy"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Trastuzumab Deruxtecan (T-DXd)",
        "value": 10.1,
        "unit": "months",
        "ci_lower": 9.5,
        "ci_upper": 11.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Physician's Choice",
        "value": 5.4,
        "unit": "months",
        "ci_lower": 4.4,
        "ci_upper": 7.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Trastuzumab Deruxtecan (T-DXd)",
        "value": 23.9,
        "unit": "months",
        "ci_lower": 20.8,
        "ci_upper": 24.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Physician's Choice",
        "value": 17.5,
        "unit": "months",
        "ci_lower": 15.2,
        "ci_upper": 22.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Trastuzumab deruxtecan (DS-8201a)"
      ],
      "OG001": [
        "Capecitabine",
        "Eribulin",
        "Gemcitabine",
        "Paclitaxel",
        "Nab-paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "ADC",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00857545",
    "brief_title": "OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission",
    "status": "COMPLETED",
    "start_date": "2010-07",
    "completion_date": "2015-09",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Gynecologic Oncology Group",
    "url": "https://clinicaltrials.gov/study/NCT00857545",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "CA125",
        "status": "LOW",
        "details": "Serum CA-125 within institutional normal limits as part of the definition of complete clinical remission"
      },
      {
        "target": "PREGNANCY",
        "status": "NEGATIVE",
        "details": "Negative serum pregnancy test prior to study entry; patients of childbearing potential must use effective contraception (nursing mothers excluded)"
      }
    ],
    "cancer_stages": [
      "I",
      "IA",
      "IB",
      "II",
      "IIA",
      "IIB",
      "III",
      "IIIA",
      "IIIB",
      "IIIC",
      "IV",
      "IVA",
      "IVB",
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Polyvalent Antigen-KLH+OPT-821 Vaccine",
        "value": 5.9,
        "unit": "Months",
        "ci_lower": 5.4,
        "ci_upper": 7.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Non-specific Immunity With OPT-821",
        "value": 6.5,
        "unit": "Months",
        "ci_lower": 5.1,
        "ci_upper": 7.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Polyvalent Antigen-KLH+OPT-821 Vaccine",
        "value": 46.5,
        "unit": "Months",
        "ci_lower": 36.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Non-specific Immunity With OPT-821",
        "value": 46.2,
        "unit": "Months",
        "ci_lower": 29.6,
        "ci_upper": 50.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Polyvalent Antigen-KLH Conjugate Vaccine",
        "Saponin-based Immunoadjuvant OBI-821"
      ],
      "OG001": [
        "Saponin-based Immunoadjuvant OBI-821"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT03761914",
    "brief_title": "Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers",
    "status": "COMPLETED",
    "start_date": "2019-09-30",
    "completion_date": "2022-07-05",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sellas Life Sciences Group",
    "url": "https://clinicaltrials.gov/study/NCT03761914",
    "cancer_types": [
      "LAML",
      "OV",
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "WT1",
        "status": "POSITIVE",
        "details": "WT1 expression by IHC on primary tumor or recent metastatic biopsy for solid tumors; on leukemic blasts in bone marrow or peripheral blood for AML; central review confirmation required prior to entry."
      },
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "Estrogen receptor negative by IHC; weak positivity (<5%) is allowed"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "Progesterone receptor negative by IHC; weak positivity (<5%) is allowed"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 negative by IHC AND non-amplified by FISH per standard criteria"
      },
      {
        "target": "KRAS",
        "status": "ANY",
        "details": "If KRAS is wild-type, prior therapy must have included cetuximab or panitumumab as part of standard CRC therapies"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Ovarian Cancer (OvC)",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Colorectal Cancer (CRC)",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ovarian Cancer (OvC)",
        "value": 2.9,
        "unit": "months",
        "ci_lower": 2.0,
        "ci_upper": 5.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Colorectal Cancer",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Ovarian Cancer (OvC)",
        "value": 18.4,
        "unit": "months",
        "ci_lower": 8.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Colorectal Cancer",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "galinpepimut-S",
        "Montanide",
        "GM-CSF",
        "pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT03708328",
    "brief_title": "A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2018-10-15",
    "completion_date": "2024-07-09",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT03708328",
    "cancer_types": [
      "NSCLC",
      "SCLC",
      "SKCM"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Tumor PD-L1 expression as determined by immunohistochemistry assay of archival tumor tissue or tissue obtained at screening"
      },
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "Any EGFR mutation (patients with EGFR mutations are not eligible)"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "ALK rearrangement (patients with ALK alterations are not eligible)"
      },
      {
        "target": "ROS1",
        "status": "NEGATIVE",
        "details": "ROS1 rearrangement (patients with ROS1 alterations are not eligible)"
      },
      {
        "target": "BRAF",
        "status": "NEGATIVE",
        "details": "BRAFV600E (V600E) mutation (patients with BRAFV600E are not eligible)"
      },
      {
        "target": "NTRK",
        "status": "NEGATIVE",
        "details": "NTRK fusion/rearrangement (patients with NTRK alterations are not eligible)"
      },
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "Negative HIV test result"
      },
      {
        "target": "HBV",
        "status": "NEGATIVE",
        "details": "Negative hepatitis B test result"
      },
      {
        "target": "HCV",
        "status": "NEGATIVE",
        "details": "Negative hepatitis C test result"
      }
    ],
    "cancer_stages": [
      "III",
      "IV",
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": true,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Part B1: Metastatic Melanoma Expansion Cohort",
        "value": 7.9,
        "unit": "percentage of participants",
        "ci_lower": 2.19,
        "ci_upper": 19.16,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Part B2: NSCLC Expansion Cohort 1",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 11.29,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Part B4: SCLC Expansion Cohort",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 18.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Part B5: ESCC Expansion Cohort",
        "value": 20.0,
        "unit": "percentage of participants",
        "ci_lower": 5.68,
        "ci_upper": 43.98,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG000",
        "arm_title": "Part B1: Metastatic Melanoma Expansion Cohort",
        "value": 36.8,
        "unit": "percentage of participants",
        "ci_lower": 23.83,
        "ci_upper": 51.47,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG001",
        "arm_title": "Part B2: NSCLC Expansion Cohort 1",
        "value": 36.0,
        "unit": "percentage of participants",
        "ci_lower": 20.24,
        "ci_upper": 54.39,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG002",
        "arm_title": "Part B4: SCLC Expansion Cohort",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 18.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG003",
        "arm_title": "Part B5: ESCC Expansion Cohort",
        "value": 60.0,
        "unit": "percentage of participants",
        "ci_lower": 35.96,
        "ci_upper": 80.91,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG000",
        "arm_title": "Part B1: Metastatic Melanoma Expansion Cohort",
        "value": 17.7,
        "unit": "months",
        "ci_lower": 3.9,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG001",
        "arm_title": "Part B2: NSCLC Expansion Cohort 1",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG002",
        "arm_title": "Part B4: SCLC Expansion Cohort",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG003",
        "arm_title": "Part B5: ESCC Expansion Cohort",
        "value": 10.6,
        "unit": "months",
        "ci_lower": 3.9,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Part B1: Metastatic Melanoma Expansion Cohort",
        "value": 1.8,
        "unit": "months",
        "ci_lower": 1.7,
        "ci_upper": 2.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Part B2: NSCLC Expansion Cohort 1",
        "value": 1.7,
        "unit": "months",
        "ci_lower": 1.6,
        "ci_upper": 1.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Part B4: SCLC Expansion Cohort",
        "value": 1.7,
        "unit": "months",
        "ci_lower": 1.6,
        "ci_upper": 1.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Part B5: ESCC Expansion Cohort",
        "value": 3.6,
        "unit": "months",
        "ci_lower": 1.5,
        "ci_upper": 5.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Lomvastomig"
      ],
      "OG001": [
        "Lomvastomig"
      ],
      "OG002": [
        "Lomvastomig"
      ],
      "OG003": [
        "Lomvastomig"
      ],
      "OG004": [
        "Lomvastomig"
      ],
      "OG005": [
        "Lomvastomig"
      ],
      "OG006": [
        "Lomvastomig"
      ],
      "OG007": [
        "Lomvastomig"
      ],
      "OG008": [
        "Lomvastomig"
      ],
      "OG009": [
        "Lomvastomig"
      ],
      "OG010": [
        "Lomvastomig"
      ],
      "OG011": [
        "Lomvastomig"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER",
      "OG002": "OTHER",
      "OG003": "OTHER",
      "OG004": "OTHER",
      "OG005": "OTHER",
      "OG006": "OTHER",
      "OG007": "OTHER",
      "OG008": "OTHER",
      "OG009": "OTHER",
      "OG010": "OTHER",
      "OG011": "OTHER"
    }
  },
  {
    "nct_id": "NCT03737994",
    "brief_title": "Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2019-07-25",
    "completion_date": "2021-07-21",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT03737994",
    "cancer_types": [
      "LUAD",
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "ALK",
        "status": "POSITIVE",
        "details": "ALK rearrangement demonstrated by FDA-approved assay (Vysis FISH or Ventana IHC) or by next-generation sequencing (NGS)"
      }
    ],
    "cancer_stages": [
      "IV",
      "IVA",
      "IVB",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": true,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Lorlatinib",
        "value": 3.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "LDK378 (Ceritinib)",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Brigatinib",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Ensartinib",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Lorlatinib",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "LDK378 (Ceritinib)",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Brigatinib",
        "value": 2.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Ensartinib",
        "value": 2.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Lorlatinib",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "LDK378 (Ceritinib)",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Brigatinib",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Ensartinib",
        "value": 2.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Lorlatinib"
      ],
      "OG001": [
        "Ceritinib"
      ],
      "OG002": [
        "Brigatinib"
      ],
      "OG003": [
        "Ensartinib"
      ],
      "OG004": [
        "Ensartinib"
      ],
      "OG005": [
        "Crizotinib"
      ],
      "OG006": [
        "Pemetrexed",
        "Cisplatin",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI",
      "OG002": "TKI",
      "OG003": "TKI",
      "OG004": "TKI",
      "OG005": "TKI",
      "OG006": "Chemo"
    }
  },
  {
    "nct_id": "NCT00871403",
    "brief_title": "Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2009-07",
    "completion_date": "2011-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "GlaxoSmithKline",
    "url": "https://clinicaltrials.gov/study/NCT00871403",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pazopanib 800 mg Plus Pemetrexed 500 mg/m^2",
        "value": 25.0,
        "unit": "weeks",
        "ci_lower": 17.3,
        "ci_upper": 34.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cisplatin 75 mg/m^2 Plus Pemetrexed 500 mg/m^2",
        "value": 22.9,
        "unit": "weeks",
        "ci_lower": 18.4,
        "ci_upper": 27.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "pazopanib",
        "pemetrexed"
      ],
      "OG001": [
        "cisplatin",
        "pemetrexed"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00871169",
    "brief_title": "Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer",
    "status": "COMPLETED",
    "start_date": "2008-10",
    "completion_date": "2015-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "New Mexico Cancer Research Alliance",
    "url": "https://clinicaltrials.gov/study/NCT00871169",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Irinotecan, Oxaliplatin, and Cetuximab",
        "value": 6.9,
        "unit": "percentage of participants",
        "ci_lower": 1.91,
        "ci_upper": 16.7,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Irinotecan",
        "Oxaliplatin",
        "Cetuximab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03768414",
    "brief_title": "Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers",
    "status": "COMPLETED",
    "start_date": "2019-02-07",
    "completion_date": "2023-10-04",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SWOG Cancer Research Network",
    "url": "https://clinicaltrials.gov/study/NCT03768414",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Gem+Cisplatin+Nab-paclitaxel",
        "value": 14.0,
        "unit": "Months",
        "ci_lower": 12.4,
        "ci_upper": 16.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Gemcitabine + Cisplatin",
        "value": 13.6,
        "unit": "Months",
        "ci_lower": 9.7,
        "ci_upper": 16.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Gem+Cisplatin+Nab-paclitaxel",
        "value": 7.5,
        "unit": "Months",
        "ci_lower": 6.4,
        "ci_upper": 8.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Gemcitabine + Cisplatin",
        "value": 6.3,
        "unit": "Months",
        "ci_lower": 4.4,
        "ci_upper": 8.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Gemcitabine Hydrochloride",
        "Cisplatin",
        "Nab-paclitaxel"
      ],
      "OG001": [
        "Gemcitabine Hydrochloride",
        "Cisplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00866697",
    "brief_title": "Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
    "status": "COMPLETED",
    "start_date": "2009-05-26",
    "completion_date": "2012-07-08",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT00866697",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "II",
      "III",
      "IV"
    ],
    "line_of_therapy": "MAINTENANCE",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Placebo",
        "value": 12.3,
        "unit": "Months",
        "ci_lower": 11.8,
        "ci_upper": 17.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Pazopanib 800 mg",
        "value": 17.9,
        "unit": "Months",
        "ci_lower": 15.9,
        "ci_upper": 21.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG001": [
        "Pazopanib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Placebo",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT03785925",
    "brief_title": "A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer",
    "status": "COMPLETED",
    "start_date": "2019-04-29",
    "completion_date": "2022-02-09",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Nektar Therapeutics",
    "url": "https://clinicaltrials.gov/study/NCT03785925",
    "cancer_types": [
      "BLCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "PD-L1 Low",
        "value": 22.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG001": [
        "Bempegaldesleukin",
        "Nivolumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "IO"
    }
  },
  {
    "nct_id": "NCT03829319",
    "brief_title": "Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)",
    "status": "COMPLETED",
    "start_date": "2019-03-25",
    "completion_date": "2023-08-11",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT03829319",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "absence of tumor-activating EGFR mutations"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "absence of ALK gene rearrangements"
      },
      {
        "target": "ROS1",
        "status": "NEGATIVE",
        "details": "absence of ROS1 gene rearrangements"
      },
      {
        "target": "KRAS",
        "status": "POSITIVE",
        "details": "presence of a KRAS gene mutation (alternative eligibility)"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib",
        "value": 12.1,
        "unit": "Months",
        "ci_lower": 10.4,
        "ci_upper": 14.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Part 2 First Course: Pembrolizumab+Chemotherapy+Placebo",
        "value": 9.5,
        "unit": "Months",
        "ci_lower": 8.3,
        "ci_upper": 10.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib",
        "value": 21.8,
        "unit": "Months",
        "ci_lower": 18.6,
        "ci_upper": 24.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Part 2 First Course: Pembrolizumab+Chemotherapy+Placebo",
        "value": 22.1,
        "unit": "Months",
        "ci_lower": 19.7,
        "ci_upper": 24.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Carboplatin",
        "Cisplatin",
        "Pemetrexed",
        "Lenvatinib"
      ],
      "OG001": [
        "Pembrolizumab",
        "Carboplatin",
        "Cisplatin",
        "Pemetrexed"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_IO",
      "OG001": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT00863655",
    "brief_title": "Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole",
    "status": "COMPLETED",
    "start_date": "2009-06-03",
    "completion_date": "2014-12-04",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT00863655",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Histological or cytological confirmation of estrogen-receptor positivity"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2\u2011overexpressing patients excluded"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Everolimus + Exemestane",
        "value": 6.93,
        "unit": "Months",
        "ci_lower": 6.44,
        "ci_upper": 8.05,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Exemestane",
        "value": 2.83,
        "unit": "Months",
        "ci_lower": 2.76,
        "ci_upper": 4.14,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Everolimus",
        "Exemestane"
      ],
      "OG001": [
        "Exemestane"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03785964",
    "brief_title": "Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)",
    "status": "COMPLETED",
    "start_date": "2019-04-17",
    "completion_date": "2022-04-07",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SpringWorks Therapeutics, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT03785964",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Double-Blind Phase - Nirogacestat",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Double-Blind Phase - Placebo",
        "value": 15.1,
        "unit": "Months",
        "ci_lower": 8.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nirogacestat oral tablet"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT00876395",
    "brief_title": "Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2009-09-10",
    "completion_date": "2014-05-30",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT00876395",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "IHC 3+ staining or in situ hybridization positive"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Everolimus + Paclitaxel + Trastuzumab",
        "value": 14.95,
        "unit": "months",
        "ci_lower": 14.55,
        "ci_upper": 17.91,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Paclitaxel + Trastuzumab",
        "value": 14.49,
        "unit": "months",
        "ci_lower": 12.29,
        "ci_upper": 17.08,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Everolimus + Paclitaxel + Trastuzumab",
        "value": 48.56,
        "unit": "Months",
        "ci_lower": 40.94,
        "ci_upper": 58.94,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Paclitaxel + Trastuzumab",
        "value": 49.97,
        "unit": "Months",
        "ci_lower": 40.84,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Everolimus",
        "Paclitaxel",
        "Trastuzumab"
      ],
      "OG001": [
        "Paclitaxel",
        "Trastuzumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00872989",
    "brief_title": "S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",
    "status": "COMPLETED",
    "start_date": "2010-03",
    "completion_date": "2013-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SWOG Cancer Research Network",
    "url": "https://clinicaltrials.gov/study/NCT00872989",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm I: Docetaxel",
        "value": 3.5,
        "unit": "Months",
        "ci_lower": 2.3,
        "ci_upper": 4.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm II: Docetaxel + Vandetanib",
        "value": 3.0,
        "unit": "Months",
        "ci_lower": 1.6,
        "ci_upper": 4.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm I: Docetaxel",
        "value": 18.0,
        "unit": "Months",
        "ci_lower": 13.7,
        "ci_upper": 26.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm II: Docetaxel + Vandetanib",
        "value": 14.0,
        "unit": "Months",
        "ci_lower": 9.9,
        "ci_upper": 19.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "docetaxel",
        "vandetanib"
      ],
      "OG001": [
        "docetaxel",
        "vandetanib"
      ],
      "OG002": [
        "vandetanib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Combo_TKI_Chemo",
      "OG002": "TKI"
    }
  },
  {
    "nct_id": "NCT03807778",
    "brief_title": "A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2019-02-04",
    "completion_date": "2021-11-08",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Takeda",
    "url": "https://clinicaltrials.gov/study/NCT03807778",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "EGFR in-frame exon 20 insertion (eg, A763_Y764insFQEA, V769_D770insASV, D770_N771insNPG, D770_N771insSVD, H773_V774insNPH, or any other in-frame exon 20 insertion) documented by local analytically validated test; central confirmation planned"
      },
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "EGFR common activating mutations (exon 19 deletion or L858R) are excluded"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV",
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Mobocertinib 160 mg, Phase 2 Part",
        "value": 28.6,
        "unit": "percentage of participants",
        "ci_lower": 10.4,
        "ci_upper": 54.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Mobocertinib"
      ],
      "OG001": [
        "Mobocertinib"
      ],
      "OG002": [
        "Mobocertinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI",
      "OG002": "TKI"
    }
  },
  {
    "nct_id": "NCT00861614",
    "brief_title": "Study of Immunotherapy to Treat Advanced Prostate Cancer",
    "status": "COMPLETED",
    "start_date": "2009-05",
    "completion_date": "2012-11",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT00861614",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [
      {
        "target": "TESTOSTERONE",
        "status": "LOW",
        "details": "<50 ng/dl"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Ipilimumab + Radiotherapy",
        "value": 11.04,
        "unit": "months",
        "ci_lower": 9.46,
        "ci_upper": 12.48,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Radiotherapy",
        "value": 10.02,
        "unit": "months",
        "ci_lower": 8.38,
        "ci_upper": 11.17,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ipilimumab + Radiotherapy",
        "value": 4.01,
        "unit": "months",
        "ci_lower": 3.65,
        "ci_upper": 4.34,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Radiotherapy",
        "value": 3.06,
        "unit": "months",
        "ci_lower": 2.86,
        "ci_upper": 3.42,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ipilimumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT00865709",
    "brief_title": "Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects",
    "status": "COMPLETED",
    "start_date": "2009-03",
    "completion_date": "2011-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bayer",
    "url": "https://clinicaltrials.gov/study/NCT00865709",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "ANY",
        "details": "Tumor tissue sample available for KRAS assessment"
      },
      {
        "target": "BRAF",
        "status": "ANY",
        "details": "Tumor tissue sample available for BRAF assessment"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6",
        "value": 9.1,
        "unit": "Months",
        "ci_lower": 7.6,
        "ci_upper": 9.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Matching Placebo + mFOLFOX6",
        "value": 8.7,
        "unit": "Months",
        "ci_lower": 7.4,
        "ci_upper": 9.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6",
        "value": 535.0,
        "unit": "days",
        "ci_lower": 437.0,
        "ci_upper": 613.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Matching Placebo + mFOLFOX6",
        "value": 552.0,
        "unit": "days",
        "ci_lower": 453.0,
        "ci_upper": 651.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Sorafenib",
        "5-FU (5-fluorouracil)",
        "Levo-leucovorin",
        "Oxaliplatin"
      ],
      "OG001": [
        "5-FU (5-fluorouracil)",
        "Levo-leucovorin",
        "Oxaliplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT03822468",
    "brief_title": "Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2019-06-11",
    "completion_date": "2021-06-11",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT03822468",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "ER-positive on most recently analyzed tissue sample by local laboratory"
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": "PgR (progesterone receptor)-positive on most recently analyzed tissue sample by local laboratory"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-negative defined as IHC 0 or 1+ (or IHC 2+ with negative in situ hybridization [FISH/CISH/SISH] on most recently analyzed tissue sample by local laboratory)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Ribociclib 400 mg",
        "value": 41.5,
        "unit": "Percentage of participants",
        "ci_lower": 34.4,
        "ci_upper": 48.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Ribociclib 600 mg",
        "value": 45.3,
        "unit": "Percentage of participants",
        "ci_lower": 38.1,
        "ci_upper": 52.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ribociclib 400 mg",
        "value": 26.9,
        "unit": "Months",
        "ci_lower": 20.3,
        "ci_upper": 30.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Ribociclib 600 mg",
        "value": 25.1,
        "unit": "Months",
        "ci_lower": 19.4,
        "ci_upper": 33.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ribociclib",
        "Letrozole",
        "Anastrozole",
        "Goserelin"
      ],
      "OG001": [
        "Ribociclib",
        "Letrozole",
        "Anastrozole",
        "Goserelin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03776812",
    "brief_title": "Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
    "status": "COMPLETED",
    "start_date": "2019-04-05",
    "completion_date": "2021-03-16",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Corcept Therapeutics",
    "url": "https://clinicaltrials.gov/study/NCT03776812",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A: Continuous Relacorilant Dosing",
        "value": 5.29,
        "unit": "Months",
        "ci_lower": 3.84,
        "ci_upper": 5.55,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Intermittent Relacorilant Dosing",
        "value": 5.55,
        "unit": "Months",
        "ci_lower": 3.68,
        "ci_upper": 7.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Arm C: Nab-paclitaxel Comparator",
        "value": 3.76,
        "unit": "Months",
        "ci_lower": 3.52,
        "ci_upper": 5.36,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A: Continuous Relacorilant Dosing",
        "value": 11.3,
        "unit": "Months",
        "ci_lower": 7.52,
        "ci_upper": 16.39,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Intermittent Relacorilant Dosing",
        "value": 13.9,
        "unit": "Months",
        "ci_lower": 11.07,
        "ci_upper": 18.43,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Arm C: Nab-paclitaxel Comparator",
        "value": 12.19,
        "unit": "Months",
        "ci_lower": 7.72,
        "ci_upper": 15.28,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Relacorilant",
        "Nab-paclitaxel"
      ],
      "OG001": [
        "Relacorilant",
        "Nab-paclitaxel"
      ],
      "OG002": [
        "Nab-paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Chemo"
    }
  },
  {
    "nct_id": "NCT00870870",
    "brief_title": "A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before",
    "status": "COMPLETED",
    "start_date": "2009-03",
    "completion_date": "2012-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00870870",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Gemcitabine/Cisplatin/Cetuximab (GCiC)",
        "value": 31.0,
        "unit": "percentage of participants",
        "ci_lower": 14.2,
        "ci_upper": 47.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "GCiC Plus Cixutumumab",
        "value": 20.0,
        "unit": "percentage of participants",
        "ci_lower": 4.3,
        "ci_upper": 35.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "GCiC",
        "value": 11.5,
        "unit": "months",
        "ci_lower": 5.3,
        "ci_upper": 14.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "GCiC Plus Cixutumumab",
        "value": 8.9,
        "unit": "months",
        "ci_lower": 7.0,
        "ci_upper": 13.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "GCiC",
        "value": 4.2,
        "unit": "months",
        "ci_lower": 2.9,
        "ci_upper": 6.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "GCiC Plus Cixutumumab",
        "value": 5.6,
        "unit": "months",
        "ci_lower": 2.6,
        "ci_upper": 7.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG000",
        "arm_title": "GCiC",
        "value": 5.8,
        "unit": "months",
        "ci_lower": 3.9,
        "ci_upper": 6.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG001",
        "arm_title": "GCiC Plus Cixutumumab",
        "value": 5.7,
        "unit": "months",
        "ci_lower": 2.7,
        "ci_upper": 11.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Gemcitabine",
        "Cisplatin",
        "Cetuximab"
      ],
      "OG001": [
        "Gemcitabine",
        "Cisplatin",
        "Cetuximab",
        "Cixutumumab"
      ],
      "OG002": [
        "Gemcitabine",
        "Cisplatin",
        "Cetuximab"
      ],
      "OG003": [
        "Gemcitabine",
        "Cisplatin",
        "Cetuximab",
        "Cixutumumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted",
      "OG003": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00871858",
    "brief_title": "Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2008-03-18",
    "completion_date": "2013-11-30",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Institut Bergoni\u00e9",
    "url": "https://clinicaltrials.gov/study/NCT00871858",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Estrogen receptor and/or progesterone receptor\u2013positive (ER+ and/or PR+)"
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": "Estrogen receptor and/or progesterone receptor\u2013positive (ER+ and/or PR+)"
      }
    ],
    "cancer_stages": [
      "IIA",
      "IIB",
      "IIIA",
      "IIIB"
    ],
    "line_of_therapy": "NEOADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Arm A (ANA)",
        "value": 58.9,
        "unit": "percentage of participants",
        "ci_lower": 45.0,
        "ci_upper": 71.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Arm B (FULV)",
        "value": 53.8,
        "unit": "percentage of participants",
        "ci_lower": 39.5,
        "ci_upper": 67.8,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "anastrozole"
      ],
      "OG001": [
        "fulvestrant"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT03800602",
    "brief_title": "Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2019-01-15",
    "completion_date": "2020-09-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Emory University",
    "url": "https://clinicaltrials.gov/study/NCT03800602",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "MSI",
        "status": "NEGATIVE",
        "details": "MSS (microsatellite stable)"
      },
      {
        "target": "RAS",
        "status": "ANY",
        "details": "Extended RAS status considered; if extended RAS wild-type, patient must have been treated with an anti-EGFR agent prior to enrollment"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (Nivolumab, Metformin)",
        "value": 2.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (Nivolumab, Metformin)",
        "value": 16.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Nivolumab, Metformin)",
        "value": 2.3,
        "unit": "months",
        "ci_lower": 1.7,
        "ci_upper": 2.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Nivolumab, Metformin)",
        "value": 5.2,
        "unit": "months",
        "ci_lower": 3.2,
        "ci_upper": 11.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Metformin",
        "Nivolumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO"
    }
  },
  {
    "nct_id": "NCT03805594",
    "brief_title": "177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer",
    "status": "COMPLETED",
    "start_date": "2019-05-10",
    "completion_date": "2024-01-10",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "University of California, San Francisco",
    "url": "https://clinicaltrials.gov/study/NCT03805594",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [
      {
        "target": "PSMA",
        "status": "POSITIVE",
        "details": "\u22653 PSMA-avid lesions on baseline 68Ga-PSMA-11 PET; lesions defined as SUVmax > liver"
      },
      {
        "target": "TESTOSTERONE",
        "status": "LOW",
        "details": "Castrate level <50 ng/dL; participants without bilateral orchiectomy must remain on LHRH analogue"
      },
      {
        "target": "ANC",
        "status": "HIGH",
        "details": "> 1.5 x 10^9/L absolute neutrophil count (ANC) required"
      },
      {
        "target": "HEMOGLOBIN",
        "status": "HIGH",
        "details": "> 9.0 g/dL"
      },
      {
        "target": "PLATELETS",
        "status": "HIGH",
        "details": "> 100,000/microliter"
      },
      {
        "target": "SERUM_CREATININE",
        "status": "LOW",
        "details": "<= 1.5 x ULN OR eGFR > 50 ml/min by Cockcroft-Gault or 24-hour urine collection"
      },
      {
        "target": "TOTAL_BILIRUBIN",
        "status": "LOW",
        "details": "<= 1.5 x ULN. In known/suspected Gilbert's syndrome, direct bilirubin <= ULN"
      },
      {
        "target": "AST",
        "status": "LOW",
        "details": "<= 2.5 x ULN (<= 5 x ULN if liver metastases)"
      },
      {
        "target": "ALT",
        "status": "LOW",
        "details": "<= 2.5 x ULN (<= 5 x ULN if liver metastases)"
      },
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "Known history of HIV is exclusion (screening not required)"
      },
      {
        "target": "HBsAg",
        "status": "NEGATIVE",
        "details": "Known hepatitis B (HBsAg reactive) is exclusion"
      },
      {
        "target": "HCV",
        "status": "NEGATIVE",
        "details": "Known active hepatitis C (HCV RNA detected) is exclusion"
      },
      {
        "target": "TB",
        "status": "NEGATIVE",
        "details": "Known active tuberculosis is exclusion"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Part B: Recommended Phase 2 Dosing Schedule (RP2DS) (Lutetium Lu 177-PSMA-617, Pembrolizumab)",
        "value": 56.0,
        "unit": "percentage of participants",
        "ci_lower": 35.0,
        "ci_upper": 76.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Lutetium Lu 177-PSMA-617",
        "Pembrolizumab"
      ],
      "OG001": [
        "Lutetium Lu 177-PSMA-617",
        "Pembrolizumab"
      ],
      "OG002": [
        "Lutetium Lu 177-PSMA-617",
        "Pembrolizumab"
      ],
      "OG003": [
        "Lutetium Lu 177-PSMA-617",
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted",
      "OG002": "Combo_IO_Targeted",
      "OG003": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT03797326",
    "brief_title": "Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)",
    "status": "COMPLETED",
    "start_date": "2019-02-12",
    "completion_date": "2024-10-28",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT03797326",
    "cancer_types": [
      "BRCA",
      "OV",
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "evaluable archival tumor tissue sample or newly obtained core/excisional biopsy required for PD-L1 assessment"
      },
      {
        "target": "MGMT",
        "status": "ANY",
        "details": "locally determined MGMT analysis result required (GBM cohort)"
      },
      {
        "target": "ER",
        "status": "ANY",
        "details": "locally determined result for estrogen receptor tumor analysis (TNBC cohort)"
      },
      {
        "target": "PR",
        "status": "ANY",
        "details": "locally determined result for progesterone receptor tumor analysis (TNBC cohort)"
      },
      {
        "target": "HER2",
        "status": "ANY",
        "details": "locally determined result for HER2 tumor analysis (TNBC cohort)"
      },
      {
        "target": "LDH",
        "status": "LOW",
        "details": "LDH < 2.0 x ULN (TNBC cohort)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort A: Triple Negative Breast Cancer (Lenva + Pembro)",
        "value": 4.2,
        "unit": "Months",
        "ci_lower": 1.7,
        "ci_upper": 6.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort B: Ovarian Cancer (Lenva + Pembro)",
        "value": 6.1,
        "unit": "Months",
        "ci_lower": 4.1,
        "ci_upper": 9.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cohort A: Triple Negative Breast Cancer (Lenva + Pembro)",
        "value": 11.4,
        "unit": "Months",
        "ci_lower": 4.1,
        "ci_upper": 21.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cohort B: Ovarian Cancer (Lenva + Pembro)",
        "value": 21.3,
        "unit": "Months",
        "ci_lower": 11.7,
        "ci_upper": 32.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Cohort C: Gastric Cancer (Lenva + Pembro)",
        "value": 4.7,
        "unit": "Months",
        "ci_lower": 3.8,
        "ci_upper": 6.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Cohort D1: Colorectal Cancer (Lenva + Pembro)",
        "value": 8.7,
        "unit": "Months",
        "ci_lower": 7.0,
        "ci_upper": 10.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG004",
        "arm_title": "Cohort D2: Colorectal Cancer (Lenva)",
        "value": 7.9,
        "unit": "Months",
        "ci_lower": 5.6,
        "ci_upper": 14.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG005",
        "arm_title": "Cohort E: Glioblastoma Multiforma (Lenva + Pembro)",
        "value": 8.6,
        "unit": "Months",
        "ci_lower": 7.4,
        "ci_upper": 10.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG006",
        "arm_title": "Cohort F: Biliary Tract Cancer (Lenva + Pembro)",
        "value": 7.9,
        "unit": "Months",
        "ci_lower": 5.6,
        "ci_upper": 9.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG007",
        "arm_title": "Cohort G: Pancreatic Cancer (Lenva + Pembro)",
        "value": 4.3,
        "unit": "Months",
        "ci_lower": 3.8,
        "ci_upper": 5.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort A: Triple Negative Breast Cancer (Lenva + Pembro)",
        "value": 22.6,
        "unit": "Percentage of Participants",
        "ci_lower": 9.6,
        "ci_upper": 41.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Cohort B: Ovarian Cancer (Lenva + Pembro)",
        "value": 25.8,
        "unit": "Percentage of Participants",
        "ci_lower": 11.9,
        "ci_upper": 44.6,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Lenvatinib"
      ],
      "OG001": [
        "Pembrolizumab",
        "Lenvatinib"
      ],
      "OG002": [
        "Lenvatinib"
      ],
      "OG003": [
        "Pembrolizumab",
        "Lenvatinib"
      ],
      "OG004": [
        "Pembrolizumab",
        "Lenvatinib"
      ],
      "OG005": [
        "Pembrolizumab",
        "Lenvatinib"
      ],
      "OG006": [
        "Pembrolizumab",
        "Lenvatinib"
      ],
      "OG007": [
        "Pembrolizumab",
        "Lenvatinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_IO",
      "OG001": "Combo_TKI_IO",
      "OG002": "TKI",
      "OG003": "Combo_TKI_IO",
      "OG004": "Combo_TKI_IO",
      "OG005": "Combo_TKI_IO",
      "OG006": "Combo_TKI_IO",
      "OG007": "Combo_TKI_IO"
    }
  },
  {
    "nct_id": "NCT00887549",
    "brief_title": "A Study of Thymidylate Synthase Expression in Patients With Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2009-04",
    "completion_date": "2010-07",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00887549",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed",
        "value": 5.5,
        "unit": "months",
        "ci_lower": 3.9,
        "ci_upper": 6.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "pemetrexed",
        "cisplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo"
    }
  },
  {
    "nct_id": "NCT03829332",
    "brief_title": "Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-na\u00efve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)",
    "status": "COMPLETED",
    "start_date": "2019-03-13",
    "completion_date": "2021-05-19",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT03829332",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "POSITIVE",
        "details": "TPS \u22651% by 22C3 pharmDx IHC at central laboratory"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + Lenvatinib",
        "value": 6.6,
        "unit": "Months",
        "ci_lower": 6.1,
        "ci_upper": 8.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Pembrolizumab + Placebo",
        "value": 4.2,
        "unit": "Months",
        "ci_lower": 4.1,
        "ci_upper": 6.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + Lenvatinib",
        "value": 14.1,
        "unit": "Months",
        "ci_lower": 11.4,
        "ci_upper": 19.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Pembrolizumab + Placebo",
        "value": 16.4,
        "unit": "Months",
        "ci_lower": 12.6,
        "ci_upper": 20.6,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Lenvatinib"
      ],
      "OG001": [
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_IO",
      "OG001": "IO"
    }
  },
  {
    "nct_id": "NCT00900627",
    "brief_title": "Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)",
    "status": "COMPLETED",
    "start_date": "2009-06",
    "completion_date": "2012-04",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT00900627",
    "cancer_types": [
      "BRCA",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "LOW",
        "details": "low HER2 expression (Phase II)"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "AZD8931 40MG bd + Paclitaxel",
        "value": 8.7,
        "unit": "Months",
        "ci_lower": 4.2,
        "ci_upper": 12.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Paclitaxel",
        "value": 9.1,
        "unit": "Months",
        "ci_lower": 3.4,
        "ci_upper": 14.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "AZD8931",
        "Paclitaxel"
      ],
      "OG001": [
        "AZD8931",
        "Paclitaxel"
      ],
      "OG002": [
        "AZD8931",
        "Paclitaxel"
      ],
      "OG003": [
        "AZD8931",
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Combo_TKI_Chemo",
      "OG002": "Combo_TKI_Chemo",
      "OG003": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT00904839",
    "brief_title": "BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2009-05",
    "completion_date": "2012-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Boehringer Ingelheim",
    "url": "https://clinicaltrials.gov/study/NCT00904839",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Nintedanib + mFolfox6",
        "value": 62.1,
        "unit": "percentage of Participants",
        "ci_lower": 50.2,
        "ci_upper": 73.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab + mFolfox6",
        "value": 70.2,
        "unit": "percentage of Participants",
        "ci_lower": 54.5,
        "ci_upper": 85.8,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "BIBF 1120",
        "mFolfox 6"
      ],
      "OG001": [
        "Bevacizumab",
        "mFolfox 6"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03829969",
    "brief_title": "Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma",
    "status": "COMPLETED",
    "start_date": "2019-01-31",
    "completion_date": "2021-03-22",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Shanghai Junshi Bioscience Co., Ltd.",
    "url": "https://clinicaltrials.gov/study/NCT03829969",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Toripalimab",
        "value": 5.7,
        "unit": "months",
        "ci_lower": 5.6,
        "ci_upper": 7.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 5.5,
        "unit": "months",
        "ci_lower": 5.2,
        "ci_upper": 5.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Toripalimab",
        "value": 17.7,
        "unit": "months",
        "ci_lower": 14.6,
        "ci_upper": 20.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 12.9,
        "unit": "months",
        "ci_lower": 11.6,
        "ci_upper": 14.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Toripalimab",
        "Paclitaxel",
        "Cisplatin"
      ],
      "OG001": [
        "Paclitaxel",
        "Cisplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00883779",
    "brief_title": "A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2009-04",
    "completion_date": "2014-12",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT00883779",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Placebo",
        "value": 6.0,
        "unit": "months",
        "ci_lower": 6.0,
        "ci_upper": 7.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Erlotinib",
        "value": 7.6,
        "unit": "months",
        "ci_lower": 7.0,
        "ci_upper": 8.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "gemcitabine",
        "Platinum chemotherapy (cisplatin or carboplatin)"
      ],
      "OG001": [
        "gemcitabine",
        "Platinum chemotherapy (cisplatin or carboplatin)",
        "erlotinib [Tarceva]"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT00892710",
    "brief_title": "Trial of Poor Performance Status Patients (ToPPS)",
    "status": "COMPLETED",
    "start_date": "2009-06",
    "completion_date": "2014-07",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SCRI Development Innovations, LLC",
    "url": "https://clinicaltrials.gov/study/NCT00892710",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed",
        "value": 2.8,
        "unit": "Months",
        "ci_lower": 1.5,
        "ci_upper": 4.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Pemetrexed/Bevacizumab",
        "value": 4.0,
        "unit": "Months",
        "ci_lower": 2.6,
        "ci_upper": 6.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Pemetrexed/Bevacizumab/Carboplatin",
        "value": 4.8,
        "unit": "Months",
        "ci_lower": 3.1,
        "ci_upper": 6.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed",
        "value": 7.7,
        "unit": "Months",
        "ci_lower": 3.0,
        "ci_upper": 11.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Pemetrexed/Bevacizumab",
        "value": 8.6,
        "unit": "Months",
        "ci_lower": 5.3,
        "ci_upper": 11.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Pemetrexed/Bevacizumab/Carboplatin",
        "value": 8.7,
        "unit": "Months",
        "ci_lower": 5.4,
        "ci_upper": 13.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pemetrexed"
      ],
      "OG001": [
        "Pemetrexed",
        "Bevacizumab"
      ],
      "OG002": [
        "Pemetrexed",
        "Bevacizumab",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03836066",
    "brief_title": "Atezolizumab Plus Bevacizumab in First Line NSCLC Patients",
    "status": "COMPLETED",
    "start_date": "2019-05-15",
    "completion_date": "2024-10-21",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Fundaci\u00f3n GECP",
    "url": "https://clinicaltrials.gov/study/NCT03836066",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "TMB",
        "status": "HIGH",
        "details": "\u226510 mutations/MB by Foundation Medicine on archival or prescreening tumour tissue; sample requirements: \u226520% tumour cellularity and minimum surface 25 mm2"
      },
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "sensitizing EGFR mutation (patients with a sensitizing EGFR mutation are excluded)"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "ALK fusion oncogene (patients with an ALK fusion are excluded)"
      },
      {
        "target": "MDM2",
        "status": "NEGATIVE",
        "details": "MDM2 amplification (patients with MDM2 amplification are excluded)"
      },
      {
        "target": "ROS1",
        "status": "NEGATIVE",
        "details": "ROS1 translocations (patients with ROS1 translocations are excluded)"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Experimental: Atezolizumab plus Bevacizumab arm",
        "value": 11.3,
        "unit": "Months",
        "ci_lower": 8.1,
        "ci_upper": 16.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Atezolizumab",
        "Bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT00880334",
    "brief_title": "Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC",
    "status": "COMPLETED",
    "start_date": "2006-09",
    "completion_date": "2013-12",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Dana-Farber Cancer Institute",
    "url": "https://clinicaltrials.gov/study/NCT00880334",
    "cancer_types": [
      "BLCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Vandetanib and Docetaxel",
        "value": 2.56,
        "unit": "months",
        "ci_lower": 1.81,
        "ci_upper": 3.06,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo and Docetaxel",
        "value": 1.58,
        "unit": "months",
        "ci_lower": 1.48,
        "ci_upper": 3.09,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "vandetanib",
        "Docetaxel"
      ],
      "OG001": [
        "Docetaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00894504",
    "brief_title": "Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2010-02",
    "completion_date": "2014-09",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SCRI Development Innovations, LLC",
    "url": "https://clinicaltrials.gov/study/NCT00894504",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "<10% staining by IHC"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "<10% staining by IHC"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "FISH-negative (FISH ratio <2.2), or IHC 0-1+, or IHC 2-3+ AND FISH-negative (FISH ratio <2.2)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Panitumumab/Gemcitabine/Carboplatin",
        "value": 4.4,
        "unit": "Months",
        "ci_lower": 3.2,
        "ci_upper": 5.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Panitumumab",
        "Carboplatin",
        "Gemcitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "OTHER",
      "OG002": "OTHER",
      "OG003": "OTHER",
      "OG004": "OTHER",
      "OG005": "OTHER",
      "OG006": "OTHER",
      "OG007": "OTHER"
    }
  },
  {
    "nct_id": "NCT00879333",
    "brief_title": "Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)",
    "status": "COMPLETED",
    "start_date": "2009-07",
    "completion_date": "2014-01",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT00879333",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Everolimus 10mg/Daily",
        "value": 5.39,
        "unit": "Months",
        "ci_lower": 4.8,
        "ci_upper": 6.01,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 4.34,
        "unit": "Months",
        "ci_lower": 3.81,
        "ci_upper": 5.49,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Everolimus 10mg/Daily",
        "value": 1.68,
        "unit": "Months",
        "ci_lower": 1.51,
        "ci_upper": 1.94,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 1.41,
        "unit": "Months",
        "ci_lower": 1.38,
        "ci_upper": 1.45,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Everolimus"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT03834493",
    "brief_title": "Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2019-07-28",
    "completion_date": "2022-12-12",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT03834493",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + Enzalutamide",
        "value": 24.7,
        "unit": "Months",
        "ci_lower": 22.0,
        "ci_upper": 26.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Enzalutamide",
        "value": 27.3,
        "unit": "Months",
        "ci_lower": 24.5,
        "ci_upper": 30.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + Enzalutamide",
        "value": 10.4,
        "unit": "Months",
        "ci_lower": 8.4,
        "ci_upper": 12.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Enzalutamide",
        "value": 9.0,
        "unit": "Months",
        "ci_lower": 8.3,
        "ci_upper": 11.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Enzalutamide"
      ],
      "OG001": [
        "Enzalutamide"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03834506",
    "brief_title": "Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-na\u00efve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)",
    "status": "COMPLETED",
    "start_date": "2019-05-02",
    "completion_date": "2022-06-20",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT03834506",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [
      {
        "target": "TESTOSTERONE",
        "status": "LOW",
        "details": "serum testosterone <50 ng/dL (<2.0 nM); ongoing androgen deprivation required"
      },
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "No known active infection"
      },
      {
        "target": "HBV",
        "status": "NEGATIVE",
        "details": "No known active infection"
      },
      {
        "target": "HCV",
        "status": "NEGATIVE",
        "details": "No known active infection"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + Docetaxel",
        "value": 19.6,
        "unit": "Months",
        "ci_lower": 18.2,
        "ci_upper": 20.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Docetaxel",
        "value": 19.0,
        "unit": "Months",
        "ci_lower": 17.9,
        "ci_upper": 20.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + Docetaxel",
        "value": 8.6,
        "unit": "Months",
        "ci_lower": 8.3,
        "ci_upper": 10.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Docetaxel",
        "value": 8.3,
        "unit": "Months",
        "ci_lower": 8.2,
        "ci_upper": 8.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Docetaxel"
      ],
      "OG001": [
        "Docetaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT03834961",
    "brief_title": "Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2019-10-25",
    "completion_date": "2024-09-30",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Children's Oncology Group",
    "url": "https://clinicaltrials.gov/study/NCT03834961",
    "cancer_types": [
      "OTHER",
      "LAML"
    ],
    "biomarkers": [
      {
        "target": "NTRK",
        "status": "POSITIVE",
        "details": "NTRK1, NTRK2, or NTRK3 gene fusion (TRK fusion) identified in a CLIA/CAP-certified laboratory by FISH, RT-PCR (primers flanking fusion junction), or next-generation sequencing (NGS). For fusions identified by FISH: an ETV6 rearrangement is sufficient for eligibility in infantile fibrosarcoma (Cohort A) and congenital mesoblastic nephroma; otherwise FISH must show an NTRK1/2/3 rearrangement."
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort A",
        "value": 94.4,
        "unit": "percentage of patients",
        "ci_lower": 80.1,
        "ci_upper": 97.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cohort A",
        "value": 100.0,
        "unit": "percentage of patients",
        "ci_lower": 100.0,
        "ci_upper": 100.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG000",
        "arm_title": "Cohort B",
        "value": 2.9,
        "unit": "years",
        "ci_lower": 0.2,
        "ci_upper": 4.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Larotrectinib Sulfate"
      ],
      "OG001": [
        "Larotrectinib Sulfate"
      ],
      "OG002": [
        "Larotrectinib Sulfate"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI",
      "OG002": "TKI"
    }
  },
  {
    "nct_id": "NCT00891930",
    "brief_title": "Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab",
    "status": "COMPLETED",
    "start_date": "2009-05-05",
    "completion_date": "2013-07-22",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "NantBioScience, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT00891930",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "wild-type KRAS required; confirmed by Amgen-approved central laboratory or experienced local laboratory assessment of archival tumor tissue (preferably from the primary tumor)"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Part 1",
        "value": 0.365,
        "unit": "months",
        "ci_lower": 0.164,
        "ci_upper": 0.808,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Part 2",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 9.74,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Panitumumab",
        "Ganitumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03834519",
    "brief_title": "Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)",
    "status": "COMPLETED",
    "start_date": "2019-05-02",
    "completion_date": "2022-03-14",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT03834519",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [
      {
        "target": "TESTOSTERONE",
        "status": "LOW",
        "details": "serum testosterone <50 ng/dL (<2.0 nM)"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + Olaparib",
        "value": 15.8,
        "unit": "Months",
        "ci_lower": 14.6,
        "ci_upper": 17.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Next-generation Hormonal Agent Monotherapy (NHA)",
        "value": 14.6,
        "unit": "Months",
        "ci_lower": 12.6,
        "ci_upper": 17.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + Olaparib",
        "value": 4.4,
        "unit": "Months",
        "ci_lower": 4.2,
        "ci_upper": 6.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Next-generation Hormonal Agent Monotherapy (NHA)",
        "value": 4.2,
        "unit": "Months",
        "ci_lower": 4.0,
        "ci_upper": 6.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Olaparib"
      ],
      "OG001": [
        "Abiraterone acetate",
        "Prednisone"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03830866",
    "brief_title": "Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)",
    "status": "COMPLETED",
    "start_date": "2019-02-15",
    "completion_date": "2022-01-20",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT03830866",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IB",
      "IIA",
      "IIB",
      "IIIA",
      "IIIB",
      "IIIC",
      "IVA",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Durvalumab + SoC CCRT",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + SoC CCRT",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Durvalumab + SoC CCRT",
        "value": 91.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + SoC CCRT",
        "value": 112.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Durvalumab",
        "Cisplatin",
        "Carboplatin"
      ],
      "OG001": [
        "Cisplatin",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT03829410",
    "brief_title": "Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation",
    "status": "COMPLETED",
    "start_date": "2019-06-24",
    "completion_date": "2024-01-29",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Cardiff Oncology",
    "url": "https://clinicaltrials.gov/study/NCT03829410",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "POSITIVE",
        "details": "KRAS mutation in exon 2, 3, or 4 in primary tumor or metastasis; assessed by CLIA-certified laboratory"
      },
      {
        "target": "BRAF",
        "status": "NEGATIVE",
        "details": "BRAF V600 mutation (concomitant KRAS and BRAF-V600 mutations excluded)"
      },
      {
        "target": "MSI",
        "status": "NEGATIVE",
        "details": "Microsatellite instability high (MSI-H) or deficient mismatch repair (dMMR) \u2014 participants with MSI-H/dMMR are ineligible"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 1b: Onvansertib 15 mg/m^2",
        "value": 42.9,
        "unit": "percentage of participants",
        "ci_lower": 9.9,
        "ci_upper": 81.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Phase 2 Part 1: Onvansertib 15 mg/m^2",
        "value": 27.3,
        "unit": "percentage of participants",
        "ci_lower": 13.3,
        "ci_upper": 45.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Phase 2 Part 2: Onvansertib 15 mg/m^2",
        "value": 15.4,
        "unit": "percentage of participants",
        "ci_lower": 1.9,
        "ci_upper": 45.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Phase 1b and 2 Total: Onvansertib 15 mg/m^2",
        "value": 26.4,
        "unit": "percentage of participants",
        "ci_lower": 15.3,
        "ci_upper": 40.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase 1b: Onvansertib 15 mg/m^2",
        "value": 18.0,
        "unit": "months",
        "ci_lower": 3.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Phase 2 Part 1: Onvansertib 15 mg/m^2",
        "value": 6.0,
        "unit": "months",
        "ci_lower": 5.6,
        "ci_upper": 11.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Phase 2 Part 2: Onvansertib 15 mg/m^2",
        "value": 8.0,
        "unit": "months",
        "ci_lower": 3.9,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Phase 1b and 2 Total: Onvansertib 15 mg/m^2",
        "value": 8.0,
        "unit": "months",
        "ci_lower": 5.8,
        "ci_upper": 13.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Phase 1b: Onvansertib 15 mg/m^2",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Phase 2 Part 1: Onvansertib 15 mg/m^2",
        "value": null,
        "unit": "months",
        "ci_lower": 19.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Phase 2 Part 2: Onvansertib 15 mg/m^2",
        "value": null,
        "unit": "months",
        "ci_lower": 14.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Phase 1b and 2 Total: Onvansertib 15 mg/m^2",
        "value": null,
        "unit": "months",
        "ci_lower": 19.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Onvansertib",
        "FOLFIRI"
      ],
      "OG001": [
        "Onvansertib",
        "FOLFIRI"
      ],
      "OG002": [
        "Onvansertib",
        "FOLFIRI"
      ],
      "OG003": [
        "Onvansertib",
        "FOLFIRI"
      ],
      "OG004": [
        "Onvansertib",
        "FOLFIRI"
      ],
      "OG005": [
        "Onvansertib",
        "FOLFIRI"
      ],
      "OG006": [
        "Onvansertib",
        "FOLFIRI"
      ],
      "OG007": [
        "Onvansertib",
        "FOLFIRI"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted",
      "OG003": "Combo_Chemo_Targeted",
      "OG004": "Combo_Chemo_Targeted",
      "OG005": "Combo_Chemo_Targeted",
      "OG006": "Combo_Chemo_Targeted",
      "OG007": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03837899",
    "brief_title": "Durvalumab and Tremelimumab for Pediatric Malignancies",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2019-03-07",
    "completion_date": "2023-02-28",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT03837899",
    "cancer_types": [
      "OTHER",
      "LAML",
      "DLBC"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg",
        "value": 11.1,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG000",
        "arm_title": "SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG001",
        "arm_title": "STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg",
        "value": 10.8,
        "unit": "months",
        "ci_lower": 10.8,
        "ci_upper": 10.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG000",
        "arm_title": "SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg",
        "value": 9.1,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG001",
        "arm_title": "STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg",
        "value": 10.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG000",
        "arm_title": "SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg",
        "value": 9.1,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG001",
        "arm_title": "STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg",
        "value": 10.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg",
        "value": 1.7,
        "unit": "months",
        "ci_lower": 1.58,
        "ci_upper": 1.91,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg",
        "value": 1.7,
        "unit": "months",
        "ci_lower": 0.89,
        "ci_upper": 2.76,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg",
        "value": 6.6,
        "unit": "months",
        "ci_lower": 2.2,
        "ci_upper": 15.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg",
        "value": 6.9,
        "unit": "months",
        "ci_lower": 3.2,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Durvalumab",
        "Tremelimumab"
      ],
      "OG001": [
        "Durvalumab",
        "Tremelimumab"
      ],
      "OG002": [
        "Durvalumab",
        "Tremelimumab"
      ],
      "OG003": [
        "Durvalumab",
        "Tremelimumab"
      ],
      "OG004": [
        "Durvalumab",
        "Tremelimumab"
      ],
      "OG005": [
        "Durvalumab",
        "Tremelimumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO",
      "OG003": "IO",
      "OG004": "IO",
      "OG005": "IO"
    }
  },
  {
    "nct_id": "NCT00885755",
    "brief_title": "A Study of Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2009-08-13",
    "completion_date": "2013-02-18",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT00885755",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER2-positive breast cancer"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [],
    "arm_drugs": {
      "OG000": [
        "trastuzumab [Herceptin]",
        "Standard taxane therapy",
        "capecitabine [Xeloda]"
      ],
      "OG001": [
        "trastuzumab [Herceptin]",
        "Standard taxane therapy",
        "capecitabine [Xeloda]"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00919061",
    "brief_title": "Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy",
    "status": "COMPLETED",
    "start_date": "2009-08",
    "completion_date": "2014-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Memorial Sloan Kettering Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT00919061",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Gemcitabine and Cisplatin Plus Sorafenib",
        "value": 51.0,
        "unit": "percentage of participants",
        "ci_lower": 34.0,
        "ci_upper": 66.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Gemcitabine",
        "Cisplatin",
        "Sorafenib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT00939991",
    "brief_title": "Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas",
    "status": "COMPLETED",
    "start_date": "2009-10",
    "completion_date": "2012-01",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Katy Peters",
    "url": "https://clinicaltrials.gov/study/NCT00939991",
    "cancer_types": [
      "GBM"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase II",
        "value": 53.8,
        "unit": "percentage of participants",
        "ci_lower": 37.2,
        "ci_upper": 67.9,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Bevacizumab",
        "Temozolomide",
        "Vorinostat"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03875092",
    "brief_title": "A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study",
    "status": "COMPLETED",
    "start_date": "2017-04-21",
    "completion_date": "2020-09-30",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT03875092",
    "cancer_types": [
      "LUSC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + Chemotherapy",
        "value": 8.3,
        "unit": "Months",
        "ci_lower": 6.2,
        "ci_upper": 10.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy",
        "value": 4.2,
        "unit": "Months",
        "ci_lower": 4.0,
        "ci_upper": 5.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + Chemotherapy",
        "value": 30.1,
        "unit": "Months",
        "ci_lower": 18.2,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy",
        "value": 12.7,
        "unit": "Months",
        "ci_lower": 9.4,
        "ci_upper": 17.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Paclitaxel"
      ],
      "OG001": [
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00917384",
    "brief_title": "Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma",
    "status": "COMPLETED",
    "start_date": "2009-08",
    "completion_date": "2012-07",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00917384",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "IMC-1121B (Ramucirumab)",
        "value": 5.2,
        "unit": "months",
        "ci_lower": 4.4,
        "ci_upper": 5.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 3.8,
        "unit": "months",
        "ci_lower": 2.8,
        "ci_upper": 4.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "IMC-1121B (Ramucirumab)",
        "value": 2.1,
        "unit": "months",
        "ci_lower": 1.5,
        "ci_upper": 2.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 1.3,
        "unit": "months",
        "ci_lower": 1.3,
        "ci_upper": 1.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "ramucirumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT00939627",
    "brief_title": "Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab",
    "status": "COMPLETED",
    "start_date": "2009-07",
    "completion_date": "2013-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT00939627",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A - Cetuximab",
        "value": 3.0,
        "unit": "months",
        "ci_lower": 1.9,
        "ci_upper": 5.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B - Cetuximab and Sorafenib Tosylate",
        "value": 3.2,
        "unit": "months",
        "ci_lower": 1.8,
        "ci_upper": 4.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A - Cetuximab",
        "value": 9.0,
        "unit": "months",
        "ci_lower": 5.2,
        "ci_upper": 12.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B - Cetuximab and Sorafenib Tosylate",
        "value": 5.7,
        "unit": "months",
        "ci_lower": 4.2,
        "ci_upper": 10.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "cetuximab"
      ],
      "OG001": [
        "cetuximab",
        "sorafenib tosylate"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Combo_TKI_Targeted"
    }
  },
  {
    "nct_id": "NCT03875235",
    "brief_title": "Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2019-04-16",
    "completion_date": "2021-08-11",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT03875235",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "UNRESECTABLE",
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Durvalumab + Gemcitabine + Cisplatin",
        "value": 12.8,
        "unit": "Months",
        "ci_lower": 11.1,
        "ci_upper": 14.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Gemcitabine + Cisplatin",
        "value": 11.5,
        "unit": "Months",
        "ci_lower": 10.1,
        "ci_upper": 12.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Durvalumab + Gemcitabine + Cisplatin",
        "value": 7.2,
        "unit": "Months",
        "ci_lower": 6.7,
        "ci_upper": 7.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Gemcitabine + Cisplatin",
        "value": 5.7,
        "unit": "Months",
        "ci_lower": 5.6,
        "ci_upper": 6.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Durvalumab",
        "Gemcitabine",
        "Cisplatin"
      ],
      "OG001": [
        "Gemcitabine",
        "Cisplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00915603",
    "brief_title": "Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2009-07",
    "completion_date": "2014-06",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SCRI Development Innovations, LLC",
    "url": "https://clinicaltrials.gov/study/NCT00915603",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-negative defined as FISH ratio <2.2, or IHC 0-1+; if IHC 2-3+ then must be FISH-negative (FISH ratio <2.2)."
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Paclitaxel/Bevacizumab/Everolimus",
        "value": 9.1,
        "unit": "months",
        "ci_lower": 6.8,
        "ci_upper": 10.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Paclitaxel/Bevacizumab/Placebo",
        "value": 7.1,
        "unit": "months",
        "ci_lower": 5.6,
        "ci_upper": 10.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Paclitaxel/Bevacizumab/Everolimus",
        "value": 17.5,
        "unit": "months",
        "ci_lower": 14.9,
        "ci_upper": 23.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Paclitaxel/Bevacizumab/Placebo",
        "value": 19.6,
        "unit": "months",
        "ci_lower": 14.0,
        "ci_upper": 27.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Paclitaxel",
        "Bevacizumab",
        "Everolimus"
      ],
      "OG001": [
        "Paclitaxel",
        "Bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03873493",
    "brief_title": "A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia",
    "status": "COMPLETED",
    "start_date": "2020-01-14",
    "completion_date": "2021-11-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AbbVie",
    "url": "https://clinicaltrials.gov/study/NCT03873493",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Venetoclax + Ibrutinib",
        "value": 7.1,
        "unit": "percentage of participants",
        "ci_lower": 0.2,
        "ci_upper": 33.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Venetoclax + Ibrutinib",
        "value": 2.7,
        "unit": "months",
        "ci_lower": 1.2,
        "ci_upper": 5.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG000",
        "arm_title": "Venetoclax + Ibrutinib",
        "value": 2.7,
        "unit": "months",
        "ci_lower": 1.2,
        "ci_upper": 5.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Venetoclax + Ibrutinib",
        "value": 7.3,
        "unit": "months",
        "ci_lower": 1.6,
        "ci_upper": 10.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Venetoclax",
        "Ibrutinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Targeted"
    }
  },
  {
    "nct_id": "NCT00918203",
    "brief_title": "A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)",
    "status": "COMPLETED",
    "start_date": "2010-01",
    "completion_date": "2013-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00918203",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV",
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Olaratumab + Paclitaxel + Carboplatin",
        "value": 19.1,
        "unit": "weeks",
        "ci_lower": 16.4,
        "ci_upper": 23.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Paclitaxel + Carboplatin",
        "value": 19.0,
        "unit": "weeks",
        "ci_lower": 15.3,
        "ci_upper": 25.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Crossover to Olaratumab",
        "value": 8.3,
        "unit": "weeks",
        "ci_lower": 5.0,
        "ci_upper": 13.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Olaratumab + Paclitaxel + Carboplatin",
        "value": 51.3,
        "unit": "weeks",
        "ci_lower": 39.7,
        "ci_upper": 68.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Paclitaxel + Carboplatin",
        "value": 50.1,
        "unit": "weeks",
        "ci_lower": 41.4,
        "ci_upper": 75.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Olaratumab",
        "Paclitaxel",
        "Carboplatin"
      ],
      "OG001": [
        "Paclitaxel",
        "Carboplatin"
      ],
      "OG002": [
        "Olaratumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo",
      "OG002": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00913835",
    "brief_title": "A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer",
    "status": "COMPLETED",
    "start_date": "2009-06",
    "completion_date": "2011-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00913835",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Olaratumab and Liposomal Doxorubicin",
        "value": 18.1,
        "unit": "weeks",
        "ci_lower": 8.7,
        "ci_upper": 27.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Liposomal Doxorubicin: Optional Olaratumab Monotherapy",
        "value": 17.3,
        "unit": "weeks",
        "ci_lower": 14.1,
        "ci_upper": 31.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Olaratumab and Liposomal Doxorubicin",
        "value": 72.3,
        "unit": "weeks",
        "ci_lower": 52.4,
        "ci_upper": 86.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Liposomal Doxorubicin: Optional Olaratumab Monotherapy",
        "value": 70.6,
        "unit": "weeks",
        "ci_lower": 51.4,
        "ci_upper": 106.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Olaratumab",
        "liposomal doxorubicin"
      ],
      "OG001": [
        "liposomal doxorubicin",
        "Olaratumab"
      ],
      "OG002": [
        "liposomal doxorubicin",
        "Olaratumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo",
      "OG002": "Chemo"
    }
  },
  {
    "nct_id": "NCT00920816",
    "brief_title": "Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer",
    "status": "COMPLETED",
    "start_date": "2009-08-25",
    "completion_date": "2012-07-27",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT00920816",
    "cancer_types": [
      "KIRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Axitinib (First-line Participants)",
        "value": 10.1,
        "unit": "months",
        "ci_lower": 7.2,
        "ci_upper": 12.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Sorafenib (First-line Participants)",
        "value": 6.5,
        "unit": "months",
        "ci_lower": 4.7,
        "ci_upper": 8.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Axitinib (First-line Participants)",
        "value": null,
        "unit": "months",
        "ci_lower": 18.1,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Sorafenib (First-line Participants)",
        "value": null,
        "unit": "months",
        "ci_lower": 18.1,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Axitinib (AG-013736)"
      ],
      "OG001": [
        "Sorafenib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT03847519",
    "brief_title": "Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2019-02-12",
    "completion_date": "2022-02-22",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Advaxis, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT03847519",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "HIGH",
        "details": "PD-L1 \u226550% by immunohistochemistry (IHC) at a central laboratory (required for Part C only)"
      },
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Eligible irrespective of PD-L1 expression for Part A"
      },
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "No EGFR sensitizing (activating) mutation (Part C exclusion). EGFR sensitizing mutations = those amenable to EGFR TKIs"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "No ALK translocation (Part C exclusion)"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Efficacy Phase Part C - ADXS-503 + 200mg Pembrolizumab",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "ADXS-503"
      ],
      "OG001": [
        "ADXS-503",
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO"
    }
  },
  {
    "nct_id": "NCT03850444",
    "brief_title": "Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study",
    "status": "COMPLETED",
    "start_date": "2016-08-01",
    "completion_date": "2018-09-04",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT03850444",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "POSITIVE",
        "details": "PD-L1 positive tumor; evaluable FFPE tissue submitted for central lab testing"
      },
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "EGFR-sensitizing mutation (must be absent)"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "EML4-ALK gene fusion (must be absent)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab",
        "value": 20.0,
        "unit": "Months",
        "ci_lower": 15.5,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy (SOC Treatment)",
        "value": 14.0,
        "unit": "Months",
        "ci_lower": 10.0,
        "ci_upper": 17.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab",
        "value": 8.3,
        "unit": "Months",
        "ci_lower": 4.2,
        "ci_upper": 10.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy (SOC Treatment)",
        "value": 6.5,
        "unit": "Months",
        "ci_lower": 4.4,
        "ci_upper": 9.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "pembrolizumab"
      ],
      "OG001": [
        "carboplatin",
        "paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00917462",
    "brief_title": "Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer",
    "status": "COMPLETED",
    "start_date": "2009-06",
    "completion_date": "2018-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Memorial Sloan Kettering Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT00917462",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "ERK",
        "status": "ANY",
        "details": "Phosphorylated extracellular signal-regulated kinase (pERK) by immunohistochemistry (IHC); tissue must be available but pERK result is not required prior to treatment (submission/testing may occur during therapy)."
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Sorafenib",
        "value": 20.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Sorafenib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT00924352",
    "brief_title": "Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2009-06",
    "completion_date": "2013-10",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Accelerated Community Oncology Research Network",
    "url": "https://clinicaltrials.gov/study/NCT00924352",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "ANY",
        "details": "HER2-negative disease OR disease refractory to HER2-directed therapy (eligibility includes HER2-negative or HER2-directed therapy-refractory disease)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ixabepilone + Dasatinib",
        "value": 6.01,
        "unit": "months",
        "ci_lower": 2.92,
        "ci_upper": 8.08,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Dasatinib",
        "Ixabepilone"
      ],
      "OG001": [
        "Dasatinib",
        "Ixabepilone"
      ],
      "OG002": [
        "Dasatinib",
        "Ixabepilone"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Combo_TKI_Chemo",
      "OG002": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT00912340",
    "brief_title": "Phase II Trial of EVEROLIMUS \u00b1 Trastuzumab in Hormone-Refractory Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2009-05",
    "completion_date": "2017-07",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Emory University",
    "url": "https://clinicaltrials.gov/study/NCT00912340",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "ER positive at primary diagnosis and at metastatic diagnosis where tissue available; hormone-receptor (ER and/or PR) positivity required to be candidate for hormonal therapy."
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": "PR positive at primary diagnosis and at metastatic diagnosis where tissue available; hormone-receptor (ER and/or PR) positivity required to be candidate for hormonal therapy."
      },
      {
        "target": "HER2",
        "status": "LOW",
        "details": "IHC 1+ or 2+ on metastatic biopsy required; HER2-negative at primary diagnosis (IHC <3+ or FISH-negative if IHC 3+). Excludes HER2 0 or 3+ on pre-treatment metastatic biopsy."
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Trastuzumab",
        "value": 2.0,
        "unit": "months",
        "ci_lower": 1.6,
        "ci_upper": 4.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Everolimus",
        "value": 5.7,
        "unit": "months",
        "ci_lower": 3.9,
        "ci_upper": 8.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Trastuzumab and Everolimus (ARM REMOVED)",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Trastuzumab"
      ],
      "OG001": [
        "Everolimus"
      ],
      "OG002": [
        "Trastuzumab",
        "Everolimus"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03884101",
    "brief_title": "Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)",
    "status": "COMPLETED",
    "start_date": "2019-04-11",
    "completion_date": "2023-10-02",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT03884101",
    "cancer_types": [
      "UCEC"
    ],
    "biomarkers": [
      {
        "target": "MMR",
        "status": "ANY",
        "details": "Determination of mismatch repair (MMR) status from archival tumor tissue or newly obtained core/excisional biopsy of a lesion not previously irradiated"
      }
    ],
    "cancer_stages": [
      "III",
      "IV",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Lenvatinib + Pembrolizumab",
        "value": 9.6,
        "unit": "Months",
        "ci_lower": 8.2,
        "ci_upper": 11.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Paclitaxel + Carboplatin",
        "value": 10.2,
        "unit": "Months",
        "ci_lower": 8.4,
        "ci_upper": 10.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Lenvatinib + Pembrolizumab",
        "value": 30.9,
        "unit": "Months",
        "ci_lower": 25.4,
        "ci_upper": 37.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Paclitaxel + Carboplatin",
        "value": 29.4,
        "unit": "Months",
        "ci_lower": 26.2,
        "ci_upper": 35.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Lenvatinib",
        "Pembrolizumab"
      ],
      "OG001": [
        "Paclitaxel",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT03853707",
    "brief_title": "Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2019-03-04",
    "completion_date": "2023-01-21",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "City of Hope Medical Center",
    "url": "https://clinicaltrials.gov/study/NCT03853707",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "LOW",
        "details": "ER <= 10% by immunohistochemistry (IHC)"
      },
      {
        "target": "PR",
        "status": "LOW",
        "details": "PR <= 10% by immunohistochemistry (IHC)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 negative per current ASCO/CAP guideline"
      },
      {
        "target": "DPYD",
        "status": "NEGATIVE",
        "details": "No DPD deficiency (patients selected to receive capecitabine/Arm C)"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A (Ipatasertib, Carboplatin, Paclitaxel)",
        "value": 4.8,
        "unit": "Months",
        "ci_lower": 2.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B (Ipatasertib and Carboplatin)",
        "value": 3.9,
        "unit": "Months",
        "ci_lower": 2.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Arm C (Ipatasertib, Capecitabine, Atezolizumab)",
        "value": 8.2,
        "unit": "Months",
        "ci_lower": 4.6,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A (Ipatasertib, Carboplatin, Paclitaxel)",
        "value": 11.2,
        "unit": "Months",
        "ci_lower": 7.2,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B (Ipatasertib and Carboplatin)",
        "value": 17.0,
        "unit": "Months",
        "ci_lower": 9.5,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Arm C (Ipatasertib, Capecitabine, Atezolizumab)",
        "value": null,
        "unit": "Months",
        "ci_lower": 11.1,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ipatasertib",
        "Carboplatin",
        "Paclitaxel"
      ],
      "OG001": [
        "Ipatasertib",
        "Carboplatin"
      ],
      "OG002": [
        "Ipatasertib",
        "Capecitabine",
        "Atezolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT03884556",
    "brief_title": "TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers",
    "status": "COMPLETED",
    "start_date": "2019-04-10",
    "completion_date": "2022-11-30",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Trishula Therapeutics, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT03884556",
    "cancer_types": [
      "OTHER",
      "DLBC"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Arm 1 Expansion: TTX-030 40 mg/kg Load/30 mg/kg Q3W",
        "value": 7.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 41.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Arm 2 (Safety Lead-in and Expansion), Combination",
        "value": 9.1,
        "unit": "percentage of participants",
        "ci_lower": 0.2,
        "ci_upper": 41.3,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "TTX-030"
      ],
      "OG001": [
        "TTX-030"
      ],
      "OG002": [
        "TTX-030"
      ],
      "OG003": [
        "TTX-030"
      ],
      "OG004": [
        "TTX-030"
      ],
      "OG005": [
        "TTX-030"
      ],
      "OG006": [
        "TTX-030"
      ],
      "OG007": [
        "TTX-030",
        "Gemcitabine",
        "nab paclitaxel"
      ],
      "OG008": [
        "TTX-030",
        "Pembrolizumab"
      ],
      "OG009": [
        "TTX-030",
        "Gemcitabine",
        "nab paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER",
      "OG002": "OTHER",
      "OG003": "OTHER",
      "OG004": "OTHER",
      "OG005": "OTHER",
      "OG006": "OTHER",
      "OG007": "OTHER",
      "OG008": "OTHER",
      "OG009": "OTHER"
    }
  },
  {
    "nct_id": "NCT00940225",
    "brief_title": "Study of Cabozantinib (XL184) in Adults With Advanced Malignancies",
    "status": "COMPLETED",
    "start_date": "2009-09",
    "completion_date": "2013-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Exelixis",
    "url": "https://clinicaltrials.gov/study/NCT00940225",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Lead-in Stage - CRPC",
        "value": 4.7,
        "unit": "percentage of participants",
        "ci_lower": 2.0,
        "ci_upper": 8.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Lead-in Stage - Melanoma",
        "value": 5.2,
        "unit": "percentage of participants",
        "ci_lower": 1.8,
        "ci_upper": 12.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Lead-in Stage - NSCLC",
        "value": 10.0,
        "unit": "percentage of participants",
        "ci_lower": 4.4,
        "ci_upper": 20.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Lead-in Stage - Pancreatic Cancer",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 15.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Lead-in Stage - Gastric/GEJ",
        "value": 4.8,
        "unit": "percentage of participants",
        "ci_lower": 0.2,
        "ci_upper": 21.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "Lead-in Stage - Hepatocellular Carcinoma",
        "value": 4.9,
        "unit": "percentage of participants",
        "ci_lower": 0.9,
        "ci_upper": 16.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG006",
        "arm_title": "Lead-in Stage - SCLC",
        "value": 4.8,
        "unit": "percentage of participants",
        "ci_lower": 0.2,
        "ci_upper": 21.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG007",
        "arm_title": "Lead-in Stage - Ovarian Cancer",
        "value": 21.7,
        "unit": "percentage of participants",
        "ci_lower": 13.1,
        "ci_upper": 32.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG008",
        "arm_title": "Lead-in Stage - Metastatic Breast Cancer",
        "value": 13.6,
        "unit": "percentage of participants",
        "ci_lower": 6.0,
        "ci_upper": 25.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG009",
        "arm_title": "Lead-in Stage - NRE Ovarian Cancer",
        "value": 10.0,
        "unit": "percentage of participants",
        "ci_lower": 3.3,
        "ci_upper": 21.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Randomized Phase - CRPC, Cabozantinib Arm",
        "value": 5.5,
        "unit": "months",
        "ci_lower": 4.0,
        "ci_upper": 8.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Randomized Phase - CRPC, Placebo Arm",
        "value": 1.4,
        "unit": "months",
        "ci_lower": 1.25,
        "ci_upper": 2.73,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Randomized Phase - Melanoma, Cabozantinib Arm",
        "value": 4.5,
        "unit": "months",
        "ci_lower": 1.8,
        "ci_upper": 15.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Randomized Phase - Melanoma, Placebo Arm",
        "value": 2.8,
        "unit": "months",
        "ci_lower": 1.45,
        "ci_upper": 5.45,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Randomized Phase - NSCLC, Cabozantinib Arm",
        "value": 2.4,
        "unit": "months",
        "ci_lower": 1.3,
        "ci_upper": 2.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG005",
        "arm_title": "Randomized Phase - NSCLC, Placebo Arm",
        "value": 2.4,
        "unit": "months",
        "ci_lower": 1.4,
        "ci_upper": 2.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG006",
        "arm_title": "Randomized Phase - Pancreatic Cancer, Cabozantinib Arm",
        "value": 2.8,
        "unit": "months",
        "ci_lower": 1.5,
        "ci_upper": 2.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG007",
        "arm_title": "Randomized Phase - Pancreatic Cancer, Placebo Arm",
        "value": 0.07,
        "unit": "months",
        "ci_lower": 0.07,
        "ci_upper": 0.07,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG008",
        "arm_title": "Randomized Phase - Gastric/GEJ, Cabozantinib Arm",
        "value": null,
        "unit": "months",
        "ci_lower": 2.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG009",
        "arm_title": "Randomized Phase - Gastric/GEJ , Placebo Arm",
        "value": 1.0,
        "unit": "months",
        "ci_lower": 0.72,
        "ci_upper": 1.38,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG010",
        "arm_title": "Randomized Phase - HCC, Cabozantinib Arm",
        "value": 2.5,
        "unit": "months",
        "ci_lower": 1.3,
        "ci_upper": 6.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG011",
        "arm_title": "Randomized Phase - HCC, Placebo Arm",
        "value": 1.4,
        "unit": "months",
        "ci_lower": 1.3,
        "ci_upper": 4.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG012",
        "arm_title": "Randomized Phase - SCLC, Cabozantinib Arm",
        "value": 5.5,
        "unit": "months",
        "ci_lower": 1.9,
        "ci_upper": 6.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG013",
        "arm_title": "Randomized Phase - SCLC, Placebo Arm",
        "value": 1.5,
        "unit": "months",
        "ci_lower": 0.85,
        "ci_upper": 2.23,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG014",
        "arm_title": "Randomized Phase - Ovarian Cancer, Cabozantinib Arm",
        "value": 4.9,
        "unit": "months",
        "ci_lower": 3.9,
        "ci_upper": 13.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG015",
        "arm_title": "Randomized Phase - Ovarian Cancer, Placebo Arm",
        "value": 1.4,
        "unit": "months",
        "ci_lower": 1.3,
        "ci_upper": 1.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG016",
        "arm_title": "Randomized Phase - MBC, Cabozantinib Arm",
        "value": 6.9,
        "unit": "months",
        "ci_lower": 5.1,
        "ci_upper": 13.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG017",
        "arm_title": "Randomized Phase - MBC, Placebo Arm",
        "value": 1.1,
        "unit": "months",
        "ci_lower": 0.7,
        "ci_upper": 1.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cabozantinib"
      ],
      "OG001": [
        "Cabozantinib"
      ],
      "OG002": [
        "Cabozantinib"
      ],
      "OG003": [
        "Cabozantinib"
      ],
      "OG004": [
        "Cabozantinib"
      ],
      "OG005": [
        "Cabozantinib"
      ],
      "OG006": [
        "Cabozantinib"
      ],
      "OG007": [
        "Cabozantinib"
      ],
      "OG008": [
        "Cabozantinib"
      ],
      "OG009": [
        "Cabozantinib"
      ],
      "OG010": [
        "Cabozantinib"
      ],
      "OG012": [
        "Cabozantinib"
      ],
      "OG014": [
        "Cabozantinib"
      ],
      "OG016": [
        "Cabozantinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI",
      "OG002": "TKI",
      "OG003": "TKI",
      "OG004": "TKI",
      "OG005": "TKI",
      "OG006": "TKI",
      "OG007": "TKI",
      "OG008": "TKI",
      "OG009": "TKI",
      "OG010": "TKI",
      "OG011": "Placebo",
      "OG012": "TKI",
      "OG013": "Placebo",
      "OG014": "TKI",
      "OG015": "Placebo",
      "OG016": "TKI",
      "OG017": "Placebo"
    }
  },
  {
    "nct_id": "NCT00962091",
    "brief_title": "Study of MLN8237 in Participants With Advanced Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2009-09-25",
    "completion_date": "2011-12-28",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Millennium Pharmaceuticals, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT00962091",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [],
    "arm_drugs": {
      "OG000": [
        "Alisertib"
      ],
      "OG001": [
        "Alisertib"
      ],
      "OG002": [
        "Alisertib"
      ],
      "OG003": [
        "Alisertib"
      ],
      "OG004": [
        "Alisertib"
      ],
      "OG005": [
        "Alisertib"
      ],
      "OG006": [
        "Alisertib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other",
      "OG004": "Targeted_Other",
      "OG005": "Targeted_Other",
      "OG006": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00942734",
    "brief_title": "Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma",
    "status": "COMPLETED",
    "start_date": "2009-07",
    "completion_date": "2014-11",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "M.D. Anderson Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT00942734",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "RAD001 + Erlotinib",
        "value": 48.57,
        "unit": "Percentage of Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "RAD001",
        "Erlotinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Targeted"
    }
  },
  {
    "nct_id": "NCT00988858",
    "brief_title": "A Study of Advanced or Metastatic Non-small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2009-11",
    "completion_date": "2012-07",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00988858",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "LY2603618 and Pemetrexed",
        "value": 9.1,
        "unit": "percentage of participants",
        "ci_lower": 3.7,
        "ci_upper": 18.2,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "LY2603618",
        "Pemetrexed"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo"
    }
  },
  {
    "nct_id": "NCT00960115",
    "brief_title": "Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy",
    "status": "COMPLETED",
    "start_date": "2008-12",
    "completion_date": "2014-05",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck KGaA, Darmstadt, Germany",
    "url": "https://clinicaltrials.gov/study/NCT00960115",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "III",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "MAINTENANCE",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Tecemotide (L-BLP25) + Cyclophosphamide",
        "value": 32.4,
        "unit": "Months",
        "ci_lower": 26.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Saline",
        "value": 32.2,
        "unit": "Months",
        "ci_lower": 19.6,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Tecemotide (L-BLP25)",
        "Cyclophosphamide"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT00983801",
    "brief_title": "Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric Cancer",
    "status": "COMPLETED",
    "start_date": "2009-11",
    "completion_date": "2011-06",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "R-Pharm",
    "url": "https://clinicaltrials.gov/study/NCT00983801",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Ixabepilone 40 mg/m^2 IV",
        "value": 15.4,
        "unit": "percentage of participants",
        "ci_lower": 6.9,
        "ci_upper": 28.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ixabepilone 40 mg/m^2 IV",
        "value": 2.8,
        "unit": "months",
        "ci_lower": 2.1,
        "ci_upper": 3.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ixabepilone"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo"
    }
  },
  {
    "nct_id": "NCT00982592",
    "brief_title": "Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer",
    "status": "COMPLETED",
    "start_date": "2009-09",
    "completion_date": "2012-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT00982592",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "UNRESECTABLE",
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm I (FOLFOX Regimen and Placebo)",
        "value": 8.77,
        "unit": "months",
        "ci_lower": 5.65,
        "ci_upper": 10.61,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm II (FOLFOX Regimen and Vismodegib)",
        "value": 8.35,
        "unit": "months",
        "ci_lower": 5.55,
        "ci_upper": 10.61,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm I (FOLFOX Regimen and Placebo)",
        "value": 15.38,
        "unit": "months",
        "ci_lower": 12.32,
        "ci_upper": 19.52,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm II (FOLFOX Regimen and Vismodegib)",
        "value": 12.12,
        "unit": "months",
        "ci_lower": 10.28,
        "ci_upper": 17.77,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "oxaliplatin",
        "leucovorin calcium",
        "fluorouracil"
      ],
      "OG001": [
        "oxaliplatin",
        "leucovorin calcium",
        "fluorouracil",
        "vismodegib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00970684",
    "brief_title": "Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2009-09",
    "completion_date": "2011-09",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Nathan Pennell, MD, PhD",
    "url": "https://clinicaltrials.gov/study/NCT00970684",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab, Docetaxel, and Gemcitabine",
        "value": 5.6,
        "unit": "months",
        "ci_lower": 3.9,
        "ci_upper": 7.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "bevacizumab",
        "docetaxel",
        "gemcitabine hydrochloride"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT01005680",
    "brief_title": "A Study Comparing Two Different Chemotherapy Types in Chinese Patients With Advanced Non Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2009-11",
    "completion_date": "2012-11",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT01005680",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed Plus Cisplatin (PC)",
        "value": 17.54,
        "unit": "months",
        "ci_lower": 13.34,
        "ci_upper": 22.67,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Gemcitabine Plus Cisplatin (GC)",
        "value": 15.51,
        "unit": "months",
        "ci_lower": 13.7,
        "ci_upper": 19.29,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed Plus Cisplatin (PC)",
        "value": 5.88,
        "unit": "months",
        "ci_lower": 4.99,
        "ci_upper": 6.47,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Gemcitabine Plus Cisplatin (GC)",
        "value": 5.85,
        "unit": "months",
        "ci_lower": 5.59,
        "ci_upper": 6.41,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pemetrexed",
        "Cisplatin"
      ],
      "OG001": [
        "Gemcitabine",
        "Cisplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00942825",
    "brief_title": "Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC)",
    "status": "COMPLETED",
    "start_date": "2009-04",
    "completion_date": "2013-07",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "CanBas Co. Ltd.",
    "url": "https://clinicaltrials.gov/study/NCT00942825",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "A CBP501 +Cisplatin + Pemetrexed",
        "value": 140.0,
        "unit": "days",
        "ci_lower": 107.0,
        "ci_upper": 171.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "B Cisplatin + Pemetrexed",
        "value": 165.0,
        "unit": "days",
        "ci_lower": 132.0,
        "ci_upper": 186.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "CBP501",
        "Cisplatin",
        "Pemetrexed"
      ],
      "OG001": [
        "Cisplatin",
        "Pemetrexed"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00976911",
    "brief_title": "AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer",
    "status": "COMPLETED",
    "start_date": "2009-10-29",
    "completion_date": "2014-07-09",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT00976911",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Chemotherapy",
        "value": 3.4,
        "unit": "months",
        "ci_lower": 2.1,
        "ci_upper": 3.75,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy + Bevacizumab",
        "value": 6.8,
        "unit": "months",
        "ci_lower": 5.62,
        "ci_upper": 7.79,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "paclitaxel",
        "topotecan"
      ],
      "OG001": [
        "paclitaxel",
        "topotecan",
        "Bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00982111",
    "brief_title": "First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin",
    "status": "COMPLETED",
    "start_date": "2009-11-02",
    "completion_date": "2012-11-14",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00982111",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Necitumumab + Pemetrexed + Cisplatin",
        "value": 11.3,
        "unit": "Months",
        "ci_lower": 9.5,
        "ci_upper": 13.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Pemetrexed + Cisplatin",
        "value": 11.5,
        "unit": "Months",
        "ci_lower": 10.1,
        "ci_upper": 13.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Necitumumab + Pemetrexed + Cisplatin",
        "value": 5.6,
        "unit": "Months",
        "ci_lower": 5.1,
        "ci_upper": 6.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Pemetrexed + Cisplatin",
        "value": 5.6,
        "unit": "Months",
        "ci_lower": 4.8,
        "ci_upper": 5.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Necitumumab",
        "Pemetrexed",
        "Cisplatin"
      ],
      "OG001": [
        "Pemetrexed",
        "Cisplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00945139",
    "brief_title": "Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)",
    "status": "COMPLETED",
    "start_date": "2007-03",
    "completion_date": "2010-12",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "New Mexico Cancer Research Alliance",
    "url": "https://clinicaltrials.gov/study/NCT00945139",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Doxil (PLD) + Avastin (Bevacizumab)",
        "value": 7.8,
        "unit": "Months",
        "ci_lower": 2.0,
        "ci_upper": 13.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Doxil (PLD) + Avastin (Bevacizumab)",
        "value": 33.2,
        "unit": "Months",
        "ci_lower": 3.0,
        "ci_upper": 37.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Doxil",
        "Avastin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00978250",
    "brief_title": "A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)",
    "status": "COMPLETED",
    "start_date": "2009-08-20",
    "completion_date": "2019-04-11",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT00978250",
    "cancer_types": [
      "HNSC",
      "NSCLC",
      "BLCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Non-Small Cell Cancer Stratum",
        "value": 2.3,
        "unit": "months",
        "ci_lower": 1.6,
        "ci_upper": 3.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Breast Cancer Stratum",
        "value": 3.7,
        "unit": "months",
        "ci_lower": 1.8,
        "ci_upper": 5.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Bladder Cancer Stratum",
        "value": 3.6,
        "unit": "months",
        "ci_lower": 1.7,
        "ci_upper": 8.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Heand and Neck Cancer Stratum",
        "value": 1.7,
        "unit": "months",
        "ci_lower": 1.7,
        "ci_upper": 4.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Non-Small Cell Cancer Stratum",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 13.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Breast Cancer Stratum",
        "value": 6.9,
        "unit": "percentage of participants",
        "ci_lower": 0.8,
        "ci_upper": 22.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Bladder Cancer Stratum",
        "value": 5.6,
        "unit": "percentage of participants",
        "ci_lower": 0.1,
        "ci_upper": 27.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Head and Neck Cancer Stratum",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 16.1,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "5-Fluoro-2'-Deoxycytidine (FdCyd)",
        "Tetrahydrouridine (THU)"
      ],
      "OG001": [
        "5-Fluoro-2'-Deoxycytidine (FdCyd)",
        "Tetrahydrouridine (THU)"
      ],
      "OG002": [
        "5-Fluoro-2'-Deoxycytidine (FdCyd)",
        "Tetrahydrouridine (THU)"
      ],
      "OG003": [
        "5-Fluoro-2'-Deoxycytidine (FdCyd)",
        "Tetrahydrouridine (THU)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo",
      "OG002": "Chemo",
      "OG003": "Chemo"
    }
  },
  {
    "nct_id": "NCT00981058",
    "brief_title": "First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin",
    "status": "COMPLETED",
    "start_date": "2010-01-07",
    "completion_date": "2013-06-17",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00981058",
    "cancer_types": [
      "LUSC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "Archived tumor tissue required for analysis of EGFR mutation status by PCR and EGFR gene copy number by FISH (minimum four paraffin-embedded slides)"
      },
      {
        "target": "KRAS",
        "status": "ANY",
        "details": "Archived tumor tissue required for analysis of KRAS mutation status by PCR"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Necitumumab + Gemcitabine + Cisplatin",
        "value": 11.5,
        "unit": "Months",
        "ci_lower": 10.4,
        "ci_upper": 12.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Gemcitabine + Cisplatin",
        "value": 9.9,
        "unit": "Months",
        "ci_lower": 8.9,
        "ci_upper": 11.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Necitumumab + Gemcitabine + Cisplatin",
        "value": 5.7,
        "unit": "months",
        "ci_lower": 5.6,
        "ci_upper": 6.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Gemcitabine + Cisplatin",
        "value": 5.5,
        "unit": "months",
        "ci_lower": 4.8,
        "ci_upper": 5.6,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Necitumumab",
        "Gemcitabine",
        "Cisplatin"
      ],
      "OG001": [
        "Gemcitabine",
        "Cisplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00950365",
    "brief_title": "Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2006-04",
    "completion_date": "2017-11-17",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Albert Einstein College of Medicine",
    "url": "https://clinicaltrials.gov/study/NCT00950365",
    "cancer_types": [
      "NSCLC",
      "LUAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A (Pemetrexed)",
        "value": 8.0,
        "unit": "months",
        "ci_lower": 0.0,
        "ci_upper": 19.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B (Pemetrexed Disodium, Erlotinib Hydrochloride)",
        "value": 20.0,
        "unit": "months",
        "ci_lower": 7.0,
        "ci_upper": 29.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A (Pemetrexed)",
        "value": 25.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B (Pemetrexed Disodium, Erlotinib Hydrochloride)",
        "value": 50.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pemetrexed Disodium"
      ],
      "OG001": [
        "Pemetrexed Disodium",
        "Erlotinib Hydrochloride"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT00942331",
    "brief_title": "Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer",
    "status": "COMPLETED",
    "start_date": "2009-07-15",
    "completion_date": "2018-11-02",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT00942331",
    "cancer_types": [
      "BLCA",
      "PRAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm II (GCB)",
        "value": 14.5,
        "unit": "months",
        "ci_lower": 13.5,
        "ci_upper": 16.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm I (GCP)",
        "value": 14.3,
        "unit": "months",
        "ci_lower": 12.1,
        "ci_upper": 16.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm II (GCB)",
        "value": 8.0,
        "unit": "months",
        "ci_lower": 7.1,
        "ci_upper": 8.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm I (GCP)",
        "value": 6.7,
        "unit": "months",
        "ci_lower": 6.3,
        "ci_upper": 7.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Gemcitabine Hydrochloride",
        "Cisplatin",
        "Bevacizumab"
      ],
      "OG001": [
        "Gemcitabine Hydrochloride",
        "Cisplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00988208",
    "brief_title": "Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer",
    "status": "COMPLETED",
    "start_date": "2009-11-11",
    "completion_date": "2012-01-13",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Celgene",
    "url": "https://clinicaltrials.gov/study/NCT00988208",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [
      {
        "target": "PSA",
        "status": "ANY",
        "details": "Rising serum Prostate Specific Antigen (PSA) used to document disease progression"
      },
      {
        "target": "TESTOSTERONE",
        "status": "LOW",
        "details": "Serum testosterone <50 ng/dL (castrate level)"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Docetaxel/Prednisone/Placebo (DP)",
        "value": null,
        "unit": "weeks",
        "ci_lower": 75.71,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Docetaxel/Prednisone/Lenalidomide (DPL)",
        "value": 77.0,
        "unit": "weeks",
        "ci_lower": 64.29,
        "ci_upper": 81.71,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Docetaxel/Prednisone/Placebo (DP)",
        "value": 46.0,
        "unit": "Weeks",
        "ci_lower": 42.14,
        "ci_upper": 53.57,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Docetaxel/Prednisone/Lenalidomide (DPL)",
        "value": 45.0,
        "unit": "Weeks",
        "ci_lower": 38.0,
        "ci_upper": 46.14,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Docetaxel",
        "Prednisone"
      ],
      "OG001": [
        "Docetaxel",
        "Prednisone",
        "Lenalidomide"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00984282",
    "brief_title": "Nexavar\u00ae Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer",
    "status": "COMPLETED",
    "start_date": "2009-10-15",
    "completion_date": "2012-08-31",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bayer",
    "url": "https://clinicaltrials.gov/study/NCT00984282",
    "cancer_types": [
      "THCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Sorafenib (Nexavar, BAY43-9006)",
        "value": 329.0,
        "unit": "Days",
        "ci_lower": 278.0,
        "ci_upper": 393.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 175.0,
        "unit": "Days",
        "ci_lower": 160.0,
        "ci_upper": 238.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Sorafenib (Nexavar, BAY43-9006)",
        "value": 52.7,
        "unit": "Percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 54.8,
        "unit": "Percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Sorafenib (Nexavar, BAY43-9006)"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT00980343",
    "brief_title": "GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery",
    "status": "COMPLETED",
    "start_date": "2010-02",
    "completion_date": "2012-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT00980343",
    "cancer_types": [
      "GBM"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm I (Pre-surgery Vismodegib)",
        "value": 0.0,
        "unit": "percentage of patients",
        "ci_lower": 0.0,
        "ci_upper": 16.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm II (no Vismodegib Pre-surgery)",
        "value": 5.0,
        "unit": "percentage of patients",
        "ci_lower": 0.1,
        "ci_upper": 24.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm 1(Pre-surgery Vismodegib)",
        "value": 7.8,
        "unit": "months",
        "ci_lower": 3.7,
        "ci_upper": 10.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm II (no Vismodegib Pre-surgery)",
        "value": 7.6,
        "unit": "months",
        "ci_lower": 5.0,
        "ci_upper": 13.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "vismodegib"
      ],
      "OG001": [
        "vismodegib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01007942",
    "brief_title": "Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2009-10",
    "completion_date": "2015-06",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT01007942",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "IHC 3+ staining or in situ hybridization positive"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Everolimus + Vinorelbine + Trastuzumab",
        "value": 7.0,
        "unit": "months",
        "ci_lower": 6.74,
        "ci_upper": 8.18,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Vinorelbine + Trastuzumab",
        "value": 5.78,
        "unit": "months",
        "ci_lower": 5.49,
        "ci_upper": 6.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Everolimus + Vinorelbine + Trastuzumab",
        "value": 23.46,
        "unit": "months",
        "ci_lower": 20.01,
        "ci_upper": 28.81,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Vinorelbine + Trastuzumab",
        "value": 24.08,
        "unit": "months",
        "ci_lower": 21.49,
        "ci_upper": 27.63,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "everolimus",
        "vinorelbine",
        "trastuzumab"
      ],
      "OG001": [
        "vinorelbine",
        "trastuzumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT04003246",
    "brief_title": "Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2020-04-03",
    "completion_date": "2022-06-15",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "University of Texas Southwestern Medical Center",
    "url": "https://clinicaltrials.gov/study/NCT04003246",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "III",
      "IIIA",
      "IIIB",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Single Arm: Therapeutic Intervention",
        "value": 208.0,
        "unit": "days",
        "ci_lower": 0.0,
        "ci_upper": 365.0,
        "dispersion_type": "MEAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Single Arm: Therapeutic Intervention",
        "value": 486.0,
        "unit": "days",
        "ci_lower": 0.0,
        "ci_upper": 1460.0,
        "dispersion_type": "MEAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Consolidative Durvalumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO"
    }
  },
  {
    "nct_id": "NCT01017874",
    "brief_title": "A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2009-11",
    "completion_date": "2013-04",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT01017874",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "EGFR mutation testing must be unknown/not performed or inconclusive at entry; participants with known EGFR mutation status are excluded."
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed + Cisplatin + Gefitinib",
        "value": 8.38,
        "unit": "months",
        "ci_lower": 6.44,
        "ci_upper": 11.14,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Gefitinib",
        "value": 9.63,
        "unit": "months",
        "ci_lower": 6.74,
        "ci_upper": 11.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed + Cisplatin + Gefitinib",
        "value": 26.87,
        "unit": "months",
        "ci_lower": 20.76,
        "ci_upper": 35.12,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Gefitinib",
        "value": 27.86,
        "unit": "months",
        "ci_lower": 21.26,
        "ci_upper": 31.36,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pemetrexed",
        "Cisplatin",
        "Gefitinib"
      ],
      "OG001": [
        "Gefitinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT01015118",
    "brief_title": "LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer",
    "status": "COMPLETED",
    "start_date": "2009-11-17",
    "completion_date": "2013-04-01",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Boehringer Ingelheim",
    "url": "https://clinicaltrials.gov/study/NCT01015118",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIB",
      "IIIA",
      "IIIB",
      "IIIC",
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Nintedanib",
        "value": 17.2,
        "unit": "Months",
        "ci_lower": 11.1,
        "ci_upper": 32.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 16.6,
        "unit": "Months",
        "ci_lower": 10.8,
        "ci_upper": 30.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nintedanib",
        "Carboplatin",
        "Paclitaxel"
      ],
      "OG001": [
        "Carboplatin",
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT03901339",
    "brief_title": "Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2019-05-08",
    "completion_date": "2023-10-20",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Gilead Sciences",
    "url": "https://clinicaltrials.gov/study/NCT03901339",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HR",
        "status": "POSITIVE",
        "details": "ER and/or PR positive (hormone receptor-positive, HR+)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-negative per standard testing"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Sacituzumab Govitecan",
        "value": 5.5,
        "unit": "months",
        "ci_lower": 4.2,
        "ci_upper": 6.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Treatment of Physician's Choice (TPC)",
        "value": 4.0,
        "unit": "months",
        "ci_lower": 3.0,
        "ci_upper": 4.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Sacituzumab Govitecan",
        "value": 14.5,
        "unit": "months",
        "ci_lower": 13.0,
        "ci_upper": 16.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Treatment of Physician's Choice (TPC)",
        "value": 11.2,
        "unit": "months",
        "ci_lower": 10.2,
        "ci_upper": 12.6,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Sacituzumab Govitecan-hziy"
      ],
      "OG001": [
        "Eribulin",
        "Capecitabine",
        "Gemcitabine",
        "Vinorelbine"
      ]
    },
    "treatment_class_map": {
      "OG000": "ADC",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT03913455",
    "brief_title": "Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2019-06-06",
    "completion_date": "2021-04-14",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Shadia Jalal, MD",
    "url": "https://clinicaltrials.gov/study/NCT03913455",
    "cancer_types": [
      "SCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Guadecitabine and Carboplatin (Platinum Sensitive)",
        "value": 1.9,
        "unit": "Months",
        "ci_lower": 1.2,
        "ci_upper": 2.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Guadecitabine and Carboplatin (Platinum Resistant)",
        "value": 1.7,
        "unit": "Months",
        "ci_lower": 0.9,
        "ci_upper": 4.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Guadecitabine and Carboplatin (Platinum Sensitive)",
        "value": 6.8,
        "unit": "Months",
        "ci_lower": 2.7,
        "ci_upper": 10.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Guadecitabine and Carboplatin (Platinum Resistant)",
        "value": 4.4,
        "unit": "Months",
        "ci_lower": 1.4,
        "ci_upper": 11.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Guadecitabine",
        "Carboplatin"
      ],
      "OG001": [
        "Guadecitabine",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT03981614",
    "brief_title": "Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2019-10-29",
    "completion_date": "2021-08-23",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Academic and Community Cancer Research United",
    "url": "https://clinicaltrials.gov/study/NCT03981614",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "POSITIVE",
        "details": "Mutation in codons 12, 13, 59, 61, 117, or 146; tested in tumor tissue (primary or metastatic) by a CLIA-certified laboratory"
      },
      {
        "target": "NRAS",
        "status": "POSITIVE",
        "details": "Mutation in codons 12, 13, 59, 61, 117, or 146; tested in tumor tissue (primary or metastatic) by a CLIA-certified laboratory"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A (Binimetinib, Palbociclib)",
        "value": 2.3,
        "unit": "months",
        "ci_lower": 2.0,
        "ci_upper": 3.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B (Trifluridine and Tipiracil Hydrochloride)",
        "value": 2.2,
        "unit": "months",
        "ci_lower": 2.1,
        "ci_upper": 2.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A (Binimetinib, Palbociclib)",
        "value": 7.7,
        "unit": "months",
        "ci_lower": 5.1,
        "ci_upper": 13.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B (Trifluridine and Tipiracil Hydrochloride)",
        "value": 6.8,
        "unit": "months",
        "ci_lower": 5.5,
        "ci_upper": 8.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Binimetinib",
        "Palbociclib"
      ],
      "OG001": [
        "Trifluridine and Tipiracil Hydrochloride"
      ],
      "OG002": [
        "Palbociclib",
        "Binimetinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Chemo",
      "OG002": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT03975647",
    "brief_title": "A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2019-10-02",
    "completion_date": "2023-06-29",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Seagen, a wholly owned subsidiary of Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT03975647",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "as determined by a sponsor-designated central laboratory"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Tucatinib+ Ado-trastuzumab Emtansine",
        "value": 9.5,
        "unit": "Months",
        "ci_lower": 7.4,
        "ci_upper": 10.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo+ Ado-trastuzumab Emtansine",
        "value": 7.4,
        "unit": "Months",
        "ci_lower": 5.6,
        "ci_upper": 8.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "tucatinib",
        "T-DM1"
      ],
      "OG001": [
        "T-DM1"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Targeted",
      "OG001": "ADC"
    }
  },
  {
    "nct_id": "NCT03972488",
    "brief_title": "Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2020-01-08",
    "completion_date": "2023-07-20",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Advanced Accelerator Applications",
    "url": "https://clinicaltrials.gov/study/NCT03972488",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "SSTR",
        "status": "POSITIVE",
        "details": "Expression of somatostatin receptors on all target lesions documented by SRI within 3 months prior to randomization (e.g., 68Ga-DOTA-TOC, 68Ga-DOTA-TATE, 64Cu-DOTA-TATE PET/CT, 111In-pentetreotide SPECT/CT, 99mTc-Tektrotyd); tumor uptake must be > normal liver uptake."
      },
      {
        "target": "KI67",
        "status": "ANY",
        "details": "Ki67 index \u226510% and \u226455%."
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Lutathera\u0000ae Plus Octreotide LAR 30 mg (Investigational Arm)",
        "value": 22.8,
        "unit": "Months",
        "ci_lower": 19.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Octreotide LAR 60 mg (Control Arm)",
        "value": 8.5,
        "unit": "Months",
        "ci_lower": 7.7,
        "ci_upper": 13.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Lutathera",
        "30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot)",
        "2.5% Lys-Arg sterile amino acid solution"
      ],
      "OG001": [
        "High dose 60 mg octreotide long-acting repeatable"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT01020786",
    "brief_title": "A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients",
    "status": "COMPLETED",
    "start_date": "2009-11",
    "completion_date": "2011-03",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT01020786",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed + Carboplatin",
        "value": 5.6,
        "unit": "months",
        "ci_lower": 4.3,
        "ci_upper": 7.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed + Carboplatin",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed + Carboplatin",
        "value": 20.2,
        "unit": "months",
        "ci_lower": 16.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pemetrexed",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo"
    }
  },
  {
    "nct_id": "NCT01008475",
    "brief_title": "EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2009-10",
    "completion_date": "2015-04",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck KGaA, Darmstadt, Germany",
    "url": "https://clinicaltrials.gov/study/NCT01008475",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "wildtype (WT); no activating KRAS mutation"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "IV"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Standard of Care (SoC)",
        "value": 5.6,
        "unit": "months",
        "ci_lower": 4.2,
        "ci_upper": 6.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "EMD 525797 500 mg + SoC",
        "value": 5.4,
        "unit": "months",
        "ci_lower": 4.1,
        "ci_upper": 6.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "EMD 525797 1000 mg + SoC",
        "value": 5.6,
        "unit": "months",
        "ci_lower": 4.1,
        "ci_upper": 6.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Standard of Care (SoC)",
        "value": 11.6,
        "unit": "months",
        "ci_lower": 9.8,
        "ci_upper": 15.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "EMD 525797 500 mg + SoC",
        "value": 15.0,
        "unit": "months",
        "ci_lower": 10.9,
        "ci_upper": 19.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "EMD 525797 1000 mg + SoC",
        "value": 14.4,
        "unit": "months",
        "ci_lower": 9.8,
        "ci_upper": 19.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "EMD 525797 250 mg",
        "Cetuximab",
        "Irinotecan"
      ],
      "OG001": [
        "EMD 525797 500 mg",
        "Cetuximab",
        "Irinotecan"
      ],
      "OG002": [
        "EMD 525797 750 mg",
        "Cetuximab",
        "Irinotecan"
      ],
      "OG003": [
        "EMD 525797 1000 mg",
        "Cetuximab",
        "Irinotecan"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted",
      "OG003": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT01013740",
    "brief_title": "Lapatinib in Combination With Vinorelbine",
    "status": "COMPLETED",
    "start_date": "2009-11-25",
    "completion_date": "2012-08-21",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT01013740",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "HIGH",
        "details": "Documented overexpression of ErbB2"
      },
      {
        "target": "DPD",
        "status": "NEGATIVE",
        "details": "No known deficiency of the enzyme dihydropyrimidine dehydrogenase (DPD)"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Lapatinib Plus Capecitabine",
        "value": 6.2,
        "unit": "months",
        "ci_lower": 4.4,
        "ci_upper": 8.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Lapatinib Plus Vinorelbine",
        "value": 6.2,
        "unit": "months",
        "ci_lower": 4.2,
        "ci_upper": 8.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Lapatinib",
        "Capecitabine"
      ],
      "OG001": [
        "Lapatinib",
        "Vinorelbine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT01009788",
    "brief_title": "ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2009-11",
    "completion_date": "2012-09",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Steven J Isakoff, MD, PhD",
    "url": "https://clinicaltrials.gov/study/NCT01009788",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "ANY",
        "details": "All immunohistochemical subtypes of breast cancer are eligible. If HER2-positive, must have progressed on prior standard HER2 therapy or have a contraindication to anti-HER2 therapy."
      },
      {
        "target": "BRCA1",
        "status": "POSITIVE",
        "details": "Known deleterious mutation required for expansion cohort; BRCA1 deleterious germline or somatic mutation"
      },
      {
        "target": "BRCA2",
        "status": "POSITIVE",
        "details": "Known deleterious mutation required for expansion cohort; BRCA2 deleterious germline or somatic mutation"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "TMZ/ABT888 Primary Cohort",
        "value": 4.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "TMZ/ABT888 Expansion Cohort",
        "value": 3.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "TMZ/ABT888 Primary Cohort",
        "value": 1.8,
        "unit": "months",
        "ci_lower": 1.6,
        "ci_upper": 2.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "TMZ/ABT888 Expansion Cohort",
        "value": 3.0,
        "unit": "months",
        "ci_lower": 2.1,
        "ci_upper": 6.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "ABT-888",
        "temozolomide"
      ],
      "OG001": [
        "ABT-888",
        "temozolomide"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT04004221",
    "brief_title": "Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer",
    "status": "COMPLETED",
    "start_date": "2017-06-16",
    "completion_date": "2019-09-16",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "BeiGene",
    "url": "https://clinicaltrials.gov/study/NCT04004221",
    "cancer_types": [
      "BLCA"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "HIGH",
        "details": "PD-L1 high by central assessment on archival tumor tissue (participants tested as PD-L1 high are eligible)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Tislelizumab",
        "value": 24.0,
        "unit": "Percentage of participants",
        "ci_lower": 16.2,
        "ci_upper": 33.41,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Tislelizumab",
        "value": 2.1,
        "unit": "Months",
        "ci_lower": 2.04,
        "ci_upper": 3.15,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Tislelizumab",
        "value": 9.8,
        "unit": "Months",
        "ci_lower": 7.46,
        "ci_upper": 12.48,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Tislelizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO"
    }
  },
  {
    "nct_id": "NCT03906071",
    "brief_title": "Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2019-07-15",
    "completion_date": "2023-03-20",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Mirati Therapeutics Inc.",
    "url": "https://clinicaltrials.gov/study/NCT03906071",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "Tumors must NOT have tested positive for EGFR mutations"
      },
      {
        "target": "ROS1",
        "status": "NEGATIVE",
        "details": "Tumors must NOT have tested positive for ROS1 rearrangements/mutations"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "Tumors must NOT have tested positive for ALK mutations or ALK fusions"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": true,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Nivolumab and Sitravatinib",
        "value": 12.22,
        "unit": "Months",
        "ci_lower": 10.41,
        "ci_upper": 13.93,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Docetaxel",
        "value": 10.58,
        "unit": "Months",
        "ci_lower": 9.4,
        "ci_upper": 12.29,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Nivolumab and Sitravatinib",
        "value": 4.4,
        "unit": "Months",
        "ci_lower": 3.91,
        "ci_upper": 5.42,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Docetaxel",
        "value": 5.42,
        "unit": "Months",
        "ci_lower": 3.91,
        "ci_upper": 5.75,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab",
        "Sitravatinib"
      ],
      "OG001": [
        "Docetaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT03941873",
    "brief_title": "A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer",
    "status": "COMPLETED",
    "start_date": "2019-02-28",
    "completion_date": "2023-03-31",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "BeiGene",
    "url": "https://clinicaltrials.gov/study/NCT03941873",
    "cancer_types": [
      "LIHC",
      "STAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "UNRESECTABLE",
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Sitravatinib Monotherapy",
        "value": 25.0,
        "unit": "Percentage of participants",
        "ci_lower": 8.7,
        "ci_upper": 49.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Sitravatinib + Tislelizumab",
        "value": 11.5,
        "unit": "Percentage of participants",
        "ci_lower": 2.4,
        "ci_upper": 30.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Sitravatinib + Tislelizumab",
        "value": 9.5,
        "unit": "Percentage of participants",
        "ci_lower": 1.2,
        "ci_upper": 30.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Sitravatinib + Tislelizumab",
        "value": 16.1,
        "unit": "Percentage of participants",
        "ci_lower": 5.5,
        "ci_upper": 33.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Sitravatinib Monotherapy",
        "value": 6.8,
        "unit": "Months",
        "ci_lower": 4.0,
        "ci_upper": 7.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Sitravatinib + Tislelizumab",
        "value": 6.8,
        "unit": "Months",
        "ci_lower": 2.8,
        "ci_upper": 8.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Sitravatinib + Tislelizumab",
        "value": 4.2,
        "unit": "Months",
        "ci_lower": 2.7,
        "ci_upper": 6.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Sitravatinib + Tislelizumab",
        "value": 3.6,
        "unit": "Months",
        "ci_lower": 2.8,
        "ci_upper": 4.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Sitravatinib"
      ],
      "OG001": [
        "Sitravatinib"
      ],
      "OG002": [
        "Sitravatinib",
        "Tislelizumab"
      ],
      "OG003": [
        "Sitravatinib",
        "Tislelizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI",
      "OG002": "Combo_TKI_IO",
      "OG003": "Combo_TKI_IO"
    }
  },
  {
    "nct_id": "NCT03974022",
    "brief_title": "Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2019-07-09",
    "completion_date": "2024-07-29",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Dizal Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT03974022",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "EGFR mutation \u2014 Part B requires EGFR exon 20 insertion (EGFR Exon20ins) confirmed in tumor tissue (local CLIA or sponsor central lab); Part A dose-expansion cohort 5: EGFR Exon20ins (treatment\u2011na\u00efve)."
      },
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER2 mutation (documented HER2 mutation in tumor tissue)."
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Part B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mg",
        "value": 45.9,
        "unit": "percentage of participants",
        "ci_lower": 33.6,
        "ci_upper": 58.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Part B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg",
        "value": 45.8,
        "unit": "percentage of participants",
        "ci_lower": 34.8,
        "ci_upper": 57.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Sunvozertinib"
      ],
      "OG001": [
        "Sunvozertinib"
      ],
      "OG002": [
        "Sunvozertinib"
      ],
      "OG003": [
        "Sunvozertinib"
      ],
      "OG004": [
        "Sunvozertinib"
      ],
      "OG005": [
        "Sunvozertinib"
      ],
      "OG006": [
        "Sunvozertinib"
      ],
      "OG007": [
        "Sunvozertinib"
      ],
      "OG008": [
        "Sunvozertinib"
      ],
      "OG009": [
        "Sunvozertinib"
      ],
      "OG010": [
        "Sunvozertinib"
      ],
      "OG011": [
        "Sunvozertinib"
      ],
      "OG012": [
        "Sunvozertinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI",
      "OG002": "TKI",
      "OG003": "TKI",
      "OG004": "TKI",
      "OG005": "TKI",
      "OG006": "TKI",
      "OG007": "TKI",
      "OG008": "TKI",
      "OG009": "TKI",
      "OG010": "TKI",
      "OG011": "TKI",
      "OG012": "TKI"
    }
  },
  {
    "nct_id": "NCT03976375",
    "brief_title": "Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)",
    "status": "COMPLETED",
    "start_date": "2019-06-26",
    "completion_date": "2023-08-11",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT03976375",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "absence of tumor-activating EGFR mutations (e.g., DEL19 or L858R)"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "absence of ALK gene rearrangements"
      },
      {
        "target": "ROS1",
        "status": "NEGATIVE",
        "details": "absence of ROS1 gene rearrangements"
      },
      {
        "target": "KRAS",
        "status": "POSITIVE",
        "details": "presence of K-ras (KRAS) mutation (acceptable alternative to absence of EGFR/ALK/ROS1)"
      },
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "tumor tissue required for PD-L1 biomarker analysis (archival sample prior to immunotherapy and a newly obtained biopsy after completion of immunotherapy prior to randomization)"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": true,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab+Lenvatinib",
        "value": 11.3,
        "unit": "Months",
        "ci_lower": 9.4,
        "ci_upper": 13.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Docetaxel",
        "value": 12.0,
        "unit": "Months",
        "ci_lower": 9.6,
        "ci_upper": 13.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Lenvatinib Monotherapy",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab+Lenvatinib",
        "value": 5.6,
        "unit": "Months",
        "ci_lower": 4.2,
        "ci_upper": 6.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Docetaxel",
        "value": 4.2,
        "unit": "Months",
        "ci_lower": 3.2,
        "ci_upper": 5.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Lenvatinib Monotherapy",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Lenvatinib"
      ],
      "OG001": [
        "Docetaxel"
      ],
      "OG002": [
        "Lenvatinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_IO",
      "OG001": "Chemo",
      "OG002": "TKI"
    }
  },
  {
    "nct_id": "NCT03932331",
    "brief_title": "Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2020-04-29",
    "completion_date": "2022-12-22",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT03932331",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "CCND1",
        "status": "POSITIVE",
        "details": "t(11;14) (q13;q32) translocation and/or overexpression of cyclin D1"
      },
      {
        "target": "CD5",
        "status": "POSITIVE",
        "details": "Expression as an associated marker for diagnosis"
      },
      {
        "target": "CD19",
        "status": "POSITIVE",
        "details": "Expression as an associated marker for diagnosis"
      },
      {
        "target": "CD20",
        "status": "POSITIVE",
        "details": "Expression as an associated marker for diagnosis"
      },
      {
        "target": "PAX5",
        "status": "POSITIVE",
        "details": "Expression as an associated marker for diagnosis"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase II MCL",
        "value": 82.4,
        "unit": "percentage of participants",
        "ci_lower": 65.5,
        "ci_upper": 93.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Phase II CLL",
        "value": 86.7,
        "unit": "percentage of participants",
        "ci_lower": 75.4,
        "ci_upper": 94.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase II MCL",
        "value": null,
        "unit": "months",
        "ci_lower": 5.55,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Phase II CLL",
        "value": null,
        "unit": "months",
        "ci_lower": 28.32,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase II MCL",
        "value": null,
        "unit": "months",
        "ci_lower": 5.55,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Phase II CLL",
        "value": null,
        "unit": "months",
        "ci_lower": 30.62,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Phase II MCL",
        "value": null,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Phase II CLL",
        "value": 96.7,
        "unit": "percentage of participants",
        "ci_lower": 87.3,
        "ci_upper": 99.2,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Acalabrutinib"
      ],
      "OG001": [
        "Acalabrutinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT03971474",
    "brief_title": "Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)",
    "status": "COMPLETED",
    "start_date": "2019-05-28",
    "completion_date": "2022-04-14",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SWOG Cancer Research Network",
    "url": "https://clinicaltrials.gov/study/NCT03971474",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "sensitizing EGFR mutations and general exclusion for EGFR alterations unless progressed following all standard of care targeted therapy"
      },
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "T790M mutation; exclusion unless progressed following all standard of care targeted therapy"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "ALK gene fusion; exclusion unless progressed following all standard of care targeted therapy"
      },
      {
        "target": "ROS1",
        "status": "NEGATIVE",
        "details": "ROS1 gene rearrangement; exclusion unless progressed following all standard of care targeted therapy"
      },
      {
        "target": "BRAF",
        "status": "NEGATIVE",
        "details": "BRAF V600E mutation; exclusion unless progressed following all standard of care targeted therapy"
      },
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Prior PD-L1 testing required for patients screened under legacy study; assay: Dako 22C3 PharmDx IHC (results required for stratification)"
      }
    ],
    "cancer_stages": [
      "IV",
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": true,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Standard of Care (Inv. Choice)",
        "value": 11.6,
        "unit": "months",
        "ci_lower": 9.9,
        "ci_upper": 13.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Ramucirumab + Pembrolizumab",
        "value": 14.5,
        "unit": "months",
        "ci_lower": 13.9,
        "ci_upper": 16.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Docetaxel",
        "Ramucirumab"
      ],
      "OG001": [
        "Ramucirumab",
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT03992456",
    "brief_title": "Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2020-04-24",
    "completion_date": "2023-12-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Academic and Community Cancer Research United",
    "url": "https://clinicaltrials.gov/study/NCT03992456",
    "cancer_types": [
      "CRC",
      "COAD",
      "READ"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "Wild-type required in KRAS codons 12, 13, 59, 61, 117, and 146 based on tumor tissue (no KRAS mutation or amplification)"
      },
      {
        "target": "NRAS",
        "status": "NEGATIVE",
        "details": "Wild-type required in NRAS codons 12, 13, 59, 61, 117, and 146 based on tumor tissue (no NRAS mutation or amplification)"
      },
      {
        "target": "BRAF",
        "status": "NEGATIVE",
        "details": "Wild-type required at BRAF codon 600 (V600) based on tumor tissue (BRAFV600E exclusion)"
      },
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "No EGFR mutation detected by Guardant360 with MAF \u22650.5% (EGFR S492R, K467, and R451C are NOT exclusions)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "No ERBB2 (HER2) amplification by Guardant360 (HER2 amplification is exclusion)"
      },
      {
        "target": "MET",
        "status": "NEGATIVE",
        "details": "No MET amplification by Guardant360 (MET amplification is exclusion)"
      },
      {
        "target": "MAF",
        "status": "HIGH",
        "details": "Maximum mutant allele frequency (MAF) by Guardant360 must be \u22650.5% (subjects with maximum MAF <0.5% are excluded)"
      },
      {
        "target": "MSI",
        "status": "HIGH",
        "details": "If tumor is dMMR or MSI-high by tumor tissue testing, prior anti\u2013PD-1 therapy (e.g., nivolumab or pembrolizumab) is required or progression/intolerance/contraindication must be documented"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A (Panitumumab)",
        "value": 7.5,
        "unit": "Months",
        "ci_lower": 7.2,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B (Regorafenib, Trifluridine and Tipiracil Hydrochloride)",
        "value": 8.3,
        "unit": "Months",
        "ci_lower": 4.9,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A (Panitumumab)",
        "value": 5.1,
        "unit": "Months",
        "ci_lower": 2.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B (Regorafenib, Trifluridine and Tipiracil Hydrochloride)",
        "value": 3.7,
        "unit": "Months",
        "ci_lower": 2.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Panitumumab"
      ],
      "OG001": [
        "Regorafenib",
        "Trifluridine and Tipiracil Hydrochloride"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT01031381",
    "brief_title": "Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer",
    "status": "COMPLETED",
    "start_date": "2010-09",
    "completion_date": "2014-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "University of Pittsburgh",
    "url": "https://clinicaltrials.gov/study/NCT01031381",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "RAD001 + Bevacizumab",
        "value": 28.0,
        "unit": "percentage of participants",
        "ci_lower": 16.67,
        "ci_upper": 42.71,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "RAD001",
        "bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT04063163",
    "brief_title": "A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC",
    "status": "COMPLETED",
    "start_date": "2019-09-12",
    "completion_date": "2024-05-07",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Shanghai Henlius Biotech",
    "url": "https://clinicaltrials.gov/study/NCT04063163",
    "cancer_types": [
      "SCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "A Groups",
        "value": 15.77,
        "unit": "month",
        "ci_lower": 13.897,
        "ci_upper": 17.413,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "B Groups",
        "value": 11.1,
        "unit": "month",
        "ci_lower": 9.955,
        "ci_upper": 12.353,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "A Groups",
        "value": 5.82,
        "unit": "month",
        "ci_lower": 5.552,
        "ci_upper": 6.932,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "B Groups",
        "value": 4.34,
        "unit": "month",
        "ci_lower": 4.205,
        "ci_upper": 4.435,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "HLX10",
        "carboplatin and etoposide"
      ],
      "OG001": [
        "carboplatin and etoposide"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT04035486",
    "brief_title": "A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2019-07-02",
    "completion_date": "2023-04-03",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT04035486",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "One of the common sensitizing EGFR mutations: exon 19 deletion (Ex19del) or L858R, either alone or in combination with other EGFR mutations (may include T790M)."
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IIIC",
      "IVA",
      "IVB",
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Randomized: AZD9291 + Chemo",
        "value": 25.5,
        "unit": "Months",
        "ci_lower": 24.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Randomized: AZD9291",
        "value": 16.7,
        "unit": "Months",
        "ci_lower": 14.1,
        "ci_upper": 21.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Osimertinib",
        "Carboplatin",
        "Pemetrexed"
      ],
      "OG001": [
        "Osimertinib",
        "Cisplatin",
        "Pemetrexed"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT04005716",
    "brief_title": "Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2019-07-22",
    "completion_date": "2023-04-19",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "BeiGene",
    "url": "https://clinicaltrials.gov/study/NCT04005716",
    "cancer_types": [
      "SCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A: Tislelizumab + Chemotherapy",
        "value": 15.5,
        "unit": "Months",
        "ci_lower": 13.5,
        "ci_upper": 17.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Placebo + Chemotherapy",
        "value": 13.5,
        "unit": "Months",
        "ci_lower": 12.1,
        "ci_upper": 14.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A: Tislelizumab + Chemotherapy",
        "value": 4.7,
        "unit": "Months",
        "ci_lower": 4.3,
        "ci_upper": 5.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Placebo + Chemotherapy",
        "value": 4.3,
        "unit": "Months",
        "ci_lower": 4.2,
        "ci_upper": 4.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Tislelizumab",
        "Cisplatin",
        "Carboplatin",
        "Etoposide"
      ],
      "OG001": [
        "Cisplatin",
        "Carboplatin",
        "Etoposide"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT04100018",
    "brief_title": "A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer",
    "status": "COMPLETED",
    "start_date": "2020-02-06",
    "completion_date": "2023-06-01",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT04100018",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Nivolumab + Docetaxel + Prednisone",
        "value": 9.43,
        "unit": "months",
        "ci_lower": 8.48,
        "ci_upper": 10.32,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Docetaxel + Prednisone",
        "value": 8.74,
        "unit": "months",
        "ci_lower": 8.38,
        "ci_upper": 9.99,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Nivolumab + Docetaxel + Prednisone",
        "value": 18.73,
        "unit": "months",
        "ci_lower": 16.95,
        "ci_upper": 21.03,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Docetaxel + Prednisone",
        "value": 18.92,
        "unit": "months",
        "ci_lower": 17.31,
        "ci_upper": 22.01,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab",
        "Docetaxel",
        "Prednisone"
      ],
      "OG001": [
        "Docetaxel",
        "Prednisone"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT04008030",
    "brief_title": "A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2019-08-05",
    "completion_date": "2024-08-28",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT04008030",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "MSI",
        "status": "HIGH",
        "details": "microsatellite instability-high (MSI-H) per local standard of practice"
      },
      {
        "target": "MMR",
        "status": "POSITIVE",
        "details": "mismatch repair deficient (dMMR) per local standard of practice"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A - Nivolumab Monotherapy",
        "value": 39.26,
        "unit": "Months",
        "ci_lower": 2.11,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B - Nivolumab + Ipilimumab",
        "value": null,
        "unit": "Months",
        "ci_lower": 53.82,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A - Nivolumab Monotherapy",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B - Nivolumab + Ipilimumab",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab"
      ],
      "OG001": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG002": [
        "Oxaliplatin",
        "Leucovorin",
        "Fluorouracil",
        "Irinotecan"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "Chemo"
    }
  },
  {
    "nct_id": "NCT04022343",
    "brief_title": "Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2019-08-06",
    "completion_date": "2022-02-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Emory University",
    "url": "https://clinicaltrials.gov/study/NCT04022343",
    "cancer_types": [
      "KIRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "NEOADJUVANT",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (cabozantinib)",
        "value": 6.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (cabozantinib)",
        "value": 11.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cabozantinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT04026412",
    "brief_title": "A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery",
    "status": "COMPLETED",
    "start_date": "2019-10-08",
    "completion_date": "2024-03-22",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT04026412",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIA",
      "IIIB",
      "IIIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A:Nivo + CCRT/Nivo + Ipi",
        "value": 16.69,
        "unit": "months",
        "ci_lower": 12.58,
        "ci_upper": 21.98,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm C: CCRT/Durva",
        "value": 15.64,
        "unit": "months",
        "ci_lower": 13.67,
        "ci_upper": 19.75,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A:Nivo + CCRT/Nivo + Ipi",
        "value": 34.6,
        "unit": "months",
        "ci_lower": 26.81,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Nivo + CCRT/Nivo",
        "value": 39.49,
        "unit": "months",
        "ci_lower": 33.48,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Arm C: CCRT/Durva",
        "value": 39.79,
        "unit": "months",
        "ci_lower": 30.92,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "nivolumab",
        "ipilimumab"
      ],
      "OG001": [
        "durvalumab"
      ],
      "OG002": [
        "durvalumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO"
    }
  },
  {
    "nct_id": "NCT04072445",
    "brief_title": "Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer",
    "status": "COMPLETED",
    "start_date": "2019-10-18",
    "completion_date": "2021-08-13",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Mayo Clinic",
    "url": "https://clinicaltrials.gov/study/NCT04072445",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Trifluridine and Tipiracil, Irinotecan)",
        "value": 37.0,
        "unit": "percentage of participants",
        "ci_lower": 19.4,
        "ci_upper": 57.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Trifluridine and Tipiracil, Irinotecan)",
        "value": 9.1,
        "unit": "months",
        "ci_lower": 8.0,
        "ci_upper": 14.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Trifluridine and Tipiracil Hydrochloride",
        "Irinotecan"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo"
    }
  },
  {
    "nct_id": "NCT04083976",
    "brief_title": "A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2019-11-20",
    "completion_date": "2023-12-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Janssen Research & Development, LLC",
    "url": "https://clinicaltrials.gov/study/NCT04083976",
    "cancer_types": [
      "BLCA",
      "UCEC",
      "LUSC"
    ],
    "biomarkers": [
      {
        "target": "FGFR",
        "status": "POSITIVE",
        "details": "FGFR mutation or FGFR gene fusion"
      },
      {
        "target": "FGFR",
        "status": "NEGATIVE",
        "details": "FGFR gatekeeper and resistance mutations"
      },
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "Pathogenic somatic mutations or gene fusions (for NSCLC participants only)"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "Pathogenic somatic mutations or gene fusions (for NSCLC participants only)"
      },
      {
        "target": "ROS1",
        "status": "NEGATIVE",
        "details": "Pathogenic somatic mutations or gene fusions (for NSCLC participants only)"
      },
      {
        "target": "NTRK",
        "status": "NEGATIVE",
        "details": "Pathogenic somatic mutations or gene fusions (for NSCLC participants only)"
      },
      {
        "target": "BRAF",
        "status": "NEGATIVE",
        "details": "V600E mutation (for NSCLC participants only)"
      },
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "Pathogenic somatic mutations (for NSCLC participants only)"
      }
    ],
    "cancer_stages": [
      "UNRESECTABLE",
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Broad Panel Cohort",
        "value": 29.5,
        "unit": "Percentage of participants",
        "ci_lower": 23.5,
        "ci_upper": 36.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Pediatric Cohort",
        "value": 66.7,
        "unit": "Percentage of participants",
        "ci_lower": 9.4,
        "ci_upper": 99.2,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Erdafitinib"
      ],
      "OG001": [
        "Erdafitinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT04122625",
    "brief_title": "Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143",
    "status": "COMPLETED",
    "start_date": "2019-04-26",
    "completion_date": "2022-04-06",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Debiopharm International SA",
    "url": "https://clinicaltrials.gov/study/NCT04122625",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": true,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Part B - Cohort 1 (SCLC): Debio 1143 200 mg + Nivolumab",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 37.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Part B - Cohort 2 (SCCHN): Debio 1143 200 mg + Nivolumab",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 37.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Part B - Cohort 3 (GI Cancers): Debio 1143 200 mg + Nivolumab",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 37.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Part B - Cohort 4 (Gynecologic Cancers): Debio 1143 200 mg + Nivolumab",
        "value": 9.1,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 41.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Debio 1143",
        "Nivolumab"
      ],
      "OG001": [
        "Debio 1143",
        "Nivolumab"
      ],
      "OG002": [
        "Debio 1143",
        "Nivolumab"
      ],
      "OG003": [
        "Debio 1143",
        "Nivolumab"
      ],
      "OG004": [
        "Debio 1143",
        "Nivolumab"
      ],
      "OG005": [
        "Debio 1143",
        "Nivolumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted",
      "OG002": "Combo_IO_Targeted",
      "OG003": "Combo_IO_Targeted",
      "OG004": "Combo_IO_Targeted",
      "OG005": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT01026493",
    "brief_title": "Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma",
    "status": "COMPLETED",
    "start_date": "2010-07",
    "completion_date": "2014-05",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Radiation Therapy Oncology Group",
    "url": "https://clinicaltrials.gov/study/NCT01026493",
    "cancer_types": [
      "GBM"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase II: Arm 1/BEV-NAIVE",
        "value": 9.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Phase II: Arm 2/BEV-NAIVE",
        "value": 9.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Phase II: Arm 1/BEV-FAILURE",
        "value": 1.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Phase II: Arm 2/BEV-FAILURE",
        "value": 1.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Phase II: Arm 1/BEV-NAIVE",
        "value": 10.3,
        "unit": "months",
        "ci_lower": 7.6,
        "ci_upper": 13.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Phase II: Arm 2/BEV-NAIVE",
        "value": 10.7,
        "unit": "months",
        "ci_lower": 7.6,
        "ci_upper": 12.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Phase II: Arm 1/BEV-FAILURE",
        "value": 4.7,
        "unit": "months",
        "ci_lower": 3.0,
        "ci_upper": 6.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Phase II: Arm 2/BEV-FAILURE",
        "value": 4.7,
        "unit": "months",
        "ci_lower": 3.4,
        "ci_upper": 7.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "ABT-888 20 mg x 21 days",
        "temozolomide 60 mg x 21 days"
      ],
      "OG001": [
        "ABT-888 40 mg x 21 days",
        "temozolomide 60 mg x 21 days"
      ],
      "OG002": [
        "ABT-888 20 mg x 21 days",
        "temozolomide 75 mg x 21 days"
      ],
      "OG003": [
        "ABT-888 40 mg x 21 days",
        "temozolomide 75 mg x 21 days"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted",
      "OG003": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT04117945",
    "brief_title": "Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2020-03-03",
    "completion_date": "2023-09-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Academic and Community Cancer Research United",
    "url": "https://clinicaltrials.gov/study/NCT04117945",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "wild type (no activating KRAS mutations)"
      },
      {
        "target": "NRAS",
        "status": "NEGATIVE",
        "details": "wild type (no activating NRAS mutations)"
      },
      {
        "target": "BRAF",
        "status": "NEGATIVE",
        "details": "V600E wildtype (no BRAF V600E mutation)"
      },
      {
        "target": "MSI",
        "status": "HIGH",
        "details": "MSI-H patients must have received prior PD-1 monoclonal antibody therapy; MSI-H patients who have not received prior PD-1 mAb therapy are excluded"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A (Regorafenib)",
        "value": 3.6,
        "unit": "months",
        "ci_lower": 0.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B (Cetuximab, Panitumumab, Irinotecan)",
        "value": 13.3,
        "unit": "months",
        "ci_lower": 7.9,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A (Regorafenib)",
        "value": 1.2,
        "unit": "months",
        "ci_lower": 0.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B (Cetuximab, Panitumumab, Irinotecan)",
        "value": 7.0,
        "unit": "months",
        "ci_lower": 3.9,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Regorafenib"
      ],
      "OG001": [
        "Cetuximab",
        "Panitumumab",
        "Irinotecan"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT04034251",
    "brief_title": "Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis",
    "status": "COMPLETED",
    "start_date": "2020-06-09",
    "completion_date": "2023-02-25",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT04034251",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "ANY",
        "details": "HER2/neu over-expressing cancers mentioned; trastuzumab allowed as prior treatment"
      },
      {
        "target": "DPYD",
        "status": "NEGATIVE",
        "details": "History of dihydropyrimidine dehydrogenase deficiency (DPYD) is an exclusion"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Paclitaxel Intraperitoneal 20mg & Intravenous 80mg Every 3Weeks & Capecitabine 825mg/m^2 Twice Daily",
        "value": 4.2,
        "unit": "Months",
        "ci_lower": 1.5,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Paclitaxel Intraperitoneal 60mg & Intravenous 80mg Every 3Weeks &Capecitabine 825mg/m^2 Twice Daily",
        "value": 13.3,
        "unit": "Months",
        "ci_lower": 1.5,
        "ci_upper": 13.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Paclitaxel Intraperitoneal 20mg & Intravenous 80mg Every 3Weeks & Capecitabine 825mg/m^2 Twice Daily",
        "value": 10.6,
        "unit": "Months",
        "ci_lower": 4.7,
        "ci_upper": 12.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Paclitaxel Intraperitoneal 60mg & Intravenous 80mg Every 3Weeks &Capecitabine 825mg/m^2 Twice Daily",
        "value": 14.7,
        "unit": "Months",
        "ci_lower": 4.0,
        "ci_upper": 17.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Paclitaxel",
        "Capecitabine"
      ],
      "OG001": [
        "Paclitaxel",
        "Capecitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT04099641",
    "brief_title": "An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients",
    "status": "COMPLETED",
    "start_date": "2019-09-11",
    "completion_date": "2021-12-20",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "OncXerna Theraputics, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT04099641",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [
      {
        "target": "MSI",
        "status": "NEGATIVE",
        "details": "microsatellite instability-high (MSI-H) excluded"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Group 1 (CPI Na\u000efve)",
        "value": 8.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Group 2 (CPI Relapse)",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Bavituximab"
      ],
      "OG001": [
        "Bavituximab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT04082364",
    "brief_title": "Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer",
    "status": "COMPLETED",
    "start_date": "2019-09-30",
    "completion_date": "2024-01-15",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "MacroGenics",
    "url": "https://clinicaltrials.gov/study/NCT04082364",
    "cancer_types": [
      "STAD",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER2 IHC 3+ required; alternatively IHC 2+ with FISH+ (cohort B). Cohort A HER2 assessed by central review; cohort B may use local review."
      },
      {
        "target": "PD-L1",
        "status": "POSITIVE",
        "details": "Cohort A requires PD-L1 (22C3) CPS \u22651% by central review. PD-L1 status not required for Cohort B."
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Chemotherapy-free Arm",
        "value": 52.1,
        "unit": "percentage of participants with CR or PR",
        "ci_lower": 37.2,
        "ci_upper": 66.7,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "margetuximab",
        "Retifanlimab"
      ],
      "OG001": [
        "Trastuzumab",
        "Chemotherapy (XELOX or mFOLFOX6)"
      ],
      "OG002": [
        "margetuximab",
        "Retifanlimab",
        "Chemotherapy (XELOX or mFOLFOX6)"
      ],
      "OG003": [
        "margetuximab",
        "Tebotelimab",
        "Chemotherapy (XELOX or mFOLFOX6)"
      ],
      "OG004": [
        "margetuximab",
        "Chemotherapy (XELOX or mFOLFOX6)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_IO",
      "OG003": "Combo_Chemo_IO",
      "OG004": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT04098068",
    "brief_title": "Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)",
    "status": "COMPLETED",
    "start_date": "2018-01-25",
    "completion_date": "2022-05-15",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
    "url": "https://clinicaltrials.gov/study/NCT04098068",
    "cancer_types": [
      "CRC",
      "UCEC",
      "STAD"
    ],
    "biomarkers": [
      {
        "target": "MSI",
        "status": "NEGATIVE",
        "details": "microsatellite stable (MSS) tumor"
      },
      {
        "target": "TMB",
        "status": "HIGH",
        "details": ">20 mutations per megabase (mut/Mb) tumor mutation burden (TMB)"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "MSI (Microsatellite Unstable) Negative With Mutator Phenotype",
        "value": 5.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "MSI (Microsatellite Unstable) Negative With Mutator Phenotype",
        "value": 41.9,
        "unit": "months",
        "ci_lower": 9.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "MSI (Microsatellite Unstable) Negative With Mutator Phenotype",
        "value": 6.8,
        "unit": "months",
        "ci_lower": 2.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO"
    }
  },
  {
    "nct_id": "NCT04047862",
    "brief_title": "Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2019-08-15",
    "completion_date": "2024-08-07",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "BeiGene",
    "url": "https://clinicaltrials.gov/study/NCT04047862",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "POSITIVE",
        "details": "PD-L1 positive required for Cohorts 3 and 10 (stage IV NSCLC)"
      },
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "Sensitizing EGFR mutations excluded in non-squamous NSCLC"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "ALK fusion excluded in non-squamous NSCLC"
      },
      {
        "target": "ROS1",
        "status": "NEGATIVE",
        "details": "ROS1 fusion excluded in non-squamous NSCLC"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "Positive HER2 expression excluded for gastric cancer participants"
      }
    ],
    "cancer_stages": [
      "IV",
      "IIIB",
      "IIIC",
      "METASTATIC",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 1b: Dose Expansion: Cohort 1",
        "value": 55.0,
        "unit": "percentage of participants",
        "ci_lower": 38.5,
        "ci_upper": 70.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Phase 1b: Dose Expansion: Cohort 2",
        "value": 54.8,
        "unit": "percentage of participants",
        "ci_lower": 38.7,
        "ci_upper": 70.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Phase 1b: Dose Expansion: Cohort 3",
        "value": 40.0,
        "unit": "percentage of participants",
        "ci_lower": 25.7,
        "ci_upper": 55.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Phase 1b: Dose Expansion: Cohort 4",
        "value": 65.9,
        "unit": "percentage of participants",
        "ci_lower": 49.4,
        "ci_upper": 79.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Phase 1b: Dose Expansion: Cohort 5",
        "value": 7.7,
        "unit": "percentage of participants",
        "ci_lower": 0.9,
        "ci_upper": 25.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "Phase 1b: Dose Expansion: Cohort 6",
        "value": 68.4,
        "unit": "percentage of participants",
        "ci_lower": 43.4,
        "ci_upper": 87.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG006",
        "arm_title": "Phase 1b: Dose Expansion: Cohort 7",
        "value": 33.3,
        "unit": "percentage of participants",
        "ci_lower": 4.3,
        "ci_upper": 77.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG007",
        "arm_title": "Phase 1b: Dose Expansion: Cohort 8",
        "value": 33.3,
        "unit": "percentage of participants",
        "ci_lower": 19.1,
        "ci_upper": 50.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG008",
        "arm_title": "Phase 1b: Dose Expansion: Cohort 9",
        "value": 50.8,
        "unit": "percentage of participants",
        "ci_lower": 37.5,
        "ci_upper": 64.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG009",
        "arm_title": "Phase 1b: Dose Optimization: Cohort 10: (Ociperlimab 450 mg + Tislelizumab 200 mg)",
        "value": 34.8,
        "unit": "percentage of participants",
        "ci_lower": 16.4,
        "ci_upper": 57.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG010",
        "arm_title": "Phase 1b: Dose Optimization: Cohort 10: (Ociperlimab 900 mg + Tislelizumab 200 mg)",
        "value": 26.3,
        "unit": "percentage of participants",
        "ci_lower": 9.1,
        "ci_upper": 51.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG011",
        "arm_title": "Phase 1b: Dose Optimization: Cohort 10: (Ociperlimab 1800 mg + Tislelizumab 200 mg)",
        "value": 34.8,
        "unit": "percentage of participants",
        "ci_lower": 16.4,
        "ci_upper": 57.3,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ociperlimab",
        "Tislelizumab"
      ],
      "OG001": [
        "Ociperlimab",
        "Tislelizumab"
      ],
      "OG002": [
        "Ociperlimab",
        "Tislelizumab"
      ],
      "OG003": [
        "Ociperlimab",
        "Tislelizumab"
      ],
      "OG004": [
        "Ociperlimab",
        "Tislelizumab"
      ],
      "OG005": [
        "Ociperlimab"
      ],
      "OG006": [
        "Ociperlimab",
        "Tislelizumab"
      ],
      "OG007": [
        "Ociperlimab",
        "Tislelizumab"
      ],
      "OG008": [
        "Ociperlimab",
        "Tislelizumab"
      ],
      "OG009": [
        "Ociperlimab",
        "Tislelizumab"
      ],
      "OG010": [
        "Ociperlimab",
        "Tislelizumab"
      ],
      "OG011": [
        "Ociperlimab",
        "Tislelizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO",
      "OG003": "IO",
      "OG004": "IO",
      "OG005": "IO",
      "OG006": "IO",
      "OG007": "IO",
      "OG008": "IO",
      "OG009": "IO",
      "OG010": "IO",
      "OG011": "IO"
    }
  },
  {
    "nct_id": "NCT04034927",
    "brief_title": "Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2019-12-04",
    "completion_date": "2021-07-31",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT04034927",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "BRCA1",
        "status": "ANY",
        "details": "Submission of germline and/or somatic BRCA testing is required for all patients. Patients with non\u2013high\u2011grade serous or non\u2013high\u2011grade endometrioid histology must have a deleterious germline or somatic BRCA1 mutation to be eligible."
      },
      {
        "target": "BRCA2",
        "status": "ANY",
        "details": "Submission of germline and/or somatic BRCA testing is required for all patients. Patients with non\u2013high\u2011grade serous or non\u2013high\u2011grade endometrioid histology must have a deleterious germline or somatic BRCA2 mutation to be eligible."
      }
    ],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm I (Olaparib)",
        "value": 24.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm II (Olaparib, Tremelimumab)",
        "value": 23.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Olaparib"
      ],
      "OG001": [
        "Olaparib",
        "Tremelimumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT04090528",
    "brief_title": "pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2019-10-21",
    "completion_date": "2024-11-24",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "University of Wisconsin, Madison",
    "url": "https://clinicaltrials.gov/study/NCT04090528",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [
      {
        "target": "PSA",
        "status": "HIGH",
        "details": "At least two consecutive rises in serum PSA obtained at minimum 1-week intervals, with the final value > 2.0 ng/mL (PCWG3 criteria)"
      },
      {
        "target": "TESTOSTERONE",
        "status": "LOW",
        "details": "Castrate serum testosterone < 50 ng/dL within 6 weeks of day 1"
      },
      {
        "target": "PAP",
        "status": "POSITIVE",
        "details": "Allowed only for non\u2011adenocarcinoma (e.g., small cell or other variant) histology if tumor expresses prostatic acid phosphatase"
      },
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "No known history of infection with HIV-1 or HIV-2"
      },
      {
        "target": "HTLV1",
        "status": "NEGATIVE",
        "details": "No known history of Human T-cell leukemia virus type 1 (HTLV-1)"
      },
      {
        "target": "HBV",
        "status": "NEGATIVE",
        "details": "No active Hepatitis B infection"
      },
      {
        "target": "HCV",
        "status": "NEGATIVE",
        "details": "No active Hepatitis C infection"
      },
      {
        "target": "WBC",
        "status": "HIGH",
        "details": "White Blood Cells >= 2000 / mm3 within 6 weeks of day 1"
      },
      {
        "target": "ANC",
        "status": "HIGH",
        "details": "Absolute Neutrophil Count (ANC) >= 1500 / mm3 within 6 weeks of day 1"
      },
      {
        "target": "HGB",
        "status": "HIGH",
        "details": "Hemoglobin >= 9.0 g/dL within 6 weeks of day 1; participants must not have received a blood transfusion within 14 days"
      },
      {
        "target": "PLATELETS",
        "status": "HIGH",
        "details": "Platelets >= 100,000 / mm3 within 6 weeks of day 1"
      },
      {
        "target": "CREATININE",
        "status": "LOW",
        "details": "Serum creatinine <= 1.5 x institutional upper limit of normal (ULN) within 6 weeks of day 1"
      },
      {
        "target": "BILIRUBIN",
        "status": "LOW",
        "details": "Total bilirubin <= 1.5 x institutional ULN OR direct bilirubin <= ULN for participants with total bilirubin > 1.5 x ULN"
      },
      {
        "target": "AST",
        "status": "LOW",
        "details": "AST (SGOT) <= 2.5 x institutional ULN within 6 weeks of day 1"
      },
      {
        "target": "ALT",
        "status": "LOW",
        "details": "ALT (SGPT) <= 2.5 x institutional ULN within 6 weeks of day 1"
      },
      {
        "target": "PT",
        "status": "LOW",
        "details": "Prothrombin Time (PT) or INR <= 1.5 x ULN unless participant is receiving anticoagulant therapy and PT/INR is within therapeutic range (only required for participants receiving biopsy)"
      },
      {
        "target": "PTT",
        "status": "LOW",
        "details": "Partial Thromboplastin Time (PTT) <= 1.5 x ULN unless participant is receiving anticoagulant therapy and PTT is within therapeutic range (only required for participants receiving biopsy)"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm 1: One DNA Vaccine",
        "value": 51.0,
        "unit": "percentage of participants",
        "ci_lower": 30.0,
        "ci_upper": 69.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm 2: Two DNA Vaccines",
        "value": 45.0,
        "unit": "percentage of participants",
        "ci_lower": 22.0,
        "ci_upper": 66.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "pTVG-HP",
        "Pembrolizumab"
      ],
      "OG001": [
        "pTVG-AR",
        "pTVG-HP",
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT01063517",
    "brief_title": "Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients",
    "status": "COMPLETED",
    "start_date": "2010-02-02",
    "completion_date": "2012-05-11",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT01063517",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [
      {
        "target": "ATM",
        "status": "ANY",
        "details": "ATM protein status assessed by IHC on archival tumor sample"
      }
    ],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Olaparib+Paclitaxel",
        "value": 3.91,
        "unit": "months",
        "ci_lower": 3.02,
        "ci_upper": 7.13,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo+Paclitaxel",
        "value": 3.55,
        "unit": "months",
        "ci_lower": 1.74,
        "ci_upper": 5.82,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Olaparib+Paclitaxel",
        "value": 13.1,
        "unit": "months",
        "ci_lower": 7.1,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo+Paclitaxel",
        "value": 8.3,
        "unit": "months",
        "ci_lower": 5.3,
        "ci_upper": 14.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "olaparib",
        "paclitaxel"
      ],
      "OG001": [
        "paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT04191096",
    "brief_title": "Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2020-02-12",
    "completion_date": "2022-10-31",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT04191096",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + Enzalutamide + ADT",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Enzalutamide + ADT",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + Enzalutamide + ADT",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Enzalutamide + ADT",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Enzalutamide",
        "Androgen Deprivation Therapy (ADT)"
      ],
      "OG001": [
        "Enzalutamide",
        "Androgen Deprivation Therapy (ADT)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT04145349",
    "brief_title": "CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2020-01-22",
    "completion_date": "2024-06-14",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT04145349",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ramucirumab + Cyclophosphamide + Vinorelbine",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cyclophosphamide + Vinorelbine",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ramucirumab",
        "Cyclophosphamide",
        "Vinorelbine"
      ],
      "OG001": [
        "Cyclophosphamide",
        "Vinorelbine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT04191135",
    "brief_title": "Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)",
    "status": "COMPLETED",
    "start_date": "2019-12-19",
    "completion_date": "2022-12-15",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT04191135",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + Olaparib",
        "value": 5.5,
        "unit": "Months",
        "ci_lower": 4.2,
        "ci_upper": 8.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Pembrolizumab + Carboplatin + Gemcitabine",
        "value": 5.6,
        "unit": "Months",
        "ci_lower": 4.3,
        "ci_upper": 6.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + Olaparib",
        "value": 25.1,
        "unit": "Months",
        "ci_lower": 18.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Pembrolizumab + Carboplatin + Gemcitabine",
        "value": 23.4,
        "unit": "Months",
        "ci_lower": 15.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Olaparib"
      ],
      "OG001": [
        "Pembrolizumab",
        "Carboplatin",
        "Gemcitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT01062399",
    "brief_title": "Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",
    "status": "COMPLETED",
    "start_date": "2010-12",
    "completion_date": "2016-06",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Radiation Therapy Oncology Group",
    "url": "https://clinicaltrials.gov/study/NCT01062399",
    "cancer_types": [
      "GBM"
    ],
    "biomarkers": [
      {
        "target": "MGMT",
        "status": "ANY",
        "details": "MGMT analysis required (e.g., methylation status)"
      },
      {
        "target": "AKT",
        "status": "ANY",
        "details": "pAKT phosphorylation analysis required (e.g., by IHC)"
      },
      {
        "target": "MTOR",
        "status": "ANY",
        "details": "pMTOR phosphorylation analysis required (e.g., by IHC)"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ph II: RT + TMZ",
        "value": 10.2,
        "unit": "months",
        "ci_lower": 7.5,
        "ci_upper": 13.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Ph II: RT + TMZ + RAD001",
        "value": 8.2,
        "unit": "months",
        "ci_lower": 6.5,
        "ci_upper": 10.6,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "temozolomide",
        "everolimus"
      ],
      "OG001": [
        "temozolomide",
        "everolimus"
      ],
      "OG002": [
        "temozolomide",
        "everolimus"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT04191499",
    "brief_title": "A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2020-01-29",
    "completion_date": "2023-09-29",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT04191499",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "PIK3CA",
        "status": "POSITIVE",
        "details": "Specified PIK3CA mutation(s) detected by a validated test on tumor tissue (fresh or archival)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-negative by standard testing (e.g., IHC and/or FISH)"
      },
      {
        "target": "HR",
        "status": "POSITIVE",
        "details": "Hormone receptor\u2013positive (ER and/or PR positive)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Inavo+Palbo+Fulv",
        "value": 15.0,
        "unit": "months",
        "ci_lower": 11.3,
        "ci_upper": 20.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Pbo+Palbo+Fulv",
        "value": 7.3,
        "unit": "months",
        "ci_lower": 5.6,
        "ci_upper": 9.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Inavolisib",
        "Palbociclib",
        "Fulvestrant"
      ],
      "OG001": [
        "Palbociclib",
        "Fulvestrant"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01040832",
    "brief_title": "EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Na\u00efve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",
    "status": "COMPLETED",
    "start_date": "2009-12",
    "completion_date": "2012-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "EMD Serono",
    "url": "https://clinicaltrials.gov/study/NCT01040832",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cetuximab Plus EMD 1201081",
        "value": 1.5,
        "unit": "months",
        "ci_lower": 1.3,
        "ci_upper": 2.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cetuximab Monotherapy",
        "value": 1.9,
        "unit": "months",
        "ci_lower": 1.5,
        "ci_upper": 2.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cetuximab Plus EMD 1201081",
        "value": 6.3,
        "unit": "months",
        "ci_lower": 4.2,
        "ci_upper": 9.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cetuximab",
        "EMD 1201081"
      ],
      "OG001": [
        "Cetuximab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT04154956",
    "brief_title": "SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2020-02-06",
    "completion_date": "2023-09-22",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sanofi",
    "url": "https://clinicaltrials.gov/study/NCT04154956",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "CEACAM5",
        "status": "POSITIVE",
        "details": "CEACAM5 expression \u22652+ in \u226550% of tumor cells by IHC on archival or fresh biopsy, assessed centrally"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": true,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Tusamitamab Ravtansine",
        "value": 5.39,
        "unit": "months",
        "ci_lower": 3.713,
        "ci_upper": 6.998,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Docetaxel",
        "value": 5.85,
        "unit": "months",
        "ci_lower": 5.52,
        "ci_upper": 7.359,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Tusamitamab Ravtansine",
        "value": 12.81,
        "unit": "months",
        "ci_lower": 11.795,
        "ci_upper": 14.16,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Docetaxel",
        "value": 11.53,
        "unit": "months",
        "ci_lower": 8.936,
        "ci_upper": 15.244,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "SAR408701",
        "Tusamitamab ravtansine"
      ],
      "OG001": [
        "Docetaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "ADC",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01057589",
    "brief_title": "A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer",
    "status": "COMPLETED",
    "start_date": "2010-02",
    "completion_date": "2012-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT01057589",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed Cisplatin Cetuximab",
        "value": 4.4,
        "unit": "months",
        "ci_lower": 3.6,
        "ci_upper": 5.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed Cisplatin Cetuximab",
        "value": 9.7,
        "unit": "months",
        "ci_lower": 6.5,
        "ci_upper": 13.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pemetrexed",
        "Cisplatin",
        "Cetuximab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT01057810",
    "brief_title": "Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer",
    "status": "COMPLETED",
    "start_date": "2010-07",
    "completion_date": "2015-04",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT01057810",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Placebo",
        "value": 29.73,
        "unit": "months",
        "ci_lower": 26.12,
        "ci_upper": 34.17,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Ipilimumab",
        "value": 28.65,
        "unit": "months",
        "ci_lower": 24.48,
        "ci_upper": 32.46,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Placebo",
        "value": 3.81,
        "unit": "months",
        "ci_lower": 2.76,
        "ci_upper": 4.11,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Ipilimumab",
        "value": 5.59,
        "unit": "months",
        "ci_lower": 5.32,
        "ci_upper": 6.28,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG001": [
        "Ipilimumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Placebo",
      "OG001": "IO"
    }
  },
  {
    "nct_id": "NCT04177810",
    "brief_title": "Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer",
    "status": "COMPLETED",
    "start_date": "2020-11-16",
    "completion_date": "2023-03-29",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
    "url": "https://clinicaltrials.gov/study/NCT04177810",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cemiplimab and Plerixafor",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cemiplimab",
        "Plerixafor"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT01058655",
    "brief_title": "RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2010-02",
    "completion_date": "2013-09",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Dana-Farber Cancer Institute",
    "url": "https://clinicaltrials.gov/study/NCT01058655",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "ANY",
        "details": "If tumor is K-RAS mutation positive, previous treatment with cetuximab or panitumumab is not required."
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "IV",
      "RECURRENT"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase II: Everolimus 10 mg + Tivozanib 1 mg [Evaluable]",
        "value": 3.0,
        "unit": "months",
        "ci_lower": 1.9,
        "ci_upper": 3.6,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Everolimus",
        "Tivozanib"
      ],
      "OG001": [
        "Everolimus",
        "Tivozanib"
      ],
      "OG002": [
        "Everolimus",
        "Tivozanib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Targeted",
      "OG001": "Combo_TKI_Targeted",
      "OG002": "Combo_TKI_Targeted"
    }
  },
  {
    "nct_id": "NCT04173507",
    "brief_title": "Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)",
    "status": "COMPLETED",
    "start_date": "2020-02-14",
    "completion_date": "2021-11-24",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SWOG Cancer Research Network",
    "url": "https://clinicaltrials.gov/study/NCT04173507",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "STK11",
        "status": "POSITIVE",
        "details": "Pathogenic somatic mutation in STK11 or STK11 bi-allelic loss on tumor as determined by the FoundationOne/LUNG-MAP assay"
      }
    ],
    "cancer_stages": [
      "IV",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": true,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Talazoparib Plus Avelumab",
        "value": 2.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 7.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG000",
        "arm_title": "Talazoparib Plus Avelumab",
        "value": 40.0,
        "unit": "percentage of participants",
        "ci_lower": 26.0,
        "ci_upper": 55.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Talazoparib Plus Avelumab",
        "value": 2.7,
        "unit": "months",
        "ci_lower": 1.6,
        "ci_upper": 3.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Talazoparib Plus Avelumab",
        "value": 7.6,
        "unit": "months",
        "ci_lower": 6.3,
        "ci_upper": 12.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Talazoparib",
        "Avelumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT01067469",
    "brief_title": "Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)",
    "status": "COMPLETED",
    "start_date": "2010-01",
    "completion_date": "2016-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "M.D. Anderson Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT01067469",
    "cancer_types": [
      "GBM"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Standard Dose Bevacizumab",
        "value": 4.11,
        "unit": "months",
        "ci_lower": 2.96,
        "ci_upper": 5.55,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Low Dose Bevacizumab + Lomustine",
        "value": 4.34,
        "unit": "months",
        "ci_lower": 2.96,
        "ci_upper": 8.34,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Standard Dose Bevacizumab",
        "value": 8.3,
        "unit": "Months",
        "ci_lower": 6.42,
        "ci_upper": 11.58,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Low Dose Bevacizumab + Lomustine",
        "value": 9.6,
        "unit": "Months",
        "ci_lower": 6.26,
        "ci_upper": 16.73,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Standard Dose Bevacizumab"
      ],
      "OG001": [
        "Low Dose Bevacizumab",
        "Lomustine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT04126733",
    "brief_title": "Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)",
    "status": "COMPLETED",
    "start_date": "2019-10-14",
    "completion_date": "2020-11-11",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bayer",
    "url": "https://clinicaltrials.gov/study/NCT04126733",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "MSI",
        "status": "NEGATIVE",
        "details": "MSS (microsatellite stable) / requires proficient MMR (pMMR); dMMR/MSI-H are excluded"
      },
      {
        "target": "RAS",
        "status": "ANY",
        "details": "Extended RAS status referenced (\"extended RAS wild type\") \u2014 if RAS WT, prior anti-EGFR therapy is required (exceptions may apply)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Regorafenib Plus Nivolumab",
        "value": 7.1,
        "unit": "percentage (%) of participants",
        "ci_lower": 2.4,
        "ci_upper": 15.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Regorafenib Plus Nivolumab",
        "value": 8.0,
        "unit": "weeks",
        "ci_lower": 7.86,
        "ci_upper": 10.57,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Regorafenib Plus Nivolumab",
        "value": 51.86,
        "unit": "weeks",
        "ci_lower": 30.29,
        "ci_upper": 69.71,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Regorafenib",
        "Nivolumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_IO"
    }
  },
  {
    "nct_id": "NCT01033032",
    "brief_title": "Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2009-12",
    "completion_date": "2013-07",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SCRI Development Innovations, LLC",
    "url": "https://clinicaltrials.gov/study/NCT01033032",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 negativity confirmed by one of: FISH-negative (FISH ratio <2.2), or IHC 0-1+, or IHC 2-3+ AND FISH-negative (FISH ratio <2.2)."
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Amrubicin",
        "value": 4.0,
        "unit": "months",
        "ci_lower": 2.5,
        "ci_upper": 5.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Amrubicin",
        "value": 14.4,
        "unit": "months",
        "ci_lower": 10.1,
        "ci_upper": 18.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Amrubicin"
      ],
      "OG001": [
        "Amrubicin"
      ],
      "OG002": [
        "Amrubicin"
      ],
      "OG003": [
        "Amrubicin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo",
      "OG002": "Chemo",
      "OG003": "Chemo"
    }
  },
  {
    "nct_id": "NCT04177108",
    "brief_title": "A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2019-11-25",
    "completion_date": "2023-02-28",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT04177108",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "Estrogen receptor (ER) negative as part of triple-negative breast cancer"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "Progesterone receptor (PR) negative as part of triple-negative breast cancer"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 negative as part of triple-negative breast cancer"
      },
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Tumor PD-L1 status used to select treatment: if PD-L1 positive, candidate for paclitaxel + atezolizumab; if unknown or non-positive, candidate for paclitaxel monotherapy"
      },
      {
        "target": "BRCA1",
        "status": "NEGATIVE",
        "details": "Known deleterious germline BRCA1 mutation excludes participation unless participant is not an appropriate candidate for a PARP-inhibitor"
      },
      {
        "target": "BRCA2",
        "status": "NEGATIVE",
        "details": "Known deleterious germline BRCA2 mutation excludes participation unless participant is not an appropriate candidate for a PARP-inhibitor"
      },
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "Negative HIV test required at screening"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1 Arm A: Ipatasertib + Atezolizumab + Paclitaxel",
        "value": 7.1,
        "unit": "months",
        "ci_lower": 5.1,
        "ci_upper": 9.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort 1 Arm B: Ipatasertib + Atezolizumab Matching Placebo + Paclitaxel",
        "value": 5.6,
        "unit": "months",
        "ci_lower": 3.7,
        "ci_upper": 8.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Cohort 1 Arm C: Ipatasertib Matching Placebo + Atezolizumab Matching Placebo + Paclitaxel",
        "value": 3.7,
        "unit": "months",
        "ci_lower": 3.6,
        "ci_upper": 5.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Cohort 2 Arm A: Ipatasertib + Atezolizumab + Paclitaxel",
        "value": 5.6,
        "unit": "months",
        "ci_lower": 5.4,
        "ci_upper": 9.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Cohort 2 Arm B: Ipatasertib Matching Placebo+ Atezolizumab + Paclitaxel",
        "value": 5.7,
        "unit": "months",
        "ci_lower": 4.0,
        "ci_upper": 9.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1 Arm A: Ipatasertib + Atezolizumab + Paclitaxel",
        "value": 15.7,
        "unit": "months",
        "ci_lower": 12.5,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cohort 1 Arm B: Ipatasertib + Atezolizumab Matching Placebo + Paclitaxel",
        "value": 15.3,
        "unit": "months",
        "ci_lower": 15.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Cohort 1 Arm C: Ipatasertib Matching Placebo + Atezolizumab Matching Placebo + Paclitaxel",
        "value": 16.6,
        "unit": "months",
        "ci_lower": 9.6,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Cohort 2 Arm A: Ipatasertib + Atezolizumab + Paclitaxel",
        "value": null,
        "unit": "months",
        "ci_lower": 14.1,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG004",
        "arm_title": "Cohort 2 Arm B: Ipatasertib Matching Placebo+ Atezolizumab + Paclitaxel",
        "value": 17.2,
        "unit": "months",
        "ci_lower": 13.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ipatasertib",
        "Atezolizumab",
        "Paclitaxel"
      ],
      "OG001": [
        "Ipatasertib",
        "Paclitaxel"
      ],
      "OG002": [
        "Paclitaxel"
      ],
      "OG003": [
        "Ipatasertib",
        "Atezolizumab",
        "Paclitaxel"
      ],
      "OG004": [
        "Atezolizumab",
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Chemo",
      "OG003": "Combo_Chemo_IO",
      "OG004": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT01041404",
    "brief_title": "ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer",
    "status": "COMPLETED",
    "start_date": "2005-09",
    "completion_date": "2010-06",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT01041404",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": null
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Fluoropyrimidine/Cisplatin (FP)",
        "value": 62.8,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)",
        "value": 56.8,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Fluoropyrimidine/Cisplatin (FP)",
        "value": 81.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)",
        "value": 76.9,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG000",
        "arm_title": "Fluoropyrimidine/Cisplatin (FP)",
        "value": 74.1,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG001",
        "arm_title": "Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)",
        "value": 70.7,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG000",
        "arm_title": "Fluoropyrimidine/Cisplatin (FP)",
        "value": 5.6,
        "unit": "months",
        "ci_lower": 5.0,
        "ci_upper": 6.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG001",
        "arm_title": "Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)",
        "value": 7.1,
        "unit": "months",
        "ci_lower": 6.0,
        "ci_upper": 8.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Fluorouracil",
        "Capecitabine",
        "Cisplatin"
      ],
      "OG001": [
        "Trastuzumab",
        "Fluorouracil",
        "Capecitabine",
        "Cisplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT04137289",
    "brief_title": "A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer",
    "status": "COMPLETED",
    "start_date": "2020-03-11",
    "completion_date": "2023-07-26",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Boehringer Ingelheim",
    "url": "https://clinicaltrials.gov/study/NCT04137289",
    "cancer_types": [
      "PAAD",
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "BI 905711 0.02 mg/kg, Q2W",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": 0.0,
        "ci_upper": 97.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "BI 905711 0.06 mg/kg, Q2W",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": 0.0,
        "ci_upper": 97.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "BI 905711 0.2 mg/kg, Q2W",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": 0.0,
        "ci_upper": 45.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "BI 905711 0.6 mg/kg, Q2W",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": 0.0,
        "ci_upper": 15.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "BI 905711 0.6 mg/kg, QW",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": 0.0,
        "ci_upper": 21.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "BI 905711 1.2 mg/kg, Q2W",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": 0.0,
        "ci_upper": 15.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG006",
        "arm_title": "BI 905711 2.4 mg/kg, Q2W",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": 0.0,
        "ci_upper": 15.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG007",
        "arm_title": "BI 905711 3.6 mg/kg, Q2W",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": 0.0,
        "ci_upper": 36.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG008",
        "arm_title": "BI 905711 4.8 mg/kg, Q2W",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": 0.0,
        "ci_upper": 41.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "BI 905711 0.02 mg/kg, Q2W",
        "value": 6.29,
        "unit": "weeks",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "BI 905711 0.06 mg/kg, Q2W",
        "value": 18.14,
        "unit": "weeks",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "BI 905711 0.2 mg/kg, Q2W",
        "value": 5.71,
        "unit": "weeks",
        "ci_lower": 1.86,
        "ci_upper": 6.14,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "BI 905711 0.6 mg/kg, Q2W",
        "value": 7.36,
        "unit": "weeks",
        "ci_lower": 5.29,
        "ci_upper": 12.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "BI 905711 0.6 mg/kg, QW",
        "value": 7.43,
        "unit": "weeks",
        "ci_lower": 7.14,
        "ci_upper": 8.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG005",
        "arm_title": "BI 905711 1.2 mg/kg, Q2W",
        "value": 6.14,
        "unit": "weeks",
        "ci_lower": 4.57,
        "ci_upper": 8.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG006",
        "arm_title": "BI 905711 2.4 mg/kg, Q2W",
        "value": 7.14,
        "unit": "weeks",
        "ci_lower": 5.43,
        "ci_upper": 12.71,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG007",
        "arm_title": "BI 905711 3.6 mg/kg, Q2W",
        "value": 11.43,
        "unit": "weeks",
        "ci_lower": 4.86,
        "ci_upper": 20.14,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG008",
        "arm_title": "BI 905711 4.8 mg/kg, Q2W",
        "value": 7.43,
        "unit": "weeks",
        "ci_lower": 4.29,
        "ci_upper": 8.14,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "BI 905711"
      ],
      "OG001": [
        "BI 905711"
      ],
      "OG002": [
        "BI 905711"
      ],
      "OG003": [
        "BI 905711"
      ],
      "OG004": [
        "BI 905711"
      ],
      "OG005": [
        "BI 905711"
      ],
      "OG006": [
        "BI 905711"
      ],
      "OG007": [
        "BI 905711"
      ],
      "OG008": [
        "BI 905711"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER",
      "OG002": "OTHER",
      "OG003": "OTHER",
      "OG004": "OTHER",
      "OG005": "OTHER",
      "OG006": "OTHER",
      "OG007": "OTHER",
      "OG008": "OTHER"
    }
  },
  {
    "nct_id": "NCT01058707",
    "brief_title": "Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies",
    "status": "COMPLETED",
    "start_date": "2010-01-04",
    "completion_date": "2019-02-07",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Millennium Pharmaceuticals, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT01058707",
    "cancer_types": [
      "NSCLC",
      "BRCA",
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": true,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "MLN0128 5 mg QD",
        "value": 15.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "MLN0128 30 mg QW",
        "value": 13.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "MLN0128 40 mg QW",
        "value": 15.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "MLN0128 5 mg QD",
        "value": 9.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "MLN0128 30 mg QW",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "MLN0128 40 mg QW",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "MLN0128 5 mg QD",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "MLN0128 30 mg QW",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "MLN0128 40 mg QW",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG000",
        "arm_title": "MLN0128 5 mg QD",
        "value": 8.9,
        "unit": "months",
        "ci_lower": 3.48,
        "ci_upper": 23.06,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG001",
        "arm_title": "MLN0128 30 mg QW",
        "value": 56.05,
        "unit": "months",
        "ci_lower": 56.05,
        "ci_upper": 56.05,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG002",
        "arm_title": "MLN0128 40 mg QW",
        "value": 20.73,
        "unit": "months",
        "ci_lower": 20.24,
        "ci_upper": 21.22,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "MLN0128"
      ],
      "OG001": [
        "MLN0128"
      ],
      "OG002": [
        "MLN0128"
      ],
      "OG003": [
        "MLN0128"
      ],
      "OG004": [
        "MLN0128"
      ],
      "OG005": [
        "MLN0128"
      ],
      "OG006": [
        "MLN0128"
      ],
      "OG007": [
        "MLN0128"
      ],
      "OG008": [
        "MLN0128"
      ],
      "OG009": [
        "MLN0128"
      ],
      "OG010": [
        "MLN0128"
      ],
      "OG011": [
        "MLN0128"
      ],
      "OG012": [
        "MLN0128"
      ],
      "OG013": [
        "MLN0128"
      ],
      "OG014": [
        "MLN0128"
      ],
      "OG015": [
        "MLN0128"
      ],
      "OG016": [
        "MLN0128"
      ],
      "OG017": [
        "MLN0128"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other",
      "OG004": "Targeted_Other",
      "OG005": "Targeted_Other",
      "OG006": "Targeted_Other",
      "OG007": "Targeted_Other",
      "OG008": "Targeted_Other",
      "OG009": "Targeted_Other",
      "OG010": "Targeted_Other",
      "OG011": "Targeted_Other",
      "OG012": "Targeted_Other",
      "OG013": "Targeted_Other",
      "OG014": "Targeted_Other",
      "OG015": "Targeted_Other",
      "OG016": "Targeted_Other",
      "OG017": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT04223856",
    "brief_title": "Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2020-03-30",
    "completion_date": "2023-08-08",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Astellas Pharma Global Development, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT04223856",
    "cancer_types": [
      "BLCA"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Archival tumor tissue comprising muscle\u2011invasive urothelial carcinoma or a biopsy of metastatic urothelial carcinoma must be provided for PD-L1 testing prior to randomization"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "UNRESECTABLE",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Enfortumab Vedotin + Pembrolizumab",
        "value": 12.5,
        "unit": "Months",
        "ci_lower": 10.4,
        "ci_upper": 16.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Standard of Care",
        "value": 6.3,
        "unit": "Months",
        "ci_lower": 6.2,
        "ci_upper": 6.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Enfortumab Vedotin + Pembrolizumab",
        "value": 31.5,
        "unit": "Months",
        "ci_lower": 25.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Standard of Care",
        "value": 16.1,
        "unit": "Months",
        "ci_lower": 13.9,
        "ci_upper": 18.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Enfortumab vedotin",
        "Pembrolizumab"
      ],
      "OG001": [
        "Gemcitabine",
        "Cisplatin",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01081951",
    "brief_title": "Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2010-02-04",
    "completion_date": "2011-10-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT01081951",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Olaparib/Carboplatin AUC4/Paclitaxel",
        "value": 12.2,
        "unit": "months",
        "ci_lower": 9.7,
        "ci_upper": 15.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Carboplatin AUC6/Paclitaxel",
        "value": 9.6,
        "unit": "months",
        "ci_lower": 9.1,
        "ci_upper": 9.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Olaparib/Carboplatin AUC4/Paclitaxel",
        "value": 54.0,
        "unit": "Participants (Number of deaths)",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Carboplatin AUC6/Paclitaxel",
        "value": 47.0,
        "unit": "Participants (Number of deaths)",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "olaparib",
        "paclitaxel",
        "carboplatin"
      ],
      "OG001": [
        "paclitaxel",
        "carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01077739",
    "brief_title": "A Study of Avastin (Bevacizumab) With XELOX or FOLFOX in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI and Avastin",
    "status": "COMPLETED",
    "start_date": "2009-07",
    "completion_date": "2012-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT01077739",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab + Oxaliplatin + Capecitabine",
        "value": 6.3,
        "unit": "Months",
        "ci_lower": 4.1,
        "ci_upper": 7.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab + FOLFOX",
        "value": 5.1,
        "unit": "Months",
        "ci_lower": 3.8,
        "ci_upper": 6.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "bevacizumab [Avastin]",
        "oxaliplatin",
        "capecitabine [Xeloda]"
      ],
      "OG001": [
        "bevacizumab [Avastin]",
        "fluorouracil (5FU)",
        "leucovorin",
        "oxaliplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT04205630",
    "brief_title": "SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma",
    "status": "COMPLETED",
    "start_date": "2020-05-28",
    "completion_date": "2023-01-26",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Byondis B.V.",
    "url": "https://clinicaltrials.gov/study/NCT04205630",
    "cancer_types": [
      "UCEC"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "IHC 1+, 2+ or 3+ OR ISH positive (HER2-expressing)"
      }
    ],
    "cancer_stages": [
      "RECURRENT",
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "SYD985",
        "value": 20.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "SYD985",
        "value": 5.6,
        "unit": "months",
        "ci_lower": 4.0,
        "ci_upper": 7.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "SYD985",
        "value": 16.3,
        "unit": "months",
        "ci_lower": 11.6,
        "ci_upper": 20.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "SYD985"
      ]
    },
    "treatment_class_map": {
      "OG000": "ADC"
    }
  },
  {
    "nct_id": "NCT04194944",
    "brief_title": "A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2020-02-17",
    "completion_date": "2023-05-01",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT04194944",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "RET",
        "status": "POSITIVE",
        "details": "RET gene fusion in tumor and/or blood from a qualified laboratory."
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IIIC",
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Selpercatinib (TRT A)",
        "value": 24.84,
        "unit": "Months",
        "ci_lower": 16.89,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Pemetrexed and Platinum With Pembrolizumab (TRT B)",
        "value": 11.17,
        "unit": "Months",
        "ci_lower": 8.77,
        "ci_upper": 16.76,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Selpercatinib (TRT A)",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Pemetrexed and Platinum With Pembrolizumab (TRT B)",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Selpercatinib"
      ],
      "OG001": [
        "Pemetrexed",
        "Carboplatin",
        "Cisplatin",
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT01091428",
    "brief_title": "Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2010-04-16",
    "completion_date": "2014-08-12",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Millennium Pharmaceuticals, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT01091428",
    "cancer_types": [
      "OV",
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "CA125",
        "status": "ANY",
        "details": "Assessable disease may be defined by cancer antigen-125 (CA-125) per modified GCIG CA-125 criteria; CA-125 used as alternative to measurable RECIST lesions"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Alisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2)",
        "value": 204.0,
        "unit": "days",
        "ci_lower": 175.0,
        "ci_upper": 230.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Paclitaxel 80 mg/m^2 (Phase 2)",
        "value": 142.0,
        "unit": "days",
        "ci_lower": 117.0,
        "ci_upper": 148.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Alisertib",
        "Paclitaxel"
      ],
      "OG001": [
        "Alisertib",
        "Paclitaxel"
      ],
      "OG002": [
        "Alisertib",
        "Paclitaxel"
      ],
      "OG003": [
        "Alisertib",
        "Paclitaxel"
      ],
      "OG004": [
        "Alisertib",
        "Paclitaxel"
      ],
      "OG005": [
        "Alisertib",
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted",
      "OG003": "Combo_Chemo_Targeted",
      "OG004": "Combo_Chemo_Targeted",
      "OG005": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT04231981",
    "brief_title": "Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma (ORPHEUS)",
    "status": "COMPLETED",
    "start_date": "2020-04-28",
    "completion_date": "2022-02-15",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "MedSIR",
    "url": "https://clinicaltrials.gov/study/NCT04231981",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IV",
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Interventional Arm",
        "value": 3.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Interventional Arm",
        "value": 2.0,
        "unit": "months",
        "ci_lower": 1.6,
        "ci_upper": 3.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Interventional Arm",
        "value": 17.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Retifanlimab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO"
    }
  },
  {
    "nct_id": "NCT04211337",
    "brief_title": "A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2020-02-11",
    "completion_date": "2023-05-22",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Loxo Oncology, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT04211337",
    "cancer_types": [
      "THCA"
    ],
    "biomarkers": [
      {
        "target": "RET",
        "status": "POSITIVE",
        "details": "Defined/acceptable RET gene alteration identified in tumor, germline DNA, or blood; tumor tissue available for retrospective central analysis of RET mutation status"
      },
      {
        "target": "RAS",
        "status": "NEGATIVE",
        "details": "No additional validated oncogenic RAS mutations that could cause resistance (e.g., KRAS/NRAS/HRAS)"
      },
      {
        "target": "BRAF",
        "status": "NEGATIVE",
        "details": "No additional validated oncogenic BRAF mutations that could cause resistance"
      },
      {
        "target": "NTRK",
        "status": "NEGATIVE",
        "details": "No NTRK gene fusions (example of additional oncogenic driver that could cause resistance)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Selpercatinib (TRT A)",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cabozantinib or Vandetanib (TRT B)",
        "value": 16.76,
        "unit": "Months",
        "ci_lower": 12.22,
        "ci_upper": 25.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Selpercatinib"
      ],
      "OG001": [
        "Cabozantinib",
        "Vandetanib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT04197310",
    "brief_title": "Cabozantinib and Nivolumab for Carcinoid Tumors",
    "status": "COMPLETED",
    "start_date": "2019-12-26",
    "completion_date": "2023-12-27",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Dana-Farber Cancer Institute",
    "url": "https://clinicaltrials.gov/study/NCT04197310",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Nivolumab + Cabozantinib",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Nivolumab + Cabozantinib",
        "value": 5.6,
        "unit": "months",
        "ci_lower": 3.5,
        "ci_upper": 9.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Nivolumab + Cabozantinib",
        "value": 16.0,
        "unit": "months",
        "ci_lower": 6.5,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab",
        "Cabozantinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_IO"
    }
  },
  {
    "nct_id": "NCT01087970",
    "brief_title": "A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer",
    "status": "COMPLETED",
    "start_date": "2010-08",
    "completion_date": "2013-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT01087970",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT",
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "UNRESECTABLE",
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cetuximab + Pemetrexed + Carboplatin/Cisplatin",
        "value": 5.1,
        "unit": "months",
        "ci_lower": 3.9,
        "ci_upper": 6.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cetuximab + Pemetrexed + Carboplatin/Cisplatin",
        "value": 11.1,
        "unit": "months",
        "ci_lower": 7.6,
        "ci_upper": 14.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cetuximab",
        "Pemetrexed",
        "Carboplatin",
        "Cisplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT04208958",
    "brief_title": "Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer",
    "status": "COMPLETED",
    "start_date": "2020-01-23",
    "completion_date": "2021-08-26",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Vedanta Biosciences, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT04208958",
    "cancer_types": [
      "SKCM",
      "STAD",
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "VE800 combination treatment with nivolumab",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "VE800 combination treatment with nivolumab",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "VE800 combination treatment with nivolumab",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "VE800",
        "Nivolumab",
        "Vancomycin Oral Capsule"
      ],
      "OG001": [
        "VE800",
        "Nivolumab",
        "Vancomycin Oral Capsule"
      ],
      "OG002": [
        "VE800",
        "Nivolumab",
        "Vancomycin Oral Capsule"
      ],
      "OG003": [
        "VE800",
        "Nivolumab",
        "Vancomycin Oral Capsule"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO",
      "OG003": "IO"
    }
  },
  {
    "nct_id": "NCT01073865",
    "brief_title": "Study to Compare Zoladex\u2122 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2010-02-26",
    "completion_date": "2012-09-19",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT01073865",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Hormone sensitivity of primary or secondary tumour tissue (ER positive)"
      },
      {
        "target": "E2",
        "status": "HIGH",
        "details": "Estradiol (E2) \u226510 pg/mL within 4 weeks of randomisation (criterion for pre\u2011menopausal)"
      },
      {
        "target": "FSH",
        "status": "LOW",
        "details": "FSH \u226430 mIU/mL within 4 weeks of randomisation (criterion for pre\u2011menopausal)"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Zoladex 10.8 mg",
        "value": 67.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Zoladex 3.6 mg",
        "value": 68.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "ZD9393 (Zoladex) 10.8 mg"
      ],
      "OG001": [
        "ZD9393 (Zoladex) 3.6 mg"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT04209855",
    "brief_title": "A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FR\u03b1) Expression",
    "status": "COMPLETED",
    "start_date": "2019-12-31",
    "completion_date": "2023-03-06",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AbbVie",
    "url": "https://clinicaltrials.gov/study/NCT04209855",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "FOLR1",
        "status": "HIGH",
        "details": "Positive/high folate receptor-alpha (FR\u03b1) expression as defined by the Ventana FOLR1 (FOLR-2.1) CDx assay"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Mirvetuximab Soravtansine",
        "value": 5.59,
        "unit": "months",
        "ci_lower": 4.34,
        "ci_upper": 5.88,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Investigator's Choice (IC) Chemotherapy",
        "value": 3.98,
        "unit": "months",
        "ci_lower": 2.86,
        "ci_upper": 4.47,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Mirvetuximab Soravtansine",
        "value": 16.85,
        "unit": "months",
        "ci_lower": 14.36,
        "ci_upper": 19.78,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Investigator's Choice (IC) Chemotherapy",
        "value": 13.34,
        "unit": "months",
        "ci_lower": 11.37,
        "ci_upper": 15.15,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Mirvetuximab Soravtansine"
      ],
      "OG001": [
        "Paclitaxel",
        "Topotecan",
        "Pegylated liposomal doxorubicin"
      ]
    },
    "treatment_class_map": {
      "OG000": "ADC",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01091454",
    "brief_title": "Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2010-06",
    "completion_date": "2012-06",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Alliance for Clinical Trials in Oncology",
    "url": "https://clinicaltrials.gov/study/NCT01091454",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "Negative by ASCO/CAP guidelines (not 3+ by IHC or FISH amplified)"
      },
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "\u22641% by IHC"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "\u22641% by IHC"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Cisplatin and Brostallicin)",
        "value": 0.511,
        "unit": "proportion of participants",
        "ci_lower": 0.386,
        "ci_upper": 0.676,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "brostallicin",
        "cisplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo"
    }
  },
  {
    "nct_id": "NCT01091259",
    "brief_title": "Irinotecan and Bevacizumab for Recurrent Ovarian Cancer",
    "status": "COMPLETED",
    "start_date": "2010-03",
    "completion_date": "2014-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "NYU Langone Health",
    "url": "https://clinicaltrials.gov/study/NCT01091259",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "CA125",
        "status": "HIGH",
        "details": ">50 U/mL on two occasions at least one week apart; used to define evaluable disease for CA125 response criteria"
      },
      {
        "target": "UPC",
        "status": "NEGATIVE",
        "details": "UPC ratio must be <1.0 (proteinuria as demonstrated by UPC ratio >=1.0 is an exclusion)"
      },
      {
        "target": "PREGNANCY_TEST",
        "status": "NEGATIVE",
        "details": "Negative pregnancy test required; pregnancy (positive pregnancy test) is excluded and effective contraception required for subjects of child-bearing potential"
      }
    ],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Irinotecan With Bevacizumab",
        "value": 55.2,
        "unit": "percentage of patients",
        "ci_lower": 39.7,
        "ci_upper": 76.6,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Irinotecan",
        "Bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT04214288",
    "brief_title": "A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2020-04-22",
    "completion_date": "2022-08-30",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT04214288",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "ER-positive (estrogen receptor positive)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-negative"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "AZD9833 75mg",
        "value": 7.2,
        "unit": "Months",
        "ci_lower": 3.7,
        "ci_upper": 10.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "AZD9833 150mg",
        "value": 7.7,
        "unit": "Months",
        "ci_lower": 5.5,
        "ci_upper": 12.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "AZD9833 300mg",
        "value": 6.3,
        "unit": "Months",
        "ci_lower": 1.9,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Fulvestrant 500 mg",
        "value": 3.7,
        "unit": "Months",
        "ci_lower": 2.0,
        "ci_upper": 6.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "AZD9833"
      ],
      "OG001": [
        "AZD9833"
      ],
      "OG002": [
        "AZD9833"
      ],
      "OG003": [
        "Fulvestrant"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01075048",
    "brief_title": "ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2010-01-26",
    "completion_date": "2012-10-12",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Daiichi Sankyo",
    "url": "https://clinicaltrials.gov/study/NCT01075048",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "wild-type KRAS (no KRAS mutation)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase 2: Placebo+Cetuximab+Irinotecan",
        "value": 7.3,
        "unit": "months",
        "ci_lower": 5.3,
        "ci_upper": 9.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Phase 2: ARQ 197+Cetuximab+Irinotecan",
        "value": 8.3,
        "unit": "months",
        "ci_lower": 5.6,
        "ci_upper": 10.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Phase 2: Placebo+Cetuximab+Irinotecan",
        "value": 17.6,
        "unit": "months",
        "ci_lower": 11.3,
        "ci_upper": 20.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Phase 2: ARQ 197+Cetuximab+Irinotecan",
        "value": null,
        "unit": "months",
        "ci_lower": 13.2,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Phase 2: Placebo+Cetuximab+Irinotecan",
        "value": 16.9,
        "unit": "months",
        "ci_lower": 12.2,
        "ci_upper": 20.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Phase 2: ARQ 197+Cetuximab+Irinotecin",
        "value": 19.8,
        "unit": "months",
        "ci_lower": 13.4,
        "ci_upper": 27.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Phase 2: Placebo+Cetuximab+Irinotecin",
        "value": 16.3,
        "unit": "months",
        "ci_lower": 11.6,
        "ci_upper": 20.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Phase 2: ARQ 197+Cetuximab+Irinotecin",
        "value": 19.8,
        "unit": "months",
        "ci_lower": 15.4,
        "ci_upper": 27.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Phase 2: Placebo+Cetuximab+Irinotecin",
        "value": 16.3,
        "unit": "months",
        "ci_lower": 11.6,
        "ci_upper": 20.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Phase 2: ARQ 197+Cetuximab+Irinotecin",
        "value": 22.3,
        "unit": "months",
        "ci_lower": 15.4,
        "ci_upper": 27.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cetuximab",
        "Irinotecan"
      ],
      "OG001": [
        "Tivantinib",
        "Cetuximab",
        "Irinotecan"
      ],
      "OG002": [
        "Tivantinib",
        "Cetuximab",
        "Irinotecan"
      ],
      "OG003": [
        "Tivantinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_TKI_Chemo",
      "OG002": "Combo_TKI_Chemo",
      "OG003": "TKI"
    }
  },
  {
    "nct_id": "NCT04233567",
    "brief_title": "Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2020-01-16",
    "completion_date": "2023-12-12",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sameek Roychowdhury",
    "url": "https://clinicaltrials.gov/study/NCT04233567",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "FGFR1",
        "status": "POSITIVE",
        "details": "FGFR1 fusion/translocation detected by CLIA-certified laboratory. (Cohort 1 allows prior FGFR inhibitor; Cohort 2 does not permit prior FGFR inhibitor; cholangiocarcinoma permitted in Cohort 1, excluded in Cohort 2)"
      },
      {
        "target": "FGFR2",
        "status": "POSITIVE",
        "details": "FGFR2 fusion/translocation detected by CLIA-certified laboratory. (Cohort 1 allows prior FGFR inhibitor; Cohort 2 does not permit prior FGFR inhibitor; cholangiocarcinoma permitted in Cohort 1, excluded in Cohort 2)"
      },
      {
        "target": "FGFR3",
        "status": "POSITIVE",
        "details": "FGFR3 fusion/translocation detected by CLIA-certified laboratory. (Cohort 1 allows prior FGFR inhibitor; Cohort 2 does not permit prior FGFR inhibitor; cholangiocarcinoma permitted in Cohort 1 and Cohort 3, excluded in Cohort 2)"
      },
      {
        "target": "FGFR",
        "status": "POSITIVE",
        "details": "Activating FGFR family alterations (point mutations, insertions/deletions, or amplifications) detected by CLIA-certified laboratory (Cohort 3). Prior therapy with a different FGFR inhibitor is not permitted for this cohort; cholangiocarcinoma permitted in Cohort 3."
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (Infigratinib)",
        "value": 13.3,
        "unit": "percentage of participants",
        "ci_lower": 3.6,
        "ci_upper": 36.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Infigratinib)",
        "value": 3.73,
        "unit": "months",
        "ci_lower": 1.87,
        "ci_upper": 7.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Infigratinib)",
        "value": 9.37,
        "unit": "months",
        "ci_lower": 3.97,
        "ci_upper": 12.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Infigratinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT01075100",
    "brief_title": "Ixabepilone + Carboplatin Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2010-01",
    "completion_date": "2013-06",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "US Oncology Research",
    "url": "https://clinicaltrials.gov/study/NCT01075100",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "Documented HER2-negative disease. (HER2+ defined in protocol as IHC 3+ or FISH >6 copies per nucleus or FISH ratio >2.2)"
      },
      {
        "target": "ER",
        "status": "ANY",
        "details": "Patients with ER+ disease that has not progressed on hormone therapy are excluded unless life\u2011threatening or rapidly progressing visceral disease"
      },
      {
        "target": "PR",
        "status": "ANY",
        "details": "Patients with PR+ disease that has not progressed on hormone therapy are excluded unless life\u2011threatening or rapidly progressing visceral disease"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Triple Negative",
        "value": 30.4,
        "unit": "percentage of participants",
        "ci_lower": 17.7,
        "ci_upper": 45.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "HR Positive",
        "value": 34.0,
        "unit": "percentage of participants",
        "ci_lower": 21.5,
        "ci_upper": 48.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Triple Negative",
        "value": 7.6,
        "unit": "months",
        "ci_lower": 4.3,
        "ci_upper": 8.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "HR Positive",
        "value": 7.6,
        "unit": "months",
        "ci_lower": 4.2,
        "ci_upper": 9.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Triple Negative",
        "value": 12.5,
        "unit": "months",
        "ci_lower": 10.2,
        "ci_upper": 14.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "HR Positive",
        "value": 17.9,
        "unit": "months",
        "ci_lower": 14.4,
        "ci_upper": 22.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ixabepilone",
        "Carboplatin"
      ],
      "OG001": [
        "Ixabepilone",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01072175",
    "brief_title": "Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212",
    "status": "COMPLETED",
    "start_date": "2010-03-26",
    "completion_date": "2012-05-31",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT01072175",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "BRAF",
        "status": "POSITIVE",
        "details": "BRAF mutation positive (any activating BRAF mutation; melanoma or colorectal cancer specified)"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Part C: Dabrafenib 150 mg",
        "value": 5.8,
        "unit": "Months",
        "ci_lower": 4.3,
        "ci_upper": 7.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Part C: Dabrafenib 150 mg + Trametinib 1 mg",
        "value": 9.2,
        "unit": "Months",
        "ci_lower": 5.7,
        "ci_upper": 11.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Part C: Dabrafenib 150 mg + Trametinib 2 mg",
        "value": 9.4,
        "unit": "Months",
        "ci_lower": 7.6,
        "ci_upper": 16.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG000",
        "arm_title": "Part C: Dabrafenib 150 mg",
        "value": 5.6,
        "unit": "Months",
        "ci_lower": 3.9,
        "ci_upper": 7.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG001",
        "arm_title": "Part C: Dabrafenib 150 mg + Trametinib 1 mg",
        "value": 11.1,
        "unit": "Months",
        "ci_lower": 7.4,
        "ci_upper": 13.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG002",
        "arm_title": "Part C: Dabrafenib 150 mg + Trametinib 2 mg",
        "value": 10.5,
        "unit": "Months",
        "ci_lower": 7.4,
        "ci_upper": 19.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG000",
        "arm_title": "Part C: Dabrafenib 150 mg",
        "value": 7.6,
        "unit": "Months",
        "ci_lower": 4.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG001",
        "arm_title": "Part C: Dabrafenib 150 mg + Trametinib 1 mg",
        "value": 9.5,
        "unit": "Months",
        "ci_lower": 5.6,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG002",
        "arm_title": "Part C: Dabrafenib 150 mg + Trametinib 2 mg",
        "value": null,
        "unit": "Months",
        "ci_lower": 6.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Part C: Dabrafenib 150 mg",
        "value": 29.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Part C: Dabrafenib 150 mg + Trametinib 1 mg",
        "value": 27.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Part C: Dabrafenib 150 mg + Trametinib 2 mg",
        "value": 41.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Part C (Crossover): Dabrafenib 150 mg + Trametinib 2 mg",
        "value": 6.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "GSK2118436"
      ],
      "OG001": [
        "GSK2118436",
        "GSK1120212"
      ],
      "OG002": [
        "GSK2118436",
        "GSK1120212"
      ],
      "OG003": [
        "GSK2118436",
        "GSK1120212"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT04282980",
    "brief_title": "A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)",
    "status": "COMPLETED",
    "start_date": "2020-04-23",
    "completion_date": "2021-02-26",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Zai Lab (Shanghai) Co., Ltd.",
    "url": "https://clinicaltrials.gov/study/NCT04282980",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "DCC-2618",
        "value": 6.44,
        "unit": "months",
        "ci_lower": 2.89,
        "ci_upper": 8.31,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "DCC-2618",
        "value": 25.56,
        "unit": "months",
        "ci_lower": 11.73,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "DCC-2618"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT04238819",
    "brief_title": "A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma",
    "status": "COMPLETED",
    "start_date": "2020-11-09",
    "completion_date": "2024-03-15",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT04238819",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Part C Cohort C1",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Abemaciclib",
        "Irinotecan",
        "Temozolomide"
      ],
      "OG001": [
        "Abemaciclib",
        "Irinotecan",
        "Temozolomide"
      ],
      "OG002": [
        "Abemaciclib",
        "Temozolomide"
      ],
      "OG003": [
        "Abemaciclib",
        "Temozolomide"
      ],
      "OG004": [
        "Abemaciclib",
        "Temozolomide"
      ],
      "OG005": [
        "Abemaciclib",
        "Temozolomide"
      ],
      "OG006": [
        "Abemaciclib",
        "Irinotecan",
        "Temozolomide"
      ],
      "OG007": [
        "Abemaciclib",
        "Irinotecan",
        "Temozolomide"
      ],
      "OG008": [
        "Abemaciclib",
        "Irinotecan",
        "Temozolomide"
      ],
      "OG009": [
        "Abemaciclib",
        "Irinotecan",
        "Temozolomide"
      ],
      "OG010": [
        "Abemaciclib",
        "Irinotecan",
        "Temozolomide"
      ],
      "OG011": [
        "Abemaciclib",
        "Irinotecan",
        "Temozolomide"
      ],
      "OG012": [
        "Abemaciclib",
        "Temozolomide"
      ],
      "OG013": [
        "Abemaciclib",
        "Temozolomide"
      ],
      "OG014": [
        "Abemaciclib",
        "Temozolomide"
      ],
      "OG015": [
        "Abemaciclib",
        "Temozolomide"
      ],
      "OG016": [
        "Abemaciclib",
        "Temozolomide"
      ],
      "OG017": [
        "Abemaciclib",
        "Temozolomide"
      ],
      "OG018": [
        "Abemaciclib",
        "Temozolomide"
      ],
      "OG019": [
        "Abemaciclib",
        "Temozolomide"
      ],
      "OG020": [
        "Abemaciclib",
        "Temozolomide"
      ],
      "OG021": [
        "Abemaciclib",
        "Temozolomide"
      ],
      "OG022": [
        "Abemaciclib",
        "Temozolomide"
      ],
      "OG023": [
        "Abemaciclib",
        "Temozolomide"
      ],
      "OG024": [
        "Abemaciclib",
        "Temozolomide"
      ],
      "OG025": [
        "Abemaciclib",
        "Temozolomide"
      ],
      "OG026": [
        "Abemaciclib",
        "Temozolomide"
      ],
      "OG027": [
        "Abemaciclib",
        "Temozolomide"
      ],
      "OG028": [
        "Abemaciclib",
        "Temozolomide"
      ],
      "OG029": [
        "Abemaciclib",
        "Temozolomide"
      ],
      "OG030": [
        "Abemaciclib",
        "Temozolomide"
      ],
      "OG031": [
        "Abemaciclib",
        "Temozolomide"
      ],
      "OG032": [
        "Abemaciclib",
        "Temozolomide"
      ],
      "OG033": [
        "Abemaciclib",
        "Temozolomide"
      ],
      "OG034": [
        "Abemaciclib",
        "Temozolomide"
      ],
      "OG035": [
        "Abemaciclib",
        "Temozolomide"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted",
      "OG003": "Combo_Chemo_Targeted",
      "OG004": "Combo_Chemo_Targeted",
      "OG005": "Combo_Chemo_Targeted",
      "OG006": "Combo_Chemo_Targeted",
      "OG007": "Combo_Chemo_Targeted",
      "OG008": "Combo_Chemo_Targeted",
      "OG009": "Combo_Chemo_Targeted",
      "OG010": "Combo_Chemo_Targeted",
      "OG011": "Combo_Chemo_Targeted",
      "OG012": "Combo_Chemo_Targeted",
      "OG013": "Combo_Chemo_Targeted",
      "OG014": "Combo_Chemo_Targeted",
      "OG015": "Combo_Chemo_Targeted",
      "OG016": "Combo_Chemo_Targeted",
      "OG017": "Combo_Chemo_Targeted",
      "OG018": "Combo_Chemo_Targeted",
      "OG019": "Combo_Chemo_Targeted",
      "OG020": "Combo_Chemo_Targeted",
      "OG021": "Combo_Chemo_Targeted",
      "OG022": "Combo_Chemo_Targeted",
      "OG023": "Combo_Chemo_Targeted",
      "OG024": "Combo_Chemo_Targeted",
      "OG025": "Combo_Chemo_Targeted",
      "OG026": "Combo_Chemo_Targeted",
      "OG027": "Combo_Chemo_Targeted",
      "OG028": "Combo_Chemo_Targeted",
      "OG029": "Combo_Chemo_Targeted",
      "OG030": "Combo_Chemo_Targeted",
      "OG031": "Combo_Chemo_Targeted",
      "OG032": "Combo_Chemo_Targeted",
      "OG033": "Combo_Chemo_Targeted",
      "OG034": "Combo_Chemo_Targeted",
      "OG035": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT01116687",
    "brief_title": "RO4929097 in Treating Patients With Metastatic Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2010-05",
    "completion_date": "2011-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT01116687",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Investigational Drug Therapy",
        "value": 0.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Investigational Drug Therapy",
        "value": 6.0,
        "unit": "months",
        "ci_lower": 3.9,
        "ci_upper": 9.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Investigational Drug Therapy",
        "value": 1.8,
        "unit": "months",
        "ci_lower": 1.8,
        "ci_upper": 1.86,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "RO4929097"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01125566",
    "brief_title": "LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment",
    "status": "COMPLETED",
    "start_date": "2010-06-22",
    "completion_date": "2013-06-08",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Boehringer Ingelheim",
    "url": "https://clinicaltrials.gov/study/NCT01125566",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER2 overexpression; archived tumour tissue required for central reassessment of HER2 status"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Afatinib + Vinorelbine (AV)",
        "value": 5.49,
        "unit": "Months",
        "ci_lower": 3.55,
        "ci_upper": 9.07,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Trastuzumab + Vinorelbine (TV)",
        "value": 5.55,
        "unit": "Months",
        "ci_lower": 3.55,
        "ci_upper": 10.84,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Afatinib + Vinorelbine (AV)",
        "value": 20.17,
        "unit": "Months",
        "ci_lower": 10.74,
        "ci_upper": 39.52,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Trastuzumab + Vinorelbine (TV)",
        "value": 29.6,
        "unit": "Months",
        "ci_lower": 13.34,
        "ci_upper": 43.99,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "BIBW 2992",
        "vinorelbine"
      ],
      "OG001": [
        "trastuzumab",
        "vinorelbine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT04325828",
    "brief_title": "A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2020-04-07",
    "completion_date": "2021-06-09",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Janssen Pharmaceutical K.K.",
    "url": "https://clinicaltrials.gov/study/NCT04325828",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [
      {
        "target": "AR",
        "status": "POSITIVE",
        "details": "Androgen receptor (AR) expression by IHC with \u22651% tumor cell nuclear staining; local test acceptable for enrollment and tissue should be available for central confirmation (central result not required to start)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Apalutamide + Goserelin",
        "value": 25.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Apalutamide + Goserelin",
        "value": 7.43,
        "unit": "months",
        "ci_lower": 3.65,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Apalutamide + Goserelin",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Apalutamide",
        "Goserelin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01125046",
    "brief_title": "Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas",
    "status": "COMPLETED",
    "start_date": "2010-06-17",
    "completion_date": "2014-03-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Northwestern University",
    "url": "https://clinicaltrials.gov/study/NCT01125046",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment With Bevacizumab",
        "value": 93.0,
        "unit": "percentage of patients",
        "ci_lower": 61.0,
        "ci_upper": 99.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment With Bevacizumab",
        "value": 85.0,
        "unit": "percentage of patients",
        "ci_lower": 61.0,
        "ci_upper": 95.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment With Bevacizumab",
        "value": 51.0,
        "unit": "percentage of patients",
        "ci_lower": 22.0,
        "ci_upper": 75.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment With Bevacizumab",
        "value": 73.0,
        "unit": "percentage of patients",
        "ci_lower": 54.0,
        "ci_upper": 85.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01129336",
    "brief_title": "Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients",
    "status": "COMPLETED",
    "start_date": "2010-06",
    "completion_date": "2012-08",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT01129336",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-negative metastatic breast cancer required"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Patients Without Bone Metastases",
        "value": 9.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Patients With Bone Metastases",
        "value": 19.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Patients Without Bone Metastases",
        "value": 6.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Patients With Bone Metastases",
        "value": 10.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Zoledronic acid",
        "Standard Therapy"
      ],
      "OG001": [
        "Zoledronic acid",
        "Standard Therapy"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT01111604",
    "brief_title": "A Study of Ramucirumab or Icrucumab in Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2010-08",
    "completion_date": "2013-12",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT01111604",
    "cancer_types": [
      "COAD",
      "READ"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "mFOLFOX-6",
        "value": 18.4,
        "unit": "Weeks",
        "ci_lower": 15.7,
        "ci_upper": 24.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "mFOLFOX-6 + Ramucirumab",
        "value": 21.4,
        "unit": "Weeks",
        "ci_lower": 16.1,
        "ci_upper": 25.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "mFOLFOX-6 + Icrucumab",
        "value": 15.9,
        "unit": "Weeks",
        "ci_lower": 14.1,
        "ci_upper": 16.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "mFOLFOX-6",
        "value": 53.6,
        "unit": "Weeks",
        "ci_lower": 36.1,
        "ci_upper": 68.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "mFOLFOX-6 + Ramucirumab",
        "value": 41.7,
        "unit": "Weeks",
        "ci_lower": 28.4,
        "ci_upper": 60.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "mFOLFOX-6 + Icrucumab",
        "value": 42.0,
        "unit": "Weeks",
        "ci_lower": 32.0,
        "ci_upper": 50.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "mFOLFOX-6"
      ],
      "OG001": [
        "mFOLFOX-6",
        "Ramucirumab"
      ],
      "OG002": [
        "mFOLFOX-6",
        "Icrucumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT01111461",
    "brief_title": "Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression",
    "status": "COMPLETED",
    "start_date": "2010-03",
    "completion_date": "2012-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eisai Inc.",
    "url": "https://clinicaltrials.gov/study/NCT01111461",
    "cancer_types": [
      "UCEC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Lenvatinib 24 mg",
        "value": 14.3,
        "unit": "Percentage of participants",
        "ci_lower": 8.8,
        "ci_upper": 21.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Lenvatinib 24 mg",
        "value": 5.6,
        "unit": "Months",
        "ci_lower": 3.7,
        "ci_upper": 6.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Lenvatinib 24 mg",
        "value": 5.4,
        "unit": "Months",
        "ci_lower": 3.7,
        "ci_upper": 6.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Lenvatinib 24 mg",
        "value": 10.6,
        "unit": "Months",
        "ci_lower": 8.9,
        "ci_upper": 14.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Lenvatinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT04256421",
    "brief_title": "A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2020-02-04",
    "completion_date": "2022-09-06",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT04256421",
    "cancer_types": [
      "SCLC"
    ],
    "biomarkers": [
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "Positive HIV test excluded"
      },
      {
        "target": "HBV",
        "status": "NEGATIVE",
        "details": "Active hepatitis B infection excluded"
      },
      {
        "target": "HCV",
        "status": "NEGATIVE",
        "details": "Active hepatitis C infection excluded"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Placebo + Atezolizumab",
        "value": 5.55,
        "unit": "months",
        "ci_lower": 5.36,
        "ci_upper": 5.85,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Tiragolumab + Atezolizumab",
        "value": 5.36,
        "unit": "months",
        "ci_lower": 4.67,
        "ci_upper": 5.52,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Placebo + Atezolizumab",
        "value": 13.14,
        "unit": "months",
        "ci_lower": 12.16,
        "ci_upper": 15.11,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Tiragolumab + Atezolizumab",
        "value": 13.11,
        "unit": "months",
        "ci_lower": 10.84,
        "ci_upper": 14.39,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Atezolizumab",
        "Carboplatin"
      ],
      "OG001": [
        "Tiragolumab",
        "Atezolizumab",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT01120184",
    "brief_title": "A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)",
    "status": "COMPLETED",
    "start_date": "2010-07-31",
    "completion_date": "2014-09-30",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT01120184",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER2-positive breast cancer (method not specified)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Trastuzumab + Taxane",
        "value": 13.7,
        "unit": "months",
        "ci_lower": 12.4,
        "ci_upper": 14.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Trastuzumab Emtansine + Placebo",
        "value": 14.1,
        "unit": "months",
        "ci_lower": 10.9,
        "ci_upper": 16.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Trastuzumab Emtansine + Pertuzumab",
        "value": 15.2,
        "unit": "months",
        "ci_lower": 12.5,
        "ci_upper": 18.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "trastuzumab [Herceptin]",
        "docetaxel",
        "paclitaxel"
      ],
      "OG001": [
        "trastuzumab emtansine"
      ],
      "OG002": [
        "trastuzumab emtansine",
        "pertuzumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "ADC",
      "OG002": "OTHER"
    }
  },
  {
    "nct_id": "NCT01104155",
    "brief_title": "Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2010-02-22",
    "completion_date": "2011-04-07",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eisai Inc.",
    "url": "https://clinicaltrials.gov/study/NCT01104155",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Eribulin Mesylate Plus Erlotinib, 21 Day Regimen",
        "value": 12.7,
        "unit": "Percentage of participants",
        "ci_lower": 5.6,
        "ci_upper": 23.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Eribulin Mesylate Plus Erlotinib, 28 Day Regimen",
        "value": 16.7,
        "unit": "Percentage of participants",
        "ci_lower": 8.3,
        "ci_upper": 28.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Eribulin Mesylate Plus Erlotinib, 21 Day Regimen",
        "value": 3.5,
        "unit": "Months",
        "ci_lower": 1.9,
        "ci_upper": 4.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Eribulin Mesylate Plus Erlotinib, 28 Day Regimen",
        "value": 3.8,
        "unit": "Months",
        "ci_lower": 3.3,
        "ci_upper": 5.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Eribulin Mesylate Plus Erlotinib, 21 Day Regimen",
        "value": 7.6,
        "unit": "Months",
        "ci_lower": 6.3,
        "ci_upper": 11.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Eribulin Mesylate Plus Erlotinib, 28 Day Regimen",
        "value": 8.5,
        "unit": "Months",
        "ci_lower": 6.2,
        "ci_upper": 13.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "eribulin mesylate",
        "erlotinib"
      ],
      "OG001": [
        "eribulin mesylate",
        "erlotinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT01118624",
    "brief_title": "Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2010-03",
    "completion_date": "2012-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Acrotech Biopharma Inc.",
    "url": "https://clinicaltrials.gov/study/NCT01118624",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 negative (advanced/metastatic disease)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Pralatrexate",
        "value": 1.0,
        "unit": "participants",
        "ci_lower": 0.1,
        "ci_upper": 22.8,
        "dispersion_type": null
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pralatrexate",
        "value": 11.3,
        "unit": "months",
        "ci_lower": 6.8,
        "ci_upper": 13.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pralatrexate"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo"
    }
  },
  {
    "nct_id": "NCT04296890",
    "brief_title": "A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression",
    "status": "COMPLETED",
    "start_date": "2020-07-23",
    "completion_date": "2021-11-16",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "ImmunoGen, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT04296890",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "FOLR1",
        "status": "POSITIVE",
        "details": "Folate Receptor \u03b1 (FR\u03b1) positivity by Ventana FOLR1 Assay (IHC)"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Mirvetuximab Soravtansine",
        "value": 32.4,
        "unit": "percentage of participants",
        "ci_lower": 23.6,
        "ci_upper": 42.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Mirvetuximab Soravtansine",
        "value": 4.27,
        "unit": "months",
        "ci_lower": 3.71,
        "ci_upper": 5.22,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Mirvetuximab Soravtansine",
        "value": 15.0,
        "unit": "months",
        "ci_lower": 11.5,
        "ci_upper": 18.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Mirvetuximab Soravtansine"
      ]
    },
    "treatment_class_map": {
      "OG000": "ADC"
    }
  },
  {
    "nct_id": "NCT01111825",
    "brief_title": "Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2010-04",
    "completion_date": "2016-07",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Puma Biotechnology, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT01111825",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "IHC 3+ or FISH \u22652.0 (HER2 overexpression and/or amplification)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "IHC <3+ or FISH <2.0 (lack of HER2 overexpression/amplification for triple-negative cohort)"
      },
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "Estrogen receptor expression <5%"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "Progesterone receptor expression <5%"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 2 Triple -ve",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Phase 2 HER2+",
        "value": 5.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Phase 2 HER2+ Dose Esc",
        "value": 14.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase 2 Triple -ve",
        "value": 1.8,
        "unit": "months",
        "ci_lower": 1.8,
        "ci_upper": 2.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Phase 2 HER2+",
        "value": 4.8,
        "unit": "months",
        "ci_lower": 2.7,
        "ci_upper": 8.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Phase 2 HER2+ Dose Esc",
        "value": 6.0,
        "unit": "months",
        "ci_lower": 3.7,
        "ci_upper": 8.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Phase 2 HER2+ Dose Esc",
        "value": 17.8,
        "unit": "months",
        "ci_lower": 13.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Temsirolimus"
      ],
      "OG001": [
        "Neratinib"
      ],
      "OG002": [
        "Neratinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "TKI",
      "OG002": "TKI"
    }
  },
  {
    "nct_id": "NCT04322539",
    "brief_title": "A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2020-08-12",
    "completion_date": "2022-07-29",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hutchison Medipharma Limited",
    "url": "https://clinicaltrials.gov/study/NCT04322539",
    "cancer_types": [
      "CRC",
      "COAD"
    ],
    "biomarkers": [
      {
        "target": "RAS",
        "status": "ANY",
        "details": "RAS status (eg, KRAS/NRAS) must be documented; if RAS wild-type, participant must have received anti\u2011EGFR therapy."
      },
      {
        "target": "BRAF",
        "status": "ANY",
        "details": "BRAF status must be documented; participants with BRAF\u2011mutant tumors must have been treated with a BRAF inhibitor if approved and available in the participant's country."
      },
      {
        "target": "MSI",
        "status": "ANY",
        "details": "MSI/MMR status must be documented; participants with MSI\u2011High (MSI\u2011H) or dMMR tumors must have been treated with immune checkpoint inhibitors if approved and available, unless ineligible."
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Fruquintinib + BSC Group",
        "value": 7.4,
        "unit": "months",
        "ci_lower": 6.7,
        "ci_upper": 8.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + BSC Group",
        "value": 4.8,
        "unit": "months",
        "ci_lower": 4.0,
        "ci_upper": 5.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Fruquintinib + BSC Group",
        "value": 3.7,
        "unit": "months",
        "ci_lower": 3.5,
        "ci_upper": 3.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + BSC Group",
        "value": 1.8,
        "unit": "months",
        "ci_lower": 1.8,
        "ci_upper": 1.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Fruquintinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT04300647",
    "brief_title": "A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer",
    "status": "COMPLETED",
    "start_date": "2020-06-30",
    "completion_date": "2021-12-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT04300647",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "POSITIVE",
        "details": "PD-L1 positive (threshold/method not specified)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Atezolizumab",
        "value": 15.6,
        "unit": "percentage of participants",
        "ci_lower": 6.5,
        "ci_upper": 29.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Tiragolumab Plus Atezolizumab",
        "value": 19.0,
        "unit": "percentage of participants",
        "ci_lower": 12.6,
        "ci_upper": 27.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Atezolizumab",
        "value": 1.9,
        "unit": "months",
        "ci_lower": 1.5,
        "ci_upper": 3.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Tiragolumab Plus Atezolizumab",
        "value": 2.8,
        "unit": "months",
        "ci_lower": 1.7,
        "ci_upper": 4.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Atezolizumab",
        "value": 10.6,
        "unit": "months",
        "ci_lower": 7.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Tiragolumab Plus Atezolizumab",
        "value": 11.0,
        "unit": "months",
        "ci_lower": 9.6,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Atezolizumab"
      ],
      "OG001": [
        "Tiragolumab",
        "Atezolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO"
    }
  },
  {
    "nct_id": "NCT04280081",
    "brief_title": "A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2020-03-16",
    "completion_date": "2021-03-25",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT04280081",
    "cancer_types": [
      "THCA",
      "LUAD"
    ],
    "biomarkers": [
      {
        "target": "RET",
        "status": "POSITIVE",
        "details": "RET gene alteration in tumor and/or blood; for cohorts 1-2 tumor tissue evidence required (blood-only not acceptable); positive germline RET mutation acceptable for medullary thyroid cancer if tumor testing unavailable"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "RET Fusion Positive Non-small Cell Lung Cancer (NSCLC) Cohort 1",
        "value": 69.2,
        "unit": "percentage of participants",
        "ci_lower": 48.2,
        "ci_upper": 85.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "RET Fusion Positive Thyroid Cancer (TC) Cohort 1",
        "value": 100.0,
        "unit": "percentage of participants",
        "ci_lower": 2.5,
        "ci_upper": 100.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "RET Mutant Medullary Thyroid Cancer (MTC) Cohort 2",
        "value": 57.7,
        "unit": "percentage of participants",
        "ci_lower": 36.9,
        "ci_upper": 76.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "All NSCLC",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "All TC",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "All MTC",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "All NSCLC",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "All TC",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "All MTC",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Selpercatinib"
      ],
      "OG001": [
        "Selpercatinib"
      ],
      "OG002": [
        "Selpercatinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI",
      "OG002": "TKI"
    }
  },
  {
    "nct_id": "NCT04251533",
    "brief_title": "Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2020-06-08",
    "completion_date": "2023-05-31",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT04251533",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "PIK3CA",
        "status": "POSITIVE",
        "details": "PIK3CA mutation \u2014 allocation to Part A (regardless of PTEN status)"
      },
      {
        "target": "PTEN",
        "status": "POSITIVE",
        "details": "PTEN loss \u2014 allocation to Part B1 or B2 (Part B2 = PTEN loss without a PIK3CA mutation)"
      },
      {
        "target": "PIK3CA",
        "status": "NEGATIVE",
        "details": "PIK3CA wild-type required for Part B2 (PTEN loss without a PIK3CA mutation)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Part A: Alpelisib + Nab-paclitaxel",
        "value": 7.2,
        "unit": "months",
        "ci_lower": 3.71,
        "ci_upper": 8.57,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Part A: Placebo + Nab-paclitaxel",
        "value": 5.6,
        "unit": "months",
        "ci_lower": 3.75,
        "ci_upper": 12.68,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Part B1: Alpelisib + Nab-paclitaxel",
        "value": 14.3,
        "unit": "percentage of participants",
        "ci_lower": 4.8,
        "ci_upper": 30.3,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "alpelisib",
        "nab-paclitaxel"
      ],
      "OG001": [
        "nab-paclitaxel"
      ],
      "OG002": [
        "alpelisib",
        "nab-paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo",
      "OG002": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT04248829",
    "brief_title": "Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2020-02-13",
    "completion_date": "2022-07-29",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Yuhan Corporation",
    "url": "https://clinicaltrials.gov/study/NCT04248829",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "Exon 19 deletion (Ex19del) or L858R, either alone or in combination with other EGFR mutations"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Lazertinib 240 mg",
        "value": 20.6,
        "unit": "Months",
        "ci_lower": 17.8,
        "ci_upper": 26.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Gefitnib 250 mg",
        "value": 9.7,
        "unit": "Months",
        "ci_lower": 9.2,
        "ci_upper": 11.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Lazertinib 240 mg",
        "value": 49.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Gefitnib 250 mg",
        "value": 64.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Lazertinib 240 mg",
        "value": 147.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Gefitnib 250 mg",
        "value": 133.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Lazertinib 240 mg/160 mg"
      ],
      "OG001": [
        "Gefitinib 250 mg"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT04408924",
    "brief_title": "Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer",
    "status": "COMPLETED",
    "start_date": "2021-01-20",
    "completion_date": "2022-04-27",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT04408924",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "200 mg Abemaciclib Twice Daily",
        "value": 6.8,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 14.3,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Abemaciclib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT04439110",
    "brief_title": "Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2015-08-12",
    "completion_date": "2019-03-09",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT04439110",
    "cancer_types": [
      "BRCA",
      "DLBC",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "HIGH",
        "details": "Amplification > 7 based on targeted custom Ampliseq panel on the Ion Torrent Personal Genome Machine (PGM)"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (Trastuzumab Emtansine)",
        "value": 2.0,
        "unit": "percentage of participants",
        "ci_lower": 1.0,
        "ci_upper": 16.5,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Trastuzumab Emtansine"
      ]
    },
    "treatment_class_map": {
      "OG000": "ADC"
    }
  },
  {
    "nct_id": "NCT01154140",
    "brief_title": "A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung",
    "status": "COMPLETED",
    "start_date": "2011-01-13",
    "completion_date": "2013-11-30",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT01154140",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "ALK",
        "status": "POSITIVE",
        "details": "Translocation or inversion events involving the ALK gene locus"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Crizotinib",
        "value": 10.9,
        "unit": "months",
        "ci_lower": 8.3,
        "ci_upper": 13.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy",
        "value": 7.0,
        "unit": "months",
        "ci_lower": 6.8,
        "ci_upper": 8.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "crizotinib"
      ],
      "OG001": [
        "pemetrexed",
        "cisplatin",
        "carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01151046",
    "brief_title": "Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2010-06",
    "completion_date": "2014-06",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merrimack Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT01151046",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "ER positive (ER+), per inclusion criteria"
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": "PR positive (PgR+); inclusion allows ER+ and/or PR+"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 negative (Her2 negative)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "MM-121 + Exemestane",
        "value": 15.9,
        "unit": "weeks",
        "ci_lower": 9.3,
        "ci_upper": 30.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Exemestane",
        "value": 10.7,
        "unit": "weeks",
        "ci_lower": 8.1,
        "ci_upper": 16.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "MM-121 + Exemestane",
        "value": null,
        "unit": "weeks",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Exemestane",
        "value": 96.3,
        "unit": "weeks",
        "ci_lower": 51.4,
        "ci_upper": 96.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "MM-121",
        "Exemestane"
      ],
      "OG001": [
        "Exemestane"
      ],
      "OG002": [
        "Exemestane"
      ],
      "OG003": [
        "MM-121",
        "Exemestane"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01170663",
    "brief_title": "A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma",
    "status": "COMPLETED",
    "start_date": "2010-12",
    "completion_date": "2013-07",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT01170663",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Ramucirumab (IMC-1211B) Plus Paclitaxel",
        "value": 9.6,
        "unit": "months",
        "ci_lower": 8.5,
        "ci_upper": 10.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo Plus Paclitaxel",
        "value": 7.4,
        "unit": "months",
        "ci_lower": 6.3,
        "ci_upper": 8.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ramucirumab (IMC-1211B) Plus Paclitaxel",
        "value": 4.4,
        "unit": "months",
        "ci_lower": 4.2,
        "ci_upper": 5.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo Plus Paclitaxel",
        "value": 2.9,
        "unit": "months",
        "ci_lower": 2.8,
        "ci_upper": 3.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ramucirumab (IMC-1211B) DP",
        "Paclitaxel"
      ],
      "OG001": [
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01174563",
    "brief_title": "A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participants With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy",
    "status": "COMPLETED",
    "start_date": "2011-05-23",
    "completion_date": "2016-12-20",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT01174563",
    "cancer_types": [
      "LUAD"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "EGFR mutation (any)"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV",
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Erlotinib",
        "value": 2.16,
        "unit": "months",
        "ci_lower": 1.51,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Erlotinib",
        "value": 6.62,
        "unit": "months",
        "ci_lower": 3.57,
        "ci_upper": 13.48,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Erlotinib",
        "value": 10.0,
        "unit": "months",
        "ci_lower": 7.31,
        "ci_upper": 23.61,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Erlotinib",
        "value": 15.28,
        "unit": "months",
        "ci_lower": 10.62,
        "ci_upper": 25.77,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "erlotinib [Tarceva]"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT04439175",
    "brief_title": "Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2016-02-25",
    "completion_date": "2020-11-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT04439175",
    "cancer_types": [
      "OTHER",
      "DLBC"
    ],
    "biomarkers": [
      {
        "target": "PIK3CA",
        "status": "POSITIVE",
        "details": "PIK3CA mutation as determined via the MATCH Master Protocol"
      },
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "No KRAS mutations detected in the tumor sample as determined by the MATCH screening assessment"
      },
      {
        "target": "PTEN",
        "status": "NEGATIVE",
        "details": "No PTEN mutation or PTEN loss; PTEN loss determined by immunohistochemistry (IHC)"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (Taselisib)",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Taselisib)",
        "value": 19.9,
        "unit": "percentage of participants",
        "ci_lower": 12.0,
        "ci_upper": 29.3,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Taselisib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01157676",
    "brief_title": "Open Vs Robotic-Assisted Radical Cystectomy: A Randomized Trial",
    "status": "COMPLETED",
    "start_date": "2011-07",
    "completion_date": "2018-12",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "sponsor": "University of Miami",
    "url": "https://clinicaltrials.gov/study/NCT01157676",
    "cancer_types": [
      "BLCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "I",
      "II",
      "III",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Open Radical Cystectomy",
        "value": 71.6,
        "unit": "percentage of participants",
        "ci_lower": 63.6,
        "ci_upper": 78.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Robotic Assisted Radical Cystectomy",
        "value": 72.3,
        "unit": "percentage of participants",
        "ci_lower": 64.3,
        "ci_upper": 78.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {},
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT04439136",
    "brief_title": "Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2015-08-12",
    "completion_date": "2021-01-22",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT04439136",
    "cancer_types": [
      "OTHER",
      "DLBC"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "activating HER2 mutation; any in-frame insertions in exon 20 considered activating mutation"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (Afatinib Dimaleate)",
        "value": 2.7,
        "unit": "percentage of participants",
        "ci_lower": 0.14,
        "ci_upper": 12.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Afatinib Dimaleate)",
        "value": 12.0,
        "unit": "percentage of participants",
        "ci_lower": 5.6,
        "ci_upper": 25.8,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Afatinib Dimaleate"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT01165021",
    "brief_title": "A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2010-11",
    "completion_date": "2013-07",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT01165021",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIA"
    ],
    "line_of_therapy": "NEOADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed + Cisplatin",
        "value": 41.2,
        "unit": "percentage of participants",
        "ci_lower": 18.4,
        "ci_upper": 67.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed + Cisplatin",
        "value": 34.6,
        "unit": "months",
        "ci_lower": 10.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed + Cisplatin",
        "value": 12.4,
        "unit": "months",
        "ci_lower": 7.0,
        "ci_upper": 21.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pemetrexed",
        "Cisplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo"
    }
  },
  {
    "nct_id": "NCT01154452",
    "brief_title": "Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma",
    "status": "COMPLETED",
    "start_date": "2010-06",
    "completion_date": "2015-02",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT01154452",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm I (Gamma-secretase Inhibitor RO4929097)",
        "value": 60.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm II (Vismodegib and Gamma-secretase Inhibitor RO4929097)",
        "value": 60.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG001": [
        "Vismodegib",
        "Gamma-Secretase Inhibitor RO4929097"
      ],
      "OG002": [
        "Gamma-Secretase Inhibitor RO4929097"
      ],
      "OG003": [
        "Vismodegib",
        "Gamma-Secretase Inhibitor RO4929097"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01142401",
    "brief_title": "Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2010-05-26",
    "completion_date": "2015-07-30",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT01142401",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Estrogen receptor positive (ER+), histologically or cytologically confirmed"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A: Fulvestrant",
        "value": 8.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Fulvestrant + Bortezomib",
        "value": 16.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Fulvestrant"
      ],
      "OG001": [
        "Fulvestrant",
        "Bortezomib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01130337",
    "brief_title": "A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer",
    "status": "COMPLETED",
    "start_date": "2010-07",
    "completion_date": "2014-06",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT01130337",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER2-positive gastric or esophagogastric junction adenocarcinoma (Sievert types I, II, III)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "NEOADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [],
    "arm_drugs": {
      "OG000": [
        "Capecitabine",
        "Oxaliplatin",
        "Trastuzumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT01160211",
    "brief_title": "A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2011-05-05",
    "completion_date": "2016-03-11",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT01160211",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "ER positive (tumor must be ER+ and/or PGR+)"
      },
      {
        "target": "PGR",
        "status": "POSITIVE",
        "details": "PGR (PgR) positive (tumor must be ER+ and/or PGR+)"
      },
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER2 overexpression or gene amplification in invasive component of primary or metastatic site: IHC 3+ and/or HER2 amplification by FISH/CISH/SISH (>6 gene copies per nucleus or HER2/Chr17 ratio \u22652.0)"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Lapatinib + Trastuzumab + Aromatase Inhibitor (AI)",
        "value": 62.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Trastuzumab + Aromatase Inhibitor (AI)",
        "value": 75.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Lapatinib + Trastuzumab + Aromatase Inhibitor (AI)",
        "value": 38.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Lapatinib + Aromatase Inhibitor (AI)",
        "value": 45.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Trastuzumab + Aromatase Inhibitor (AI)",
        "value": 39.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Lapatinib",
        "Trastuzumab",
        "Aromatase Inhibitor"
      ],
      "OG001": [
        "Trastuzumab",
        "Aromatase Inhibitor"
      ],
      "OG002": [
        "Trastuzumab",
        "Aromatase Inhibitor"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Targeted",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT04420598",
    "brief_title": "DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease",
    "status": "COMPLETED",
    "start_date": "2020-05-25",
    "completion_date": "2021-09-30",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "MedSIR",
    "url": "https://clinicaltrials.gov/study/NCT04420598",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "IHC 3+ or ISH \u2265 2.0 or average HER2 copy number \u2265 6.0 signals (per 2018 ASCO/CAP guidelines)"
      },
      {
        "target": "HER2",
        "status": "LOW",
        "details": "HER2-low defined as IHC 2+ with ISH-negative, or IHC 1+ (ISH-negative or untested) per 2018 ASCO/CAP guidelines"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort 2",
        "value": 7.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Cohort 3",
        "value": 5.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Cohort 4",
        "value": 3.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cohort 5",
        "value": 13.3,
        "unit": "months",
        "ci_lower": 2.5,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Trastuzumab deruxtecan"
      ],
      "OG001": [
        "Trastuzumab deruxtecan"
      ],
      "OG002": [
        "Trastuzumab deruxtecan"
      ],
      "OG003": [
        "Trastuzumab deruxtecan"
      ],
      "OG004": [
        "Trastuzumab deruxtecan"
      ]
    },
    "treatment_class_map": {
      "OG000": "ADC",
      "OG001": "ADC",
      "OG002": "ADC",
      "OG003": "ADC",
      "OG004": "ADC"
    }
  },
  {
    "nct_id": "NCT04439123",
    "brief_title": "Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2016-05-31",
    "completion_date": "2019-11-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT04439123",
    "cancer_types": [
      "DLBC",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "AKT",
        "status": "POSITIVE",
        "details": "AKT mutation as determined via the MATCH Master Protocol"
      },
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "Known mutation (any) \u2014 patients with such mutations are not eligible"
      },
      {
        "target": "NRAS",
        "status": "NEGATIVE",
        "details": "Known mutation (any) \u2014 patients with such mutations are not eligible"
      },
      {
        "target": "HRAS",
        "status": "NEGATIVE",
        "details": "Known mutation (any) \u2014 patients with such mutations are not eligible"
      },
      {
        "target": "BRAF",
        "status": "NEGATIVE",
        "details": "Known mutation (any) \u2014 patients with such mutations are not eligible"
      },
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Estrogen receptor >1% by immunohistochemistry (hormone receptor\u2013positive defined as ER and/or PR >1%)"
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": "Progesterone receptor >1% by immunohistochemistry (hormone receptor\u2013positive defined as ER and/or PR >1%)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "No overexpression by IHC and no amplification by in-situ hybridization (relevant for unresectable HER2-negative breast cancer subgroup)"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (Capivasertib)",
        "value": 28.6,
        "unit": "percentage of participants",
        "ci_lower": 15.0,
        "ci_upper": 46.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Capivasertib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT04439149",
    "brief_title": "Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2016-05-05",
    "completion_date": "2020-11-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT04439149",
    "cancer_types": [
      "DLBC",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "PTEN",
        "status": "POSITIVE",
        "details": "PTEN gene mutation or deletion required; must have PTEN expression by IHC (any amount of staining considered positive); complete loss of PTEN by IHC is excluded (those patients go to MATCH subprotocol EAY131-P)"
      },
      {
        "target": "PIK3CA",
        "status": "NEGATIVE",
        "details": "No co-existing activating aberrations in PI3K/MTOR or MAPK pathways"
      },
      {
        "target": "PIK3R1",
        "status": "NEGATIVE",
        "details": "No co-existing activating aberrations in PI3K/MTOR or MAPK pathways"
      },
      {
        "target": "BRAF",
        "status": "NEGATIVE",
        "details": "No co-existing activating aberrations in PI3K/MTOR or MAPK pathways"
      },
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "No co-existing activating aberrations in PI3K/MTOR or MAPK pathways"
      },
      {
        "target": "AKT1",
        "status": "NEGATIVE",
        "details": "No co-existing activating aberrations in PI3K/MTOR or MAPK pathways"
      },
      {
        "target": "TSC1",
        "status": "NEGATIVE",
        "details": "No co-existing activating aberrations in PI3K/MTOR or MAPK pathways"
      },
      {
        "target": "TSC2",
        "status": "NEGATIVE",
        "details": "No co-existing activating aberrations in PI3K/MTOR or MAPK pathways"
      },
      {
        "target": "MTOR",
        "status": "NEGATIVE",
        "details": "No co-existing activating aberrations in PI3K/MTOR or MAPK pathways"
      },
      {
        "target": "NF2",
        "status": "NEGATIVE",
        "details": "No co-existing activating aberrations in PI3K/MTOR or MAPK pathways"
      },
      {
        "target": "NRAS",
        "status": "NEGATIVE",
        "details": "No co-existing activating aberrations in PI3K/MTOR or MAPK pathways"
      },
      {
        "target": "HRAS",
        "status": "NEGATIVE",
        "details": "No co-existing activating aberrations in PI3K/MTOR or MAPK pathways"
      },
      {
        "target": "NF1",
        "status": "NEGATIVE",
        "details": "No co-existing activating aberrations in PI3K/MTOR or MAPK pathways"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (GSK2636771)",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment (GSK2636771)",
        "value": 4.8,
        "unit": "percentage of participants",
        "ci_lower": 0.6,
        "ci_upper": 16.6,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "GSK2636771"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT04345913",
    "brief_title": "Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2021-03-01",
    "completion_date": "2024-03-28",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT04345913",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "ER < 10% (estrogen receptor negative)"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "PR < 10% (progesterone receptor negative)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 negative / unamplified"
      },
      {
        "target": "PTEN",
        "status": "ANY",
        "details": "Known mutation status required from archival tumor tissue; PTEN analysis"
      },
      {
        "target": "PIK3CA",
        "status": "ANY",
        "details": "Known mutation status required from archival tumor tissue; PIK3CA analysis"
      },
      {
        "target": "AKT",
        "status": "NEGATIVE",
        "details": "Known tumor AKT mutation excluded based on archival tumor tissue analysis"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Group I (Phase II, Eribulin)",
        "value": 3.9,
        "unit": "months",
        "ci_lower": 0.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Group II (Phase II, DL1, Eribulin, Copanlisib)",
        "value": 3.3,
        "unit": "months",
        "ci_lower": 1.7,
        "ci_upper": 5.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Copanlisib Hydrochloride",
        "Eribulin Mesylate"
      ],
      "OG001": [
        "Copanlisib Hydrochloride",
        "Eribulin Mesylate"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT04400474",
    "brief_title": "Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study",
    "status": "COMPLETED",
    "start_date": "2020-10-07",
    "completion_date": "2023-11-23",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Grupo Espanol de Tumores Neuroendocrinos",
    "url": "https://clinicaltrials.gov/study/NCT04400474",
    "cancer_types": [
      "THCA",
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "LungNET (Lung Typical Andatypical Carcinoids) Cabozantinib 40 mg + Atezolizumab 1200 mg",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "ATC (Anaplastic Thyroid Cancer) Cabozantinib 40 mg + Atezolizumab 1200 mg",
        "value": 2.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "ACC (Adrenocortical Carcinoma) Cabozantinib 40 mg + Atezolizumab 1200 mg",
        "value": 2.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "PPGL (Pheochromocytoma/Paraganglioma) Cabozantinib 40 mg + Atezolizumab 1200 mg",
        "value": 2.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "G1-2 GEP-NET (Well-differentiated Gastroenteropancreatic NET)",
        "value": 4.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "G3 EP-NEN (Extrapulmonary Neuroendocrine Neoplasms.)",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "LungNET (Lung Typical and Atypical Carcinoids)",
        "value": 8.4,
        "unit": "months",
        "ci_lower": 7.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "ATC (Anaplastic Thyroid Cancer)",
        "value": 4.1,
        "unit": "months",
        "ci_lower": 2.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "ACC (Adrenocortical Carcinoma)",
        "value": 2.9,
        "unit": "months",
        "ci_lower": 2.8,
        "ci_upper": 5.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "PPGL (Pheochromocytoma/Paraganglioma)",
        "value": 8.6,
        "unit": "months",
        "ci_lower": 5.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "G1-2 GEP-NET (Well-differentiated Gastroenteropancreatic NET)",
        "value": 13.0,
        "unit": "months",
        "ci_lower": 11.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG005",
        "arm_title": "G3 EP-NEN (Extrapulmonary Neuroendocrine Neoplasms.)",
        "value": 2.7,
        "unit": "months",
        "ci_lower": 2.6,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "LungNET (Lung Typical and Atypical Carcinoids)",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "ATC (Anaplastic Thyroid Cancer)",
        "value": 6.1,
        "unit": "months",
        "ci_lower": 4.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "ACC (Adrenocortical Carcinoma)",
        "value": 13.5,
        "unit": "months",
        "ci_lower": 9.2,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "PPGL (Pheochromocytoma/Paraganglioma)",
        "value": 26.7,
        "unit": "months",
        "ci_lower": 9.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG004",
        "arm_title": "G1-2 GEP-NET (Well-differentiated Gastroenteropancreatic NET)",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG005",
        "arm_title": "G3 EP-NEN (Extrapulmonary Neuroendocrine Neoplasms.)",
        "value": 5.4,
        "unit": "months",
        "ci_lower": 3.6,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cabozantinib 40 mg",
        "Atezolizumab 1200 mg"
      ],
      "OG001": [
        "Cabozantinib 40 mg",
        "Atezolizumab 1200 mg"
      ],
      "OG002": [
        "Cabozantinib 40 mg",
        "Atezolizumab 1200 mg"
      ],
      "OG003": [
        "Cabozantinib 40 mg",
        "Atezolizumab 1200 mg"
      ],
      "OG004": [
        "Cabozantinib 40 mg",
        "Atezolizumab 1200 mg"
      ],
      "OG005": [
        "Cabozantinib 40 mg",
        "Atezolizumab 1200 mg"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_IO",
      "OG001": "Combo_TKI_IO",
      "OG002": "Combo_TKI_IO",
      "OG003": "Combo_TKI_IO",
      "OG004": "Combo_TKI_IO",
      "OG005": "Combo_TKI_IO"
    }
  },
  {
    "nct_id": "NCT04381650",
    "brief_title": "A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2020-08-17",
    "completion_date": "2024-10-29",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Takeda",
    "url": "https://clinicaltrials.gov/study/NCT04381650",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "sensitizing/driver mutation; Phase 1 nonsquamous NSCLC with known driver mutations must have progressed after commercially available targeted therapy; in Phase 2 participants with driver mutations are not eligible"
      },
      {
        "target": "BRAF",
        "status": "POSITIVE",
        "details": "V600E mutation; Phase 1 nonsquamous NSCLC with known driver mutations must have progressed after commercially available targeted therapy; in Phase 2 participants with driver mutations are not eligible"
      },
      {
        "target": "ROS1",
        "status": "POSITIVE",
        "details": "driver alteration (sensitizing/rearrangement); Phase 1 nonsquamous NSCLC with known driver mutations must have progressed after commercially available targeted therapy; in Phase 2 participants with driver mutations are not eligible"
      },
      {
        "target": "NTRK",
        "status": "POSITIVE",
        "details": "gene fusions; Phase 1 nonsquamous NSCLC with known driver mutations must have progressed after commercially available targeted therapy; in Phase 2 participants with driver mutations are not eligible"
      },
      {
        "target": "ALK",
        "status": "POSITIVE",
        "details": "rearrangements; Phase 1 nonsquamous NSCLC with known driver mutations must have progressed after commercially available targeted therapy; in Phase 2 participants with driver mutations are not eligible"
      },
      {
        "target": "MSI",
        "status": "NEGATIVE",
        "details": "microsatellite stable (MSS) required for colorectal cancer cohort (CPI\u2011na\u00efve MSS-CRC)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE",
      "LOCALLY_ADVANCED",
      "IV",
      "IVB",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Dose Expansion: Cohort A: Non-squamous NSCLC TAK-981 90 mg",
        "value": 20.0,
        "unit": "percentage of participants",
        "ci_lower": 2.52,
        "ci_upper": 55.61,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Dose Expansion: Cohort A: Non-squamous NSCLC TAK-981 120 mg",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 36.94,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Dose Expansion: Cohort B: Cervical Cancer TAK-981 90 mg",
        "value": 30.0,
        "unit": "percentage of participants",
        "ci_lower": 11.89,
        "ci_upper": 54.28,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Dose Expansion: Cohort C: MSS-CRC TAK-981 90 mg",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 33.63,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Dose Expansion: Cohort D: Cutaneous Melanoma TAK-981 90 mg",
        "value": 25.0,
        "unit": "percentage of participants",
        "ci_lower": 10.69,
        "ci_upper": 44.87,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "Dose Expansion: Cohort E: Squamous NSCLC TAK-981 90 mg",
        "value": 7.7,
        "unit": "percentage of participants",
        "ci_lower": 0.19,
        "ci_upper": 36.03,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG006",
        "arm_title": "Dose Expansion: Cohort F: CPI Refractory Squamous and Non-squamous NSCLC TAK-981 90 mg",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 60.24,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "TAK-981",
        "Pembrolizumab"
      ],
      "OG001": [
        "TAK-981",
        "Pembrolizumab"
      ],
      "OG002": [
        "TAK-981",
        "Pembrolizumab"
      ],
      "OG003": [
        "TAK-981",
        "Pembrolizumab"
      ],
      "OG004": [
        "TAK-981",
        "Pembrolizumab"
      ],
      "OG005": [
        "TAK-981",
        "Pembrolizumab"
      ],
      "OG006": [
        "TAK-981",
        "Pembrolizumab"
      ],
      "OG007": [
        "TAK-981",
        "Pembrolizumab"
      ],
      "OG008": [
        "TAK-981",
        "Pembrolizumab"
      ],
      "OG009": [
        "TAK-981",
        "Pembrolizumab"
      ],
      "OG010": [
        "TAK-981",
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted",
      "OG002": "Combo_IO_Targeted",
      "OG003": "Combo_IO_Targeted",
      "OG004": "Combo_IO_Targeted",
      "OG005": "Combo_IO_Targeted",
      "OG006": "Combo_IO_Targeted",
      "OG007": "Combo_IO_Targeted",
      "OG008": "Combo_IO_Targeted",
      "OG009": "Combo_IO_Targeted",
      "OG010": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT04439331",
    "brief_title": "Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2015-11-19",
    "completion_date": "2020-11-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT04439331",
    "cancer_types": [
      "DLBC",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "NF2",
        "status": "POSITIVE",
        "details": "inactivating mutation"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (Defactinib)",
        "value": 3.2,
        "unit": "percentage of participants",
        "ci_lower": 0.17,
        "ci_upper": 14.9,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Defactinib Hydrochloride"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT04439344",
    "brief_title": "Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2016-05-31",
    "completion_date": "2019-05-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT04439344",
    "cancer_types": [
      "DLBC",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "NRAS",
        "status": "POSITIVE",
        "details": "Mutation in codon 12, 13, or 61"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (Binimetinib)",
        "value": 0.021,
        "unit": "percentage of participants",
        "ci_lower": 0.001,
        "ci_upper": 0.097,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Binimetinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT04439318",
    "brief_title": "Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2016-02-25",
    "completion_date": "2020-06-30",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT04439318",
    "cancer_types": [
      "DLBC",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "NF1",
        "status": "POSITIVE",
        "details": "Deleterious inactivating mutations of NF1, or another NF1 aberration, as determined via the MATCH Master Protocol"
      }
    ],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (Trametinib)",
        "value": 4.3,
        "unit": "percentage of participants",
        "ci_lower": 0.8,
        "ci_upper": 13.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Trametinib)",
        "value": 21.0,
        "unit": "percentage of participants",
        "ci_lower": 12.0,
        "ci_upper": 34.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Trametinib Dimethyl Sulfoxide"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01191697",
    "brief_title": "CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer",
    "status": "COMPLETED",
    "start_date": "2011-02",
    "completion_date": "2021-12",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Dana-Farber Cancer Institute",
    "url": "https://clinicaltrials.gov/study/NCT01191697",
    "cancer_types": [
      "STAD",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER2-positive esophageal, gastroesophageal junction, or gastric adenocarcinoma (tumor sample required)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Trastuzumab, Bevacizumab, Oxaliplatin and Capecitabine",
        "value": 81.0,
        "unit": "percentage of patients",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "trastuzumab",
        "bevacizumab",
        "oxaliplatin",
        "capecitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT04439240",
    "brief_title": "Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)",
    "status": "COMPLETED",
    "start_date": "2016-05-31",
    "completion_date": "2019-06-06",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT04439240",
    "cancer_types": [
      "DLBC",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "FGFR1",
        "status": "POSITIVE",
        "details": "Mutation or translocation as determined by the MATCH screening assessment"
      },
      {
        "target": "FGFR2",
        "status": "POSITIVE",
        "details": "Mutation or translocation as determined by the MATCH screening assessment"
      },
      {
        "target": "FGFR3",
        "status": "POSITIVE",
        "details": "Mutation or translocation as determined by the MATCH screening assessment"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (AZD4547)",
        "value": 8.0,
        "unit": "percentage of participants",
        "ci_lower": 3.0,
        "ci_upper": 18.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "AZD4547"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT01177007",
    "brief_title": "Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2010-09",
    "completion_date": "2014-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Yale University",
    "url": "https://clinicaltrials.gov/study/NCT01177007",
    "cancer_types": [
      "CRC",
      "BRCA",
      "PAAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "TheraSphere",
        "value": 10.3,
        "unit": "months",
        "ci_lower": 7.6,
        "ci_upper": 13.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "TheraSphere",
        "value": 22.0,
        "unit": "months",
        "ci_lower": 0.0,
        "ci_upper": 45.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "TheraSphere",
        "value": 9.5,
        "unit": "months",
        "ci_lower": 2.4,
        "ci_upper": 16.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "TheraSphere",
        "value": 15.8,
        "unit": "months",
        "ci_lower": 2.8,
        "ci_upper": 28.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "TheraSphere (Yttrium-90 glass microspheres)"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER"
    }
  },
  {
    "nct_id": "NCT01201265",
    "brief_title": "A Study of Bevacizumab in Combination With Gemcitabine and Carboplatin in Participants With Triple Negative Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2011-02",
    "completion_date": "2015-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT01201265",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "Estrogen receptor-negative disease"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "Progesterone receptor-negative disease"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-negative disease (triple-negative breast cancer)"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "All Participants",
        "value": 255.0,
        "unit": "days",
        "ci_lower": 157.0,
        "ci_upper": 465.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "All Participants",
        "value": 475.0,
        "unit": "days",
        "ci_lower": 358.0,
        "ci_upper": 759.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Bevacizumab",
        "Carboplatin",
        "Gemcitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT04439279",
    "brief_title": "Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2015-08-12",
    "completion_date": "2019-03-18",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT04439279",
    "cancer_types": [
      "DLBC",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "BRAF",
        "status": "POSITIVE",
        "details": "non-V600 BRAF mutation or BRAF fusion or other BRAF aberration as identified via the MATCH Master Protocol"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Subprotocol R",
        "value": 3.0,
        "unit": "percentage of participants",
        "ci_lower": 0.1,
        "ci_upper": 16.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Trametinib Dimethyl Sulfoxide"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01177397",
    "brief_title": "Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma",
    "status": "COMPLETED",
    "start_date": "2010-07-20",
    "completion_date": "2016-11-15",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Celgene",
    "url": "https://clinicaltrials.gov/study/NCT01177397",
    "cancer_types": [
      "NSCLC",
      "BRCA",
      "DLBC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Part B: Glioblastoma Multiforme (GBM)",
        "value": 0.0,
        "unit": "Percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "CC-223"
      ],
      "OG001": [
        "CC-223"
      ],
      "OG002": [
        "CC-223"
      ],
      "OG003": [
        "CC-223"
      ],
      "OG004": [
        "CC-223"
      ],
      "OG005": [
        "CC-223"
      ],
      "OG006": [
        "CC-223"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other",
      "OG004": "Targeted_Other",
      "OG005": "Targeted_Other",
      "OG006": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01196741",
    "brief_title": "Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer",
    "status": "COMPLETED",
    "start_date": "2011-03",
    "completion_date": "2012-11",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "University College, London",
    "url": "https://clinicaltrials.gov/study/NCT01196741",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Saracatinib Plus Weekly Paclitaxel",
        "value": 29.0,
        "unit": "percentage of participants",
        "ci_lower": 22.0,
        "ci_upper": 37.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo Plus Weekly Paclitaxel",
        "value": 34.0,
        "unit": "percentage of participants",
        "ci_lower": 23.0,
        "ci_upper": 46.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Saracatinib",
        "Paclitaxel"
      ],
      "OG001": [
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT04439214",
    "brief_title": "Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)",
    "status": "COMPLETED",
    "start_date": "2016-05-31",
    "completion_date": "2018-10-11",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT04439214",
    "cancer_types": [
      "DLBC",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "MMR",
        "status": "POSITIVE",
        "details": "Mismatch repair deficiency (dMMR) as determined by the MATCH Master Protocol"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (Nivolumab)",
        "value": 35.7,
        "unit": "percentage of participants",
        "ci_lower": 23.5,
        "ci_upper": 49.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Nivolumab)",
        "value": 51.3,
        "unit": "percentage of participants",
        "ci_lower": 38.2,
        "ci_upper": 64.5,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO"
    }
  },
  {
    "nct_id": "NCT01183858",
    "brief_title": "A Study of Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS)",
    "status": "COMPLETED",
    "start_date": "2010-10",
    "completion_date": "2013-10",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT01183858",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV",
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Erlotinib 150 mg",
        "value": 6.86,
        "unit": "weeks",
        "ci_lower": 6.29,
        "ci_upper": 12.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Erlotinib 300 mg",
        "value": 7.0,
        "unit": "weeks",
        "ci_lower": 6.29,
        "ci_upper": 11.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Erlotinib 150 mg",
        "value": 6.77,
        "unit": "months",
        "ci_lower": 5.65,
        "ci_upper": 8.77,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Erlotinib 300 mg",
        "value": 6.83,
        "unit": "months",
        "ci_lower": 5.39,
        "ci_upper": 8.48,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Erlotinib"
      ],
      "OG001": [
        "Erlotinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT01194453",
    "brief_title": "Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2009-11",
    "completion_date": "2010-09",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sun Yat-sen University",
    "url": "https://clinicaltrials.gov/study/NCT01194453",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Group A",
        "value": 168.0,
        "unit": "day",
        "ci_lower": 139.0,
        "ci_upper": 183.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Group B",
        "value": 140.0,
        "unit": "day",
        "ci_lower": 113.0,
        "ci_upper": 164.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "cisplatin",
        "pemetrexed",
        "dexamethasone",
        "vitamin B12",
        "folic acid"
      ],
      "OG001": [
        "cisplatin",
        "gemcitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01180959",
    "brief_title": "Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy",
    "status": "COMPLETED",
    "start_date": "2011-04-14",
    "completion_date": "2021-05-19",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "M.D. Anderson Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT01180959",
    "cancer_types": [
      "LIHC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "UNRESECTABLE",
      "METASTATIC",
      "RECURRENT",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "2L",
    "prior_tki": true,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Erlotinib + Bevacizumab",
        "value": 43.0,
        "unit": "months",
        "ci_lower": 28.0,
        "ci_upper": 59.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Erlotinib + Bevacizumab",
        "value": 9.9,
        "unit": "months",
        "ci_lower": 8.3,
        "ci_upper": 15.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Erlotinib",
        "Bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Targeted"
    }
  },
  {
    "nct_id": "NCT04439201",
    "brief_title": "Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2016-05-31",
    "completion_date": "2021-03-09",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT04439201",
    "cancer_types": [
      "DLBC",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "CCND1",
        "status": "HIGH",
        "details": "Amplification of CCND1 as determined by the MATCH Master Protocol"
      },
      {
        "target": "CCND2",
        "status": "HIGH",
        "details": "Amplification of CCND2 as determined by the MATCH Master Protocol"
      },
      {
        "target": "CCND3",
        "status": "HIGH",
        "details": "Amplification of CCND3 as determined by the MATCH Master Protocol"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (Palbociclib)",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Palbociclib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01196390",
    "brief_title": "Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",
    "status": "COMPLETED",
    "start_date": "2011-02-14",
    "completion_date": "2019-12-23",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT01196390",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER2-expressing adenocarcinoma of the esophagus; central HER2 testing required prior to step 2 registration"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": "NEOADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Chemoradiation and Trastuzumab (Arm 1)",
        "value": 19.6,
        "unit": "Months",
        "ci_lower": 13.5,
        "ci_upper": 26.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Chemoradiation (Arm 2)",
        "value": 14.2,
        "unit": "Months",
        "ci_lower": 10.5,
        "ci_upper": 23.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Trastuzumab",
        "Paclitaxel",
        "Carboplatin"
      ],
      "OG001": [
        "Paclitaxel",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01183780",
    "brief_title": "A Study in Second Line Metastatic Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2010-12-02",
    "completion_date": "2014-07-17",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT01183780",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "ANY",
        "details": "Eligible irrespective of KRAS mutation status"
      },
      {
        "target": "UGT1A1",
        "status": "NEGATIVE",
        "details": "Must NOT have UGT1A1*6/*6, UGT1A1*28/*28, or UGT1A1*6/*28 genotypes (Gilbert's syndrome-related genotypes excluded)"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Ramucirumab + FOLFIRI",
        "value": 13.3,
        "unit": "months",
        "ci_lower": 12.4,
        "ci_upper": 14.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + FOLFIRI",
        "value": 11.7,
        "unit": "months",
        "ci_lower": 10.8,
        "ci_upper": 12.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ramucirumab + FOLFIRI",
        "value": 5.7,
        "unit": "months",
        "ci_lower": 5.5,
        "ci_upper": 6.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + FOLFIRI",
        "value": 4.5,
        "unit": "months",
        "ci_lower": 4.2,
        "ci_upper": 5.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ramucirumab",
        "Irinotecan",
        "Folinic Acid",
        "5-Fluorouracil"
      ],
      "OG001": [
        "Irinotecan",
        "Folinic Acid",
        "5-Fluorouracil"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT04446117",
    "brief_title": "Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2020-10-19",
    "completion_date": "2024-04-19",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Exelixis",
    "url": "https://clinicaltrials.gov/study/NCT04446117",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [
      {
        "target": "PSA",
        "status": "ANY",
        "details": "PSA progression per protocol-defined criteria (progressive disease may be defined by PSA progression)"
      },
      {
        "target": "TESTOSTERONE",
        "status": "LOW",
        "details": "Serum testosterone \u2264 50 ng/dL (\u2264 1.73 nmol/L) at screening"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Experimental Arm: Cabozantinib and Atezolizumab",
        "value": 6.34,
        "unit": "months",
        "ci_lower": 6.18,
        "ci_upper": 8.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Control Arm: Second NHT",
        "value": 4.17,
        "unit": "months",
        "ci_lower": 3.71,
        "ci_upper": 5.65,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Experimental Arm: Cabozantinib and Atezolizumab",
        "value": 14.78,
        "unit": "months",
        "ci_lower": 13.37,
        "ci_upper": 16.66,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Control Arm: Second NHT",
        "value": 14.98,
        "unit": "months",
        "ci_lower": 13.01,
        "ci_upper": 18.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cabozantinib",
        "Atezolizumab"
      ],
      "OG001": [
        "Abiraterone Acetate",
        "Prednisone",
        "Enzalutamide"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_IO",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT04447755",
    "brief_title": "A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)",
    "status": "COMPLETED",
    "start_date": "2020-07-30",
    "completion_date": "2022-09-16",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT04447755",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Ewing Sarcoma",
        "value": 22.2,
        "unit": "Percentage of Participants",
        "ci_lower": 2.8,
        "ci_upper": 60.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Rhabdomyosarcoma",
        "value": 11.8,
        "unit": "Percentage of Participants",
        "ci_lower": 1.5,
        "ci_upper": 36.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "High Grade Glioma",
        "value": 0.0,
        "unit": "Percentage of Participants",
        "ci_lower": 0.0,
        "ci_upper": 45.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Diffuse Midline Glioma",
        "value": 0.0,
        "unit": "Percentage of Participants",
        "ci_lower": 0.0,
        "ci_upper": 33.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Medulloblastoma",
        "value": 0.0,
        "unit": "Percentage of Participants",
        "ci_lower": 0.0,
        "ci_upper": 33.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "Ependymoma",
        "value": 0.0,
        "unit": "Percentage of Participants",
        "ci_lower": 0.0,
        "ci_upper": 33.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG006",
        "arm_title": "Other Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma",
        "value": 7.7,
        "unit": "Percentage of Participants",
        "ci_lower": 2.5,
        "ci_upper": 17.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ewing Sarcoma",
        "value": 3.0,
        "unit": "Months",
        "ci_lower": 0.3,
        "ci_upper": 9.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Rhabdomyosarcoma",
        "value": 2.6,
        "unit": "Months",
        "ci_lower": 1.2,
        "ci_upper": 5.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "High Grade Glioma",
        "value": 1.9,
        "unit": "Months",
        "ci_lower": 1.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Diffuse Midline Glioma",
        "value": 1.8,
        "unit": "Months",
        "ci_lower": 0.5,
        "ci_upper": 4.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Medulloblastoma",
        "value": 3.4,
        "unit": "Months",
        "ci_lower": 0.5,
        "ci_upper": 8.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG005",
        "arm_title": "Ependymoma",
        "value": 2.5,
        "unit": "Months",
        "ci_lower": 1.2,
        "ci_upper": 7.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG006",
        "arm_title": "Other Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma",
        "value": 3.8,
        "unit": "Months",
        "ci_lower": 3.2,
        "ci_upper": 5.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Lenvatinib"
      ],
      "OG001": [
        "Lenvatinib"
      ],
      "OG002": [
        "Lenvatinib"
      ],
      "OG003": [
        "Lenvatinib"
      ],
      "OG004": [
        "Lenvatinib"
      ],
      "OG005": [
        "Lenvatinib"
      ],
      "OG006": [
        "Lenvatinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI",
      "OG002": "TKI",
      "OG003": "TKI",
      "OG004": "TKI",
      "OG005": "TKI",
      "OG006": "TKI"
    }
  },
  {
    "nct_id": "NCT04456699",
    "brief_title": "Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)",
    "status": "COMPLETED",
    "start_date": "2020-08-19",
    "completion_date": "2023-03-27",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT04456699",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IV",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "MAINTENANCE",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Olaparib + Bevacizumab",
        "value": 3.7,
        "unit": "Months",
        "ci_lower": 3.4,
        "ci_upper": 5.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Olaparib",
        "value": 3.6,
        "unit": "Months",
        "ci_lower": 2.0,
        "ci_upper": 3.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Bevacizumab + Chemotherapy",
        "value": 5.5,
        "unit": "Months",
        "ci_lower": 3.8,
        "ci_upper": 5.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Olaparib + Bevacizumab",
        "value": 21.2,
        "unit": "Months",
        "ci_lower": 15.1,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Olaparib",
        "value": 21.6,
        "unit": "Months",
        "ci_lower": 17.2,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Bevacizumab + Chemotherapy",
        "value": 19.9,
        "unit": "Months",
        "ci_lower": 13.8,
        "ci_upper": 22.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Olaparib",
        "Bevacizumab"
      ],
      "OG001": [
        "Olaparib"
      ],
      "OG002": [
        "Bevacizumab",
        "Capecitabine",
        "5-FU",
        "Leucovorin/ levoleucovorin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT04439188",
    "brief_title": "Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2016-03-21",
    "completion_date": "2020-11-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT04439188",
    "cancer_types": [
      "DLBC",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "PTEN",
        "status": "NEGATIVE",
        "details": "Complete loss of cytoplasmic and nuclear PTEN staining by MATCH PTEN IHC assay at MD Anderson required (PTEN loss by IHC). PTEN mutation/deletion status may be any."
      },
      {
        "target": "PIK3CA",
        "status": "NEGATIVE",
        "details": "Must NOT have co-existing activating aberration (listed as examples of excluded co-alterations activating PI3K/MTOR or MAPK pathways)."
      },
      {
        "target": "PIK3R1",
        "status": "NEGATIVE",
        "details": "Must NOT have co-existing activating aberration (listed as examples of excluded co-alterations activating PI3K/MTOR or MAPK pathways)."
      },
      {
        "target": "BRAF",
        "status": "NEGATIVE",
        "details": "Must NOT have co-existing activating aberration (listed as examples of excluded co-alterations activating PI3K/MTOR or MAPK pathways)."
      },
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "Must NOT have co-existing activating aberration (listed as examples of excluded co-alterations activating PI3K/MTOR or MAPK pathways)."
      },
      {
        "target": "AKT1",
        "status": "NEGATIVE",
        "details": "Must NOT have co-existing activating aberration (listed as examples of excluded co-alterations activating PI3K/MTOR or MAPK pathways)."
      },
      {
        "target": "TSC1",
        "status": "NEGATIVE",
        "details": "Must NOT have co-existing activating aberration (listed as examples of excluded co-alterations activating PI3K/MTOR or MAPK pathways)."
      },
      {
        "target": "TSC2",
        "status": "NEGATIVE",
        "details": "Must NOT have co-existing activating aberration (listed as examples of excluded co-alterations activating PI3K/MTOR or MAPK pathways)."
      },
      {
        "target": "MTOR",
        "status": "NEGATIVE",
        "details": "Must NOT have co-existing activating aberration (listed as examples of excluded co-alterations activating PI3K/MTOR or MAPK pathways)."
      },
      {
        "target": "NF2",
        "status": "NEGATIVE",
        "details": "Must NOT have co-existing activating aberration (listed as examples of excluded co-alterations activating PI3K/MTOR or MAPK pathways)."
      },
      {
        "target": "NRAS",
        "status": "NEGATIVE",
        "details": "Must NOT have co-existing activating aberration (listed as examples of excluded co-alterations activating PI3K/MTOR or MAPK pathways)."
      },
      {
        "target": "HRAS",
        "status": "NEGATIVE",
        "details": "Must NOT have co-existing activating aberration (listed as examples of excluded co-alterations activating PI3K/MTOR or MAPK pathways)."
      },
      {
        "target": "NF1",
        "status": "NEGATIVE",
        "details": "Must NOT have co-existing activating aberration (listed as examples of excluded co-alterations activating PI3K/MTOR or MAPK pathways)."
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (GSK2636771)",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment (GSK2636771)",
        "value": 3.3,
        "unit": "percentage of participants",
        "ci_lower": 0.4,
        "ci_upper": 12.1,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "PI3K-beta Inhibitor GSK2636771"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01204710",
    "brief_title": "A Study of Olaratumab (IMC-3G3) in Prostate Cancer",
    "status": "COMPLETED",
    "start_date": "2010-10",
    "completion_date": "2012-09",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT01204710",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [
      {
        "target": "PSA",
        "status": "HIGH",
        "details": "\u226510 ng/mL"
      },
      {
        "target": "TESTOSTERONE",
        "status": "LOW",
        "details": "<50 nanograms per milliliter (ng/mL) (castrate level)"
      },
      {
        "target": "PROTEINURIA",
        "status": "LOW",
        "details": "\u22641 on dipstick or routine urinalysis"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "IV"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Olaratumab + Mitoxantrone",
        "value": 2.3,
        "unit": "months",
        "ci_lower": 2.2,
        "ci_upper": 2.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Mitoxantrone",
        "value": 2.4,
        "unit": "months",
        "ci_lower": 2.2,
        "ci_upper": 3.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Olaratumab + Mitoxantrone",
        "value": 14.2,
        "unit": "months",
        "ci_lower": 12.2,
        "ci_upper": 16.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Mitoxantrone",
        "value": 12.8,
        "unit": "months",
        "ci_lower": 8.1,
        "ci_upper": 16.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Olaratumab",
        "Mitoxantrone",
        "Prednisone"
      ],
      "OG001": [
        "Mitoxantrone",
        "Prednisone"
      ],
      "OG002": [
        "Mitoxantrone",
        "Prednisone"
      ],
      "OG003": [
        "Mitoxantrone",
        "Prednisone"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo",
      "OG002": "Chemo",
      "OG003": "Chemo"
    }
  },
  {
    "nct_id": "NCT01231659",
    "brief_title": "Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2011-08-09",
    "completion_date": "2012-11-20",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT01231659",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "estrogen receptor positive"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Everolimus + Letrozole",
        "value": 37.2,
        "unit": "Percentage of Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Everolimus + Letrozole",
        "value": 9.0,
        "unit": "Months",
        "ci_lower": 0.2,
        "ci_upper": 59.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Everolimus + Letrozole",
        "value": 22.3,
        "unit": "Months",
        "ci_lower": 0.2,
        "ci_upper": 65.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Everolimus",
        "Letrozole"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT04488822",
    "brief_title": "A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2020-09-25",
    "completion_date": "2021-10-27",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Daiichi Sankyo Co., Ltd.",
    "url": "https://clinicaltrials.gov/study/NCT04488822",
    "cancer_types": [
      "TGCT"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "UNRESECTABLE",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Pexidartinib",
        "value": 9.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pexidartinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT01226719",
    "brief_title": "FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only",
    "status": "COMPLETED",
    "start_date": "2010-12",
    "completion_date": "2014-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SCRI Development Innovations, LLC",
    "url": "https://clinicaltrials.gov/study/NCT01226719",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "wild-type KRAS required (i.e., no KRAS mutation) prior to study entry"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "FOLFOXIRI+Panitumumab Regimen",
        "value": 75.0,
        "unit": "percentage of evaluable participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "FOLFOXIRI+Panitumumab Regimen",
        "value": 13.3,
        "unit": "months",
        "ci_lower": 4.2,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "FOLFOXIRI+Panitumumab Regimen",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Panitumumab",
        "Oxaliplatin",
        "Irinotecan",
        "Leucovorin",
        "5-Fluorouracil"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT01227928",
    "brief_title": "Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women",
    "status": "COMPLETED",
    "start_date": "2010-09",
    "completion_date": "2012-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "GlaxoSmithKline",
    "url": "https://clinicaltrials.gov/study/NCT01227928",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "II",
      "III",
      "IV"
    ],
    "line_of_therapy": "MAINTENANCE",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Placebo",
        "value": 18.1,
        "unit": "months",
        "ci_lower": 12.1,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Pazopanib 800 Milligrams",
        "value": 18.1,
        "unit": "months",
        "ci_lower": 18.0,
        "ci_upper": 18.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG001": [
        "Pazopanib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Placebo",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT01227889",
    "brief_title": "A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma",
    "status": "COMPLETED",
    "start_date": "2010-12-23",
    "completion_date": "2011-12-19",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "GlaxoSmithKline",
    "url": "https://clinicaltrials.gov/study/NCT01227889",
    "cancer_types": [
      "SKCM"
    ],
    "biomarkers": [
      {
        "target": "BRAF",
        "status": "POSITIVE",
        "details": "V600E mutation"
      }
    ],
    "cancer_stages": [
      "III",
      "IV",
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "GSK2118436 150 mg BID",
        "value": 6.9,
        "unit": "Months",
        "ci_lower": 5.5,
        "ci_upper": 9.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "DTIC 1000 mg/m^2 in RP",
        "value": 2.7,
        "unit": "Months",
        "ci_lower": 1.4,
        "ci_upper": 3.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "GSK2118436"
      ],
      "OG001": [
        "Dacarbazine (DTIC)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT04555837",
    "brief_title": "Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer",
    "status": "COMPLETED",
    "start_date": "2020-09-15",
    "completion_date": "2025-04-08",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "M.D. Anderson Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT04555837",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [
      {
        "target": "HPV",
        "status": "POSITIVE",
        "details": "HPV positive by p16 IHC, HPV RNA ISH, RNAscope (mRNA ISH), DNA ISH, DNA PCR, or qRT PCR"
      },
      {
        "target": "RB1",
        "status": "NEGATIVE",
        "details": "No Rb protein expression in tumor by IHC (Rb-deficient)"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": true,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase II",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Alisertib"
      ],
      "OG001": [
        "Pembrolizumab",
        "Alisertib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT01222767",
    "brief_title": "Study of Zalypsis\u00ae (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy",
    "status": "COMPLETED",
    "start_date": "2010-12",
    "completion_date": "2012-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "PharmaMar",
    "url": "https://clinicaltrials.gov/study/NCT01222767",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "PM00104",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "PM00104",
        "value": 1.8,
        "unit": "months",
        "ci_lower": 0.9,
        "ci_upper": 3.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "PM00104",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Zalypsis"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo"
    }
  },
  {
    "nct_id": "NCT01228734",
    "brief_title": "A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients",
    "status": "COMPLETED",
    "start_date": "2010-09-09",
    "completion_date": "2016-01-25",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck KGaA, Darmstadt, Germany",
    "url": "https://clinicaltrials.gov/study/NCT01228734",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "RAS",
        "status": "NEGATIVE",
        "details": "RAS wild-type in tumor tissue (KRAS and NRAS)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cetuximab + FOLFOX-4",
        "value": 9.2,
        "unit": "months",
        "ci_lower": 8.8,
        "ci_upper": 10.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "FOLFOX-4",
        "value": 7.4,
        "unit": "months",
        "ci_lower": 5.8,
        "ci_upper": 7.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cetuximab + FOLFOX-4",
        "value": 20.8,
        "unit": "months",
        "ci_lower": 16.3,
        "ci_upper": 23.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "FOLFOX-4",
        "value": 16.5,
        "unit": "months",
        "ci_lower": 14.8,
        "ci_upper": 19.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cetuximab",
        "Oxaliplatin",
        "Folinic Acid",
        "5Fluorouracil"
      ],
      "OG001": [
        "Oxaliplatin",
        "Folinic Acid",
        "5Fluorouracil"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT04466891",
    "brief_title": "A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers",
    "status": "COMPLETED",
    "start_date": "2020-10-01",
    "completion_date": "2023-07-28",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Jazz Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT04466891",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER2 amplification by ISH assay (central laboratory) on new biopsy or archival tissue; FNAs and bone metastasis biopsies not acceptable"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort I",
        "value": 33.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Cohort II",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort I",
        "value": 5.49,
        "unit": "months",
        "ci_lower": 3.65,
        "ci_upper": 7.29,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort II",
        "value": 1.87,
        "unit": "months",
        "ci_lower": 1.22,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cohort I",
        "value": 15.54,
        "unit": "months",
        "ci_lower": 10.38,
        "ci_upper": 18.66,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cohort II",
        "value": 5.52,
        "unit": "months",
        "ci_lower": 1.22,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "ZW25 (Zanidatamab)"
      ],
      "OG001": [
        "ZW25 (Zanidatamab)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01208103",
    "brief_title": "Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma",
    "status": "COMPLETED",
    "start_date": "2011-05-06",
    "completion_date": "2018-03-07",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "M.D. Anderson Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT01208103",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "DPYD",
        "status": "NEGATIVE",
        "details": "dihydropyrimidine (DPD) deficiency"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab + Capecitabine + Oxaliplatin",
        "value": 68.0,
        "unit": "percentage of participants",
        "ci_lower": 52.0,
        "ci_upper": 88.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Bevacizumab",
        "Capecitabine",
        "Oxaliplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT04564027",
    "brief_title": "A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer",
    "status": "COMPLETED",
    "start_date": "2020-12-01",
    "completion_date": "2025-02-18",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT04564027",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "ATM",
        "status": "POSITIVE",
        "details": "Deleterious or suspected deleterious ATM mutation in tumour or blood (germline or ctDNA); confirmation by NGS; availability of tumour specimen for central testing of ATM protein loss by IHC"
      },
      {
        "target": "TESTOSTERONE",
        "status": "LOW",
        "details": "Serum testosterone \u2264 50 ng/dL (\u2264 1.75 nmol/L) within 28 days before enrolment (requirement for mCRPC)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort A (aST): 160 mg of Ceralasertib",
        "value": 7.14,
        "unit": "Percentage of participants",
        "ci_lower": 1.9,
        "ci_upper": 17.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort A (aST): 160 mg of Ceralasertib",
        "value": 3.7,
        "unit": "Months",
        "ci_lower": 1.9,
        "ci_upper": 5.6,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ceralasertib"
      ],
      "OG001": [
        "Ceralasertib"
      ],
      "OG002": [
        "Ceralasertib"
      ],
      "OG003": [
        "Ceralasertib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01222689",
    "brief_title": "Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer",
    "status": "COMPLETED",
    "start_date": "2010-11",
    "completion_date": "2013-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT01222689",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [
      {
        "target": "CA19-9",
        "status": "HIGH",
        "details": "> 2 x ULN (serum) as alternative to radiographic measurable disease"
      },
      {
        "target": "HCG",
        "status": "NEGATIVE",
        "details": "Negative serum or urine beta-human chorionic gonadotropin (HCG) required for women of childbearing potential"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Erlotinib Hydrochloride, Selumetinib)",
        "value": 7.3,
        "unit": "months",
        "ci_lower": 5.2,
        "ci_upper": 8.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "erlotinib hydrochloride",
        "selumetinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Targeted"
    }
  },
  {
    "nct_id": "NCT04513665",
    "brief_title": "ZW25 in Women With Endometrial Cancers",
    "status": "COMPLETED",
    "start_date": "2020-08-12",
    "completion_date": "2024-03-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Memorial Sloan Kettering Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT04513665",
    "cancer_types": [
      "UCEC"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER2 overexpressing defined as IHC 3+ OR IHC 2+ with gene amplification by FISH (HER2/CEP17 ratio \u2265 2) OR HER2 amplified (fold change \u2265 2) on MSK IMPACT"
      }
    ],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Stage 1",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Stage 2",
        "value": null,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "ZW25"
      ],
      "OG001": [
        "ZW25"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT04495621",
    "brief_title": "MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)",
    "status": "COMPLETED",
    "start_date": "2020-07-20",
    "completion_date": "2024-01-12",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Menarini Group",
    "url": "https://clinicaltrials.gov/study/NCT04495621",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "exons 2, 3 and 4 wild-type (N/K-RAS)"
      },
      {
        "target": "NRAS",
        "status": "NEGATIVE",
        "details": "exons 2, 3 and 4 wild-type (N/K-RAS)"
      },
      {
        "target": "BRAF",
        "status": "NEGATIVE",
        "details": "wild-type"
      },
      {
        "target": "PIK3CA",
        "status": "POSITIVE",
        "details": "mutated"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 1b (Dose Confirmation)",
        "value": 40.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Phase 2 (Cohort Expansion)",
        "value": 14.2,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase 1b (Dose Confirmation)",
        "value": 121.0,
        "unit": "days",
        "ci_lower": 75.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Phase 2 (Cohort Expansion)",
        "value": 162.0,
        "unit": "days",
        "ci_lower": 57.0,
        "ci_upper": 218.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Phase 1b (Dose Confirmation)",
        "value": 471.0,
        "unit": "days",
        "ci_lower": 171.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Phase 2 (Cohort Expansion)",
        "value": 308.0,
        "unit": "days",
        "ci_lower": 177.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "MEN1611",
        "Cetuximab"
      ],
      "OG001": [
        "MEN1611",
        "Cetuximab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT04491955",
    "brief_title": "Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers",
    "status": "COMPLETED",
    "start_date": "2020-09-22",
    "completion_date": "2022-10-25",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT04491955",
    "cancer_types": [
      "CRC",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "MSI",
        "status": "NEGATIVE",
        "details": "Microsatellite instability-high (MSI-H) / microsatellite unstable disease excluded; microsatellite stable (MSS) required."
      },
      {
        "target": "MMR",
        "status": "NEGATIVE",
        "details": "Mismatch repair deficiency (dMMR) excluded; MMR proficient required."
      },
      {
        "target": "HIV",
        "status": "LOW",
        "details": "If seropositive, viral load must be undetectable by quantitative PCR; HIV+ participants must be on stable ART \u22654 weeks and have no opportunistic infections or Castleman\u2019s disease within 12 months."
      },
      {
        "target": "HBV",
        "status": "LOW",
        "details": "If seropositive, viral load must be undetectable by quantitative PCR."
      },
      {
        "target": "HCV",
        "status": "LOW",
        "details": "If seropositive, viral load must be undetectable by quantitative PCR."
      },
      {
        "target": "CD4",
        "status": "HIGH",
        "details": "For HIV+ participants, CD4 count must be \u2265200 cells/mm3 at enrollment."
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241)",
        "value": 0.0,
        "unit": "Proportion of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241)",
        "value": 1.8,
        "unit": "Months",
        "ci_lower": 1.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort 2, Arm 2a Dose Level (DL) 1, Quad Therapy Dose Escalation",
        "value": 1.8,
        "unit": "Months",
        "ci_lower": 1.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Cohort 2, Arm 2a, Dose Level (DL) DL2, Quad Therapy Dose Escalation",
        "value": 1.8,
        "unit": "Months",
        "ci_lower": 1.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Cohort 2, Arm 2b Dose Level (DL)2, Quad Therapy Fixed Dose",
        "value": 0.92,
        "unit": "Months",
        "ci_lower": 0.92,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241)",
        "value": 19.0,
        "unit": "Months",
        "ci_lower": 12.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cohort 2, Arm 2a Dose Level (DL) 1, Quad Therapy Dose Escalation",
        "value": 19.0,
        "unit": "Months",
        "ci_lower": 15.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Cohort 2, Arm 2a, Dose Level (DL) DL2, Quad Therapy Dose Escalation",
        "value": 4.5,
        "unit": "Months",
        "ci_lower": 4.5,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Cohort 2, Arm 2b Dose Level (DL)2, Quad Therapy Fixed Dose",
        "value": 7.0,
        "unit": "Months",
        "ci_lower": 4.9,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "CV301",
        "MSB0011359C",
        "N-803"
      ],
      "OG001": [
        "CV301",
        "MSB0011359C",
        "N-803",
        "NHS-IL12"
      ],
      "OG002": [
        "CV301",
        "MSB0011359C",
        "N-803",
        "NHS-IL12"
      ],
      "OG003": [
        "CV301",
        "MSB0011359C",
        "N-803",
        "NHS-IL12"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO",
      "OG003": "IO"
    }
  },
  {
    "nct_id": "NCT01234337",
    "brief_title": "Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2011-02-21",
    "completion_date": "2014-05-12",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bayer",
    "url": "https://clinicaltrials.gov/study/NCT01234337",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-negative adenocarcinoma of the breast; HER2 status must be determined by an accredited laboratory"
      },
      {
        "target": "ER",
        "status": "ANY",
        "details": "Estrogen receptor (ER) status must be known; unknown hormone receptor status (estrogen and progesterone receptor) is excluded"
      },
      {
        "target": "PR",
        "status": "ANY",
        "details": "Progesterone receptor (PR) status must be known; unknown hormone receptor status (estrogen and progesterone receptor) is excluded"
      },
      {
        "target": "DPYD",
        "status": "NEGATIVE",
        "details": "History of DHPD (dihydropyrimidine dehydrogenase) reaction to fluoropyrimidine or known/suspected DPD deficiency is excluded"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "UNRESECTABLE",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Sorafenib (Nexavar, BAY43-9006) + Capecitabine",
        "value": 166.0,
        "unit": "days",
        "ci_lower": 131.0,
        "ci_upper": 206.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Capecitabine",
        "value": 165.0,
        "unit": "days",
        "ci_lower": 126.0,
        "ci_upper": 204.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Sorafenib (Nexavar, BAY43-9006) + Capecitabine",
        "value": 575.0,
        "unit": "days",
        "ci_lower": 467.0,
        "ci_upper": 645.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Capecitabine",
        "value": 616.0,
        "unit": "days",
        "ci_lower": 546.0,
        "ci_upper": 687.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Sorafenib (Nexavar, BAY43-9006)",
        "Capecitabine"
      ],
      "OG001": [
        "Capecitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01234402",
    "brief_title": "Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients",
    "status": "COMPLETED",
    "start_date": "2011-03",
    "completion_date": "2013-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT01234402",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "If HER2-positive, must have progressed on or following trastuzumab"
      },
      {
        "target": "HORMONE_RECEPTOR",
        "status": "POSITIVE",
        "details": "Hormone receptor\u2013positive (ER and/or PR) patients must have progressed on or following hormone therapy"
      },
      {
        "target": "DPYD",
        "status": "NEGATIVE",
        "details": "Known dihydropyrimidine dehydrogenase deficiency is exclusionary"
      },
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "Known HIV/AIDS infection is exclusionary"
      }
    ],
    "cancer_stages": [
      "III",
      "IV",
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ramucirumab + Capecitabine",
        "value": 22.1,
        "unit": "Weeks",
        "ci_lower": 12.1,
        "ci_upper": 36.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Icrucumab + Capecitabine",
        "value": 7.3,
        "unit": "Weeks",
        "ci_lower": 6.3,
        "ci_upper": 13.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Capecitabine",
        "value": 19.0,
        "unit": "Weeks",
        "ci_lower": 12.1,
        "ci_upper": 24.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Ramucirumab + Capecitabine",
        "value": 67.4,
        "unit": "Weeks",
        "ci_lower": 41.3,
        "ci_upper": 82.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Icrucumab + Capecitabine",
        "value": 62.1,
        "unit": "Weeks",
        "ci_lower": 41.0,
        "ci_upper": 84.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Capecitabine",
        "value": 71.6,
        "unit": "Weeks",
        "ci_lower": 57.4,
        "ci_upper": 89.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ramucirumab",
        "Capecitabine"
      ],
      "OG001": [
        "Icrucumab",
        "Capecitabine"
      ],
      "OG002": [
        "Capecitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Chemo"
    }
  },
  {
    "nct_id": "NCT04479241",
    "brief_title": "LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma",
    "status": "COMPLETED",
    "start_date": "2020-10-21",
    "completion_date": "2024-06-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Istari Oncology, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT04479241",
    "cancer_types": [
      "GBM"
    ],
    "biomarkers": [
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "Known immunosuppressive disease/human immunodeficiency virus infection excluded; must be HIV negative"
      },
      {
        "target": "HBV",
        "status": "NEGATIVE",
        "details": "Known active hepatitis B infection excluded based on positive viral DNA; must be HBV DNA negative"
      },
      {
        "target": "HCV",
        "status": "NEGATIVE",
        "details": "Known active hepatitis C infection excluded based on positive viral RNA; must be HCV RNA negative"
      },
      {
        "target": "PV",
        "status": "POSITIVE",
        "details": "Prior vaccination against poliovirus required or proof of anti-poliovirus immunity; booster with trivalent inactivated poliovirus vaccine (IPOL) 1\u20136 weeks prior to lerapolturev infusion"
      }
    ],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Lerapolturev + Pembrolizumab",
        "value": 0.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG000",
        "arm_title": "Lerapolturev + Pembrolizumab",
        "value": null,
        "unit": null,
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      }
    ],
    "arm_drugs": {
      "OG000": [
        "lerapolturev",
        "pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER"
    }
  },
  {
    "nct_id": "NCT04484142",
    "brief_title": "Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2021-03-30",
    "completion_date": "2023-03-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Daiichi Sankyo",
    "url": "https://clinicaltrials.gov/study/NCT04484142",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "activating EGFR mutation required (overexpression without activating mutation NOT sufficient); evaluate for T790M after progression if osimertinib not received/available"
      },
      {
        "target": "ALK",
        "status": "POSITIVE",
        "details": null
      },
      {
        "target": "ROS1",
        "status": "POSITIVE",
        "details": null
      },
      {
        "target": "NTRK",
        "status": "POSITIVE",
        "details": null
      },
      {
        "target": "BRAF",
        "status": "POSITIVE",
        "details": null
      },
      {
        "target": "MET",
        "status": "POSITIVE",
        "details": "exon 14 skipping"
      },
      {
        "target": "RET",
        "status": "POSITIVE",
        "details": null
      },
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "KRAS mutation alone (in absence of any of the specified actionable alterations) excludes enrollment"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IIIC",
      "IV",
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": true,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Dato DXd 6.0 mg/kg Q3W",
        "value": 35.8,
        "unit": "percentage of participants",
        "ci_lower": 27.8,
        "ci_upper": 44.4,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Datopotamab deruxtecan (DS-1062a)"
      ]
    },
    "treatment_class_map": {
      "OG000": "ADC"
    }
  },
  {
    "nct_id": "NCT04494425",
    "brief_title": "Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2020-07-24",
    "completion_date": "2024-03-18",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT04494425",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "LOW",
        "details": "HER2-low defined as IHC 2+/ISH- or IHC 1+ (ISH- or untested); central laboratory confirmation on a metastatic tissue sample required; must never have been HER2-positive; adequate tumor sample required for HER2 assessment"
      },
      {
        "target": "HR",
        "status": "POSITIVE",
        "details": "Documented hormone receptor (HR) positive disease in the metastatic setting (ER and/or PR positive)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "T-DXd",
        "value": 13.2,
        "unit": "Months",
        "ci_lower": 11.4,
        "ci_upper": 15.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy",
        "value": 8.1,
        "unit": "Months",
        "ci_lower": 7.0,
        "ci_upper": 9.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "T-DXd",
        "value": 28.9,
        "unit": "Months",
        "ci_lower": 25.7,
        "ci_upper": 33.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy",
        "value": 27.1,
        "unit": "Months",
        "ci_lower": 23.5,
        "ci_upper": 29.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "T-DXd",
        "value": 60.4,
        "unit": "Percent",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy",
        "value": 37.9,
        "unit": "Percent",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "T-DXd",
        "value": 60.4,
        "unit": "Percent",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy",
        "value": 40.4,
        "unit": "Percent",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG000",
        "arm_title": "T-DXd",
        "value": 13.6,
        "unit": "Months",
        "ci_lower": 6.2,
        "ci_upper": 24.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy",
        "value": 7.3,
        "unit": "Months",
        "ci_lower": 4.2,
        "ci_upper": 15.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG000",
        "arm_title": "T-DXd",
        "value": 12.0,
        "unit": "Months",
        "ci_lower": 6.6,
        "ci_upper": 20.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy",
        "value": 6.9,
        "unit": "Months",
        "ci_lower": 3.1,
        "ci_upper": 11.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Trastuzumab deruxtecan"
      ],
      "OG001": [
        "Capecitabine",
        "Paclitaxel",
        "Nab-Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "ADC",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01268150",
    "brief_title": "A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2011-02",
    "completion_date": "2012-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eisai Inc.",
    "url": "https://clinicaltrials.gov/study/NCT01268150",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-negative by FISH or 0 or 1+ by IHC staining"
      }
    ],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Eribulin Mesylate",
        "value": 28.6,
        "unit": "Percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Eribulin Mesylate",
        "value": 6.8,
        "unit": "Months",
        "ci_lower": 4.44,
        "ci_upper": 7.59,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Eribulin mesylate"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo"
    }
  },
  {
    "nct_id": "NCT00004259",
    "brief_title": "Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas",
    "status": "COMPLETED",
    "start_date": "2000-06",
    "completion_date": "2015-02-01",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Radiation Therapy Oncology Group",
    "url": "https://clinicaltrials.gov/study/NCT00004259",
    "cancer_types": [
      "LGG"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Radiation Therapy + Temozolomide (TMZ)",
        "value": 3.9,
        "unit": "years",
        "ci_lower": 3.0,
        "ci_upper": 7.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "RT + BCNU/CCNU",
        "value": 3.8,
        "unit": "years",
        "ci_lower": 2.2,
        "ci_upper": 7.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "TMZ 200mg/m2"
      ],
      "OG001": [
        "BCNU 80mg/m2",
        "CCNU"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT04622774",
    "brief_title": "First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2020-10-29",
    "completion_date": "2023-12-28",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "ImmunoGen, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT04622774",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Dose Expansion - NSCLC: IMGC936 6.0 mg/kg",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 0.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Dose Expansion - TNBC: IMGC936 6.0 mg/kg",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 0.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "IMGC936"
      ],
      "OG001": [
        "IMGC936"
      ],
      "OG002": [
        "IMGC936"
      ],
      "OG003": [
        "IMGC936"
      ],
      "OG004": [
        "IMGC936"
      ],
      "OG005": [
        "IMGC936"
      ],
      "OG006": [
        "IMGC936"
      ],
      "OG007": [
        "IMGC936"
      ],
      "OG008": [
        "IMGC936"
      ],
      "OG009": [
        "IMGC936"
      ]
    },
    "treatment_class_map": {
      "OG000": "ADC",
      "OG001": "ADC",
      "OG002": "ADC",
      "OG003": "ADC",
      "OG004": "ADC",
      "OG005": "ADC",
      "OG006": "ADC",
      "OG007": "ADC",
      "OG008": "ADC",
      "OG009": "ADC"
    }
  },
  {
    "nct_id": "NCT00028769",
    "brief_title": "S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer",
    "status": "COMPLETED",
    "start_date": "2001-12",
    "completion_date": "2010-06",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SWOG Cancer Research Network",
    "url": "https://clinicaltrials.gov/study/NCT00028769",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "CAD + Chemo",
        "value": 13.0,
        "unit": "months",
        "ci_lower": 10.0,
        "ci_upper": 16.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "CAD + Chemo",
        "value": 38.0,
        "unit": "months",
        "ci_lower": 28.0,
        "ci_upper": 49.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "goserelin",
        "leuprolide"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER"
    }
  },
  {
    "nct_id": "NCT01250379",
    "brief_title": "A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)",
    "status": "COMPLETED",
    "start_date": "2011-02",
    "completion_date": "2013-12",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT01250379",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-negative breast cancer"
      }
    ],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "CT Arm",
        "value": 88.7,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "CT+BV Arm",
        "value": 93.9,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "CT Arm",
        "value": 40.7,
        "unit": "percentage of participants",
        "ci_lower": 34.3,
        "ci_upper": 47.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "CT+BV Arm",
        "value": 54.2,
        "unit": "percentage of participants",
        "ci_lower": 47.7,
        "ci_upper": 60.3,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Chemotherapy"
      ],
      "OG001": [
        "Chemotherapy",
        "bevacizumab [Avastin]"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT04623775",
    "brief_title": "A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2021-02-17",
    "completion_date": "2024-01-11",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT04623775",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "mutations sensitive to available targeted therapy"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "rearrangements sensitive to available targeted therapy"
      },
      {
        "target": "ROS1",
        "status": "NEGATIVE",
        "details": "rearrangements/sensitive alterations to available targeted therapy"
      },
      {
        "target": "BRAF",
        "status": "NEGATIVE",
        "details": "V600E"
      }
    ],
    "cancer_stages": [
      "IVA",
      "IVB",
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Part 2: Treatment C",
        "value": 50.6,
        "unit": "Percentage of Participants",
        "ci_lower": 43.8,
        "ci_upper": 57.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Part 2: Treatment D",
        "value": 43.0,
        "unit": "Percentage of Participants",
        "ci_lower": 36.2,
        "ci_upper": 50.1,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab",
        "Relatlimab",
        "Carboplatin",
        "Cisplatin",
        "Paclitaxel",
        "Nab-Paclitaxel",
        "Pemetrexed"
      ],
      "OG001": [
        "Nivolumab",
        "Relatlimab",
        "Carboplatin",
        "Cisplatin",
        "Paclitaxel",
        "Nab-Paclitaxel",
        "Pemetrexed"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT00003869",
    "brief_title": "Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "1999-04",
    "completion_date": "2008-05",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT00003869",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "III",
      "IV"
    ],
    "line_of_therapy": "MAINTENANCE",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Carboxyamidotriazole",
        "value": 11.4,
        "unit": "Months",
        "ci_lower": 9.2,
        "ci_upper": 13.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 10.5,
        "unit": "Months",
        "ci_lower": 8.9,
        "ci_upper": 12.6,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "carboxyamidotriazole"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT04619004",
    "brief_title": "HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2021-02-02",
    "completion_date": "2022-11-21",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Daiichi Sankyo",
    "url": "https://clinicaltrials.gov/study/NCT04619004",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "EGFR-activating mutation: exon 19 deletion or L858R; detected from tumor tissue or blood (liquid biopsy)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": true,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Patritumab Deruxtecan 5.6 mg/kg",
        "value": 64.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Patritumab Deruxtecan Up-Titration",
        "value": 8.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Patritumab Deruxtecan 5.6 mg/kg",
        "value": 5.5,
        "unit": "months",
        "ci_lower": 5.1,
        "ci_upper": 5.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Patritumab Deruxtecan Up-Titration",
        "value": 6.7,
        "unit": "months",
        "ci_lower": 4.2,
        "ci_upper": 8.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Patritumab Deruxtecan 5.6 mg/kg",
        "value": 5.5,
        "unit": "months",
        "ci_lower": 4.2,
        "ci_upper": 5.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Patritumab Deruxtecan Up-Titration",
        "value": 5.3,
        "unit": "months",
        "ci_lower": 4.0,
        "ci_upper": 8.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Patritumab Deruxtecan (Fixed dose)"
      ],
      "OG001": [
        "Patritumab Deruxtecan (Up-Titration)"
      ]
    },
    "treatment_class_map": {
      "OG000": "ADC",
      "OG001": "ADC"
    }
  },
  {
    "nct_id": "NCT01235962",
    "brief_title": "A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)",
    "status": "COMPLETED",
    "start_date": "2010-11-30",
    "completion_date": "2015-10-15",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT01235962",
    "cancer_types": [
      "KIRC"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "ITT Pazopanib 600 mg",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "ITT Placebo 600 mg",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "pazopanib"
      ],
      "OG002": [
        "pazopanib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Placebo",
      "OG002": "TKI",
      "OG003": "Placebo"
    }
  },
  {
    "nct_id": "NCT04567615",
    "brief_title": "A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2021-02-04",
    "completion_date": "2023-08-31",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT04567615",
    "cancer_types": [
      "LIHC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": true,
    "prior_io": false,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment A",
        "value": 13.3,
        "unit": "Percentage",
        "ci_lower": 7.9,
        "ci_upper": 20.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Treatment B",
        "value": 10.5,
        "unit": "Percentage",
        "ci_lower": 5.6,
        "ci_upper": 17.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Treatment C",
        "value": 12.5,
        "unit": "Percentage",
        "ci_lower": 2.7,
        "ci_upper": 32.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment A",
        "value": 2.0,
        "unit": "Months",
        "ci_lower": 1.91,
        "ci_upper": 3.75,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Treatment B",
        "value": 2.0,
        "unit": "Months",
        "ci_lower": 1.87,
        "ci_upper": 3.71,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Treatment C",
        "value": 1.94,
        "unit": "Months",
        "ci_lower": 1.74,
        "ci_upper": 3.71,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Treatment A",
        "value": 12.68,
        "unit": "Months",
        "ci_lower": 9.4,
        "ci_upper": 18.76,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Treatment B",
        "value": 12.19,
        "unit": "Months",
        "ci_lower": 9.49,
        "ci_upper": 14.52,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Treatment C",
        "value": 8.21,
        "unit": "Months",
        "ci_lower": 4.76,
        "ci_upper": 16.92,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab"
      ],
      "OG001": [
        "Nivolumab",
        "Relatlimab"
      ],
      "OG002": [
        "Nivolumab",
        "Relatlimab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO"
    }
  },
  {
    "nct_id": "NCT01259089",
    "brief_title": "Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2011-04-27",
    "completion_date": "2013-06-04",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Northwestern University",
    "url": "https://clinicaltrials.gov/study/NCT01259089",
    "cancer_types": [
      "NSCLC",
      "LUAD"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "Either prior RECIST-defined response (CR or PR) to an EGFR-TKI (erlotinib or gefitinib) OR documented activating EGFR mutation: G719X, exon 19 deletion, L858R, L861Q; requires progression on erlotinib/gefitinib, \u22656 months prior TKI use and post-resistance biopsy."
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV"
    ],
    "line_of_therapy": null,
    "prior_tki": true,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Arm I",
        "value": 4.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm I",
        "value": 1.7,
        "unit": "Months",
        "ci_lower": 1.1,
        "ci_upper": 4.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm I",
        "value": 7.4,
        "unit": "Months",
        "ci_lower": 4.0,
        "ci_upper": 17.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Hsp90 inhibitor AUY922",
        "erlotinib hydrochloride"
      ],
      "OG001": [
        "Hsp90 inhibitor AUY922",
        "erlotinib hydrochloride"
      ],
      "OG002": [
        "Hsp90 inhibitor AUY922",
        "erlotinib hydrochloride"
      ],
      "OG003": [
        "Hsp90 inhibitor AUY922",
        "erlotinib hydrochloride"
      ],
      "OG004": [
        "Hsp90 inhibitor AUY922",
        "erlotinib hydrochloride"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Targeted",
      "OG001": "Combo_TKI_Targeted",
      "OG002": "Combo_TKI_Targeted",
      "OG003": "Combo_TKI_Targeted",
      "OG004": "Combo_TKI_Targeted"
    }
  },
  {
    "nct_id": "NCT04576455",
    "brief_title": "A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2020-11-27",
    "completion_date": "2022-02-18",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT04576455",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Documented ER-positive tumor assessed locally"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-negative tumor assessed locally"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Giredestrant",
        "value": 5.55,
        "unit": "months",
        "ci_lower": 4.93,
        "ci_upper": 7.36,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Physician's Choice of Endocrine Monotherapy",
        "value": 5.36,
        "unit": "months",
        "ci_lower": 3.71,
        "ci_upper": 5.55,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Giredestrant",
        "value": 27.5,
        "unit": "Months",
        "ci_lower": 23.2,
        "ci_upper": 32.69,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Physician's Choice of Endocrine Monotherapy",
        "value": 29.77,
        "unit": "Months",
        "ci_lower": 26.78,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Giredestrant",
        "LHRH Agonist"
      ],
      "OG001": [
        "Fulvestrant",
        "Aromatase inhibitor",
        "LHRH Agonist"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT04606771",
    "brief_title": "A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2020-09-28",
    "completion_date": "2022-12-21",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT04606771",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "EGFR mutation known to be associated with EGFR TKI sensitivity (e.g., exon 19 deletion and/or L858R) as permitted in the osimertinib label"
      },
      {
        "target": "MET",
        "status": "HIGH",
        "details": "MET amplification as determined by central MET FISH testing on tumor specimen collected after progression on prior osimertinib"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": true,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Savolitinib Plus Osimertinib",
        "value": 57.1,
        "unit": "Percentage of participants",
        "ci_lower": 28.86,
        "ci_upper": 82.34,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Savolitinib Plus Placebo",
        "value": 12.5,
        "unit": "Percentage of participants",
        "ci_lower": 1.55,
        "ci_upper": 38.35,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Savolitinib Plus Osimertinib",
        "value": 7.36,
        "unit": "Months",
        "ci_lower": 5.55,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Savolitinib Plus Placebo",
        "value": 1.64,
        "unit": "Months",
        "ci_lower": 1.28,
        "ci_upper": 4.07,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Savolitinib Plus Osimertinib",
        "value": null,
        "unit": "Months",
        "ci_lower": 9.56,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Savolitinib Plus Placebo",
        "value": 13.37,
        "unit": "Months",
        "ci_lower": 7.82,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Osimertinib",
        "Savolitinib"
      ],
      "OG001": [
        "Savolitinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT01253161",
    "brief_title": "Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)",
    "status": "COMPLETED",
    "start_date": "2011-02-01",
    "completion_date": "2021-10-06",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
    "url": "https://clinicaltrials.gov/study/NCT01253161",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pasireotide LAR Treatment",
        "value": 11.0,
        "unit": "months",
        "ci_lower": 7.6,
        "ci_upper": 16.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pasireotide Long Acting Release (LAR)"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER"
    }
  },
  {
    "nct_id": "NCT01251536",
    "brief_title": "Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2010-12",
    "completion_date": "2016-06",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Universitaire Ziekenhuizen KU Leuven",
    "url": "https://clinicaltrials.gov/study/NCT01251536",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "wild-type (no activating KRAS mutations)"
      },
      {
        "target": "DPYD",
        "status": "NEGATIVE",
        "details": "no dihydropyrimidine dehydrogenase (DPD) deficiency"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A - Dose Escalation of Cetuximab",
        "value": 45.0,
        "unit": "percent probability",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B - Standard Dose of Cetuximab",
        "value": 48.0,
        "unit": "percent probability",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Not Allocated",
        "value": 0.0,
        "unit": "percent probability",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "ITT / Safety Set",
        "value": 55.0,
        "unit": "percent probability",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A - Dose Escalation of Cetuximab",
        "value": 28.4,
        "unit": "months",
        "ci_lower": 12.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B - Standard Dose of Cetuximab",
        "value": 31.4,
        "unit": "months",
        "ci_lower": 25.5,
        "ci_upper": 34.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Not Allocated",
        "value": 4.9,
        "unit": "months",
        "ci_lower": 1.0,
        "ci_upper": 12.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "ITT / Safety Set",
        "value": 29.8,
        "unit": "months",
        "ci_lower": 22.4,
        "ci_upper": 33.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cetuximab",
        "FOLFIRI"
      ],
      "OG001": [
        "Cetuximab",
        "FOLFIRI"
      ],
      "OG002": [
        "Cetuximab",
        "FOLFIRI"
      ],
      "OG003": [
        "Cetuximab",
        "FOLFIRI"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted",
      "OG003": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT00022672",
    "brief_title": "A Study to Evaluate the Efficacy and Safety of Herceptin\u00ae (Trastuzumab) in Combination With Arimidex\u00ae (Anastrozole) an Aromatase Inhibitor Compared to Arimidex\u00ae Alone in Patients With Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2001-01",
    "completion_date": "2009-10",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT00022672",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Hormone receptor positive (ER and/or PR)"
      },
      {
        "target": "HER2",
        "status": "HIGH",
        "details": "HER2 overexpression"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Trastuzumab + Anastrozole",
        "value": 4.8,
        "unit": "Months",
        "ci_lower": 3.7,
        "ci_upper": 7.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Anastrozole",
        "value": 2.4,
        "unit": "Months",
        "ci_lower": 2.0,
        "ci_upper": 4.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Trastuzumab + Anastrozole",
        "value": 5.8,
        "unit": "Months",
        "ci_lower": 4.6,
        "ci_upper": 8.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Anastrozole",
        "value": 2.9,
        "unit": "Months",
        "ci_lower": 2.1,
        "ci_upper": 4.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "trastuzumab (Herceptin\u00174)",
        "anastrazole (Arimidex\u00174)"
      ],
      "OG001": [
        "anastrazole (Arimidex\u00174)"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT01246960",
    "brief_title": "A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer",
    "status": "COMPLETED",
    "start_date": "2011-04",
    "completion_date": "2013-09",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT01246960",
    "cancer_types": [
      "STAD",
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ramucirumab and mFOLFOX6",
        "value": 6.4,
        "unit": "months",
        "ci_lower": 5.8,
        "ci_upper": 9.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo and mFOLFOX6",
        "value": 6.7,
        "unit": "months",
        "ci_lower": 5.6,
        "ci_upper": 7.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Ramucirumab and mFOLFOX6",
        "value": 11.7,
        "unit": "months",
        "ci_lower": 10.2,
        "ci_upper": 14.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo and mFOLFOX6",
        "value": 11.5,
        "unit": "months",
        "ci_lower": 9.0,
        "ci_upper": 15.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ramucirumab",
        "Oxaliplatin",
        "Leucovorin",
        "5-Fluorouracil"
      ],
      "OG001": [
        "Oxaliplatin",
        "Leucovorin",
        "5-Fluorouracil"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00002663",
    "brief_title": "Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies",
    "status": "COMPLETED",
    "start_date": "1995-03",
    "completion_date": "2019-07",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Atara Biotherapeutics",
    "url": "https://clinicaltrials.gov/study/NCT00002663",
    "cancer_types": [
      "DLBC",
      "HNSC",
      "STAD"
    ],
    "biomarkers": [
      {
        "target": "EBV",
        "status": "POSITIVE",
        "details": "EBV antigen positive lymphoproliferative disease, lymphoma, or other EBV-associated malignancy"
      },
      {
        "target": "EBV",
        "status": "HIGH",
        "details": "blood EBV DNA exceeding 500 copies/ml"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "EBV+ PTLD-HCT R/R Rituximab (Tab-cel Only)",
        "value": 63.6,
        "unit": "Percentage of participants",
        "ci_lower": 30.8,
        "ci_upper": 89.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "EBV+ PTLD-SOT R/R Rituximab + Chemo (Tab-cel Only)",
        "value": 50.0,
        "unit": "Percentage of participants",
        "ci_lower": 6.8,
        "ci_upper": 93.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "EBV+ LMS (Tab-cel Only)",
        "value": 0.0,
        "unit": "Percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 52.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "EBV+ PTLD-HCT R/R Rituximab (EBV-CTLs Only)",
        "value": 43.5,
        "unit": "Percentage of participants",
        "ci_lower": 23.2,
        "ci_upper": 65.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "EBV+ Viremia (EBV-CTLs Only)",
        "value": 57.1,
        "unit": "Percentage of participants",
        "ci_lower": 18.4,
        "ci_upper": 90.1,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "tabelecleucel (tab-cel, ATA129)"
      ],
      "OG001": [
        "tabelecleucel (tab-cel, ATA129)"
      ],
      "OG002": [
        "tabelecleucel (tab-cel, ATA129)"
      ],
      "OG003": [
        "Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)"
      ],
      "OG004": [
        "Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER",
      "OG002": "OTHER",
      "OG003": "OTHER",
      "OG004": "OTHER"
    }
  },
  {
    "nct_id": "NCT00036270",
    "brief_title": "Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane",
    "status": "COMPLETED",
    "start_date": "2001-08",
    "completion_date": "2008-10",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT00036270",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "At least one hormone receptor (ER or PR) must be positive; patients with both ER and PR negative or with ER/PR unknown status are excluded."
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": "At least one hormone receptor (ER or PR) must be positive; patients with both ER and PR negative or with ER/PR unknown status are excluded."
      }
    ],
    "cancer_stages": [
      "I",
      "II",
      "III"
    ],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [],
    "arm_drugs": {
      "OG000": [
        "exemestane"
      ],
      "OG001": [
        "tamoxifen",
        "exemestane"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT04630756",
    "brief_title": "AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer",
    "status": "COMPLETED",
    "start_date": "2021-02-17",
    "completion_date": "2023-09-08",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT04630756",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Module 1 Part A: AZD4573 9 mg + 100g Acalabrutinib BID",
        "value": 2.1,
        "unit": "Months",
        "ci_lower": 0.3,
        "ci_upper": 6.44,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Module 1 Part B: AZD4573 12 mg + 100g Acalabrutinib BID",
        "value": 2.8,
        "unit": "Months",
        "ci_lower": 1.91,
        "ci_upper": 3.98,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Module 1 Part A: AZD4573 9 mg + 100g Acalabrutinib BID",
        "value": null,
        "unit": "Months",
        "ci_lower": 3.52,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Module 1 Part B: AZD4573 12 mg + 100g Acalabrutinib BID",
        "value": 8.8,
        "unit": "Months",
        "ci_lower": 3.91,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Module 1 Part A: AZD4573 9 mg + 100g Acalabrutinib BID",
        "value": 44.4,
        "unit": "Percentage of participants with response",
        "ci_lower": 13.7,
        "ci_upper": 78.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Module 1 Part B: AZD4573 12 mg + 100g Acalabrutinib BID",
        "value": 50.0,
        "unit": "Percentage of participants with response",
        "ci_lower": 30.6,
        "ci_upper": 69.4,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "AZD4573",
        "Acalabrutinib"
      ],
      "OG001": [
        "AZD4573",
        "Acalabrutinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Targeted",
      "OG001": "Combo_TKI_Targeted"
    }
  },
  {
    "nct_id": "NCT01285609",
    "brief_title": "Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin",
    "status": "COMPLETED",
    "start_date": "2011-01-16",
    "completion_date": "2015-06-09",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT01285609",
    "cancer_types": [
      "LUSC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IV",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Ipilimumab With Paclitaxel/Carboplatin",
        "value": 13.37,
        "unit": "months",
        "ci_lower": 11.76,
        "ci_upper": 14.78,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo With Paclitaxel/Carboplatin",
        "value": 12.42,
        "unit": "months",
        "ci_lower": 11.6,
        "ci_upper": 13.63,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ipilimumab",
        "Paclitaxel",
        "Carboplatin"
      ],
      "OG001": [
        "Paclitaxel",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00058123",
    "brief_title": "Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma",
    "status": "COMPLETED",
    "start_date": "2003-03-07",
    "completion_date": "2007-10-06",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
    "url": "https://clinicaltrials.gov/study/NCT00058123",
    "cancer_types": [
      "LGG"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Poly-ICLC Recurrent Gliomas",
        "value": 5.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Poly-ICLC Recurrent Gliomas",
        "value": 24.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "poly ICLC"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER"
    }
  },
  {
    "nct_id": "NCT04676412",
    "brief_title": "Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-na\u00efve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study",
    "status": "COMPLETED",
    "start_date": "2019-10-23",
    "completion_date": "2021-05-19",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT04676412",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "POSITIVE",
        "details": "Tumor Proportion Score (TPS) \u22651% by 22C3 pharmDx IHC at a central laboratory"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + Lenvatinib",
        "value": 6.1,
        "unit": "Months",
        "ci_lower": 4.2,
        "ci_upper": 8.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Pembrolizumab + Placebo",
        "value": 10.3,
        "unit": "Months",
        "ci_lower": 5.6,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + Lenvatinib",
        "value": 11.4,
        "unit": "Months",
        "ci_lower": 8.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Pembrolizumab + Placebo",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Lenvatinib"
      ],
      "OG001": [
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_IO",
      "OG001": "IO"
    }
  },
  {
    "nct_id": "NCT00080301",
    "brief_title": "Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2003-09",
    "completion_date": "2006-11",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "R-Pharm",
    "url": "https://clinicaltrials.gov/study/NCT00080301",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ixabepilone + Capecitabine",
        "value": 5.85,
        "unit": "Months",
        "ci_lower": 5.45,
        "ci_upper": 6.97,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Capecitabine",
        "value": 4.17,
        "unit": "Months",
        "ci_lower": 3.81,
        "ci_upper": 4.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Ixabepilone + Capecitabine",
        "value": 12.9,
        "unit": "Months",
        "ci_lower": 11.5,
        "ci_upper": 14.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Capecitabine",
        "value": 11.1,
        "unit": "Months",
        "ci_lower": 10.0,
        "ci_upper": 12.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ixabepilone",
        "Capecitabine"
      ],
      "OG001": [
        "Capecitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT04677504",
    "brief_title": "A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer",
    "status": "COMPLETED",
    "start_date": "2021-02-23",
    "completion_date": "2022-05-16",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT04677504",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm B: Atezo+PBO+CisGem (Cycle*1-8), Followed by Atezo+PBO (Cycle*9 and Beyond)",
        "value": 7.92,
        "unit": "Months",
        "ci_lower": 6.18,
        "ci_upper": 8.41,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm A: Atezo+Bev+CisGem (Cycle*1-8), Followed by Atezo+Bev (Cycle*9 and Beyond)",
        "value": 8.35,
        "unit": "Months",
        "ci_lower": 6.83,
        "ci_upper": 9.96,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm B: Atezo+PBO+CisGem (Cycle*1-8), Followed by Atezo+PBO (Cycle*9 and Beyond)",
        "value": 14.59,
        "unit": "Months",
        "ci_lower": 11.17,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm A: Atezo+Bev+CisGem (Cycle*1-8), Followed by Atezo+Bev (Cycle*9 and Beyond)",
        "value": 14.85,
        "unit": "Months",
        "ci_lower": 11.63,
        "ci_upper": 17.97,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Atezolizumab",
        "Cisplatin",
        "Gemcitabine"
      ],
      "OG001": [
        "Atezolizumab",
        "Bevacizumab",
        "Cisplatin",
        "Gemcitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT04646005",
    "brief_title": "Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy",
    "status": "COMPLETED",
    "start_date": "2021-06-28",
    "completion_date": "2023-05-22",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Regeneron Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT04646005",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "HPV16",
        "status": "POSITIVE",
        "details": "HPV16 genotype positivity by PCR as determined by a specified central reference laboratory"
      }
    ],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "ISA 101b + Cemiplimab 350 mg Q3W",
        "value": 17.7,
        "unit": "Percentage of Participants",
        "ci_lower": 10.7,
        "ci_upper": 24.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "ISA 101b + Cemiplimab 350 mg Q3W",
        "value": 3.0,
        "unit": "Months",
        "ci_lower": 1.7,
        "ci_upper": 4.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "ISA 101b + Cemiplimab 350 mg Q3W",
        "value": 14.3,
        "unit": "Months",
        "ci_lower": 11.7,
        "ci_upper": 17.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "ISA101b",
        "Cemiplimab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO"
    }
  },
  {
    "nct_id": "NCT00053352",
    "brief_title": "Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors",
    "status": "COMPLETED",
    "start_date": "2003-11-03",
    "completion_date": "2013-10-01",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Children's Oncology Group",
    "url": "https://clinicaltrials.gov/study/NCT00053352",
    "cancer_types": [
      "TGCT"
    ],
    "biomarkers": [
      {
        "target": "AFP",
        "status": "ANY",
        "details": "Alpha-fetoprotein (AFP) tumor marker known"
      },
      {
        "target": "HCG",
        "status": "ANY",
        "details": "Beta human chorionic gonadotropin tumor marker (beta-hCG) known"
      }
    ],
    "cancer_stages": [
      "I",
      "II",
      "III",
      "IV",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm I",
        "value": 97.0,
        "unit": "Percent Probability",
        "ci_lower": 93.0,
        "ci_upper": 99.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm 2",
        "value": 99.0,
        "unit": "Percent Probability",
        "ci_lower": 92.8,
        "ci_upper": 99.9,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {},
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT01288911",
    "brief_title": "A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer",
    "status": "COMPLETED",
    "start_date": "2011-03-22",
    "completion_date": "2014-10-19",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Astellas Pharma Inc",
    "url": "https://clinicaltrials.gov/study/NCT01288911",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [
      {
        "target": "PSA",
        "status": "HIGH",
        "details": "PSA progression: minimum of three rising PSA values \u22651 week apart; PSA value should be \u22652 \u00b5g/L (2 ng/mL)"
      },
      {
        "target": "TESTOSTERONE",
        "status": "LOW",
        "details": "Castrate levels of testosterone required (ongoing androgen deprivation therapy with LHRH agonist/antagonist at stable dose/schedule or bilateral orchiectomy)"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Enzalutamide",
        "value": 15.7,
        "unit": "months",
        "ci_lower": 11.5,
        "ci_upper": 19.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Bicalutamide",
        "value": 5.8,
        "unit": "months",
        "ci_lower": 4.8,
        "ci_upper": 8.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "enzalutamide"
      ],
      "OG001": [
        "bicalutamide"
      ],
      "OG002": [
        "enzalutamide",
        "bicalutamide"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER",
      "OG002": "OTHER"
    }
  },
  {
    "nct_id": "NCT00049127",
    "brief_title": "Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor",
    "status": "COMPLETED",
    "start_date": "2003-06",
    "completion_date": "2011-08",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Alliance for Clinical Trials in Oncology",
    "url": "https://clinicaltrials.gov/study/NCT00049127",
    "cancer_types": [
      "LGG"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Study 1 Arm C",
        "value": 33.35,
        "unit": "percentage of patients",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Study 2 Arm A",
        "value": null,
        "unit": "percentage of patients",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Study 2 Arm B",
        "value": 33.3,
        "unit": "percentage of patients",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Study 3 Arm D",
        "value": null,
        "unit": "percentage of patients",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Study 3 Arm E",
        "value": 25.0,
        "unit": "percentage of patients",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Imatinib Mesylate"
      ],
      "OG001": [
        "Imatinib Mesylate"
      ],
      "OG002": [
        "Imatinib Mesylate"
      ],
      "OG003": [
        "Imatinib Mesylate"
      ],
      "OG004": [
        "Imatinib Mesylate"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI",
      "OG002": "TKI",
      "OG003": "TKI",
      "OG004": "TKI"
    }
  },
  {
    "nct_id": "NCT00064077",
    "brief_title": "Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix",
    "status": "COMPLETED",
    "start_date": "2003-05",
    "completion_date": "2011-01",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Gynecologic Oncology Group",
    "url": "https://clinicaltrials.gov/study/NCT00064077",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IVB",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm I (Paclitaxel, Cisplatin)",
        "value": 12.87,
        "unit": "months",
        "ci_lower": 10.02,
        "ci_upper": 16.76,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm II (Vinorelbine, Cisplatin)",
        "value": 9.99,
        "unit": "months",
        "ci_lower": 8.25,
        "ci_upper": 12.25,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Arm III (Gemcitabine, Cisplatin)",
        "value": 10.28,
        "unit": "months",
        "ci_lower": 7.62,
        "ci_upper": 11.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Arm IV (Topotecan, Cisplatin)",
        "value": 10.25,
        "unit": "months",
        "ci_lower": 8.61,
        "ci_upper": 11.66,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm I (Paclitaxel, Cisplatin)",
        "value": 5.82,
        "unit": "months",
        "ci_lower": 4.53,
        "ci_upper": 7.59,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm II (Vinorelbine, Cisplatin)",
        "value": 3.98,
        "unit": "months",
        "ci_lower": 3.19,
        "ci_upper": 5.16,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Arm III (Gemcitabine, Cisplatin)",
        "value": 4.7,
        "unit": "months",
        "ci_lower": 3.58,
        "ci_upper": 5.59,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Arm IV (Topotecan, Cisplatin)",
        "value": 4.57,
        "unit": "months",
        "ci_lower": 3.71,
        "ci_upper": 5.75,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Paclitaxel",
        "Cisplatin"
      ],
      "OG001": [
        "Vinorelbine Tartrate",
        "Cisplatin"
      ],
      "OG002": [
        "Gemcitabine Hydrochloride",
        "Cisplatin"
      ],
      "OG003": [
        "Topotecan Hydrochloride",
        "Cisplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo",
      "OG002": "Chemo",
      "OG003": "Chemo"
    }
  },
  {
    "nct_id": "NCT01287754",
    "brief_title": "A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations",
    "status": "COMPLETED",
    "start_date": "2011-10",
    "completion_date": "2013-11",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT01287754",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "EGFR mutations"
      }
    ],
    "cancer_stages": [
      "III",
      "IV",
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Erlotinib",
        "value": 13.7,
        "unit": "months",
        "ci_lower": 2.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Erlotinib",
        "value": 17.8,
        "unit": "months",
        "ci_lower": 17.6,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Untreated",
        "value": 11.3,
        "unit": "months",
        "ci_lower": 8.4,
        "ci_upper": 11.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "erlotinib [Tarceva]"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT04633122",
    "brief_title": "A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib",
    "status": "COMPLETED",
    "start_date": "2020-11-25",
    "completion_date": "2022-07-20",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Zai Lab (Shanghai) Co., Ltd.",
    "url": "https://clinicaltrials.gov/study/NCT04633122",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "KIT",
        "status": "ANY",
        "details": "Provide molecular test report with KIT mutation status prior to randomization"
      },
      {
        "target": "PDGFRA",
        "status": "ANY",
        "details": "Provide molecular test report with PDGFRA mutation status prior to randomization"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": true,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ripretinib",
        "value": 10.3,
        "unit": "Months",
        "ci_lower": 5.5,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Sunitinib",
        "value": 8.3,
        "unit": "Months",
        "ci_lower": 4.9,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ripretinib"
      ],
      "OG001": [
        "Sunitinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT00038467",
    "brief_title": "Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",
    "status": "COMPLETED",
    "start_date": "1998-02",
    "completion_date": "2003-06",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT00038467",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "ER-positive primary tumor (estrogen receptor positive)"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [],
    "arm_drugs": {
      "OG000": [
        "Exemestane"
      ],
      "OG001": [
        "Tamoxifen"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT04639219",
    "brief_title": "A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2020-12-30",
    "completion_date": "2023-01-25",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT04639219",
    "cancer_types": [
      "BRCA",
      "STAD",
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "Pre-specified activating HER2 mutations: S310F, S310Y, G660D, R678Q, D769Y, D769H, V777L, Y772_A775dup / A775_G776insYVMA, L755S, G778_P780dup / P780_Y781insGSP, T862A, V842I; locally determined by NGS or validated nucleic acid-based methods (eg, qPCR, digital PCR); FFPE tumor sample required"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 overexpressing (IHC3+ or IHC2+/ISH+) breast, gastric or gastroesophageal junction adenocarcinoma are excluded"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 mutant NSCLC is excluded"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "T-DXd",
        "value": 29.4,
        "unit": "percentage of participants",
        "ci_lower": 20.8,
        "ci_upper": 39.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "T-DXd",
        "value": 5.4,
        "unit": "months",
        "ci_lower": 2.7,
        "ci_upper": 7.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "T-DXd",
        "value": 4.4,
        "unit": "months",
        "ci_lower": 2.8,
        "ci_upper": 5.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "T-DXd",
        "value": 10.9,
        "unit": "months",
        "ci_lower": 8.3,
        "ci_upper": 14.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Trastuzumab deruxtecan"
      ]
    },
    "treatment_class_map": {
      "OG000": "ADC"
    }
  },
  {
    "nct_id": "NCT04632992",
    "brief_title": "A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response",
    "status": "COMPLETED",
    "start_date": "2021-01-13",
    "completion_date": "2023-12-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Genentech, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT04632992",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "BIOMARKER",
        "status": "POSITIVE",
        "details": "Positive biomarker result required from a CLIA-certified (or equivalent) diagnostic laboratory \u2014 genomic alteration or protein expression from tissue or blood; specific biomarker depends on treatment arm"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm B: Inavolisib (GDC-0077)",
        "value": 4.24,
        "unit": "months",
        "ci_lower": 1.84,
        "ci_upper": 8.08,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm C: Alectinib",
        "value": 4.98,
        "unit": "months",
        "ci_lower": 1.54,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Arm D: Ipatasertib",
        "value": 3.48,
        "unit": "months",
        "ci_lower": 1.87,
        "ci_upper": 6.47,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Arm E: Atezolizumab + Chemotherapy",
        "value": 3.94,
        "unit": "months",
        "ci_lower": 2.17,
        "ci_upper": 8.38,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Arm F: Trastuzumab Emtansine + Atezolizumab",
        "value": 4.73,
        "unit": "months",
        "ci_lower": 2.07,
        "ci_upper": 10.22,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG005",
        "arm_title": "Arm G: PH FDC SC",
        "value": 2.46,
        "unit": "months",
        "ci_lower": 1.77,
        "ci_upper": 5.16,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG006",
        "arm_title": "Arm H: PH FDC SC + Chemotherapy",
        "value": 3.02,
        "unit": "months",
        "ci_lower": 1.54,
        "ci_upper": 5.52,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG007",
        "arm_title": "Arm I: Trastuzumab Emtansine + Tucatinib",
        "value": 2.69,
        "unit": "months",
        "ci_lower": 1.94,
        "ci_upper": 6.18,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG008",
        "arm_title": "Arm J: Trastuzumab Emtansine + Atezolizumab",
        "value": 1.87,
        "unit": "months",
        "ci_lower": 1.71,
        "ci_upper": 2.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG009",
        "arm_title": "Arm K: Ipatasertib + Atezolizumab",
        "value": 2.1,
        "unit": "months",
        "ci_lower": 1.64,
        "ci_upper": 3.48,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG010",
        "arm_title": "Arm L: Ipatasertib + Atezolizumab",
        "value": 3.61,
        "unit": "months",
        "ci_lower": 2.33,
        "ci_upper": 6.34,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG011",
        "arm_title": "Arm M: Ipatasertib + Paclitaxel",
        "value": 5.98,
        "unit": "months",
        "ci_lower": 1.28,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG012",
        "arm_title": "Arm N: Atezolizumab + Tiragolumab",
        "value": 4.76,
        "unit": "months",
        "ci_lower": 1.87,
        "ci_upper": 16.43,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG013",
        "arm_title": "Arm O: Pralsetinib",
        "value": 7.1,
        "unit": "months",
        "ci_lower": 1.84,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Inavolisib"
      ],
      "OG001": [
        "Alectinib"
      ],
      "OG002": [
        "Ipatasertib"
      ],
      "OG003": [
        "Atezolizumab",
        "Investigator's Choice of Chemotherapy"
      ],
      "OG004": [
        "Trastuzumab Emtansine",
        "Atezolizumab"
      ],
      "OG005": [
        "Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf"
      ],
      "OG006": [
        "Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf",
        "Investigator's Choice of Chemotherapy"
      ],
      "OG007": [
        "Trastuzumab Emtansine",
        "Tucatinib"
      ],
      "OG008": [
        "Trastuzumab Emtansine",
        "Atezolizumab"
      ],
      "OG009": [
        "Ipatasertib",
        "Atezolizumab"
      ],
      "OG010": [
        "Ipatasertib",
        "Atezolizumab"
      ],
      "OG011": [
        "Ipatasertib",
        "Paclitaxel"
      ],
      "OG012": [
        "Atezolizumab",
        "Tiragolumab"
      ],
      "OG013": [
        "Pralsetinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "TKI",
      "OG002": "Targeted_Other",
      "OG003": "Combo_Chemo_IO",
      "OG004": "Combo_IO_Targeted",
      "OG005": "Targeted_Other",
      "OG006": "Combo_Chemo_Targeted",
      "OG007": "Combo_TKI_Targeted",
      "OG008": "Combo_IO_Targeted",
      "OG009": "Combo_IO_Targeted",
      "OG010": "Combo_IO_Targeted",
      "OG011": "Combo_Chemo_Targeted",
      "OG012": "IO",
      "OG013": "TKI"
    }
  },
  {
    "nct_id": "NCT01275222",
    "brief_title": "Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors",
    "status": "COMPLETED",
    "start_date": "2002-11-13",
    "completion_date": "2008-09-03",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT01275222",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": true,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase l: RAD001 20mg/Week",
        "value": 0.0,
        "unit": "Percentage of Participants",
        "ci_lower": 0.0,
        "ci_upper": 0.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Phase l: RAD001 2.5mg/Day + Glivec 600mg/Day",
        "value": 1.0,
        "unit": "Percentage of Participants",
        "ci_lower": 0.2,
        "ci_upper": 36.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Phase l: RAD001 5mg/Day + Glivec 600mg/Day",
        "value": 0.0,
        "unit": "Percentage of Participants",
        "ci_lower": 0.0,
        "ci_upper": 0.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Phase l: RAD001 2.5mg/Day + Glivec 800mg/Day",
        "value": 0.0,
        "unit": "Percentage of Participants",
        "ci_lower": 0.0,
        "ci_upper": 0.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Phase ll - Stratum l (First-line Resistant/Refractory): RAD001 2.5mg/Day + Glivec 600mg/Day",
        "value": 0.0,
        "unit": "Percentage of Participants",
        "ci_lower": 0.0,
        "ci_upper": 0.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "Phase ll: Stratum ll (Post Second-line Therapy)",
        "value": 1.0,
        "unit": "Percentage of Participants",
        "ci_lower": 0.1,
        "ci_upper": 11.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Phase l: RAD001 20mg/Week",
        "value": 9.4,
        "unit": "months",
        "ci_lower": 5.6,
        "ci_upper": 13.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Phase l: RAD001 5mg/Day + Glivec 600mg/Day",
        "value": 10.9,
        "unit": "months",
        "ci_lower": 3.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Phase l: RAD001 2.5mg/Day + Glivec 600mg/Day",
        "value": 18.7,
        "unit": "months",
        "ci_lower": 3.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Phase l: RAD001 2.5mg/Day + Glivec 800mg/Day",
        "value": null,
        "unit": "months",
        "ci_lower": 12.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG004",
        "arm_title": "Phase ll - Stratum l (First-line Resistant/Refractory): RAD001 2.5mg/Day + Glivec 600mg/Day",
        "value": 14.9,
        "unit": "months",
        "ci_lower": 14.9,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG005",
        "arm_title": "Phase ll: Stratum ll (Post Second-line Therapy)",
        "value": 10.7,
        "unit": "months",
        "ci_lower": 6.3,
        "ci_upper": 16.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase ll - Stratum l (First-line Resistant/Refractory): RAD001 2.5mg/Day + Glivec 600mg/Day",
        "value": 17.4,
        "unit": "Percentage of participants",
        "ci_lower": 5.0,
        "ci_upper": 38.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Phase ll: Stratum ll (Post Second-line Therapy)",
        "value": 37.1,
        "unit": "Percentage of participants",
        "ci_lower": 21.5,
        "ci_upper": 55.1,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "RAD001"
      ],
      "OG001": [
        "RAD001",
        "Imatinib 600mg/day (Glevec is the brand name for imatinib)"
      ],
      "OG002": [
        "RAD001",
        "Imatinib 600mg/day (Glevec is the brand name for imatinib)"
      ],
      "OG003": [
        "RAD001",
        "Imatinib 800mg/day (Glevec is the brand name for imatinib)"
      ],
      "OG004": [
        "RAD001",
        "Imatinib 600mg/day (Glevec is the brand name for imatinib)"
      ],
      "OG005": [
        "RAD001",
        "Imatinib 600mg/day (Glevec is the brand name for imatinib)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Combo_TKI_Targeted",
      "OG002": "Combo_TKI_Targeted",
      "OG003": "Combo_TKI_Targeted",
      "OG004": "Combo_TKI_Targeted",
      "OG005": "Combo_TKI_Targeted"
    }
  },
  {
    "nct_id": "NCT01286987",
    "brief_title": "Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2011-01-03",
    "completion_date": "2015-03-31",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT01286987",
    "cancer_types": [
      "BRCA",
      "OV",
      "PRAD"
    ],
    "biomarkers": [
      {
        "target": "BRCA",
        "status": "POSITIVE",
        "details": "Deleterious or pathogenic BRCA mutation (required for expansion cohorts; e.g., breast/ovarian/prostate/pancreatic per protocol)"
      },
      {
        "target": "CA125",
        "status": "HIGH",
        "details": "Increased CA-125 used as alternative measure of measurable disease (ovarian cancer)"
      },
      {
        "target": "PSA",
        "status": "HIGH",
        "details": "Increased PSA used as alternative measure of measurable disease (prostate cancer)"
      },
      {
        "target": "CA199",
        "status": "HIGH",
        "details": "Increased CA 19-9 used as alternative measure of measurable disease (pancreatic cancer)"
      }
    ],
    "cancer_stages": [
      "UNRESECTABLE",
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Part 1 and Part 2: Talazoparib (Breast Cancer)",
        "value": 8.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Part 1 and Part 2: Talazoparib (Ovarian/ Peritoneal Cancer)",
        "value": 12.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Part 1 and Part 2: Talazoparib (Pancreatic Cancer)",
        "value": 2.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Part 1 and Part 2: Talazoparib (Ewing Cancer)",
        "value": 0.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Part 2: Talazoparib (SCLC Cancer)",
        "value": 2.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "Part 1 and Part 2: Talazoparib (Prostate Cancer)",
        "value": 0.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG006",
        "arm_title": "Part 1: Talazoparib (Colorectal Cancer)",
        "value": 0.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Part 1 and Part 2: Talazoparib (Breast Cancer)",
        "value": 29.3,
        "unit": "weeks",
        "ci_lower": 12.1,
        "ci_upper": 43.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Part 1 and Part 2: Talazoparib (Ovarian/ Peritoneal Cancer)",
        "value": 32.1,
        "unit": "weeks",
        "ci_lower": 18.9,
        "ci_upper": 38.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Part 1 and Part 2: Talazoparib (Pancreatic Cancer)",
        "value": 5.3,
        "unit": "weeks",
        "ci_lower": 2.4,
        "ci_upper": 21.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Part 1 and Part 2: Talazoparib (Ewing Cancer)",
        "value": 6.2,
        "unit": "weeks",
        "ci_lower": 3.1,
        "ci_upper": 14.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Part 2: Talazoparib (SCLC Cancer)",
        "value": 11.1,
        "unit": "weeks",
        "ci_lower": 4.3,
        "ci_upper": 13.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG005",
        "arm_title": "Part 1 and Part 2: Talazoparib (Prostate Cancer)",
        "value": 12.1,
        "unit": "weeks",
        "ci_lower": 12.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG000",
        "arm_title": "Part 1 and Part 2: Talazoparib (Breast Cancer)",
        "value": 32.2,
        "unit": "weeks",
        "ci_lower": 20.1,
        "ci_upper": 64.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG001",
        "arm_title": "Part 1 and Part 2: Talazoparib (Ovarian/ Peritoneal Cancer)",
        "value": 26.9,
        "unit": "weeks",
        "ci_lower": 15.7,
        "ci_upper": 35.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG002",
        "arm_title": "Part 1 and Part 2: Talazoparib (Pancreatic Cancer)",
        "value": null,
        "unit": "weeks",
        "ci_lower": 21.6,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG004",
        "arm_title": "Part 2: Talazoparib (SCLC Cancer)",
        "value": 13.6,
        "unit": "weeks",
        "ci_lower": 12.0,
        "ci_upper": 15.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Talazoparib"
      ],
      "OG001": [
        "Talazoparib"
      ],
      "OG002": [
        "Talazoparib"
      ],
      "OG003": [
        "Talazoparib"
      ],
      "OG004": [
        "Talazoparib"
      ],
      "OG005": [
        "Talazoparib"
      ],
      "OG006": [
        "Talazoparib"
      ],
      "OG007": [
        "Talazoparib"
      ],
      "OG008": [
        "Talazoparib"
      ],
      "OG009": [
        "Talazoparib"
      ],
      "OG010": [
        "Talazoparib"
      ],
      "OG011": [
        "Talazoparib"
      ],
      "OG012": [
        "Talazoparib"
      ],
      "OG013": [
        "Talazoparib"
      ],
      "OG014": [
        "Talazoparib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other",
      "OG004": "Targeted_Other",
      "OG005": "Targeted_Other",
      "OG006": "Targeted_Other",
      "OG007": "Targeted_Other",
      "OG008": "Targeted_Other",
      "OG009": "Targeted_Other",
      "OG010": "Targeted_Other",
      "OG011": "Targeted_Other",
      "OG012": "Targeted_Other",
      "OG013": "Targeted_Other",
      "OG014": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01270880",
    "brief_title": "Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy",
    "status": "COMPLETED",
    "start_date": "2011-01",
    "completion_date": "2014-07",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Barbara Ann Karmanos Cancer Institute",
    "url": "https://clinicaltrials.gov/study/NCT01270880",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [
      {
        "target": "PSA",
        "status": "ANY",
        "details": "Rising PSA (progression) required; for patients with no measurable disease must show 2 successive elevations and PSA >=5 ng/mL; no minimum PSA for patients with measurable disease"
      },
      {
        "target": "TESTOSTERONE",
        "status": "LOW",
        "details": "Documented castrate level: testosterone <= 0.5 ng/mL; LHRH agonist continued if required"
      },
      {
        "target": "NEUTROPHILS",
        "status": "HIGH",
        "details": "Absolute neutrophil count >= 1,500 cells/uL"
      },
      {
        "target": "PLATELETS",
        "status": "HIGH",
        "details": "Platelets >= 100,000 /uL"
      },
      {
        "target": "HEMOGLOBIN",
        "status": "HIGH",
        "details": "Hemoglobin >= 9.0 g/dL"
      },
      {
        "target": "CREATININE",
        "status": "LOW",
        "details": "Serum creatinine <= 1.5 x ULN (or if >1.5 x ULN, creatinine clearance >= 50 mL/min)"
      },
      {
        "target": "BILIRUBIN",
        "status": "LOW",
        "details": "Total bilirubin <= 1.5 x ULN"
      },
      {
        "target": "AST",
        "status": "LOW",
        "details": "AST (SGOT) and/or ALT (SGPT) <= 2.5 x institutional ULN for patients without documented bone mets or with liver mets; for patients with bone mets AST/ALT < 2.5 x ULN (special ALP allowances described)"
      },
      {
        "target": "ALT",
        "status": "LOW",
        "details": "AST (SGOT) and/or ALT (SGPT) <= 2.5 x institutional ULN for patients without documented bone mets or with liver mets; for patients with bone mets AST/ALT < 2.5 x ULN (special ALP allowances described)"
      },
      {
        "target": "ALKALINE_PHOSPHATASE",
        "status": "ANY",
        "details": "Alkaline phosphatase may be up to 4 x ULN if transaminases are <= ULN; if alkaline phosphatase <= ULN transaminases may be up to 2.5 x ULN"
      },
      {
        "target": "LVEF",
        "status": "HIGH",
        "details": "Ventricular ejection fraction (LVEF/Ef) > 55% at baseline is required"
      },
      {
        "target": "QTC",
        "status": "LOW",
        "details": "Baseline QTc <= 450 msec required"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Enzyme Inhibitor Therapy)",
        "value": 0.0,
        "unit": "proportion with 6+ months PFS",
        "ci_lower": 0.0,
        "ci_upper": 0.137,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Enzyme Inhibitor Therapy)",
        "value": 12.5,
        "unit": "months",
        "ci_lower": 1.5,
        "ci_upper": 17.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Hsp90 inhibitor STA-9090"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT00045032",
    "brief_title": "Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2001-11",
    "completion_date": "2005-03",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT00045032",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "IHC 3+ or positive FISH"
      },
      {
        "target": "HORMONE_RECEPTOR",
        "status": "ANY",
        "details": "Known hormone receptor status (ER and/or PR) required but no specific value mandated"
      }
    ],
    "cancer_stages": [
      "I",
      "II",
      "III"
    ],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Observation Arm",
        "value": 12.9,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Herceptin 1-Year Arm",
        "value": 7.5,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Observation Arm",
        "value": 78.18,
        "unit": "percentage of participants",
        "ci_lower": 75.0,
        "ci_upper": 81.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Herceptin 1-Year Arm",
        "value": 85.8,
        "unit": "percentage of participants",
        "ci_lower": 83.0,
        "ci_upper": 89.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Observation Arm",
        "value": 75.2,
        "unit": "percentage of participants",
        "ci_lower": 73.1,
        "ci_upper": 77.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Herceptin 1-Year Arm",
        "value": 81.3,
        "unit": "percentage of participants",
        "ci_lower": 79.4,
        "ci_upper": 83.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Herceptin 2-Year Arm",
        "value": 83.5,
        "unit": "percentage of participants",
        "ci_lower": 81.7,
        "ci_upper": 85.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Observation Arm",
        "value": 70.0,
        "unit": "percentage of participants",
        "ci_lower": 67.8,
        "ci_upper": 72.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Herceptin 1-Year Arm",
        "value": 75.9,
        "unit": "percentage of participants",
        "ci_lower": 73.8,
        "ci_upper": 78.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Herceptin 2-Year Arm",
        "value": 76.5,
        "unit": "percentage of participants",
        "ci_lower": 74.4,
        "ci_upper": 78.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Observation Arm",
        "value": 66.0,
        "unit": "percentage of participants",
        "ci_lower": 63.6,
        "ci_upper": 68.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Herceptin 1-Year Arm",
        "value": 72.4,
        "unit": "percentage of participants",
        "ci_lower": 70.2,
        "ci_upper": 74.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Herceptin 2-Year Arm",
        "value": 72.5,
        "unit": "percentage of participants",
        "ci_lower": 70.4,
        "ci_upper": 74.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Observation Arm",
        "value": 64.8,
        "unit": "percentage of participants",
        "ci_lower": 62.4,
        "ci_upper": 67.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Herceptin 1-Year Arm",
        "value": 71.2,
        "unit": "percentage of participants",
        "ci_lower": 69.0,
        "ci_upper": 73.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Herceptin 2-Year Arm",
        "value": 71.0,
        "unit": "percentage of participants",
        "ci_lower": 68.7,
        "ci_upper": 73.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Observation Arm",
        "value": 63.5,
        "unit": "percentage of participants",
        "ci_lower": 61.2,
        "ci_upper": 65.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Herceptin 1-Year Arm",
        "value": 70.3,
        "unit": "percentage of participants",
        "ci_lower": 68.1,
        "ci_upper": 72.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Herceptin 2-Year Arm",
        "value": 69.2,
        "unit": "percentage of participants",
        "ci_lower": 67.0,
        "ci_upper": 71.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Observation Arm",
        "value": 62.5,
        "unit": "percentage of participants",
        "ci_lower": 60.1,
        "ci_upper": 64.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Herceptin 1-Year Arm",
        "value": 69.3,
        "unit": "percentage of participants",
        "ci_lower": 67.0,
        "ci_upper": 71.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Herceptin 2-Year Arm",
        "value": 68.5,
        "unit": "percentage of participants",
        "ci_lower": 66.2,
        "ci_upper": 70.7,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG001": [
        "Herceptin"
      ],
      "OG002": [
        "Herceptin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Placebo",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT04656652",
    "brief_title": "Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2020-12-21",
    "completion_date": "2024-05-10",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Daiichi Sankyo",
    "url": "https://clinicaltrials.gov/study/NCT04656652",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "Documented negative test results required for participants without actionable genomic alterations"
      },
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "Actionable EGFR mutation (e.g., L858R or exon 19 deletion). Note: tumors with L858R or exon 19 deletion must have received osimertinib prior to study if applicable"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "Documented negative test results required for participants without actionable genomic alterations"
      },
      {
        "target": "ALK",
        "status": "POSITIVE",
        "details": "Actionable ALK alteration"
      },
      {
        "target": "ROS1",
        "status": "NEGATIVE",
        "details": "No known genomic alteration required for participants without actionable genomic alterations"
      },
      {
        "target": "ROS1",
        "status": "POSITIVE",
        "details": "Actionable ROS1 alteration"
      },
      {
        "target": "NTRK",
        "status": "NEGATIVE",
        "details": "No known genomic alteration required for participants without actionable genomic alterations"
      },
      {
        "target": "NTRK",
        "status": "POSITIVE",
        "details": "Actionable NTRK alteration/fusion"
      },
      {
        "target": "BRAF",
        "status": "NEGATIVE",
        "details": "No known genomic alteration required for participants without actionable genomic alterations"
      },
      {
        "target": "BRAF",
        "status": "POSITIVE",
        "details": "Actionable BRAF alteration (e.g., V600) as applicable"
      },
      {
        "target": "MET",
        "status": "NEGATIVE",
        "details": "No MET exon 14 skipping allowed for participants without actionable genomic alterations"
      },
      {
        "target": "MET",
        "status": "POSITIVE",
        "details": "MET exon 14 skipping"
      },
      {
        "target": "RET",
        "status": "NEGATIVE",
        "details": "No known genomic alteration required for participants without actionable genomic alterations"
      },
      {
        "target": "RET",
        "status": "POSITIVE",
        "details": "Actionable RET alteration/rearrangement"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IIIC",
      "IV",
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "DS-1062a 6.0 mg/kg",
        "value": 4.4,
        "unit": "months",
        "ci_lower": 4.2,
        "ci_upper": 5.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Docetaxel 75 mg/m^2",
        "value": 3.7,
        "unit": "months",
        "ci_lower": 2.9,
        "ci_upper": 4.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "DS-1062a 6.0 mg/kg",
        "value": 12.9,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Docetaxel 75 mg/m^2",
        "value": 11.8,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "DS-1062a"
      ],
      "OG001": [
        "Docetaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "ADC",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00069121",
    "brief_title": "A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer",
    "status": "COMPLETED",
    "start_date": "2003-04-18",
    "completion_date": "2011-04-21",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT00069121",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "III"
    ],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [],
    "arm_drugs": {
      "OG000": [
        "5-Fluorouracil (5-FU)",
        "Leucovorin (LV)"
      ],
      "OG001": [
        "Capecitabine",
        "Oxaliplatin"
      ],
      "OG002": [
        "Capecitabine",
        "Oxaliplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo",
      "OG002": "Chemo"
    }
  },
  {
    "nct_id": "NCT00081159",
    "brief_title": "Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases",
    "status": "COMPLETED",
    "start_date": "2004-07",
    "completion_date": "2014-09",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "M.D. Anderson Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT00081159",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "HAT, Doxorubicin, Zoledronate + Strontium Chloride",
        "value": 12.9,
        "unit": "Months",
        "ci_lower": 8.9,
        "ci_upper": 72.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "HAT, Doxorubicin + Zoledronate",
        "value": 18.5,
        "unit": "Months",
        "ci_lower": 9.7,
        "ci_upper": 49.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "HAT, Doxorubicin, Zoledronate + Strontium Chloride",
        "value": 47.4,
        "unit": "Months",
        "ci_lower": 35.9,
        "ci_upper": 87.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "HAT, Doxorubicin + Zoledronate",
        "value": 53.5,
        "unit": "Months",
        "ci_lower": 38.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Doxorubicin hydrochloride",
        "Goserelin acetate",
        "Leuprolide acetate",
        "Zoledronic acid",
        "Strontium Chloride"
      ],
      "OG001": [
        "Doxorubicin hydrochloride",
        "Goserelin acetate",
        "Leuprolide acetate",
        "Zoledronic acid"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01308580",
    "brief_title": "Cabazitaxel at 20 mg/m\u00b2 Compared to 25 mg/m\u00b2 With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer",
    "status": "COMPLETED",
    "start_date": "2011-04",
    "completion_date": "2015-08",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sanofi",
    "url": "https://clinicaltrials.gov/study/NCT01308580",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cabazitaxel 20 mg/m^2",
        "value": 13.4,
        "unit": "months",
        "ci_lower": 12.19,
        "ci_upper": 14.88,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cabazitaxel 25 mg/m^2",
        "value": 14.5,
        "unit": "months",
        "ci_lower": 13.47,
        "ci_upper": 15.28,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cabazitaxel",
        "Prednisone"
      ],
      "OG001": [
        "Cabazitaxel",
        "Prednisone"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT04685135",
    "brief_title": "Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2021-02-23",
    "completion_date": "2023-12-30",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Mirati Therapeutics Inc.",
    "url": "https://clinicaltrials.gov/study/NCT04685135",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "POSITIVE",
        "details": "G12C mutation"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Adagrasib",
        "value": 5.49,
        "unit": "months",
        "ci_lower": 4.53,
        "ci_upper": 6.67,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Docetaxel",
        "value": 3.84,
        "unit": "months",
        "ci_lower": 2.73,
        "ci_upper": 4.73,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Adagrasib"
      ],
      "OG001": [
        "Docetaxel"
      ],
      "OG002": [
        "Adagrasib"
      ],
      "OG003": [
        "Adagrasib"
      ],
      "OG004": [
        "Adagrasib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Chemo",
      "OG002": "TKI",
      "OG003": "TKI",
      "OG004": "TKI"
    }
  },
  {
    "nct_id": "NCT01308567",
    "brief_title": "Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer",
    "status": "COMPLETED",
    "start_date": "2011-05-05",
    "completion_date": "2015-09",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sanofi",
    "url": "https://clinicaltrials.gov/study/NCT01308567",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Docetaxel 75 mg/m^2",
        "value": 24.3,
        "unit": "months",
        "ci_lower": 22.18,
        "ci_upper": 27.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cabazitaxel 20 mg/m^2",
        "value": 24.5,
        "unit": "months",
        "ci_lower": 21.75,
        "ci_upper": 27.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Cabazitaxel 25 mg/m^2",
        "value": 25.2,
        "unit": "months",
        "ci_lower": 22.9,
        "ci_upper": 26.97,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Docetaxel 75 mg/m^2",
        "value": 5.3,
        "unit": "months",
        "ci_lower": 4.86,
        "ci_upper": 5.78,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cabazitaxel 20 mg/m^2",
        "value": 4.4,
        "unit": "months",
        "ci_lower": 3.91,
        "ci_upper": 5.09,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Cabazitaxel 25 mg/m^2",
        "value": 5.1,
        "unit": "months",
        "ci_lower": 4.6,
        "ci_upper": 5.72,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Docetaxel (XRP6976)",
        "Prednisone"
      ],
      "OG001": [
        "Cabazitaxel (XRP6258)",
        "Prednisone"
      ],
      "OG002": [
        "Cabazitaxel (XRP6258)",
        "Prednisone"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo",
      "OG002": "Chemo"
    }
  },
  {
    "nct_id": "NCT04716933",
    "brief_title": "Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study",
    "status": "COMPLETED",
    "start_date": "2019-11-05",
    "completion_date": "2023-08-11",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT04716933",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "absence of tumor-activating EGFR mutations"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "absence of ALK gene rearrangements"
      },
      {
        "target": "ROS1",
        "status": "NEGATIVE",
        "details": "absence of ROS1 gene rearrangements"
      },
      {
        "target": "KRAS",
        "status": "POSITIVE",
        "details": "presence of a KRAS gene mutation (alternative eligibility)"
      },
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "evaluable archival tumor tissue or newly obtained core/excisional biopsy for central PD-L1 testing"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib",
        "value": 15.3,
        "unit": "Months",
        "ci_lower": 12.2,
        "ci_upper": 19.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo",
        "value": 9.2,
        "unit": "Months",
        "ci_lower": 8.2,
        "ci_upper": 12.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib",
        "value": 26.6,
        "unit": "Months",
        "ci_lower": 22.2,
        "ci_upper": 35.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo",
        "value": 22.0,
        "unit": "Months",
        "ci_lower": 16.6,
        "ci_upper": 24.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pemetrexed",
        "Carboplatin",
        "Cisplatin",
        "Pembrolizumab",
        "Lenvatinib"
      ],
      "OG001": [
        "Pemetrexed",
        "Carboplatin",
        "Cisplatin",
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_IO",
      "OG001": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT00069095",
    "brief_title": "A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2003-07",
    "completion_date": "2006-01",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT00069095",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV",
        "value": 259.0,
        "unit": "days",
        "ci_lower": 245.0,
        "ci_upper": 268.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "XELOX/XELOX+P/XELOX+BV",
        "value": 241.0,
        "unit": "days",
        "ci_lower": 229.0,
        "ci_upper": 254.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV",
        "value": 549.0,
        "unit": "days",
        "ci_lower": 528.0,
        "ci_upper": 576.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "XELOX/XELOX+P/XELOX+BV",
        "value": 577.0,
        "unit": "days",
        "ci_lower": 535.0,
        "ci_upper": 615.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Oxaliplatin",
        "Leucovorin",
        "Fluorouracil",
        "Bevacizumab"
      ],
      "OG001": [
        "Oxaliplatin",
        "Capecitabine",
        "Bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT01306942",
    "brief_title": "Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients",
    "status": "COMPLETED",
    "start_date": "2011-07",
    "completion_date": "2013-12",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Spanish Breast Cancer Research Group",
    "url": "https://clinicaltrials.gov/study/NCT01306942",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER2 overexpression by IHC 3+ (HercepTest\u00ae, DAKO) or positive FISH for HER2 amplification; central laboratory testing; FFPE tumor tissue from metastatic site (or primary if unavailable) recommended"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase II:Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m2",
        "value": 23.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Dasatinib",
        "Trastuzumab",
        "Paclitaxel"
      ],
      "OG001": [
        "Dasatinib",
        "Trastuzumab",
        "Paclitaxel"
      ],
      "OG002": [
        "Dasatinib",
        "Trastuzumab",
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Combo_TKI_Chemo",
      "OG002": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT00068575",
    "brief_title": "Chemotherapy, Interferon Alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer",
    "status": "COMPLETED",
    "start_date": "2002-05",
    "completion_date": "2010-12",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "M.D. Anderson Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT00068575",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "I",
      "II",
      "III"
    ],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Postoperative Chemoradiation Regimen",
        "value": 42.0,
        "unit": "Months",
        "ci_lower": 32.1,
        "ci_upper": 64.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cisplatin",
        "Recombinant Interferon Alfa"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER"
    }
  },
  {
    "nct_id": "NCT01298570",
    "brief_title": "Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2011-04-07",
    "completion_date": "2016-11-15",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "UNC Lineberger Comprehensive Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT01298570",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A",
        "value": 6.1,
        "unit": "Months",
        "ci_lower": 5.5,
        "ci_upper": 7.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B",
        "value": 5.3,
        "unit": "Months",
        "ci_lower": 4.1,
        "ci_upper": 6.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A",
        "value": 13.8,
        "unit": "Months",
        "ci_lower": 10.5,
        "ci_upper": 14.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B",
        "value": 11.7,
        "unit": "Months",
        "ci_lower": 9.0,
        "ci_upper": 15.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Regorafenib (BAY 73-4506)",
        "FOLFIRI"
      ],
      "OG001": [
        "FOLFIRI"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00065468",
    "brief_title": "Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma",
    "status": "COMPLETED",
    "start_date": "2003-07",
    "completion_date": "2006-06",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT00065468",
    "cancer_types": [
      "KIRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IV",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Interferon Alfa",
        "value": 7.3,
        "unit": "months",
        "ci_lower": 6.1,
        "ci_upper": 8.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Temsirolimus",
        "value": 10.9,
        "unit": "months",
        "ci_lower": 8.6,
        "ci_upper": 12.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Interferon Alfa and Temsirolimus",
        "value": 8.4,
        "unit": "months",
        "ci_lower": 6.6,
        "ci_upper": 10.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Interferon Alfa",
        "value": 3.2,
        "unit": "months",
        "ci_lower": 2.2,
        "ci_upper": 4.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Temsirolimus",
        "value": 5.6,
        "unit": "months",
        "ci_lower": 3.9,
        "ci_upper": 7.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Interferon Alfa and Temsirolimus",
        "value": 4.9,
        "unit": "months",
        "ci_lower": 3.9,
        "ci_upper": 6.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Interferon Alfa"
      ],
      "OG001": [
        "Temsirolimus (CCI-779)"
      ],
      "OG002": [
        "Interferon Alfa",
        "Temsirolimus (CCI-779)"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "Targeted_Other",
      "OG002": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT01301729",
    "brief_title": "A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment",
    "status": "COMPLETED",
    "start_date": "2011-03",
    "completion_date": "2014-07",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT01301729",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER2-positive primary disease; prior (neo)adjuvant Herceptin received, relapse \u22656 months after stopping (neo)adjuvant therapy"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Trastuzumab",
        "value": 9.9,
        "unit": "months",
        "ci_lower": 6.28,
        "ci_upper": 13.63,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Trastuzumab",
        "value": null,
        "unit": "months",
        "ci_lower": 22.64,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Trastuzumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01295827",
    "brief_title": "Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)",
    "status": "COMPLETED",
    "start_date": "2011-03-04",
    "completion_date": "2018-11-05",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT01295827",
    "cancer_types": [
      "NSCLC",
      "SKCM",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "POSITIVE",
        "details": "PD-L1 gene expression (method/threshold not specified)"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG006",
        "arm_title": "MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D)",
        "value": 30.2,
        "unit": "Percentage of Participants",
        "ci_lower": 23.3,
        "ci_upper": 37.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG007",
        "arm_title": "MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D)",
        "value": 29.4,
        "unit": "Percentage of Participants",
        "ci_lower": 24.4,
        "ci_upper": 34.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG008",
        "arm_title": "MEL: Pembrolizumab 10 mg/kg Q2W (Part B)",
        "value": 36.7,
        "unit": "Percentage of Participants",
        "ci_lower": 29.6,
        "ci_upper": 44.2,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab"
      ],
      "OG001": [
        "Pembrolizumab"
      ],
      "OG002": [
        "Pembrolizumab"
      ],
      "OG003": [
        "Pembrolizumab"
      ],
      "OG004": [
        "Pembrolizumab"
      ],
      "OG005": [
        "Pembrolizumab"
      ],
      "OG006": [
        "Pembrolizumab"
      ],
      "OG007": [
        "Pembrolizumab"
      ],
      "OG008": [
        "Pembrolizumab"
      ],
      "OG009": [
        "Pembrolizumab"
      ],
      "OG010": [
        "Pembrolizumab"
      ],
      "OG011": [
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO",
      "OG003": "IO",
      "OG004": "IO",
      "OG005": "IO",
      "OG006": "IO",
      "OG007": "IO",
      "OG008": "IO",
      "OG009": "IO",
      "OG010": "IO",
      "OG011": "IO"
    }
  },
  {
    "nct_id": "NCT04737187",
    "brief_title": "Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients",
    "status": "COMPLETED",
    "start_date": "2020-11-25",
    "completion_date": "2022-07-19",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Taiho Oncology, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT04737187",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "RAS",
        "status": "ANY",
        "details": "Mutant or wild-type based on local assessment of tumor biopsy"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Trifluridine/Tipiracil + Bevacizumab",
        "value": 10.78,
        "unit": "months",
        "ci_lower": 9.36,
        "ci_upper": 11.83,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Trifluridine/Tipiracil",
        "value": 7.46,
        "unit": "months",
        "ci_lower": 6.34,
        "ci_upper": 8.57,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Trifluridine/Tipiracil + Bevacizumab",
        "value": 0.77,
        "unit": "probability of participants",
        "ci_lower": 0.72,
        "ci_upper": 0.82,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Trifluridine/Tipiracil",
        "value": 0.61,
        "unit": "probability of participants",
        "ci_lower": 0.55,
        "ci_upper": 0.67,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Trifluridine/Tipiracil + Bevacizumab",
        "value": 0.43,
        "unit": "probability of participants",
        "ci_lower": 0.36,
        "ci_upper": 0.49,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Trifluridine/Tipiracil",
        "value": 0.3,
        "unit": "probability of participants",
        "ci_lower": 0.24,
        "ci_upper": 0.36,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Trifluridine/Tipiracil + Bevacizumab",
        "value": 0.28,
        "unit": "probability of participants",
        "ci_lower": 0.19,
        "ci_upper": 0.37,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Trifluridine/Tipiracil",
        "value": 0.15,
        "unit": "probability of participants",
        "ci_lower": 0.09,
        "ci_upper": 0.22,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Trifluridine/Tipiracil",
        "Bevacizumab"
      ],
      "OG001": [
        "Trifluridine/Tipiracil"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01297491",
    "brief_title": "Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2011-05",
    "completion_date": "2014-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT01297491",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "PI3K",
        "status": "POSITIVE",
        "details": "Activated PI3K pathway (e.g., PIK3CA mutation, PTEN loss, or other pathway activation)"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Squamous BKM120 100mg qd",
        "value": 23.3,
        "unit": "Percentage of participants",
        "ci_lower": 9.9,
        "ci_upper": 42.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Non-Squamous BKM120 100mg qd",
        "value": 20.0,
        "unit": "Percentage of participants",
        "ci_lower": 7.7,
        "ci_upper": 38.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Squamous BKM120 100mg qd",
        "value": 7.98,
        "unit": "Months",
        "ci_lower": 5.95,
        "ci_upper": 10.09,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Non-Squamous BKM120 100mg qd",
        "value": 7.2,
        "unit": "Months",
        "ci_lower": 4.01,
        "ci_upper": 9.92,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "BKM120"
      ],
      "OG001": [
        "BKM120"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT04716634",
    "brief_title": "Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2021-04-19",
    "completion_date": "2024-02-22",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "BeiGene",
    "url": "https://clinicaltrials.gov/study/NCT04716634",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV",
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Gastric Cancer (GC): Tislelizumab and Fruquintinib",
        "value": 12.9,
        "unit": "percentage of participants",
        "ci_lower": 3.6,
        "ci_upper": 29.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Colorectal Cancer (CRC): Tislelizumab and Fruquintinib",
        "value": 9.7,
        "unit": "percentage of participants",
        "ci_lower": 2.0,
        "ci_upper": 25.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "PD-L1 + NSCLC: Tislelizumab and Fruquintinib",
        "value": 40.9,
        "unit": "percentage of participants",
        "ci_lower": 20.7,
        "ci_upper": 63.6,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Tislelizumab",
        "Fruquintinib"
      ],
      "OG001": [
        "Tislelizumab",
        "Fruquintinib"
      ],
      "OG002": [
        "Tislelizumab",
        "Fruquintinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_IO",
      "OG001": "Combo_TKI_IO",
      "OG002": "Combo_TKI_IO"
    }
  },
  {
    "nct_id": "NCT04725188",
    "brief_title": "Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)",
    "status": "COMPLETED",
    "start_date": "2021-04-20",
    "completion_date": "2023-01-26",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT04725188",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "No indication for EGFR-directed therapy (no actionable EGFR alteration)"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "No indication for ALK-directed therapy (no actionable ALK alteration)"
      },
      {
        "target": "ROS1",
        "status": "NEGATIVE",
        "details": "No indication for ROS1-directed therapy (no actionable ROS1 alteration)"
      },
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Tumor tissue must be provided for PD-L1 biomarker analysis from archival sample or newly obtained core/excisional biopsy of a non-irradiated lesion; no PD-L1 expression threshold required for eligibility"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": true,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel",
        "value": 5.6,
        "unit": "Months",
        "ci_lower": 3.9,
        "ci_upper": 6.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm 2: Pembrolizumab/Vibostolimab Coformulation",
        "value": 2.7,
        "unit": "Months",
        "ci_lower": 1.8,
        "ci_upper": 4.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Arm 3: Placebo + Docetaxel",
        "value": 3.2,
        "unit": "Months",
        "ci_lower": 2.8,
        "ci_upper": 5.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel",
        "value": 10.2,
        "unit": "Months",
        "ci_lower": 8.6,
        "ci_upper": 14.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm 2: Pembrolizumab/Vibostolimab Coformulation",
        "value": 7.5,
        "unit": "Months",
        "ci_lower": 5.2,
        "ci_upper": 13.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Arm 3: Placebo + Docetaxel",
        "value": 8.8,
        "unit": "Months",
        "ci_lower": 6.4,
        "ci_upper": 11.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab/Vibostolimab coformulation",
        "Docetaxel"
      ],
      "OG001": [
        "Pembrolizumab/Vibostolimab coformulation"
      ],
      "OG002": [
        "Docetaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "IO",
      "OG002": "Chemo"
    }
  },
  {
    "nct_id": "NCT04704154",
    "brief_title": "A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2021-02-03",
    "completion_date": "2023-03-09",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bayer",
    "url": "https://clinicaltrials.gov/study/NCT04704154",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "HPV",
        "status": "ANY",
        "details": "Documented status required for oropharyngeal cancer"
      },
      {
        "target": "P16",
        "status": "ANY",
        "details": "Documented status required for oropharyngeal cancer (p16 immunohistochemistry)"
      },
      {
        "target": "MSI",
        "status": "NEGATIVE",
        "details": "Excludes known deficient mismatch repair / MSI-high cancers (dMMR/MSI-H)"
      },
      {
        "target": "NTRK",
        "status": "NEGATIVE",
        "details": "Excludes known NTRK gene fusions"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "HNSCC (IO Naive)",
        "value": 6.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "HNSCC (IO Treated)",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "ESCC",
        "value": 15.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "PDAC",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Biliary Tract Cancer (BTC)",
        "value": 2.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "GBM/AA",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "HNSCC (IO Naive)",
        "value": 79.0,
        "unit": "Days",
        "ci_lower": 50.0,
        "ci_upper": 227.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "HNSCC (IO Treated)",
        "value": 105.0,
        "unit": "Days",
        "ci_lower": 52.0,
        "ci_upper": 115.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "ESCC",
        "value": 259.0,
        "unit": "Days",
        "ci_lower": 110.0,
        "ci_upper": 472.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "PDAC",
        "value": 53.0,
        "unit": "Days",
        "ci_lower": 48.0,
        "ci_upper": 111.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Biliary Tract Cancer (BTC)",
        "value": 98.0,
        "unit": "Days",
        "ci_lower": 55.0,
        "ci_upper": 112.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG005",
        "arm_title": "GBM/AA",
        "value": 55.0,
        "unit": "Days",
        "ci_lower": 52.0,
        "ci_upper": 84.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "HNSCC (IO Naive)",
        "value": 358.0,
        "unit": "Days",
        "ci_lower": 198.0,
        "ci_upper": 418.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "HNSCC (IO Treated)",
        "value": 355.0,
        "unit": "Days",
        "ci_lower": 126.0,
        "ci_upper": 614.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "ESCC",
        "value": 627.0,
        "unit": "Days",
        "ci_lower": 431.0,
        "ci_upper": 865.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "PDAC",
        "value": 259.0,
        "unit": "Days",
        "ci_lower": 134.0,
        "ci_upper": 311.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG004",
        "arm_title": "Biliary Tract Cancer (BTC)",
        "value": 246.0,
        "unit": "Days",
        "ci_lower": 176.0,
        "ci_upper": 386.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG005",
        "arm_title": "GBM/AA",
        "value": 245.0,
        "unit": "Days",
        "ci_lower": 127.0,
        "ci_upper": 377.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Regorafenib",
        "Nivolumab"
      ],
      "OG001": [
        "Regorafenib",
        "Nivolumab"
      ],
      "OG002": [
        "Regorafenib",
        "Nivolumab"
      ],
      "OG003": [
        "Regorafenib",
        "Nivolumab"
      ],
      "OG004": [
        "Regorafenib",
        "Nivolumab"
      ],
      "OG005": [
        "Regorafenib",
        "Nivolumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_IO",
      "OG001": "Combo_TKI_IO",
      "OG002": "Combo_TKI_IO",
      "OG003": "Combo_TKI_IO",
      "OG004": "Combo_TKI_IO",
      "OG005": "Combo_TKI_IO"
    }
  },
  {
    "nct_id": "NCT04693234",
    "brief_title": "AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer",
    "status": "COMPLETED",
    "start_date": "2021-02-15",
    "completion_date": "2022-06-16",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "BeiGene",
    "url": "https://clinicaltrials.gov/study/NCT04693234",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Mandatory determination of PD-L1 expression from archival tissue or baseline biopsy (fresh tumor biopsy strongly recommended)"
      }
    ],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort 1: Ociperlimab + Tislelizumab",
        "value": 26.2,
        "unit": "percentage of participants",
        "ci_lower": 17.2,
        "ci_upper": 36.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1: Ociperlimab + Tislelizumab",
        "value": 3.5,
        "unit": "Months",
        "ci_lower": 2.6,
        "ci_upper": 4.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort 2: Tislelizumab",
        "value": 5.7,
        "unit": "Months",
        "ci_lower": 2.3,
        "ci_upper": 8.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1: Ociperlimab + Tislelizumab",
        "value": 3.9,
        "unit": "Months",
        "ci_lower": 2.6,
        "ci_upper": 4.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort 2: Tislelizumab",
        "value": 5.7,
        "unit": "Months",
        "ci_lower": 2.6,
        "ci_upper": 9.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1: Ociperlimab + Tislelizumab",
        "value": 9.0,
        "unit": "Months",
        "ci_lower": 8.1,
        "ci_upper": 10.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cohort 2: Tislelizumab",
        "value": null,
        "unit": "Months",
        "ci_lower": 10.5,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ociperlimab",
        "Tislelizumab"
      ],
      "OG001": [
        "Tislelizumab"
      ],
      "OG002": [
        "Tislelizumab"
      ],
      "OG003": [
        "Tislelizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO",
      "OG003": "IO"
    }
  },
  {
    "nct_id": "NCT00073528",
    "brief_title": "Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2003-12-09",
    "completion_date": "2008-06-03",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT00073528",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Estrogen receptor positive (ER+); trial requires ER+ and/or PR+"
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": "Progesterone receptor positive (PgR+/PR+); trial requires ER+ and/or PR+"
      },
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "Archived tumor tissue required to assess intra-tumoral expression of ErbB1 (EGFR)"
      },
      {
        "target": "HER2",
        "status": "ANY",
        "details": "Archived tumor tissue required to assess intra-tumoral expression of ErbB2 (HER2)"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Placebo + Letrozole 2.5 mg",
        "value": 89.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Lapatinib 1500 mg + Letrozole 2.5 mg",
        "value": 88.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Placebo + Letrozole 2.5 mg",
        "value": 140.3,
        "unit": "Weeks",
        "ci_lower": 92.1,
        "ci_upper": 159.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Lapatinib 1500 mg + Letrozole 2.5 mg",
        "value": 144.7,
        "unit": "Weeks",
        "ci_lower": 95.6,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Placebo + Letrozole 2.5 mg",
        "value": 14.8,
        "unit": "Percent response rate",
        "ci_lower": 8.7,
        "ci_upper": 22.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Lapatinib 1500 mg + Letrozole 2.5 mg",
        "value": 27.9,
        "unit": "Percent response rate",
        "ci_lower": 19.8,
        "ci_upper": 37.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG000",
        "arm_title": "Placebo + Letrozole 2.5 mg",
        "value": 84.4,
        "unit": "weeks",
        "ci_lower": 29.1,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG001",
        "arm_title": "Lapatinib 1500 mg + Letrozole 2.5 mg",
        "value": 47.4,
        "unit": "weeks",
        "ci_lower": 25.1,
        "ci_upper": 108.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG000",
        "arm_title": "Placebo + Letrozole 2.5 mg",
        "value": 13.0,
        "unit": "weeks",
        "ci_lower": 12.0,
        "ci_upper": 23.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG001",
        "arm_title": "Lapatinib 1500 mg + Letrozole 2.5 mg",
        "value": 35.4,
        "unit": "weeks",
        "ci_lower": 24.1,
        "ci_upper": 39.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Letrozole"
      ],
      "OG001": [
        "Lapatinib",
        "Letrozole"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT01332630",
    "brief_title": "TPI 287 in Breast Cancer Metastatic to the Brain",
    "status": "COMPLETED",
    "start_date": "2011-08-16",
    "completion_date": "2017-04-14",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "M.D. Anderson Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT01332630",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "TPI 287",
        "value": 21.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "TPI 287",
        "Dexamethasone",
        "Benadryl",
        "Ranitidine"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER"
    }
  },
  {
    "nct_id": "NCT01326104",
    "brief_title": "Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor",
    "status": "COMPLETED",
    "start_date": "2010-09-07",
    "completion_date": "2020-03-28",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "University of Florida",
    "url": "https://clinicaltrials.gov/study/NCT01326104",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Group A",
        "value": 215.0,
        "unit": "Days",
        "ci_lower": 110.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Group B",
        "value": 69.0,
        "unit": "Days",
        "ci_lower": 41.0,
        "ci_upper": 151.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "High dose chemotherapy",
        "TTRNA-xALT",
        "TTRNA-DCs"
      ],
      "OG001": [
        "NMA salvage chemotherapy",
        "TTRNA-xALT",
        "TTRNA-DCs"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00110994",
    "brief_title": "Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma",
    "status": "COMPLETED",
    "start_date": "2005-04",
    "completion_date": "2006-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bayer",
    "url": "https://clinicaltrials.gov/study/NCT00110994",
    "cancer_types": [
      "SKCM"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "III",
      "IV",
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Sorafenib (Nexavar, BAY43-9006) + Dacarbazine",
        "value": 148.0,
        "unit": "days",
        "ci_lower": 112.0,
        "ci_upper": 196.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Dacarbazine",
        "value": 82.0,
        "unit": "days",
        "ci_lower": 43.0,
        "ci_upper": 125.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Sorafenib (Nexavar, BAY43-9006) + Dacarbazine",
        "value": 319.0,
        "unit": "days",
        "ci_lower": 245.0,
        "ci_upper": 492.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Dacarbazine",
        "value": 359.0,
        "unit": "days",
        "ci_lower": 285.0,
        "ci_upper": 504.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Sorafenib (Nexavar, BAY43-9006)",
        "Dacarbazine"
      ],
      "OG001": [
        "Dacarbazine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00102804",
    "brief_title": "Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC)",
    "status": "COMPLETED",
    "start_date": "2005-03",
    "completion_date": "2007-08",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00102804",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV"
    ],
    "line_of_therapy": "MAINTENANCE",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed and BSC",
        "value": 4.27,
        "unit": "months",
        "ci_lower": 4.07,
        "ci_upper": 4.73,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo and BSC",
        "value": 2.6,
        "unit": "months",
        "ci_lower": 1.68,
        "ci_upper": 2.83,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pemetrexed and BSC",
        "value": 13.37,
        "unit": "months",
        "ci_lower": 11.93,
        "ci_upper": 15.87,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo and BSC",
        "value": 10.58,
        "unit": "months",
        "ci_lower": 8.74,
        "ci_upper": 12.02,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pemetrexed"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT00090610",
    "brief_title": "Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer",
    "status": "COMPLETED",
    "start_date": "2003-10",
    "completion_date": "2009-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Duke University",
    "url": "https://clinicaltrials.gov/study/NCT00090610",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "CA125",
        "status": "LOW",
        "details": "CA125 < 70 on two occasions at least one week apart"
      }
    ],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm 1",
        "value": 13.7,
        "unit": "months",
        "ci_lower": 9.9,
        "ci_upper": 16.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm 2",
        "value": 8.4,
        "unit": "months",
        "ci_lower": 7.1,
        "ci_upper": 11.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm 1",
        "value": 33.2,
        "unit": "months",
        "ci_lower": 32.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm 2",
        "value": 30.1,
        "unit": "months",
        "ci_lower": 29.3,
        "ci_upper": 43.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Docetaxel",
        "Carboplatin"
      ],
      "OG001": [
        "Docetaxel",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT00089973",
    "brief_title": "Study Of Ispinesib In Subjects With Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2004-06-30",
    "completion_date": "2006-08-25",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "GlaxoSmithKline",
    "url": "https://clinicaltrials.gov/study/NCT00089973",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "SB-715992",
        "value": 8.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "SB-715992",
        "value": 5.86,
        "unit": "week",
        "ci_lower": 5.57,
        "ci_upper": 6.14,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ispinesib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01323530",
    "brief_title": "A Confirmation Study of Eribulin in Combination With Capecitabine",
    "status": "COMPLETED",
    "start_date": "2010-01-26",
    "completion_date": "2014-07-28",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eisai Limited",
    "url": "https://clinicaltrials.gov/study/NCT01323530",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 2: Eribulin Mesilate 1.4 mg/m^2",
        "value": 42.9,
        "unit": "percentage of participants",
        "ci_lower": 27.7,
        "ci_upper": 59.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Eribulin mesylate",
        "Capecitabine"
      ],
      "OG001": [
        "Eribulin mesylate",
        "Capecitabine"
      ],
      "OG002": [
        "Eribulin mesylate",
        "Capecitabine"
      ],
      "OG003": [
        "Eribulin mesylate",
        "Capecitabine"
      ],
      "OG004": [
        "Eribulin mesylate",
        "Capecitabine"
      ],
      "OG005": [
        "Eribulin mesylate",
        "Capecitabine"
      ],
      "OG006": [
        "Eribulin mesylate",
        "Capecitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo",
      "OG002": "Chemo",
      "OG003": "Chemo",
      "OG004": "Chemo",
      "OG005": "Chemo",
      "OG006": "Chemo"
    }
  },
  {
    "nct_id": "NCT00095199",
    "brief_title": "Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2005-01",
    "completion_date": "2011-07",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT00095199",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "Tumor tissue available for immunohistochemical determination of EGFR expression (EGFR expression by IHC)"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV",
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cetuximab & Pemetrexed",
        "value": 2.89,
        "unit": "Months",
        "ci_lower": 2.69,
        "ci_upper": 3.22,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Pemetrexed",
        "value": 2.76,
        "unit": "Months",
        "ci_lower": 2.53,
        "ci_upper": 3.29,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Cetuximab & Docetaxel",
        "value": 2.37,
        "unit": "Months",
        "ci_lower": 1.61,
        "ci_upper": 2.89,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Docetaxel",
        "value": 1.54,
        "unit": "Months",
        "ci_lower": 1.45,
        "ci_upper": 2.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cetuximab & Pemetrexed",
        "value": 6.93,
        "unit": "Months",
        "ci_lower": 6.28,
        "ci_upper": 7.85,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Pemetrexed",
        "value": 7.79,
        "unit": "Months",
        "ci_lower": 6.77,
        "ci_upper": 8.41,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Cetuximab & Docetaxel",
        "value": 5.75,
        "unit": "Months",
        "ci_lower": 4.73,
        "ci_upper": 8.31,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Docetaxel",
        "value": 8.15,
        "unit": "Months",
        "ci_lower": 6.11,
        "ci_upper": 9.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cetuximab",
        "Pemetrexed"
      ],
      "OG001": [
        "Pemetrexed"
      ],
      "OG002": [
        "Cetuximab",
        "Docetaxel"
      ],
      "OG003": [
        "Docetaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo",
      "OG002": "Combo_Chemo_Targeted",
      "OG003": "Chemo"
    }
  },
  {
    "nct_id": "NCT00082433",
    "brief_title": "Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2003-11",
    "completion_date": "2008-03",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "R-Pharm",
    "url": "https://clinicaltrials.gov/study/NCT00082433",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ixabepilone + Capecitabine",
        "value": 6.24,
        "unit": "months",
        "ci_lower": 5.59,
        "ci_upper": 6.77,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Capecitabine",
        "value": 4.4,
        "unit": "months",
        "ci_lower": 4.14,
        "ci_upper": 5.42,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Ixabepilone + Capecitabine",
        "value": 16.39,
        "unit": "months",
        "ci_lower": 14.95,
        "ci_upper": 17.91,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Capecitabine",
        "value": 15.64,
        "unit": "months",
        "ci_lower": 13.86,
        "ci_upper": 17.02,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ixabepilone",
        "Capecitabine"
      ],
      "OG001": [
        "Capecitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT04761198",
    "brief_title": "A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors",
    "status": "COMPLETED",
    "start_date": "2021-03-23",
    "completion_date": "2023-10-30",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Mereo BioPharma",
    "url": "https://clinicaltrials.gov/study/NCT04761198",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort A: Endometrial Cancer CPI (PD-1/PD-L1) Naive",
        "value": 20.0,
        "unit": "percentage of participants",
        "ci_lower": 2.52,
        "ci_upper": 55.61,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Cohort B: Head and Neck Squamous Cell Carcinoma",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 97.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Cohort C: Cervical Carcinoma",
        "value": 37.5,
        "unit": "percentage of participants",
        "ci_lower": 8.52,
        "ci_upper": 75.51,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Cohort E: TMB-H + MSS Solid Tumors",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 33.63,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Cohort F: Rare Tumors (Uveal)",
        "value": 25.0,
        "unit": "percentage of participants",
        "ci_lower": 3.19,
        "ci_upper": 65.09,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "Cohort F: Rare Tumors (De-diff LPS)",
        "value": 10.0,
        "unit": "percentage of participants",
        "ci_lower": 0.25,
        "ci_upper": 44.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG006",
        "arm_title": "Cohort F: Rare Tumors (UPS)",
        "value": 16.7,
        "unit": "percentage of participants",
        "ci_lower": 0.42,
        "ci_upper": 64.12,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG007",
        "arm_title": "Cohort F: Rare Tumors (Other Sarcoma)",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 70.76,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG008",
        "arm_title": "Cohort F: Rare Tumors (GCT)",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 60.24,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG009",
        "arm_title": "Cohort G: Endometrial Cancer Post- CPI (PD-1/PD-L1 Treated)",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 70.76,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG010",
        "arm_title": "Cohort H: Ovarian Cancer",
        "value": 10.0,
        "unit": "percentage of participants",
        "ci_lower": 0.25,
        "ci_upper": 44.5,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Etigilimab",
        "Nivolumab"
      ],
      "OG001": [
        "Etigilimab",
        "Nivolumab"
      ],
      "OG002": [
        "Etigilimab",
        "Nivolumab"
      ],
      "OG003": [
        "Etigilimab",
        "Nivolumab"
      ],
      "OG004": [
        "Etigilimab",
        "Nivolumab"
      ],
      "OG005": [
        "Etigilimab",
        "Nivolumab"
      ],
      "OG006": [
        "Etigilimab",
        "Nivolumab"
      ],
      "OG007": [
        "Etigilimab",
        "Nivolumab"
      ],
      "OG008": [
        "Etigilimab",
        "Nivolumab"
      ],
      "OG009": [
        "Etigilimab",
        "Nivolumab"
      ],
      "OG010": [
        "Etigilimab",
        "Nivolumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO",
      "OG003": "IO",
      "OG004": "IO",
      "OG005": "IO",
      "OG006": "IO",
      "OG007": "IO",
      "OG008": "IO",
      "OG009": "IO",
      "OG010": "IO"
    }
  },
  {
    "nct_id": "NCT01321554",
    "brief_title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)",
    "status": "COMPLETED",
    "start_date": "2011-03-17",
    "completion_date": "2013-11-15",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eisai Inc.",
    "url": "https://clinicaltrials.gov/study/NCT01321554",
    "cancer_types": [
      "THCA"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Randomization Phase: Lenvatinib 24 mg",
        "value": 18.3,
        "unit": "months",
        "ci_lower": 15.1,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Randomization Phase: Placebo",
        "value": 3.6,
        "unit": "months",
        "ci_lower": 2.2,
        "ci_upper": 3.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Randomization Phase: Lenvatinib 24 mg",
        "value": null,
        "unit": "months",
        "ci_lower": 22.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Randomization Phase: Placebo",
        "value": null,
        "unit": "months",
        "ci_lower": 14.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Lenvatinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT01328951",
    "brief_title": "A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy",
    "status": "COMPLETED",
    "start_date": "2011-09",
    "completion_date": "2015-12",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT01328951",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "EGFR-activating mutation"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "MAINTENANCE",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Late Erlotinib",
        "value": 9.46,
        "unit": "months",
        "ci_lower": 8.38,
        "ci_upper": 11.33,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Early Erlotinib",
        "value": 9.72,
        "unit": "months",
        "ci_lower": 8.57,
        "ci_upper": 11.17,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Late Erlotinib",
        "value": 41.75,
        "unit": "percentage of participants",
        "ci_lower": 36.2,
        "ci_upper": 47.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Early Erlotinib",
        "value": 42.15,
        "unit": "percentage of participants",
        "ci_lower": 36.6,
        "ci_upper": 47.7,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG001": [
        "Erlotinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Placebo",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT04744831",
    "brief_title": "Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2021-03-05",
    "completion_date": "2022-11-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Daiichi Sankyo",
    "url": "https://clinicaltrials.gov/study/NCT04744831",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "BRAF",
        "status": "NEGATIVE",
        "details": "BRAF wild-type"
      },
      {
        "target": "RAS",
        "status": "ANY",
        "details": "RAS status must be identified in primary or metastatic site"
      },
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER2-overexpressing by central lab defined as IHC 3+ or IHC 2+ with ISH positive"
      }
    ],
    "cancer_stages": [
      "UNRESECTABLE",
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Stage 1: T-DXd 5.4 mg/kg Q3W",
        "value": 45.0,
        "unit": "percentage of participants",
        "ci_lower": 29.3,
        "ci_upper": 61.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Stage 2: T-DXd 5.4 mg/kg Q3W",
        "value": 31.0,
        "unit": "percentage of participants",
        "ci_lower": 17.6,
        "ci_upper": 47.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Stage 1: T-DXd 6.4 mg/kg Q3W",
        "value": 27.5,
        "unit": "percentage of participants",
        "ci_lower": 14.6,
        "ci_upper": 43.9,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "DS-8201a 5.4 mg/kg Q3W"
      ],
      "OG001": [
        "DS-8201a 5.4 mg/kg Q3W"
      ],
      "OG002": [
        "DS-8201a 6.4 mg/kg Q3W"
      ]
    },
    "treatment_class_map": {
      "OG000": "ADC",
      "OG001": "ADC",
      "OG002": "ADC"
    }
  },
  {
    "nct_id": "NCT01336634",
    "brief_title": "Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.",
    "status": "COMPLETED",
    "start_date": "2011-08-05",
    "completion_date": "2015-10-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT01336634",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "BRAF",
        "status": "POSITIVE",
        "details": "V600E mutation; must be confirmed in tumor tissue in a CLIA-certified (or equivalent) lab; adequate archived or fresh biopsy available for central validation"
      },
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "Previously tested for presence of EGFR mutation; if EGFR mutation is present the subject is eligible only if they have previously received EGFR inhibitor(s)"
      },
      {
        "target": "ALK",
        "status": "ANY",
        "details": "Previously tested for presence of ALK mutation; if ALK mutation is present the subject is eligible only if they have previously received ALK inhibitor(s)"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort A (Dabrafenib Monotherapy)",
        "value": 27.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD",
        "value": 39.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD",
        "value": 23.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD",
        "value": 4.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort A (Dabrafenib Monotherapy)",
        "value": 5.4,
        "unit": "Months",
        "ci_lower": 2.8,
        "ci_upper": 6.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD",
        "value": 10.2,
        "unit": "Months",
        "ci_lower": 6.9,
        "ci_upper": 16.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD",
        "value": 10.8,
        "unit": "Months",
        "ci_lower": 7.0,
        "ci_upper": 14.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD",
        "value": 11.0,
        "unit": "Months",
        "ci_lower": 3.0,
        "ci_upper": 18.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cohort A (Dabrafenib Monotherapy)",
        "value": 12.7,
        "unit": "Months",
        "ci_lower": 7.3,
        "ci_upper": 16.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD",
        "value": 18.2,
        "unit": "Months",
        "ci_lower": 14.3,
        "ci_upper": 28.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD",
        "value": 17.3,
        "unit": "Months",
        "ci_lower": 12.3,
        "ci_upper": 40.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Dabrafenib"
      ],
      "OG001": [
        "Dabrafenib",
        "Trametinib"
      ],
      "OG002": [
        "Dabrafenib",
        "Trametinib"
      ],
      "OG003": [
        "Dabrafenib",
        "Trametinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT04768686",
    "brief_title": "FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric Cancer",
    "status": "COMPLETED",
    "start_date": "2021-05-18",
    "completion_date": "2024-08-12",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hanmi Pharmaceutical Company Limited",
    "url": "https://clinicaltrials.gov/study/NCT04768686",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [
      {
        "target": "EBV",
        "status": "POSITIVE",
        "details": "Cohort 2: Epstein-Barr Virus positive by standard methods (e.g., EBER ISH or LMP-1 IHC); checkpoint inhibitor\u2013na\u00efve; \u22651 prior systemic treatment"
      },
      {
        "target": "EBV",
        "status": "NEGATIVE",
        "details": "Cohort 1: Epstein-Barr Virus negative; checkpoint inhibitor\u2013na\u00efve; disease progression after \u22652 prior systemic treatments"
      },
      {
        "target": "MSI",
        "status": "NEGATIVE",
        "details": "MSI-H status excluded (patient must not be MSI-H)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort 1: EBV Negative / CPI na\u00efve Gastric Cancer",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 30.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Cohort 2: EBV Positive / CPI na\u00efve Gastric Cancer",
        "value": 60.0,
        "unit": "percentage of participants",
        "ci_lower": 26.2,
        "ci_upper": 87.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1: EBV Negative / CPI na\u00efve Gastric Cancer",
        "value": 1.4,
        "unit": "months",
        "ci_lower": 1.1,
        "ci_upper": 1.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort 2: EBV Positive / CPI na\u00efve Gastric Cancer",
        "value": 10.4,
        "unit": "months",
        "ci_lower": 1.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1: EBV Negative / CPI na\u00efve Gastric Cancer",
        "value": 7.5,
        "unit": "months",
        "ci_lower": 1.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cohort 2: EBV Positive / CPI na\u00efve Gastric Cancer",
        "value": null,
        "unit": "months",
        "ci_lower": 2.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "FLX475",
        "Pembrolizumab"
      ],
      "OG001": [
        "FLX475",
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_IO",
      "OG001": "Combo_TKI_IO"
    }
  },
  {
    "nct_id": "NCT04738487",
    "brief_title": "Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2021-04-07",
    "completion_date": "2024-09-05",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT04738487",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "POSITIVE",
        "details": "PD-L1 expression \u22651% of tumor cells by IHC at a central laboratory"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "Absence of ALK gene rearrangements"
      },
      {
        "target": "ROS1",
        "status": "NEGATIVE",
        "details": "Absence of ROS1 gene rearrangements"
      },
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "EGFR-directed therapy not indicated as primary therapy (i.e., actionable EGFR mutations that would warrant EGFR-directed therapy are excluded)"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab/Vibostolimab",
        "value": 15.7,
        "unit": "Months",
        "ci_lower": 12.4,
        "ci_upper": 24.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Pembrolizumab",
        "value": 20.3,
        "unit": "Months",
        "ci_lower": 16.7,
        "ci_upper": 24.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Vibostolimab"
      ],
      "OG001": [
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO"
    }
  },
  {
    "nct_id": "NCT00085202",
    "brief_title": "Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor",
    "status": "COMPLETED",
    "start_date": "2003-08",
    "completion_date": "2016-12",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "St. Jude Children's Research Hospital",
    "url": "https://clinicaltrials.gov/study/NCT00085202",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Overall Study - Positive ERBB2",
        "value": 79.2,
        "unit": "probability of PFS at 2 years",
        "ci_lower": 70.4,
        "ci_upper": 88.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Average-Risk Group - Positive ERBB2",
        "value": 83.3,
        "unit": "probability of PFS at 2 years",
        "ci_lower": 73.5,
        "ci_upper": 93.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "High-Risk Group - Positive ERBB2",
        "value": 69.6,
        "unit": "probability of PFS at 2 years",
        "ci_lower": 50.8,
        "ci_upper": 88.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Overall Study - Negative ERBB2",
        "value": 86.7,
        "unit": "probability of PFS at 2 years",
        "ci_lower": 76.9,
        "ci_upper": 96.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Average-Risk Group - Negative ERBB2",
        "value": 93.5,
        "unit": "probability of PFS at 2 years",
        "ci_lower": 85.1,
        "ci_upper": 100.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "High-Risk Group - Negative ERBB2",
        "value": 71.4,
        "unit": "probability of PFS at 2 years",
        "ci_lower": 48.9,
        "ci_upper": 93.9,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {},
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER",
      "OG002": "OTHER",
      "OG003": "OTHER",
      "OG004": "OTHER",
      "OG005": "OTHER",
      "OG006": "OTHER",
      "OG007": "OTHER"
    }
  },
  {
    "nct_id": "NCT04739761",
    "brief_title": "A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2021-06-22",
    "completion_date": "2024-02-08",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT04739761",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER2-positive status as determined per American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines (IHC/ISH)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [],
    "arm_drugs": {
      "OG000": [
        "Trastuzumab Deruxtecan"
      ],
      "OG001": [
        "Trastuzumab Deruxtecan"
      ]
    },
    "treatment_class_map": {
      "OG000": "ADC",
      "OG001": "ADC"
    }
  },
  {
    "nct_id": "NCT01319565",
    "brief_title": "Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...",
    "status": "COMPLETED",
    "start_date": "2011-03-24",
    "completion_date": "2024-09-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT01319565",
    "cancer_types": [
      "SKCM"
    ],
    "biomarkers": [
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "Seronegative for human immunodeficiency virus (HIV) antibody"
      },
      {
        "target": "HBV",
        "status": "NEGATIVE",
        "details": "Seronegative for hepatitis B antigen"
      },
      {
        "target": "HCV",
        "status": "NEGATIVE",
        "details": "Seronegative for hepatitis C antibody or antigen"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Arm 1: Tumor Infiltrating Lymphocytes (TIL) + High Dose (HD) Interleukin-2 (IL-2)",
        "value": 47.1,
        "unit": "Percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Arm 2: Tumor Infiltrating Lymphocytes + High Dose Interleukin-2 + 1200 Total Body Irradiation (TBI)",
        "value": 64.6,
        "unit": "Percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm 01: Tumor Infiltrating Lymphocytes (TIL) + High Dose (HD) Interleukin-2 (IL-2)",
        "value": 36.2,
        "unit": "Months",
        "ci_lower": 1.2,
        "ci_upper": 158.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm 2: Tumor Infiltrating Lymphocytes + High Dose Interleukin-2 + 1200 Total Body Irradiation (TBI)",
        "value": 37.3,
        "unit": "Months",
        "ci_lower": 2.5,
        "ci_upper": 138.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm 01: Tumor Infiltrating Lymphocytes (TIL) + High Dose (HD) Interleukin-2 (IL-2)",
        "value": 6.8,
        "unit": "Months",
        "ci_lower": 1.1,
        "ci_upper": 158.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm 2: Tumor Infiltrating Lymphocytes + High Dose Interleukin-2 + 1200 Total Body Irradiation (TBI)",
        "value": 9.3,
        "unit": "Months",
        "ci_lower": 0.5,
        "ci_upper": 109.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Aldesleukin",
        "Cyclophosphamide",
        "Fludarabine",
        "Young TIL"
      ],
      "OG001": [
        "Aldesleukin",
        "Cyclophosphamide",
        "Fludarabine",
        "Young TIL"
      ],
      "OG002": [
        "Aldesleukin",
        "Cyclophosphamide",
        "Fludarabine",
        "Young TIL"
      ],
      "OG003": [
        "Aldesleukin",
        "Cyclophosphamide",
        "Fludarabine",
        "Young TIL"
      ],
      "OG004": [
        "Aldesleukin",
        "Cyclophosphamide",
        "Fludarabine",
        "Young TIL"
      ],
      "OG005": [
        "Aldesleukin",
        "Cyclophosphamide",
        "Fludarabine",
        "Young TIL"
      ],
      "OG006": [
        "Aldesleukin",
        "Cyclophosphamide",
        "Fludarabine",
        "Young TIL"
      ],
      "OG007": [
        "Aldesleukin",
        "Cyclophosphamide",
        "Fludarabine",
        "Young TIL"
      ],
      "OG008": [
        "Aldesleukin",
        "Cyclophosphamide",
        "Fludarabine",
        "Young TIL"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Combo_Chemo_IO",
      "OG002": "Combo_Chemo_IO",
      "OG003": "Combo_Chemo_IO",
      "OG004": "Combo_Chemo_IO",
      "OG005": "Combo_Chemo_IO",
      "OG006": "Combo_Chemo_IO",
      "OG007": "Combo_Chemo_IO",
      "OG008": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT04751929",
    "brief_title": "Abemaciclib With or Without Atezolizumab for mCRPC",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2021-08-20",
    "completion_date": "2024-06-17",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Dana-Farber Cancer Institute",
    "url": "https://clinicaltrials.gov/study/NCT04751929",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Biomarker-Unselected Abemaciclib Monotherapy (Randomized)",
        "value": 100.0,
        "unit": "percentage of participants",
        "ci_lower": 100.0,
        "ci_upper": 100.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Biomarker-Unselected Abemaciclib + Atezolizumab (Randomized)",
        "value": null,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "CDK12 Mutation Atezolizumab Monotherapy (Non-Randomized)",
        "value": 50.0,
        "unit": "percentage of participants",
        "ci_lower": 10.0,
        "ci_upper": 81.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized)",
        "value": null,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Biomarker-Unselected Abemaciclib Monotherapy (Randomized)",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 0.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Biomarker-Unselected Abemaciclib + Atezolizumab (Randomized)",
        "value": 12.5,
        "unit": "percentage of participants",
        "ci_lower": 0.6,
        "ci_upper": 47.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "CDK12 Mutation Atezolizumab Monotherapy (Non-Randomized)",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 0.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized)",
        "value": null,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Abemaciclib"
      ],
      "OG001": [
        "Abemaciclib",
        "Atezolizumab"
      ],
      "OG002": [
        "Atezolizumab"
      ],
      "OG003": [
        "Abemaciclib",
        "Atezolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Combo_IO_Targeted",
      "OG002": "IO",
      "OG003": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT00112502",
    "brief_title": "Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme",
    "status": "COMPLETED",
    "start_date": "2005-09",
    "completion_date": "2014-09",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "M.D. Anderson Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT00112502",
    "cancer_types": [
      "GBM"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Thalidomide: Arm II, Arm VI, Arm VII and Arm VIII",
        "value": 7.6,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "No Thalidomide: Arm I, Arm III, Arm IV and Arm V",
        "value": 8.7,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Temozolomide",
        "Thalidomide",
        "Celecoxib",
        "Isotretinoin"
      ],
      "OG001": [
        "Temozolomide",
        "Celecoxib",
        "Isotretinoin"
      ],
      "OG002": [
        "Temozolomide",
        "Celecoxib"
      ],
      "OG003": [
        "Temozolomide",
        "Isotretinoin"
      ],
      "OG004": [
        "Temozolomide",
        "Isotretinoin",
        "Celecoxib"
      ],
      "OG005": [
        "Temozolomide",
        "Thalidomide",
        "Celecoxib"
      ],
      "OG006": [
        "Temozolomide",
        "Thalidomide",
        "Isotretinoin"
      ],
      "OG007": [
        "Temozolomide",
        "Thalidomide",
        "Isotretinoin",
        "Celecoxib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo",
      "OG002": "Chemo",
      "OG003": "Chemo",
      "OG004": "Chemo",
      "OG005": "Chemo",
      "OG006": "Chemo",
      "OG007": "Chemo"
    }
  },
  {
    "nct_id": "NCT00113217",
    "brief_title": "Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma",
    "status": "COMPLETED",
    "start_date": "2005-02",
    "completion_date": "2012-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "M.D. Anderson Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT00113217",
    "cancer_types": [
      "KIRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "NEOADJUVANT",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab",
        "value": 11.0,
        "unit": "months",
        "ci_lower": 5.5,
        "ci_upper": 15.6,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01350245",
    "brief_title": "Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor",
    "status": "COMPLETED",
    "start_date": "2010-07",
    "completion_date": "2013-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sidney Kimmel Cancer Center at Thomas Jefferson University",
    "url": "https://clinicaltrials.gov/study/NCT01350245",
    "cancer_types": [
      "LAML",
      "DLBC",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "HLA",
        "status": "ANY",
        "details": "Related donor must be a two-or-more allele mismatch at the HLA-A, HLA-B, HLA-C, HLA-DR loci"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "TJU 2 Step Regimen",
        "value": 78.6,
        "unit": "percentage of patients",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "TJU 2 Step Regimen",
        "value": 85.0,
        "unit": "percentage of probability",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Donor Lymphocyte Infusion (DLI)",
        "Cyclophosphamide",
        "Mycophenolate Mofetil (MMF)",
        "Tacrolimus"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER"
    }
  },
  {
    "nct_id": "NCT01374425",
    "brief_title": "Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC)",
    "status": "COMPLETED",
    "start_date": "2011-08",
    "completion_date": "2015-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Genentech, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT01374425",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "UGT1A1",
        "status": "NEGATIVE",
        "details": "Homozygosity for the UGT1A1*28 allele (evidence of Gilbert's syndrome)"
      },
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "Known positivity for human immunodeficiency virus (HIV) is excluded"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab + mFOLFOX6",
        "value": 10.09,
        "unit": "months",
        "ci_lower": 8.8,
        "ci_upper": 11.56,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab + FOLFIRI",
        "value": 12.55,
        "unit": "months",
        "ci_lower": 10.48,
        "ci_upper": 14.29,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab + mFOLFOX6",
        "value": 23.85,
        "unit": "months",
        "ci_lower": 20.4,
        "ci_upper": 26.05,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab + FOLFIRI",
        "value": 27.47,
        "unit": "months",
        "ci_lower": 24.64,
        "ci_upper": 36.73,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Bevacizumab",
        "Oxaliplatin",
        "Leucovorin",
        "5-Fluorouracil"
      ],
      "OG001": [
        "Bevacizumab",
        "Irinotecan",
        "Leucovorin",
        "5-Fluorouracil"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT01373164",
    "brief_title": "A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer",
    "status": "COMPLETED",
    "start_date": "2011-06",
    "completion_date": "2015-11",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT01373164",
    "cancer_types": [
      "PAAD",
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "II",
      "III",
      "IV",
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Phase 2: 300 mg Galunisertib + Gemcitabine",
        "value": 8.9,
        "unit": "Months",
        "ci_lower": 7.3,
        "ci_upper": 11.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Phase 2: Placebo + Gemcitabine",
        "value": 7.1,
        "unit": "Months",
        "ci_lower": 5.8,
        "ci_upper": 9.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase 2: 300 mg Galunisertib + Gemcitabine",
        "value": 4.11,
        "unit": "Months",
        "ci_lower": 2.66,
        "ci_upper": 5.42,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Phase 2: Placebo + Gemcitabine",
        "value": 2.86,
        "unit": "Months",
        "ci_lower": 1.94,
        "ci_upper": 3.75,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Galunisertib",
        "Gemcitabine"
      ],
      "OG001": [
        "Gemcitabine"
      ],
      "OG002": [
        "Galunisertib",
        "Gemcitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo",
      "OG002": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT01364727",
    "brief_title": "A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies",
    "status": "COMPLETED",
    "start_date": "2011-06",
    "completion_date": "2014-07",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Heather Wakelee",
    "url": "https://clinicaltrials.gov/study/NCT01364727",
    "cancer_types": [
      "THYM"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Amrubicin",
        "value": 6.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Amrubicin",
        "value": 8.5,
        "unit": "Months",
        "ci_lower": 6.7,
        "ci_upper": 38.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Amrubicin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo"
    }
  },
  {
    "nct_id": "NCT04882241",
    "brief_title": "Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension",
    "status": "COMPLETED",
    "start_date": "2020-07-29",
    "completion_date": "2024-02-16",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT04882241",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "II",
      "III",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "NEOADJUVANT",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + XP/FP",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + XP/FP",
        "value": null,
        "unit": "Months",
        "ci_lower": 25.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Cisplatin",
        "Capecitabine",
        "5-fluorouracil"
      ],
      "OG001": [
        "Cisplatin",
        "Capecitabine",
        "5-fluorouracil"
      ],
      "OG002": [
        "Pembrolizumab",
        "Cisplatin",
        "Capecitabine",
        "5-fluorouracil",
        "Docetaxel",
        "Oxaliplatin",
        "Leucovorin"
      ],
      "OG003": [
        "Cisplatin",
        "Capecitabine",
        "5-fluorouracil",
        "Docetaxel",
        "Oxaliplatin",
        "Leucovorin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Chemo",
      "OG002": "Combo_Chemo_IO",
      "OG003": "Chemo"
    }
  },
  {
    "nct_id": "NCT01360840",
    "brief_title": "EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer",
    "status": "COMPLETED",
    "start_date": "2011-04",
    "completion_date": "2013-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "EMD Serono",
    "url": "https://clinicaltrials.gov/study/NCT01360840",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Placebo + SoC",
        "value": 3.3,
        "unit": "months",
        "ci_lower": 2.8,
        "ci_upper": 4.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "EMD 525797 750 mg + SoC",
        "value": 3.4,
        "unit": "months",
        "ci_lower": 2.8,
        "ci_upper": 5.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "EMD 525797 1500 mg + SoC",
        "value": 4.3,
        "unit": "months",
        "ci_lower": 2.8,
        "ci_upper": 6.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Placebo + SoC",
        "value": null,
        "unit": "months",
        "ci_lower": 14.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "EMD 525797 750 mg + SoC",
        "value": null,
        "unit": "months",
        "ci_lower": 12.9,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "EMD 525797 1500 mg + SoC",
        "value": null,
        "unit": "months",
        "ci_lower": 14.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG000",
        "arm_title": "Placebo + SoC",
        "value": 3.3,
        "unit": "months",
        "ci_lower": 2.8,
        "ci_upper": 5.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG001",
        "arm_title": "EMD 525797 750 mg + SoC",
        "value": 3.4,
        "unit": "months",
        "ci_lower": 2.8,
        "ci_upper": 5.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG002",
        "arm_title": "EMD 525797 1500 mg + SoC",
        "value": 4.6,
        "unit": "months",
        "ci_lower": 2.8,
        "ci_upper": 6.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG001": [
        "EMD 525797"
      ],
      "OG002": [
        "EMD 525797"
      ]
    },
    "treatment_class_map": {
      "OG000": "Placebo",
      "OG001": "OTHER",
      "OG002": "OTHER"
    }
  },
  {
    "nct_id": "NCT01362296",
    "brief_title": "An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2011-09",
    "completion_date": "2012-09",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "GlaxoSmithKline",
    "url": "https://clinicaltrials.gov/study/NCT01362296",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "POSITIVE",
        "details": "positive mutational status"
      },
      {
        "target": "NRAS",
        "status": "POSITIVE",
        "details": "positive mutational status"
      },
      {
        "target": "BRAF",
        "status": "POSITIVE",
        "details": "positive mutational status"
      },
      {
        "target": "MEK1",
        "status": "POSITIVE",
        "details": "positive mutational status"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "GSK1120212 2 mg in RP",
        "value": 11.7,
        "unit": "Weeks",
        "ci_lower": 7.0,
        "ci_upper": 12.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Docetaxel 75 mg/m^2 in RP",
        "value": 11.4,
        "unit": "Weeks",
        "ci_lower": 6.1,
        "ci_upper": 18.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "GSK1120212 2 mg in RP",
        "value": 8.1,
        "unit": "Months",
        "ci_lower": 6.8,
        "ci_upper": 10.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Docetaxel 75 mg/m^2 in RP",
        "value": 9.9,
        "unit": "Months",
        "ci_lower": 5.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "GSK1120212"
      ],
      "OG001": [
        "docetaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01351415",
    "brief_title": "A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)",
    "status": "COMPLETED",
    "start_date": "2011-06-25",
    "completion_date": "2016-06-25",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT01351415",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "EGFR mutation\u2013positive disease by local laboratory testing is excluded"
      }
    ],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab + Standard of Care",
        "value": 11.86,
        "unit": "Months",
        "ci_lower": 10.22,
        "ci_upper": 13.67,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Standard of Care",
        "value": 10.22,
        "unit": "Months",
        "ci_lower": 8.61,
        "ci_upper": 11.93,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Bevacizumab",
        "Erlotinib",
        "Docetaxel",
        "Pemetrexed"
      ],
      "OG001": [
        "Erlotinib",
        "Docetaxel",
        "Pemetrexed"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT01373294",
    "brief_title": "Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer",
    "status": "COMPLETED",
    "start_date": "2011-11-30",
    "completion_date": "2015-01-09",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
    "url": "https://clinicaltrials.gov/study/NCT01373294",
    "cancer_types": [
      "BLCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "I",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "A: Combination Arm",
        "value": 8.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Bacille Calmette-Gu\u00e9rin (BCG)",
        "Lenalidomide"
      ],
      "OG001": [
        "Bacille Calmette-Gu\u00e9rin (BCG)"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT01345682",
    "brief_title": "LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy",
    "status": "COMPLETED",
    "start_date": "2012-01-05",
    "completion_date": "2014-03-15",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Boehringer Ingelheim",
    "url": "https://clinicaltrials.gov/study/NCT01345682",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Afatinib (BIBW 2992)",
        "value": 2.63,
        "unit": "months",
        "ci_lower": 2.1,
        "ci_upper": 2.73,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Methotrexate",
        "value": 1.74,
        "unit": "months",
        "ci_lower": 1.48,
        "ci_upper": 2.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Afatinib (BIBW 2992)",
        "value": 6.87,
        "unit": "months",
        "ci_lower": 6.14,
        "ci_upper": 7.79,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Methotrexate",
        "value": 6.01,
        "unit": "months",
        "ci_lower": 5.16,
        "ci_upper": 7.75,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Afatinib"
      ],
      "OG001": [
        "Methotrexate"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01360554",
    "brief_title": "ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2011-06-16",
    "completion_date": "2013-09-30",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT01360554",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo)",
        "value": 2.6,
        "unit": "Months",
        "ci_lower": 1.9,
        "ci_upper": 2.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo)",
        "value": 2.5,
        "unit": "Months",
        "ci_lower": 1.9,
        "ci_upper": 2.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo)",
        "value": 7.9,
        "unit": "Months",
        "ci_lower": 6.8,
        "ci_upper": 9.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo)",
        "value": 8.3,
        "unit": "Months",
        "ci_lower": 7.4,
        "ci_upper": 9.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Dacomitinib"
      ],
      "OG001": [
        "Erlotinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT04865289",
    "brief_title": "Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study",
    "status": "COMPLETED",
    "start_date": "2019-10-22",
    "completion_date": "2023-10-02",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT04865289",
    "cancer_types": [
      "UCEC"
    ],
    "biomarkers": [
      {
        "target": "MMR",
        "status": "ANY",
        "details": "Mismatch repair (MMR) status to be determined from archival or new tumor tissue (e.g., dMMR/MSI-H vs pMMR/MSS)"
      }
    ],
    "cancer_stages": [
      "III",
      "IV",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Lenvatinib + Pembrolizumab",
        "value": 10.3,
        "unit": "Months",
        "ci_lower": 6.4,
        "ci_upper": 12.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Paclitaxel + Carboplatin",
        "value": 10.2,
        "unit": "Months",
        "ci_lower": 8.3,
        "ci_upper": 10.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Lenvatinib + Pembrolizumab",
        "value": 37.1,
        "unit": "Months",
        "ci_lower": 19.5,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Paclitaxel + Carboplatin",
        "value": null,
        "unit": "Months",
        "ci_lower": 21.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Lenvatinib",
        "Pembrolizumab"
      ],
      "OG001": [
        "Paclitaxel",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01351350",
    "brief_title": "Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies",
    "status": "COMPLETED",
    "start_date": "2011-02-28",
    "completion_date": "2017-09-15",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Millennium Pharmaceuticals, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT01351350",
    "cancer_types": [
      "BRCA",
      "STAD",
      "DLBC"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2- or unknown participants eligible for expansion phase (Arm A)"
      },
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER2+ participants eligible for expansion phase (Arm B)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "MLN0128P 30 or 40 mg QW",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "MLN0128P 6, 7, 8, 9 or 10 mg QD\u0000d73d QW",
        "value": 9.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "MLN0128P 7 mg QD\u0000d75d QW",
        "value": 44.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Expansion Cohort MLN0128P 8 mg QD\u0000d73d QW HER2-",
        "value": 10.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Expansion Cohort MLN0128PH 8mg QDx3d QW HER2+ Plus Trastuzumab",
        "value": 20.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "MLN0128",
        "paclitaxel"
      ],
      "OG001": [
        "MLN0128",
        "paclitaxel"
      ],
      "OG002": [
        "MLN0128",
        "paclitaxel"
      ],
      "OG003": [
        "MLN0128",
        "paclitaxel"
      ],
      "OG004": [
        "MLN0128",
        "paclitaxel"
      ],
      "OG005": [
        "MLN0128",
        "paclitaxel"
      ],
      "OG006": [
        "MLN0128",
        "paclitaxel"
      ],
      "OG007": [
        "MLN0128",
        "paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted",
      "OG003": "Combo_Chemo_Targeted",
      "OG004": "Combo_Chemo_Targeted",
      "OG005": "Combo_Chemo_Targeted",
      "OG006": "Combo_Chemo_Targeted",
      "OG007": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT01357161",
    "brief_title": "A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)",
    "status": "COMPLETED",
    "start_date": "2011-07-26",
    "completion_date": "2016-08-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT01357161",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "TP53",
        "status": "POSITIVE",
        "details": "p53 (TP53) gene mutation in tumor"
      }
    ],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Part 2: MK-1775 225 mg + Paclitaxel +Carboplatin",
        "value": 34.14,
        "unit": "weeks",
        "ci_lower": 29.86,
        "ci_upper": 43.14,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Part 2: Placebo + Paclitaxel +Carboplatin",
        "value": 31.86,
        "unit": "weeks",
        "ci_lower": 24.43,
        "ci_upper": 35.57,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Part 2: MK-1775 225 mg + Paclitaxel +Carboplatin",
        "value": null,
        "unit": "months",
        "ci_lower": 20.34,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Part 2: Placebo + Paclitaxel +Carboplatin",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "adavosertib",
        "paclitaxel",
        "carboplatin"
      ],
      "OG001": [
        "adavosertib",
        "paclitaxel",
        "carboplatin"
      ],
      "OG002": [
        "paclitaxel",
        "carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Chemo"
    }
  },
  {
    "nct_id": "NCT00113373",
    "brief_title": "Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer",
    "status": "COMPLETED",
    "start_date": "2005-05",
    "completion_date": "2011-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT00113373",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Lapatinib",
        "value": 8.0,
        "unit": "percentage of participants",
        "ci_lower": 1.4,
        "ci_upper": 23.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Lapatinib",
        "value": 10.5,
        "unit": "months",
        "ci_lower": 3.4,
        "ci_upper": 17.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "lapatinib ditosylate"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "OTHER",
      "OG002": "OTHER",
      "OG003": "OTHER",
      "OG004": "OTHER"
    }
  },
  {
    "nct_id": "NCT04880863",
    "brief_title": "NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC",
    "status": "COMPLETED",
    "start_date": "2021-10-26",
    "completion_date": "2024-01-30",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "NeoTX Therapeutics Ltd.",
    "url": "https://clinicaltrials.gov/study/NCT04880863",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "Driver mutation positive tumor (example given as prior exposure to EGFR inhibitors)"
      },
      {
        "target": "ALK",
        "status": "POSITIVE",
        "details": "Driver mutation positive tumor (example given as prior exposure to ALK inhibitors)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment",
        "value": 15.6,
        "unit": "percentage of responders",
        "ci_lower": 5.3,
        "ci_upper": 32.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment",
        "value": 8.8,
        "unit": "months",
        "ci_lower": 6.1,
        "ci_upper": 15.2,
        "dispersion_type": "MEAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment",
        "value": 8.8,
        "unit": "months",
        "ci_lower": 6.4,
        "ci_upper": 11.7,
        "dispersion_type": "MEAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "NAP (Naptumomab estafenatox)",
        "Docetaxel",
        "Obinutuzumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT01343043",
    "brief_title": "A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1\u1d9c\u00b2\u2075\u2079T in HLA-A2+ Patients With Synovial Sarcoma",
    "status": "COMPLETED",
    "start_date": "2012-09-27",
    "completion_date": "2019-06-18",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "GlaxoSmithKline",
    "url": "https://clinicaltrials.gov/study/NCT01343043",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "NYESO1",
        "status": "POSITIVE",
        "details": "NY-ESO-1 expression by IHC. Cohort 1: 2+ and/or 3+ in \u226550% of cells; Cohort 2: \u22651+ in \u22651% of cells but not exceed 2+ and/or 3+ in \u226550% of cells; Cohorts 3\u20134: 2+ and/or 3+ in \u226550% of cells."
      },
      {
        "target": "HLA-A02",
        "status": "POSITIVE",
        "details": "HLA high-resolution typing positive for HLA-A*02:01, HLA-A*02:05 and/or HLA-A*02:06."
      },
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "No active HIV infection."
      },
      {
        "target": "HBV",
        "status": "NEGATIVE",
        "details": "No active hepatitis B infection (seronegative for hepatitis B surface antigen [HBsAg])."
      },
      {
        "target": "HCV",
        "status": "NEGATIVE",
        "details": "No active hepatitis C infection (seronegative for hepatitis C antibody)."
      },
      {
        "target": "HTLV",
        "status": "NEGATIVE",
        "details": "No active HTLV-1/2 infection."
      }
    ],
    "cancer_stages": [
      "UNRESECTABLE",
      "METASTATIC",
      "RECURRENT",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort 1: High NY-ESO-1 Expression Treated With Regimen A",
        "value": 50.0,
        "unit": "Percentage of Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Cohort 2: Low NY-ESO-1 Expression Treated With Regimen A",
        "value": 30.8,
        "unit": "Percentage of Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Cohort 3: High NY-ESO-1 Expression Treated With Regimen B",
        "value": 20.0,
        "unit": "Percentage of Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Cohort 4: High NY-ESO-1 Expression Treated With Regimen C",
        "value": 26.7,
        "unit": "Percentage of Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1: High NY-ESO-1 Expression Treated With Regimen A",
        "value": 15.4,
        "unit": "Weeks",
        "ci_lower": 8.6,
        "ci_upper": 37.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort 2: Low NY-ESO-1 Expression Treated With Regimen A",
        "value": 13.1,
        "unit": "Weeks",
        "ci_lower": 8.3,
        "ci_upper": 13.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Cohort 3: High NY-ESO-1 Expression Treated With Regimen B",
        "value": 8.6,
        "unit": "Weeks",
        "ci_lower": 8.3,
        "ci_upper": 12.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Cohort 4: High NY-ESO-1 Expression Treated With Regimen C",
        "value": 22.4,
        "unit": "Weeks",
        "ci_lower": 11.6,
        "ci_upper": 38.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1: High NY-ESO-1 Expression Treated With Regimen A",
        "value": 80.7,
        "unit": "Weeks",
        "ci_lower": 45.3,
        "ci_upper": 212.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cohort 2: Low NY-ESO-1 Expression Treated With Regimen A",
        "value": 43.1,
        "unit": "Weeks",
        "ci_lower": 19.4,
        "ci_upper": 85.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Cohort 3: High NY-ESO-1 Expression Treated With Regimen B",
        "value": 86.4,
        "unit": "Weeks",
        "ci_lower": 68.1,
        "ci_upper": 104.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Cohort 4: High NY-ESO-1 Expression Treated With Regimen C",
        "value": 105.3,
        "unit": "Weeks",
        "ci_lower": 50.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "NY-ESO-1(c259)T Cells",
        "Fludarabine",
        "Cyclophosphamide"
      ],
      "OG001": [
        "NY-ESO-1(c259)T Cells",
        "Fludarabine",
        "Cyclophosphamide"
      ],
      "OG002": [
        "NY-ESO-1(c259)T Cells",
        "Fludarabine",
        "Cyclophosphamide"
      ],
      "OG003": [
        "NY-ESO-1(c259)T Cells",
        "Fludarabine",
        "Cyclophosphamide"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER",
      "OG002": "OTHER",
      "OG003": "OTHER"
    }
  },
  {
    "nct_id": "NCT04776148",
    "brief_title": "Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)",
    "status": "COMPLETED",
    "start_date": "2021-03-29",
    "completion_date": "2024-09-27",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT04776148",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "MSI",
        "status": "NEGATIVE",
        "details": "Tumor must be determined NOT microsatellite instability-high (MSI-H) / mismatch repair deficient (dMMR) by local testing"
      },
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "RAS (KRAS/NRAS) wild-type \u2014 if RAS wild-type, anti-EGFR therapy (cetuximab or panitumumab) should have been given as part of prior standard treatment"
      },
      {
        "target": "NRAS",
        "status": "NEGATIVE",
        "details": "RAS (KRAS/NRAS) wild-type \u2014 if RAS wild-type, anti-EGFR therapy (cetuximab or panitumumab) should have been given as part of prior standard treatment"
      },
      {
        "target": "BRAF",
        "status": "POSITIVE",
        "details": "BRAF V600E mutation \u2014 if present, prior standard treatment should have included a BRAF inhibitor in combination with cetuximab \u00b1 binimetinib"
      }
    ],
    "cancer_stages": [
      "IV",
      "IVA",
      "IVB",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Lenvatinib+Pembrolizumab",
        "value": 9.8,
        "unit": "Months",
        "ci_lower": 8.4,
        "ci_upper": 11.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Standard of Care (SOC) Treatment",
        "value": 9.3,
        "unit": "Months",
        "ci_lower": 8.2,
        "ci_upper": 10.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "pembrolizumab",
        "lenvatinib"
      ],
      "OG001": [
        "regorafenib",
        "TAS-102 (trifluridine and tipiracil)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_IO",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT01417000",
    "brief_title": "Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer",
    "status": "COMPLETED",
    "start_date": "2011-09-21",
    "completion_date": "2016-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Aduro Biotech, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT01417000",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cy/GVAX + CRS-207",
        "value": 6.28,
        "unit": "months",
        "ci_lower": 4.47,
        "ci_upper": 9.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cy/GVAX",
        "value": 4.07,
        "unit": "months",
        "ci_lower": 3.32,
        "ci_upper": 5.42,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cyclophosphamide",
        "GVAX Pancreas",
        "CRS-207"
      ],
      "OG001": [
        "Cyclophosphamide",
        "GVAX Pancreas"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT01404650",
    "brief_title": "Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor",
    "status": "COMPLETED",
    "start_date": "2011-12",
    "completion_date": "2015-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SCRI Development Innovations, LLC",
    "url": "https://clinicaltrials.gov/study/NCT01404650",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": true,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "AUY922",
        "value": 3.9,
        "unit": "months",
        "ci_lower": 2.5,
        "ci_upper": 5.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "AUY922",
        "value": 8.5,
        "unit": "months",
        "ci_lower": 5.2,
        "ci_upper": 16.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "AUY922"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01383707",
    "brief_title": "A Study of Bevacizumab and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2011-08-12",
    "completion_date": "2014-05-28",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT01383707",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab + mFOLFOX-6",
        "value": 54.5,
        "unit": "percentage of participants",
        "ci_lower": 42.8,
        "ci_upper": 65.9,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Bevacizumab",
        "5-Fluorouracil (5-FU)",
        "Levofolinic acid",
        "Oxaliplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT01446016",
    "brief_title": "Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT)",
    "status": "COMPLETED",
    "start_date": "2011-09",
    "completion_date": "2019-03-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "The Methodist Hospital Research Institute",
    "url": "https://clinicaltrials.gov/study/NCT01446016",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Chloroquine With Taxane or Taxane-Like (Paclitaxel, Docetaxel, Abraxane, Ixabepilone) Chemotherapy",
        "value": 45.16,
        "unit": "percentage of participants",
        "ci_lower": 29.2,
        "ci_upper": 62.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Chloroquine With Taxane or Taxane-Like (Paclitaxel, Docetaxel, Abraxane, Ixabepilone) Chemotherapy",
        "value": 12.4,
        "unit": "months",
        "ci_lower": 4.9,
        "ci_upper": 24.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Chloroquine With Taxane or Taxane-Like (Paclitaxel, Docetaxel, Abraxane, Ixabepilone) Chemotherapy",
        "value": 25.4,
        "unit": "months",
        "ci_lower": 13.7,
        "ci_upper": 83.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Chloroquine",
        "Paclitaxel",
        "Docetaxel",
        "Abraxane",
        "Ixabepilone"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo"
    }
  },
  {
    "nct_id": "NCT01457417",
    "brief_title": "A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2012-01",
    "completion_date": "2013-12",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Leap Therapeutics, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT01457417",
    "cancer_types": [
      "OTHER",
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [],
    "arm_drugs": {
      "OG000": [
        "DKN-01"
      ],
      "OG001": [
        "DKN-01"
      ],
      "OG002": [
        "DKN-01"
      ],
      "OG003": [
        "DKN-01"
      ],
      "OG004": [
        "DKN-01"
      ],
      "OG005": [
        "DKN-01"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other",
      "OG004": "Targeted_Other",
      "OG005": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01450319",
    "brief_title": "Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable Fc\u03b3RIIa (CD32) Genotype",
    "status": "COMPLETED",
    "start_date": "2011-12",
    "completion_date": "2014-12",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck KGaA, Darmstadt, Germany",
    "url": "https://clinicaltrials.gov/study/NCT01450319",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "POSITIVE",
        "details": "K-RAS mutated (mutated KRAS)"
      },
      {
        "target": "FCGR2A",
        "status": "POSITIVE",
        "details": "Presence of H allele at Fc\u03b3RIIa-131 (CD32 polymorphism); favorable FCGR2A genotype required"
      },
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "EGFR expression in tumor sample (EGFR expression required)"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cetuximab",
        "value": 6.71,
        "unit": "Months",
        "ci_lower": 5.42,
        "ci_upper": 8.05,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cetuximab",
        "value": 2.53,
        "unit": "Months",
        "ci_lower": 2.43,
        "ci_upper": 2.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cetuximab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01446159",
    "brief_title": "Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2011-06-13",
    "completion_date": "2019-06-28",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "MedImmune LLC",
    "url": "https://clinicaltrials.gov/study/NCT01446159",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "At least one hormone receptor required; tumors positive for ER, PgR, or both"
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": "At least one hormone receptor required; tumors positive for ER, PgR, or both"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-negative by FISH, CISH or IHC"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "MEDI-573 45 mg/kg + AI",
        "value": 12.65,
        "unit": "Months",
        "ci_lower": 8.15,
        "ci_upper": 15.54,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Aromatase Inhibitor",
        "value": 11.33,
        "unit": "Months",
        "ci_lower": 8.54,
        "ci_upper": 15.54,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "MEDI-573",
        "Aromatase Inhibitor"
      ],
      "OG001": [
        "MEDI-573",
        "Aromatase Inhibitor"
      ],
      "OG002": [
        "MEDI-573",
        "Aromatase Inhibitor"
      ],
      "OG003": [
        "Aromatase Inhibitor"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER",
      "OG002": "OTHER",
      "OG003": "OTHER"
    }
  },
  {
    "nct_id": "NCT01454934",
    "brief_title": "A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2011-12-09",
    "completion_date": "2014-05-30",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eisai Inc.",
    "url": "https://clinicaltrials.gov/study/NCT01454934",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "Documented presence or absence of EGFR mutations prior to enrolment; if EGFR\u2011mutant, prior EGFR TKI must have been given as one of the prior regimens"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "UNRESECTABLE",
      "RECURRENT"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A: Eribulin Mesylate",
        "value": 9.5,
        "unit": "months",
        "ci_lower": 7.4,
        "ci_upper": 11.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Vinorelbine, Gemcitabine, Docetaxel, or Pemetrexed",
        "value": 9.5,
        "unit": "months",
        "ci_lower": 8.5,
        "ci_upper": 11.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A: Eribulin Mesylate",
        "value": 3.0,
        "unit": "months",
        "ci_lower": 2.6,
        "ci_upper": 3.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Vinorelbine, Gemcitabine, Docetaxel, or Pemetrexed",
        "value": 2.8,
        "unit": "months",
        "ci_lower": 2.6,
        "ci_upper": 3.6,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Eribulin"
      ],
      "OG001": [
        "Vinorelbine",
        "Gemcitabine",
        "Docetaxel",
        "Pemetrexed"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01392183",
    "brief_title": "Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)",
    "status": "COMPLETED",
    "start_date": "2012-10-24",
    "completion_date": "2019-09-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "M.D. Anderson Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT01392183",
    "cancer_types": [
      "KIRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Temsirolimus (Control Group)",
        "value": 2.7,
        "unit": "months",
        "ci_lower": 1.2,
        "ci_upper": 24.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Pazopanib (Treatment Group)",
        "value": 5.2,
        "unit": "months",
        "ci_lower": 0.4,
        "ci_upper": 34.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Temsirolimus (Control Group)",
        "value": 7.1,
        "unit": "months",
        "ci_lower": 2.4,
        "ci_upper": 68.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Pazopanib (Treatment Group)",
        "value": 11.9,
        "unit": "months",
        "ci_lower": 1.3,
        "ci_upper": 63.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Temsirolimus"
      ],
      "OG001": [
        "Pazopanib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT01466036",
    "brief_title": "Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors",
    "status": "COMPLETED",
    "start_date": "2012-07",
    "completion_date": "2021-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Dana-Farber Cancer Institute",
    "url": "https://clinicaltrials.gov/study/NCT01466036",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Metastatic or Unresectable PNET",
        "value": 3.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Metastatic or Unresectable Carcinoid",
        "value": 7.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Metastatic or Unresectable PNET",
        "value": 21.1,
        "unit": "months",
        "ci_lower": 8.6,
        "ci_upper": 32.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Metastatic or Unresectable Carcinoid",
        "value": 17.6,
        "unit": "months",
        "ci_lower": 8.3,
        "ci_upper": 23.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Metastatic or Unresectable PNET",
        "value": 37.3,
        "unit": "months",
        "ci_lower": 14.5,
        "ci_upper": 70.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Metastatic or Unresectable Carcinoid",
        "value": 36.1,
        "unit": "months",
        "ci_lower": 20.6,
        "ci_upper": 65.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cabozantinib"
      ],
      "OG001": [
        "Cabozantinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT01378962",
    "brief_title": "A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER)",
    "status": "COMPLETED",
    "start_date": "2011-03-31",
    "completion_date": "2013-06-30",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT01378962",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Erlotinib 150 mg",
        "value": 12.58,
        "unit": "months",
        "ci_lower": 10.25,
        "ci_upper": 16.95,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Erlotinib 150 mg",
        "value": 17.48,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "erlotinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT01435122",
    "brief_title": "A Study of Axitinib in Advanced Carcinoid Tumors",
    "status": "COMPLETED",
    "start_date": "2011-10-25",
    "completion_date": "2017-01-11",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
    "url": "https://clinicaltrials.gov/study/NCT01435122",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Axitinib Administration",
        "value": 74.5,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Axitinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT01437449",
    "brief_title": "Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)",
    "status": "COMPLETED",
    "start_date": "2011-10",
    "completion_date": "2018-09-11",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Stanford University",
    "url": "https://clinicaltrials.gov/study/NCT01437449",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cisplatin + Docetaxel + Cetuximab",
        "value": 15.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cisplatin + Docetaxel + Cetuximab",
        "value": 4.8,
        "unit": "months",
        "ci_lower": 2.7,
        "ci_upper": 6.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cisplatin + Docetaxel + Cetuximab",
        "value": 14.7,
        "unit": "months",
        "ci_lower": 8.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cisplatin",
        "Docetaxel",
        "Cetuximab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT01433172",
    "brief_title": "Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2012-03-26",
    "completion_date": "2016-01-31",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
    "url": "https://clinicaltrials.gov/study/NCT01433172",
    "cancer_types": [
      "LUAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase II Arm A GM.CD40L Cells Vaccinations",
        "value": 2.4,
        "unit": "months",
        "ci_lower": 1.6,
        "ci_upper": 4.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Phase II Arm B GM.CD40L.CCL21 Vaccinations",
        "value": 3.1,
        "unit": "months",
        "ci_lower": 1.6,
        "ci_upper": 4.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Phase I - GM.CD40L.CCL21 Vaccinations"
      ],
      "OG001": [
        "Phase II - GM.CD40L.CCL21 Vaccinations"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT01427933",
    "brief_title": "A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2011-11",
    "completion_date": "2013-09",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT01427933",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "ANY",
        "details": "If the patient has HER2-positive disease, they must have received HER2-directed treatment or be a non-candidate for HER2-directed treatment"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ramucirumab and Eribulin",
        "value": 4.4,
        "unit": "months",
        "ci_lower": 3.1,
        "ci_upper": 6.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Eribulin Monotherapy",
        "value": 4.1,
        "unit": "months",
        "ci_lower": 3.2,
        "ci_upper": 5.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Ramucirumab and Eribulin",
        "value": 13.5,
        "unit": "Months",
        "ci_lower": 10.4,
        "ci_upper": 17.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Eribulin Monotherapy",
        "value": 11.5,
        "unit": "Months",
        "ci_lower": 9.0,
        "ci_upper": 17.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ramucirumab (IMC-1121B)",
        "Eribulin"
      ],
      "OG001": [
        "Eribulin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01401959",
    "brief_title": "Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy",
    "status": "COMPLETED",
    "start_date": "2011-09-23",
    "completion_date": "2017-04-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SCRI Development Innovations, LLC",
    "url": "https://clinicaltrials.gov/study/NCT01401959",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "ANY",
        "details": "HER2-positive patients may have received trastuzumab as part of neoadjuvant therapy; LVEF required for patients receiving trastuzumab with eribulin."
      }
    ],
    "cancer_stages": [
      "I",
      "II",
      "III",
      "IIIA",
      "IIIB",
      "IIIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [],
    "arm_drugs": {
      "OG000": [
        "Eribulin"
      ],
      "OG001": [
        "Eribulin"
      ],
      "OG002": [
        "Eribulin",
        "Trastuzumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo",
      "OG002": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT01461538",
    "brief_title": "Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies",
    "status": "COMPLETED",
    "start_date": "2011-10",
    "completion_date": "2014-12",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Seagen Inc.",
    "url": "https://clinicaltrials.gov/study/NCT01461538",
    "cancer_types": [
      "LLBC",
      "LAML",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "CD30",
        "status": "POSITIVE",
        "details": "CD30-positive nonlymphomatous malignancy confirmed by central review"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Solid Tumors",
        "value": 12.0,
        "unit": "percentage of participants",
        "ci_lower": 4.9,
        "ci_upper": 22.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Leukemia",
        "value": 14.0,
        "unit": "percentage of participants",
        "ci_lower": 1.8,
        "ci_upper": 42.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Solid Tumors",
        "value": 2.1,
        "unit": "months",
        "ci_lower": 1.3,
        "ci_upper": 2.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Leukemia",
        "value": 0.7,
        "unit": "months",
        "ci_lower": 0.7,
        "ci_upper": 1.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG002": [
        "brentuximab vedotin"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER",
      "OG002": "ADC"
    }
  },
  {
    "nct_id": "NCT01379534",
    "brief_title": "A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer",
    "status": "COMPLETED",
    "start_date": "2011-11",
    "completion_date": "2014-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT01379534",
    "cancer_types": [
      "UCEC"
    ],
    "biomarkers": [
      {
        "target": "FGFR2",
        "status": "ANY",
        "details": "FGFR2 mutated or wild-type; tissue required (archival or fixed fresh biopsy)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "FGFR2 (MUT)",
        "value": 31.8,
        "unit": "Percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "FGFR2 (WT)",
        "value": 29.0,
        "unit": "Percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "FGFR2 (MUT)",
        "value": 20.2,
        "unit": "Months",
        "ci_lower": 8.2,
        "ci_upper": 20.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "FGFR2 (WT)",
        "value": 9.3,
        "unit": "Months",
        "ci_lower": 6.0,
        "ci_upper": 15.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "TKI258"
      ],
      "OG001": [
        "TKI258"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT01381874",
    "brief_title": "A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy",
    "status": "COMPLETED",
    "start_date": "2011-08-24",
    "completion_date": "2014-07-28",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Janssen Research & Development, LLC",
    "url": "https://clinicaltrials.gov/study/NCT01381874",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Estrogen receptor positive (ER+)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 (Human epidermal growth factor receptor 2) negative"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Exemestane",
        "value": 3.68,
        "unit": "Months",
        "ci_lower": 1.94,
        "ci_upper": 5.26,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Abiraterone Acetate + Prednisone",
        "value": 3.65,
        "unit": "Months",
        "ci_lower": 2.73,
        "ci_upper": 5.59,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Abiraterone Acetate + Exemestane + Prednisone",
        "value": 4.47,
        "unit": "Months",
        "ci_lower": 3.68,
        "ci_upper": 5.59,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Exemestane",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Abiraterone Acetate + Prednisone",
        "value": 26.41,
        "unit": "Months",
        "ci_lower": 23.49,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Abiraterone Acetate + Exemestane + Prednisone",
        "value": null,
        "unit": "Months",
        "ci_lower": 23.79,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Exemestane"
      ],
      "OG001": [
        "Abiraterone acetate",
        "Prednisone"
      ],
      "OG002": [
        "Abiraterone acetate",
        "Exemestane",
        "Prednisone"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01395758",
    "brief_title": "Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2011-07",
    "completion_date": "2016-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)",
    "url": "https://clinicaltrials.gov/study/NCT01395758",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "POSITIVE",
        "details": "Documented KRAS mutation positive status per Lung Cancer Mutation Consortium (LCMC) guidelines"
      },
      {
        "target": "MET",
        "status": "ANY",
        "details": "Subject must agree to allow testing for c-Met status if archival and/or fresh tissue biopsy samples are available"
      },
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "Known EGFR-mutation positive status is excluded"
      }
    ],
    "cancer_stages": [
      "IVA",
      "IVB",
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Tivantinib Plus Erlotinib Arm",
        "value": 7.3,
        "unit": "weeks",
        "ci_lower": 6.86,
        "ci_upper": 24.14,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy Arm",
        "value": 18.6,
        "unit": "weeks",
        "ci_lower": 7.0,
        "ci_upper": 25.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Tivantinib Plus Erlotinib Arm",
        "value": 6.8,
        "unit": "months",
        "ci_lower": 4.97,
        "ci_upper": 10.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy Arm",
        "value": 8.5,
        "unit": "months",
        "ci_lower": 6.37,
        "ci_upper": 13.97,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Tivantinib Plus Erlotinib Crossover Period",
        "value": 2.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Tivantinib",
        "Erlotinib"
      ],
      "OG001": [
        "Pemetrexed",
        "Docetaxel",
        "Gemcitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01496313",
    "brief_title": "To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer",
    "status": "COMPLETED",
    "start_date": "2012-06-08",
    "completion_date": "2014-04-02",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sanofi",
    "url": "https://clinicaltrials.gov/study/NCT01496313",
    "cancer_types": [
      "THCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Vandetanib 150 mg",
        "value": 0.2,
        "unit": "Proportion of participants",
        "ci_lower": 0.105,
        "ci_upper": 0.348,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Vandetanib 300 mg",
        "value": 0.29,
        "unit": "Proportion of participants",
        "ci_lower": 0.176,
        "ci_upper": 0.445,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "150mg vandetanib"
      ],
      "OG001": [
        "300mg vandetanib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT04934722",
    "brief_title": "Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension",
    "status": "COMPLETED",
    "start_date": "2021-05-25",
    "completion_date": "2022-10-31",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT04934722",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + Enzalutamide + ADT",
        "value": 14.4,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Enzalutamide + ADT",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab + Enzalutamide + ADT",
        "value": null,
        "unit": "Months",
        "ci_lower": 14.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Enzalutamide + ADT",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Enzalutamide",
        "Androgen Deprivation Therapy (ADT)"
      ],
      "OG001": [
        "Enzalutamide",
        "Androgen Deprivation Therapy (ADT)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01512745",
    "brief_title": "Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer",
    "status": "COMPLETED",
    "start_date": "2011-01",
    "completion_date": "2013-05",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Jiangsu HengRui Medicine Co., Ltd.",
    "url": "https://clinicaltrials.gov/study/NCT01512745",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Apatinib",
        "value": 2.6,
        "unit": "Months",
        "ci_lower": 2.0,
        "ci_upper": 2.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 1.8,
        "unit": "Months",
        "ci_lower": 1.4,
        "ci_upper": 1.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Apatinib",
        "value": 6.5,
        "unit": "Months",
        "ci_lower": 4.8,
        "ci_upper": 7.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 4.7,
        "unit": "Months",
        "ci_lower": 3.6,
        "ci_upper": 5.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "apatinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT01498289",
    "brief_title": "S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",
    "status": "COMPLETED",
    "start_date": "2012-02",
    "completion_date": "2018-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SWOG Cancer Research Network",
    "url": "https://clinicaltrials.gov/study/NCT01498289",
    "cancer_types": [
      "STAD",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER-2 (HER2) expression negative; if not tested prior to consent, submit specimen \u2014 HER-2 positive or unevaluable patients are excluded"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm I FOLFOX",
        "value": 4.7,
        "unit": "months",
        "ci_lower": 2.1,
        "ci_upper": 8.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm II IT",
        "value": 5.3,
        "unit": "months",
        "ci_lower": 0.9,
        "ci_upper": 11.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm I",
        "value": 11.4,
        "unit": "months",
        "ci_lower": 9.8,
        "ci_upper": 13.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm II",
        "value": 8.7,
        "unit": "months",
        "ci_lower": 6.0,
        "ci_upper": 10.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "fluorouracil",
        "oxaliplatin",
        "leucovorin calcium"
      ],
      "OG001": [
        "irinotecan hydrochloride",
        "docetaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01513174",
    "brief_title": "Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone",
    "status": "COMPLETED",
    "start_date": "2011-08",
    "completion_date": "2016-07",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Spanish Lung Cancer Group",
    "url": "https://clinicaltrials.gov/study/NCT01513174",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "At least one EGFR mutation: exon 19 deletion or L858R (with or without T790M)"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Control Gefitinib",
        "value": 10.9,
        "unit": "Month",
        "ci_lower": 9.3,
        "ci_upper": 13.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Experimental: Gefitinib in Combination With Olaparib",
        "value": 10.9,
        "unit": "Month",
        "ci_lower": 8.6,
        "ci_upper": 13.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Control Gefitinib",
        "value": 23.1,
        "unit": "Month",
        "ci_lower": 19.1,
        "ci_upper": 28.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Experimental: Gefitinib in Combination With Olaparib",
        "value": 23.3,
        "unit": "Month",
        "ci_lower": 16.2,
        "ci_upper": 26.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Gefitinib"
      ],
      "OG001": [
        "Gefitinib",
        "Olaparib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Combo_TKI_Targeted"
    }
  },
  {
    "nct_id": "NCT01500720",
    "brief_title": "Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2012-03",
    "completion_date": "2014-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sanofi",
    "url": "https://clinicaltrials.gov/study/NCT01500720",
    "cancer_types": [
      "SCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cabazitaxel",
        "value": 1.4,
        "unit": "months",
        "ci_lower": 1.4,
        "ci_upper": 1.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Topotecan",
        "value": 3.0,
        "unit": "months",
        "ci_lower": 2.7,
        "ci_upper": 4.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cabazitaxel",
        "value": 5.2,
        "unit": "months",
        "ci_lower": 3.38,
        "ci_upper": 6.11,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Topotecan",
        "value": 6.8,
        "unit": "months",
        "ci_lower": 5.03,
        "ci_upper": 8.08,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cabazitaxel"
      ],
      "OG001": [
        "Topotecan"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT04975308",
    "brief_title": "A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2021-10-04",
    "completion_date": "2024-06-24",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT04975308",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": null
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": null
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A: Imlunestrant",
        "value": 5.55,
        "unit": "Months",
        "ci_lower": 5.32,
        "ci_upper": 7.26,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Investigator's Choice of Endocrine Therapy",
        "value": 5.52,
        "unit": "Months",
        "ci_lower": 4.6,
        "ci_upper": 5.62,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Imlunestrant"
      ],
      "OG001": [
        "Exemestane",
        "Fulvestrant"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT04995419",
    "brief_title": "A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor Therapy",
    "status": "COMPLETED",
    "start_date": "2021-07-22",
    "completion_date": "2022-05-13",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Astellas Pharma China, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT04995419",
    "cancer_types": [
      "BLCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": true,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Enfortumab Vedotin 1.25 mg/kg",
        "value": 37.5,
        "unit": "percentage of participants",
        "ci_lower": 22.7,
        "ci_upper": 54.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Enfortumab Vedotin 1.25 mg/kg",
        "value": 4.67,
        "unit": "months",
        "ci_lower": 3.65,
        "ci_upper": 5.62,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Enfortumab Vedotin 1.25 mg/kg",
        "value": null,
        "unit": "months",
        "ci_lower": 6.74,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Enfortumab vedotin"
      ]
    },
    "treatment_class_map": {
      "OG000": "ADC"
    }
  },
  {
    "nct_id": "NCT01478594",
    "brief_title": "A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy",
    "status": "COMPLETED",
    "start_date": "2011-12",
    "completion_date": "2013-09",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AVEO Pharmaceuticals, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT01478594",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Tivozanib + mFOLFOX6",
        "value": 9.4,
        "unit": "Months",
        "ci_lower": 8.5,
        "ci_upper": 10.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab + mFOLFOX6",
        "value": 10.7,
        "unit": "Months",
        "ci_lower": 7.5,
        "ci_upper": 12.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Tivozanib + mFOLFOX6",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab + mFOLFOX6",
        "value": null,
        "unit": "Months",
        "ci_lower": 12.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Tivozanib",
        "mFOLFOX6"
      ],
      "OG001": [
        "Bevacizumab",
        "mFOLFOX6"
      ],
      "OG002": [
        "Bevacizumab",
        "mFOLFOX6"
      ],
      "OG003": [
        "Bevacizumab",
        "mFOLFOX6"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted",
      "OG003": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT04907851",
    "brief_title": "A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)",
    "status": "COMPLETED",
    "start_date": "2021-12-10",
    "completion_date": "2023-11-30",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Redx Pharma Ltd",
    "url": "https://clinicaltrials.gov/study/NCT04907851",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "RNF43",
        "status": "POSITIVE",
        "details": "loss-of-function tumour mutation in RNF43"
      }
    ],
    "cancer_stages": [
      "III",
      "IV",
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Module 1-RNF43 Mutated Advanced (Unresectable)/Metastatic Pancreatic Cancer (Stage III/IV)",
        "value": null,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Module 2-Advanced (Unresectable)/Metastatic Biliary Tract Cancer (Stage III/IV)",
        "value": 6.1,
        "unit": "percentage of participants",
        "ci_lower": 0.73,
        "ci_upper": 20.53,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Module 3-Advanced (Unresectable)/Metastatic Biliary Tract Cancer (Stage Ill/IV) Combination Therapy",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 14.59,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "RXC004"
      ],
      "OG001": [
        "RXC004"
      ],
      "OG002": [
        "RXC004",
        "pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT01491737",
    "brief_title": "A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2012-02-17",
    "completion_date": "2016-03-17",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT01491737",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER2-positive as assessed by local laboratory on primary or metastatic tumor"
      },
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Estrogen receptor-positive (hormone receptor-positive defined as ER and/or PR)"
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": "Progesterone receptor-positive (hormone receptor-positive defined as ER and/or PR)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy",
        "value": 18.89,
        "unit": "months",
        "ci_lower": 14.09,
        "ci_upper": 27.66,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Trastuzumab + AI +/- Chemotherapy",
        "value": 15.8,
        "unit": "months",
        "ci_lower": 11.04,
        "ci_upper": 18.56,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy",
        "value": 20.63,
        "unit": "months",
        "ci_lower": 14.39,
        "ci_upper": 28.35,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Trastuzumab + AI +/- Chemotherapy",
        "value": 15.8,
        "unit": "months",
        "ci_lower": 11.04,
        "ci_upper": 18.66,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pertuzumab",
        "Trastuzumab",
        "Aromatase Inhibitor",
        "Induction Chemotherapy"
      ],
      "OG001": [
        "Trastuzumab",
        "Aromatase Inhibitor",
        "Induction Chemotherapy"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01505530",
    "brief_title": "A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer",
    "status": "COMPLETED",
    "start_date": "2011-12",
    "completion_date": "2014-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT01505530",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "300 mg LY2495655 + Chemotherapy",
        "value": 8.02,
        "unit": "months",
        "ci_lower": 5.95,
        "ci_upper": 10.02,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "100 mg LY2495655 + Chemotherapy",
        "value": 9.82,
        "unit": "months",
        "ci_lower": 5.85,
        "ci_upper": 13.54,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Placebo + Chemotherapy",
        "value": 10.45,
        "unit": "months",
        "ci_lower": 8.38,
        "ci_upper": 14.49,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "300 mg LY2495655 + Chemotherapy",
        "value": 4.9,
        "unit": "months",
        "ci_lower": 3.32,
        "ci_upper": 6.01,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "100 mg LY2495655 + Chemotherapy",
        "value": 6.87,
        "unit": "months",
        "ci_lower": 5.36,
        "ci_upper": 7.89,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Placebo + Chemotherapy",
        "value": 8.21,
        "unit": "months",
        "ci_lower": 4.99,
        "ci_upper": 9.36,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "LY2495655",
        "Standard of Care Chemotherapy"
      ],
      "OG001": [
        "LY2495655",
        "Standard of Care Chemotherapy"
      ],
      "OG002": [
        "Standard of Care Chemotherapy"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER",
      "OG002": "Chemo"
    }
  },
  {
    "nct_id": "NCT01506609",
    "brief_title": "Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2012-01-23",
    "completion_date": "2018-12-13",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AbbVie",
    "url": "https://clinicaltrials.gov/study/NCT01506609",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "BRCA1",
        "status": "POSITIVE",
        "details": "deleterious germline mutation"
      },
      {
        "target": "BRCA2",
        "status": "POSITIVE",
        "details": "deleterious germline mutation"
      },
      {
        "target": "HER2",
        "status": "ANY",
        "details": "If HER2 positive, must have received and progressed on \u22651 prior HER2-directed therapy or be ineligible for anti-HER2 therapy"
      }
    ],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Group 2 Placebo + Carboplatin/Paclitaxel",
        "value": 12.3,
        "unit": "months",
        "ci_lower": 9.3,
        "ci_upper": 14.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Group 2 Veliparib + Carboplatin/Paclitaxel",
        "value": 14.1,
        "unit": "months",
        "ci_lower": 11.5,
        "ci_upper": 16.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Group 2 Veliparib + TMZ",
        "value": 7.4,
        "unit": "months",
        "ci_lower": 5.9,
        "ci_upper": 8.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Group 2 Placebo + Carboplatin/Paclitaxel",
        "value": 25.4,
        "unit": "months",
        "ci_lower": 18.3,
        "ci_upper": 32.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Group 2 Veliparib + Carboplatin/Paclitaxel",
        "value": 28.3,
        "unit": "months",
        "ci_lower": 24.9,
        "ci_upper": 33.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Group 2 Veliparib + TMZ",
        "value": 19.1,
        "unit": "months",
        "ci_lower": 14.3,
        "ci_upper": 21.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Carboplatin",
        "Paclitaxel"
      ],
      "OG001": [
        "Veliparib",
        "Carboplatin",
        "Paclitaxel"
      ],
      "OG002": [
        "Veliparib",
        "Temozolomide"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT01498484",
    "brief_title": "Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies",
    "status": "COMPLETED",
    "start_date": "2011-12",
    "completion_date": "2019-07",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Atara Biotherapeutics",
    "url": "https://clinicaltrials.gov/study/NCT01498484",
    "cancer_types": [
      "DLBC",
      "HNSC",
      "STAD"
    ],
    "biomarkers": [
      {
        "target": "EBV",
        "status": "POSITIVE",
        "details": "EBV antigen positive lymphoproliferative disease, lymphoma or other EBV-associated malignancy"
      },
      {
        "target": "EBV",
        "status": "HIGH",
        "details": "EBV DNA >500 copies/ml by quantitative real-time PCR (including persistent or recurrent elevations >500 copies/ml after prior treatment)"
      },
      {
        "target": "HLA",
        "status": "ANY",
        "details": "Third-party EBV-specific T cells must be matched for at least 2 HLA antigens and restricted by an allele shared with the EBV+ malignancy (if known) or with the donor/patient in transplant recipients"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "HCT EBV+ PTLD R/R Rituximab",
        "value": 68.0,
        "unit": "Percentage of participants",
        "ci_lower": 46.5,
        "ci_upper": 85.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "SOT EBV+ PTLD R/R Rituximab",
        "value": 50.0,
        "unit": "Percentage of participants",
        "ci_lower": 18.7,
        "ci_upper": 81.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "EBV+ Lymphoma",
        "value": 16.0,
        "unit": "Percentage of participants",
        "ci_lower": 4.5,
        "ci_upper": 36.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "EBV+ NPC",
        "value": 14.3,
        "unit": "Percentage of participants",
        "ci_lower": 1.8,
        "ci_upper": 42.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "HCT EBV+ PTLD R/R Rituximab",
        "value": null,
        "unit": "Months",
        "ci_lower": 7.1,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "SOT EBV+ PTLD R/R Rituximab",
        "value": 14.9,
        "unit": "Months",
        "ci_lower": 0.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "EBV+ Lymphoma",
        "value": 12.3,
        "unit": "Months",
        "ci_lower": 1.5,
        "ci_upper": 21.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "EBV+ NPC",
        "value": null,
        "unit": "Months",
        "ci_lower": 4.9,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "tabelecleucel"
      ],
      "OG001": [
        "tabelecleucel"
      ],
      "OG002": [
        "tabelecleucel"
      ],
      "OG003": [
        "tabelecleucel"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER",
      "OG002": "OTHER",
      "OG003": "OTHER"
    }
  },
  {
    "nct_id": "NCT04999969",
    "brief_title": "Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2021-12-10",
    "completion_date": "2024-10-07",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT04999969",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "CD8",
        "status": "POSITIVE",
        "details": "Presence of tumoural CD8+ T cells based on a predetermined benchmarked PDAC external sample; archival (metastatic-stage) or fresh tumour specimen required for testing"
      },
      {
        "target": "GUSTAVE_ROUSSY_IMMUNE_SCORE",
        "status": "LOW",
        "details": "Gustave Roussy Immune Score of 0 or 1 required"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "AZD0171 + Durvalumab + Chemotherapy",
        "value": 53.8,
        "unit": "Percentage",
        "ci_lower": 47.79,
        "ci_upper": 59.5,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "AZD0171",
        "Durvalumab",
        "Gemcitabine",
        "Nab-paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT04907539",
    "brief_title": "A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)",
    "status": "COMPLETED",
    "start_date": "2021-11-08",
    "completion_date": "2024-04-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Redx Pharma Ltd",
    "url": "https://clinicaltrials.gov/study/NCT04907539",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "RNF43",
        "status": "POSITIVE",
        "details": "Documented tumour tissue aberration"
      },
      {
        "target": "RSPO",
        "status": "POSITIVE",
        "details": "Documented tumour tissue aberration (R-spondin)"
      },
      {
        "target": "MSI",
        "status": "NEGATIVE",
        "details": "Microsatellite stable (MSS) \u2014 i.e., not MSI-high"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "DCR",
        "arm_id": "OG000",
        "arm_title": "Arm A: RXC004 Monotherapy",
        "value": 18.2,
        "unit": "Percentage of patients",
        "ci_lower": 3.33,
        "ci_upper": 47.01,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Arm B: RXC004+Nivolumab",
        "value": 14.3,
        "unit": "Percentage of patients",
        "ci_lower": 0.73,
        "ci_upper": 52.07,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "RXC004"
      ],
      "OG001": [
        "RXC004",
        "Nivolumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT04952597",
    "brief_title": "Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2021-07-15",
    "completion_date": "2023-07-26",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "BeiGene",
    "url": "https://clinicaltrials.gov/study/NCT04952597",
    "cancer_types": [
      "SCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "I",
      "II",
      "III",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A: Ociperlimab + Tislelizumab",
        "value": 12.6,
        "unit": "Months",
        "ci_lower": 8.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Tislelizumab",
        "value": 13.2,
        "unit": "Months",
        "ci_lower": 8.5,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Arm C: Concurrent Chemoradiotherapy (cCRT)",
        "value": 9.5,
        "unit": "Months",
        "ci_lower": 8.3,
        "ci_upper": 14.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A: Ociperlimab + Tislelizumab",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Tislelizumab",
        "value": null,
        "unit": "months",
        "ci_lower": 19.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Arm C: Concurrent Chemoradiotherapy (cCRT)",
        "value": null,
        "unit": "months",
        "ci_lower": 20.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ociperlimab",
        "Tislelizumab"
      ],
      "OG001": [
        "Tislelizumab"
      ],
      "OG002": [
        "Cisplatin",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "Chemo"
    }
  },
  {
    "nct_id": "NCT04941287",
    "brief_title": "Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2021-12-15",
    "completion_date": "2024-01-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT04941287",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Arm A (Cobimetinib, Atezolizumab, Varlilumab)",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Arm B (Atezolizumab, Varlilumab)",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A (Cobimetinib, Atezolizumab, Varlilumab)",
        "value": 2.4,
        "unit": "months",
        "ci_lower": 1.97,
        "ci_upper": 5.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B (Atezolizumab, Varlilumab)",
        "value": 1.84,
        "unit": "months",
        "ci_lower": 1.64,
        "ci_upper": 2.43,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cobimetinib",
        "Atezolizumab",
        "Varlilumab"
      ],
      "OG001": [
        "Atezolizumab",
        "Varlilumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "IO"
    }
  },
  {
    "nct_id": "NCT01489865",
    "brief_title": "ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer",
    "status": "COMPLETED",
    "start_date": "2011-01-03",
    "completion_date": "2018-12-26",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Georgetown University",
    "url": "https://clinicaltrials.gov/study/NCT01489865",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [
      {
        "target": "BRCA1",
        "status": "POSITIVE",
        "details": "Known BRCA-associated genetic mutation; deleterious or indeterminate mutation qualifies"
      },
      {
        "target": "BRCA2",
        "status": "POSITIVE",
        "details": "Known BRCA-associated genetic mutation; deleterious or indeterminate mutation qualifies"
      },
      {
        "target": "PALB2",
        "status": "POSITIVE",
        "details": "Known deleterious or indeterminate mutation in PALB2 (referred to as PALBB2 in source)"
      },
      {
        "target": "FANC",
        "status": "POSITIVE",
        "details": "Known deleterious or indeterminate mutation in one of the FANC genes (Fanconi anemia genes)"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "ABT-888 and mFOLFOX-6 Phase II",
        "value": 4.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase 1: ABT-888 40mg (Cohort 1)",
        "value": 126.5,
        "unit": "days",
        "ci_lower": 65.0,
        "ci_upper": 509.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Phase 1: ABT-888 60 mg (Cohort 2)",
        "value": 49.0,
        "unit": "days",
        "ci_lower": 42.0,
        "ci_upper": 58.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Phase 1: ABT-888 80 mg (Cohort 3)",
        "value": 159.0,
        "unit": "days",
        "ci_lower": 91.0,
        "ci_upper": 948.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Phase 1: ABT-888 100 mg (Cohort 4)",
        "value": 77.0,
        "unit": "days",
        "ci_lower": 56.0,
        "ci_upper": 106.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Phase 1: ABT-888 150 mg (Cohort 5)",
        "value": 132.0,
        "unit": "days",
        "ci_lower": 37.0,
        "ci_upper": 671.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG005",
        "arm_title": "Phase 1: ABT-888 200 mg (Cohort 6)",
        "value": 148.0,
        "unit": "days",
        "ci_lower": 33.0,
        "ci_upper": 209.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG006",
        "arm_title": "Phase 1: ABT-888 250 mg (Cohort 7)",
        "value": 60.5,
        "unit": "days",
        "ci_lower": 49.0,
        "ci_upper": 122.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG007",
        "arm_title": "Phase 2: ABT-888 at Recommended Phase 2 Dose (200mg)",
        "value": 102.0,
        "unit": "days",
        "ci_lower": 15.0,
        "ci_upper": 3431.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Phase 1: ABT-888 40mg (Cohort 1)",
        "value": 153.0,
        "unit": "days",
        "ci_lower": 89.0,
        "ci_upper": 750.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Phase 1: ABT-888 60 mg (Cohort 2)",
        "value": 89.0,
        "unit": "days",
        "ci_lower": 58.0,
        "ci_upper": 169.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Phase 1: ABT-888 80 mg (Cohort 3)",
        "value": 325.0,
        "unit": "days",
        "ci_lower": 159.0,
        "ci_upper": 948.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Phase 1: ABT-888 100 mg (Cohort 4)",
        "value": 294.0,
        "unit": "days",
        "ci_lower": 146.0,
        "ci_upper": 320.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG004",
        "arm_title": "Phase 1: ABT-888 150 mg (Cohort 5)",
        "value": 211.0,
        "unit": "days",
        "ci_lower": 37.0,
        "ci_upper": 671.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG005",
        "arm_title": "Phase 1: ABT-888 200 mg (Cohort 6)",
        "value": 176.0,
        "unit": "days",
        "ci_lower": 104.0,
        "ci_upper": 319.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG006",
        "arm_title": "Phase 1: ABT-888 250 mg (Cohort 7)",
        "value": 145.5,
        "unit": "days",
        "ci_lower": 49.0,
        "ci_upper": 336.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG007",
        "arm_title": "Phase 2: ABT-888 at Recommended Phase 2 Dose (200mg)",
        "value": 260.0,
        "unit": "days",
        "ci_lower": 15.0,
        "ci_upper": 3431.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "ABT-888",
        "mFOLFOX-6"
      ],
      "OG001": [
        "ABT-888",
        "mFOLFOX-6"
      ],
      "OG002": [
        "ABT-888",
        "mFOLFOX-6"
      ],
      "OG003": [
        "ABT-888",
        "mFOLFOX-6"
      ],
      "OG004": [
        "ABT-888",
        "mFOLFOX-6"
      ],
      "OG005": [
        "ABT-888",
        "mFOLFOX-6"
      ],
      "OG006": [
        "ABT-888",
        "mFOLFOX-6"
      ],
      "OG007": [
        "ABT-888",
        "mFOLFOX-6"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted",
      "OG003": "Combo_Chemo_Targeted",
      "OG004": "Combo_Chemo_Targeted",
      "OG005": "Combo_Chemo_Targeted",
      "OG006": "Combo_Chemo_Targeted",
      "OG007": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT05012098",
    "brief_title": "Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).",
    "status": "COMPLETED",
    "start_date": "2022-06-21",
    "completion_date": "2024-07-09",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT05012098",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [
      {
        "target": "CD4",
        "status": "HIGH",
        "details": ">=200 cells/mm3; on stable antiretroviral therapy >=4 weeks; no opportunistic infections or Castleman's disease within 12 months prior to enrollment"
      },
      {
        "target": "HIV",
        "status": "ANY",
        "details": "HIV-positive allowed if CD4 >=200 and on stable ART >=4 weeks with no recent opportunistic infections"
      },
      {
        "target": "HBV",
        "status": "NEGATIVE",
        "details": "HBV DNA viral load undetectable on suppressive therapy, if indicated"
      },
      {
        "target": "HCV",
        "status": "NEGATIVE",
        "details": "HCV RNA negative"
      },
      {
        "target": "ANC",
        "status": "HIGH",
        "details": ">=1,500/mcL"
      },
      {
        "target": "HEMOGLOBIN",
        "status": "HIGH",
        "details": ">=9 g/dL (transfusions allowed)"
      },
      {
        "target": "PLATELETS",
        "status": "HIGH",
        "details": ">=100,000/mcL"
      },
      {
        "target": "CREATININE",
        "status": "LOW",
        "details": "Serum creatinine <=1.5 x ULN OR measured/estimated CrCl or eGFR (CKD-EPI) >=30 mL/min/1.73m2 if creatinine >1.5 x ULN"
      },
      {
        "target": "BILIRUBIN",
        "status": "LOW",
        "details": "Total bilirubin <=1.5 x ULN OR direct bilirubin <=ULN for participants with total bilirubin >1.5 x ULN"
      },
      {
        "target": "AST",
        "status": "LOW",
        "details": "AST (SGOT) <=2.5 x ULN"
      },
      {
        "target": "ALT",
        "status": "LOW",
        "details": "ALT (SGPT) <=2.5 x ULN"
      }
    ],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort 1/Arm 1: Treatment With Bintrafusp Alfa - Immune Checkpoint",
        "value": 0.0,
        "unit": "Percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 0.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1/Arm 1: Treatment With Bintrafusp Alfa-Immune Checkpoint",
        "value": null,
        "unit": "Months",
        "ci_lower": 7.9,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cohort 2/Arm 1: Treatment With Bintrafusp Alfa- Immune Checkpoint Blockade Resistant (ICB-R)",
        "value": 2.1,
        "unit": "Months",
        "ci_lower": 2.1,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1/Arm 1: Treatment With Bintrafusp Alfa - Immune Checkpoint",
        "value": 9.3,
        "unit": "Months",
        "ci_lower": 1.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort 2/Arm 1: Treatment With Bintrafusp Alfa - Immune Checkpoint Blockade Resistant (ICB-R)",
        "value": 2.99,
        "unit": "Months",
        "ci_lower": 0.9,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Bintrafusp alfa/M7824"
      ],
      "OG001": [
        "Bintrafusp alfa/M7824"
      ],
      "OG002": [
        "Bintrafusp alfa/M7824"
      ],
      "OG003": [
        "Bintrafusp alfa/M7824"
      ],
      "OG004": [
        "Bintrafusp alfa/M7824"
      ],
      "OG005": [
        "Bintrafusp alfa/M7824"
      ],
      "OG006": [
        "Bintrafusp alfa/M7824"
      ],
      "OG007": [
        "Bintrafusp alfa/M7824"
      ],
      "OG008": [
        "Bintrafusp alfa/M7824"
      ],
      "OG009": [
        "Bintrafusp alfa/M7824"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO",
      "OG003": "IO",
      "OG004": "IO",
      "OG005": "IO",
      "OG006": "IO",
      "OG007": "IO",
      "OG008": "IO",
      "OG009": "IO"
    }
  },
  {
    "nct_id": "NCT05014776",
    "brief_title": "Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2022-08-22",
    "completion_date": "2024-04-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
    "url": "https://clinicaltrials.gov/study/NCT05014776",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Arm A - Tadalafil, Pembrolizumab, Ipilimumab, CRS-207",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Tadalafil",
        "Pembrolizumab",
        "Ipilimumab",
        "CRS-207"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO"
    }
  },
  {
    "nct_id": "NCT01525550",
    "brief_title": "A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors",
    "status": "COMPLETED",
    "start_date": "2012-06-06",
    "completion_date": "2016-03-19",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT01525550",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Sunitinib: Treatment Naive Cohort",
        "value": 13.2,
        "unit": "months",
        "ci_lower": 7.4,
        "ci_upper": 16.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Sunitinib: Later-Line Cohort",
        "value": 13.0,
        "unit": "months",
        "ci_lower": 9.2,
        "ci_upper": 20.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "sunitinib"
      ],
      "OG001": [
        "sunitinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT05226598",
    "brief_title": "Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2022-03-24",
    "completion_date": "2024-09-24",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT05226598",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "MK-7684A + Chemotherapy",
        "value": 19.4,
        "unit": "Months",
        "ci_lower": 17.2,
        "ci_upper": 23.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Pembrolizumab + Chemotherapy",
        "value": 23.5,
        "unit": "Months",
        "ci_lower": 19.6,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab/Vibostolimab",
        "Paclitaxel",
        "Nab-paclitaxel"
      ],
      "OG001": [
        "Pembrolizumab",
        "Paclitaxel",
        "Nab-paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT05059262",
    "brief_title": "Study of Vimseltinib for Tenosynovial Giant Cell Tumor",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2021-10-14",
    "completion_date": "2023-08-10",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Deciphera Pharmaceuticals, LLC",
    "url": "https://clinicaltrials.gov/study/NCT05059262",
    "cancer_types": [
      "TGCT"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Vimseltinib",
        "value": 39.8,
        "unit": "percentage of participants with CR or PR",
        "ci_lower": 29.2,
        "ci_upper": 51.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 0.0,
        "unit": "percentage of participants with CR or PR",
        "ci_lower": 0.0,
        "ci_upper": 8.8,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Vimseltinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT01516216",
    "brief_title": "Study of Vitamin D in Untreated Metastatic Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2012-04-13",
    "completion_date": "2019-11-09",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Dana-Farber Cancer Institute",
    "url": "https://clinicaltrials.gov/study/NCT01516216",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "ANY",
        "details": "wild-type and mutant patients are eligible"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Chemotherapy + Standard Dose Vitamin D",
        "value": 11.0,
        "unit": "Months",
        "ci_lower": 9.5,
        "ci_upper": 14.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy + Higher Dose Vitamin D",
        "value": 13.0,
        "unit": "Months",
        "ci_lower": 10.1,
        "ci_upper": 14.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Chemotherapy + Standard Dose Vitamin D",
        "value": 24.3,
        "unit": "Months",
        "ci_lower": 20.3,
        "ci_upper": 32.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy + Higher Dose Vitamin D",
        "value": 24.3,
        "unit": "Months",
        "ci_lower": 19.0,
        "ci_upper": 33.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "FOLFOX",
        "Bevacizumab"
      ],
      "OG001": [
        "FOLFOX",
        "Bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT01515748",
    "brief_title": "Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer",
    "status": "COMPLETED",
    "start_date": "2011-12-30",
    "completion_date": "2019-01-21",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sanofi",
    "url": "https://clinicaltrials.gov/study/NCT01515748",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "NEOADJUVANT",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Surgery + Adjuvant Chemotherapy (SC)",
        "value": 60.24,
        "unit": "percentage of participants",
        "ci_lower": 53.55,
        "ci_upper": 66.28,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC)",
        "value": 66.82,
        "unit": "percentage of participants",
        "ci_lower": 60.13,
        "ci_upper": 72.65,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Surgery + Adjuvant Chemotherapy (SC)",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC)",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + 5-chloro-2, 4-dihydroxypyridine (CDHP) (Gimeracil) + Oxo (Oteracil)"
      ],
      "OG001": [
        "Docetaxel (XRP6976)",
        "Oxaliplatin (SR96669)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01532089",
    "brief_title": "Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations",
    "status": "COMPLETED",
    "start_date": "2012-03-16",
    "completion_date": "2018-02-13",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Academic and Community Cancer Research United",
    "url": "https://clinicaltrials.gov/study/NCT01532089",
    "cancer_types": [
      "NSCLC",
      "LUAD"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "Activating EGFR defined as exon 19 deletion or exon 21 L858R mutation; EGFR mutation testing must be performed at a CLIA-certified laboratory and method/report must be available"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A (Erlotinib Hydrochloride)",
        "value": 13.5,
        "unit": "months",
        "ci_lower": 8.8,
        "ci_upper": 21.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B (Erlotinib Hydrochloride, Bevacizumab)",
        "value": 17.9,
        "unit": "months",
        "ci_lower": 13.3,
        "ci_upper": 24.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A (Erlotinib Hydrochloride)",
        "value": 50.6,
        "unit": "months",
        "ci_lower": 49.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B (Erlotinib Hydrochloride, Bevacizumab)",
        "value": 32.4,
        "unit": "months",
        "ci_lower": 26.9,
        "ci_upper": 54.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Arm A (Erlotinib Hydrochloride)",
        "value": 83.0,
        "unit": "percentage of patients",
        "ci_lower": 69.0,
        "ci_upper": 93.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Arm B (Erlotinib Hydrochloride, Bevacizumab)",
        "value": 81.0,
        "unit": "percentage of patients",
        "ci_lower": 67.0,
        "ci_upper": 92.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Erlotinib Hydrochloride"
      ],
      "OG001": [
        "Erlotinib Hydrochloride",
        "Bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Combo_TKI_Targeted"
    }
  },
  {
    "nct_id": "NCT05014815",
    "brief_title": "Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2021-11-16",
    "completion_date": "2024-09-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "BeiGene",
    "url": "https://clinicaltrials.gov/study/NCT05014815",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Archival tumor tissue or fresh biopsy required; evaluable PD-L1 result required for enrollment; PD-L1 level assessment and retrospective biomarker analyses"
      },
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "EGFR-sensitizing mutations excluded; for non-squamous with unknown EGFR status, tissue-based or EBUS-TBNA EGFR testing required prior to enrollment"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "ALK fusion oncogene excluded"
      },
      {
        "target": "BRAF",
        "status": "NEGATIVE",
        "details": "BRAF V600E mutation excluded"
      },
      {
        "target": "ROS1",
        "status": "NEGATIVE",
        "details": "ROS1 rearrangement excluded"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A (O+T+C)",
        "value": 8.2,
        "unit": "Months",
        "ci_lower": 6.2,
        "ci_upper": 10.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B (P+T+C)",
        "value": 8.1,
        "unit": "Months",
        "ci_lower": 6.0,
        "ci_upper": 10.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A (O+T+C)",
        "value": 20.6,
        "unit": "Months",
        "ci_lower": 14.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B (P+T+C)",
        "value": 19.4,
        "unit": "Months",
        "ci_lower": 15.4,
        "ci_upper": 23.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ociperlimab",
        "Tislelizumab",
        "Carboplatin",
        "Paclitaxel",
        "Nab paclitaxel",
        "Cisplatin",
        "Pemetrexed"
      ],
      "OG001": [
        "Tislelizumab",
        "Carboplatin",
        "Paclitaxel",
        "Nab paclitaxel",
        "Cisplatin",
        "Pemetrexed"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT01515787",
    "brief_title": "PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2012-06-12",
    "completion_date": "2022-12-31",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Alliance for Clinical Trials in Oncology",
    "url": "https://clinicaltrials.gov/study/NCT01515787",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIA",
      "IIIA",
      "IIIB"
    ],
    "line_of_therapy": "NEOADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [],
    "arm_drugs": {
      "OG000": [
        "FOLFOX (oxaliplatin; leucovorin; 5-fluorouracil)"
      ],
      "OG001": [
        "5-fluorouracil",
        "capecitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01529112",
    "brief_title": "A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments",
    "status": "COMPLETED",
    "start_date": "2011-11",
    "completion_date": "2014-01-21",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eisai Inc.",
    "url": "https://clinicaltrials.gov/study/NCT01529112",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "If known EGFR\u2011activating mutation, must have received erlotinib (or gefitinib outside US); participants of unknown EGFR status who had not received erlotinib/gefitinib should be tested for EGFR\u2011activating mutations prior to entry."
      },
      {
        "target": "ALK",
        "status": "ANY",
        "details": "In countries where crizotinib was approved, ALK\u2011positive participants must have received crizotinib."
      },
      {
        "target": "KRAS",
        "status": "ANY",
        "details": "KRAS\u2011mutated participants were noted and were not required to have prior erlotinib/gefitinib."
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Lenvatinib",
        "value": 20.9,
        "unit": "weeks",
        "ci_lower": 15.86,
        "ci_upper": 23.86,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Lenvatinib Matched Placebo",
        "value": 7.9,
        "unit": "weeks",
        "ci_lower": 7.43,
        "ci_upper": 8.14,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Lenvatinib",
        "value": 38.4,
        "unit": "weeks",
        "ci_lower": 26.57,
        "ci_upper": 47.86,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Lenvatinib Matched Placebo",
        "value": 24.1,
        "unit": "weeks",
        "ci_lower": 15.29,
        "ci_upper": 36.43,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Lenvatinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT01525589",
    "brief_title": "A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2012-06-13",
    "completion_date": "2018-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "PharmaMar",
    "url": "https://clinicaltrials.gov/study/NCT01525589",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "BRCA1",
        "status": "POSITIVE",
        "details": "deleterious germline BRCA1 mutation (Cohorts A and A1)"
      },
      {
        "target": "BRCA2",
        "status": "POSITIVE",
        "details": "deleterious germline BRCA2 mutation (Cohorts A and A1)"
      },
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER2 overexpressing metastatic breast cancer (patients with this must have failed at least one prior trastuzumab-containing regimen)"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort A (BRCA+)",
        "value": 40.7,
        "unit": "percentage",
        "ci_lower": 27.6,
        "ci_upper": 55.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Cohort A1 (BRCA+/PARPi)",
        "value": 5.0,
        "unit": "percentage",
        "ci_lower": 0.1,
        "ci_upper": 24.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Cohort B (Unselected)",
        "value": 8.8,
        "unit": "percentage",
        "ci_lower": 1.9,
        "ci_upper": 23.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort A (BRCA+)",
        "value": 4.6,
        "unit": "months",
        "ci_lower": 3.0,
        "ci_upper": 6.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort A1 (BRCA+/PARPi)",
        "value": 1.4,
        "unit": "months",
        "ci_lower": 1.3,
        "ci_upper": 3.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Cohort B (Unselected)",
        "value": 2.5,
        "unit": "months",
        "ci_lower": 1.3,
        "ci_upper": 3.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cohort A (BRCA+)",
        "value": 18.6,
        "unit": "months",
        "ci_lower": 10.9,
        "ci_upper": 22.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cohort A1 (BRCA+/PARPi)",
        "value": 8.1,
        "unit": "months",
        "ci_lower": 4.6,
        "ci_upper": 14.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Cohort B (Unselected)",
        "value": 12.1,
        "unit": "months",
        "ci_lower": 6.6,
        "ci_upper": 17.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "PM01183"
      ],
      "OG001": [
        "PM01183"
      ],
      "OG002": [
        "PM01183"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER",
      "OG002": "OTHER"
    }
  },
  {
    "nct_id": "NCT05014828",
    "brief_title": "To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2021-09-18",
    "completion_date": "2023-10-20",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "BeiGene",
    "url": "https://clinicaltrials.gov/study/NCT05014828",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Tumor tissue provided for central PD-L1 assessment in the NSCLC cohort during screening; used for retrospective exploratory biomarker analyses"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Squamous Cell Carcinoma of the Head and Neck (SCCHN)",
        "value": 29.6,
        "unit": "Percentage of participants",
        "ci_lower": 13.8,
        "ci_upper": 50.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Renal Cell Carcinoma (RCC)",
        "value": 60.9,
        "unit": "Percentage of participants",
        "ci_lower": 38.5,
        "ci_upper": 80.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Non-Small Cell Lung Cancer (NSCLC)",
        "value": 20.0,
        "unit": "Percentage of participants",
        "ci_lower": 0.5,
        "ci_upper": 71.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Gastric Cancer (GC)",
        "value": 33.3,
        "unit": "Percentage of participants",
        "ci_lower": 0.8,
        "ci_upper": 90.6,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Tislelizumab",
        "lenvatinib"
      ],
      "OG001": [
        "Tislelizumab",
        "lenvatinib"
      ],
      "OG002": [
        "Tislelizumab",
        "lenvatinib"
      ],
      "OG003": [
        "Tislelizumab",
        "lenvatinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_IO",
      "OG001": "Combo_TKI_IO",
      "OG002": "Combo_TKI_IO",
      "OG003": "Combo_TKI_IO"
    }
  },
  {
    "nct_id": "NCT05064059",
    "brief_title": "A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)",
    "status": "COMPLETED",
    "start_date": "2021-11-10",
    "completion_date": "2024-08-15",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT05064059",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "POSITIVE",
        "details": "PD-L1 positivity required (threshold/method not specified)"
      },
      {
        "target": "MSI",
        "status": "NEGATIVE",
        "details": "dMMR/MSI-H excluded (must be MSS / pMMR)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Favezelimab/Pembrolizumab",
        "value": 7.3,
        "unit": "Months",
        "ci_lower": 5.8,
        "ci_upper": 8.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Standard of Care (Regorafenib or TAS-102)",
        "value": 8.5,
        "unit": "Months",
        "ci_lower": 7.5,
        "ci_upper": 9.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Favezelimab/Pembrolizumab",
        "value": 2.1,
        "unit": "Months",
        "ci_lower": 2.1,
        "ci_upper": 2.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Standard of Care (Regorafenib or TAS-102)",
        "value": 2.6,
        "unit": "Months",
        "ci_lower": 2.2,
        "ci_upper": 3.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "favezelimab",
        "pembrolizumab"
      ],
      "OG001": [
        "regorafenib",
        "TAS-102"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT05169567",
    "brief_title": "Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2022-03-11",
    "completion_date": "2024-02-08",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT05169567",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HR",
        "status": "POSITIVE",
        "details": "Hormone receptor (ER and/or PR) positive (HR+)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-negative"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A: Abemaciclib Plus Fulvestrant",
        "value": 6.0,
        "unit": "Months",
        "ci_lower": 5.6,
        "ci_upper": 8.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Placebo Plus Fulvestrant",
        "value": 5.3,
        "unit": "Months",
        "ci_lower": 3.7,
        "ci_upper": 5.6,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Abemaciclib",
        "Fulvestrant"
      ],
      "OG001": [
        "Fulvestrant"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT01520870",
    "brief_title": "Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.",
    "status": "COMPLETED",
    "start_date": "2012-02",
    "completion_date": "2015-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Grupo Espa\u00f1ol de Investigaci\u00f3n en Neurooncolog\u00eda",
    "url": "https://clinicaltrials.gov/study/NCT01520870",
    "cancer_types": [
      "GBM"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "EGFR gene amplification by FISH"
      },
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "EGFRvIII mutation detected by PCR"
      }
    ],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "PF-299804 (Dacomitinib)",
        "value": 4.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "PF-299804 (Dacomitinib)",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "PF-299804 (Dacomitinib)",
        "value": 7.8,
        "unit": "Months",
        "ci_lower": 5.6,
        "ci_upper": 10.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "PF-299804 (Dacomitinib)",
        "value": 6.7,
        "unit": "Months",
        "ci_lower": 4.3,
        "ci_upper": 9.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "PF-299804 (Dacomitinib)",
        "value": 7.4,
        "unit": "Months",
        "ci_lower": 5.6,
        "ci_upper": 9.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "PF-299804 (Dacomitinib)"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT05104567",
    "brief_title": "A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)",
    "status": "COMPLETED",
    "start_date": "2021-12-09",
    "completion_date": "2023-07-26",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sanofi",
    "url": "https://clinicaltrials.gov/study/NCT05104567",
    "cancer_types": [
      "CRC",
      "STAD",
      "LIHC"
    ],
    "biomarkers": [
      {
        "target": "MSI",
        "status": "NEGATIVE",
        "details": "Non-MSI-High disease required (non-MSI-H)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort A: ESCC Post PD-1/PD-L1: Pegenzileukin 24 mcg/kg + Pembrolizumab as 2/3L Therapy",
        "value": 20.0,
        "unit": "percentage of participants",
        "ci_lower": 1.0,
        "ci_upper": 65.7,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "THOR-707",
        "Pembrolizumab"
      ],
      "OG001": [
        "THOR-707",
        "Pembrolizumab"
      ],
      "OG002": [
        "THOR-707",
        "Pembrolizumab"
      ],
      "OG003": [
        "THOR-707",
        "Pembrolizumab"
      ],
      "OG004": [
        "THOR-707",
        "Pembrolizumab"
      ],
      "OG005": [
        "THOR-707",
        "Pembrolizumab"
      ],
      "OG006": [
        "THOR-707",
        "Cetuximab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted",
      "OG002": "Combo_IO_Targeted",
      "OG003": "Combo_IO_Targeted",
      "OG004": "Combo_IO_Targeted",
      "OG005": "Combo_IO_Targeted",
      "OG006": "OTHER"
    }
  },
  {
    "nct_id": "NCT05246514",
    "brief_title": "A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2022-07-13",
    "completion_date": "2023-09-23",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT05246514",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "exon 19 or 20 mutation documented by central FFPE tumour tissue testing"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "T-DXd Arm",
        "value": 58.3,
        "unit": "Percentage of participants",
        "ci_lower": 46.1,
        "ci_upper": 69.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "T-DXd Arm",
        "value": null,
        "unit": "Months",
        "ci_lower": 7.2,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "T-DXd Arm",
        "value": 10.8,
        "unit": "Months",
        "ci_lower": 7.2,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "T-DXd Arm",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Trastuzumab deruxtecan"
      ]
    },
    "treatment_class_map": {
      "OG000": "ADC"
    }
  },
  {
    "nct_id": "NCT05089734",
    "brief_title": "Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2021-11-17",
    "completion_date": "2023-11-29",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Gilead Sciences",
    "url": "https://clinicaltrials.gov/study/NCT05089734",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "EGFR testing required prior to enrollment; testing is optional for squamous histology. If EGFR-positive, patient must have received at least 1 locally approved/available TKI appropriate to the alteration."
      },
      {
        "target": "ALK",
        "status": "ANY",
        "details": "ALK testing required prior to enrollment; testing is optional for squamous histology. If ALK-positive, patient must have received at least 1 locally approved/available TKI appropriate to the alteration."
      },
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "PD-1/PD-L1 results required prior to enrollment (no expression threshold specified)."
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": true,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Sacituzumab Govitecan (SG)",
        "value": 11.1,
        "unit": "months",
        "ci_lower": 9.4,
        "ci_upper": 12.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Docetaxel",
        "value": 9.8,
        "unit": "months",
        "ci_lower": 8.1,
        "ci_upper": 10.6,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Sacituzumab Govitecan-hziy (SG)"
      ],
      "OG001": [
        "Docetaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "ADC",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT05091346",
    "brief_title": "A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2021-10-27",
    "completion_date": "2024-10-15",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eisai Inc.",
    "url": "https://clinicaltrials.gov/study/NCT05091346",
    "cancer_types": [
      "SKCM",
      "LIHC",
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "MSI",
        "status": "NEGATIVE",
        "details": "Microsatellite instability-high (MSI-H) / DNA mismatch repair-deficient (dMMR) tumors are excluded (CRC cohort only)"
      },
      {
        "target": "HBV",
        "status": "NEGATIVE",
        "details": "Active hepatitis B (positive serology) excluded for melanoma and CRC cohorts; note for HCC cohort dual active HBV+HCV infection at study entry is excluded"
      },
      {
        "target": "HCV",
        "status": "NEGATIVE",
        "details": "Active hepatitis C (positive serology) excluded for melanoma and CRC cohorts; note for HCC cohort dual active HBV+HCV infection at study entry is excluded"
      },
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "Known HIV infection excluded (HIV positive participants not eligible)"
      }
    ],
    "cancer_stages": [
      "III",
      "IV",
      "UNRESECTABLE",
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": null,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 2, Dose Expansion, HCC: E7386 120 mg + Pembrolizumab 200 mg",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 19.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Phase 2, Dose Expansion, Melanoma: E7386 120 mg + Pembrolizumab 200 mg",
        "value": 6.9,
        "unit": "percentage of participants",
        "ci_lower": 0.8,
        "ci_upper": 22.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Phase 2, Dose Expansion, CRC: E7386 120 mg + Pembrolizumab 200 mg",
        "value": 3.2,
        "unit": "percentage of participants",
        "ci_lower": 0.1,
        "ci_upper": 16.7,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "E7386",
        "Pembrolizumab"
      ],
      "OG001": [
        "E7386",
        "Pembrolizumab"
      ],
      "OG002": [
        "E7386",
        "Pembrolizumab"
      ],
      "OG003": [
        "E7386",
        "Pembrolizumab"
      ],
      "OG004": [
        "E7386",
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER",
      "OG002": "OTHER",
      "OG003": "OTHER",
      "OG004": "OTHER"
    }
  },
  {
    "nct_id": "NCT01524783",
    "brief_title": "Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)",
    "status": "COMPLETED",
    "start_date": "2012-03-30",
    "completion_date": "2014-11-28",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT01524783",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Everolimus + BSC",
        "value": 90.1,
        "unit": "Percent event-free probability in PFS",
        "ci_lower": 84.8,
        "ci_upper": 93.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + BSC",
        "value": 74.6,
        "unit": "Percent event-free probability in PFS",
        "ci_lower": 64.3,
        "ci_upper": 82.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Everolimus + BSC",
        "value": 81.2,
        "unit": "Percent event-free probability in PFS",
        "ci_lower": 74.9,
        "ci_upper": 86.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + BSC",
        "value": 49.1,
        "unit": "Percent event-free probability in PFS",
        "ci_lower": 38.1,
        "ci_upper": 59.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Everolimus + BSC",
        "value": 72.1,
        "unit": "Percent event-free probability in PFS",
        "ci_lower": 65.0,
        "ci_upper": 78.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + BSC",
        "value": 40.1,
        "unit": "Percent event-free probability in PFS",
        "ci_lower": 29.5,
        "ci_upper": 50.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Everolimus + BSC",
        "value": 62.4,
        "unit": "Percent event-free probability in PFS",
        "ci_lower": 54.8,
        "ci_upper": 69.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + BSC",
        "value": 35.8,
        "unit": "Percent event-free probability in PFS",
        "ci_lower": 25.4,
        "ci_upper": 46.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Everolimus + BSC",
        "value": 51.7,
        "unit": "Percent event-free probability in PFS",
        "ci_lower": 44.0,
        "ci_upper": 59.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + BSC",
        "value": 31.3,
        "unit": "Percent event-free probability in PFS",
        "ci_lower": 21.3,
        "ci_upper": 41.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Everolimus + BSC",
        "value": 44.4,
        "unit": "Percent event-free probability in PFS",
        "ci_lower": 36.7,
        "ci_upper": 51.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + BSC",
        "value": 28.1,
        "unit": "Percent event-free probability in PFS",
        "ci_lower": 18.5,
        "ci_upper": 38.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Everolimus + BSC",
        "value": 40.1,
        "unit": "Percent event-free probability in PFS",
        "ci_lower": 32.5,
        "ci_upper": 47.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + BSC",
        "value": 26.4,
        "unit": "Percent event-free probability in PFS",
        "ci_lower": 16.9,
        "ci_upper": 36.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Everolimus + BSC",
        "value": 31.8,
        "unit": "Percent event-free probability in PFS",
        "ci_lower": 24.1,
        "ci_upper": 39.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + BSC",
        "value": 24.4,
        "unit": "Percent event-free probability in PFS",
        "ci_lower": 15.0,
        "ci_upper": 34.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Everolimus + BSC",
        "value": 27.6,
        "unit": "Percent event-free probability in PFS",
        "ci_lower": 19.0,
        "ci_upper": 36.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + BSC",
        "value": 17.4,
        "unit": "Percent event-free probability in PFS",
        "ci_lower": 9.0,
        "ci_upper": 28.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Everolimus + BSC",
        "value": 22.0,
        "unit": "Percent event-free probability in PFS",
        "ci_lower": 13.0,
        "ci_upper": 32.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + BSC",
        "value": 17.4,
        "unit": "Percent event-free probability in PFS",
        "ci_lower": 9.0,
        "ci_upper": 28.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Everolimus + BSC",
        "value": null,
        "unit": "Percent event-free probability in PFS",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + BSC",
        "value": 17.4,
        "unit": "Percent event-free probability in PFS",
        "ci_lower": 9.0,
        "ci_upper": 28.2,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Everolimus"
      ],
      "OG001": [
        "Everolimus"
      ],
      "OG002": [
        "Everolimus"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Placebo"
    }
  },
  {
    "nct_id": "NCT01519414",
    "brief_title": "Tivantinib in Treating Patients With Metastatic Prostate Cancer",
    "status": "COMPLETED",
    "start_date": "2012-01-11",
    "completion_date": "2015-08-18",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT01519414",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [
      {
        "target": "PSA",
        "status": "HIGH",
        "details": ">= 2 ng/mL"
      },
      {
        "target": "TESTOSTERONE",
        "status": "LOW",
        "details": "< 50 ng/dL (castrate testosterone level)"
      },
      {
        "target": "ANC",
        "status": "HIGH",
        "details": ">= 1,500/mcL"
      },
      {
        "target": "PLATELETS",
        "status": "HIGH",
        "details": ">= 100,000/mcL"
      },
      {
        "target": "BILIRUBIN",
        "status": "ANY",
        "details": "within institutional normal limits"
      },
      {
        "target": "AST",
        "status": "ANY",
        "details": "<= 2.0 x institutional upper limit of normal"
      },
      {
        "target": "ALT",
        "status": "ANY",
        "details": "<= 2.0 x institutional upper limit of normal"
      },
      {
        "target": "CREATININE",
        "status": "ANY",
        "details": "within institutional normal limits OR creatinine clearance >= 40 mL/min/1.73 m^2"
      },
      {
        "target": "HBA1C",
        "status": "LOW",
        "details": "< 8.0% (patients with HbA1c >= 8.0% are excluded)"
      },
      {
        "target": "GLUCOSE",
        "status": "LOW",
        "details": "fasting < 189 mg/dL (fasting glucose >= 189 mg/dL excluded)"
      },
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "known HIV seropositivity excluded"
      },
      {
        "target": "QTc",
        "status": "LOW",
        "details": "QTcF or QTcB < 470 ms per institutional standard (QTc >= 470 ms excluded)"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm I (Tivantinib)",
        "value": 5.5,
        "unit": "months",
        "ci_lower": 3.2,
        "ci_upper": 8.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm II (Placebo)",
        "value": 3.7,
        "unit": "months",
        "ci_lower": 2.7,
        "ci_upper": 5.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Tivantinib"
      ],
      "OG002": [
        "Tivantinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Placebo",
      "OG002": "TKI"
    }
  },
  {
    "nct_id": "NCT01575548",
    "brief_title": "Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2012-08-08",
    "completion_date": "2018-07-17",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT01575548",
    "cancer_types": [
      "KIRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IV",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A (Pazopanib)",
        "value": 17.0,
        "unit": "months",
        "ci_lower": 14.0,
        "ci_upper": 20.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B (Placebo)",
        "value": 14.2,
        "unit": "months",
        "ci_lower": 9.1,
        "ci_upper": 23.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pazopanib Hydrochloride"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT06212752",
    "brief_title": "A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2023-06-13",
    "completion_date": "2024-11-06",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT06212752",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy",
        "value": 64.3,
        "unit": "Percentage of participants",
        "ci_lower": 44.1,
        "ci_upper": 81.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy",
        "value": 18.2,
        "unit": "Percentage of participants",
        "ci_lower": 2.3,
        "ci_upper": 51.8,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab (+) Berahyaluronidase alfa",
        "Pemetrexed",
        "Cisplatin",
        "Carboplatin",
        "Paclitaxel",
        "Nab-paclitaxel"
      ],
      "OG001": [
        "Pembrolizumab",
        "Pemetrexed",
        "Cisplatin",
        "Carboplatin",
        "Paclitaxel",
        "Nab-paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT01578239",
    "brief_title": "A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours",
    "status": "COMPLETED",
    "start_date": "2012-09-06",
    "completion_date": "2015-07-31",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Advanced Accelerator Applications",
    "url": "https://clinicaltrials.gov/study/NCT01578239",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "SSTR",
        "status": "POSITIVE",
        "details": "Documented somatostatin receptor expression on all target lesions by positive OctreoScan within 24 weeks; lesion uptake \u2265 normal liver uptake on planar imaging; OctreoScan performed while on fixed-dose Octreotide LAR"
      },
      {
        "target": "Ki67",
        "status": "LOW",
        "details": "Ki67 index \u226420% (to be centrally confirmed)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "177Lu-DOTA0-Tyr3-Octreotate",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Octreotide LAR",
        "value": 8.5,
        "unit": "months",
        "ci_lower": 5.8,
        "ci_upper": 9.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "177Lu-DOTA0-Tyr3-Octreotate",
        "value": 48.0,
        "unit": "Months",
        "ci_lower": 37.4,
        "ci_upper": 55.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Octreotide LAR",
        "value": 36.3,
        "unit": "Months",
        "ci_lower": 25.9,
        "ci_upper": 51.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "177Lu-DOTA0-Tyr3-Octreotate",
        "Octreotide LAR"
      ],
      "OG001": [
        "Octreotide LAR"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT06351371",
    "brief_title": "Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2018-07-03",
    "completion_date": "2022-06-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT06351371",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "FGFR",
        "status": "POSITIVE",
        "details": "FGFR mutation or fusion as determined via the MATCH Master Protocol"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Subprotocol K2 (FGFR Mutation or Fusion)",
        "value": 16.0,
        "unit": "percentage of participants",
        "ci_lower": 5.7,
        "ci_upper": 33.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Subprotocol K2 (FGFR Mutation or Fusion)",
        "value": 38.6,
        "unit": "percentage of participants",
        "ci_lower": 22.2,
        "ci_upper": 54.8,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Erdafitinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT01588990",
    "brief_title": "A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2012-06-26",
    "completion_date": "2016-09-15",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT01588990",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Bevacizumab: Phase A and Phase B",
        "value": 1.4,
        "unit": "hazard ratio",
        "ci_lower": 0.9,
        "ci_upper": 2.2,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Bevacizumab",
        "Oxaliplatin",
        "Capecitabine",
        "Leucovorin",
        "5-Fluouracil",
        "Irinotecan"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT05490771",
    "brief_title": "Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2018-06-20",
    "completion_date": "2021-01-06",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT05490771",
    "cancer_types": [
      "DLBC",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "PIK3CA",
        "status": "POSITIVE",
        "details": "PIK3CA mutation as determined via the MATCH Master Protocol"
      },
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "Activating KRAS mutations (must not have)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 positive defined as 3+ by IHC or FISH ratio >= 2 (breast cancer excluded)"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (Copanlisib)",
        "value": 16.0,
        "unit": "percentage of participants",
        "ci_lower": 6.0,
        "ci_upper": 33.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Copanlisib Hydrochloride"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01572727",
    "brief_title": "A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation",
    "status": "COMPLETED",
    "start_date": "2012-08",
    "completion_date": "2015-06",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT01572727",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 negative disease"
      },
      {
        "target": "PI3K",
        "status": "ANY",
        "details": "Tumor sample must be shipped to central lab to determine PI3K activation status (includes with or without PI3K activation)"
      },
      {
        "target": "ER",
        "status": "ANY",
        "details": "Known hormone receptor status required (ER)"
      },
      {
        "target": "PR",
        "status": "ANY",
        "details": "Known hormone receptor status required (PR)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "BKM120 and Paclitaxel",
        "value": 8.0,
        "unit": "Months",
        "ci_lower": 7.2,
        "ci_upper": 9.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo and Paclitaxel",
        "value": 9.2,
        "unit": "Months",
        "ci_lower": 7.3,
        "ci_upper": 11.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "BKM120 and Paclitaxel",
        "value": 29.5,
        "unit": "Months",
        "ci_lower": 25.0,
        "ci_upper": 30.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo and Paclitaxel",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "BKM120",
        "Paclitaxel"
      ],
      "OG001": [
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01543698",
    "brief_title": "A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2012-05-28",
    "completion_date": "2023-03-09",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT01543698",
    "cancer_types": [
      "SKCM",
      "CRC",
      "THCA"
    ],
    "biomarkers": [
      {
        "target": "BRAF",
        "status": "POSITIVE",
        "details": "BRAF V600 mutation (e.g., V600E)"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IIIC",
      "IV",
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "DCR",
        "arm_id": "OG000",
        "arm_title": "Phase 2: Arm 1 (mCRC): Encorafenib + Binimetinib",
        "value": 63.6,
        "unit": "Percentage of participants",
        "ci_lower": 30.8,
        "ci_upper": 89.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 2: Arm 2 (Prior BRAFi Melanoma): Encorafenib + Binimetinib",
        "value": 42.3,
        "unit": "Percentage of participants",
        "ci_lower": 23.4,
        "ci_upper": 63.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Phase 2: Arm 3 (BRAFi-na\u000efve Melanoma): Encorafenib + Binimetinib",
        "value": 66.7,
        "unit": "Percentage of participants",
        "ci_lower": 50.5,
        "ci_upper": 80.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Phase 2: Arm A (BRAFi-na\u000efve Melanoma): Encorafenib + Binimetinib + Ribociclib",
        "value": 59.5,
        "unit": "Percentage of participants",
        "ci_lower": 43.3,
        "ci_upper": 74.4,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Encorafenib",
        "Binimetinib"
      ],
      "OG001": [
        "Encorafenib",
        "Binimetinib"
      ],
      "OG002": [
        "Encorafenib",
        "Binimetinib"
      ],
      "OG003": [
        "Encorafenib",
        "Binimetinib"
      ],
      "OG004": [
        "Encorafenib",
        "Binimetinib"
      ],
      "OG005": [
        "Encorafenib",
        "Binimetinib"
      ],
      "OG006": [
        "Encorafenib",
        "Binimetinib"
      ],
      "OG007": [
        "Encorafenib",
        "Binimetinib",
        "Ribociclib"
      ],
      "OG008": [
        "Encorafenib",
        "Binimetinib",
        "Ribociclib"
      ],
      "OG009": [
        "Encorafenib",
        "Binimetinib",
        "Ribociclib"
      ],
      "OG010": [
        "Encorafenib",
        "Binimetinib",
        "Ribociclib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other",
      "OG004": "Targeted_Other",
      "OG005": "Targeted_Other",
      "OG006": "Targeted_Other",
      "OG007": "Targeted_Other",
      "OG008": "Targeted_Other",
      "OG009": "Targeted_Other",
      "OG010": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01560416",
    "brief_title": "Fulvestrant With or Without Ganetespib in HR+ Breast Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2012-06",
    "completion_date": "2016-06",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Dana-Farber Cancer Institute",
    "url": "https://clinicaltrials.gov/study/NCT01560416",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Estrogen receptor positive (hormone receptor positive)"
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": "Progesterone receptor positive (hormone receptor positive)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 negative"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "ARM A - Fulvestrant",
        "value": 3.7,
        "unit": "months",
        "ci_lower": 1.0,
        "ci_upper": 12.0,
        "dispersion_type": "MEAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B - Fulvestrant+Ganetespib",
        "value": 3.6,
        "unit": "months",
        "ci_lower": 2.0,
        "ci_upper": 7.5,
        "dispersion_type": "MEAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "ARM A - Fulvestrant",
        "value": 25.9,
        "unit": "months",
        "ci_lower": 23.1,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B - Fulvestrant+Ganetespib",
        "value": 29.2,
        "unit": "months",
        "ci_lower": 26.9,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Fulvestrant"
      ],
      "OG001": [
        "Fulvestrant",
        "Ganetespib"
      ],
      "OG002": [
        "Fulvestrant",
        "Ganetespib"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER",
      "OG002": "OTHER"
    }
  },
  {
    "nct_id": "NCT01532687",
    "brief_title": "Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma",
    "status": "COMPLETED",
    "start_date": "2012-03-13",
    "completion_date": "2019-10-31",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "OHSU Knight Cancer Institute",
    "url": "https://clinicaltrials.gov/study/NCT01532687",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Gemcitabine Hydrochloride Plus Pazopanib Hydrochloride",
        "value": 4.5,
        "unit": "months",
        "ci_lower": 3.0,
        "ci_upper": 8.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Gemcitabine Hydrochloride Plus Placebo",
        "value": 1.6,
        "unit": "months",
        "ci_lower": 1.4,
        "ci_upper": 4.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Gemcitabine Hydrochloride Plus Pazopanib Hydrochloride",
        "value": 11.0,
        "unit": "months",
        "ci_lower": 9.6,
        "ci_upper": 20.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Gemcitabine Hydrochloride Plus Placebo",
        "value": 15.6,
        "unit": "months",
        "ci_lower": 6.1,
        "ci_upper": 27.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Gemcitabine Hydrochloride",
        "Pazopanib Hydrochloride"
      ],
      "OG001": [
        "Gemcitabine Hydrochloride"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01553188",
    "brief_title": "AMG 386 and Abiraterone for Advanced Prostate Cancer",
    "status": "COMPLETED",
    "start_date": "2012-02-08",
    "completion_date": "2017-04-20",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT01553188",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "DL 1 Run in - 15mg/kg",
        "value": 2.8,
        "unit": "Months",
        "ci_lower": 1.9,
        "ci_upper": 3.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "DL 2 Run in - 30mg/kg",
        "value": 9.0,
        "unit": "Months",
        "ci_lower": 1.8,
        "ci_upper": 29.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Abiraterone, Prednisone and AMG",
        "value": 11.5,
        "unit": "Months",
        "ci_lower": 5.5,
        "ci_upper": 19.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Abiraterone and Prednisone Only",
        "value": 10.1,
        "unit": "Months",
        "ci_lower": 2.7,
        "ci_upper": 13.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "DL 1 Run in - 15mg/kg",
        "value": 11.1,
        "unit": "Months",
        "ci_lower": 5.4,
        "ci_upper": 16.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "DL 2 Run in - 30mg/kg",
        "value": 27.9,
        "unit": "Months",
        "ci_lower": 10.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Abiraterone, Prednisone and AMG",
        "value": 31.1,
        "unit": "Months",
        "ci_lower": 18.8,
        "ci_upper": 43.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Abiraterone and Prednisone Only",
        "value": 25.5,
        "unit": "Months",
        "ci_lower": 8.1,
        "ci_upper": 34.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "AMG 386",
        "Abiraterone"
      ],
      "OG001": [
        "AMG 386",
        "Abiraterone"
      ],
      "OG002": [
        "AMG 386",
        "Abiraterone",
        "Prednisone"
      ],
      "OG003": [
        "Abiraterone",
        "Prednisone"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT05751629",
    "brief_title": "Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer",
    "status": "COMPLETED",
    "start_date": "2018-11-15",
    "completion_date": "2022-04-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Tesaro, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT05751629",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort A (Dostarlimab + Bevacizumab + Niraparib)",
        "value": 17.9,
        "unit": "Percentage of participants",
        "ci_lower": 10.3,
        "ci_upper": 28.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort A (Dostarlimab + Bevacizumab + Niraparib)",
        "value": 7.92,
        "unit": "Months",
        "ci_lower": 4.17,
        "ci_upper": 10.87,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cohort A (Dostarlimab + Bevacizumab + Niraparib)",
        "value": 22.05,
        "unit": "Months",
        "ci_lower": 11.14,
        "ci_upper": 26.25,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Dostarlimab",
        "Bevacizumab",
        "Niraparib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT05600309",
    "brief_title": "A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study",
    "status": "COMPLETED",
    "start_date": "2022-06-14",
    "completion_date": "2024-08-15",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT05600309",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "POSITIVE",
        "details": "PD-L1 positive tumor status (threshold/method not specified)"
      },
      {
        "target": "MSI",
        "status": "NEGATIVE",
        "details": "dMMR/MSI-H (must NOT have deficient mismatch repair / MSI\u2011High)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Favezelimab/Pembrolizumab",
        "value": 9.6,
        "unit": "Months",
        "ci_lower": 6.7,
        "ci_upper": 15.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Standard of Care (Regorafenib or TAS-102)",
        "value": 9.2,
        "unit": "Months",
        "ci_lower": 5.6,
        "ci_upper": 14.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "favezelimab",
        "pembrolizumab"
      ],
      "OG001": [
        "regorafenib",
        "TAS-102"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT01575522",
    "brief_title": "Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2012-03",
    "completion_date": "2013-07",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT01575522",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "Invasive tumor must be estrogen-receptor negative (ER-) or <10% staining by IHC (hormone-receptor poor)"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "Invasive tumor must be progesterone-receptor negative (PR-) or <10% staining by IHC (hormone-receptor poor)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-negative defined as IHC 0 or 1+, or FISH < 2.0"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Tivantinib)",
        "value": 1.2,
        "unit": "months",
        "ci_lower": 1.0,
        "ci_upper": 1.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Tivantinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT05775289",
    "brief_title": "A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2023-03-15",
    "completion_date": "2024-06-20",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT05775289",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Known tumor PD-L1 status required"
      },
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "Any EGFR gene mutation (EGFR-mutant NSCLC excluded)"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "ALK fusion oncogene (ALK-positive NSCLC excluded)"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IIIC",
      "IV",
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembro + Chemotherapy",
        "value": 7.13,
        "unit": "Months",
        "ci_lower": 5.59,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Tobe + Chemotherapy",
        "value": 7.62,
        "unit": "Months",
        "ci_lower": 5.62,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Pembro + Chemotherapy",
        "value": 46.2,
        "unit": "Percent of participants",
        "ci_lower": 36.28,
        "ci_upper": 56.34,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Tobe + Chemotherapy",
        "value": 41.1,
        "unit": "Percent of participants",
        "ci_lower": 31.51,
        "ci_upper": 51.44,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Pemetrexed",
        "Carboplatin"
      ],
      "OG001": [
        "Tobemstomig",
        "Pemetrexed",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT01570036",
    "brief_title": "Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax",
    "status": "COMPLETED",
    "start_date": "2013-05-21",
    "completion_date": "2018-09-28",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "George E. Peoples",
    "url": "https://clinicaltrials.gov/study/NCT01570036",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "LOW",
        "details": "IHC 1+ or 2+ required; if IHC 2+ must be non-amplified by FISH or Dual-ISH (\u22642.0). Excludes IHC 0, IHC 3+, or FISH/Dual-ISH >2.0."
      },
      {
        "target": "HLA-A",
        "status": "POSITIVE",
        "details": "Positive for HLA-A2, A3, A24, or A26 required."
      },
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "Required only for node-negative patients (AJCC N0 or N0(i+)) \u2014 must be negative for both ER and PR."
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "Required only for node-negative patients (AJCC N0 or N0(i+)) \u2014 must be negative for both ER and PR."
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [],
    "arm_drugs": {
      "OG000": [
        "Herceptin",
        "NeuVax vaccine"
      ],
      "OG001": [
        "Herceptin",
        "GM-CSF"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT06360588",
    "brief_title": "Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2018-10-08",
    "completion_date": "2023-01-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT06360588",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "PTEN",
        "status": "LOW",
        "details": "Complete loss of cytoplasmic and nuclear PTEN by immunohistochemistry (IHC); PTEN IHC required (mutation/deletion status may be any)"
      },
      {
        "target": "NRAS",
        "status": "NEGATIVE",
        "details": "No co-existing aberrations in MAPK or PI3K/MTOR pathways as determined by MATCH screening assessment"
      },
      {
        "target": "HRAS",
        "status": "NEGATIVE",
        "details": "No co-existing aberrations in MAPK or PI3K/MTOR pathways as determined by MATCH screening assessment"
      },
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "No co-existing aberrations in MAPK or PI3K/MTOR pathways as determined by MATCH screening assessment"
      },
      {
        "target": "BRAF",
        "status": "NEGATIVE",
        "details": "No co-existing aberrations in MAPK or PI3K/MTOR pathways as determined by MATCH screening assessment"
      },
      {
        "target": "PIK3CA",
        "status": "NEGATIVE",
        "details": "No co-existing aberrations in MAPK or PI3K/MTOR pathways as determined by MATCH screening assessment"
      },
      {
        "target": "AKT",
        "status": "NEGATIVE",
        "details": "No co-existing aberrations in MAPK or PI3K/MTOR pathways as determined by MATCH screening assessment"
      },
      {
        "target": "MTOR",
        "status": "NEGATIVE",
        "details": "No co-existing aberrations in MAPK or PI3K/MTOR pathways as determined by MATCH screening assessment"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "Excludes HER2\u2011positive breast cancer (HER2 3+ by IHC or FISH ratio \u22652)"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Subprotocol Z1G (PTEN Loss)",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 13.9,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Copanlisib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT05460273",
    "brief_title": "A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2022-07-11",
    "completion_date": "2023-11-07",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT05460273",
    "cancer_types": [
      "NSCLC",
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "Documented negative test results required for subset without actionable genomic alterations; local testing required if unavailable."
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "Documented negative test results required for subset without actionable genomic alterations; local testing required if unavailable."
      },
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "Actionable genomic alteration; participant must have received 1\u20132 prior lines of applicable targeted therapy for the alteration."
      },
      {
        "target": "ALK",
        "status": "POSITIVE",
        "details": "Actionable genomic alteration; participant must have received 1\u20132 prior lines of applicable targeted therapy for the alteration."
      },
      {
        "target": "ROS1",
        "status": "POSITIVE",
        "details": "Actionable genomic alteration; participant must have received 1\u20132 prior lines of applicable targeted therapy for the alteration."
      },
      {
        "target": "MET",
        "status": "POSITIVE",
        "details": "Exon 14 skipping (METex14) actionable alteration; participant must have received 1\u20132 prior lines of applicable targeted therapy."
      },
      {
        "target": "RET",
        "status": "POSITIVE",
        "details": "Actionable genomic alteration; participant must have received 1\u20132 prior lines of applicable targeted therapy for the alteration."
      },
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "Oestrogen receptor\u2013negative expression requirement for the TNBC cohort."
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "Progesterone receptor\u2013negative expression requirement for the TNBC cohort."
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2\u2011negative expression requirement for the TNBC cohort."
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IIIC",
      "IV",
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "TNBC Cohort",
        "value": 33.8,
        "unit": "Percentage of participants",
        "ci_lower": 23.4,
        "ci_upper": 45.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "NSCLC Cohort",
        "value": 45.0,
        "unit": "Percentage of participants",
        "ci_lower": 29.3,
        "ci_upper": 61.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "TNBC Cohort",
        "value": 5.3,
        "unit": "Month",
        "ci_lower": 4.2,
        "ci_upper": 6.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "NSCLC Cohort",
        "value": 7.4,
        "unit": "Month",
        "ci_lower": 5.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "TNBC Cohort",
        "value": 13.5,
        "unit": "Month",
        "ci_lower": 10.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "NSCLC Cohort",
        "value": null,
        "unit": "Month",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Datopotamab Deruxtecan (Dato-DXd)"
      ],
      "OG001": [
        "Datopotamab Deruxtecan (Dato-DXd)"
      ]
    },
    "treatment_class_map": {
      "OG000": "ADC",
      "OG001": "ADC"
    }
  },
  {
    "nct_id": "NCT05578872",
    "brief_title": "A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).",
    "status": "COMPLETED",
    "start_date": "2022-12-16",
    "completion_date": "2024-08-01",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Anaveon AG",
    "url": "https://clinicaltrials.gov/study/NCT05578872",
    "cancer_types": [
      "SKCM"
    ],
    "biomarkers": [
      {
        "target": "BRAF",
        "status": "ANY",
        "details": "BRAFV600 status considered for allowed number of prior systemic therapy lines (BRAFV600 positive: up to 3 prior lines allowed; BRAF wild-type: up to 2 prior lines allowed)"
      },
      {
        "target": "LDH",
        "status": "LOW",
        "details": "LDH must be <2\u00d7 upper limit of normal (patients with LDH \u22652\u00d7ULN are excluded)"
      }
    ],
    "cancer_stages": [
      "III",
      "IV",
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": true,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "ANV419 Single Agent, Low Dose",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "ANV419 Single Agent, High Dose",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG000",
        "arm_title": "ANV419 Single Agent, Low Dose",
        "value": null,
        "unit": null,
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG001",
        "arm_title": "ANV419 Single Agent, High Dose",
        "value": null,
        "unit": null,
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG000",
        "arm_title": "ANV419 Single Agent, Low Dose",
        "value": 5.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG001",
        "arm_title": "ANV419 Single Agent, High Dose",
        "value": 7.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "ANV419 Single Agent, Low Dose",
        "value": 2.2,
        "unit": "months",
        "ci_lower": 1.8,
        "ci_upper": 2.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "ANV419 Single Agent, High Dose",
        "value": 2.4,
        "unit": "months",
        "ci_lower": 1.4,
        "ci_upper": 4.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "ANV419 Single Agent, Low Dose",
        "value": 0.8,
        "unit": "Proportion of participants",
        "ci_lower": 0.5,
        "ci_upper": 0.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "ANV419 Single Agent, High Dose",
        "value": 0.8,
        "unit": "Proportion of participants",
        "ci_lower": 0.5,
        "ci_upper": 0.9,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "ANV419"
      ],
      "OG001": [
        "ANV419"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT05613088",
    "brief_title": "A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
    "status": "COMPLETED",
    "start_date": "2023-02-01",
    "completion_date": "2024-06-17",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT05613088",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "FOLR1",
        "status": "ANY",
        "details": "Tissue must be available for FR\u03b1 assessment (FFPE \u22645 years old or newly-obtained biopsy) prior to randomization."
      }
    ],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "MORAb-202",
        "value": 20.0,
        "unit": "Percent of participants",
        "ci_lower": 11.4,
        "ci_upper": 31.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Investigator's Choice (IC) Chemotherapy",
        "value": 13.9,
        "unit": "Percent of participants",
        "ci_lower": 4.7,
        "ci_upper": 29.5,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "MORAb-202"
      ],
      "OG001": [
        "Paclitaxel",
        "Pegylated Liposomal Doxorubicin (PLD)",
        "Topotecan"
      ]
    },
    "treatment_class_map": {
      "OG000": "ADC",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01648348",
    "brief_title": "Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme",
    "status": "COMPLETED",
    "start_date": "2012-11",
    "completion_date": "2016-05-11",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT01648348",
    "cancer_types": [
      "GBM",
      "LGG"
    ],
    "biomarkers": [
      {
        "target": "1p19q",
        "status": "NEGATIVE",
        "details": "1p/19q co-deletion (GBM with oligodendroglial features are excluded if 1p/19q co-deleted)"
      }
    ],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase II: Bev + TRC105 (Arm I)",
        "value": 2.9,
        "unit": "months",
        "ci_lower": 2.8,
        "ci_upper": 4.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Phase II: Bev Alone (Arm II)",
        "value": 3.2,
        "unit": "months",
        "ci_lower": 2.6,
        "ci_upper": 4.6,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Bevacizumab",
        "TRC105"
      ],
      "OG001": [
        "Bevacizumab",
        "TRC105"
      ],
      "OG002": [
        "Bevacizumab",
        "TRC105"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT06400251",
    "brief_title": "Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2019-08-08",
    "completion_date": "2023-06-27",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT06400251",
    "cancer_types": [
      "OTHER",
      "DLBC"
    ],
    "biomarkers": [
      {
        "target": "AKT",
        "status": "POSITIVE",
        "details": "AKT mutation as determined via the MATCH Master Protocol"
      },
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "Known KRAS mutations excluded"
      },
      {
        "target": "NRAS",
        "status": "NEGATIVE",
        "details": "Known NRAS mutations excluded"
      },
      {
        "target": "HRAS",
        "status": "NEGATIVE",
        "details": "Known HRAS mutations excluded"
      },
      {
        "target": "BRAF",
        "status": "NEGATIVE",
        "details": "Known BRAF mutations excluded"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (Ipatasertib)",
        "value": 24.1,
        "unit": "percentage of participants",
        "ci_lower": 11.9,
        "ci_upper": 40.6,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ipatasertib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01647828",
    "brief_title": "A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer",
    "status": "COMPLETED",
    "start_date": "2012-10",
    "completion_date": "2016-04",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "OncoMed Pharmaceuticals, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT01647828",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "P2: Placebo + Nab-P + Gem",
        "value": 60.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "P2: OMP-59R5 15 mg/kg + Nab-P + Gem",
        "value": 71.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "OMP-59R5",
        "Gemcitabine"
      ],
      "OG001": [
        "OMP-59R5",
        "Gemcitabine"
      ],
      "OG002": [
        "OMP-59R5",
        "Nab-Paclitaxel",
        "Gemcitabine"
      ],
      "OG003": [
        "OMP-59R5",
        "Nab-Paclitaxel",
        "Gemcitabine"
      ],
      "OG004": [
        "OMP-59R5",
        "Nab-Paclitaxel",
        "Gemcitabine"
      ],
      "OG005": [
        "OMP-59R5",
        "Nab-Paclitaxel",
        "Gemcitabine"
      ],
      "OG006": [
        "OMP-59R5",
        "Nab-Paclitaxel",
        "Gemcitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted",
      "OG003": "Combo_Chemo_Targeted",
      "OG004": "Combo_Chemo_Targeted",
      "OG005": "Combo_Chemo_Targeted",
      "OG006": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT01639001",
    "brief_title": "A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients",
    "status": "COMPLETED",
    "start_date": "2012-09-29",
    "completion_date": "2015-06-30",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT01639001",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "ALK",
        "status": "POSITIVE",
        "details": "Translocation or inversion events involving the ALK gene locus"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Crizotinib",
        "value": 11.1,
        "unit": "Months",
        "ci_lower": 8.3,
        "ci_upper": 12.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy",
        "value": 6.8,
        "unit": "Months",
        "ci_lower": 5.7,
        "ci_upper": 7.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Crizotinib",
        "value": 33.7,
        "unit": "Months",
        "ci_lower": 26.5,
        "ci_upper": 42.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy",
        "value": 32.9,
        "unit": "Months",
        "ci_lower": 23.9,
        "ci_upper": 43.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Crizotinib"
      ],
      "OG001": [
        "Pemetrexed",
        "Cisplatin",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01602380",
    "brief_title": "A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2012-10-17",
    "completion_date": "2016-04-11",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT01602380",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Hormone receptor positive on primary or metastatic tumour by local laboratory assessment (ER and/or PR)"
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": "Hormone receptor positive on primary or metastatic tumour by local laboratory assessment (ER and/or PR)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Fulvestrant 500 mg",
        "value": 16.6,
        "unit": "Months",
        "ci_lower": 13.83,
        "ci_upper": 20.99,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Anastrozole 1 mg",
        "value": 13.8,
        "unit": "Months",
        "ci_lower": 11.99,
        "ci_upper": 16.59,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Fulvestrant 500 mg",
        "value": 68.3,
        "unit": "Percentage of patients",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Anastrozole 1 mg",
        "value": 67.7,
        "unit": "Percentage of patients",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "faslodex 500mg"
      ],
      "OG001": [
        "arimidex 1mg"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT01605227",
    "brief_title": "Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100",
    "status": "COMPLETED",
    "start_date": "2012-07",
    "completion_date": "2014-09",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Exelixis",
    "url": "https://clinicaltrials.gov/study/NCT01605227",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cabozantinib",
        "value": 11.0,
        "unit": "months",
        "ci_lower": 10.09,
        "ci_upper": 11.63,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Prednisone",
        "value": 9.8,
        "unit": "months",
        "ci_lower": 9.0,
        "ci_upper": 11.53,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cabozantinib",
        "value": 5.6,
        "unit": "months",
        "ci_lower": 5.49,
        "ci_upper": 5.62,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Prednisone",
        "value": 2.8,
        "unit": "months",
        "ci_lower": 2.79,
        "ci_upper": 2.86,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "cabozantinib"
      ],
      "OG001": [
        "prednisone"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT01625286",
    "brief_title": "Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients",
    "status": "COMPLETED",
    "start_date": "2012-10-03",
    "completion_date": "2017-01-28",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT01625286",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "ER-positive required in Part B"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-negative required in Part B"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG005",
        "arm_title": "Part B AZD5363",
        "value": 10.9,
        "unit": "Months",
        "ci_lower": 8.3,
        "ci_upper": 12.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG006",
        "arm_title": "Part B Placebo",
        "value": 8.4,
        "unit": "Months",
        "ci_lower": 8.2,
        "ci_upper": 10.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "AZD5363",
        "Paclitaxel"
      ],
      "OG001": [
        "AZD5363",
        "Paclitaxel"
      ],
      "OG002": [
        "AZD5363",
        "Paclitaxel"
      ],
      "OG003": [
        "AZD5363",
        "Paclitaxel"
      ],
      "OG004": [
        "AZD5363",
        "Paclitaxel"
      ],
      "OG005": [
        "AZD5363",
        "Paclitaxel"
      ],
      "OG006": [
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted",
      "OG003": "Combo_Chemo_Targeted",
      "OG004": "Combo_Chemo_Targeted",
      "OG005": "Combo_Chemo_Targeted",
      "OG006": "Chemo"
    }
  },
  {
    "nct_id": "NCT01610336",
    "brief_title": "A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment",
    "status": "COMPLETED",
    "start_date": "2012-04-05",
    "completion_date": "2016-06-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT01610336",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "Documented EGFR mutation"
      },
      {
        "target": "MET",
        "status": "ANY",
        "details": "c-MET dysregulation (e.g., amplification or overexpression)"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": true,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "INC280 400 mg Cap BID Phase II",
        "value": 12.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "INC280 400 mg Tab BID Phase II",
        "value": 17.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "INC280",
        "Capmatinib"
      ],
      "OG001": [
        "INC280",
        "Capmatinib"
      ],
      "OG002": [
        "INC280",
        "Capmatinib"
      ],
      "OG003": [
        "INC280",
        "Capmatinib"
      ],
      "OG004": [
        "INC280",
        "Capmatinib"
      ],
      "OG005": [
        "INC280",
        "Capmatinib"
      ],
      "OG006": [
        "INC280",
        "Capmatinib"
      ],
      "OG007": [
        "INC280",
        "Capmatinib"
      ],
      "OG008": [
        "INC280",
        "Capmatinib"
      ],
      "OG009": [
        "INC280",
        "Capmatinib"
      ],
      "OG010": [
        "INC280",
        "Capmatinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI",
      "OG002": "TKI",
      "OG003": "TKI",
      "OG004": "TKI",
      "OG005": "TKI",
      "OG006": "TKI",
      "OG007": "TKI",
      "OG008": "TKI",
      "OG009": "TKI",
      "OG010": "TKI"
    }
  },
  {
    "nct_id": "NCT06385483",
    "brief_title": "Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2018-02-28",
    "completion_date": "2022-12-06",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT06385483",
    "cancer_types": [
      "DLBC",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "Activating EGFR mutations: exon 19 deletion (del 19) OR L858R; also includes EGFR G719A, G719C, G719D, G719S, L861Q, S768I"
      },
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "EGFR exon 20 insertion alone is excluded (except if specifically approved via the dynamic actionable mutation of interest [aMOI] process)"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (Afatinib)",
        "value": 11.8,
        "unit": "percentage of participants",
        "ci_lower": 2.1,
        "ci_upper": 32.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Afatinib)",
        "value": 15.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 30.7,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Afatinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT01633541",
    "brief_title": "Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer",
    "status": "COMPLETED",
    "start_date": "2012-03",
    "completion_date": "2021-11-06",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "University of Michigan Rogel Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT01633541",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "III",
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Platinum/Docetaxal + AT-101",
        "value": 55.0,
        "unit": "percentage of participants",
        "ci_lower": 35.0,
        "ci_upper": 71.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Active Comparator Arm",
        "value": 65.0,
        "unit": "percentage of participants",
        "ci_lower": 36.0,
        "ci_upper": 84.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Platinum/Docetaxal + AT-101",
        "value": 27.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "AT-101",
        "Docetaxel",
        "Cisplatin",
        "Carboplatin"
      ],
      "OG001": [
        "Docetaxel",
        "Cisplatin",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01605396",
    "brief_title": "A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)",
    "status": "COMPLETED",
    "start_date": "2012-07-04",
    "completion_date": "2014-02-19",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT01605396",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Estrogen receptor positive, determined locally"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER-2 negative, determined locally"
      },
      {
        "target": "Ki67",
        "status": "HIGH",
        "details": "Ki67 >= 15% as measured by central laboratory"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ridaforolimus + Dalotuzumab + Exemestane",
        "value": 23.29,
        "unit": "Weeks",
        "ci_lower": 8.71,
        "ci_upper": 38.43,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Ridaforolimus + Exemestane",
        "value": 31.86,
        "unit": "Weeks",
        "ci_lower": 16.0,
        "ci_upper": 39.29,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Ridaforolimus + Dalotuzumab + Exemestane",
        "value": null,
        "unit": "Weeks",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Ridaforolimus + Exemestane",
        "value": null,
        "unit": "Weeks",
        "ci_lower": 60.6,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ridaforolimus",
        "Dalotuzumab",
        "Exemestane"
      ],
      "OG001": [
        "Ridaforolimus",
        "Exemestane"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT06390839",
    "brief_title": "Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2017-03-22",
    "completion_date": "2022-01-15",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT06390839",
    "cancer_types": [
      "OTHER",
      "DLBC"
    ],
    "biomarkers": [
      {
        "target": "CDK4",
        "status": "HIGH",
        "details": "amplification (or other CDK4/CDK6 aberration as determined via MATCH Master Protocol)"
      },
      {
        "target": "CDK6",
        "status": "HIGH",
        "details": "amplification (or other CDK4/CDK6 aberration as determined via MATCH Master Protocol)"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (Palbociclib)",
        "value": 4.0,
        "unit": "percentage of participants",
        "ci_lower": 0.2,
        "ci_upper": 17.6,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Palbociclib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01609543",
    "brief_title": "A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations",
    "status": "COMPLETED",
    "start_date": "2012-05",
    "completion_date": "2015-01",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT01609543",
    "cancer_types": [
      "LUAD"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "activating mutation"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV",
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Erlotinib Hydrochloride",
        "value": 12.846,
        "unit": "Months",
        "ci_lower": 9.901,
        "ci_upper": 15.791,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "erlotinib [Tarceva]"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT01642004",
    "brief_title": "Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)",
    "status": "COMPLETED",
    "start_date": "2012-10-16",
    "completion_date": "2014-11-17",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT01642004",
    "cancer_types": [
      "LUSC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Nivolumab",
        "value": 9.23,
        "unit": "months",
        "ci_lower": 7.33,
        "ci_upper": 13.27,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Docetaxel",
        "value": 6.01,
        "unit": "months",
        "ci_lower": 5.13,
        "ci_upper": 7.33,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab"
      ],
      "OG001": [
        "Docetaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT06390826",
    "brief_title": "Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2016-11-01",
    "completion_date": "2023-04-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT06390826",
    "cancer_types": [
      "OTHER",
      "DLBC"
    ],
    "biomarkers": [
      {
        "target": "KIT",
        "status": "POSITIVE",
        "details": "Somatic cKIT mutation in exon 9, 11, 13 or 14; excludes exon 17 or 18 mutations"
      },
      {
        "target": "PDGFRA",
        "status": "NEGATIVE",
        "details": "No activating PDGFRA variants or fusions"
      },
      {
        "target": "PDGFRB",
        "status": "NEGATIVE",
        "details": "No activating PDGFRB variants or fusions"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (Sunitinib)",
        "value": 22.2,
        "unit": "percentage of participants",
        "ci_lower": 4.1,
        "ci_upper": 55.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Sunitinib)",
        "value": 33.3,
        "unit": "percentage of participants",
        "ci_lower": 15.4,
        "ci_upper": 72.4,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Sunitinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT06400238",
    "brief_title": "Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2018-10-15",
    "completion_date": "2023-01-27",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT06400238",
    "cancer_types": [
      "DLBC",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "PTEN",
        "status": "POSITIVE",
        "details": "Mutation in PTEN with \u22651% PTEN expression by immunohistochemistry (IHC) as determined via MATCH Master Protocol"
      },
      {
        "target": "NRAS",
        "status": "NEGATIVE",
        "details": "No co\u2011existing aberration as determined by MATCH screening assessment"
      },
      {
        "target": "HRAS",
        "status": "NEGATIVE",
        "details": "No co\u2011existing aberration as determined by MATCH screening assessment"
      },
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "No co\u2011existing aberration as determined by MATCH screening assessment"
      },
      {
        "target": "BRAF",
        "status": "NEGATIVE",
        "details": "No co\u2011existing aberration as determined by MATCH screening assessment"
      },
      {
        "target": "PIK3CA",
        "status": "NEGATIVE",
        "details": "No co\u2011existing aberration as determined by MATCH screening assessment"
      },
      {
        "target": "AKT",
        "status": "NEGATIVE",
        "details": "No co\u2011existing aberration as determined by MATCH screening assessment"
      },
      {
        "target": "MTOR",
        "status": "NEGATIVE",
        "details": "No co\u2011existing aberration as determined by MATCH screening assessment"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "Excludes HER2\u2011positive breast cancer (HER2 positive = IHC 3+ or FISH ratio \u22652)"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (Copanlisib)",
        "value": 3.4,
        "unit": "percentage of participants",
        "ci_lower": 0.2,
        "ci_upper": 15.3,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Copanlisib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01631552",
    "brief_title": "Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer",
    "status": "COMPLETED",
    "start_date": "2012-12-17",
    "completion_date": "2019-03-01",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Gilead Sciences",
    "url": "https://clinicaltrials.gov/study/NCT01631552",
    "cancer_types": [
      "BRCA",
      "NSCLC",
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "TNBC Target Population",
        "value": 34.3,
        "unit": "Percentage of participants",
        "ci_lower": 25.4,
        "ci_upper": 44.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "TNBC Target Population",
        "value": 5.6,
        "unit": "months",
        "ci_lower": 4.8,
        "ci_upper": 6.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "HR+/HER2- mBC Population",
        "value": 5.5,
        "unit": "months",
        "ci_lower": 3.6,
        "ci_upper": 7.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "mUC Population",
        "value": 6.8,
        "unit": "months",
        "ci_lower": 3.6,
        "ci_upper": 9.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "TNBC Target Population",
        "value": 13.0,
        "unit": "months",
        "ci_lower": 11.2,
        "ci_upper": 14.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "HR+/HER2- mBC Population",
        "value": 12.0,
        "unit": "months",
        "ci_lower": 9.0,
        "ci_upper": 18.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "mUC Population",
        "value": 16.8,
        "unit": "months",
        "ci_lower": 9.0,
        "ci_upper": 21.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Sacituzumab Govitecan-hziy (SG)"
      ],
      "OG001": [
        "Sacituzumab Govitecan-hziy (SG)"
      ],
      "OG002": [
        "Sacituzumab Govitecan-hziy (SG)"
      ],
      "OG003": [
        "Sacituzumab Govitecan-hziy (SG)"
      ]
    },
    "treatment_class_map": {
      "OG000": "ADC",
      "OG001": "ADC",
      "OG002": "ADC",
      "OG003": "ADC"
    }
  },
  {
    "nct_id": "NCT01602666",
    "brief_title": "Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors",
    "status": "COMPLETED",
    "start_date": "2012-06-27",
    "completion_date": "2024-09-30",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Children's Oncology Group",
    "url": "https://clinicaltrials.gov/study/NCT01602666",
    "cancer_types": [
      "TGCT"
    ],
    "biomarkers": [
      {
        "target": "AFP",
        "status": "HIGH",
        "details": "serum and/or CSF AFP >10 ng/mL or greater than institutional normal (NGGCT eligibility)"
      },
      {
        "target": "AFP",
        "status": "NEGATIVE",
        "details": "institutional normal or <=10 ng/mL in both serum and CSF (required for germinoma eligibility)"
      },
      {
        "target": "HCG",
        "status": "HIGH",
        "details": "serum and/or CSF hCG beta >100 mIU/mL (NGGCT eligibility irrespective of biopsy)"
      },
      {
        "target": "HCG",
        "status": "LOW",
        "details": "serum and/or CSF hCG beta 5 to <=50 mIU/mL (germinoma eligibility); in bifocal/pineal+DI or histologically confirmed germinoma hCG beta <=100 mIU/mL acceptable"
      },
      {
        "target": "CSF_CYTOLOGY",
        "status": "NEGATIVE",
        "details": "no malignant cells in lumbar CSF (patients with positive CSF cytology are considered metastatic and ineligible)"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Stratum 1 Localized Non-Germinomatous Germ Cell Tumors (NGGCT)",
        "value": 83.33,
        "unit": "percentage of patients",
        "ci_lower": 72.13,
        "ci_upper": 91.38,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Carboplatin",
        "Etoposide"
      ],
      "OG001": [
        "Carboplatin",
        "Etoposide"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01610284",
    "brief_title": "Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor",
    "status": "COMPLETED",
    "start_date": "2012-08-07",
    "completion_date": "2015-04-29",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT01610284",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": null
      },
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Hormone receptor\u2013positive (ER and/or PR) by standard breast cancer tests"
      },
      {
        "target": "PI3K",
        "status": "ANY",
        "details": "Tumor sample must be shipped for identification of PI3K activation status"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "BKM120 100mg + Fulvestrant",
        "value": 6.9,
        "unit": "Months",
        "ci_lower": 6.8,
        "ci_upper": 7.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Fulvestrant",
        "value": 5.0,
        "unit": "Months",
        "ci_lower": 4.0,
        "ci_upper": 5.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "BKM120 100mg + Fulvestrant",
        "value": 6.8,
        "unit": "Months",
        "ci_lower": 5.0,
        "ci_upper": 7.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Fulvestrant",
        "value": 4.5,
        "unit": "Months",
        "ci_lower": 3.3,
        "ci_upper": 5.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "BKM120 100mg + Fulvestrant",
        "value": 6.8,
        "unit": "Months",
        "ci_lower": 4.9,
        "ci_upper": 7.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Fulvestrant",
        "value": 4.0,
        "unit": "Months",
        "ci_lower": 3.1,
        "ci_upper": 5.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "BKM120 100mg + Fulvestrant",
        "value": 6.9,
        "unit": "Months",
        "ci_lower": 4.6,
        "ci_upper": 7.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Fulvestrant",
        "value": 4.6,
        "unit": "Months",
        "ci_lower": 3.3,
        "ci_upper": 5.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "BKM120 100mg + Fulvestrant",
        "value": 8.7,
        "unit": "Months",
        "ci_lower": 7.0,
        "ci_upper": 12.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Fulvestrant",
        "value": 6.8,
        "unit": "Months",
        "ci_lower": 5.0,
        "ci_upper": 8.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "BKM120 100mg + Fulvestrant",
        "value": 33.2,
        "unit": "Months",
        "ci_lower": 30.0,
        "ci_upper": 37.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Fulvestrant",
        "value": 30.4,
        "unit": "Months",
        "ci_lower": 27.9,
        "ci_upper": 32.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "BKM120 100mg + Fulvestrant",
        "value": 30.9,
        "unit": "Months",
        "ci_lower": 25.1,
        "ci_upper": 35.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Fulvestrant",
        "value": 28.9,
        "unit": "Months",
        "ci_lower": 25.9,
        "ci_upper": 31.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "BKM120 100mg + Fulvestrant",
        "value": 33.6,
        "unit": "Months",
        "ci_lower": 23.8,
        "ci_upper": 40.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Fulvestrant",
        "value": 27.5,
        "unit": "Months",
        "ci_lower": 24.4,
        "ci_upper": 31.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "BKM120 100mg + Fulvestrant",
        "value": 28.8,
        "unit": "Months",
        "ci_lower": 23.0,
        "ci_upper": 33.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Fulvestrant",
        "value": 30.0,
        "unit": "Months",
        "ci_lower": 26.0,
        "ci_upper": 33.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "BKM120 100mg + Fulvestrant",
        "value": 42.3,
        "unit": "Months",
        "ci_lower": 36.5,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Fulvestrant",
        "value": 36.0,
        "unit": "Months",
        "ci_lower": 31.0,
        "ci_upper": 43.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "BKM120",
        "Fulvestrant"
      ],
      "OG001": [
        "Fulvestrant"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT06926673",
    "brief_title": "Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3",
    "status": "COMPLETED",
    "start_date": "2021-12-23",
    "completion_date": "2024-05-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "GlaxoSmithKline",
    "url": "https://clinicaltrials.gov/study/NCT06926673",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "BRAF",
        "status": "POSITIVE",
        "details": "Must have progressed after receiving locally available standard-of-care treatment for the BRAF molecular alteration."
      },
      {
        "target": "HBsAg",
        "status": "NEGATIVE",
        "details": "HBsAg positive participants are excluded; HBsAg must be negative at screening (within 3 months prior to first dose)."
      },
      {
        "target": "HCV",
        "status": "NEGATIVE",
        "details": "HCV infection excluded \u2014 both HCV antibody and HCV RNA must be negative at screening (within 3 months prior to first dose)."
      },
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "Known HIV infection is exclusionary."
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IIIC",
      "IV",
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm 4: Dostarlimab + Belrestotug [Low Dose (LD)]",
        "value": null,
        "unit": null,
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)]",
        "value": null,
        "unit": null,
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Arm 4: Dostarlimab + Belrestotug [High Dose (HD)]",
        "value": null,
        "unit": null,
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MD",
        "value": null,
        "unit": null,
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG004",
        "arm_title": "Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HD",
        "value": null,
        "unit": null,
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG005",
        "arm_title": "Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LD",
        "value": null,
        "unit": null,
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG006",
        "arm_title": "Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD",
        "value": null,
        "unit": null,
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Dostarlimab",
        "Belrestotug"
      ],
      "OG001": [
        "Dostarlimab",
        "Belrestotug"
      ],
      "OG002": [
        "Dostarlimab",
        "Belrestotug"
      ],
      "OG003": [
        "Dostarlimab",
        "Belrestotug",
        "Nelistotug"
      ],
      "OG004": [
        "Dostarlimab",
        "Belrestotug",
        "Nelistotug"
      ],
      "OG005": [
        "Dostarlimab",
        "Belrestotug",
        "Nelistotug"
      ],
      "OG006": [
        "Dostarlimab",
        "Belrestotug",
        "Nelistotug"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted",
      "OG002": "Combo_IO_Targeted",
      "OG003": "Combo_IO_Targeted",
      "OG004": "Combo_IO_Targeted",
      "OG005": "Combo_IO_Targeted",
      "OG006": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT01698918",
    "brief_title": "Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2013-03-07",
    "completion_date": "2015-12-17",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT01698918",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "ER+ (estrogen receptor positive)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2- (HER2 negative)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Everolimus+Letrozole (First-line Treatment)",
        "value": null,
        "unit": "Months",
        "ci_lower": 18.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Everolimus+Letrozole/Exemestane (First-line Treatment and Second-line Treatment)",
        "value": null,
        "unit": "Months",
        "ci_lower": 37.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Everolimus",
        "Letrozole"
      ],
      "OG001": [
        "Everolimus",
        "Exemestane"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01652976",
    "brief_title": "Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma",
    "status": "COMPLETED",
    "start_date": "2012-07",
    "completion_date": "2018-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "University of Florida",
    "url": "https://clinicaltrials.gov/study/NCT01652976",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Dasatinib and mFOLFOX6",
        "value": 4.0,
        "unit": "months",
        "ci_lower": 2.3,
        "ci_upper": 8.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Dasatinib and mFOLFOX6",
        "value": 10.6,
        "unit": "months",
        "ci_lower": 6.9,
        "ci_upper": 12.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Dasatinib",
        "mFOLFOX6"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT01666730",
    "brief_title": "Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer",
    "status": "COMPLETED",
    "start_date": "2013-02-21",
    "completion_date": "2018-08-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Case Comprehensive Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT01666730",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Metformin Hydrochloride, FOLFOX)",
        "value": 7.1,
        "unit": "Months",
        "ci_lower": 5.0,
        "ci_upper": 9.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "metformin hydrochloride",
        "leucovorin calcium",
        "fluorouracil",
        "oxaliplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo"
    }
  },
  {
    "nct_id": "NCT01684878",
    "brief_title": "Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)",
    "status": "COMPLETED",
    "start_date": "2012-10-22",
    "completion_date": "2015-01-30",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT01684878",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "HER3",
        "status": "LOW",
        "details": "low HER3 mRNA expression"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Part 2: Pertuzumab+Chemotherapy",
        "value": 4.27,
        "unit": "months",
        "ci_lower": 3.65,
        "ci_upper": 6.11,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Part 2: Placebo+Chemotherapy",
        "value": 2.74,
        "unit": "months",
        "ci_lower": 2.14,
        "ci_upper": 4.73,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Part 2: Pertuzumab+Chemotherapy",
        "value": 10.18,
        "unit": "months",
        "ci_lower": 6.67,
        "ci_upper": 15.24,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Part 2: Placebo+Chemotherapy",
        "value": 8.36,
        "unit": "months",
        "ci_lower": 6.14,
        "ci_upper": 11.99,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pertuzumab",
        "Topotecan (Chemotherapy)"
      ],
      "OG001": [
        "Pertuzumab",
        "Paclitaxel (Chemotherapy)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT01658436",
    "brief_title": "BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.",
    "status": "COMPLETED",
    "start_date": "2012-11",
    "completion_date": "2015-07",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT01658436",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "BEZ235 300 mg/400 mg Bid",
        "value": 51.6,
        "unit": "Percentage of participants",
        "ci_lower": 35.7,
        "ci_upper": 67.3,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "BEZ235"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01685060",
    "brief_title": "LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib",
    "status": "COMPLETED",
    "start_date": "2012-11-26",
    "completion_date": "2016-03-29",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT01685060",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "ALK",
        "status": "POSITIVE",
        "details": "ALK rearrangement by FDA-approved FISH assay (Abbott Molecular Inc.)"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV"
    ],
    "line_of_therapy": null,
    "prior_tki": true,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "LDK378 750mg",
        "value": 40.7,
        "unit": "Percentage of participants",
        "ci_lower": 32.5,
        "ci_upper": 49.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "LDK378 750mg",
        "value": 5.8,
        "unit": "months",
        "ci_lower": 5.4,
        "ci_upper": 7.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "LDK378 750mg",
        "value": 15.6,
        "unit": "Months",
        "ci_lower": 13.6,
        "ci_upper": 24.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "LDK378",
        "Ceritinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT01684215",
    "brief_title": "A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2012-10-19",
    "completion_date": "2016-03-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT01684215",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "ER-positive based on local laboratory results"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-negative based on local laboratory results using sponsor-approved assays"
      }
    ],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC",
      "UNRESECTABLE",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort",
        "value": 75.6,
        "unit": "percentage of participants",
        "ci_lower": 62.4,
        "ci_upper": 84.7,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "PD-0332991"
      ],
      "OG001": [
        "PD-0332991"
      ],
      "OG002": [
        "PD-0332991",
        "letrozole"
      ],
      "OG003": [
        "PD-0332991",
        "letrozole"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01703091",
    "brief_title": "A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2012-12",
    "completion_date": "2014-12",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT01703091",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "For non-squamous tumors EGFR mutation status must be known prior to randomization; if an activating EGFR mutation is present, prior EGFR\u2011TKI monotherapy (one regimen) is required."
      }
    ],
    "cancer_stages": [
      "IV",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ramucirumab + Docetaxel",
        "value": 5.22,
        "unit": "Months",
        "ci_lower": 3.52,
        "ci_upper": 6.97,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Docetaxel",
        "value": 4.21,
        "unit": "Months",
        "ci_lower": 2.83,
        "ci_upper": 5.62,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Ramucirumab + Docetaxel",
        "value": 15.15,
        "unit": "Months",
        "ci_lower": 12.45,
        "ci_upper": 26.55,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Docetaxel",
        "value": 14.65,
        "unit": "Months",
        "ci_lower": 11.93,
        "ci_upper": 24.44,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ramucirumab",
        "Docetaxel"
      ],
      "OG001": [
        "Docetaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01693562",
    "brief_title": "A Phase 1/2 Study to Evaluate MEDI4736",
    "status": "COMPLETED",
    "start_date": "2012-09-05",
    "completion_date": "2020-02-28",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "MedImmune LLC",
    "url": "https://clinicaltrials.gov/study/NCT01693562",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Expansion Non-squamous NSCLC 3L+ Cohort",
        "value": 10.3,
        "unit": "Percentage of participants",
        "ci_lower": 4.2,
        "ci_upper": 20.1,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "MEDI4736 (Durvalumab)"
      ],
      "OG001": [
        "MEDI4736 (Durvalumab)"
      ],
      "OG002": [
        "MEDI4736 (Durvalumab)"
      ],
      "OG003": [
        "MEDI4736 (Durvalumab)"
      ],
      "OG004": [
        "MEDI4736 (Durvalumab)"
      ],
      "OG005": [
        "MEDI4736 (Durvalumab)"
      ],
      "OG006": [
        "MEDI4736 (Durvalumab)"
      ],
      "OG007": [
        "MEDI4736 (Durvalumab)"
      ],
      "OG008": [
        "MEDI4736 (Durvalumab)"
      ],
      "OG009": [
        "MEDI4736 (Durvalumab)"
      ],
      "OG010": [
        "MEDI4736 (Durvalumab)"
      ],
      "OG011": [
        "MEDI4736 (Durvalumab)"
      ],
      "OG012": [
        "MEDI4736 (Durvalumab)"
      ],
      "OG013": [
        "MEDI4736 (Durvalumab)"
      ],
      "OG014": [
        "MEDI4736 (Durvalumab)"
      ],
      "OG015": [
        "MEDI4736 (Durvalumab)"
      ],
      "OG016": [
        "MEDI4736 (Durvalumab)"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO",
      "OG003": "IO",
      "OG004": "IO",
      "OG005": "IO",
      "OG006": "IO",
      "OG007": "IO",
      "OG008": "IO",
      "OG009": "IO",
      "OG010": "IO",
      "OG011": "IO",
      "OG012": "IO",
      "OG013": "IO",
      "OG014": "IO",
      "OG015": "IO",
      "OG016": "IO"
    }
  },
  {
    "nct_id": "NCT01663857",
    "brief_title": "A Study LY2228820 for Recurrent Ovarian Cancer",
    "status": "COMPLETED",
    "start_date": "2012-07",
    "completion_date": "2017-05-25",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT01663857",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "LY2228820 + Gemcitabine +Carboplatin",
        "value": 10.25,
        "unit": "months",
        "ci_lower": 7.85,
        "ci_upper": 10.87,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Gemcitabine + Carboplatin",
        "value": 8.44,
        "unit": "months",
        "ci_lower": 7.56,
        "ci_upper": 9.33,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "LY2228820",
        "Gemcitabine",
        "Carboplatin"
      ],
      "OG001": [
        "Gemcitabine",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01661270",
    "brief_title": "A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy",
    "status": "COMPLETED",
    "start_date": "2012-07",
    "completion_date": "2014-10",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sanofi",
    "url": "https://clinicaltrials.gov/study/NCT01661270",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Placebo",
        "value": 5.59,
        "unit": "months",
        "ci_lower": 4.632,
        "ci_upper": 6.111,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Aflibercept",
        "value": 6.93,
        "unit": "months",
        "ci_lower": 6.045,
        "ci_upper": 7.655,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Placebo",
        "value": 11.93,
        "unit": "months",
        "ci_lower": 10.086,
        "ci_upper": 14.292,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Aflibercept",
        "value": 14.59,
        "unit": "months",
        "ci_lower": 13.175,
        "ci_upper": 16.46,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Irinotecan",
        "5-Fluorouracil",
        "Leucovorin"
      ],
      "OG001": [
        "Aflibercept",
        "Irinotecan",
        "5-Fluorouracil",
        "Leucovorin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT01685138",
    "brief_title": "LDK378 in Crizotinib na\u00efve Adult Patients With ALK-activated Non-small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2012-12-20",
    "completion_date": "2018-01-22",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT01685138",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "ALK",
        "status": "POSITIVE",
        "details": "ALK rearrangement by FDA-approved Vysis ALK break-apart FISH assay (Abbott Molecular Inc.)"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV",
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": null,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "LDK378 (Ceritinib)",
        "value": 67.7,
        "unit": "Percentage of participants",
        "ci_lower": 58.8,
        "ci_upper": 75.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "LDK378 (Ceritinib)",
        "value": 16.6,
        "unit": "Months",
        "ci_lower": 11.0,
        "ci_upper": 23.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "LDK378 (Ceritinib)",
        "value": 19.4,
        "unit": "Months",
        "ci_lower": 10.9,
        "ci_upper": 29.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "LDK378 (Ceritinib)",
        "value": 51.3,
        "unit": "Months",
        "ci_lower": 42.7,
        "ci_upper": 55.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "LDK378",
        "Ceritinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT01653912",
    "brief_title": "Dose-finding Study in Platinum-Resistant Ovarian Cancer",
    "status": "COMPLETED",
    "start_date": "2012-11",
    "completion_date": "2015-07",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Accenture",
    "url": "https://clinicaltrials.gov/study/NCT01653912",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 2 (Treatment Group): GSK2110183",
        "value": 32.1,
        "unit": "Percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase 2 (Treatment Group): GSK2110183",
        "value": 6.5,
        "unit": "Months",
        "ci_lower": 4.4,
        "ci_upper": 8.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "GSK2110183",
        "carboplatin",
        "paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT01663727",
    "brief_title": "Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2012-08-27",
    "completion_date": "2014-11-30",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT01663727",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": null
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Paclitaxel+Placebo",
        "value": 8.8,
        "unit": "months",
        "ci_lower": 7.4,
        "ci_upper": 9.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Paclitaxel+ Bevacizumab",
        "value": 11.0,
        "unit": "months",
        "ci_lower": 9.5,
        "ci_upper": 12.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Paclitaxel+Placebo",
        "value": 25.8,
        "unit": "months",
        "ci_lower": 21.8,
        "ci_upper": 30.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Paclitaxel+ Bevacizumab",
        "value": 28.8,
        "unit": "months",
        "ci_lower": 22.8,
        "ci_upper": 32.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Paclitaxel"
      ],
      "OG001": [
        "Paclitaxel",
        "Bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT01661972",
    "brief_title": "Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2012-08",
    "completion_date": "2016-06-12",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "John Strickler, M.D.",
    "url": "https://clinicaltrials.gov/study/NCT01661972",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "wildtype (no KRAS mutation); prior EGFR\u2011targeting agent (or contraindication) required for KRAS wildtype subjects"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase 2",
        "value": 3.91,
        "unit": "Months",
        "ci_lower": 2.3,
        "ci_upper": 4.47,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Capecitabine",
        "Aflibercept"
      ],
      "OG001": [
        "Capecitabine",
        "Aflibercept"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT01664923",
    "brief_title": "Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer",
    "status": "COMPLETED",
    "start_date": "2012-08",
    "completion_date": "2015-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT01664923",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [
      {
        "target": "TESTOSTERONE",
        "status": "LOW",
        "details": "Serum testosterone \u2264 50 ng/dL (1.73 nmol/L) at Screening"
      },
      {
        "target": "PSA",
        "status": "ANY",
        "details": "Progressive disease defined by PSA progression (rising PSA) and/or radiographic progression while on primary androgen deprivation therapy"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Enzalutamide",
        "value": 19.4,
        "unit": "months",
        "ci_lower": 16.5,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Bicalutamide",
        "value": 5.7,
        "unit": "months",
        "ci_lower": 5.6,
        "ci_upper": 8.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Enzalutamide"
      ],
      "OG001": [
        "Bicalutamide"
      ],
      "OG002": [
        "Enzalutamide"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01673867",
    "brief_title": "Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC",
    "status": "COMPLETED",
    "start_date": "2012-11-02",
    "completion_date": "2015-02-05",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT01673867",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV",
      "METASTATIC",
      "RECURRENT",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Nivolumab",
        "value": 12.19,
        "unit": "Months",
        "ci_lower": 9.66,
        "ci_upper": 14.98,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Docetaxel",
        "value": 9.36,
        "unit": "Months",
        "ci_lower": 8.05,
        "ci_upper": 10.68,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Nivolumab",
        "value": 2.33,
        "unit": "Months",
        "ci_lower": 2.17,
        "ci_upper": 3.32,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Docetaxel",
        "value": 4.44,
        "unit": "Months",
        "ci_lower": 3.45,
        "ci_upper": 4.86,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab"
      ],
      "OG001": [
        "Docetaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01683994",
    "brief_title": "Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer",
    "status": "COMPLETED",
    "start_date": "2012-09-07",
    "completion_date": "2018-07-01",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT01683994",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [
      {
        "target": "PSA",
        "status": "HIGH",
        "details": "Two consecutively rising PSA values above baseline at minimum 1-week intervals to document progression"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ph I Dose Level 1:Cabozantinib + Docetaxel + Prednisone",
        "value": 8.0,
        "unit": "months",
        "ci_lower": 2.0,
        "ci_upper": 39.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Ph I Dose Level 2:Cabozantinib + Docetaxel + Prednisone",
        "value": 13.0,
        "unit": "months",
        "ci_lower": 8.0,
        "ci_upper": 21.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Ph I Dose Level 3:Cabozantinib + Docetaxel + Prednisone",
        "value": 6.0,
        "unit": "months",
        "ci_lower": 2.0,
        "ci_upper": 13.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Ph II Arm A: Docetaxel + Prednisone",
        "value": 10.0,
        "unit": "months",
        "ci_lower": 1.0,
        "ci_upper": 10.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Ph II Arm B: Cabozantinib + Docetaxel + Prednisone",
        "value": 6.5,
        "unit": "months",
        "ci_lower": 2.0,
        "ci_upper": 24.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cabozantinib",
        "Docetaxel",
        "Prednisone"
      ],
      "OG001": [
        "Cabozantinib",
        "Docetaxel",
        "Prednisone"
      ],
      "OG002": [
        "Cabozantinib",
        "Docetaxel",
        "Prednisone"
      ],
      "OG003": [
        "Docetaxel",
        "Prednisone"
      ],
      "OG004": [
        "Cabozantinib",
        "Docetaxel",
        "Prednisone"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Combo_TKI_Chemo",
      "OG002": "Combo_TKI_Chemo",
      "OG003": "Chemo",
      "OG004": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT01714739",
    "brief_title": "A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2012-10-07",
    "completion_date": "2019-12-13",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT01714739",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Part 1/2 Liri 0.1 + Nivo 3",
        "value": 25.0,
        "unit": "Percentage of participants",
        "ci_lower": 0.6,
        "ci_upper": 80.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Part 1/2: Liri 0.3 + Nivo 3",
        "value": 37.5,
        "unit": "Percentage of participants",
        "ci_lower": 15.2,
        "ci_upper": 64.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Part 1/2: Liri 1 + Nivo 3",
        "value": 40.0,
        "unit": "Percentage of participants",
        "ci_lower": 16.3,
        "ci_upper": 67.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Part 1/2: Liri 3 + Nivo 3",
        "value": 14.6,
        "unit": "Percentage of participants",
        "ci_lower": 10.8,
        "ci_upper": 19.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Part 3: PBO + Nivo 240",
        "value": 50.0,
        "unit": "Percentage of participants",
        "ci_lower": 1.3,
        "ci_upper": 98.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "Part 3: Liri 240 + Nivo 240",
        "value": 0.0,
        "unit": "Percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 70.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG006",
        "arm_title": "Part 5: Liri 3 + Nivo 3 + Ipi 1",
        "value": 0.0,
        "unit": "Percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 30.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Part 3: PBO + Nivo 240",
        "value": null,
        "unit": "Years",
        "ci_lower": 0.2,
        "ci_upper": 1.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Part 3: Liri 240 + Nivo 240",
        "value": 0.3,
        "unit": "Years",
        "ci_lower": 0.1,
        "ci_upper": 0.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Part 3: PBO + Nivo 240",
        "value": null,
        "unit": "Months",
        "ci_lower": 1.1,
        "ci_upper": 11.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Part 3: Liri 240 + Nivo 240",
        "value": 1.6,
        "unit": "Months",
        "ci_lower": 1.1,
        "ci_upper": 7.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Lirilumab",
        "Nivolumab"
      ],
      "OG001": [
        "Lirilumab",
        "Nivolumab"
      ],
      "OG002": [
        "Lirilumab",
        "Nivolumab"
      ],
      "OG003": [
        "Lirilumab",
        "Nivolumab"
      ],
      "OG004": [
        "Lirilumab",
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG005": [
        "Lirilumab",
        "Nivolumab"
      ],
      "OG006": [
        "Lirilumab",
        "Nivolumab",
        "Ipilimumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO",
      "OG003": "IO",
      "OG004": "IO",
      "OG005": "IO",
      "OG006": "IO"
    }
  },
  {
    "nct_id": "NCT01708954",
    "brief_title": "Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2013-02-13",
    "completion_date": "2015-08-14",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT01708954",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "No EGFR tyrosine kinase inhibitor\u2013sensitizing mutation (at minimum testing must have included EGFR exon 19 deletion and exon 21 L858R); EGFR testing may be inconclusive or unknown with alternative driver mutation allowed"
      },
      {
        "target": "KRAS",
        "status": "POSITIVE",
        "details": "Acceptable alternative driver mutation if EGFR status is unknown or testing inconclusive"
      },
      {
        "target": "BRAF",
        "status": "POSITIVE",
        "details": "Acceptable alternative driver mutation if EGFR status is unknown or testing inconclusive"
      },
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "Acceptable alternative driver mutation if EGFR status is unknown or testing inconclusive; refers to HER2 mutation"
      },
      {
        "target": "RET",
        "status": "POSITIVE",
        "details": "Acceptable alternative driver alteration if EGFR status is unknown or testing inconclusive; refers to RET rearrangement/fusion"
      },
      {
        "target": "MET",
        "status": "ANY",
        "details": "Sufficient pathology material must be available for submission for MET immunohistochemical (IHC) testing (IHC testing required/submission of tumor sample)"
      }
    ],
    "cancer_stages": [
      "IV",
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A (Erlotinib)",
        "value": 1.8,
        "unit": "months",
        "ci_lower": 1.7,
        "ci_upper": 2.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B (Cabozantinib)",
        "value": 4.3,
        "unit": "months",
        "ci_lower": 3.6,
        "ci_upper": 7.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Arm C (Erlotinib+Cabozantinib)",
        "value": 4.7,
        "unit": "months",
        "ci_lower": 2.4,
        "ci_upper": 7.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A (Erlotinib)",
        "value": 5.1,
        "unit": "months",
        "ci_lower": 3.3,
        "ci_upper": 9.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B (Cabozantinib)",
        "value": 9.2,
        "unit": "months",
        "ci_lower": 5.1,
        "ci_upper": 15.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Arm C (Erlotinib+Cabozantinib)",
        "value": 13.3,
        "unit": "months",
        "ci_lower": 7.6,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Erlotinib Hydrochloride"
      ],
      "OG001": [
        "Cabozantinib S-malate"
      ],
      "OG002": [
        "Erlotinib Hydrochloride",
        "Cabozantinib S-malate"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI",
      "OG002": "TKI"
    }
  },
  {
    "nct_id": "NCT01788566",
    "brief_title": "A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2013-03",
    "completion_date": "2014-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT01788566",
    "cancer_types": [
      "LUSC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Gemcitabine + Cisplatin + Necitumumab",
        "value": 48.1,
        "unit": "Percentage of participants",
        "ci_lower": 34.34,
        "ci_upper": 62.16,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Gemcitabine + Cisplatin + Necitumumab",
        "value": 11.7,
        "unit": "months",
        "ci_lower": 7.59,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Gemcitabine + Cisplatin + Necitumumab",
        "value": 5.6,
        "unit": "months",
        "ci_lower": 3.68,
        "ci_upper": 6.87,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Necitumumab",
        "Gemcitabine",
        "Cisplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT01715285",
    "brief_title": "A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)",
    "status": "COMPLETED",
    "start_date": "2013-02-12",
    "completion_date": "2016-10-31",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Janssen Research & Development, LLC",
    "url": "https://clinicaltrials.gov/study/NCT01715285",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Abiraterone Acetate+Prednisone+ADT",
        "value": 33.02,
        "unit": "Months",
        "ci_lower": 29.57,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + ADT",
        "value": 14.78,
        "unit": "Months",
        "ci_lower": 14.69,
        "ci_upper": 18.27,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Abiraterone Acetate+Prednisone+ADT",
        "value": 53.32,
        "unit": "months",
        "ci_lower": 48.23,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + ADT",
        "value": 36.53,
        "unit": "months",
        "ci_lower": 33.54,
        "ci_upper": 39.95,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Abiraterone acetate",
        "Prednisone"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT01769391",
    "brief_title": "A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2013-01",
    "completion_date": "2015-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT01769391",
    "cancer_types": [
      "LUSC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "EGFR protein expression by IHC; archived or recent tumor tissue required (minimum of 5 unstained slides or a paraffin-embedded tissue block)"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Necitumumab +Paclitaxel+Carboplatin",
        "value": 48.9,
        "unit": "percentage of participants",
        "ci_lower": 38.5,
        "ci_upper": 59.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Paclitaxel + Carboplatin",
        "value": 40.0,
        "unit": "percentage of participants",
        "ci_lower": 26.4,
        "ci_upper": 54.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Necitumumab +Paclitaxel+Carboplatin",
        "value": 13.2,
        "unit": "months",
        "ci_lower": 9.7,
        "ci_upper": 15.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Paclitaxel + Carboplatin",
        "value": 11.2,
        "unit": "months",
        "ci_lower": 8.2,
        "ci_upper": 12.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Necitumumab +Paclitaxel+Carboplatin",
        "value": 5.4,
        "unit": "months",
        "ci_lower": 4.2,
        "ci_upper": 5.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Paclitaxel + Carboplatin",
        "value": 5.6,
        "unit": "months",
        "ci_lower": 4.3,
        "ci_upper": 6.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Necitumumab",
        "Paclitaxel",
        "Carboplatin"
      ],
      "OG001": [
        "Paclitaxel",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01721954",
    "brief_title": "FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2013-05-01",
    "completion_date": "2016-12-23",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sirtex Medical",
    "url": "https://clinicaltrials.gov/study/NCT01721954",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IV",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "mFOLFOX6 Plus SIRT",
        "value": 25.9,
        "unit": "months",
        "ci_lower": 23.1,
        "ci_upper": 29.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "mFOLFOX6 Alone",
        "value": 25.0,
        "unit": "months",
        "ci_lower": 22.1,
        "ci_upper": 28.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "FOLFOX6m"
      ],
      "OG001": [
        "FOLFOX6m"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01783444",
    "brief_title": "A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.",
    "status": "COMPLETED",
    "start_date": "2013-02-26",
    "completion_date": "2018-07-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT01783444",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "estrogen-receptor positive (ER+)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Everolimus 10 mg + Exemestane 25 mg",
        "value": 8.41,
        "unit": "Months",
        "ci_lower": 6.6,
        "ci_upper": 9.72,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Everolimus 10 mg",
        "value": 6.77,
        "unit": "Months",
        "ci_lower": 5.52,
        "ci_upper": 7.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Everolimus 10 mg + Exemestane 25 mg",
        "value": 23.06,
        "unit": "Months",
        "ci_lower": 19.48,
        "ci_upper": 27.96,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Everolimus 10 mg",
        "value": 29.27,
        "unit": "Months",
        "ci_lower": 24.28,
        "ci_upper": 31.77,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Capecitabine 1250 mg/m2",
        "value": 25.56,
        "unit": "Months",
        "ci_lower": 23.82,
        "ci_upper": 33.35,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Everolimus",
        "Exemestane"
      ],
      "OG001": [
        "Everolimus"
      ],
      "OG002": [
        "Capecitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Chemo"
    }
  },
  {
    "nct_id": "NCT01747551",
    "brief_title": "FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer",
    "status": "COMPLETED",
    "start_date": "2013-01",
    "completion_date": "2016-11-29",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Dana-Farber Cancer Institute",
    "url": "https://clinicaltrials.gov/study/NCT01747551",
    "cancer_types": [
      "STAD",
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "UNRESECTABLE",
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "mFOLFOX6 + Ziv-aflibercept",
        "value": 60.5,
        "unit": "percent probability",
        "ci_lower": 44.3,
        "ci_upper": 73.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "mFOLFOX6 + Placebo",
        "value": 57.1,
        "unit": "percent probability",
        "ci_lower": 33.8,
        "ci_upper": 74.9,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Oxaliplatin",
        "Leucovorin",
        "Fluorouracil",
        "Ziv-aflibercept"
      ],
      "OG001": [
        "Oxaliplatin",
        "Leucovorin",
        "Fluorouracil"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01753713",
    "brief_title": "Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma",
    "status": "COMPLETED",
    "start_date": "2012-12-20",
    "completion_date": "2015-01-28",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Manmeet Ahluwalia, MD",
    "url": "https://clinicaltrials.gov/study/NCT01753713",
    "cancer_types": [
      "GBM"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Anti-angiogenic Therapy Naive Patients",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Anti-angiogenic Therapy Patients",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG000",
        "arm_title": "Anti-angiogenic Therapy Naive Patients",
        "value": 1.8,
        "unit": "Months",
        "ci_lower": 1.3,
        "ci_upper": 2.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG001",
        "arm_title": "Anti-angiogenic Therapy Patients",
        "value": 1.8,
        "unit": "Months",
        "ci_lower": 0.7,
        "ci_upper": 1.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "dovitinib"
      ],
      "OG001": [
        "dovitinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT01730729",
    "brief_title": "Cabergoline in Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2013-02-11",
    "completion_date": "2015-12-15",
    "phase": "EARLY_PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Northwestern University",
    "url": "https://clinicaltrials.gov/study/NCT01730729",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "PRLR",
        "status": "POSITIVE",
        "details": "positive staining for prolactin receptor on tumor (IHC; primary or metastatic tissue acceptable)"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (Cabergoline)",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Cabergoline)",
        "value": 1.84,
        "unit": "Months",
        "ci_lower": 1.84,
        "ci_upper": 3.68,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Cabergoline)",
        "value": 10.41,
        "unit": "Months",
        "ci_lower": 7.06,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "cabergoline"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER"
    }
  },
  {
    "nct_id": "NCT01763788",
    "brief_title": "A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)",
    "status": "COMPLETED",
    "start_date": "2013-05-07",
    "completion_date": "2017-06-28",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT01763788",
    "cancer_types": [
      "LUSC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "EGFR protein expression by IHC; formalin-fixed paraffin-embedded tumor tissue block or \u22655 unstained slides required prior to randomization"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Phase 2: GC+N (Gemcitabine, Cisplatin + Necitumumab)",
        "value": 14.92,
        "unit": "Months",
        "ci_lower": 13.37,
        "ci_upper": 18.17,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Phase 2: GC (Gemcitabine, Cisplatin)",
        "value": 10.84,
        "unit": "Months",
        "ci_lower": 8.9,
        "ci_upper": 14.39,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Gemcitabine",
        "Cisplatin"
      ],
      "OG001": [
        "Gemcitabine",
        "Cisplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01721759",
    "brief_title": "Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens",
    "status": "COMPLETED",
    "start_date": "2012-11-16",
    "completion_date": "2014-01-22",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT01721759",
    "cancer_types": [
      "LUSC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV",
      "RECURRENT",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Nivolumab, 3 mg/kg",
        "value": 14.5,
        "unit": "Percentage of Participants",
        "ci_lower": 8.7,
        "ci_upper": 22.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG000",
        "arm_title": "Nivolumab, 3 mg/kg",
        "value": 12.0,
        "unit": "Months",
        "ci_lower": 6.7,
        "ci_upper": 19.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO"
    }
  },
  {
    "nct_id": "NCT01750281",
    "brief_title": "Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.",
    "status": "COMPLETED",
    "start_date": "2012-12-18",
    "completion_date": "2016-01-27",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT01750281",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "Prospective confirmation of KRAS mutation negative status via an AZ-approved laboratory"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV",
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Placebo + Docetaxel 75 mg/m^2",
        "value": 4.3,
        "unit": "Months",
        "ci_lower": 1.4,
        "ci_upper": 5.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Selumetinib 75 mg BD + Docetaxel 60 mg/m^2",
        "value": 3.0,
        "unit": "Months",
        "ci_lower": 1.4,
        "ci_upper": 5.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Selumetinib 75 mg BD + Docetaxel 75 mg/m^2",
        "value": 4.2,
        "unit": "Months",
        "ci_lower": 1.6,
        "ci_upper": 6.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Placebo + Docetaxel 75 mg/m^2",
        "value": 11.5,
        "unit": "Months",
        "ci_lower": 4.6,
        "ci_upper": 28.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Selumetinib 75 mg BD + Docetaxel 60 mg/m^2",
        "value": 5.7,
        "unit": "Months",
        "ci_lower": 3.1,
        "ci_upper": 12.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Selumetinib 75 mg BD + Docetaxel 75 mg/m^2",
        "value": 7.7,
        "unit": "Months",
        "ci_lower": 3.8,
        "ci_upper": 19.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Docetaxel 75 mg/m2"
      ],
      "OG001": [
        "Selumetinib 75 mg",
        "Docetaxel 60 mg/m2"
      ],
      "OG002": [
        "Selumetinib 75 mg",
        "Docetaxel 75 mg/m2"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT01740427",
    "brief_title": "A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)",
    "status": "COMPLETED",
    "start_date": "2013-02-22",
    "completion_date": "2016-02-26",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT01740427",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Estrogen receptor positive (ER+)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 negative disease (HER2\u2212); HER2 positive excluded"
      }
    ],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Palbociclib Plus Letrozole",
        "value": 24.8,
        "unit": "Months",
        "ci_lower": 22.1,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo Plus Letrozole",
        "value": 14.5,
        "unit": "Months",
        "ci_lower": 12.9,
        "ci_upper": 17.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Palbociclib Plus Letrozole",
        "value": 53.9,
        "unit": "Months",
        "ci_lower": 49.8,
        "ci_upper": 60.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo Plus Letrozole",
        "value": 51.2,
        "unit": "Months",
        "ci_lower": 43.7,
        "ci_upper": 58.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "PD-0332991",
        "Letrozole"
      ],
      "OG001": [
        "Letrozole"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT01775930",
    "brief_title": "Carfilzomib in Refractory Renal Cell Carcinoma (RCC)",
    "status": "COMPLETED",
    "start_date": "2013-10",
    "completion_date": "2019-01-18",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "M.D. Anderson Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT01775930",
    "cancer_types": [
      "KIRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Carfilzomib Treatment",
        "value": 1.8,
        "unit": "Months",
        "ci_lower": 0.08,
        "ci_upper": 3.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Carfilzomib Treatment",
        "value": 13.2,
        "unit": "Months",
        "ci_lower": 1.9,
        "ci_upper": 14.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Carfilzomib"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER"
    }
  },
  {
    "nct_id": "NCT01802632",
    "brief_title": "AZD9291 First Time In Patients Ascending Dose Study",
    "status": "COMPLETED",
    "start_date": "2013-03-04",
    "completion_date": "2015-05-01",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT01802632",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "Tumour harbouring an EGFR mutation known to be associated with EGFR TKI sensitivity (e.g., G719X, exon 19 deletion, L858R, L861Q). Note: non-1st-line patients must have this OR documented clinical benefit from prior EGFR TKI."
      },
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "EGFR T790M mutation \u2014 central analysis result must be obtained prior to entry; for dose expansion/extension cohorts T790M status must be confirmed (positive or negative) on a biopsy taken after progression on the most recent regimen."
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": true,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Dose Expansion",
        "value": 61.7,
        "unit": "% of participants",
        "ci_lower": 54.1,
        "ci_upper": 68.9,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "AZD9291"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT01751451",
    "brief_title": "3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy",
    "status": "COMPLETED",
    "start_date": "2012-12-18",
    "completion_date": "2020-09-28",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Memorial Sloan Kettering Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT01751451",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [
      {
        "target": "PSA",
        "status": "HIGH",
        "details": "Rising PSA defined as \u226550% increase to a level of \u22651 ng/mL based on at least 3 PSA determinations (may be non-sequential); PSADT \u22649 months calculated by MSKCC nomogram"
      },
      {
        "target": "TESTOSTERONE",
        "status": "HIGH",
        "details": "Serum testosterone \u2265150 ng/dL"
      }
    ],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Abiraterone Acetate",
        "value": 5.1,
        "unit": "percentage change of PSA",
        "ci_lower": 1.0,
        "ci_upper": 17.0,
        "dispersion_type": "MEAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Abiraterone Acetate and Degarelix",
        "value": 17.1,
        "unit": "percentage change of PSA",
        "ci_lower": 7.0,
        "ci_upper": 32.0,
        "dispersion_type": "MEAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Degarelix",
        "value": 11.9,
        "unit": "percentage change of PSA",
        "ci_lower": 4.0,
        "ci_upper": 26.0,
        "dispersion_type": "MEAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Abiraterone acetate",
        "Prednisone"
      ],
      "OG001": [
        "Abiraterone acetate",
        "Degarelix",
        "Prednisone"
      ],
      "OG002": [
        "Degarelix"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01767155",
    "brief_title": "Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer",
    "status": "COMPLETED",
    "start_date": "2013-04",
    "completion_date": "2017-01-30",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AEterna Zentaris",
    "url": "https://clinicaltrials.gov/study/NCT01767155",
    "cancer_types": [
      "UCEC"
    ],
    "biomarkers": [
      {
        "target": "GNRHR",
        "status": "ANY",
        "details": "LHRH (GnRH) receptor expression; availability of fresh or archival FFPE tumor specimen for analysis"
      }
    ],
    "cancer_stages": [
      "III",
      "IV",
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "AEZS-108 / Zoptarelin Doxorubicin",
        "value": 196.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Doxorubicin/ Standard Chemotherapy",
        "value": 188.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "AEZS-108 / Zoptarelin Doxorubicin",
        "value": 60.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Doxorubicin/ Standard Chemotherapy",
        "value": 67.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "AEZS-108 / Zoptarelin Doxorubicin",
        "value": 171.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Doxorubicin/ Standard Chemotherapy",
        "value": 174.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "AEZS-108 / Zoptarelin Doxorubicin",
        "value": 111.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Doxorubicin/ Standard Chemotherapy",
        "value": 106.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "AEZS-108 / Zoptarelin Doxorubicin",
        "value": 166.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Doxorubicin/ Standard Chemotherapy",
        "value": 148.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "AEZS-108 / Zoptarelin Doxorubicin",
        "value": 90.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Doxorubicin/ Standard Chemotherapy",
        "value": 107.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "AEZS-108 / Zoptarelin Doxorubicin",
        "value": 69.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Doxorubicin/ Standard Chemotherapy",
        "value": 51.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "AEZS-108 / Zoptarelin Doxorubicin",
        "value": 28.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Doxorubicin/ Standard Chemotherapy",
        "value": 12.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "AEZS-108 / zoptarelin doxorubicin"
      ],
      "OG001": [
        "doxorubicin"
      ]
    },
    "treatment_class_map": {
      "OG000": "ADC",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01774721",
    "brief_title": "ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.",
    "status": "COMPLETED",
    "start_date": "2013-05-09",
    "completion_date": "2016-07-29",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT01774721",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "exon 19 deletion or L858R (exon 21); exon 20 T790M may be present concomitantly"
      },
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "Any other EGFR mutations other than exon 19 deletion or L858R (except T790M which is allowed)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Dacomitinib",
        "value": 14.7,
        "unit": "months",
        "ci_lower": 11.1,
        "ci_upper": 16.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Gefitinib",
        "value": 9.2,
        "unit": "months",
        "ci_lower": 9.1,
        "ci_upper": 11.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Dacomitinib"
      ],
      "OG001": [
        "Gefitinib"
      ],
      "OG002": [
        "Dacomitinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI",
      "OG002": "TKI"
    }
  },
  {
    "nct_id": "NCT01743469",
    "brief_title": "A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers",
    "status": "COMPLETED",
    "start_date": "2012-12",
    "completion_date": "2014-12",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Ipsen",
    "url": "https://clinicaltrials.gov/study/NCT01743469",
    "cancer_types": [
      "LIHC",
      "OV",
      "KIRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE",
      "RECURRENT",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "2L",
    "prior_tki": true,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Hepatocellular Carcinoma Cohort",
        "value": 26.9,
        "unit": "percentage of participants",
        "ci_lower": 15.57,
        "ci_upper": 41.02,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Ovarian Carcinoma Cohort",
        "value": 7.3,
        "unit": "percentage of participants",
        "ci_lower": 2.02,
        "ci_upper": 17.59,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Renal Cell Carcinoma Cohort",
        "value": 13.2,
        "unit": "percentage of participants",
        "ci_lower": 4.41,
        "ci_upper": 28.09,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Gastric Carcinoma Cohort",
        "value": 9.5,
        "unit": "percentage of participants",
        "ci_lower": 1.17,
        "ci_upper": 30.38,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Hepatocellular Carcinoma Cohort",
        "value": 29.29,
        "unit": "Weeks",
        "ci_lower": 25.0,
        "ci_upper": 38.71,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Ovarian Carcinoma Cohort",
        "value": null,
        "unit": "Weeks",
        "ci_lower": 30.71,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Renal Cell Carcinoma Cohort",
        "value": 32.71,
        "unit": "Weeks",
        "ci_lower": 26.43,
        "ci_upper": 40.86,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Gastric Carcinoma Cohort",
        "value": 21.57,
        "unit": "Weeks",
        "ci_lower": 13.86,
        "ci_upper": 33.29,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Tasquinimod"
      ],
      "OG001": [
        "Tasquinimod"
      ],
      "OG002": [
        "Tasquinimod"
      ],
      "OG003": [
        "Tasquinimod"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER",
      "OG002": "OTHER",
      "OG003": "OTHER"
    }
  },
  {
    "nct_id": "NCT01719380",
    "brief_title": "Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2012-11-23",
    "completion_date": "2015-10-31",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT01719380",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "BRAF",
        "status": "POSITIVE",
        "details": "BRAF mutation"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase 2: LGX818 200 mg + Cetuximab",
        "value": 4.2,
        "unit": "months",
        "ci_lower": 3.0,
        "ci_upper": 5.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Phase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab",
        "value": 4.9,
        "unit": "months",
        "ci_lower": 4.0,
        "ci_upper": 7.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Phase 1b: LGX818 100 mg + Cetuximab",
        "value": 15.0,
        "unit": "months",
        "ci_lower": 14.8,
        "ci_upper": 15.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Phase 1b: LGX818 200 mg + Cetuximab",
        "value": 5.4,
        "unit": "months",
        "ci_lower": 1.2,
        "ci_upper": 7.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Phase 1b: LGX818 400 mg + Cetuximab",
        "value": null,
        "unit": "months",
        "ci_lower": 2.9,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Phase 1b: LGX818 450 mg + Cetuximab",
        "value": 16.6,
        "unit": "months",
        "ci_lower": 3.9,
        "ci_upper": 23.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG004",
        "arm_title": "Phase 1b: LGX818 200 mg + BYL719 100 mg + Cetuximab",
        "value": 6.6,
        "unit": "months",
        "ci_lower": 5.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG005",
        "arm_title": "Phase 1b: LGX818 200 mg + BYL719 200 mg + Cetuximab",
        "value": 8.7,
        "unit": "months",
        "ci_lower": 3.8,
        "ci_upper": 27.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG006",
        "arm_title": "Phase 1b: LGX818 200 mg + BYL719 300 mg + Cetuximab",
        "value": 9.8,
        "unit": "months",
        "ci_lower": 3.7,
        "ci_upper": 25.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG007",
        "arm_title": "Phase 1b: LGX818 300 mg + BYL719 200 mg + Cetuximab",
        "value": null,
        "unit": "months",
        "ci_lower": 5.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG008",
        "arm_title": "Phase 2: LGX818 200 mg + Cetuximab",
        "value": 9.3,
        "unit": "months",
        "ci_lower": 5.8,
        "ci_upper": 15.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG009",
        "arm_title": "Phase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab",
        "value": 8.5,
        "unit": "months",
        "ci_lower": 6.1,
        "ci_upper": 15.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "LGX818",
        "Cetuximab"
      ],
      "OG001": [
        "LGX818",
        "Cetuximab"
      ],
      "OG002": [
        "LGX818",
        "Cetuximab"
      ],
      "OG003": [
        "LGX818",
        "Cetuximab"
      ],
      "OG004": [
        "LGX818",
        "BYL719",
        "Cetuximab"
      ],
      "OG005": [
        "LGX818",
        "BYL719",
        "Cetuximab"
      ],
      "OG006": [
        "LGX818",
        "BYL719",
        "Cetuximab"
      ],
      "OG007": [
        "LGX818",
        "BYL719",
        "Cetuximab"
      ],
      "OG008": [
        "LGX818",
        "Cetuximab"
      ],
      "OG009": [
        "LGX818",
        "BYL719",
        "Cetuximab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other",
      "OG004": "Targeted_Other",
      "OG005": "Targeted_Other",
      "OG006": "Targeted_Other",
      "OG007": "Targeted_Other",
      "OG008": "Targeted_Other",
      "OG009": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01750918",
    "brief_title": "BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)",
    "status": "COMPLETED",
    "start_date": "2012-12-19",
    "completion_date": "2020-06-18",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT01750918",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "BRAF",
        "status": "POSITIVE",
        "details": "V600E mutation"
      },
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "wild-type required for Part 3; known KRAS mutation excludes enrollment in Parts 1, 2 and BRAF-mutant patients in Part 4"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [],
    "arm_drugs": {
      "OG000": [
        "Dabrafenib",
        "Trametinib",
        "Panitumumab"
      ],
      "OG001": [
        "Dabrafenib",
        "Trametinib",
        "Panitumumab"
      ],
      "OG002": [
        "Dabrafenib",
        "Trametinib",
        "Panitumumab"
      ],
      "OG003": [
        "Dabrafenib",
        "Trametinib",
        "Panitumumab"
      ],
      "OG004": [
        "Trametinib",
        "Panitumumab"
      ],
      "OG005": [
        "Trametinib",
        "Panitumumab"
      ],
      "OG006": [
        "Trametinib",
        "Panitumumab"
      ],
      "OG007": [
        "Dabrafenib",
        "Panitumumab"
      ],
      "OG008": [
        "Trametinib",
        "Panitumumab"
      ],
      "OG009": [
        "Trametinib",
        "Panitumumab"
      ],
      "OG010": [
        "Dabrafenib",
        "Panitumumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other",
      "OG004": "Targeted_Other",
      "OG005": "Targeted_Other",
      "OG006": "Targeted_Other",
      "OG007": "Targeted_Other",
      "OG008": "Targeted_Other",
      "OG009": "Targeted_Other",
      "OG010": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01876511",
    "brief_title": "Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)",
    "status": "COMPLETED",
    "start_date": "2013-09",
    "completion_date": "2019-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
    "url": "https://clinicaltrials.gov/study/NCT01876511",
    "cancer_types": [
      "CRC",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "MSI",
        "status": "POSITIVE",
        "details": "Cohort A: colorectal MSI-positive; Cohort C: non-colorectal MSI-positive"
      },
      {
        "target": "MSI",
        "status": "NEGATIVE",
        "details": "Cohort B: colorectal MSI-negative"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort A: MSI Positive Colorectal Cancer",
        "value": 88.0,
        "unit": "percentage of participants",
        "ci_lower": 75.0,
        "ci_upper": 100.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort B: MSI Negative Colorectal Cancer",
        "value": 12.0,
        "unit": "percentage of participants",
        "ci_lower": 4.0,
        "ci_upper": 36.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort A: MSI Positive Colorectal Cancer",
        "value": 67.0,
        "unit": "percentage of participants",
        "ci_lower": 45.0,
        "ci_upper": 84.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Cohort B: MSI Negative Colorectal Cancer",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 14.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "MK-3475"
      ],
      "OG001": [
        "MK-3475"
      ],
      "OG002": [
        "MK-3475"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO"
    }
  },
  {
    "nct_id": "NCT01811498",
    "brief_title": "Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM",
    "status": "COMPLETED",
    "start_date": "2013-02",
    "completion_date": "2021-08",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Northwell Health",
    "url": "https://clinicaltrials.gov/study/NCT01811498",
    "cancer_types": [
      "GBM"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "SIACI of Bevacizumab",
        "value": 91.3,
        "unit": "percentage of participants",
        "ci_lower": 69.5,
        "ci_upper": 97.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "SIACI of Bevacizumab",
        "value": 23.1,
        "unit": "months",
        "ci_lower": 12.2,
        "ci_upper": 36.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01828112",
    "brief_title": "LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib",
    "status": "COMPLETED",
    "start_date": "2013-06-28",
    "completion_date": "2016-01-26",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT01828112",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "ALK",
        "status": "POSITIVE",
        "details": "Anaplastic lymphoma kinase (ALK) positive as assessed by the FDA-approved Abbott FISH Test"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV",
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": true,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ceritinib",
        "value": 5.4,
        "unit": "months",
        "ci_lower": 4.1,
        "ci_upper": 6.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy",
        "value": 1.6,
        "unit": "months",
        "ci_lower": 1.4,
        "ci_upper": 2.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Ceritinib",
        "value": 17.7,
        "unit": "months",
        "ci_lower": 14.2,
        "ci_upper": 23.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy",
        "value": 20.1,
        "unit": "months",
        "ci_lower": 11.9,
        "ci_upper": 31.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ceritinib"
      ],
      "OG001": [
        "Pemetrexed",
        "Docetaxel"
      ],
      "OG002": [
        "Ceritinib",
        "Pemetrexed",
        "Docetaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Chemo",
      "OG002": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT01847274",
    "brief_title": "A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer",
    "status": "COMPLETED",
    "start_date": "2013-06-21",
    "completion_date": "2016-04-22",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Tesaro, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT01847274",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "BRCA",
        "status": "POSITIVE",
        "details": "germline BRCA mutation (gBRCAmut)"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": "MAINTENANCE",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "gBRCA Niraparib",
        "value": 21.0,
        "unit": "months",
        "ci_lower": 12.9,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "gBRCA Placebo",
        "value": 5.5,
        "unit": "months",
        "ci_lower": 3.8,
        "ci_upper": 7.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Niraparib"
      ],
      "OG002": [
        "Niraparib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Placebo",
      "OG002": "Targeted_Other",
      "OG003": "Placebo"
    }
  },
  {
    "nct_id": "NCT01841736",
    "brief_title": "Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2013-09-20",
    "completion_date": "2019-03-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT01841736",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm I (Pazopanib Hydrochloride)",
        "value": 11.6,
        "unit": "months",
        "ci_lower": 11.0,
        "ci_upper": 13.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm II (Placebo)",
        "value": 8.5,
        "unit": "months",
        "ci_lower": 5.8,
        "ci_upper": 8.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm I (Pazopanib Hydrochloride)",
        "value": 41.3,
        "unit": "months",
        "ci_lower": 31.9,
        "ci_upper": 44.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm II (Placebo)",
        "value": 42.4,
        "unit": "months",
        "ci_lower": 29.7,
        "ci_upper": 50.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pazopanib Hydrochloride"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT01853748",
    "brief_title": "T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2013-05",
    "completion_date": "2019-08-26",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Dana-Farber Cancer Institute",
    "url": "https://clinicaltrials.gov/study/NCT01853748",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "Confirmed by central testing: IHC 3+, or FISH HER2/CEP17 <2.0 with average HER2 copy number >=6.0, or FISH HER2/CEP17 >=2.0."
      },
      {
        "target": "ER",
        "status": "ANY",
        "details": "ER determination required (status not specified for eligibility)."
      },
      {
        "target": "PR",
        "status": "ANY",
        "details": "PR determination required (status not specified for eligibility)."
      }
    ],
    "cancer_stages": [
      "I"
    ],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [],
    "arm_drugs": {
      "OG000": [
        "Trastuzumab emtansine"
      ],
      "OG001": [
        "Paclitaxel",
        "Trastuzumab"
      ],
      "OG002": [
        "Trastuzumab emtansine"
      ],
      "OG003": [
        "Paclitaxel",
        "Trastuzumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "ADC",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "ADC",
      "OG003": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT01858389",
    "brief_title": "A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2013-07",
    "completion_date": "2015-09",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT01858389",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "T790M mutation"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Dacomitinib, 45/60 mg, With T790M Mutation",
        "value": 6.3,
        "unit": "Percentage of participants",
        "ci_lower": 0.2,
        "ci_upper": 30.2,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Dacomitinib"
      ],
      "OG001": [
        "Dacomitinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT01835158",
    "brief_title": "Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer",
    "status": "COMPLETED",
    "start_date": "2013-07-08",
    "completion_date": "2016-04-18",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT01835158",
    "cancer_types": [
      "KIRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "IV",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm I (Cabozantinib-s-malate)",
        "value": 8.2,
        "unit": "Months",
        "ci_lower": 6.2,
        "ci_upper": 8.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm II (Sunitinib Malate)",
        "value": 5.6,
        "unit": "Months",
        "ci_lower": 3.4,
        "ci_upper": 8.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm I (Cabozantinib-s-malate)",
        "value": 30.3,
        "unit": "Months",
        "ci_lower": 14.6,
        "ci_upper": 35.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm II (Sunitinib Malate)",
        "value": 21.8,
        "unit": "Months",
        "ci_lower": 16.3,
        "ci_upper": 27.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cabozantinib S-malate"
      ],
      "OG001": [
        "Sunitinib Malate"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT01839487",
    "brief_title": "PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer",
    "status": "COMPLETED",
    "start_date": "2013-05-14",
    "completion_date": "2018-05-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Halozyme Therapeutics",
    "url": "https://clinicaltrials.gov/study/NCT01839487",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine",
        "value": 6.05,
        "unit": "months",
        "ci_lower": 5.36,
        "ci_upper": 7.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "AG: Nab-paclitaxel + Gemcitabine",
        "value": 5.26,
        "unit": "months",
        "ci_lower": 3.91,
        "ci_upper": 6.54,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "PEGPH20",
        "Nab-paclitaxel",
        "Gemcitabine"
      ],
      "OG001": [
        "Nab-paclitaxel",
        "Gemcitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01846611",
    "brief_title": "A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
    "status": "COMPLETED",
    "start_date": "2013-10-16",
    "completion_date": "2018-01-18",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Janssen Research & Development, LLC",
    "url": "https://clinicaltrials.gov/study/NCT01846611",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "BRCA1",
        "status": "ANY",
        "details": "Known BRCA1 mutation status required; if unknown, blood sample collected with results available prior to randomization"
      },
      {
        "target": "BRCA2",
        "status": "ANY",
        "details": "Known BRCA2 mutation status required; if unknown, blood sample collected with results available prior to randomization"
      }
    ],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Trabectedin + DOXIL",
        "value": 23.82,
        "unit": "months",
        "ci_lower": 20.3,
        "ci_upper": 26.12,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "DOXIL",
        "value": 22.21,
        "unit": "months",
        "ci_lower": 18.1,
        "ci_upper": 24.67,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Trabectedin + DOXIL",
        "value": 7.52,
        "unit": "months",
        "ci_lower": 6.93,
        "ci_upper": 9.43,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "DOXIL",
        "value": 7.26,
        "unit": "months",
        "ci_lower": 6.14,
        "ci_upper": 7.59,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "DOXIL",
        "Trabectedin"
      ],
      "OG001": [
        "DOXIL"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01853644",
    "brief_title": "Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer",
    "status": "COMPLETED",
    "start_date": "2013-06-06",
    "completion_date": "2018-10-02",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Northwestern University",
    "url": "https://clinicaltrials.gov/study/NCT01853644",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "CA125",
        "status": "HIGH",
        "details": "CA-125 \u22652\u00d7 upper limit of normal within the last 60 days (confirmatory at baseline); used to qualify non-measurable disease per protocol/RECIST"
      }
    ],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (Tivozanib)",
        "value": 4.0,
        "unit": "participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Tivozanib)",
        "value": 4.06,
        "unit": "months",
        "ci_lower": 1.74,
        "ci_upper": 5.78,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Tivozanib)",
        "value": 8.64,
        "unit": "months",
        "ci_lower": 5.39,
        "ci_upper": 12.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Tivozanib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT01874353",
    "brief_title": "Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2013-09-03",
    "completion_date": "2016-09-19",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT01874353",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "BRCA1",
        "status": "POSITIVE",
        "details": "Deleterious or suspected deleterious (known or predicted loss of function) mutation in BRCA1"
      },
      {
        "target": "BRCA2",
        "status": "POSITIVE",
        "details": "Deleterious or suspected deleterious (known or predicted loss of function) mutation in BRCA2"
      },
      {
        "target": "CA125",
        "status": "ANY",
        "details": "No evidence of a rising CA-125 following completion of the last chemotherapy course"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Olaparib 300mg Tablets (Global Cohort)",
        "value": 19.1,
        "unit": "Months",
        "ci_lower": 16.3,
        "ci_upper": 25.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo Tablets (Global Cohort)",
        "value": 5.5,
        "unit": "Months",
        "ci_lower": 5.2,
        "ci_upper": 5.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Olaparib 300mg Tablets (China Cohort)",
        "value": 13.8,
        "unit": "Months",
        "ci_lower": 6.5,
        "ci_upper": 16.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Placebo Tablets (China Cohort)",
        "value": 5.5,
        "unit": "Months",
        "ci_lower": 2.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Olaparib 300mg tablets"
      ],
      "OG002": [
        "Olaparib 300mg tablets"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Placebo",
      "OG002": "Targeted_Other",
      "OG003": "Placebo"
    }
  },
  {
    "nct_id": "NCT01814501",
    "brief_title": "Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab",
    "status": "COMPLETED",
    "start_date": "2013-02-01",
    "completion_date": "2018-08-06",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "John Hays",
    "url": "https://clinicaltrials.gov/study/NCT01814501",
    "cancer_types": [
      "COAD",
      "READ"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "wild-type / unmutated required (no KRAS mutation)"
      },
      {
        "target": "NRAS",
        "status": "NEGATIVE",
        "details": "wild-type / unmutated required (no NRAS mutation)"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Panitumumab, Combination Chemotherapy)",
        "value": 255.921,
        "unit": "days to progression",
        "ci_lower": 189.162,
        "ci_upper": 322.68,
        "dispersion_type": "MEAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Panitumumab, Combination Chemotherapy)",
        "value": 471.0,
        "unit": "days",
        "ci_lower": 32.34,
        "ci_upper": 909.66,
        "dispersion_type": "MEAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "panitumumab",
        "irinotecan hydrochloride",
        "fluorouracil",
        "leucovorin calcium"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT01828099",
    "brief_title": "LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2013-07-09",
    "completion_date": "2016-06-24",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT01828099",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "ALK",
        "status": "POSITIVE",
        "details": "Positive by Ventana Immunohistochemistry (IHC) test performed at Novartis designated central laboratories"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV",
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ceritinib",
        "value": 16.6,
        "unit": "Months",
        "ci_lower": 12.6,
        "ci_upper": 27.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy",
        "value": 8.1,
        "unit": "Months",
        "ci_lower": 5.8,
        "ci_upper": 11.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Ceritinib",
        "value": 62.9,
        "unit": "Months",
        "ci_lower": 44.2,
        "ci_upper": 77.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy",
        "value": 40.7,
        "unit": "Months",
        "ci_lower": 28.5,
        "ci_upper": 54.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ceritinib"
      ],
      "OG001": [
        "Pemetrexed",
        "Cisplatin",
        "Carboplatin"
      ],
      "OG002": [
        "Ceritinib",
        "Pemetrexed",
        "Cisplatin",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Chemo",
      "OG002": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT01827787",
    "brief_title": "Eribulin in HER2 Negative Metastatic BrCa",
    "status": "COMPLETED",
    "start_date": "2013-05",
    "completion_date": "2016-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Dana-Farber Cancer Institute",
    "url": "https://clinicaltrials.gov/study/NCT01827787",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": null
      }
    ],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort 1: HR+/HER2-",
        "value": 35.6,
        "unit": "percentage of participants",
        "ci_lower": 24.0,
        "ci_upper": 49.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Cohort 2: TNBC",
        "value": 13.2,
        "unit": "percentage of participants",
        "ci_lower": 5.0,
        "ci_upper": 26.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1: HR+/HER2-",
        "value": 6.2,
        "unit": "months",
        "ci_lower": 5.9,
        "ci_upper": 8.7,
        "dispersion_type": "MEAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort 2: TNBC",
        "value": 4.0,
        "unit": "months",
        "ci_lower": 3.5,
        "ci_upper": 4.8,
        "dispersion_type": "MEAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1: HR+/HER2-",
        "value": 20.0,
        "unit": "months",
        "ci_lower": 20.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cohort 2: TNBC",
        "value": 11.3,
        "unit": "months",
        "ci_lower": 9.1,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Eribulin"
      ],
      "OG001": [
        "Eribulin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01827267",
    "brief_title": "Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2013-07-01",
    "completion_date": "2016-09-20",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Puma Biotechnology, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT01827267",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "Documented somatic ErbB2 (HER2) activating mutation"
      },
      {
        "target": "ALK",
        "status": "ANY",
        "details": "If ALK translocation is present, patient must have received crizotinib unless intolerant"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Neratinib",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Neratinib+Temsirolimus",
        "value": 6.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Neratinib",
        "value": 2.9,
        "unit": "months",
        "ci_lower": 1.4,
        "ci_upper": 9.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Neratinib+Temsirolimus",
        "value": 4.0,
        "unit": "months",
        "ci_lower": 2.9,
        "ci_upper": 5.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Neratinib",
        "value": 10.0,
        "unit": "months",
        "ci_lower": 4.9,
        "ci_upper": 18.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Neratinib+Temsirolimus",
        "value": 15.1,
        "unit": "months",
        "ci_lower": 10.8,
        "ci_upper": 17.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "neratinib"
      ],
      "OG001": [
        "neratinib",
        "temsirolimus"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Combo_TKI_Targeted"
    }
  },
  {
    "nct_id": "NCT01829217",
    "brief_title": "Sunitinib in Never-Smokers With Lung Adenocarcinoma",
    "status": "COMPLETED",
    "start_date": "2013-05",
    "completion_date": "2017-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Dana-Farber Cancer Institute",
    "url": "https://clinicaltrials.gov/study/NCT01829217",
    "cancer_types": [
      "LUAD"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "wild-type for EGFR mutations"
      },
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "wild-type for KRAS mutations"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "wild-type for ALK mutations"
      },
      {
        "target": "RET",
        "status": "POSITIVE",
        "details": "harbor a RET rearrangement"
      }
    ],
    "cancer_stages": [
      "IV",
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Sunitinib",
        "value": 7.69,
        "unit": "percentage of participants",
        "ci_lower": 0.22,
        "ci_upper": 36.05,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Sunitinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT01817751",
    "brief_title": "Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma",
    "status": "COMPLETED",
    "start_date": "2013-04-11",
    "completion_date": "2020-08-27",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Virginia Commonwealth University",
    "url": "https://clinicaltrials.gov/study/NCT01817751",
    "cancer_types": [
      "GBM",
      "LGG"
    ],
    "biomarkers": [
      {
        "target": "PDGFRA",
        "status": "POSITIVE",
        "details": "Patients will be registered to combination treatment schema only if PDGFRa-positive (platelet-derived growth factor receptor alpha); pre-registration for PDGFRa analysis required if study proceeds to selected-patient enrollment"
      },
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "Known human immunodeficiency virus (HIV) positivity is excluded"
      },
      {
        "target": "POLG",
        "status": "NEGATIVE",
        "details": "No known mitochondrial disorder caused by mutations in mitochondrial DNA polymerase \u03b3 (POLG)"
      },
      {
        "target": "PREGNANCY",
        "status": "NEGATIVE",
        "details": "Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to start of treatment; women who are pregnant or nursing are excluded"
      }
    ],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Sorafenib Tosylate, Valproic Acid, Sildenafil)",
        "value": 8.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "sorafenib tosylate",
        "valproic acid",
        "sildenafil citrate"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT01844986",
    "brief_title": "Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2013-08-26",
    "completion_date": "2018-05-17",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT01844986",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "BRCA1",
        "status": "POSITIVE",
        "details": "Deleterious or suspected deleterious mutation (known or predicted loss of function). Variants of uncertain significance/benign polymorphisms are not acceptable."
      },
      {
        "target": "BRCA2",
        "status": "POSITIVE",
        "details": "Deleterious or suspected deleterious mutation (known or predicted loss of function). Variants of uncertain significance/benign polymorphisms are not acceptable."
      }
    ],
    "cancer_stages": [
      "III",
      "IV"
    ],
    "line_of_therapy": "MAINTENANCE",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Olaparib 300mg Tablets (Global Cohort)",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo Tablets (Global Cohort)",
        "value": 13.8,
        "unit": "Months",
        "ci_lower": 11.1,
        "ci_upper": 18.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Olaparib 300mg Tablets (China Cohort)",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Placebo Tablets (China Cohort)",
        "value": 9.3,
        "unit": "Months",
        "ci_lower": 6.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Olaparib 300mg Tablets (Global Cohort)",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo Tablets (Global Cohort)",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Olaparib 300mg Tablets (China Cohort)",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Placebo Tablets (China Cohort)",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG000",
        "arm_title": "Olaparib 300mg Tablets (Global Cohort)",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG001",
        "arm_title": "Placebo Tablets (Global Cohort)",
        "value": 12.0,
        "unit": "Months",
        "ci_lower": 10.8,
        "ci_upper": 16.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG002",
        "arm_title": "Olaparib 300mg Tablets (China Cohort)",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG003",
        "arm_title": "Placebo Tablets (China Cohort)",
        "value": 8.9,
        "unit": "Months",
        "ci_lower": 6.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Olaparib 300mg tablets"
      ],
      "OG002": [
        "Olaparib 300mg tablets"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Placebo",
      "OG002": "Targeted_Other",
      "OG003": "Placebo"
    }
  },
  {
    "nct_id": "NCT01868022",
    "brief_title": "Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling",
    "status": "COMPLETED",
    "start_date": "2013-10-09",
    "completion_date": "2017-10-24",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "GlaxoSmithKline",
    "url": "https://clinicaltrials.gov/study/NCT01868022",
    "cancer_types": [
      "BLCA",
      "LUSC",
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "FGFR1",
        "status": "POSITIVE",
        "details": "FGFR1 gene amplification by central laboratory testing using FISH. Inclusion if FGFR1/CEN8 ratio >=2 OR average FGFR1 signals per tumor nucleus >=6 OR >=50% of tumor nuclei contain >=5 FGFR1 signals."
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV",
      "RECURRENT",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "5 mg/kg GSK3052230 + Paclitaxel + Carboplatin: Arm A",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "10 mg/kg GSK3052230 + Paclitaxel + Carboplatin: Arm A",
        "value": 2.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "20 mg/kg GSK3052230 + Paclitaxel + Carboplatin: Arm A",
        "value": 6.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "5 mg/kg GSK3052230 + Docetaxel: Arm B",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "10 mg/kg GSK3052230 + Docetaxel: Arm B",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "20 mg/kg GSK3052230 + Docetaxel: Arm B",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG006",
        "arm_title": "10 mg/kg GSK3052230 + Pemetrexed + Cisplatin: Arm C",
        "value": 2.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG007",
        "arm_title": "15 mg/kg GSK3052230 + Pemetrexed + Cisplatin: Arm C",
        "value": 11.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG008",
        "arm_title": "20 mg/kg GSK3052230 + Pemetrexed + Cisplatin: Arm C",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "5 mg/kg GSK3052230 + Paclitaxel + Carboplatin: Arm A",
        "value": 4.1,
        "unit": "Months",
        "ci_lower": 1.4,
        "ci_upper": 5.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "10 mg/kg GSK3052230 + Paclitaxel + Carboplatin: Arm A",
        "value": null,
        "unit": "Months",
        "ci_lower": 5.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "20 mg/kg GSK3052230 + Paclitaxel + Carboplatin: Arm A",
        "value": 5.5,
        "unit": "Months",
        "ci_lower": 3.7,
        "ci_upper": 6.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "5 mg/kg GSK3052230 + Docetaxel: Arm B",
        "value": 4.6,
        "unit": "Months",
        "ci_lower": 1.3,
        "ci_upper": 4.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "10 mg/kg GSK3052230 + Docetaxel: Arm B",
        "value": 9.5,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG005",
        "arm_title": "20 mg/kg GSK3052230 + Docetaxel: Arm B",
        "value": 5.1,
        "unit": "Months",
        "ci_lower": 4.0,
        "ci_upper": 6.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG006",
        "arm_title": "10 mg/kg GSK3052230 + Pemetrexed + Cisplatin: Arm C",
        "value": 4.6,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG007",
        "arm_title": "15 mg/kg GSK3052230 + Pemetrexed + Cisplatin: Arm C",
        "value": 7.4,
        "unit": "Months",
        "ci_lower": 6.7,
        "ci_upper": 13.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG008",
        "arm_title": "20 mg/kg GSK3052230 + Pemetrexed + Cisplatin: Arm C",
        "value": 4.1,
        "unit": "Months",
        "ci_lower": 0.9,
        "ci_upper": 8.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "GSK3052230",
        "paclitaxel",
        "carboplatin"
      ],
      "OG001": [
        "GSK3052230",
        "paclitaxel",
        "carboplatin"
      ],
      "OG002": [
        "GSK3052230",
        "paclitaxel",
        "carboplatin"
      ],
      "OG003": [
        "GSK3052230",
        "docetaxel"
      ],
      "OG004": [
        "GSK3052230",
        "docetaxel"
      ],
      "OG005": [
        "GSK3052230",
        "docetaxel"
      ],
      "OG006": [
        "GSK3052230",
        "pemetrexed",
        "cisplatin"
      ],
      "OG007": [
        "GSK3052230",
        "pemetrexed",
        "cisplatin"
      ],
      "OG008": [
        "GSK3052230",
        "pemetrexed",
        "cisplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted",
      "OG003": "Combo_Chemo_Targeted",
      "OG004": "Combo_Chemo_Targeted",
      "OG005": "Combo_Chemo_Targeted",
      "OG006": "Combo_Chemo_Targeted",
      "OG007": "Combo_Chemo_Targeted",
      "OG008": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT01891344",
    "brief_title": "A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)",
    "status": "COMPLETED",
    "start_date": "2013-10-30",
    "completion_date": "2019-11-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "pharmaand GmbH",
    "url": "https://clinicaltrials.gov/study/NCT01891344",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "BRCA",
        "status": "POSITIVE",
        "details": "deleterious germline BRCA mutation (gBRCA)"
      }
    ],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Part 2: tBRCA",
        "value": 22.7,
        "unit": "Months",
        "ci_lower": 16.7,
        "ci_upper": 28.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Part 2: Non-tBRCA LOH+",
        "value": 14.7,
        "unit": "Months",
        "ci_lower": 10.8,
        "ci_upper": 19.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Part 2: Non-tBRCA LOH-",
        "value": 13.3,
        "unit": "Months",
        "ci_lower": 9.1,
        "ci_upper": 16.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Part 2: Non-tBRCA LOH Unknown",
        "value": 14.1,
        "unit": "Months",
        "ci_lower": 7.4,
        "ci_upper": 20.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Oral rucaparib"
      ],
      "OG001": [
        "Oral rucaparib"
      ],
      "OG002": [
        "Oral rucaparib"
      ],
      "OG003": [
        "Oral rucaparib"
      ],
      "OG004": [
        "Oral rucaparib"
      ],
      "OG005": [
        "Oral rucaparib"
      ],
      "OG006": [
        "Oral rucaparib"
      ],
      "OG007": [
        "Oral rucaparib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other",
      "OG004": "Targeted_Other",
      "OG005": "Targeted_Other",
      "OG006": "Targeted_Other",
      "OG007": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01940276",
    "brief_title": "Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer",
    "status": "COMPLETED",
    "start_date": "2013-10",
    "completion_date": "2019-10-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Duke University",
    "url": "https://clinicaltrials.gov/study/NCT01940276",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [
      {
        "target": "PSA",
        "status": "HIGH",
        "details": "PSA \u2265 2.0 ng/mL"
      },
      {
        "target": "TESTOSTERONE",
        "status": "LOW",
        "details": "Screening serum testosterone <50 ng/dL"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Abiraterone Acetate and Prednisone: White Men",
        "value": 16.8,
        "unit": "Months",
        "ci_lower": 11.0,
        "ci_upper": 33.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Abiraterone Acetate and Prednisone: African American Men",
        "value": 16.6,
        "unit": "Months",
        "ci_lower": 12.6,
        "ci_upper": 22.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Abiraterone Acetate and Prednisone: White Men",
        "value": 35.7,
        "unit": "Months",
        "ci_lower": 27.1,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Abiraterone Acetate and Prednisone: African American Men",
        "value": 35.9,
        "unit": "Months",
        "ci_lower": 24.5,
        "ci_upper": 43.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Abiraterone acetate",
        "Prednisone"
      ],
      "OG001": [
        "Abiraterone acetate",
        "Prednisone"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01896479",
    "brief_title": "A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2015-02-25",
    "completion_date": "2020-07-15",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Exelixis",
    "url": "https://clinicaltrials.gov/study/NCT01896479",
    "cancer_types": [
      "THCA"
    ],
    "biomarkers": [
      {
        "target": "RET",
        "status": "ANY",
        "details": "Must have RET mutational status assessed; if no documentation confirming a RET mutation, a tumor sample (screening or within 6 months prior to randomization) will be tested."
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cabozantinib (XL184) 60 mg",
        "value": 11.0,
        "unit": "months",
        "ci_lower": 8.3,
        "ci_upper": 13.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cabozantinib (XL184) 140 mg",
        "value": 13.9,
        "unit": "months",
        "ci_lower": 9.0,
        "ci_upper": 16.6,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cabozantinib (XL184) 60 mg"
      ],
      "OG001": [
        "Cabozantinib (XL184) 140 mg"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT01913639",
    "brief_title": "FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer",
    "status": "COMPLETED",
    "start_date": "2013-07",
    "completion_date": "2019-06",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Memorial Sloan Kettering Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT01913639",
    "cancer_types": [
      "STAD",
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "FOLFOX Plus Regorafenib",
        "value": 53.0,
        "unit": "percentage of participants",
        "ci_lower": 38.0,
        "ci_upper": 71.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "FOLFOX Plus Regorafenib",
        "value": 14.2,
        "unit": "months",
        "ci_lower": 8.1,
        "ci_upper": 20.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Regorafenib",
        "5-Fluorouracil",
        "Leucovorin",
        "Oxaliplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT01881230",
    "brief_title": "Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)",
    "status": "COMPLETED",
    "start_date": "2013-09-26",
    "completion_date": "2016-10-28",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Celgene",
    "url": "https://clinicaltrials.gov/study/NCT01881230",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "Estrogen Receptor (ER) <1% of tumor cell nuclei immunoreactive; requires positive intrinsic controls (sample can express ER)"
      },
      {
        "target": "PgR",
        "status": "NEGATIVE",
        "details": "Progesterone Receptor (PgR) <1% of tumor cell nuclei immunoreactive; requires positive intrinsic controls (sample can express PgR)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 negative per ASCO/CAP guidelines: IHC 0 or 1; if IHC 2+, must be FISH negative (or equivalent negative test)"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A: Nab-Paclitaxel + Gemcitabine",
        "value": 5.5,
        "unit": "months",
        "ci_lower": 4.1,
        "ci_upper": 7.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Nab-Paclitaxel + Carboplatin",
        "value": 8.3,
        "unit": "months",
        "ci_lower": 5.7,
        "ci_upper": 10.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Arm C: Gemcitabine + Carboplatin",
        "value": 6.0,
        "unit": "months",
        "ci_lower": 4.7,
        "ci_upper": 7.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A: Nab-Paclitaxel + Gemcitabine",
        "value": 12.1,
        "unit": "months",
        "ci_lower": 9.4,
        "ci_upper": 15.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Nab-Paclitaxel + Carboplatin",
        "value": 16.8,
        "unit": "months",
        "ci_lower": 11.3,
        "ci_upper": 20.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Arm C: Gemcitabine + Carboplatin",
        "value": 12.6,
        "unit": "months",
        "ci_lower": 10.1,
        "ci_upper": 16.6,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "nab-Paclitaxel",
        "Gemcitabine"
      ],
      "OG001": [
        "nab-Paclitaxel",
        "Carboplatin"
      ],
      "OG002": [
        "Gemcitabine",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo",
      "OG002": "Chemo"
    }
  },
  {
    "nct_id": "NCT01933932",
    "brief_title": "Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2013-09-25",
    "completion_date": "2016-06-07",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT01933932",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "POSITIVE",
        "details": "KRAS mutation positive tumour sample as determined by designated testing laboratory"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV",
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Selumetinib + Docetaxel",
        "value": 3.9,
        "unit": "Months",
        "ci_lower": 1.5,
        "ci_upper": 5.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Docetaxel",
        "value": 2.8,
        "unit": "Months",
        "ci_lower": 1.4,
        "ci_upper": 5.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Selumetinib + Docetaxel",
        "value": 8.7,
        "unit": "Months",
        "ci_lower": 3.6,
        "ci_upper": 16.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Docetaxel",
        "value": 7.9,
        "unit": "Months",
        "ci_lower": 3.8,
        "ci_upper": 20.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Selumetinib",
        "Docetaxel"
      ],
      "OG001": [
        "Docetaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01903993",
    "brief_title": "A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - \"POPLAR\"",
    "status": "COMPLETED",
    "start_date": "2013-08-06",
    "completion_date": "2015-11-19",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT01903993",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV",
      "RECURRENT",
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Docetaxel",
        "value": 9.7,
        "unit": "months",
        "ci_lower": 8.6,
        "ci_upper": 12.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Atezolizumab",
        "value": 12.6,
        "unit": "months",
        "ci_lower": 9.7,
        "ci_upper": 16.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Docetaxel",
        "value": 3.4,
        "unit": "months",
        "ci_lower": 2.8,
        "ci_upper": 4.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Atezolizumab",
        "value": 2.7,
        "unit": "months",
        "ci_lower": 2.0,
        "ci_upper": 4.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Docetaxel"
      ],
      "OG001": [
        "Atezolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "IO"
    }
  },
  {
    "nct_id": "NCT01926197",
    "brief_title": "Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer",
    "status": "COMPLETED",
    "start_date": "2013-08-14",
    "completion_date": "2021-09-30",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Stanford University",
    "url": "https://clinicaltrials.gov/study/NCT01926197",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Modified FOLFIRINOX",
        "value": 6.5,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Modified FOLFIRINOX Plus Stereotactic Body Radiotherapy",
        "value": 8.4,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Modified FOLFIRINOX",
        "value": 12.9,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Modified FOLFIRINOX Plus Stereotactic Body Radiotherapy",
        "value": 13.4,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Oxaliplatin",
        "Irinotecan",
        "Leucovorin",
        "5FU"
      ],
      "OG001": [
        "Oxaliplatin",
        "Irinotecan",
        "Leucovorin",
        "5FU"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01942135",
    "brief_title": "Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)",
    "status": "COMPLETED",
    "start_date": "2013-09-26",
    "completion_date": "2014-12-05",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT01942135",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Hormone receptor positive (ER and/or PR positive)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": null
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Palbociclib + Fulvestrant",
        "value": 9.2,
        "unit": "months",
        "ci_lower": 7.5,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Fulvestrant",
        "value": 3.8,
        "unit": "months",
        "ci_lower": 3.5,
        "ci_upper": 5.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Palbociclib",
        "Fulvestrant"
      ],
      "OG001": [
        "Fulvestrant"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT01927341",
    "brief_title": "Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors",
    "status": "COMPLETED",
    "start_date": "2013-11-19",
    "completion_date": "2016-01-25",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT01927341",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "RAS",
        "status": "ANY",
        "details": "Written documentation of mutant or wild-type RAS"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 2: Mutant RAS EGFRi-Naive: Binimetinib + Panitumumab",
        "value": 0.0,
        "unit": "Percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 0.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Phase 2: Mutant RAS Anti-EGFRi: Binimetinib + Panitumumab",
        "value": 0.0,
        "unit": "Percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 0.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Phase 2: WT RAS Anti-EGFRi: Binimetinib + Panitumumab",
        "value": 6.7,
        "unit": "Percentage of participants",
        "ci_lower": 0.2,
        "ci_upper": 31.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Phase 2: WT RAS EGFRi-Naive: Binimetinib + Panitumumab",
        "value": 0.0,
        "unit": "Percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 0.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Binimetinib",
        "Panitumumab"
      ],
      "OG001": [
        "Binimetinib",
        "Panitumumab"
      ],
      "OG002": [
        "Binimetinib",
        "Panitumumab"
      ],
      "OG003": [
        "Binimetinib",
        "Panitumumab"
      ],
      "OG004": [
        "Binimetinib",
        "Panitumumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other",
      "OG004": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01935336",
    "brief_title": "Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers",
    "status": "COMPLETED",
    "start_date": "2013-09-24",
    "completion_date": "2017-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "University of Colorado, Denver",
    "url": "https://clinicaltrials.gov/study/NCT01935336",
    "cancer_types": [
      "NSCLC",
      "SCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "Adenocarcinoma patients must NOT possess EGFR mutations (Part B). Part A requires prior testing and excludes known EGFR-mutant adenocarcinoma."
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "Adenocarcinoma patients must NOT possess ALK rearrangements (Part B). Part A requires prior testing and excludes known ALK-rearranged adenocarcinoma."
      },
      {
        "target": "FGFR1",
        "status": "ANY",
        "details": "FGFR1 status determined by SISH and ISH; cohorts include FGFR1 SISH+ ISH+, SISH+ ISH\u2212, SISH\u2212 ISH+, and SISH\u2212 ISH\u2212 (double negative cohort)."
      },
      {
        "target": "RET",
        "status": "POSITIVE",
        "details": "RET alteration required by FISH (RET FISH+ cohort)."
      }
    ],
    "cancer_stages": [
      "IIIA",
      "IIIB",
      "IV",
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Ponatinib SISH+/ISH+",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Ponatinib SISH+/ISH-",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Ponatinib SISH-/ISH+",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Ponatinib SISH-/ISH-",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ponatinib"
      ],
      "OG001": [
        "Ponatinib"
      ],
      "OG002": [
        "Ponatinib"
      ],
      "OG003": [
        "Ponatinib"
      ],
      "OG004": [
        "Ponatinib"
      ],
      "OG005": [
        "Ponatinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI",
      "OG002": "TKI",
      "OG003": "TKI",
      "OG004": "TKI",
      "OG005": "TKI"
    }
  },
  {
    "nct_id": "NCT01908101",
    "brief_title": "Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2014-01-08",
    "completion_date": "2019-05-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "University of Washington",
    "url": "https://clinicaltrials.gov/study/NCT01908101",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "CA15-3",
        "status": "HIGH",
        "details": "Rising serum CA15-3 documented by two consecutive measurements \u226514 days apart with second value \u226520% increase over first and CA15-3 \u226540 units/mL; most recent within 42 days prior to registration"
      },
      {
        "target": "CA27.29",
        "status": "HIGH",
        "details": "Rising serum CA27.29 documented by two consecutive measurements \u226514 days apart with second value \u226520% increase over first and CA27.29 \u226540 units/mL; most recent within 42 days prior to registration"
      },
      {
        "target": "CEA",
        "status": "HIGH",
        "details": "Rising serum CEA documented by two consecutive measurements \u226514 days apart with second value \u226520% increase over first and CEA \u22654 ng/mL; most recent within 42 days prior to registration"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Eribulin Mesylate)",
        "value": 3.5,
        "unit": "months",
        "ci_lower": 2.6,
        "ci_upper": 4.6,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Eribulin Mesylate"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo"
    }
  },
  {
    "nct_id": "NCT01896531",
    "brief_title": "A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer",
    "status": "COMPLETED",
    "start_date": "2013-08-14",
    "completion_date": "2015-06-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Genentech, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT01896531",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "Known HER2-positive gastric/GEJ adenocarcinoma excluded"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ipatasertib + mFOLFOX6",
        "value": 6.57,
        "unit": "months",
        "ci_lower": 5.72,
        "ci_upper": 7.52,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + mFOLFOX6",
        "value": 7.52,
        "unit": "months",
        "ci_lower": 6.24,
        "ci_upper": 8.11,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ipatasertib + mFOLFOX6",
        "value": 7.1,
        "unit": "months",
        "ci_lower": 5.39,
        "ci_upper": 9.92,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + mFOLFOX6",
        "value": 7.39,
        "unit": "months",
        "ci_lower": 6.51,
        "ci_upper": 14.69,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Ipatasertib + mFOLFOX6",
        "value": 11.96,
        "unit": "months",
        "ci_lower": 10.28,
        "ci_upper": 14.55,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + mFOLFOX6",
        "value": 15.31,
        "unit": "months",
        "ci_lower": 13.54,
        "ci_upper": 16.92,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Ipatasertib + mFOLFOX6",
        "value": 14.82,
        "unit": "months",
        "ci_lower": 11.99,
        "ci_upper": 18.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + mFOLFOX6",
        "value": 21.78,
        "unit": "months",
        "ci_lower": 14.13,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Ipatasertib + mFOLFOX6",
        "value": 11.66,
        "unit": "months",
        "ci_lower": 9.92,
        "ci_upper": 18.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + mFOLFOX6",
        "value": 17.22,
        "unit": "months",
        "ci_lower": 12.71,
        "ci_upper": 23.29,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ipatasertib",
        "5-Fluorouracil",
        "Leucovorin",
        "Oxaliplatin"
      ],
      "OG001": [
        "5-Fluorouracil",
        "Leucovorin",
        "Oxaliplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01905657",
    "brief_title": "Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)",
    "status": "COMPLETED",
    "start_date": "2013-08-09",
    "completion_date": "2015-09-30",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT01905657",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "POSITIVE",
        "details": "PD-L1 positive per central laboratory review"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab 2 mg/kg",
        "value": 14.9,
        "unit": "Months",
        "ci_lower": 10.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Pembrolizumab 10 mg/kg",
        "value": 17.3,
        "unit": "Months",
        "ci_lower": 11.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Docetaxel 75 mg/m^2",
        "value": 8.2,
        "unit": "Months",
        "ci_lower": 6.4,
        "ci_upper": 10.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab 2 mg/kg",
        "value": 10.4,
        "unit": "Months",
        "ci_lower": 9.4,
        "ci_upper": 11.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Pembrolizumab 10 mg/kg",
        "value": 12.7,
        "unit": "Months",
        "ci_lower": 10.0,
        "ci_upper": 17.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Docetaxel 75 mg/m^2",
        "value": 8.5,
        "unit": "Months",
        "ci_lower": 7.5,
        "ci_upper": 9.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab 2 mg/kg",
        "value": 5.2,
        "unit": "Months",
        "ci_lower": 4.0,
        "ci_upper": 6.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Pembrolizumab 10 mg/kg",
        "value": 5.2,
        "unit": "Months",
        "ci_lower": 4.1,
        "ci_upper": 8.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Docetaxel 75 mg/m^2",
        "value": 4.1,
        "unit": "Months",
        "ci_lower": 3.6,
        "ci_upper": 4.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab 2 mg/kg",
        "value": 3.9,
        "unit": "Months",
        "ci_lower": 3.1,
        "ci_upper": 4.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Pembrolizumab 10 mg/kg",
        "value": 4.0,
        "unit": "Months",
        "ci_lower": 2.6,
        "ci_upper": 4.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Docetaxel 75 mg/m^2",
        "value": 4.0,
        "unit": "Months",
        "ci_lower": 3.1,
        "ci_upper": 4.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab"
      ],
      "OG001": [
        "Pembrolizumab"
      ],
      "OG002": [
        "Docetaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "Chemo"
    }
  },
  {
    "nct_id": "NCT01897571",
    "brief_title": "Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL",
    "status": "COMPLETED",
    "start_date": "2013-06-13",
    "completion_date": "2021-08-24",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Epizyme, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT01897571",
    "cancer_types": [
      "DLBC",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "EZH2",
        "status": "ANY",
        "details": "Archival tumor tissue must be successfully tested for EZH2 mutation status (DLBCL only)"
      },
      {
        "target": "HBV",
        "status": "NEGATIVE",
        "details": "Hepatitis B surface antigen negative required for subjects with hepatitis B"
      },
      {
        "target": "HCV",
        "status": "NEGATIVE",
        "details": "Undetectable HCV RNA required for subjects with hepatitis C"
      },
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "Immunocompromised patients excluded, including known HIV infection"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": true,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 2 Group 1: Tazemetostat in R/R FL With Mutant EZH2",
        "value": 34.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Phase 2 Group 2: Tazemetostat in R/R FL With Wild-Type EZH2",
        "value": 19.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Phase 2 Group 3: Tazemetostat in R/R DLBCL Monotherapy",
        "value": 30.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Phase 2 Group 4: Tazemetostat + Prednisolone in R/R DLBCL Combination Therapy",
        "value": 8.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Tazemetostat"
      ],
      "OG001": [
        "Tazemetostat"
      ],
      "OG002": [
        "Tazemetostat"
      ],
      "OG003": [
        "Tazemetostat",
        "Prednisolone"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "OTHER"
    }
  },
  {
    "nct_id": "NCT01915498",
    "brief_title": "Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation",
    "status": "COMPLETED",
    "start_date": "2013-08-27",
    "completion_date": "2019-07-25",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Celgene",
    "url": "https://clinicaltrials.gov/study/NCT01915498",
    "cancer_types": [
      "LAML"
    ],
    "biomarkers": [
      {
        "target": "IDH2",
        "status": "POSITIVE",
        "details": "Documented IDH2 gene mutation. Central confirmation required in Phase 2 on bone marrow aspirate and peripheral blood; local testing acceptable in dose escalation/Part 1."
      },
      {
        "target": "CYTOGENETICS",
        "status": "NEGATIVE",
        "details": "Excludes patients with favorable\u2011risk cytogenetics (inv(16), t(16;16), t(8;21), t(15;17)) for certain relapse\u2011within\u20111\u2011year eligibility in Phase 2."
      },
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "Known infection with HIV is exclusionary (active HIV infection not allowed)."
      },
      {
        "target": "HBV",
        "status": "NEGATIVE",
        "details": "Active hepatitis B infection is exclusionary."
      },
      {
        "target": "HCV",
        "status": "NEGATIVE",
        "details": "Active hepatitis C infection is exclusionary."
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 2: Enasidenib 100 mg QD",
        "value": 37.1,
        "unit": "percentage of participants",
        "ci_lower": 27.9,
        "ci_upper": 47.1,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Enasidenib"
      ],
      "OG001": [
        "Enasidenib"
      ],
      "OG002": [
        "Enasidenib"
      ],
      "OG003": [
        "Enasidenib"
      ],
      "OG004": [
        "Enasidenib"
      ],
      "OG005": [
        "Enasidenib"
      ],
      "OG006": [
        "Enasidenib"
      ],
      "OG007": [
        "Enasidenib"
      ],
      "OG008": [
        "Enasidenib"
      ],
      "OG009": [
        "Enasidenib"
      ],
      "OG010": [
        "Enasidenib"
      ],
      "OG011": [
        "Enasidenib"
      ],
      "OG012": [
        "Enasidenib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other",
      "OG004": "Targeted_Other",
      "OG005": "Targeted_Other",
      "OG006": "Targeted_Other",
      "OG007": "Targeted_Other",
      "OG008": "Targeted_Other",
      "OG009": "Targeted_Other",
      "OG010": "Targeted_Other",
      "OG011": "Targeted_Other",
      "OG012": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01931098",
    "brief_title": "Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab",
    "status": "COMPLETED",
    "start_date": "2015-12-10",
    "completion_date": "2019-09-12",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT01931098",
    "cancer_types": [
      "GBM"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Glioblastoma or Gliosarcoma With No Prior Bevacizumab Exposure (3 months)",
        "value": 0.44,
        "unit": "proportion of participants",
        "ci_lower": 0.14,
        "ci_upper": 0.72,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Glioblastoma or Gliosarcoma With Prior Bevacizumab Exposure (3 months)",
        "value": 0.18,
        "unit": "proportion of participants",
        "ci_lower": 0.06,
        "ci_upper": 0.36,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Glioblastoma or Gliosarcoma With No Prior Bevacizumab Exposure (6 months)",
        "value": 0.11,
        "unit": "proportion of participants",
        "ci_lower": 0.01,
        "ci_upper": 0.39,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Glioblastoma or Gliosarcoma With Prior Bevacizumab Exposure (6 months)",
        "value": 0.0,
        "unit": "proportion of participants",
        "ci_lower": 0.0,
        "ci_upper": 0.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Glioblastoma or Gliosarcoma With No Prior Bevacizumab Exposure",
        "value": 7.1,
        "unit": "Months",
        "ci_lower": 2.9,
        "ci_upper": 8.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Glioblastoma or Gliosarcoma With Prior Bevacizumab Exposure",
        "value": 6.3,
        "unit": "Months",
        "ci_lower": 2.8,
        "ci_upper": 9.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "topotecan",
        "pazopanib"
      ],
      "OG001": [
        "topotecan",
        "pazopanib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo",
      "OG001": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT01896856",
    "brief_title": "Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2013-10-23",
    "completion_date": "2019-08-26",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
    "url": "https://clinicaltrials.gov/study/NCT01896856",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase 2: Arm A SGI-110 + Irinotecan",
        "value": 2.37,
        "unit": "months",
        "ci_lower": 2.2,
        "ci_upper": 3.52,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Phase 2: Arm B Regorafenib or TAS-102",
        "value": 2.09,
        "unit": "months",
        "ci_lower": 1.91,
        "ci_upper": 2.99,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "SGI-110",
        "Irinotecan"
      ],
      "OG001": [
        "SGI-110",
        "Irinotecan"
      ],
      "OG002": [
        "SGI-110",
        "Irinotecan",
        "Filgrastim",
        "Pegfilgrastim"
      ],
      "OG003": [
        "SGI-110",
        "Irinotecan",
        "Filgrastim",
        "Pegfilgrastim"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted",
      "OG003": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT01876784",
    "brief_title": "Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer",
    "status": "COMPLETED",
    "start_date": "2013-09-17",
    "completion_date": "2015-08-30",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Genzyme, a Sanofi Company",
    "url": "https://clinicaltrials.gov/study/NCT01876784",
    "cancer_types": [
      "THCA"
    ],
    "biomarkers": [
      {
        "target": "TSH",
        "status": "LOW",
        "details": "TSH suppression below 0.5 mU/L"
      },
      {
        "target": "HCG",
        "status": "NEGATIVE",
        "details": "Urine or serum pregnancy test negative for female participants of childbearing potential"
      },
      {
        "target": "ALT",
        "status": "LOW",
        "details": "ALT \u22642.5\u00d7ULN (or \u22645\u00d7ULN if judged related to liver metastases)"
      },
      {
        "target": "AST",
        "status": "LOW",
        "details": "AST \u22642.5\u00d7ULN (or \u22645\u00d7ULN if judged related to liver metastases)"
      },
      {
        "target": "ALP",
        "status": "LOW",
        "details": "ALP \u22642.5\u00d7ULN (or \u22645\u00d7ULN if judged related to liver metastases)"
      },
      {
        "target": "BILIRUBIN",
        "status": "LOW",
        "details": "Serum bilirubin \u22641.5\u00d7ULN (does not apply to known Gilbert's disease)"
      },
      {
        "target": "CREATININE_CLEARANCE",
        "status": "HIGH",
        "details": ">=50 mL/min calculated by Cockcroft-Gault formula"
      },
      {
        "target": "QTcB",
        "status": "LOW",
        "details": "Bazett-corrected QT interval (QTcB) measurable and \u2264480 ms; no history of QT prolongation or congenital long QT syndrome; not on QT-prolonging drugs"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Randomized Treatment Period: Vandetanib",
        "value": 10.0,
        "unit": "months",
        "ci_lower": 6.0,
        "ci_upper": 11.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Randomized Treatment Period: Placebo",
        "value": 5.7,
        "unit": "months",
        "ci_lower": 5.5,
        "ci_upper": 8.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Vandetanib/Vandetanib",
        "value": null,
        "unit": "months",
        "ci_lower": 31.6,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo/Vandetanib",
        "value": null,
        "unit": "months",
        "ci_lower": 32.1,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Vandetanib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT01928394",
    "brief_title": "A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2013-10-24",
    "completion_date": "2019-02-05",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT01928394",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "TNBC Arm N",
        "value": 5.6,
        "unit": "Percentage of Participants",
        "ci_lower": 0.1,
        "ci_upper": 27.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "TNBC Arm N-I Dose Level 1",
        "value": 0.0,
        "unit": "Percentage of Participants",
        "ci_lower": 0.0,
        "ci_upper": 70.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "TNBC Arm N-I Dose Level 2",
        "value": 0.0,
        "unit": "Percentage of Participants",
        "ci_lower": 0.0,
        "ci_upper": 18.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "GC Arm N",
        "value": 11.9,
        "unit": "Percentage of Participants",
        "ci_lower": 4.9,
        "ci_upper": 22.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "GC Arm N-I Dose Level 1",
        "value": 0.0,
        "unit": "Percentage of Participants",
        "ci_lower": 0.0,
        "ci_upper": 70.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "GC Arm N-I Dose Level 2",
        "value": 24.5,
        "unit": "Percentage of Participants",
        "ci_lower": 13.3,
        "ci_upper": 38.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG006",
        "arm_title": "GC Arm N-I Dose Level 2b",
        "value": 7.7,
        "unit": "Percentage of Participants",
        "ci_lower": 2.1,
        "ci_upper": 18.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG007",
        "arm_title": "PC Arm N",
        "value": 0.0,
        "unit": "Percentage of Participants",
        "ci_lower": 0.0,
        "ci_upper": 18.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG008",
        "arm_title": "PC Arm N-I Dose Level 1",
        "value": 0.0,
        "unit": "Percentage of Participants",
        "ci_lower": 0.0,
        "ci_upper": 70.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG009",
        "arm_title": "PC Arm N-I Dose Level 2",
        "value": 0.0,
        "unit": "Percentage of Participants",
        "ci_lower": 0.0,
        "ci_upper": 18.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG010",
        "arm_title": "PC Arm N-I Dose Level 2d",
        "value": 6.7,
        "unit": "Percentage of Participants",
        "ci_lower": 0.8,
        "ci_upper": 22.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG011",
        "arm_title": "SCLC Arm N - Pre-expansion",
        "value": 13.3,
        "unit": "Percentage of Participants",
        "ci_lower": 7.3,
        "ci_upper": 21.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG012",
        "arm_title": "SCLC Arm N-I Dose Level 2 - Pre-expansion",
        "value": 26.2,
        "unit": "Percentage of Participants",
        "ci_lower": 15.8,
        "ci_upper": 39.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG013",
        "arm_title": "SCLC Arm N Expansion",
        "value": 11.6,
        "unit": "Percentage of Participants",
        "ci_lower": 6.9,
        "ci_upper": 17.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG014",
        "arm_title": "SCLC Arm N-I Dose Level 2- Expansion",
        "value": 21.9,
        "unit": "Percentage of Participants",
        "ci_lower": 14.1,
        "ci_upper": 31.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG015",
        "arm_title": "SCLC Arm N-I Dose Level 1 -",
        "value": 33.3,
        "unit": "Percentage of Participants",
        "ci_lower": 0.8,
        "ci_upper": 90.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG016",
        "arm_title": "SCLC Arm N-I Dose Level 2b",
        "value": 18.2,
        "unit": "Percentage of Participants",
        "ci_lower": 9.1,
        "ci_upper": 30.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG017",
        "arm_title": "SCLC Arm N- All Treated",
        "value": 11.8,
        "unit": "Percentage of Participants",
        "ci_lower": 8.1,
        "ci_upper": 16.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG018",
        "arm_title": "SCLC Arm N-I Dose Level 2 - All Treated",
        "value": 22.3,
        "unit": "Percentage of Participants",
        "ci_lower": 16.0,
        "ci_upper": 29.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG019",
        "arm_title": "BC Arm N",
        "value": 25.6,
        "unit": "Percentage of Participants",
        "ci_lower": 16.4,
        "ci_upper": 36.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG020",
        "arm_title": "BC Arm N-I Dose Level 2",
        "value": 38.0,
        "unit": "Percentage of Participants",
        "ci_lower": 28.1,
        "ci_upper": 48.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG021",
        "arm_title": "BC Arm N-I Dose Level 2b",
        "value": 26.9,
        "unit": "Percentage of Participants",
        "ci_lower": 18.7,
        "ci_upper": 36.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG022",
        "arm_title": "OC Arm N-I Dose Level 2",
        "value": 12.2,
        "unit": "Percentage of Participants",
        "ci_lower": 4.1,
        "ci_upper": 26.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG023",
        "arm_title": "OC Arm N-I Dose Level 2b:",
        "value": 7.0,
        "unit": "Percentage of Participants",
        "ci_lower": 1.5,
        "ci_upper": 19.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG024",
        "arm_title": "OC Arm N-I Dose Level 2c:",
        "value": 9.5,
        "unit": "Percentage of Participants",
        "ci_lower": 2.7,
        "ci_upper": 22.6,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab"
      ],
      "OG001": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG002": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG003": [
        "Nivolumab"
      ],
      "OG004": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG005": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG006": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG007": [
        "Nivolumab"
      ],
      "OG008": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG009": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG010": [
        "Nivolumab",
        "Ipilimumab",
        "Cobimetinib"
      ],
      "OG011": [
        "Nivolumab"
      ],
      "OG012": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG013": [
        "Nivolumab"
      ],
      "OG014": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG015": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG016": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG017": [
        "Nivolumab"
      ],
      "OG018": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG019": [
        "Nivolumab"
      ],
      "OG020": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG021": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG022": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG023": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG024": [
        "Nivolumab",
        "Ipilimumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO",
      "OG003": "IO",
      "OG004": "IO",
      "OG005": "IO",
      "OG006": "IO",
      "OG007": "IO",
      "OG008": "IO",
      "OG009": "IO",
      "OG010": "Combo_IO_Targeted",
      "OG011": "IO",
      "OG012": "IO",
      "OG013": "IO",
      "OG014": "IO",
      "OG015": "IO",
      "OG016": "IO",
      "OG017": "IO",
      "OG018": "IO",
      "OG019": "IO",
      "OG020": "IO",
      "OG021": "IO",
      "OG022": "IO",
      "OG023": "IO",
      "OG024": "IO"
    }
  },
  {
    "nct_id": "NCT01995513",
    "brief_title": "Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients",
    "status": "COMPLETED",
    "start_date": "2013-10-22",
    "completion_date": "2016-11-15",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT01995513",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Enzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mg",
        "value": 5.7,
        "unit": "months",
        "ci_lower": 4.6,
        "ci_upper": 8.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo+Abiraterone 1000mg+ Prednisone 10mg",
        "value": 5.6,
        "unit": "months",
        "ci_lower": 4.5,
        "ci_upper": 7.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Enzalutamide",
        "Abiraterone",
        "Prednisone"
      ],
      "OG001": [
        "Abiraterone",
        "Prednisone"
      ],
      "OG002": [
        "Enzalutamide",
        "Abiraterone",
        "Prednisone"
      ],
      "OG003": [
        "Abiraterone",
        "Prednisone"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER",
      "OG002": "OTHER",
      "OG003": "OTHER"
    }
  },
  {
    "nct_id": "NCT01989676",
    "brief_title": "A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin\u00ae [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)",
    "status": "COMPLETED",
    "start_date": "2014-02-24",
    "completion_date": "2016-08-24",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT01989676",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER2 gene amplification or overexpression; tumor tissue available for central review of HER2 status"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "PF-05280014",
        "value": 62.5,
        "unit": "percentage of participants",
        "ci_lower": 57.2,
        "ci_upper": 67.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Trastuzumab-EU",
        "value": 66.5,
        "unit": "percentage of participants",
        "ci_lower": 61.3,
        "ci_upper": 71.4,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "PF-05280014",
        "Paclitaxel"
      ],
      "OG001": [
        "Herceptin",
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT01962103",
    "brief_title": "Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2013-12-04",
    "completion_date": "2017-12-05",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Celgene",
    "url": "https://clinicaltrials.gov/study/NCT01962103",
    "cancer_types": [
      "OTHER",
      "SKCM"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 2: Ewing's Sarcoma",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 24.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Phase 2: Neuroblastoma",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 23.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Phase 2: Rhabdomyosarcoma",
        "value": 7.1,
        "unit": "percentage of participants",
        "ci_lower": 0.2,
        "ci_upper": 33.9,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "nab-paclitaxel"
      ],
      "OG001": [
        "nab-paclitaxel"
      ],
      "OG002": [
        "nab-paclitaxel"
      ],
      "OG003": [
        "nab-paclitaxel"
      ],
      "OG004": [
        "nab-paclitaxel"
      ],
      "OG005": [
        "nab-paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo",
      "OG002": "Chemo",
      "OG003": "Chemo",
      "OG004": "Chemo",
      "OG005": "Chemo"
    }
  },
  {
    "nct_id": "NCT01983878",
    "brief_title": "A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction Cancer",
    "status": "COMPLETED",
    "start_date": "2013-12",
    "completion_date": "2015-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT01983878",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ramucirumab 8 mg/kg",
        "value": 23.8,
        "unit": "Percentage of Participants",
        "ci_lower": 12.4,
        "ci_upper": 37.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Ramucirumab 8 mg/kg",
        "value": 8.6,
        "unit": "Months",
        "ci_lower": 5.7,
        "ci_upper": 10.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ramucirumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01963481",
    "brief_title": "Exemestane and Cyclophosphamide for Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2013-09",
    "completion_date": "2017-10-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "NYU Langone Health",
    "url": "https://clinicaltrials.gov/study/NCT01963481",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "ER expression by standard IHC per ASCO/CAP guidelines (1\u2013100%); metastatic biopsy preferred but primary tumor acceptable if metastasis not feasible"
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": "PR expression by standard IHC per ASCO/CAP guidelines (1\u2013100%); metastatic biopsy preferred but primary tumor acceptable if metastasis not feasible"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 negative by ASCO/CAP guidelines (IHC 0\u20131+ or 2+ with HER2/17 ratio on FISH \u2264 1.8)"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Exemestane and Cyclophosphamide",
        "value": 50.1,
        "unit": "percent of participants",
        "ci_lower": 33.0,
        "ci_upper": 76.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Exemestane",
        "Cyclophosphamide"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER"
    }
  },
  {
    "nct_id": "NCT01955837",
    "brief_title": "Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia",
    "status": "COMPLETED",
    "start_date": "2013-09",
    "completion_date": "2016-02-16",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Taiho Pharmaceutical Co., Ltd.",
    "url": "https://clinicaltrials.gov/study/NCT01955837",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "TAS-102\uff08Trifluridine/Tipiracil\uff09",
        "value": 7.8,
        "unit": "Months",
        "ci_lower": 7.1,
        "ci_upper": 8.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 7.1,
        "unit": "Months",
        "ci_lower": 5.9,
        "ci_upper": 8.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "TAS-102\uff08Trifluridine/Tipiracil\uff09",
        "value": 2.0,
        "unit": "Months",
        "ci_lower": 1.9,
        "ci_upper": 2.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 1.8,
        "unit": "Months",
        "ci_lower": 1.7,
        "ci_upper": 1.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "TAS-102"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT01951586",
    "brief_title": "Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2013-12-31",
    "completion_date": "2016-07-29",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Amgen",
    "url": "https://clinicaltrials.gov/study/NCT01951586",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "sensitizing/activating EGFR mutation"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "EML4-ALK translocation"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Placebo",
        "value": 10.9,
        "unit": "months",
        "ci_lower": 9.26,
        "ci_upper": 15.54,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Denosumab",
        "value": 10.7,
        "unit": "months",
        "ci_lower": 8.54,
        "ci_upper": 12.35,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Standard Chemotherapy"
      ],
      "OG001": [
        "Denosumab",
        "Standard Chemotherapy"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT01964924",
    "brief_title": "Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2013-10-02",
    "completion_date": "2017-01-20",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT01964924",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "Negative for estrogen receptor by institutional guidelines"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "Negative for progesterone receptor by institutional guidelines"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "Negative for HER2 by institutional guidelines"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Treatment (Trametinib, Akt Inhibitor GSK2141795)",
        "value": 2.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Trametinib, Akt Inhibitor GSK2141795)",
        "value": 43.143,
        "unit": "weeks",
        "ci_lower": 33.0,
        "ci_upper": 99.286,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Trametinib, Akt Inhibitor GSK2141795) PART 1:",
        "value": 7.71,
        "unit": "weeks",
        "ci_lower": 4.43,
        "ci_upper": 8.29,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Treatment (Trametinib, Akt Inhibitor GSK2141795) PART 2:",
        "value": 7.86,
        "unit": "weeks",
        "ci_lower": 5.86,
        "ci_upper": 13.86,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Trametinib"
      ],
      "OG001": [
        "Trametinib",
        "Akt Inhibitor GSK2141795"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01958021",
    "brief_title": "Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2013-12-17",
    "completion_date": "2016-01-29",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT01958021",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Estrogen receptor positive by local laboratory (histology and/or cytology)"
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": "Progesterone receptor positive by local laboratory (histology and/or cytology)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 negative defined as negative ISH or IHC 0/1+/2+ with a negative ISH required if IHC = 2+ (ISH methods: FISH, CISH, SISH) by local laboratory"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ribociclib + Letrozole",
        "value": null,
        "unit": "months",
        "ci_lower": 19.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Letrozole",
        "value": 14.7,
        "unit": "months",
        "ci_lower": 13.0,
        "ci_upper": 16.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Ribociclib + Letrozole",
        "value": 63.9,
        "unit": "Months",
        "ci_lower": 52.4,
        "ci_upper": 71.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Letrozole",
        "value": 51.4,
        "unit": "Months",
        "ci_lower": 47.2,
        "ci_upper": 59.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ribociclib",
        "Letrozole"
      ],
      "OG001": [
        "Letrozole"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01954745",
    "brief_title": "Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma",
    "status": "COMPLETED",
    "start_date": "2013-09",
    "completion_date": "2015-06",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Massachusetts General Hospital",
    "url": "https://clinicaltrials.gov/study/NCT01954745",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cabozantinib",
        "value": 1.8,
        "unit": "months",
        "ci_lower": 1.6,
        "ci_upper": 5.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cabozantinib",
        "value": 5.2,
        "unit": "months",
        "ci_lower": 2.7,
        "ci_upper": 10.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cabozantinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT02000622",
    "brief_title": "Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2014-03-27",
    "completion_date": "2016-12-09",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT02000622",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "BRCA1",
        "status": "POSITIVE",
        "details": "Germline mutation in BRCA1 predicted or suspected deleterious"
      },
      {
        "target": "BRCA2",
        "status": "POSITIVE",
        "details": "Germline mutation in BRCA2 predicted or suspected deleterious"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "Patients with HER2 positive disease are excluded (must be HER2 negative)"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Olaparib 300 mg bd",
        "value": 7.0,
        "unit": "Months",
        "ci_lower": 5.7,
        "ci_upper": 8.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy",
        "value": 4.2,
        "unit": "Months",
        "ci_lower": 2.8,
        "ci_upper": 4.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Olaparib 300 mg bd",
        "value": 19.3,
        "unit": "Months",
        "ci_lower": 16.7,
        "ci_upper": 21.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy",
        "value": 19.6,
        "unit": "Months",
        "ci_lower": 14.1,
        "ci_upper": 24.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Olaparib"
      ],
      "OG001": [
        "Capecitabine",
        "Vinorelbine",
        "Eribulin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01982955",
    "brief_title": "Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)",
    "status": "COMPLETED",
    "start_date": "2013-12-23",
    "completion_date": "2017-12-12",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck KGaA, Darmstadt, Germany",
    "url": "https://clinicaltrials.gov/study/NCT01982955",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "activating mutation of EGFR (documented or determined by central laboratory)"
      },
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "T790M mutation (as determined by central laboratory using a validated PCR test) \u2014 required NEGATIVE for the randomized part"
      },
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "T790M mutation (as determined by central laboratory using a validated PCR test) \u2014 required POSITIVE for the single-arm cohort (mainland China sites only)"
      },
      {
        "target": "MET",
        "status": "POSITIVE",
        "details": "c-Met overexpression by IHC (IHC 2+ or IHC 3+) and/or c-Met amplification and/or increased MET gene copy number determined by ISH (central laboratory)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": true,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase 2: Tepotinib 500 mg + Gefitinib 250 mg (MET + T790 Negative)",
        "value": 4.86,
        "unit": "Months",
        "ci_lower": 3.88,
        "ci_upper": 6.87,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Phase 2: Pemetrexed and Cisplatin/Carboplatin (MET + T790 Negative)",
        "value": 4.37,
        "unit": "Months",
        "ci_lower": 4.17,
        "ci_upper": 6.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Tepotinib",
        "Gefitinib"
      ],
      "OG001": [
        "Tepotinib",
        "Gefitinib"
      ],
      "OG002": [
        "Tepotinib",
        "Gefitinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI",
      "OG002": "TKI"
    }
  },
  {
    "nct_id": "NCT02004262",
    "brief_title": "Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting",
    "status": "COMPLETED",
    "start_date": "2014-02-05",
    "completion_date": "2016-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Aduro Biotech, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT02004262",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Primary Cohort: Cy/GVAX + CRS-207",
        "value": 3.8,
        "unit": "months",
        "ci_lower": 2.9,
        "ci_upper": 5.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Primary Cohort: CRS-207",
        "value": 5.4,
        "unit": "months",
        "ci_lower": 4.2,
        "ci_upper": 6.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Primary Cohort: Chemotherapy",
        "value": 4.6,
        "unit": "months",
        "ci_lower": 4.2,
        "ci_upper": 5.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "cyclophosphamide",
        "GVAX Pancreas Vaccine",
        "CRS-207"
      ],
      "OG001": [
        "CRS-207"
      ],
      "OG002": [
        "Chemotherapy"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "IO",
      "OG002": "Chemo"
    }
  },
  {
    "nct_id": "NCT01997333",
    "brief_title": "Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2013-11",
    "completion_date": "2017-11-30",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Celldex Therapeutics",
    "url": "https://clinicaltrials.gov/study/NCT01997333",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "LOW",
        "details": "minimal or no expression; <10% of cells positive by IHC"
      },
      {
        "target": "PR",
        "status": "LOW",
        "details": "minimal or no expression; <10% of cells positive by IHC"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "IHC 0 or 1+ or copy number <4.0 signals/cell"
      },
      {
        "target": "GPNMB",
        "status": "POSITIVE",
        "details": "gpNMB over-expression; confirmed by central lab on advanced (locally advanced/recurrent or metastatic) tissue sample"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Capecitabine",
        "value": 2.8,
        "unit": "months",
        "ci_lower": 1.6,
        "ci_upper": 3.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "CDX-011",
        "value": 2.9,
        "unit": "months",
        "ci_lower": 2.8,
        "ci_upper": 3.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Capecitabine",
        "value": 8.7,
        "unit": "months",
        "ci_lower": 6.9,
        "ci_upper": 10.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "CDX-011",
        "value": 8.9,
        "unit": "months",
        "ci_lower": 7.9,
        "ci_upper": 10.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Capecitabine"
      ],
      "OG001": [
        "CDX-011"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "ADC"
    }
  },
  {
    "nct_id": "NCT01945775",
    "brief_title": "A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)",
    "status": "COMPLETED",
    "start_date": "2013-10-14",
    "completion_date": "2017-09-15",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT01945775",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "BRCA1",
        "status": "POSITIVE",
        "details": "Deleterious, suspected deleterious, or pathogenic germline BRCA1 mutation confirmed by Myriad Genetics or other sponsor-approved laboratory"
      },
      {
        "target": "BRCA2",
        "status": "POSITIVE",
        "details": "Deleterious, suspected deleterious, or pathogenic germline BRCA2 mutation confirmed by Myriad Genetics or other sponsor-approved laboratory"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-positive breast cancer excluded (must be HER2-negative)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Talazoparib",
        "value": 8.6,
        "unit": "months",
        "ci_lower": 7.2,
        "ci_upper": 9.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Physician's Choice Treatment",
        "value": 5.6,
        "unit": "months",
        "ci_lower": 4.2,
        "ci_upper": 6.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Talazoparib",
        "value": 19.3,
        "unit": "months",
        "ci_lower": 16.6,
        "ci_upper": 22.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Physician's Choice Treatment",
        "value": 19.5,
        "unit": "months",
        "ci_lower": 17.4,
        "ci_upper": 22.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "talazoparib"
      ],
      "OG001": [
        "capecitabine",
        "eribulin",
        "gemcitabine",
        "vinorelbine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01943851",
    "brief_title": "A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies",
    "status": "COMPLETED",
    "start_date": "2014-05-14",
    "completion_date": "2020-04-30",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "GlaxoSmithKline",
    "url": "https://clinicaltrials.gov/study/NCT01943851",
    "cancer_types": [
      "LAML",
      "DLBC"
    ],
    "biomarkers": [
      {
        "target": "MYC",
        "status": "POSITIVE",
        "details": "Rearrangement and/or overexpression; required for double- or triple-hit lymphoma sub-cohort (must be present along with BCL2 and/or BCL6)."
      },
      {
        "target": "BCL2",
        "status": "POSITIVE",
        "details": "Rearrangement and/or overexpression; required along with MYC (double-hit) or with MYC and BCL6 (triple-hit) for the double-/triple-hit lymphoma sub-cohort."
      },
      {
        "target": "BCL6",
        "status": "POSITIVE",
        "details": "Rearrangement and/or overexpression; may be part of the double- or triple-hit definition when present with MYC and/or BCL2."
      },
      {
        "target": "CD20",
        "status": "POSITIVE",
        "details": "If the tumor expresses CD20, subjects must have received at least one line of immunochemotherapy with an anti-CD20 antibody as part of prior therapy."
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": null,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Part 2: GSK525762 75 mg QD MDS",
        "value": 25.0,
        "unit": "Percentage of participants",
        "ci_lower": 7.3,
        "ci_upper": 52.4,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "GSK525762"
      ],
      "OG001": [
        "GSK525762"
      ],
      "OG002": [
        "GSK525762"
      ],
      "OG003": [
        "GSK525762"
      ],
      "OG004": [
        "GSK525762"
      ],
      "OG005": [
        "GSK525762"
      ],
      "OG006": [
        "GSK525762"
      ],
      "OG007": [
        "GSK525762"
      ],
      "OG008": [
        "GSK525762"
      ],
      "OG009": [
        "GSK525762"
      ],
      "OG010": [
        "GSK525762"
      ],
      "OG011": [
        "GSK525762"
      ],
      "OG012": [
        "GSK525762"
      ],
      "OG013": [
        "GSK525762"
      ],
      "OG014": [
        "GSK525762"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other",
      "OG004": "Targeted_Other",
      "OG005": "Targeted_Other",
      "OG006": "Targeted_Other",
      "OG007": "Targeted_Other",
      "OG008": "Targeted_Other",
      "OG009": "Targeted_Other",
      "OG010": "Targeted_Other",
      "OG011": "Targeted_Other",
      "OG012": "Targeted_Other",
      "OG013": "Targeted_Other",
      "OG014": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT01945021",
    "brief_title": "Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC",
    "status": "COMPLETED",
    "start_date": "2013-09-30",
    "completion_date": "2015-07-31",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT01945021",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "ROS1",
        "status": "POSITIVE",
        "details": "Positive for translocation or inversion events involving the ROS1 gene"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "Negative for translocation or inversion events involving the ALK gene"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Crizotinib 250 mg",
        "value": 88.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Crizotinib 250 mg",
        "value": 15.9,
        "unit": "Months",
        "ci_lower": 12.9,
        "ci_upper": 24.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Crizotinib 250 mg",
        "value": 44.2,
        "unit": "Months",
        "ci_lower": 32.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Crizotinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT01953003",
    "brief_title": "Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2013-09",
    "completion_date": "2017-07",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pierre Fabre Medicament",
    "url": "https://clinicaltrials.gov/study/NCT01953003",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "Her-2 negative carcinoma of the breast (Her-2 negative)"
      },
      {
        "target": "DPYD",
        "status": "NEGATIVE",
        "details": "Known or suspected dihydropyrimidine dehydrogenase (DPD) deficiency excluded"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A : iv Vinflunine Plus Capecitabine \u2014 Number of events (Participants)",
        "value": 42.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A : iv Vinflunine Plus Capecitabine \u2014 Number of censored observations (Participants)",
        "value": 14.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B : Capecitabine \u2014 Number of events (Participants)",
        "value": 46.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B : Capecitabine \u2014 Number of censored observations (Participants)",
        "value": 10.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "vinflunine",
        "Capecitabine"
      ],
      "OG001": [
        "Capecitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01964430",
    "brief_title": "Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the \"Apact\" Study)",
    "status": "COMPLETED",
    "start_date": "2014-03-28",
    "completion_date": "2022-06-30",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Celgene",
    "url": "https://clinicaltrials.gov/study/NCT01964430",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [
      {
        "target": "CA19-9",
        "status": "LOW",
        "details": "<100 U/mL assessed within 14 days of randomization"
      },
      {
        "target": "ANC",
        "status": "HIGH",
        "details": "Absolute neutrophil count \u22651500 cells/mm^3"
      },
      {
        "target": "Platelet",
        "status": "HIGH",
        "details": "Platelet count \u2265100,000/mm^3"
      },
      {
        "target": "Hemoglobin",
        "status": "HIGH",
        "details": "Hemoglobin \u22659 g/dL"
      },
      {
        "target": "AST",
        "status": "LOW",
        "details": "AST \u22642.5\u00d7 upper limit of normal (ULN)"
      },
      {
        "target": "ALT",
        "status": "LOW",
        "details": "ALT \u22642.5\u00d7 upper limit of normal (ULN)"
      },
      {
        "target": "Bilirubin",
        "status": "LOW",
        "details": "Total bilirubin \u2264ULN (Gilbert's syndrome allowed up to 1.5\u00d7ULN)"
      },
      {
        "target": "Alkaline phosphatase",
        "status": "LOW",
        "details": "Alkaline phosphatase \u22642.5\u00d7ULN"
      },
      {
        "target": "Creatinine clearance",
        "status": "HIGH",
        "details": "Serum creatinine within ULN or calculated creatinine clearance \u226550 mL/min/1.73 m^2 (use Cockcroft\u2011Gault; use actual body weight, or lean body weight if BMI >30)"
      },
      {
        "target": "PT",
        "status": "ANY",
        "details": "Prothrombin time within normal limits (\u00b115%)"
      },
      {
        "target": "PTT",
        "status": "ANY",
        "details": "Partial thromboplastin time within normal limits (\u00b115%)"
      }
    ],
    "cancer_stages": [
      "I",
      "II"
    ],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Nab-Paclitaxel and Gemcitabine",
        "value": 19.4,
        "unit": "months",
        "ci_lower": 16.62,
        "ci_upper": 21.91,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Gemcitabine",
        "value": 18.8,
        "unit": "months",
        "ci_lower": 13.83,
        "ci_upper": 20.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Nab-Paclitaxel and Gemcitabine",
        "value": 20.7,
        "unit": "months",
        "ci_lower": 19.38,
        "ci_upper": 22.83,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Gemcitabine",
        "value": 17.7,
        "unit": "months",
        "ci_lower": 14.78,
        "ci_upper": 19.91,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Nab-Paclitaxel and Gemcitabine",
        "value": 41.8,
        "unit": "months",
        "ci_lower": 35.55,
        "ci_upper": 47.28,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Gemcitabine",
        "value": 37.7,
        "unit": "months",
        "ci_lower": 31.11,
        "ci_upper": 40.51,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Nab-Paclitaxel and Gemcitabine",
        "value": 90.2,
        "unit": "months",
        "ci_lower": 83.55,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Gemcitabine",
        "value": 83.0,
        "unit": "months",
        "ci_lower": 61.93,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "nab-Paclitaxel",
        "Gemcitabine"
      ],
      "OG001": [
        "Gemcitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT01956669",
    "brief_title": "Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2014-10-08",
    "completion_date": "2019-11-05",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT01956669",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort 1: Rhabdomyosarcoma (RMS)",
        "value": 8.3,
        "unit": "Percentage of Participants",
        "ci_lower": 0.4,
        "ci_upper": 33.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS)",
        "value": 0.0,
        "unit": "Percentage of Participants",
        "ci_lower": 0.0,
        "ci_upper": 23.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Cohort 3: Ewing Sarcoma/pPNET (Ewing)",
        "value": 0.0,
        "unit": "Percentage of Participants",
        "ci_lower": 0.0,
        "ci_upper": 25.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1: Rhabdomyosarcoma (RMS)",
        "value": 1.8,
        "unit": "Months",
        "ci_lower": 1.0,
        "ci_upper": 1.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS)",
        "value": 1.8,
        "unit": "Months",
        "ci_lower": 0.3,
        "ci_upper": 13.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Cohort 3: Ewing Sarcoma/pPNET (Ewing)",
        "value": 2.3,
        "unit": "Months",
        "ci_lower": 0.2,
        "ci_upper": 13.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Cohort 4 (Osteosarcoma)",
        "value": 1.9,
        "unit": "Months",
        "ci_lower": 0.5,
        "ci_upper": 5.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Cohort 5: Measurable Neuroblastoma (mNeuroblastoma)",
        "value": 4.9,
        "unit": "Months",
        "ci_lower": 0.8,
        "ci_upper": 6.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG005",
        "arm_title": "Cohort 6: Evaluable Neuroblastoma (eNeuroblastma)",
        "value": 5.4,
        "unit": "Months",
        "ci_lower": 3.6,
        "ci_upper": 24.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG006",
        "arm_title": "Cohort 7 (Hepatoblastoma)",
        "value": 1.8,
        "unit": "Months",
        "ci_lower": 0.5,
        "ci_upper": 1.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG000",
        "arm_title": "Cohort 1: Rhabdomyosarcoma (RMS)",
        "value": 1.8,
        "unit": "Months",
        "ci_lower": 2.2,
        "ci_upper": 14.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG001",
        "arm_title": "Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS)",
        "value": 14.6,
        "unit": "Months",
        "ci_lower": 1.5,
        "ci_upper": 20.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG002",
        "arm_title": "Cohort 3: Ewing Sarcoma/pPNET (Ewing)",
        "value": null,
        "unit": "Months",
        "ci_lower": 4.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG003",
        "arm_title": "Cohort 4 (Osteosarcoma)",
        "value": 5.5,
        "unit": "Months",
        "ci_lower": 1.5,
        "ci_upper": 7.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG004",
        "arm_title": "Cohort 5: Measurable Neuroblastoma (mNeuroblastoma)",
        "value": 5.4,
        "unit": "Months",
        "ci_lower": 0.8,
        "ci_upper": 24.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG005",
        "arm_title": "Cohort 6: Evaluable Neuroblastoma (eNeuroblastma)",
        "value": 14.9,
        "unit": "Months",
        "ci_lower": 5.4,
        "ci_upper": 24.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG006",
        "arm_title": "Cohort 7 (Hepatoblastoma)",
        "value": 1.8,
        "unit": "Months",
        "ci_lower": 0.5,
        "ci_upper": 1.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1: Rhabdomyosarcoma (RMS)",
        "value": 5.6,
        "unit": "Months",
        "ci_lower": 2.2,
        "ci_upper": 14.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS)",
        "value": 14.6,
        "unit": "Months",
        "ci_lower": 1.5,
        "ci_upper": 20.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Cohort 3: Ewing Sarcoma/pPNET (Ewing)",
        "value": null,
        "unit": "Months",
        "ci_lower": 4.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Cohort 4 (Osteosarcoma)",
        "value": 5.5,
        "unit": "Months",
        "ci_lower": 1.5,
        "ci_upper": 7.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG004",
        "arm_title": "Cohort 5: Measurable Neuroblastoma (mNeuroblastoma)",
        "value": null,
        "unit": "Months",
        "ci_lower": 2.6,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG005",
        "arm_title": "Cohort 6: Evaluable Neuroblastoma (eNeuroblastma)",
        "value": 5.4,
        "unit": "Months",
        "ci_lower": 3.6,
        "ci_upper": 24.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG006",
        "arm_title": "Cohort 7 (Hepatoblastoma)",
        "value": 5.7,
        "unit": "Months",
        "ci_lower": 0.6,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pazopanib"
      ],
      "OG001": [
        "Pazopanib"
      ],
      "OG002": [
        "Pazopanib"
      ],
      "OG003": [
        "Pazopanib"
      ],
      "OG004": [
        "Pazopanib"
      ],
      "OG005": [
        "Pazopanib"
      ],
      "OG006": [
        "Pazopanib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI",
      "OG002": "TKI",
      "OG003": "TKI",
      "OG004": "TKI",
      "OG005": "TKI",
      "OG006": "TKI"
    }
  },
  {
    "nct_id": "NCT02017015",
    "brief_title": "Safety and Efficacy Study of Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer",
    "status": "COMPLETED",
    "start_date": "2013-12-24",
    "completion_date": "2015-06-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Celgene",
    "url": "https://clinicaltrials.gov/study/NCT02017015",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Nab-paclitaxel and Gemcitabine",
        "value": 35.0,
        "unit": "percentage of participants",
        "ci_lower": 24.8,
        "ci_upper": 46.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Nab-paclitaxel With Gemcitabine",
        "value": 9.2,
        "unit": "months",
        "ci_lower": 7.6,
        "ci_upper": 11.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "nab-paclitaxel",
        "Gemcitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo"
    }
  },
  {
    "nct_id": "NCT02006667",
    "brief_title": "A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial Cancer",
    "status": "COMPLETED",
    "start_date": "2001-01",
    "completion_date": "2010-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT02006667",
    "cancer_types": [
      "BLCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "overexpression by IHC (2+ or 3+)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Trastuzumab/Gemcitabine/Cisplatin",
        "value": 92.3,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Trastuzumab/Gemcitabine/Cisplatin",
        "value": 84.6,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "trastuzumab",
        "gemcitabine",
        "cisplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02038647",
    "brief_title": "Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)",
    "status": "COMPLETED",
    "start_date": "2014-05-12",
    "completion_date": "2016-01-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Millennium Pharmaceuticals, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT02038647",
    "cancer_types": [
      "SCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Alisertib + Paclitaxel",
        "value": 101.0,
        "unit": "days",
        "ci_lower": 80.0,
        "ci_upper": 113.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Paclitaxel",
        "value": 66.0,
        "unit": "days",
        "ci_lower": 53.0,
        "ci_upper": 83.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Alisertib + Paclitaxel",
        "value": 186.0,
        "unit": "days",
        "ci_lower": 150.0,
        "ci_upper": 219.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Paclitaxel",
        "value": 165.0,
        "unit": "days",
        "ci_lower": 128.0,
        "ci_upper": 183.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Alisertib",
        "Paclitaxel"
      ],
      "OG001": [
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT02016872",
    "brief_title": "Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients",
    "status": "COMPLETED",
    "start_date": "2013-12-16",
    "completion_date": "2024-07-08",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Memorial Sloan Kettering Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT02016872",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "18F-FMISO PET/CT",
        "value": 58.3,
        "unit": "% of pts with progression free survival",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "18F-FMISO PET/CT",
        "value": 40.0,
        "unit": "% of participants alive",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "18F-FMISO"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER"
    }
  },
  {
    "nct_id": "NCT02046733",
    "brief_title": "Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease",
    "status": "COMPLETED",
    "start_date": "2015-12-18",
    "completion_date": "2020-05-25",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "ETOP IBCSG Partners Foundation",
    "url": "https://clinicaltrials.gov/study/NCT02046733",
    "cancer_types": [
      "SCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "I",
      "IA",
      "IB",
      "II",
      "IIA",
      "IIB",
      "III",
      "IIIA",
      "IIIB"
    ],
    "line_of_therapy": "MAINTENANCE",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Observation",
        "value": 14.5,
        "unit": "months",
        "ci_lower": 8.2,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Nivolumab + Ipilimumab",
        "value": 10.7,
        "unit": "months",
        "ci_lower": 7.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG001": [
        "Nivolumab",
        "Ipilimumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Placebo",
      "OG001": "IO"
    }
  },
  {
    "nct_id": "NCT02082210",
    "brief_title": "A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer",
    "status": "COMPLETED",
    "start_date": "2014-03-07",
    "completion_date": "2017-12-05",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT02082210",
    "cancer_types": [
      "STAD",
      "NSCLC",
      "LIHC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Part B - Gastric",
        "value": 6.3,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 30.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Part B - HCC",
        "value": 6.7,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 20.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Part B - RCC",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 20.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Part B - NSCLC",
        "value": 6.7,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 30.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ramucirumab",
        "Emibetuzumab"
      ],
      "OG001": [
        "Ramucirumab",
        "Emibetuzumab"
      ],
      "OG002": [
        "Ramucirumab",
        "Emibetuzumab"
      ],
      "OG003": [
        "Ramucirumab",
        "Emibetuzumab"
      ],
      "OG004": [
        "Ramucirumab",
        "Emibetuzumab"
      ],
      "OG005": [
        "Ramucirumab",
        "Emibetuzumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other",
      "OG004": "Targeted_Other",
      "OG005": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02008227",
    "brief_title": "A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy",
    "status": "COMPLETED",
    "start_date": "2014-03-11",
    "completion_date": "2016-07-07",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT02008227",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV",
      "RECURRENT",
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Docetaxel",
        "value": 9.6,
        "unit": "Months",
        "ci_lower": 8.6,
        "ci_upper": 11.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Atezolizumab",
        "value": 13.8,
        "unit": "Months",
        "ci_lower": 11.8,
        "ci_upper": 15.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Docetaxel",
        "value": 9.8,
        "unit": "Months",
        "ci_lower": 8.8,
        "ci_upper": 11.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Atezolizumab",
        "value": 13.3,
        "unit": "Months",
        "ci_lower": 11.3,
        "ci_upper": 14.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Docetaxel"
      ],
      "OG001": [
        "Atezolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "IO"
    }
  },
  {
    "nct_id": "NCT02075840",
    "brief_title": "A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants",
    "status": "COMPLETED",
    "start_date": "2014-08-19",
    "completion_date": "2017-02-09",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT02075840",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "ALK",
        "status": "POSITIVE",
        "details": "Assessed by Ventana immunohistochemistry (IHC) test"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV",
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Alectinib",
        "value": null,
        "unit": "months",
        "ci_lower": 17.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Crizotinib",
        "value": 11.1,
        "unit": "months",
        "ci_lower": 9.1,
        "ci_upper": 13.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Alectinib",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Crizotinib",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Alectinib"
      ],
      "OG001": [
        "Crizotinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT02007512",
    "brief_title": "Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2013-12-16",
    "completion_date": "2016-09-23",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT02007512",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "ER positive (patients with ER+ or PR+ tumors eligible)"
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": "PR (PgR) positive (patients with ER+ or PR+ tumors eligible)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 normal (non-amplified/non-overexpressed)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1: Enzalutamide 160 mg + Exemestane 50 mg",
        "value": 11.8,
        "unit": "months",
        "ci_lower": 7.3,
        "ci_upper": 15.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort 1: Placebo + Exemestane 25 mg",
        "value": 5.8,
        "unit": "months",
        "ci_lower": 3.5,
        "ci_upper": 10.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Cohort 2: Enzalutamide 160 mg + Exemestane 50 mg",
        "value": 3.6,
        "unit": "months",
        "ci_lower": 1.9,
        "ci_upper": 5.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Cohort 2: Placebo + Exemestane 25 mg",
        "value": 3.9,
        "unit": "months",
        "ci_lower": 2.6,
        "ci_upper": 5.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Enzalutamide",
        "exemestane"
      ],
      "OG001": [
        "exemestane"
      ],
      "OG002": [
        "Enzalutamide",
        "exemestane"
      ],
      "OG003": [
        "exemestane"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER",
      "OG002": "OTHER",
      "OG003": "OTHER"
    }
  },
  {
    "nct_id": "NCT02083653",
    "brief_title": "Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2014-03-06",
    "completion_date": "2016-10-24",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Symphogen A/S",
    "url": "https://clinicaltrials.gov/study/NCT02083653",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "KRAS wild-type at initial diagnosis"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A: Sym004 (12 mg/kg)",
        "value": 7.9,
        "unit": "months",
        "ci_lower": 6.5,
        "ci_upper": 9.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Sym004 (9/6 mg/kg)",
        "value": 10.3,
        "unit": "months",
        "ci_lower": 9.0,
        "ci_upper": 12.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Arm C: Investigator's Choice",
        "value": 9.6,
        "unit": "months",
        "ci_lower": 8.3,
        "ci_upper": 12.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A: Sym004 (12 mg/kg)",
        "value": 2.8,
        "unit": "months",
        "ci_lower": 1.8,
        "ci_upper": 3.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Sym004 (9/6 mg/kg)",
        "value": 2.7,
        "unit": "months",
        "ci_lower": 2.6,
        "ci_upper": 3.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Arm C: Investigator's Choice",
        "value": 2.6,
        "unit": "months",
        "ci_lower": 1.4,
        "ci_upper": 3.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Sym004 (12 mg/kg)"
      ],
      "OG001": [
        "Sym004 (9/6 mg/kg)"
      ],
      "OG002": [
        "Fluorouracil (5-FU)",
        "Capecitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Chemo"
    }
  },
  {
    "nct_id": "NCT02083354",
    "brief_title": "Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma",
    "status": "COMPLETED",
    "start_date": "2014-03-18",
    "completion_date": "2018-02-23",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT02083354",
    "cancer_types": [
      "SKCM"
    ],
    "biomarkers": [
      {
        "target": "BRAF",
        "status": "POSITIVE",
        "details": "V600 mutation; test performed at a designated central laboratory"
      },
      {
        "target": "RAS",
        "status": "NEGATIVE",
        "details": "History of malignancy with a confirmed activating RAS mutation is excluded; prospective RAS testing not required but prior results must be used if available"
      }
    ],
    "cancer_stages": [
      "IIIC",
      "IV",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Arm 1",
        "value": 61.0,
        "unit": "Percentage of Participants",
        "ci_lower": 49.2,
        "ci_upper": 72.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm 1",
        "value": 9.17,
        "unit": "months",
        "ci_lower": 7.26,
        "ci_upper": 12.88,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm 1",
        "value": 22.9,
        "unit": "Months",
        "ci_lower": 16.62,
        "ci_upper": 27.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Dabrafenib",
        "Trametinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02034110",
    "brief_title": "Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers",
    "status": "COMPLETED",
    "start_date": "2014-03-12",
    "completion_date": "2021-12-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT02034110",
    "cancer_types": [
      "THCA",
      "GBM",
      "LGG"
    ],
    "biomarkers": [
      {
        "target": "BRAF",
        "status": "POSITIVE",
        "details": "V600E mutation; confirmed by approved local laboratory or sponsor-designated central laboratory using sponsor-designated assay; archived or fresh tumor sample required"
      },
      {
        "target": "RAS",
        "status": "NEGATIVE",
        "details": "Any activating RAS mutation excludes eligibility; prospective RAS testing not required but use prior results if available"
      },
      {
        "target": "HBsAg",
        "status": "NEGATIVE",
        "details": "No detectable hepatitis B surface antigen (HBsAg) at screening"
      },
      {
        "target": "HCV",
        "status": "NEGATIVE",
        "details": "No positive hepatitis C antibody within 3 months prior to first dose; if antibody positive, must have confirmatory negative HCV RNA PCR"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Anaplastic Thyroid Cancer (ATC)",
        "value": 56.0,
        "unit": "Percentage of Participants",
        "ci_lower": 38.1,
        "ci_upper": 72.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Anaplastic Thyroid Cancer (ATC)",
        "value": 56.0,
        "unit": "Percentage of Participants",
        "ci_lower": 38.1,
        "ci_upper": 72.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Anaplastic Thyroid Cancer (ATC)",
        "value": 53.0,
        "unit": "Percentage of Participants",
        "ci_lower": 35.5,
        "ci_upper": 69.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Anaplastic Thyroid Cancer (ATC)",
        "value": 53.0,
        "unit": "Percentage of Participants",
        "ci_lower": 35.5,
        "ci_upper": 69.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Anaplastic Thyroid Cancer (ATC)",
        "value": 29.1,
        "unit": "Weeks",
        "ci_lower": 20.3,
        "ci_upper": 59.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Anaplastic Thyroid Cancer (ATC)",
        "value": 24.1,
        "unit": "Weeks",
        "ci_lower": 16.1,
        "ci_upper": 56.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Anaplastic Thyroid Cancer (ATC)",
        "value": 62.9,
        "unit": "Weeks",
        "ci_lower": 29.6,
        "ci_upper": 100.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Dabrafenib",
        "Trametinib"
      ],
      "OG001": [
        "Dabrafenib",
        "Trametinib"
      ],
      "OG002": [
        "Dabrafenib",
        "Trametinib"
      ],
      "OG003": [
        "Dabrafenib",
        "Trametinib"
      ],
      "OG004": [
        "Dabrafenib",
        "Trametinib"
      ],
      "OG005": [
        "Dabrafenib",
        "Trametinib"
      ],
      "OG006": [
        "Dabrafenib",
        "Trametinib"
      ],
      "OG007": [
        "Dabrafenib",
        "Trametinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other",
      "OG004": "Targeted_Other",
      "OG005": "Targeted_Other",
      "OG006": "Targeted_Other",
      "OG007": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02007070",
    "brief_title": "Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025)",
    "status": "COMPLETED",
    "start_date": "2014-02-28",
    "completion_date": "2015-07-09",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT02007070",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "POSITIVE",
        "details": "per central laboratory review"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab 10 mg/kg",
        "value": 27.3,
        "unit": "Percentage of Participants",
        "ci_lower": 6.0,
        "ci_upper": 61.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab 10 mg/kg",
        "value": 4.1,
        "unit": "Months",
        "ci_lower": 1.6,
        "ci_upper": 19.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab 10 mg/kg",
        "value": null,
        "unit": "Days",
        "ci_lower": 454.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab 10 mg/kg",
        "value": 17.9,
        "unit": "Months",
        "ci_lower": 5.9,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO"
    }
  },
  {
    "nct_id": "NCT02066532",
    "brief_title": "Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2014-06",
    "completion_date": "2020-10-14",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Dawn L. Hershman",
    "url": "https://clinicaltrials.gov/study/NCT02066532",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "IHC 3+ or amplification by in situ hybridization per 2013 recommendations (e.g., single\u2011probe avg HER2 copy \u22656 signals/cell; dual\u2011probe HER2/CEP17 ratio \u22652.0 with avg HER2 \u22654 signals/cell; dual\u2011probe ratio \u22652.0 with avg HER2 <4 signals/cell; dual\u2011probe ratio <2.0 with avg HER2 >6 signals/cell)."
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ruxolitinib/Trastuzumab",
        "value": 8.3,
        "unit": "Weeks",
        "ci_lower": 7.1,
        "ci_upper": 13.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ruxolitinib",
        "Trastuzumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02061761",
    "brief_title": "A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies",
    "status": "COMPLETED",
    "start_date": "2014-03-13",
    "completion_date": "2022-02-16",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT02061761",
    "cancer_types": [
      "DLBC"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "HL Naive BMS-986016 160mg + Nivolumab",
        "value": 61.9,
        "unit": "Percentage of participants",
        "ci_lower": 38.4,
        "ci_upper": 81.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "DLBCL BMS-986016 160mg + Nivolumab",
        "value": 6.7,
        "unit": "Percentage of participants",
        "ci_lower": 0.2,
        "ci_upper": 31.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "HL Post I/O BMS-986016 160mg + Nivolumab",
        "value": 15.0,
        "unit": "Percentage of participants",
        "ci_lower": 3.2,
        "ci_upper": 37.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG000",
        "arm_title": "HL Naive BMS-986016 160mg + Nivolumab",
        "value": 14.16,
        "unit": "Months",
        "ci_lower": 2.56,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG001",
        "arm_title": "DLBCL BMS-986016 160mg + Nivolumab",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG002",
        "arm_title": "HL Post I/O BMS-986016 160mg + Nivolumab",
        "value": 6.37,
        "unit": "Months",
        "ci_lower": 1.84,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "BMS-986016"
      ],
      "OG001": [
        "BMS-986016"
      ],
      "OG002": [
        "BMS-986016"
      ],
      "OG003": [
        "BMS-986016"
      ],
      "OG004": [
        "BMS-986016",
        "BMS-936558"
      ],
      "OG005": [
        "BMS-986016",
        "BMS-936558"
      ],
      "OG006": [
        "BMS-986016",
        "BMS-936558"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO",
      "OG003": "IO",
      "OG004": "IO",
      "OG005": "IO",
      "OG006": "IO"
    }
  },
  {
    "nct_id": "NCT02047253",
    "brief_title": "Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment",
    "status": "COMPLETED",
    "start_date": "2014-04",
    "completion_date": "2017-06-08",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "University of Alabama at Birmingham",
    "url": "https://clinicaltrials.gov/study/NCT02047253",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [
      {
        "target": "PSA",
        "status": "HIGH",
        "details": ">2 ng/mL (last confirmatory sample must be >2 ng/mL); PSA progression defined as baseline increase followed by any PSA increase \u22651 week apart"
      },
      {
        "target": "TESTOSTERONE",
        "status": "LOW",
        "details": "<50 ng/dL while on androgen ablation (LHRH agonist/antagonist or orchiectomy)"
      },
      {
        "target": "LVEF",
        "status": "HIGH",
        "details": ">=40% by 2-D transthoracic echocardiogram (ECHO) or MUGA"
      },
      {
        "target": "HISTOLOGY",
        "status": "ANY",
        "details": "Histologically proven adenocarcinoma of the prostate"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Carfilzomib",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Carfilzomib",
        "value": 11.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Carfilzomib",
        "Dexamethasone",
        "Acyclovir"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER"
    }
  },
  {
    "nct_id": "NCT02060188",
    "brief_title": "A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread",
    "status": "COMPLETED",
    "start_date": "2014-03-12",
    "completion_date": "2024-10-22",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT02060188",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "MSI",
        "status": "POSITIVE",
        "details": "Microsatellite instability detected by an accredited laboratory"
      }
    ],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort 1: Nivolumab Monotherapy",
        "value": 40.5,
        "unit": "percentage of participants",
        "ci_lower": 29.3,
        "ci_upper": 52.6,
        "dispersion_type": "95% Confidence Interval"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Cohort 2: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg",
        "value": 66.4,
        "unit": "percentage of participants",
        "ci_lower": 57.2,
        "ci_upper": 74.8,
        "dispersion_type": "95% Confidence Interval"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Cohort 3: Nivolumab 3 mg/kg Q2W with Ipilimumab 1 mg/kg Q6W",
        "value": 71.1,
        "unit": "percentage of participants",
        "ci_lower": 55.7,
        "ci_upper": 83.6,
        "dispersion_type": "95% Confidence Interval"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Cohort 4: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg + Cobimetinib 60 mg",
        "value": 3.3,
        "unit": "percentage of participants",
        "ci_lower": 0.1,
        "ci_upper": 17.2,
        "dispersion_type": "95% Confidence Interval"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Cohort 5: Nivolumab 240 mg + BMS-986016 80 mg",
        "value": 50.0,
        "unit": "percentage of participants",
        "ci_lower": 35.5,
        "ci_upper": 64.5,
        "dispersion_type": "95% Confidence Interval"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "Cohort 6: Nivolumab FD + Daratumumab 16 mg/kg",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 8.0,
        "dispersion_type": "95% Confidence Interval"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG006",
        "arm_title": "MSS: Nivolumab 3 mg/kg Q2W with Ipilimumab 1 mg/kg Q6W",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 25.9,
        "dispersion_type": "95% Confidence Interval"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG007",
        "arm_title": "Non-MSI-H: Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 63.2,
        "dispersion_type": "95% Confidence Interval"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG008",
        "arm_title": "Non-MSI-H: Nivolumab 1 mg/kg + Ipilimumab 1 mg/kg",
        "value": 10.0,
        "unit": "percentage of participants",
        "ci_lower": 0.5,
        "ci_upper": 39.4,
        "dispersion_type": "95% Confidence Interval"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab"
      ],
      "OG001": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG002": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG003": [
        "Nivolumab",
        "Ipilimumab",
        "Cobimetinib"
      ],
      "OG004": [
        "Nivolumab",
        "BMS-986016"
      ],
      "OG005": [
        "Nivolumab",
        "Daratumumab"
      ],
      "OG006": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG007": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG008": [
        "Nivolumab",
        "Ipilimumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO",
      "OG003": "Combo_IO_Targeted",
      "OG004": "IO",
      "OG005": "Combo_IO_Targeted",
      "OG006": "IO",
      "OG007": "IO",
      "OG008": "IO"
    }
  },
  {
    "nct_id": "NCT02028507",
    "brief_title": "Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors",
    "status": "COMPLETED",
    "start_date": "2014-03-13",
    "completion_date": "2019-01-14",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Spanish Breast Cancer Research Group",
    "url": "https://clinicaltrials.gov/study/NCT02028507",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "ER and/or PR \u22651% positive cells by immunohistochemistry (HR+ definition)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "IHC 0 or 1+ or negative by ISH (HER2/CEP17 ratio <2 or HER2 copy number <4)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1: Palbociclib Plus Exemestane",
        "value": 7.3,
        "unit": "month",
        "ci_lower": 5.6,
        "ci_upper": 9.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort 1: Capecitabine",
        "value": 9.4,
        "unit": "month",
        "ci_lower": 7.4,
        "ci_upper": 11.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Cohort 2: Palbociclib Plus Fulvestrant",
        "value": 7.5,
        "unit": "month",
        "ci_lower": 5.7,
        "ci_upper": 10.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Cohort 2: Capecitabine",
        "value": 10.0,
        "unit": "month",
        "ci_lower": 6.3,
        "ci_upper": 12.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Palbociclib",
        "Exemestane"
      ],
      "OG001": [
        "Capecitabine"
      ],
      "OG002": [
        "Palbociclib",
        "Fulvestrant"
      ],
      "OG003": [
        "Capecitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Chemo",
      "OG002": "Targeted_Other",
      "OG003": "Chemo"
    }
  },
  {
    "nct_id": "NCT02031458",
    "brief_title": "A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2014-01-22",
    "completion_date": "2015-05-28",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT02031458",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "POSITIVE",
        "details": "PD-L1 expression by IHC on tumor-infiltrating immune cells and/or tumor cells performed by a central laboratory; FFPE tumor specimen required."
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV",
      "RECURRENT",
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort 1: First Line Atezolizumab",
        "value": 26.2,
        "unit": "percentage of participants",
        "ci_lower": 16.0,
        "ci_upper": 38.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Cohort 2: Second Line Atezolizumab",
        "value": 23.8,
        "unit": "percentage of participants",
        "ci_lower": 16.5,
        "ci_upper": 32.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Cohort 3: Third Line and Beyond Atezolizumab",
        "value": 27.0,
        "unit": "percentage of participants",
        "ci_lower": 19.1,
        "ci_upper": 36.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Cohorts 2 + 3",
        "value": 25.35,
        "unit": "percentage of participants",
        "ci_lower": 19.9,
        "ci_upper": 31.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort 1: First Line Atezolizumab",
        "value": 21.1,
        "unit": "percentage of participants",
        "ci_lower": 14.3,
        "ci_upper": 29.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Cohort 2: Second Line Atezolizumab",
        "value": 17.4,
        "unit": "percentage of participants",
        "ci_lower": 12.9,
        "ci_upper": 22.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Cohort 3: Third Line and Beyond Atezolizumab",
        "value": 18.2,
        "unit": "percentage of participants",
        "ci_lower": 13.5,
        "ci_upper": 23.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Cohorts 2 + 3",
        "value": 17.8,
        "unit": "percentage of participants",
        "ci_lower": 14.5,
        "ci_upper": 21.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort 1: First Line Atezolizumab",
        "value": 19.4,
        "unit": "percentage of participants",
        "ci_lower": 13.2,
        "ci_upper": 27.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Cohort 2: Second Line Atezolizumab",
        "value": 17.2,
        "unit": "percentage of participants",
        "ci_lower": 12.9,
        "ci_upper": 22.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Cohort 3: Third Line and Beyond Atezolizumab",
        "value": 17.4,
        "unit": "percentage of participants",
        "ci_lower": 12.9,
        "ci_upper": 22.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Cohorts 2 + 3",
        "value": 17.3,
        "unit": "percentage of participants",
        "ci_lower": 14.2,
        "ci_upper": 20.8,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Atezolizumab"
      ],
      "OG001": [
        "Atezolizumab"
      ],
      "OG002": [
        "Atezolizumab"
      ],
      "OG003": [
        "Atezolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO",
      "OG003": "IO"
    }
  },
  {
    "nct_id": "NCT02054806",
    "brief_title": "Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)",
    "status": "COMPLETED",
    "start_date": "2014-02-17",
    "completion_date": "2021-04-30",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT02054806",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab"
      ],
      "OG001": [
        "Pembrolizumab"
      ],
      "OG002": [
        "Pembrolizumab"
      ],
      "OG003": [
        "Pembrolizumab"
      ],
      "OG004": [
        "Pembrolizumab"
      ],
      "OG005": [
        "Pembrolizumab"
      ],
      "OG006": [
        "Pembrolizumab"
      ],
      "OG007": [
        "Pembrolizumab"
      ],
      "OG008": [
        "Pembrolizumab"
      ],
      "OG009": [
        "Pembrolizumab"
      ],
      "OG010": [
        "Pembrolizumab"
      ],
      "OG011": [
        "Pembrolizumab"
      ],
      "OG012": [
        "Pembrolizumab"
      ],
      "OG013": [
        "Pembrolizumab"
      ],
      "OG014": [
        "Pembrolizumab"
      ],
      "OG015": [
        "Pembrolizumab"
      ],
      "OG016": [
        "Pembrolizumab"
      ],
      "OG017": [
        "Pembrolizumab"
      ],
      "OG018": [
        "Pembrolizumab"
      ],
      "OG019": [
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO",
      "OG003": "IO",
      "OG004": "IO",
      "OG005": "IO",
      "OG006": "IO",
      "OG007": "IO",
      "OG008": "IO",
      "OG009": "IO",
      "OG010": "IO",
      "OG011": "IO",
      "OG012": "IO",
      "OG013": "IO",
      "OG014": "IO",
      "OG015": "IO",
      "OG016": "IO",
      "OG017": "IO",
      "OG018": "IO",
      "OG019": "IO"
    }
  },
  {
    "nct_id": "NCT02092298",
    "brief_title": "Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Metastatic Gastric Cancer",
    "status": "COMPLETED",
    "start_date": "2014-05-08",
    "completion_date": "2020-05-12",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "M.D. Anderson Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT02092298",
    "cancer_types": [
      "STAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "NEOADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Hyperthermic Intraperitoneal Chemotherapy (HIPEC)",
        "value": 30.2,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Mitomycin C",
        "Cisplatin",
        "Sodium Thiosulfate"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo"
    }
  },
  {
    "nct_id": "NCT02101788",
    "brief_title": "Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer",
    "status": "COMPLETED",
    "start_date": "2014-04-11",
    "completion_date": "2019-04-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT02101788",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A - Control Arm",
        "value": 7.2,
        "unit": "months",
        "ci_lower": 5.6,
        "ci_upper": 9.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B - Experimental Arm",
        "value": 13.0,
        "unit": "months",
        "ci_lower": 9.9,
        "ci_upper": 15.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A - Control Arm",
        "value": 29.2,
        "unit": "Months",
        "ci_lower": 23.5,
        "ci_upper": 51.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B - Experimental Arm",
        "value": 37.0,
        "unit": "Months",
        "ci_lower": 30.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Letrozole",
        "Tamoxifen Citrate",
        "Paclitaxel",
        "Pegylated Liposomal Doxorubicin Hydrochloride"
      ],
      "OG001": [
        "Trametinib Dimethyl Sulfoxide"
      ],
      "OG002": [
        "Trametinib Dimethyl Sulfoxide"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "OTHER"
    }
  },
  {
    "nct_id": "NCT02098343",
    "brief_title": "p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246",
    "status": "COMPLETED",
    "start_date": "2014-03",
    "completion_date": "2019-04",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Aprea Therapeutics",
    "url": "https://clinicaltrials.gov/study/NCT02098343",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "TP53",
        "status": "POSITIVE",
        "details": "Positive nuclear immunohistochemical (IHC) staining for p53"
      }
    ],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase Ib. APR-246 (35mg/kg) + Carboplatin/PLD.",
        "value": 330.0,
        "unit": "days",
        "ci_lower": 280.0,
        "ci_upper": 444.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Phase Ib. APR-246 (50mg/kg) + Carboplatin/PLD.",
        "value": 277.5,
        "unit": "days",
        "ci_lower": 175.0,
        "ci_upper": 375.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Phase Ib. APR-246 (67.5mg/kg) + Carboplatin/PLD.",
        "value": 313.0,
        "unit": "days",
        "ci_lower": 98.0,
        "ci_upper": 590.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Phase II: Arm A. APR-246 + Carboplatin/PLD.",
        "value": 283.0,
        "unit": "days",
        "ci_lower": 240.0,
        "ci_upper": 314.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Phase II: Arm B. Carboplatin/PLD.",
        "value": 295.0,
        "unit": "days",
        "ci_lower": 259.0,
        "ci_upper": 335.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "APR-246",
        "Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)"
      ],
      "OG001": [
        "APR-246",
        "Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)"
      ],
      "OG002": [
        "APR-246",
        "Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)"
      ],
      "OG003": [
        "APR-246",
        "Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)"
      ],
      "OG004": [
        "Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted",
      "OG003": "Combo_Chemo_Targeted",
      "OG004": "Chemo"
    }
  },
  {
    "nct_id": "NCT02152631",
    "brief_title": "A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2014-10-03",
    "completion_date": "2017-09-15",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT02152631",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "POSITIVE",
        "details": "Detectable mutation in codons 12 or 13 of the KRAS oncogene (tumor tissue); central lab assay (local lab KRAS+ allowed for up to 10% of randomized participants)"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Abemaciclib",
        "value": 7.4,
        "unit": "months",
        "ci_lower": 6.5,
        "ci_upper": 8.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Erlotinib",
        "value": 7.8,
        "unit": "months",
        "ci_lower": 6.4,
        "ci_upper": 9.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Abemaciclib",
        "value": 3.6,
        "unit": "months",
        "ci_lower": 2.8,
        "ci_upper": 3.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Erlotinib",
        "value": 1.9,
        "unit": "months",
        "ci_lower": 1.9,
        "ci_upper": 2.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Abemaciclib"
      ],
      "OG001": [
        "Erlotinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT02087423",
    "brief_title": "A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2014-02-25",
    "completion_date": "2016-06-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT02087423",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "POSITIVE",
        "details": "\u226525% of tumor cells with membrane staining (Cohorts 1 & 2) or \u226590% of tumor cells with membrane staining (Cohort 3); assessed by IHC"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort 1 (EGFR/ALK+) PD-L1+ (>=25%)",
        "value": 12.2,
        "unit": "% of patients evaluable for response",
        "ci_lower": 5.7,
        "ci_upper": 21.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Cohort 1 (EGFR/ALK+) PD-L1+ (<25%)",
        "value": 3.6,
        "unit": "% of patients evaluable for response",
        "ci_lower": 0.1,
        "ci_upper": 18.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Cohort 2 PD-L1+ (>=25%)",
        "value": 16.4,
        "unit": "% of patients evaluable for response",
        "ci_lower": 10.8,
        "ci_upper": 23.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Cohort 2 PD-L1+ (<25%)",
        "value": 7.5,
        "unit": "% of patients evaluable for response",
        "ci_lower": 3.1,
        "ci_upper": 14.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Cohort 3 (TC>=90%)",
        "value": 30.9,
        "unit": "% of patients evaluable for response",
        "ci_lower": 20.2,
        "ci_upper": 43.3,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "MEDI4736"
      ],
      "OG001": [
        "MEDI4736"
      ],
      "OG002": [
        "MEDI4736"
      ],
      "OG003": [
        "MEDI4736"
      ],
      "OG004": [
        "MEDI4736"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO",
      "OG003": "IO",
      "OG004": "IO"
    }
  },
  {
    "nct_id": "NCT02101385",
    "brief_title": "Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2014-04-03",
    "completion_date": "2021-02-21",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bryan Schneider, MD",
    "url": "https://clinicaltrials.gov/study/NCT02101385",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "ER considered negative if \u22641% of cells stain weakly positive"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "PR considered negative if \u22641% of cells stain weakly positive"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 considered negative if IHC 0 or 1+ or IHC 2+ with FISH ratio <2.0 or <6 copies per cell"
      }
    ],
    "cancer_stages": [
      "I",
      "II",
      "III"
    ],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [],
    "arm_drugs": {
      "OG000": [
        "Genomically Directed Monotherapy"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT02103062",
    "brief_title": "Phase 2 Study With Abraxane (Nab\u00aePaclitaxel) in Metastatic Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2014-05-05",
    "completion_date": "2014-11-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Celgene",
    "url": "https://clinicaltrials.gov/study/NCT02103062",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "ANY",
        "details": "Known mutated or wild-type KRAS status required (mutated or wild-type); NRAS mutation status may be unknown."
      },
      {
        "target": "RAS",
        "status": "ANY",
        "details": "RAS status relevant (if RAS wild-type tumors, prior anti-EGFR therapy such as cetuximab or panitumumab is required)."
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "RAS Wildtype: Nab\u00174-Paclitaxel",
        "value": 20.0,
        "unit": "percentage of participants",
        "ci_lower": 4.0,
        "ci_upper": 48.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "RAS Mutated: Nab\u00174-Paclitaxel",
        "value": 20.0,
        "unit": "percentage of participants",
        "ci_lower": 4.0,
        "ci_upper": 48.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "nab-paclitaxel"
      ],
      "OG001": [
        "nab-paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT02102490",
    "brief_title": "A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread",
    "status": "COMPLETED",
    "start_date": "2014-06-10",
    "completion_date": "2016-04-30",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT02102490",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HR",
        "status": "POSITIVE",
        "details": "Hormone Receptor positive (ER and/or PR)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-negative"
      }
    ],
    "cancer_stages": [
      "RECURRENT",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Abemaciclib",
        "value": 19.7,
        "unit": "Percentage of participants",
        "ci_lower": 13.3,
        "ci_upper": 27.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Abemaciclib",
        "value": 22.32,
        "unit": "Months",
        "ci_lower": 17.72,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Abemaciclib",
        "value": 6.0,
        "unit": "Months",
        "ci_lower": 4.2,
        "ci_upper": 7.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Abemaciclib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02162719",
    "brief_title": "A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors",
    "status": "COMPLETED",
    "start_date": "2014-08-19",
    "completion_date": "2016-06-07",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Genentech, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT02162719",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": null
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": null
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": null
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "UNRESECTABLE",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ipatasertib and Paclitaxel",
        "value": 6.18,
        "unit": "Months",
        "ci_lower": 4.57,
        "ci_upper": 7.33,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo and Paclitaxel",
        "value": 4.93,
        "unit": "Months",
        "ci_lower": 3.58,
        "ci_upper": 5.36,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Ipatasertib and Paclitaxel",
        "value": 25.8,
        "unit": "months",
        "ci_lower": 18.6,
        "ci_upper": 28.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo and Paclitaxel",
        "value": 16.9,
        "unit": "months",
        "ci_lower": 14.6,
        "ci_upper": 24.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG000",
        "arm_title": "Ipatasertib and Paclitaxel",
        "value": 6.18,
        "unit": "Months",
        "ci_lower": 4.57,
        "ci_upper": 7.33,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG001",
        "arm_title": "Placebo and Paclitaxel",
        "value": 4.96,
        "unit": "Months",
        "ci_lower": 3.61,
        "ci_upper": 5.39,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG000",
        "arm_title": "Ipatasertib and Paclitaxel",
        "value": 6.18,
        "unit": "Months",
        "ci_lower": 3.65,
        "ci_upper": 9.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG001",
        "arm_title": "Placebo and Paclitaxel",
        "value": 3.94,
        "unit": "Months",
        "ci_lower": 2.53,
        "ci_upper": 7.33,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ipatasertib",
        "Paclitaxel"
      ],
      "OG001": [
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT02118337",
    "brief_title": "A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies",
    "status": "COMPLETED",
    "start_date": "2014-05-19",
    "completion_date": "2020-03-17",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "MedImmune LLC",
    "url": "https://clinicaltrials.gov/study/NCT02118337",
    "cancer_types": [
      "KIRC"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "MEDI0680 20 mg/kg",
        "value": 0.0,
        "unit": "Percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 60.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "MEDI0680 20 mg/kg + Durvalumab 750 mg",
        "value": 16.7,
        "unit": "Percentage of participants",
        "ci_lower": 7.0,
        "ci_upper": 31.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Nivolumab 240 mg",
        "value": 23.8,
        "unit": "Percentage of participants",
        "ci_lower": 8.2,
        "ci_upper": 47.2,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "MEDI0680",
        "Durvalumab"
      ],
      "OG001": [
        "MEDI0680",
        "Durvalumab"
      ],
      "OG002": [
        "MEDI0680",
        "Durvalumab"
      ],
      "OG003": [
        "MEDI0680",
        "Durvalumab"
      ],
      "OG004": [
        "MEDI0680",
        "Durvalumab"
      ],
      "OG005": [
        "MEDI0680",
        "Durvalumab"
      ],
      "OG006": [
        "MEDI0680"
      ],
      "OG007": [
        "MEDI0680",
        "Durvalumab"
      ],
      "OG008": [
        "Nivolumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO",
      "OG003": "IO",
      "OG004": "IO",
      "OG005": "IO",
      "OG006": "IO",
      "OG007": "IO",
      "OG008": "IO"
    }
  },
  {
    "nct_id": "NCT02107703",
    "brief_title": "A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2014-07-22",
    "completion_date": "2017-02-14",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT02107703",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HR",
        "status": "POSITIVE",
        "details": "hormone receptor positive (ER and/or PR)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-negative"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Abemaciclib + Fulvestrant",
        "value": 16.4,
        "unit": "Months",
        "ci_lower": 14.4,
        "ci_upper": 19.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Fulvestrant",
        "value": 9.3,
        "unit": "Months",
        "ci_lower": 7.4,
        "ci_upper": 11.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Abemaciclib + Fulvestrant",
        "value": 45.8,
        "unit": "Months",
        "ci_lower": 38.96,
        "ci_upper": 52.64,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Fulvestrant",
        "value": 37.25,
        "unit": "Months",
        "ci_lower": 34.36,
        "ci_upper": 43.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Abemaciclib",
        "Fulvestrant"
      ],
      "OG001": [
        "Fulvestrant"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02094261",
    "brief_title": "Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours",
    "status": "COMPLETED",
    "start_date": "2014-05-20",
    "completion_date": "2015-05-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT02094261",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "sensitizing EGFR mutations including G719X, exon 19 deletion, L858R, L861Q"
      },
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "T790M mutation; central confirmation required from a biopsy taken after progression on most recent treatment regimen"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": true,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "AZD9291 80mg",
        "value": 70.9,
        "unit": "Percent",
        "ci_lower": 64.0,
        "ci_upper": 77.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "AZD9291 80mg",
        "value": 8.6,
        "unit": "Months",
        "ci_lower": 8.28,
        "ci_upper": 9.72,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "AZD9291"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT02115282",
    "brief_title": "Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2014-03-29",
    "completion_date": "2020-05-05",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT02115282",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": ">=1% nuclear staining by IHC (ER) for hormone receptor positivity; histologically confirmed adenocarcinoma"
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": ">=1% nuclear staining by IHC (PR) for hormone receptor positivity; histologically confirmed adenocarcinoma"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "Must NOT be HER2 IHC 3+, or have ISH ratio >=2.0, or average HER2 copy number >=6 signals/cell"
      }
    ],
    "cancer_stages": [
      "III",
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A (Exemestane, Entinostat)",
        "value": 3.3,
        "unit": "Months",
        "ci_lower": 3.1,
        "ci_upper": 5.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B (Exemestane, Placebo)",
        "value": 3.1,
        "unit": "Months",
        "ci_lower": 3.0,
        "ci_upper": 3.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A (Exemestane, Entinostat)",
        "value": 23.4,
        "unit": "Months",
        "ci_lower": 21.2,
        "ci_upper": 25.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B (Exemestane, Placebo)",
        "value": 21.7,
        "unit": "Months",
        "ci_lower": 19.3,
        "ci_upper": 27.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Exemestane",
        "Entinostat"
      ],
      "OG001": [
        "Exemestane"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT02129556",
    "brief_title": "Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2014-12",
    "completion_date": "2017-08-04",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "ETOP IBCSG Partners Foundation",
    "url": "https://clinicaltrials.gov/study/NCT02129556",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER2 positivity by IHC 3+ OR ERBB2 amplification (ERBB2/centromere ratio \u22652.0 or mean gene copy number \u22656); central confirmation on metastatic or unresectable loco\u2011regional biopsy (FFPE) required"
      },
      {
        "target": "PD-L1",
        "status": "POSITIVE",
        "details": "Presence of PD-L1 expression assessed by IHC required for main cohort (note: during phase II a parallel secondary cohort of 15 PD-L1\u2011negative patients will be enrolled)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase Ib",
        "value": 0.17,
        "unit": "proportion of participants",
        "ci_lower": 0.01,
        "ci_upper": 0.58,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Phase II PD-L1+",
        "value": 0.15,
        "unit": "proportion of participants",
        "ci_lower": 0.07,
        "ci_upper": 0.29,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Phase II PD-L1-",
        "value": 0.0,
        "unit": "proportion of participants",
        "ci_lower": 0.0,
        "ci_upper": 0.18,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "MK-3475",
        "Pembrolizumab"
      ],
      "OG001": [
        "MK-3475",
        "Pembrolizumab"
      ],
      "OG002": [
        "MK-3475",
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO"
    }
  },
  {
    "nct_id": "NCT02115542",
    "brief_title": "Single Agent Regorafenib in Refractory Advanced Biliary Cancers",
    "status": "COMPLETED",
    "start_date": "2014-06-05",
    "completion_date": "2018-12-10",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
    "url": "https://clinicaltrials.gov/study/NCT02115542",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "UNRESECTABLE",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Regorafenib Monotherapy",
        "value": 7.9,
        "unit": "months",
        "ci_lower": 0.0,
        "ci_upper": 18.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Regorafenib Monotherapy",
        "value": 2.8,
        "unit": "months",
        "ci_lower": 1.1,
        "ci_upper": 4.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Regorafenib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT02139358",
    "brief_title": "Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2014-09-05",
    "completion_date": "2018-04-24",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
    "url": "https://clinicaltrials.gov/study/NCT02139358",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "IHC 3+ or FISH ratio \u22652.0"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Dose Escalation / Phase II Treatment",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Dose Escalation / Phase II Treatment",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Dose Escalation / Phase II Treatment",
        "value": 8.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Dose Escalation / Phase II Treatment",
        "value": 6.4883,
        "unit": "months",
        "ci_lower": 2.7807,
        "ci_upper": 9.0372,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Dose Escalation / Phase II Treatment",
        "value": 11.3545,
        "unit": "months",
        "ci_lower": 6.2897,
        "ci_upper": 14.0028,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Gemcitabine",
        "Trastuzumab",
        "Pertuzumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02123823",
    "brief_title": "BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2014-05-15",
    "completion_date": "2016-11-25",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Boehringer Ingelheim",
    "url": "https://clinicaltrials.gov/study/NCT02123823",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Tumors must be positive for estrogen receptor (ER) and/or progesterone receptor (PR); at least one of ER or PR required"
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": "Tumors must be positive for estrogen receptor (ER) and/or progesterone receptor (PR); at least one of ER or PR required"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 negative per local lab testing"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Xentuzumab (BI 836845) 1000 mg + Everolimus 10 mg + Exemestane 25 mg - Phase II",
        "value": 7.3,
        "unit": "Months",
        "ci_lower": 3.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Everolimus 10 mg + Exemestane 25 mg - Phase II",
        "value": 5.6,
        "unit": "Months",
        "ci_lower": 3.7,
        "ci_upper": 9.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "BI 836845 (xentuzumab)",
        "Everolimus",
        "Exemestane"
      ],
      "OG001": [
        "Everolimus",
        "Exemestane"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02149108",
    "brief_title": "Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)",
    "status": "COMPLETED",
    "start_date": "2014-09-25",
    "completion_date": "2016-05-13",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Boehringer Ingelheim",
    "url": "https://clinicaltrials.gov/study/NCT02149108",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "K\u2011Ras wild\u2011type (wt) \u2014 cetuximab or panitumumab required for patients with KRAS wild\u2011type tumors"
      },
      {
        "target": "RAS",
        "status": "NEGATIVE",
        "details": "Ras wild\u2011type (wt) \u2014 cetuximab or panitumumab required for patients with RAS wild\u2011type tumors"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Placebo",
        "value": 1.38,
        "unit": "Months",
        "ci_lower": 1.38,
        "ci_upper": 1.41,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Nintedanib",
        "value": 1.51,
        "unit": "Months",
        "ci_lower": 1.45,
        "ci_upper": 2.17,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Placebo",
        "value": 6.05,
        "unit": "Months",
        "ci_lower": 5.22,
        "ci_upper": 6.97,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Nintedanib",
        "value": 6.44,
        "unit": "Months",
        "ci_lower": 5.98,
        "ci_upper": 7.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG001": [
        "Nintedanib (BIBF 1120)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Placebo",
      "OG001": "TKI"
    }
  },
  {
    "nct_id": "NCT02108964",
    "brief_title": "A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies",
    "status": "COMPLETED",
    "start_date": "2014-06-06",
    "completion_date": "2018-03-22",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT02108964",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "EGFR-mutant NSCLC (EGFR mutation required)"
      },
      {
        "target": "HCV",
        "status": "NEGATIVE",
        "details": "Undetectable HCV-RNA required; HCV antibody may be positive but detectable HCV-RNA is not eligible"
      },
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "No known history of HIV seropositivity (HIV serology negative required)"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV",
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "EGF816 150 mg (Phase II Part)",
        "value": 64.4,
        "unit": "Percentage of participants",
        "ci_lower": 48.8,
        "ci_upper": 78.1,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "EGF816"
      ],
      "OG001": [
        "EGF816"
      ],
      "OG002": [
        "EGF816"
      ],
      "OG003": [
        "EGF816"
      ],
      "OG004": [
        "EGF816"
      ],
      "OG005": [
        "EGF816"
      ],
      "OG006": [
        "EGF816"
      ],
      "OG007": [
        "EGF816"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI",
      "OG002": "TKI",
      "OG003": "TKI",
      "OG004": "TKI",
      "OG005": "TKI",
      "OG006": "TKI",
      "OG007": "TKI"
    }
  },
  {
    "nct_id": "NCT02130466",
    "brief_title": "A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)",
    "status": "COMPLETED",
    "start_date": "2014-05-29",
    "completion_date": "2021-07-14",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT02130466",
    "cancer_types": [
      "SKCM"
    ],
    "biomarkers": [
      {
        "target": "BRAF",
        "status": "POSITIVE",
        "details": "V600E or V600K; required for Parts 1, 2 and 3"
      },
      {
        "target": "BRAF",
        "status": "NEGATIVE",
        "details": "Wild type; cohort allowed in Parts 1, 2, 4 and 5 with documented progression of \u22651 measurable lesion after prior therapy (if prior therapy was received)"
      }
    ],
    "cancer_stages": [
      "III",
      "IV",
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Part 2:Pembrolizumab 2 mg/kg+Trametinib 1.5 mg",
        "value": 50.0,
        "unit": "Percentage of Participants",
        "ci_lower": 1.3,
        "ci_upper": 98.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Part 3:Pembrolizumab 2 mg/kg+Dabrafenib 150 mg+Trametinib 2 mg",
        "value": 17.0,
        "unit": "Months",
        "ci_lower": 11.3,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Part 3:Placebo+Dabrafenib 150 mg+Trametinib 2 mg",
        "value": 9.9,
        "unit": "Months",
        "ci_lower": 6.7,
        "ci_upper": 15.6,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Dabrafenib",
        "Trametinib"
      ],
      "OG001": [
        "Pembrolizumab",
        "Trametinib"
      ],
      "OG002": [
        "Pembrolizumab",
        "Trametinib"
      ],
      "OG003": [
        "Pembrolizumab",
        "Dabrafenib",
        "Trametinib"
      ],
      "OG004": [
        "Pembrolizumab",
        "Trametinib"
      ],
      "OG005": [
        "Pembrolizumab",
        "Trametinib"
      ],
      "OG006": [
        "Pembrolizumab",
        "Trametinib"
      ],
      "OG007": [
        "Pembrolizumab",
        "Trametinib"
      ],
      "OG008": [
        "Pembrolizumab",
        "Trametinib"
      ],
      "OG009": [
        "Pembrolizumab",
        "Trametinib"
      ],
      "OG010": [
        "Pembrolizumab",
        "Trametinib"
      ],
      "OG011": [
        "Pembrolizumab",
        "Trametinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted",
      "OG002": "Combo_IO_Targeted",
      "OG003": "Combo_IO_Targeted",
      "OG004": "Combo_IO_Targeted",
      "OG005": "Combo_IO_Targeted",
      "OG006": "Combo_IO_Targeted",
      "OG007": "Combo_IO_Targeted",
      "OG008": "Combo_IO_Targeted",
      "OG009": "Combo_IO_Targeted",
      "OG010": "Combo_IO_Targeted",
      "OG011": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT02279732",
    "brief_title": "Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin",
    "status": "COMPLETED",
    "start_date": "2014-10-13",
    "completion_date": "2018-05-03",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT02279732",
    "cancer_types": [
      "LUSC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IV",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Ipi + PAC/CAR",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + PAC/CAR",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ipilimumab",
        "Paclitaxel",
        "Carboplatin"
      ],
      "OG001": [
        "Paclitaxel",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT02278120",
    "brief_title": "Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2014-11-20",
    "completion_date": "2017-08-21",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT02278120",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": null
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": null
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": null
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ribociclib + NSAI/Tamoxifen + Goserelin",
        "value": 23.8,
        "unit": "Months",
        "ci_lower": 19.2,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + NSAI/Tamoxifen+ Goserelin",
        "value": 13.0,
        "unit": "Months",
        "ci_lower": 11.0,
        "ci_upper": 16.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Ribociclib + NSAI/Tamoxifen + Goserelin",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + NSAI/Tamoxifen+ Goserelin",
        "value": 40.9,
        "unit": "Months",
        "ci_lower": 37.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ribociclib",
        "Tamoxifen",
        "Letrozole",
        "Anastrozole",
        "Goserelin"
      ],
      "OG001": [
        "Tamoxifen",
        "Letrozole",
        "Anastrozole",
        "Goserelin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT02200757",
    "brief_title": "Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2015-04-20",
    "completion_date": "2017-05-15",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "ImmunityBio, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT02200757",
    "cancer_types": [
      "SCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Aldoxorubicin",
        "value": 1.5,
        "unit": "Months",
        "ci_lower": 1.4,
        "ci_upper": 2.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Topotecan",
        "value": 2.7,
        "unit": "Months",
        "ci_lower": 1.5,
        "ci_upper": 3.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Aldoxorubicin"
      ],
      "OG001": [
        "Topotecan"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT02269943",
    "brief_title": "Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma",
    "status": "COMPLETED",
    "start_date": "2015-02-13",
    "completion_date": "2017-04-20",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Celgene",
    "url": "https://clinicaltrials.gov/study/NCT02269943",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "CC-486 200 mg",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "CC-486 300 mg",
        "value": 15.0,
        "unit": "percentage of participants",
        "ci_lower": 4.2,
        "ci_upper": 34.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "CC-486 200 mg",
        "value": 6.2,
        "unit": "months",
        "ci_lower": 1.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "CC-486 300 mg",
        "value": 4.4,
        "unit": "months",
        "ci_lower": 1.6,
        "ci_upper": 7.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "CC-486"
      ],
      "OG001": [
        "CC-486"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT02196688",
    "brief_title": "Study of Fruquintinib in Patients With Metastatic Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2014-04",
    "completion_date": "2015-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hutchison Medipharma Limited",
    "url": "https://clinicaltrials.gov/study/NCT02196688",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment Arm",
        "value": 4.731,
        "unit": "months",
        "ci_lower": 2.858,
        "ci_upper": 5.585,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Control Arm",
        "value": 0.986,
        "unit": "months",
        "ci_lower": 0.953,
        "ci_upper": 1.577,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Treatment Arm",
        "value": 7.721,
        "unit": "months",
        "ci_lower": 6.899,
        "ci_upper": 10.283,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Control Arm",
        "value": 5.52,
        "unit": "months",
        "ci_lower": 3.614,
        "ci_upper": 11.302,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "fruquintinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT02246621",
    "brief_title": "A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2014-11-06",
    "completion_date": "2017-01-31",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT02246621",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Hormone receptor-positive (ER and/or PR)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": null
      }
    ],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Abemaciclib + NSAI",
        "value": 28.18,
        "unit": "Months",
        "ci_lower": 23.51,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + NSAI",
        "value": 14.76,
        "unit": "Months",
        "ci_lower": 11.24,
        "ci_upper": 19.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Abemaciclib",
        "Anastrozole",
        "Letrozole"
      ],
      "OG001": [
        "Anastrozole",
        "Letrozole"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT02260440",
    "brief_title": "A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2015-01",
    "completion_date": "2016-03",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Anuradha Krishnamurthy",
    "url": "https://clinicaltrials.gov/study/NCT02260440",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab and Azacitidine",
        "value": 3.0,
        "unit": "percentage of participants",
        "ci_lower": 1.0,
        "ci_upper": 17.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab and Azacitidine",
        "value": 2.1,
        "unit": "months",
        "ci_lower": 1.8,
        "ci_upper": 2.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab and Azacitidine",
        "value": 6.2,
        "unit": "months",
        "ci_lower": 3.5,
        "ci_upper": 8.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Azacitidine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT02220894",
    "brief_title": "Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)",
    "status": "COMPLETED",
    "start_date": "2014-10-30",
    "completion_date": "2018-09-04",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT02220894",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "POSITIVE",
        "details": "Tumor PD-L1 expression positive; tumor tissue submitted and assessed by central laboratory; no threshold specified"
      },
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "EGFR-sensitizing mutation must be absent"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "EML4-ALK gene fusion must be absent"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab",
        "value": 20.0,
        "unit": "Months",
        "ci_lower": 15.9,
        "ci_upper": 24.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy (SOC Treatment)",
        "value": 12.2,
        "unit": "Months",
        "ci_lower": 10.4,
        "ci_upper": 14.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab",
        "value": 6.5,
        "unit": "Months",
        "ci_lower": 5.9,
        "ci_upper": 8.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Chemotherapy (SOC Treatment)",
        "value": 6.4,
        "unit": "Months",
        "ci_lower": 6.2,
        "ci_upper": 7.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "pembrolizumab"
      ],
      "OG001": [
        "carboplatin",
        "paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT02204072",
    "brief_title": "BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)",
    "status": "COMPLETED",
    "start_date": "2014-11-11",
    "completion_date": "2019-10-18",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Boehringer Ingelheim",
    "url": "https://clinicaltrials.gov/study/NCT02204072",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "IV"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [],
    "arm_drugs": {
      "OG000": [
        "BI 836845",
        "Enzalutamide"
      ],
      "OG001": [
        "BI 836845",
        "Enzalutamide"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02252042",
    "brief_title": "Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)",
    "status": "COMPLETED",
    "start_date": "2014-11-17",
    "completion_date": "2017-05-15",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT02252042",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Tumor tissue available for PD-L1 biomarker analysis"
      }
    ],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab",
        "value": 8.4,
        "unit": "Months",
        "ci_lower": 6.5,
        "ci_upper": 9.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Standard Treatment",
        "value": 7.1,
        "unit": "Months",
        "ci_lower": 5.9,
        "ci_upper": 8.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab"
      ],
      "OG001": [
        "Methotrexate",
        "Docetaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT02264990",
    "brief_title": "Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers",
    "status": "COMPLETED",
    "start_date": "2014-09-30",
    "completion_date": "2019-11-14",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AbbVie",
    "url": "https://clinicaltrials.gov/study/NCT02264990",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "untreated exon 19 deletion or L858R mutation (exon 21)"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "known gene rearrangement"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Investigator's Choice Chemotherapy",
        "value": 12.1,
        "unit": "months",
        "ci_lower": 10.0,
        "ci_upper": 13.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Veliparib + Carboplatin + Paclitaxel",
        "value": 12.1,
        "unit": "months",
        "ci_lower": 10.4,
        "ci_upper": 14.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Investigator's Choice Chemotherapy",
        "value": 6.7,
        "unit": "months",
        "ci_lower": 5.6,
        "ci_upper": 7.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Veliparib + Carboplatin + Paclitaxel",
        "value": 5.9,
        "unit": "months",
        "ci_lower": 5.0,
        "ci_upper": 6.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Carboplatin",
        "Paclitaxel",
        "Cisplatin",
        "Pemetrexed"
      ],
      "OG001": [
        "Veliparib",
        "Carboplatin",
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02187783",
    "brief_title": "LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)",
    "status": "COMPLETED",
    "start_date": "2014-08-25",
    "completion_date": "2018-01-17",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT02187783",
    "cancer_types": [
      "BRCA",
      "NSCLC",
      "SKCM"
    ],
    "biomarkers": [
      {
        "target": "CDK4",
        "status": "POSITIVE",
        "details": "amplification or mutation"
      },
      {
        "target": "CDK6",
        "status": "POSITIVE",
        "details": "amplification or mutation"
      },
      {
        "target": "CCND1",
        "status": "POSITIVE",
        "details": "amplification"
      },
      {
        "target": "CCND3",
        "status": "POSITIVE",
        "details": "amplification"
      },
      {
        "target": "CDKN2A",
        "status": "POSITIVE",
        "details": "mutation (p16)"
      }
    ],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Ribociclib 600 mg",
        "value": 3.0,
        "unit": "participant",
        "ci_lower": 0.6,
        "ci_upper": 8.1,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ribociclib (LEE011)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02260531",
    "brief_title": "Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases",
    "status": "COMPLETED",
    "start_date": "2014-11",
    "completion_date": "2019-01-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Dana-Farber Cancer Institute",
    "url": "https://clinicaltrials.gov/study/NCT02260531",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1 - Cabozantinib, Trastuzumab for HER2+",
        "value": 4.1,
        "unit": "Months",
        "ci_lower": 2.8,
        "ci_upper": 6.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort 2 - Cabozantinib for ER+ and/or PR+",
        "value": 0.8,
        "unit": "Months",
        "ci_lower": 0.5,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Cohort 3 - Cabozantinib for ER-, PR-, HER2-",
        "value": 2.4,
        "unit": "Months",
        "ci_lower": 2.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1 - Cabozantinib, Trastuzumab for HER2+",
        "value": 13.8,
        "unit": "Months",
        "ci_lower": 8.2,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cohort 2 - Cabozantinib for ER+ and/or PR+",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Cohort 3 - Cabozantinib for ER-, PR-, HER2-",
        "value": 5.1,
        "unit": "Months",
        "ci_lower": 2.1,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cabozantinib",
        "Trastuzumab"
      ],
      "OG001": [
        "Cabozantinib"
      ],
      "OG002": [
        "Cabozantinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Targeted",
      "OG001": "TKI",
      "OG002": "TKI"
    }
  },
  {
    "nct_id": "NCT02276027",
    "brief_title": "A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2015-01-20",
    "completion_date": "2019-10-15",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT02276027",
    "cancer_types": [
      "NSCLC",
      "LUAD",
      "LUSC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IIIB",
      "IV"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "BYL719 350 mg QD",
        "value": 0.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "INC280 400 mg BID Tab/600 mg BID Cap",
        "value": 3.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "LDK378 750 mg QD",
        "value": 19.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "MEK162 45 mg BID",
        "value": 2.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "BYL719 350 mg QD",
        "value": 4.99,
        "unit": "Months",
        "ci_lower": 0.3,
        "ci_upper": 9.69,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "INC280 400 mg BID Tab/600 mg BID Cap",
        "value": 13.26,
        "unit": "Months",
        "ci_lower": 1.18,
        "ci_upper": 23.33,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "LDK378 750 mg QD",
        "value": null,
        "unit": "Months",
        "ci_lower": 19.35,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "MEK162 45 mg BID",
        "value": 9.2,
        "unit": "Months",
        "ci_lower": 3.52,
        "ci_upper": 11.93,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "BYL719 350 mg QD",
        "value": 2.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "INC280 400 mg BID Tab/600 mg BID Cap",
        "value": 16.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "LDK378 750 mg QD",
        "value": 19.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "MEK162 45 mg BID",
        "value": 19.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "BYL719"
      ],
      "OG001": [
        "INC280"
      ],
      "OG002": [
        "LDK378"
      ],
      "OG003": [
        "MEK162"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "TKI",
      "OG002": "TKI",
      "OG003": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02236000",
    "brief_title": "A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2014-08",
    "completion_date": "2020-12",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "NSABP Foundation Inc",
    "url": "https://clinicaltrials.gov/study/NCT02236000",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER2-positive by local testing per ASCO-CAP HER2 test guidelines"
      },
      {
        "target": "ER",
        "status": "ANY",
        "details": "ER analysis must be performed prior to study entry; eligible regardless of ER status"
      },
      {
        "target": "PGR",
        "status": "ANY",
        "details": "PgR analysis required only if ER analysis is negative; eligible regardless of PgR status"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "IV"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Neratinib and T-DM1",
        "value": 31.8,
        "unit": "percentage of participants",
        "ci_lower": 15.99,
        "ci_upper": 51.55,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Neratinib",
        "T-DM1"
      ],
      "OG001": [
        "Neratinib",
        "T-DM1"
      ],
      "OG002": [
        "Neratinib",
        "T-DM1"
      ],
      "OG003": [
        "Neratinib",
        "T-DM1"
      ],
      "OG004": [
        "Neratinib",
        "T-DM1"
      ],
      "OG005": [
        "Neratinib",
        "T-DM1"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Targeted",
      "OG001": "Combo_TKI_Targeted",
      "OG002": "Combo_TKI_Targeted",
      "OG003": "Combo_TKI_Targeted",
      "OG004": "Combo_TKI_Targeted",
      "OG005": "Combo_TKI_Targeted"
    }
  },
  {
    "nct_id": "NCT02256436",
    "brief_title": "A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)",
    "status": "COMPLETED",
    "start_date": "2014-10-22",
    "completion_date": "2016-09-07",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT02256436",
    "cancer_types": [
      "BLCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Control",
        "value": 3.3,
        "unit": "Months",
        "ci_lower": 2.3,
        "ci_upper": 3.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Pembrolizumab",
        "value": 2.1,
        "unit": "Months",
        "ci_lower": 2.0,
        "ci_upper": 2.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Control",
        "value": 7.4,
        "unit": "Months",
        "ci_lower": 6.1,
        "ci_upper": 8.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Pembrolizumab",
        "value": 10.3,
        "unit": "Months",
        "ci_lower": 8.0,
        "ci_upper": 11.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "paclitaxel",
        "docetaxel",
        "vinflunine"
      ],
      "OG001": [
        "pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "IO"
    }
  },
  {
    "nct_id": "NCT02163694",
    "brief_title": "A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2014-04-08",
    "completion_date": "2019-04-05",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AbbVie",
    "url": "https://clinicaltrials.gov/study/NCT02163694",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "BRCA1",
        "status": "POSITIVE",
        "details": "Germline deleterious or suspected deleterious BRCA1 mutation"
      },
      {
        "target": "BRCA2",
        "status": "POSITIVE",
        "details": "Germline deleterious or suspected deleterious BRCA2 mutation"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-negative required"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Placebo + C/P",
        "value": 12.6,
        "unit": "Months",
        "ci_lower": 10.6,
        "ci_upper": 14.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Veliparib + C/P",
        "value": 14.6,
        "unit": "Months",
        "ci_lower": 12.5,
        "ci_upper": 17.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Placebo + C/P",
        "value": 28.2,
        "unit": "Months",
        "ci_lower": 24.7,
        "ci_upper": 32.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Veliparib + C/P",
        "value": 32.4,
        "unit": "Months",
        "ci_lower": 27.4,
        "ci_upper": 38.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Carboplatin",
        "Paclitaxel"
      ],
      "OG001": [
        "Veliparib",
        "Carboplatin",
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02272790",
    "brief_title": "Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
    "status": "COMPLETED",
    "start_date": "2015-01-30",
    "completion_date": "2018-12-13",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT02272790",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "III",
      "IV",
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Arm A",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Arm B",
        "value": 11.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Arm C",
        "value": 7.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Arm C2",
        "value": 8.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Arm D-175 mg",
        "value": 2.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "Arm D-225 mg",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm A",
        "value": 1.7,
        "unit": "Months",
        "ci_lower": 1.6,
        "ci_upper": 5.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B",
        "value": 5.5,
        "unit": "Months",
        "ci_lower": 3.8,
        "ci_upper": 7.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Arm C",
        "value": 4.2,
        "unit": "Months",
        "ci_lower": 3.9,
        "ci_upper": 5.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Arm C2",
        "value": 12.0,
        "unit": "Months",
        "ci_lower": 8.6,
        "ci_upper": 13.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Arm D-175 mg",
        "value": 2.7,
        "unit": "Months",
        "ci_lower": 1.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG005",
        "arm_title": "Arm D-225 mg",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm A",
        "value": 16.0,
        "unit": "Months",
        "ci_lower": 6.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B",
        "value": null,
        "unit": "Months",
        "ci_lower": 15.6,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Arm C",
        "value": 8.9,
        "unit": "Months",
        "ci_lower": 8.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Arm C2",
        "value": 19.2,
        "unit": "Months",
        "ci_lower": 12.4,
        "ci_upper": 19.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG004",
        "arm_title": "Arm D-175 mg",
        "value": 3.8,
        "unit": "Months",
        "ci_lower": 2.0,
        "ci_upper": 6.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG005",
        "arm_title": "Arm D-225 mg",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Adavosertib",
        "Gemcitabine"
      ],
      "OG001": [
        "Adavosertib",
        "Paclitaxel"
      ],
      "OG002": [
        "Adavosertib",
        "Carboplatin"
      ],
      "OG003": [
        "Adavosertib",
        "Carboplatin"
      ],
      "OG004": [
        "Adavosertib",
        "PLD"
      ],
      "OG005": [
        "Adavosertib",
        "PLD"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted",
      "OG003": "Combo_Chemo_Targeted",
      "OG004": "Combo_Chemo_Targeted",
      "OG005": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02240238",
    "brief_title": "Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer",
    "status": "COMPLETED",
    "start_date": "2014-05",
    "completion_date": "2019-05-06",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "NanoCarrier Co., Ltd.",
    "url": "https://clinicaltrials.gov/study/NCT02240238",
    "cancer_types": [
      "NSCLC",
      "BLCA",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Not known to be PD-L1 positive; known high PD-L1 expression defined as TPS \u226550% is excluded"
      },
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "Known sensitizing EGFR mutation \u2014 if present, patient must have received 1 to 2 prior targeted therapies before enrollment"
      },
      {
        "target": "ALK",
        "status": "ANY",
        "details": "Known ALK fusion oncogene \u2014 if present, patient must have received 1 to 2 prior targeted therapies before enrollment"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase 2 Cohort 1 (NSCLC)",
        "value": 116.0,
        "unit": "days",
        "ci_lower": 84.0,
        "ci_upper": 182.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Phase 2 Cohort 2 (Biliary Tract Cancer)",
        "value": 128.0,
        "unit": "days",
        "ci_lower": 86.0,
        "ci_upper": 181.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Phase 2 Cohort 3 (Bladder Cancer)",
        "value": 204.0,
        "unit": "days",
        "ci_lower": 130.0,
        "ci_upper": 233.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Phase 2 Cohort 1 (NSCLC)",
        "value": 275.0,
        "unit": "days",
        "ci_lower": 119.0,
        "ci_upper": 366.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Phase 2 Cohort 2 (Biliary Tract Cancer)",
        "value": 350.0,
        "unit": "days",
        "ci_lower": 262.0,
        "ci_upper": 497.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Phase 2 Cohort 3 (Bladder Cancer)",
        "value": 316.0,
        "unit": "days",
        "ci_lower": 196.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "NC-6004",
        "Gemcitabine"
      ],
      "OG001": [
        "NC-6004",
        "Gemcitabine"
      ],
      "OG002": [
        "NC-6004",
        "Gemcitabine"
      ],
      "OG003": [
        "NC-6004",
        "Gemcitabine"
      ],
      "OG004": [
        "NC-6004",
        "Gemcitabine"
      ],
      "OG005": [
        "NC-6004",
        "Gemcitabine"
      ],
      "OG006": [
        "NC-6004",
        "Gemcitabine"
      ],
      "OG007": [
        "NC-6004",
        "Gemcitabine"
      ],
      "OG008": [
        "NC-6004",
        "Gemcitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo",
      "OG002": "Chemo",
      "OG003": "Chemo",
      "OG004": "Chemo",
      "OG005": "Chemo",
      "OG006": "Chemo",
      "OG007": "Chemo",
      "OG008": "Chemo"
    }
  },
  {
    "nct_id": "NCT02178722",
    "brief_title": "Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers",
    "status": "COMPLETED",
    "start_date": "2014-07-17",
    "completion_date": "2018-11-26",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Incyte Corporation",
    "url": "https://clinicaltrials.gov/study/NCT02178722",
    "cancer_types": [
      "CRC",
      "UCEC",
      "HNSC"
    ],
    "biomarkers": [
      {
        "target": "BRAF",
        "status": "POSITIVE",
        "details": "V600E-activating BRAF mutation (documentation required)"
      },
      {
        "target": "MSI",
        "status": "HIGH",
        "details": "MSI-high status as determined on CRC tumor"
      },
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "Estrogen receptor negative (required for triple negative breast cancer)"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "Progesterone receptor (PgR) negative (required for triple negative breast cancer)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 negative as per ASCO/CAP guidelines (required for triple negative breast cancer)"
      }
    ],
    "cancer_stages": [
      "I",
      "II",
      "III",
      "IV",
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [],
    "arm_drugs": {
      "OG000": [
        "INCB024360",
        "MK-3475"
      ],
      "OG001": [
        "INCB024360",
        "MK-3475"
      ],
      "OG002": [
        "INCB024360",
        "MK-3475"
      ],
      "OG003": [
        "INCB024360",
        "MK-3475"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted",
      "OG002": "Combo_IO_Targeted",
      "OG003": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT02282020",
    "brief_title": "Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments",
    "status": "COMPLETED",
    "start_date": "2015-02-06",
    "completion_date": "2018-10-10",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT02282020",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "BRCA1",
        "status": "POSITIVE",
        "details": "Germline BRCA1 mutation predicted or suspected to be deleterious (loss-of-function)"
      },
      {
        "target": "BRCA2",
        "status": "POSITIVE",
        "details": "Germline BRCA2 mutation predicted or suspected to be deleterious (loss-of-function)"
      }
    ],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Olaparib 300 mg BID",
        "value": 109.0,
        "unit": "Count of Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Single Agent Chemotherapy",
        "value": 37.0,
        "unit": "Count of Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "OLAPARIB"
      ],
      "OG001": [
        "Paclitaxel",
        "Topotecan",
        "Pegylated liposomal doxorubicin",
        "Gemcitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT02318784",
    "brief_title": "Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers",
    "status": "COMPLETED",
    "start_date": "2015-07-15",
    "completion_date": "2021-05-15",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SCRI Development Innovations, LLC",
    "url": "https://clinicaltrials.gov/study/NCT02318784",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Carfilzomib",
        "value": 3.226,
        "unit": "percentage of participants",
        "ci_lower": 0.4,
        "ci_upper": 11.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Carfilzomib",
        "value": 8.0,
        "unit": "months",
        "ci_lower": 2.9,
        "ci_upper": 11.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Carfilzomib"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER"
    }
  },
  {
    "nct_id": "NCT02317991",
    "brief_title": "Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer",
    "status": "COMPLETED",
    "start_date": "2015-05-05",
    "completion_date": "2021-05-21",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SCRI Development Innovations, LLC",
    "url": "https://clinicaltrials.gov/study/NCT02317991",
    "cancer_types": [
      "STAD",
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Nab-paclitaxel and Ramucirumab",
        "value": 3.8,
        "unit": "months",
        "ci_lower": 3.4,
        "ci_upper": 5.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Nab-paclitaxel and Ramucirumab",
        "value": 8.0,
        "unit": "months",
        "ci_lower": 6.4,
        "ci_upper": 10.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "nab-paclitaxel",
        "ramucirumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02318277",
    "brief_title": "A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)",
    "status": "COMPLETED",
    "start_date": "2015-01-05",
    "completion_date": "2019-08-28",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Incyte Corporation",
    "url": "https://clinicaltrials.gov/study/NCT02318277",
    "cancer_types": [
      "HNSC",
      "NSCLC",
      "BLCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase II : Epacadostat (100 mg) + Durvalumab (10 mg/kg)",
        "value": 6.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Phase II : Epacadostat (300 mg) + Durvalumab (10 mg/kg)",
        "value": 12.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Epacadostat",
        "Durvalumab"
      ],
      "OG001": [
        "Epacadostat",
        "Durvalumab"
      ],
      "OG002": [
        "Epacadostat",
        "Durvalumab"
      ],
      "OG003": [
        "Epacadostat",
        "Durvalumab"
      ],
      "OG004": [
        "Epacadostat",
        "Durvalumab"
      ],
      "OG005": [
        "Epacadostat",
        "Durvalumab"
      ],
      "OG006": [
        "Epacadostat",
        "Durvalumab"
      ],
      "OG007": [
        "Epacadostat",
        "Durvalumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted",
      "OG002": "Combo_IO_Targeted",
      "OG003": "Combo_IO_Targeted",
      "OG004": "Combo_IO_Targeted",
      "OG005": "Combo_IO_Targeted",
      "OG006": "Combo_IO_Targeted",
      "OG007": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT02289950",
    "brief_title": "A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer",
    "status": "COMPLETED",
    "start_date": "2015-03-19",
    "completion_date": "2019-05-31",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eisai Inc.",
    "url": "https://clinicaltrials.gov/study/NCT02289950",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "CA125",
        "status": "LOW",
        "details": "\u22643 x ULN (\u2264105 U/mL) confirmed within 2 weeks of randomization using a centralized laboratory assay"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Farletuzumab 5 mg/kg + Carboplatin/Paclitaxel or Carboplatin/PLD",
        "value": 11.73,
        "unit": "Months",
        "ci_lower": 10.22,
        "ci_upper": 13.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Carboplatin/Paclitaxel or Carboplatin/PLD",
        "value": 10.78,
        "unit": "Months",
        "ci_lower": 9.49,
        "ci_upper": 13.17,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Farletuzumab 5 mg/kg + Carboplatin/Paclitaxel or Carboplatin/PLD",
        "value": 43.07,
        "unit": "Months",
        "ci_lower": 37.13,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Carboplatin/Paclitaxel or Carboplatin/PLD",
        "value": 42.45,
        "unit": "Months",
        "ci_lower": 37.85,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Farletuzumab",
        "Carboplatin",
        "Paclitaxel",
        "PLD"
      ],
      "OG001": [
        "Carboplatin",
        "Paclitaxel",
        "PLD"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT02288247",
    "brief_title": "A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone",
    "status": "COMPLETED",
    "start_date": "2014-12-01",
    "completion_date": "2020-04-30",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Astellas Pharma Europe Ltd.",
    "url": "https://clinicaltrials.gov/study/NCT02288247",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [
      {
        "target": "PSA",
        "status": "ANY",
        "details": "PSA progression defined as a minimum of three rising PSA levels with an interval of \u22651 week between each determination."
      },
      {
        "target": "TESTOSTERONE",
        "status": "LOW",
        "details": "Castrate levels of testosterone (ongoing ADT with LHRH agonist/antagonist or bilateral orchiectomy)."
      },
      {
        "target": "NEUROENDOCRINE",
        "status": "NEGATIVE",
        "details": "Histology must be adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features."
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Enzalutamide",
        "value": 9.53,
        "unit": "months",
        "ci_lower": 8.25,
        "ci_upper": 10.87,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 8.28,
        "unit": "months",
        "ci_lower": 6.28,
        "ci_upper": 8.71,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Enzalutamide"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT02297438",
    "brief_title": "A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]",
    "status": "COMPLETED",
    "start_date": "2015-03-23",
    "completion_date": "2020-08-31",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT02297438",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Estrogen receptor positive (ER+)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "No HER2 positive disease (HER2 negative)"
      }
    ],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Palbociclib + Letrozole",
        "value": 21.5,
        "unit": "Months",
        "ci_lower": 16.6,
        "ci_upper": 24.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Letrozole",
        "value": 13.9,
        "unit": "Months",
        "ci_lower": 13.7,
        "ci_upper": 16.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Palbociclib + Letrozole",
        "value": 51.7,
        "unit": "Months",
        "ci_lower": 43.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Letrozole",
        "value": 51.5,
        "unit": "Months",
        "ci_lower": 41.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Palbociclib",
        "Letrozole"
      ],
      "OG001": [
        "Letrozole"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02325739",
    "brief_title": "FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression",
    "status": "COMPLETED",
    "start_date": "2014-12-29",
    "completion_date": "2019-05-30",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT02325739",
    "cancer_types": [
      "LIHC",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "FGFR4",
        "status": "POSITIVE",
        "details": "positive FGFR4 expression"
      },
      {
        "target": "KLB",
        "status": "POSITIVE",
        "details": "positive KLB expression"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": true,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "PhaseII: Group 3 - FGF401 120 mg QD",
        "value": 0.0,
        "unit": "Percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 16.8,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "FGF401"
      ],
      "OG001": [
        "FGF401"
      ],
      "OG002": [
        "FGF401"
      ],
      "OG003": [
        "FGF401"
      ],
      "OG004": [
        "FGF401"
      ],
      "OG005": [
        "FGF401"
      ],
      "OG006": [
        "FGF401",
        "PDR001"
      ],
      "OG007": [
        "FGF401",
        "PDR001"
      ],
      "OG008": [
        "FGF401"
      ],
      "OG009": [
        "FGF401"
      ],
      "OG010": [
        "FGF401"
      ],
      "OG011": [
        "FGF401",
        "PDR001"
      ],
      "OG012": [
        "FGF401",
        "PDR001"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI",
      "OG002": "TKI",
      "OG003": "TKI",
      "OG004": "TKI",
      "OG005": "TKI",
      "OG006": "Combo_TKI_IO",
      "OG007": "Combo_TKI_IO",
      "OG008": "TKI",
      "OG009": "TKI",
      "OG010": "TKI",
      "OG011": "Combo_TKI_IO",
      "OG012": "Combo_TKI_IO",
      "OG013": "OTHER"
    }
  },
  {
    "nct_id": "NCT02296125",
    "brief_title": "AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2014-12-03",
    "completion_date": "2017-06-19",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT02296125",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "Exon 19 deletion (Ex19del) or L858R substitution"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Osimertinib 80 mg (Global Cohort)",
        "value": 18.9,
        "unit": "Months",
        "ci_lower": 15.2,
        "ci_upper": 21.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "SoC EGFR-TKI (Global Cohort)",
        "value": 10.2,
        "unit": "Months",
        "ci_lower": 9.6,
        "ci_upper": 11.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Osimertinib 80 mg (China Cohort)",
        "value": 17.8,
        "unit": "Months",
        "ci_lower": 13.6,
        "ci_upper": 20.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "SoC EGFR-TKI (China Cohort)",
        "value": 9.8,
        "unit": "Months",
        "ci_lower": 8.3,
        "ci_upper": 13.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Osimertinib"
      ],
      "OG001": [
        "Gefitinib",
        "Erlotinib"
      ],
      "OG002": [
        "Osimertinib"
      ],
      "OG003": [
        "Gefitinib",
        "Erlotinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI",
      "OG002": "TKI",
      "OG003": "TKI"
    }
  },
  {
    "nct_id": "NCT02302807",
    "brief_title": "A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]",
    "status": "COMPLETED",
    "start_date": "2015-01-13",
    "completion_date": "2017-03-13",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT02302807",
    "cancer_types": [
      "BLCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "IC2/3 Chemotherapy",
        "value": 10.6,
        "unit": "Months",
        "ci_lower": 8.4,
        "ci_upper": 12.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "IC2/3 Atezolizumab",
        "value": 11.1,
        "unit": "Months",
        "ci_lower": 8.6,
        "ci_upper": 15.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "IC1/2/3 Chemotherapy",
        "value": 8.2,
        "unit": "Months",
        "ci_lower": 7.4,
        "ci_upper": 9.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "IC1/2/3 Atezolizumab",
        "value": 8.9,
        "unit": "Months",
        "ci_lower": 8.2,
        "ci_upper": 10.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG004",
        "arm_title": "Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)",
        "value": 8.0,
        "unit": "Months",
        "ci_lower": 7.2,
        "ci_upper": 8.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG005",
        "arm_title": "Atezolizumab",
        "value": 8.6,
        "unit": "Months",
        "ci_lower": 7.8,
        "ci_upper": 9.6,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Vinflunine",
        "Paclitaxel",
        "Docetaxel"
      ],
      "OG001": [
        "Atezolizumab"
      ],
      "OG002": [
        "Vinflunine",
        "Paclitaxel",
        "Docetaxel"
      ],
      "OG003": [
        "Atezolizumab"
      ],
      "OG004": [
        "Vinflunine",
        "Paclitaxel",
        "Docetaxel"
      ],
      "OG005": [
        "Atezolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "IO",
      "OG002": "Chemo",
      "OG003": "IO",
      "OG004": "Chemo",
      "OG005": "IO"
    }
  },
  {
    "nct_id": "NCT02311933",
    "brief_title": "Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2015-05-28",
    "completion_date": "2020-11-06",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT02311933",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": ">= 10% nuclear staining (estrogen receptor positive)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 negative per 2013 ASCO/CAP guidelines (e.g., IHC 0-1+ and not amplified by ISH; 2+ not amplified by ISH; or IHC not done and not amplified by ISH)"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm I (Z-endoxifen Hydrochloride)",
        "value": 130.0,
        "unit": "days",
        "ci_lower": 76.0,
        "ci_upper": 138.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm II (Tamoxifen Citrate)",
        "value": 42.0,
        "unit": "days",
        "ci_lower": 24.0,
        "ci_upper": 129.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Endoxifen Hydrochloride"
      ],
      "OG001": [
        "Tamoxifen Citrate"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT02304367",
    "brief_title": "Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)",
    "status": "COMPLETED",
    "start_date": "2015-03-24",
    "completion_date": "2017-07-27",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Kyowa Kirin, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT02304367",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "FGF23",
        "status": "HIGH",
        "details": "FGF23 \u2265 100 pg/mL by Kainos assay"
      },
      {
        "target": "Phosphorus",
        "status": "LOW",
        "details": "Fasting serum phosphorus < 2.5 mg/dL"
      },
      {
        "target": "TmP/GFR",
        "status": "LOW",
        "details": "TmP/GFR (renal tubular maximum reabsorption rate of phosphate to GFR) < 2.5 mg/dL"
      },
      {
        "target": "eGFR",
        "status": "ANY",
        "details": "Estimated glomerular filtration rate (eGFR) \u2265 60 mL/min by Cockcroft-Gault; subjects with eGFR \u2265 30 and < 60 mL/min may be eligible if decline in renal function is not related to nephrocalcinosis (investigator judgment)"
      },
      {
        "target": "Calcium",
        "status": "LOW",
        "details": "Corrected serum calcium < 10.8 mg/dL"
      },
      {
        "target": "Pregnancy",
        "status": "NEGATIVE",
        "details": "Negative urine pregnancy test at Screening and Baseline; females of child-bearing potential must use effective contraception during study and for 12 weeks after last dose"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [],
    "arm_drugs": {
      "OG000": [
        "Burosumab"
      ],
      "OG001": [
        "Burosumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02305758",
    "brief_title": "Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2014-12-02",
    "completion_date": "2017-09-22",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AbbVie",
    "url": "https://clinicaltrials.gov/study/NCT02305758",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Veliparib + Modified FOLFIRI \u0000b1 Bevacizumab",
        "value": 361.0,
        "unit": "days",
        "ci_lower": 289.0,
        "ci_upper": 453.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + FOLFIRI \u0000b1 Bevacizumab",
        "value": 337.0,
        "unit": "days",
        "ci_lower": 233.0,
        "ci_upper": 421.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Veliparib + Modified FOLFIRI \u0000b1 Bevacizumab",
        "value": 770.0,
        "unit": "days",
        "ci_lower": 609.0,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + FOLFIRI \u0000b1 Bevacizumab",
        "value": 811.0,
        "unit": "days",
        "ci_lower": 678.0,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Veliparib",
        "Modified FOLFIRI",
        "Bevacizumab"
      ],
      "OG001": [
        "FOLFIRI",
        "Bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02316002",
    "brief_title": "Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2015-01-21",
    "completion_date": "2018-09-30",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Abramson Cancer Center at Penn Medicine",
    "url": "https://clinicaltrials.gov/study/NCT02316002",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Provision of tumor tissue (FFPE) for PD-L1 immunohistochemistry; recommended fresh sectioning within 7 days and fixation 24\u201348 hours"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab",
        "value": 19.1,
        "unit": "Months",
        "ci_lower": 9.4,
        "ci_upper": 28.7,
        "dispersion_type": "MEAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO"
    }
  },
  {
    "nct_id": "NCT02329847",
    "brief_title": "A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies",
    "status": "COMPLETED",
    "start_date": "2015-03-11",
    "completion_date": "2022-02-09",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Janssen Research & Development, LLC",
    "url": "https://clinicaltrials.gov/study/NCT02329847",
    "cancer_types": [
      "DLBC",
      "LAML"
    ],
    "biomarkers": [
      {
        "target": "17p",
        "status": "POSITIVE",
        "details": "Deletion of short arm of chromosome 17 based on institutional assessment"
      },
      {
        "target": "11q",
        "status": "POSITIVE",
        "details": "Deletion of 11q based on institutional assessment"
      },
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "Known history of Human Immunodeficiency Virus (HIV) is exclusionary"
      },
      {
        "target": "HBV",
        "status": "NEGATIVE",
        "details": "Known history of Hepatitis B is exclusionary"
      },
      {
        "target": "HCV",
        "status": "NEGATIVE",
        "details": "Known history of Hepatitis C is exclusionary"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Ibrutinib and Nivolumab: Chronic Lymphocytic Leukemia (CLL)",
        "value": 63.3,
        "unit": "Percentage of Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg",
        "value": 2.0,
        "unit": "Months",
        "ci_lower": 1.1,
        "ci_upper": 24.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg",
        "value": 9.1,
        "unit": "Months",
        "ci_lower": 0.7,
        "ci_upper": 20.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg",
        "value": 21.6,
        "unit": "Months",
        "ci_lower": 12.0,
        "ci_upper": 21.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg",
        "value": 7.6,
        "unit": "Months",
        "ci_lower": 2.9,
        "ci_upper": 12.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg",
        "value": 3.2,
        "unit": "Months",
        "ci_lower": 2.1,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG005",
        "arm_title": "Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg",
        "value": 5.0,
        "unit": "Months",
        "ci_lower": 2.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg",
        "value": 12.4,
        "unit": "Months",
        "ci_lower": 2.0,
        "ci_upper": 28.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg",
        "value": null,
        "unit": "Months",
        "ci_lower": 0.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg",
        "value": null,
        "unit": "Months",
        "ci_lower": 21.6,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG004",
        "arm_title": "Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg",
        "value": 19.0,
        "unit": "Months",
        "ci_lower": 7.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG005",
        "arm_title": "Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg",
        "value": 10.3,
        "unit": "Months",
        "ci_lower": 4.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ibrutinib",
        "Nivolumab"
      ],
      "OG001": [
        "Ibrutinib",
        "Nivolumab"
      ],
      "OG002": [
        "Ibrutinib",
        "Nivolumab"
      ],
      "OG003": [
        "Ibrutinib",
        "Nivolumab"
      ],
      "OG004": [
        "Ibrutinib",
        "Nivolumab"
      ],
      "OG005": [
        "Ibrutinib",
        "Nivolumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_IO",
      "OG001": "Combo_TKI_IO",
      "OG002": "Combo_TKI_IO",
      "OG003": "Combo_TKI_IO",
      "OG004": "Combo_TKI_IO",
      "OG005": "Combo_TKI_IO"
    }
  },
  {
    "nct_id": "NCT02297698",
    "brief_title": "Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients",
    "status": "COMPLETED",
    "start_date": "2014-10",
    "completion_date": "2021-12",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Cancer Insight, LLC",
    "url": "https://clinicaltrials.gov/study/NCT02297698",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER2-positive per ASCO-CAP guidelines"
      },
      {
        "target": "HLA-A",
        "status": "POSITIVE",
        "details": "Presence of HLA\u2011A allele A2, A3, A24 or A26 (HLA-A2+ or HLA-A3+ or HLA-A24+ or HLA-A26+)"
      },
      {
        "target": "HORMONE_RECEPTOR",
        "status": "NEGATIVE",
        "details": "Required for eligibility when patient has 1\u20133 positive lymph nodes (pN1); patients with \u22654 positive nodes are eligible regardless of hormone receptor status"
      }
    ],
    "cancer_stages": [
      "I",
      "II",
      "III"
    ],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [],
    "arm_drugs": {
      "OG000": [
        "Trastuzumab",
        "NeuVax vaccine"
      ],
      "OG001": [
        "Trastuzumab",
        "GM-CSF"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02327078",
    "brief_title": "A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)",
    "status": "COMPLETED",
    "start_date": "2014-11-26",
    "completion_date": "2020-06-16",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Incyte Corporation",
    "url": "https://clinicaltrials.gov/study/NCT02327078",
    "cancer_types": [
      "SKCM",
      "DLBC",
      "HNSC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 2: Epacadostat 100 mg + Nivolumab 240 in Colorectal Cancer",
        "value": 3.8,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Phase 2: Epacadostat 300 mg + Nivolumab 240 mg in DLBCL",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Phase 2: Epacadostat 100/300 mg + Nivolumab 240 mg in Melanoma(I/O Naive)",
        "value": 62.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Phase 2 Epacadostat 100mg + Nivolumab 480 mg in Melanoma (I/O Relapsed)",
        "value": 28.6,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Phase 2 Epacadostat 100mg + Nivolumab 480 mg in Melanoma (I/O Refractory)",
        "value": 28.6,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "Phase 2 Epacadostat 100/300 mg + Nivolumab 240 mg in NSCLC",
        "value": 20.7,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG006",
        "arm_title": "Phase 2 Epacadostat 100/300 mg + Nivolumab 240 mg in Ovarian Cancer",
        "value": 13.8,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG007",
        "arm_title": "Phase 2 Epacadostat 100/300 mg + Nivolumab 240 mg in SCCHN",
        "value": 25.8,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG008",
        "arm_title": "Phase 2 Epacadostat 100/300 mg + Nivolumab 240 mg in Glioblastoma",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase 2: Epacadostat 100 mg + Nivolumab 240 in Colorectal Cancer",
        "value": 1.78,
        "unit": "months",
        "ci_lower": 1.74,
        "ci_upper": 1.81,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Phase 2: Epacadostat 300 mg + Nivolumab 240 mg in DLBCL",
        "value": 1.64,
        "unit": "months",
        "ci_lower": 1.35,
        "ci_upper": 3.52,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Phase 2: Epacadostat 100/300 mg + Nivolumab 240 mg in Melanoma(I/O Naive)",
        "value": null,
        "unit": "months",
        "ci_lower": 9.51,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Phase 2 Epacadostat 100mg + Nivolumab 480 mg in Melanoma (I/O Relapsed)",
        "value": 1.76,
        "unit": "months",
        "ci_lower": 0.46,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Phase 2 Epacadostat 100mg + Nivolumab 480 mg in Melanoma (I/O Refractory)",
        "value": 2.55,
        "unit": "months",
        "ci_lower": 0.59,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG005",
        "arm_title": "Phase 2 Epacadostat 100/300 mg + Nivolumab 240 mg in NSCLC",
        "value": 1.88,
        "unit": "months",
        "ci_lower": 1.78,
        "ci_upper": 2.04,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG006",
        "arm_title": "Phase 2 Epacadostat 100/300 mg + Nivolumab 240 mg in Ovarian Cancer",
        "value": 1.88,
        "unit": "months",
        "ci_lower": 1.68,
        "ci_upper": 3.52,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG007",
        "arm_title": "Phase 2 Epacadostat 100/300 mg + Nivolumab 240 mg in SCCHN",
        "value": 3.62,
        "unit": "months",
        "ci_lower": 1.78,
        "ci_upper": 9.08,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG008",
        "arm_title": "Phase 2 Epacadostat 100/300 mg + Nivolumab 240 mg in Glioblastoma",
        "value": 1.84,
        "unit": "months",
        "ci_lower": 1.78,
        "ci_upper": 2.63,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Phase 2: Epacadostat 100/300 mg + Nivolumab 240 mg",
        "value": 0.458,
        "unit": "proportion of participants",
        "ci_lower": 0.297,
        "ci_upper": 0.605,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Epacadostat",
        "Nivolumab"
      ],
      "OG001": [
        "Epacadostat",
        "Nivolumab"
      ],
      "OG002": [
        "Epacadostat",
        "Nivolumab"
      ],
      "OG003": [
        "Epacadostat",
        "Nivolumab"
      ],
      "OG004": [
        "Epacadostat",
        "Nivolumab",
        "5-FU",
        "Platinum"
      ],
      "OG005": [
        "Epacadostat",
        "Nivolumab",
        "Pemetrexed",
        "Platinum"
      ],
      "OG006": [
        "Epacadostat",
        "Nivolumab",
        "Paclitaxel",
        "Platinum"
      ],
      "OG007": [
        "Epacadostat",
        "Nivolumab"
      ],
      "OG008": [
        "Epacadostat",
        "Nivolumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted",
      "OG002": "Combo_IO_Targeted",
      "OG003": "Combo_IO_Targeted",
      "OG004": "Combo_Chemo_IO",
      "OG005": "Combo_Chemo_IO",
      "OG006": "Combo_Chemo_IO",
      "OG007": "Combo_IO_Targeted",
      "OG008": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT02292758",
    "brief_title": "Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery",
    "status": "COMPLETED",
    "start_date": "2014-12-12",
    "completion_date": "2019-03-20",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Academic and Community Cancer Research United",
    "url": "https://clinicaltrials.gov/study/NCT02292758",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "Mutations in exons 2, 3, or 4 excluded"
      },
      {
        "target": "NRAS",
        "status": "NEGATIVE",
        "details": "Mutations in exons 2, 3, or 4 excluded"
      },
      {
        "target": "UGT1A1",
        "status": "NEGATIVE",
        "details": "Known homozygosity for the UGT1A1*28 allele excluded (special screening not required)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm I (Irinotecan, Cetuximab, Bevacizumab)",
        "value": 9.7,
        "unit": "months",
        "ci_lower": 7.1,
        "ci_upper": 13.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm II (Irinotecan, Cetuximab, Placebo)",
        "value": 5.5,
        "unit": "months",
        "ci_lower": 3.8,
        "ci_upper": 10.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm I (Irinotecan, Cetuximab, Bevacizumab)",
        "value": 19.7,
        "unit": "months",
        "ci_lower": 14.9,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm II (Irinotecan, Cetuximab, Placebo)",
        "value": 10.2,
        "unit": "months",
        "ci_lower": 7.9,
        "ci_upper": 16.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Irinotecan",
        "Cetuximab",
        "Bevacizumab"
      ],
      "OG001": [
        "Irinotecan",
        "Cetuximab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02291913",
    "brief_title": "Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2014-12-18",
    "completion_date": "2019-01-31",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "SCRI Development Innovations, LLC",
    "url": "https://clinicaltrials.gov/study/NCT02291913",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "IHC positive on most recent biopsy; study requires ER and/or PR-positive tumors (either ER or PR positive)"
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": "IHC positive on most recent biopsy; study requires ER and/or PR-positive tumors (either ER or PR positive)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-negative defined as FISH-negative (FISH ratio <2.0), or IHC 0-1+, or IHC 2-3+ AND FISH-negative (FISH ratio <2.0)"
      },
      {
        "target": "HBV",
        "status": "NEGATIVE",
        "details": "Known active infection excluded; HBV DNA PCR must be negative"
      },
      {
        "target": "HCV",
        "status": "NEGATIVE",
        "details": "Known active infection excluded; HCV RNA PCR must be negative"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Everolimus",
        "value": 7.2,
        "unit": "months",
        "ci_lower": 4.1,
        "ci_upper": 10.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG000",
        "arm_title": "Everolimus",
        "value": 8.8,
        "unit": "months",
        "ci_lower": 1.8,
        "ci_upper": 11.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Everolimus",
        "value": 26.7,
        "unit": "months",
        "ci_lower": 16.3,
        "ci_upper": 26.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Everolimus",
        "Tamoxifen",
        "Fulvestrant",
        "Anastrozole",
        "Exemestane",
        "Letrozole",
        "Toremifine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02291289",
    "brief_title": "A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)",
    "status": "COMPLETED",
    "start_date": "2015-04-17",
    "completion_date": "2019-05-31",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT02291289",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,Vemurafenib",
        "value": 9.99,
        "unit": "months",
        "ci_lower": 7.72,
        "ci_upper": 12.55,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort 1 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab",
        "value": 11.6,
        "unit": "months",
        "ci_lower": 3.58,
        "ci_upper": 15.67,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Cohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,Atezolizumab",
        "value": 7.13,
        "unit": "months",
        "ci_lower": 6.14,
        "ci_upper": 8.41,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Cohort 2 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab",
        "value": 7.36,
        "unit": "months",
        "ci_lower": 5.82,
        "ci_upper": 8.94,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Cohort 3 (MP): Capecitabine,Trastuzumab,Pertuzumab",
        "value": 4.44,
        "unit": "months",
        "ci_lower": 3.55,
        "ci_upper": 14.69,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG005",
        "arm_title": "Cohort 3 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab",
        "value": 4.04,
        "unit": "months",
        "ci_lower": 4.04,
        "ci_upper": 5.39,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG006",
        "arm_title": "Cohort 4 (MP): Cobimetinib,Atezolizumab",
        "value": 3.75,
        "unit": "months",
        "ci_lower": 3.42,
        "ci_upper": 3.91,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG007",
        "arm_title": "Cohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab",
        "value": 7.79,
        "unit": "months",
        "ci_lower": 3.98,
        "ci_upper": 9.46,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,Vemurafenib",
        "value": 24.02,
        "unit": "months",
        "ci_lower": 16.07,
        "ci_upper": 34.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cohort 1 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab",
        "value": 21.73,
        "unit": "months",
        "ci_lower": 7.92,
        "ci_upper": 37.19,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Cohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,Atezolizumab",
        "value": 22.54,
        "unit": "months",
        "ci_lower": 20.04,
        "ci_upper": 26.87,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Cohort 2 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab",
        "value": 22.24,
        "unit": "months",
        "ci_lower": 18.5,
        "ci_upper": 25.13,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG004",
        "arm_title": "Cohort 3 (MP): Capecitabine,Trastuzumab,Pertuzumab",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": 16.07,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG005",
        "arm_title": "Cohort 3 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab",
        "value": 14.59,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG006",
        "arm_title": "Cohort 4 (MP): Cobimetinib,Atezolizumab",
        "value": 22.6,
        "unit": "months",
        "ci_lower": 14.23,
        "ci_upper": 27.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG007",
        "arm_title": "Cohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab",
        "value": 25.17,
        "unit": "months",
        "ci_lower": 15.9,
        "ci_upper": 32.59,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "5-FU/LV",
        "Cetuximab",
        "Vemurafenib"
      ],
      "OG001": [
        "5-FU/LV",
        "Capecitabine",
        "Bevacizumab"
      ],
      "OG002": [
        "5-FU/LV",
        "Capecitabine",
        "Bevacizumab",
        "Atezolizumab"
      ],
      "OG003": [
        "5-FU/LV",
        "Capecitabine",
        "Bevacizumab"
      ],
      "OG004": [
        "Capecitabine",
        "Trastuzumab",
        "Pertuzumab"
      ],
      "OG005": [
        "5-FU/LV",
        "Capecitabine",
        "Bevacizumab"
      ],
      "OG006": [
        "Cobimetinib",
        "Atezolizumab"
      ],
      "OG007": [
        "5-FU/LV",
        "Capecitabine",
        "Bevacizumab"
      ],
      "OG008": [
        "5-FU/LV",
        "Capecitabine",
        "Bevacizumab"
      ],
      "OG010": [
        "Cobimetinib",
        "Atezolizumab"
      ],
      "OG011": [
        "5-FU/LV",
        "Capecitabine",
        "Bevacizumab"
      ],
      "OG012": [
        "5-FU/LV",
        "Cetuximab",
        "Vemurafenib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_IO",
      "OG003": "Combo_Chemo_Targeted",
      "OG004": "Combo_Chemo_Targeted",
      "OG005": "Combo_Chemo_Targeted",
      "OG006": "Combo_IO_Targeted",
      "OG007": "Combo_Chemo_Targeted",
      "OG008": "Combo_Chemo_Targeted",
      "OG009": "OTHER",
      "OG010": "Combo_IO_Targeted",
      "OG011": "Combo_Chemo_Targeted",
      "OG012": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02399215",
    "brief_title": "Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors",
    "status": "COMPLETED",
    "start_date": "2015-05-15",
    "completion_date": "2019-09-01",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Roswell Park Cancer Institute",
    "url": "https://clinicaltrials.gov/study/NCT02399215",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Nintedanib)",
        "value": 11.0,
        "unit": "months",
        "ci_lower": 5.5,
        "ci_upper": 19.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nintedanib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT02395016",
    "brief_title": "A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer",
    "status": "COMPLETED",
    "start_date": "2015-04",
    "completion_date": "2021-11",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Biotech Pharmaceutical Co., Ltd.",
    "url": "https://clinicaltrials.gov/study/NCT02395016",
    "cancer_types": [
      "PAAD"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "K-RAS wild-type in tumor tissue required"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Nimotuzumab- Gemcitabine Group",
        "value": 10.9,
        "unit": "months",
        "ci_lower": 5.6,
        "ci_upper": 16.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo-Gemcitabine Group",
        "value": 8.5,
        "unit": "months",
        "ci_lower": 5.7,
        "ci_upper": 10.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Nimotuzumab- Gemcitabine Group",
        "value": 4.2,
        "unit": "months",
        "ci_lower": 2.7,
        "ci_upper": 7.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo-Gemcitabine Group",
        "value": 3.6,
        "unit": "months",
        "ci_lower": 2.0,
        "ci_upper": 5.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "nimotuzumab",
        "Gemcitabine"
      ],
      "OG001": [
        "Gemcitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT02347917",
    "brief_title": "A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma",
    "status": "COMPLETED",
    "start_date": "2015-02",
    "completion_date": "2018-05-31",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Sumitomo Pharma Co., Ltd.",
    "url": "https://clinicaltrials.gov/study/NCT02347917",
    "cancer_types": [
      "MESO",
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "MPM: BBI608 + Pem + CDDP (Phase 2 Part)",
        "value": 5.59,
        "unit": "month",
        "ci_lower": 2.89,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "MPM: BBI608 + Pem + CDDP (Phase 2 Part Including 1 Participant With MPM in Phase 1 Part)",
        "value": 5.59,
        "unit": "month",
        "ci_lower": 2.89,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "BBI608",
        "Pemetrexed",
        "Cisplatin"
      ],
      "OG001": [
        "BBI608",
        "Pemetrexed",
        "Cisplatin"
      ],
      "OG002": [
        "BBI608",
        "Pemetrexed",
        "Cisplatin"
      ],
      "OG003": [
        "BBI608",
        "Pemetrexed",
        "Cisplatin"
      ],
      "OG004": [
        "BBI608",
        "Pemetrexed",
        "Cisplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted",
      "OG003": "Combo_Chemo_Targeted",
      "OG004": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02352948",
    "brief_title": "A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2015-01-13",
    "completion_date": "2018-02-09",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT02352948",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "PD-L1 used to determine/stratify treatment arms"
      },
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "known EGFR tyrosine kinase activating mutations"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "ALK rearrangements"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV",
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Sub-study A: Durvalumab",
        "value": 11.7,
        "unit": "months",
        "ci_lower": 8.2,
        "ci_upper": 17.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Sub-study A: SoC",
        "value": 6.8,
        "unit": "months",
        "ci_lower": 4.9,
        "ci_upper": 10.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Sub-study B: Durvalumab+Tremelimumab",
        "value": 11.5,
        "unit": "months",
        "ci_lower": 8.7,
        "ci_upper": 14.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Sub-study B: SoC",
        "value": 8.7,
        "unit": "months",
        "ci_lower": 6.5,
        "ci_upper": 11.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Sub-study A: Durvalumab",
        "value": 3.8,
        "unit": "months",
        "ci_lower": 1.9,
        "ci_upper": 5.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Sub-study A: SoC",
        "value": 2.2,
        "unit": "months",
        "ci_lower": 1.9,
        "ci_upper": 3.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Sub-study B: Durvalumab+Tremelimumab",
        "value": 3.5,
        "unit": "months",
        "ci_lower": 2.3,
        "ci_upper": 4.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Sub-study B: SoC",
        "value": 3.5,
        "unit": "months",
        "ci_lower": 1.9,
        "ci_upper": 3.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "MEDI4736 (durvalumab)"
      ],
      "OG001": [
        "Erlotinib",
        "Gemcitabine",
        "Vinorelbine"
      ],
      "OG002": [
        "MEDI4736 (durvalumab)",
        "tremelimumab (anti-CTLA4)"
      ],
      "OG003": [
        "Erlotinib",
        "Gemcitabine",
        "Vinorelbine"
      ],
      "OG004": [
        "MEDI4736 (durvalumab)"
      ],
      "OG005": [
        "tremelimumab (anti-CTLA4)"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "OTHER",
      "OG002": "IO",
      "OG003": "OTHER",
      "OG004": "IO",
      "OG005": "IO"
    }
  },
  {
    "nct_id": "NCT02392637",
    "brief_title": "Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers",
    "status": "COMPLETED",
    "start_date": "2015-04-02",
    "completion_date": "2020-08-13",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "M.D. Anderson Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT02392637",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "High Dosage",
        "value": 11.4,
        "unit": "months",
        "ci_lower": 6.0,
        "ci_upper": 15.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Low Dosage",
        "value": 14.9,
        "unit": "months",
        "ci_lower": 3.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "High Dose",
        "value": 19.5,
        "unit": "months",
        "ci_lower": 10.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Low Dose",
        "value": 15.7,
        "unit": "months",
        "ci_lower": 8.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Gemcitabine Hydrochloride",
        "Cisplatin",
        "Nab-paclitaxel"
      ],
      "OG001": [
        "Gemcitabine Hydrochloride",
        "Cisplatin",
        "Nab-paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT02364999",
    "brief_title": "A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC",
    "status": "COMPLETED",
    "start_date": "2015-04",
    "completion_date": "2017-05",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pfizer",
    "url": "https://clinicaltrials.gov/study/NCT02364999",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "Known sensitizing EGFR mutations (for example exon 19 deletion or L858R)"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "EML4-ALK translocation (ALK rearrangement) positive mutations"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV",
      "RECURRENT",
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "PF-06439535",
        "value": 45.3,
        "unit": "percentage of participants",
        "ci_lower": 40.01,
        "ci_upper": 50.57,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Bevacizumab-EU",
        "value": 44.6,
        "unit": "percentage of participants",
        "ci_lower": 39.4,
        "ci_upper": 49.89,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "PF-06439535",
        "Paclitaxel",
        "Carboplatin"
      ],
      "OG001": [
        "Bevacizumab-EU",
        "Paclitaxel",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02403271",
    "brief_title": "A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2015-03",
    "completion_date": "2017-08",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Pharmacyclics LLC.",
    "url": "https://clinicaltrials.gov/study/NCT02403271",
    "cancer_types": [
      "NSCLC",
      "BRCA",
      "PAAD"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "Breast cancer cohort: HER2-positive"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "Triple-negative breast cancer (ER/PR/HER2 negative)"
      },
      {
        "target": "ESR1",
        "status": "NEGATIVE",
        "details": "Triple-negative breast cancer (ER/PR/HER2 negative) \u2014 estrogen receptor negative"
      },
      {
        "target": "PGR",
        "status": "NEGATIVE",
        "details": "Triple-negative breast cancer (ER/PR/HER2 negative) \u2014 progesterone receptor negative"
      }
    ],
    "cancer_stages": [
      "III",
      "IV",
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 2",
        "value": 2.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ibrutinib",
        "Durvalumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_IO"
    }
  },
  {
    "nct_id": "NCT02370238",
    "brief_title": "A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2015-07-29",
    "completion_date": "2019-02-20",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Domp\u00e9 Farmaceutici S.p.A",
    "url": "https://clinicaltrials.gov/study/NCT02370238",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "<1% ER+ cells by IHC (estrogen receptor)"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "<1% PgR/PR+ cells by IHC (progesterone receptor)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 IHC 0 or 1+ and/or ISH HER2 gene copy number <4 or HER2/CEP17 ratio <2"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Paclitaxel+Reparixin (Group 1) - ITT Population",
        "value": 166.0,
        "unit": "Days",
        "ci_lower": 62.0,
        "ci_upper": 292.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Paclitaxel+Placebo (Group 2)",
        "value": 171.0,
        "unit": "Days",
        "ci_lower": 105.0,
        "ci_upper": 393.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Paclitaxel+Reparixin (Group 1) - ITT Population",
        "value": 483.0,
        "unit": "Days",
        "ci_lower": 272.0,
        "ci_upper": 812.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Paclitaxel+Placebo (Group 2)",
        "value": 531.0,
        "unit": "Days",
        "ci_lower": 334.0,
        "ci_upper": 787.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "paclitaxel",
        "Reparixin"
      ],
      "OG001": [
        "paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT02367794",
    "brief_title": "A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]",
    "status": "COMPLETED",
    "start_date": "2015-06-11",
    "completion_date": "2018-10-03",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT02367794",
    "cancer_types": [
      "LUSC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm C: Nab-Paclitaxel + Carboplatin",
        "value": 5.6,
        "unit": "Months",
        "ci_lower": 5.5,
        "ci_upper": 5.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin",
        "value": 6.5,
        "unit": "Months",
        "ci_lower": 5.7,
        "ci_upper": 7.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Arm A: Atezolizumab + Paclitaxel + Carboplatin",
        "value": 5.6,
        "unit": "Months",
        "ci_lower": 5.5,
        "ci_upper": 6.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm C: Nab-Paclitaxel + Carboplatin",
        "value": 13.5,
        "unit": "Months",
        "ci_lower": 12.2,
        "ci_upper": 15.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin",
        "value": 14.2,
        "unit": "Months",
        "ci_lower": 12.3,
        "ci_upper": 16.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Arm A: Atezolizumab + Paclitaxel + Carboplatin",
        "value": 12.6,
        "unit": "Months",
        "ci_lower": 11.6,
        "ci_upper": 14.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nab-Paclitaxel",
        "Carboplatin"
      ],
      "OG001": [
        "Atezolizumab",
        "Nab-Paclitaxel",
        "Carboplatin"
      ],
      "OG002": [
        "Atezolizumab",
        "Paclitaxel",
        "Carboplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_IO",
      "OG002": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT02392507",
    "brief_title": "A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC",
    "status": "COMPLETED",
    "start_date": "2015-10-12",
    "completion_date": "2018-01-29",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT02392507",
    "cancer_types": [
      "LUSC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IV"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Necitumumab + Nab-Paclitaxel + Carboplatin",
        "value": 51.0,
        "unit": "percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": null
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Necitumumab + Nab-Paclitaxel + Carboplatin",
        "value": 5.59,
        "unit": "Months",
        "ci_lower": 4.24,
        "ci_upper": 7.69,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Necitumumab + Nab-Paclitaxel + Carboplatin",
        "value": 15.54,
        "unit": "Months",
        "ci_lower": 10.18,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Necitumumab",
        "Nab-Paclitaxel",
        "Carboplatin"
      ],
      "OG001": [
        "Carboplatin"
      ],
      "OG002": [
        "Nab-Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo",
      "OG002": "Chemo"
    }
  },
  {
    "nct_id": "NCT02404441",
    "brief_title": "Phase I/II Study of PDR001 in Patients With Advanced Malignancies",
    "status": "COMPLETED",
    "start_date": "2015-04-27",
    "completion_date": "2020-07-21",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT02404441",
    "cancer_types": [
      "SKCM",
      "NSCLC",
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "Negative for exon 19 deletions and for L858R mutation at a minimum; if more extensive testing performed, tumor must not harbor any known activating EGFR mutations in Exons 18-21"
      },
      {
        "target": "ALK",
        "status": "ANY",
        "details": "Patients must be tested for ALK translocation if no EGFR mutation detected; ALK translocation-positive patients must have progressed following treatment with a corresponding ALK inhibitor"
      },
      {
        "target": "BRAF",
        "status": "ANY",
        "details": "All patients must be tested for BRAF mutations; for melanoma, V600 mutation-positive patients must have progression during or after treatment with a BRAF inhibitor"
      },
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "Part of 'triple negative' breast cancer group (ER negative)"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "Part of 'triple negative' breast cancer group (PR negative)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "Part of 'triple negative' breast cancer group (HER2 negative)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "NSCLC 400 mg/q4w",
        "value": 15.3,
        "unit": "Percentage of participants",
        "ci_lower": 8.2,
        "ci_upper": 25.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Melanoma 400 mg/q4w",
        "value": 27.9,
        "unit": "Percentage of participants",
        "ci_lower": 18.6,
        "ci_upper": 38.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "TNBC 400 mg/q4w",
        "value": 0.0,
        "unit": "Percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 7.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "NSCLC 300 mg/q3w",
        "value": 6.8,
        "unit": "Percentage of participants",
        "ci_lower": 2.3,
        "ci_upper": 14.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "ATC 400 mg/q4w",
        "value": 19.0,
        "unit": "Percentage of participants",
        "ci_lower": 9.8,
        "ci_upper": 31.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "All Phase II Patients",
        "value": 14.6,
        "unit": "Percentage of participants",
        "ci_lower": 11.1,
        "ci_upper": 18.6,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "PDR001"
      ],
      "OG001": [
        "PDR001"
      ],
      "OG002": [
        "PDR001"
      ],
      "OG003": [
        "PDR001"
      ],
      "OG004": [
        "PDR001"
      ],
      "OG005": [
        "PDR001"
      ],
      "OG006": [
        "PDR001"
      ],
      "OG007": [
        "PDR001"
      ],
      "OG008": [
        "PDR001"
      ],
      "OG009": [
        "PDR001"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO",
      "OG003": "IO",
      "OG004": "IO",
      "OG005": "IO",
      "OG006": "IO",
      "OG007": "IO",
      "OG008": "IO",
      "OG009": "IO"
    }
  },
  {
    "nct_id": "NCT02379247",
    "brief_title": "BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2015-02",
    "completion_date": "2017-09-21",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Priyanka Sharma",
    "url": "https://clinicaltrials.gov/study/NCT02379247",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 IHC 0 or 1+ and/or HER2 FISH negative"
      }
    ],
    "cancer_stages": [
      "III",
      "LOCALLY_ADVANCED",
      "IV",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Participants Treated at the RP2D",
        "value": 17.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "All Evaluable Participants",
        "value": 8.7,
        "unit": "months",
        "ci_lower": 5.5,
        "ci_upper": 11.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "All Evaluable Participants",
        "value": 18.5,
        "unit": "months",
        "ci_lower": 9.6,
        "ci_upper": 27.4,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "BYL-719 (alpelisib)",
        "Nab-paclitaxel"
      ],
      "OG001": [
        "BYL-719 (alpelisib)",
        "Nab-paclitaxel"
      ],
      "OG002": [
        "BYL-719 (alpelisib)",
        "Nab-paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02358031",
    "brief_title": "A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)",
    "status": "COMPLETED",
    "start_date": "2015-03-19",
    "completion_date": "2019-02-25",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT02358031",
    "cancer_types": [
      "HNSC"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Tumor PD-L1 testing required; tissue from a core or excisional biopsy (FNA not sufficient). Newly obtained biopsy within 90 days preferred. PD-L1 by IHC."
      },
      {
        "target": "HPV",
        "status": "ANY",
        "details": "Have results from testing of human papillomavirus (HPV) status for oropharyngeal cancer (required for oropharyngeal primary tumors)."
      }
    ],
    "cancer_stages": [
      "RECURRENT",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Pembrolizumab + Chemotherapy (Pembro Combo)",
        "value": 4.9,
        "unit": "Months",
        "ci_lower": 4.7,
        "ci_upper": 6.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Cetuximab + Chemotherapy (Control)",
        "value": 5.2,
        "unit": "Months",
        "ci_lower": 4.9,
        "ci_upper": 6.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab Monotherapy (Pembro Mono)",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Pembrolizumab + Chemotherapy (Pembro Combo)",
        "value": 13.0,
        "unit": "Months",
        "ci_lower": 10.9,
        "ci_upper": 14.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Cetuximab + Chemotherapy (Control)",
        "value": 10.7,
        "unit": "Months",
        "ci_lower": 9.3,
        "ci_upper": 11.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab Monotherapy (Pembro Mono)",
        "value": null,
        "unit": "Months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab"
      ],
      "OG001": [
        "Pembrolizumab",
        "Cisplatin",
        "Carboplatin"
      ],
      "OG002": [
        "Cetuximab",
        "Cisplatin"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "Combo_Chemo_IO",
      "OG002": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02335424",
    "brief_title": "Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)",
    "status": "COMPLETED",
    "start_date": "2015-02-24",
    "completion_date": "2018-06-19",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT02335424",
    "cancer_types": [
      "BLCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab 200 mg",
        "value": 28.9,
        "unit": "Percentage of participants",
        "ci_lower": 24.3,
        "ci_upper": 33.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab 200 mg",
        "value": 35.8,
        "unit": "Months",
        "ci_lower": 20.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab 200 mg",
        "value": 2.5,
        "unit": "Months",
        "ci_lower": 2.1,
        "ci_upper": 3.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Pembrolizumab 200 mg",
        "value": 11.3,
        "unit": "Months",
        "ci_lower": 9.7,
        "ci_upper": 13.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO"
    }
  },
  {
    "nct_id": "NCT02394795",
    "brief_title": "Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC",
    "status": "COMPLETED",
    "start_date": "2015-05-29",
    "completion_date": "2022-01-14",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Takeda",
    "url": "https://clinicaltrials.gov/study/NCT02394795",
    "cancer_types": [
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "KRAS",
        "status": "NEGATIVE",
        "details": "Wild-type required \u2014 no mutation in KRAS EXON2 (codon 12,13), EXON3 (codon 59,61), EXON4 (codon 117,146); testing by in vitro diagnostic listed in National Health Insurance; not considered wild-type if any listed codon is unevaluable or not tested."
      },
      {
        "target": "NRAS",
        "status": "NEGATIVE",
        "details": "Wild-type required \u2014 no mutation in NRAS EXON2 (codon 12,13), EXON3 (codon 59,61), EXON4 (codon 117,146); testing by in vitro diagnostic listed in National Health Insurance; not considered wild-type if any listed codon is unevaluable or not tested."
      }
    ],
    "cancer_stages": [
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Group P; mFOLFOX6 + Panitumumab Combination Therapy",
        "value": 37.85,
        "unit": "Months",
        "ci_lower": 34.1,
        "ci_upper": 42.58,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Group B; mFOLFOX6 + Bevacizumab Combination Therapy",
        "value": 34.3,
        "unit": "Months",
        "ci_lower": 30.92,
        "ci_upper": 40.28,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "oxaliplatin",
        "levofolinate calcium",
        "5-FU",
        "panitumumab"
      ],
      "OG001": [
        "oxaliplatin",
        "levofolinate calcium",
        "5-FU",
        "bevacizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02354586",
    "brief_title": "A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens",
    "status": "COMPLETED",
    "start_date": "2015-03-23",
    "completion_date": "2018-02-28",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Tesaro, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT02354586",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "HRD",
        "status": "ANY",
        "details": "tumor HRD testing required (tumor)"
      },
      {
        "target": "BRCA",
        "status": "ANY",
        "details": "germline BRCA mutation testing required (blood gBRCAmut)"
      }
    ],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Niraparib 300 mg",
        "value": 27.66,
        "unit": "Percentage of participants",
        "ci_lower": 15.6,
        "ci_upper": 42.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Niraparib 300 mg",
        "value": 3.5,
        "unit": "Months",
        "ci_lower": 3.2,
        "ci_upper": 3.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Niraparib 300 mg",
        "value": 17.2,
        "unit": "Months",
        "ci_lower": 14.9,
        "ci_upper": 19.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Niraparib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02393755",
    "brief_title": "Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer",
    "status": "COMPLETED",
    "start_date": "2015-05-08",
    "completion_date": "2017-11-01",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Roswell Park Cancer Institute",
    "url": "https://clinicaltrials.gov/study/NCT02393755",
    "cancer_types": [
      "COAD",
      "READ"
    ],
    "biomarkers": [
      {
        "target": "RAS",
        "status": "NEGATIVE",
        "details": "wild-type (no RAS mutations); mentioned because RAS wild-type patients are expected to have received prior anti-EGFR therapy (e.g., panitumumab or cetuximab)"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Treatment (Capecitabine, Nintedanib)",
        "value": 41.7,
        "unit": "percentage of participants",
        "ci_lower": 29.2,
        "ci_upper": 55.3,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Capecitabine",
        "Nintedanib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT02336451",
    "brief_title": "A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges",
    "status": "COMPLETED",
    "start_date": "2015-04-01",
    "completion_date": "2019-02-06",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT02336451",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "ALK",
        "status": "POSITIVE",
        "details": "ALK rearrangement by Vysis ALK Break Apart FISH Probe Kit (if not available locally, central lab confirmation required; must wait for central result before starting)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "IV"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Arm 1 (PrALKi=Y, PrBRad=Y)",
        "value": 35.7,
        "unit": "Percentage of participants",
        "ci_lower": 21.6,
        "ci_upper": 52.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Arm 2 (PrALKi=Y, PrBRad=N)",
        "value": 30.0,
        "unit": "Percentage of participants",
        "ci_lower": 16.6,
        "ci_upper": 46.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Arm 3 (PrALKi=N, PrBRad=Y)",
        "value": 50.0,
        "unit": "Percentage of participants",
        "ci_lower": 21.1,
        "ci_upper": 78.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Arm 4 (PrALKi=N, PrBRad=N)",
        "value": 59.1,
        "unit": "Percentage of participants",
        "ci_lower": 43.2,
        "ci_upper": 73.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Arm 5 (LepDis)",
        "value": 16.7,
        "unit": "Percentage of participants",
        "ci_lower": 3.6,
        "ci_upper": 41.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm 1 (PrALKi=Y, PrBRad=Y)",
        "value": 7.2,
        "unit": "months",
        "ci_lower": 3.3,
        "ci_upper": 10.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm 2 (PrALKi=Y, PrBRad=N)",
        "value": 5.6,
        "unit": "months",
        "ci_lower": 3.6,
        "ci_upper": 9.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Arm 3 (PrALKi=N, PrBRad=Y)",
        "value": null,
        "unit": "months",
        "ci_lower": 1.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Arm 4 (PrALKi=N, PrBRad=N)",
        "value": 7.9,
        "unit": "months",
        "ci_lower": 5.5,
        "ci_upper": 9.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Arm 5 (LepDis)",
        "value": 5.2,
        "unit": "months",
        "ci_lower": 1.6,
        "ci_upper": 7.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Arm 1 (PrALKi=Y, PrBRad=Y)",
        "value": 5.0,
        "unit": "months",
        "ci_lower": 3.3,
        "ci_upper": 9.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Arm 2 (PrALKi=Y, PrBRad=N)",
        "value": 5.5,
        "unit": "months",
        "ci_lower": 3.6,
        "ci_upper": 7.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Arm 3 (PrALKi=N, PrBRad=Y)",
        "value": 15.5,
        "unit": "months",
        "ci_lower": 1.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Arm 4 (PrALKi=N, PrBRad=N)",
        "value": 7.7,
        "unit": "months",
        "ci_lower": 5.5,
        "ci_upper": 9.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG004",
        "arm_title": "Arm 5 (LepDis)",
        "value": 3.6,
        "unit": "months",
        "ci_lower": 1.6,
        "ci_upper": 5.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm 1 (PrALKi=Y, PrBRad=Y)",
        "value": 24.0,
        "unit": "months",
        "ci_lower": 12.6,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm 2 (PrALKi=Y, PrBRad=N)",
        "value": null,
        "unit": "months",
        "ci_lower": 16.2,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Arm 3 (PrALKi=N, PrBRad=Y)",
        "value": null,
        "unit": "months",
        "ci_lower": 1.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Arm 4 (PrALKi=N, PrBRad=N)",
        "value": null,
        "unit": "months",
        "ci_lower": 26.5,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG004",
        "arm_title": "Arm 5 (LepDis)",
        "value": 7.2,
        "unit": "months",
        "ci_lower": 1.6,
        "ci_upper": 16.9,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ceritinib"
      ],
      "OG001": [
        "Ceritinib"
      ],
      "OG002": [
        "Ceritinib"
      ],
      "OG003": [
        "Ceritinib"
      ],
      "OG004": [
        "Ceritinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "TKI",
      "OG002": "TKI",
      "OG003": "TKI",
      "OG004": "TKI"
    }
  },
  {
    "nct_id": "NCT02383927",
    "brief_title": "Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations",
    "status": "COMPLETED",
    "start_date": "2015-05-13",
    "completion_date": "2020-12-14",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Kura Oncology, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT02383927",
    "cancer_types": [
      "HNSC",
      "THCA"
    ],
    "biomarkers": [
      {
        "target": "HRAS",
        "status": "POSITIVE",
        "details": "missense HRAS mutation; variant allele frequency (VAF) > 20% (subjects with HRAS mutant VAF \u2265 35% may be enrolled despite serum albumin < 3.5 g/dL)"
      }
    ],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort 1",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 25.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Cohort 2/Stage 1",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 32.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Cohort 2/Stage 2",
        "value": 43.5,
        "unit": "percentage of participants",
        "ci_lower": 25.6,
        "ci_upper": 63.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Cohort 3",
        "value": 28.6,
        "unit": "percentage of participants",
        "ci_lower": 8.2,
        "ci_upper": 64.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1",
        "value": 4.6,
        "unit": "months",
        "ci_lower": 3.1,
        "ci_upper": 8.4,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort 2/Stage 1",
        "value": 6.4,
        "unit": "months",
        "ci_lower": 1.8,
        "ci_upper": 10.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Cohort 2/Stage 2",
        "value": 5.5,
        "unit": "months",
        "ci_lower": 3.6,
        "ci_upper": 9.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Cohort 3",
        "value": 8.0,
        "unit": "months",
        "ci_lower": 3.7,
        "ci_upper": 9.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1",
        "value": 36.7,
        "unit": "months",
        "ci_lower": 8.7,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cohort 2/Stage 1",
        "value": 13.8,
        "unit": "months",
        "ci_lower": 5.3,
        "ci_upper": 29.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Cohort 2/Stage 2",
        "value": 10.8,
        "unit": "months",
        "ci_lower": 7.0,
        "ci_upper": 14.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG003",
        "arm_title": "Cohort 3",
        "value": 10.4,
        "unit": "months",
        "ci_lower": 6.2,
        "ci_upper": 16.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Tipifarnib"
      ],
      "OG001": [
        "Tipifarnib"
      ],
      "OG002": [
        "Tipifarnib"
      ],
      "OG003": [
        "Tipifarnib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02387996",
    "brief_title": "A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer",
    "status": "COMPLETED",
    "start_date": "2015-03-09",
    "completion_date": "2016-04-15",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT02387996",
    "cancer_types": [
      "BLCA"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "UNRESECTABLE",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Nivolumab 3 mg/kg",
        "value": 19.6,
        "unit": "Percent of participants",
        "ci_lower": 15.0,
        "ci_upper": 24.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "TTR",
        "arm_id": "OG000",
        "arm_title": "Nivolumab 3 mg/kg",
        "value": 1.87,
        "unit": "Months",
        "ci_lower": 1.6,
        "ci_upper": 5.9,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "DoR",
        "arm_id": "OG000",
        "arm_title": "Nivolumab 3 mg/kg",
        "value": null,
        "unit": "Months",
        "ci_lower": 7.43,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO"
    }
  },
  {
    "nct_id": "NCT02425891",
    "brief_title": "A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)",
    "status": "COMPLETED",
    "start_date": "2015-06-23",
    "completion_date": "2020-04-14",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT02425891",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "Absence of HER2 expression as documented by pathology report"
      },
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "Absence of estrogen receptor expression as documented by pathology report"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "Absence of progesterone receptor expression as documented by pathology report"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Placebo Plus Nab-Paclitaxel",
        "value": 5.49,
        "unit": "Months",
        "ci_lower": 5.32,
        "ci_upper": 5.59,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Atezolizumab Plus Nab-Paclitaxel",
        "value": 7.16,
        "unit": "Months",
        "ci_lower": 5.59,
        "ci_upper": 7.46,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Placebo Plus Nab-Paclitaxel",
        "value": 18.73,
        "unit": "Months",
        "ci_lower": 16.85,
        "ci_upper": 20.76,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Atezolizumab Plus Nab-Paclitaxel",
        "value": 21.03,
        "unit": "Months",
        "ci_lower": 19.02,
        "ci_upper": 23.36,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nab-Paclitaxel"
      ],
      "OG001": [
        "Atezolizumab",
        "Nab-Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT02407054",
    "brief_title": "A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer",
    "status": "COMPLETED",
    "start_date": "2015-04-29",
    "completion_date": "2018-09-26",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT02407054",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Part B: 200 mg LY3023414 BID + 160 mg Enzalutamide QD",
        "value": 3.78,
        "unit": "months",
        "ci_lower": 2.89,
        "ci_upper": 5.06,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Part B: Placebo + 160 mg Enzalutamide QD",
        "value": 2.83,
        "unit": "months",
        "ci_lower": 2.27,
        "ci_upper": 3.22,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "LY3023414",
        "Enzalutamide"
      ],
      "OG001": [
        "Enzalutamide"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02450539",
    "brief_title": "A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2015-08-06",
    "completion_date": "2017-03-31",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT02450539",
    "cancer_types": [
      "LUSC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IV"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Abemaciclib",
        "value": 2.53,
        "unit": "months",
        "ci_lower": 1.68,
        "ci_upper": 2.89,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Docetaxel",
        "value": 4.21,
        "unit": "months",
        "ci_lower": 2.79,
        "ci_upper": 5.65,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Abemaciclib",
        "value": 7.0,
        "unit": "Months",
        "ci_lower": 5.0,
        "ci_upper": 8.78,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Docetaxel",
        "value": 12.39,
        "unit": "Months",
        "ci_lower": 7.13,
        "ci_upper": 15.98,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Abemaciclib"
      ],
      "OG001": [
        "Docetaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT02450903",
    "brief_title": "LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.",
    "status": "COMPLETED",
    "start_date": "2015-08-21",
    "completion_date": "2017-07-31",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT02450903",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "ALK",
        "status": "POSITIVE",
        "details": "ALK rearrangement by Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular Inc.)"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV",
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": true,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "LDK378 (Ceritinib)",
        "value": 25.0,
        "unit": "Percentage of participants",
        "ci_lower": 8.7,
        "ci_upper": 49.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "LDK378 (Ceritinib)",
        "value": 3.7,
        "unit": "Months",
        "ci_lower": 1.9,
        "ci_upper": 5.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "LDK378 (Ceritinib)",
        "value": 17.3,
        "unit": "Months",
        "ci_lower": 9.1,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "LDK378"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT02437318",
    "brief_title": "Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.",
    "status": "COMPLETED",
    "start_date": "2015-07-23",
    "completion_date": "2018-06-12",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT02437318",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "PIK3CA",
        "status": "ANY",
        "details": "PIK3CA status must be identified (known)"
      },
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Estrogen-receptor positive as determined by local laboratory"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 negative breast cancer"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant",
        "value": 11.0,
        "unit": "Months",
        "ci_lower": 7.49,
        "ci_upper": 14.52,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant",
        "value": 5.7,
        "unit": "Months",
        "ci_lower": 3.65,
        "ci_upper": 7.36,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant",
        "value": 39.3,
        "unit": "Months",
        "ci_lower": 34.1,
        "ci_upper": 44.85,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant",
        "value": 31.4,
        "unit": "Months",
        "ci_lower": 26.78,
        "ci_upper": 41.3,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Alpelisib",
        "Fulvestrant"
      ],
      "OG001": [
        "Fulvestrant"
      ],
      "OG002": [
        "Alpelisib",
        "Fulvestrant"
      ],
      "OG003": [
        "Fulvestrant"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "OTHER",
      "OG002": "Targeted_Other",
      "OG003": "OTHER"
    }
  },
  {
    "nct_id": "NCT02440425",
    "brief_title": "Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer",
    "status": "COMPLETED",
    "start_date": "2015-10-20",
    "completion_date": "2020-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
    "url": "https://clinicaltrials.gov/study/NCT02440425",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Combination Therapy",
        "value": 58.6,
        "unit": "percentage of participants",
        "ci_lower": 41.0,
        "ci_upper": 72.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Combination Therapy",
        "value": 26.3,
        "unit": "months",
        "ci_lower": 13.4,
        "ci_upper": 35.1,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab",
        "Paclitaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT02409342",
    "brief_title": "A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]",
    "status": "COMPLETED",
    "start_date": "2015-07-20",
    "completion_date": "2020-02-04",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT02409342",
    "cancer_types": [
      "LUAD",
      "LUSC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "Known sensitizing EGFR mutation excluded"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "Known ALK fusion oncogene excluded"
      },
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Tumor PD-L1 expression required as determined by immunohistochemistry (IHC) on archival or screening tumor tissue; no threshold specified"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)",
        "value": 13.1,
        "unit": "Months",
        "ci_lower": 7.4,
        "ci_upper": 16.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Atezolizumab",
        "value": 20.2,
        "unit": "Months",
        "ci_lower": 16.5,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Carboplatin",
        "Cisplatin",
        "Pemetrexed",
        "Gemcitabine"
      ],
      "OG001": [
        "Atezolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "IO"
    }
  },
  {
    "nct_id": "NCT02411448",
    "brief_title": "A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2015-05-06",
    "completion_date": "2019-01-23",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT02411448",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "exon 19 deletion or exon 21 (L858R) substitution mutation"
      },
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "T790M mutation"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Part B: Ramucirumab+ Erlotinib",
        "value": 19.4,
        "unit": "Months",
        "ci_lower": 15.4,
        "ci_upper": 21.6,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Part B: Placebo+ Erlotinib",
        "value": 12.4,
        "unit": "Months",
        "ci_lower": 11.0,
        "ci_upper": 13.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Part B: Ramucirumab+ Erlotinib",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Part B: Placebo+ Erlotinib",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ramucirumab",
        "Erlotinib"
      ],
      "OG001": [
        "Erlotinib"
      ],
      "OG002": [
        "Erlotinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_TKI_Targeted",
      "OG001": "TKI",
      "OG002": "TKI"
    }
  },
  {
    "nct_id": "NCT02435680",
    "brief_title": "Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)",
    "status": "COMPLETED",
    "start_date": "2015-08-10",
    "completion_date": "2020-01-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT02435680",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "Estrogen receptor negative (ER-) by local laboratory testing"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "Progesterone receptor negative (PgR-) by local laboratory testing"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 negative by local laboratory testing; if IHC HER2 2+ then a negative FISH is required"
      },
      {
        "target": "TAM",
        "status": "HIGH",
        "details": "High tumor-associated macrophage (TAM) content on pre-treatment tumor biopsy as assessed by the central laboratory"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "All MCS110+Carboplatin+Gemcitabine",
        "value": 5.6,
        "unit": "months",
        "ci_lower": 4.5,
        "ci_upper": 8.7,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Carboplatin+Gemcitabine",
        "value": 5.5,
        "unit": "months",
        "ci_lower": 3.5,
        "ci_upper": 7.5,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "MCS110",
        "carboplatin",
        "gemcitabine"
      ],
      "OG001": [
        "carboplatin",
        "gemcitabine"
      ],
      "OG002": [
        "carboplatin",
        "gemcitabine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Chemo",
      "OG002": "Chemo"
    }
  },
  {
    "nct_id": "NCT02451930",
    "brief_title": "A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC",
    "status": "COMPLETED",
    "start_date": "2015-09-04",
    "completion_date": "2017-01-26",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT02451930",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "activating mutations; prior EGFR-TKI required if EGFR-activating mutation present"
      },
      {
        "target": "ALK",
        "status": "POSITIVE",
        "details": "translocation; prior ALK inhibitor required if ALK translocation present"
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Part A Cohort 1: 600 mg Neci + 200 mg Pembro",
        "value": 66.7,
        "unit": "Percentage of Participants",
        "ci_lower": 9.4,
        "ci_upper": 99.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Part A Cohort 2, Part B: 800 mg Neci + 200 mg Pembro",
        "value": 21.3,
        "unit": "Percentage of Participants",
        "ci_lower": 11.9,
        "ci_upper": 33.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Part A Cohort 2 and Part B: 800 mg Neci + 200 mg Pembro",
        "value": 3.98,
        "unit": "Months",
        "ci_lower": 2.23,
        "ci_upper": 6.87,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Part A Cohort 2, Part B: 800 mg Neci + 200 mg Pembro",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Necitumumab",
        "Pembrolizumab"
      ],
      "OG001": [
        "Necitumumab",
        "Pembrolizumab"
      ],
      "OG002": [
        "Necitumumab",
        "Pembrolizumab"
      ],
      "OG003": [
        "Necitumumab",
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted",
      "OG002": "Combo_IO_Targeted",
      "OG003": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT02447003",
    "brief_title": "Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)",
    "status": "COMPLETED",
    "start_date": "2015-06-11",
    "completion_date": "2019-02-18",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Merck Sharp & Dohme LLC",
    "url": "https://clinicaltrials.gov/study/NCT02447003",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "PD-L1",
        "status": "POSITIVE",
        "details": "PD-L1-positive metastatic TNBC required for first-line monotherapy (assay/threshold not specified)"
      },
      {
        "target": "PD-L1",
        "status": "HIGH",
        "details": "PD-L1 strong positive required for second-line-plus monotherapy (threshold/definition not specified)"
      },
      {
        "target": "ER",
        "status": "NEGATIVE",
        "details": "Part of triple-negative breast cancer confirmation by central laboratory (ER negative)"
      },
      {
        "target": "PR",
        "status": "NEGATIVE",
        "details": "Part of triple-negative breast cancer confirmation by central laboratory (PR negative)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "Part of triple-negative breast cancer confirmation by central laboratory (HER2 negative)"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort A: Pembrolizumab",
        "value": 5.3,
        "unit": "Percentage of participants",
        "ci_lower": 2.7,
        "ci_upper": 9.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Cohort B: Pembrolizumab",
        "value": null,
        "unit": "Percentage of participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort A: Pembrolizumab",
        "value": 2.0,
        "unit": "Months",
        "ci_lower": 1.9,
        "ci_upper": 2.0,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort B: Pembrolizumab",
        "value": 2.1,
        "unit": "Months",
        "ci_lower": 2.0,
        "ci_upper": 2.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Cohort A: Pembrolizumab",
        "value": 9.0,
        "unit": "Months",
        "ci_lower": 7.6,
        "ci_upper": 11.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Cohort B: Pembrolizumab",
        "value": 18.0,
        "unit": "Months",
        "ci_lower": 12.9,
        "ci_upper": 23.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pembrolizumab"
      ],
      "OG001": [
        "Pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO"
    }
  },
  {
    "nct_id": "NCT02429427",
    "brief_title": "European Celecoxib Trial in Primary Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2005-12",
    "completion_date": "2019-03",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Imperial College London",
    "url": "https://clinicaltrials.gov/study/NCT02429427",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "ANY",
        "details": "ER (estrogen receptor) status must be known; if hormone\u2011receptor negative, patient must have received (neo)adjuvant chemotherapy (>=4 cycles) prior to study entry"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2 (Human epidermal growth factor receptor 2) positive patients are excluded; HER2 FISH positive excluded and HER2 status must be known"
      }
    ],
    "cancer_stages": [],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Celecoxib",
        "value": 91.0,
        "unit": "Percentage of participants",
        "ci_lower": 90.0,
        "ci_upper": 93.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 90.0,
        "unit": "Percentage of participants",
        "ci_lower": 87.0,
        "ci_upper": 92.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Celecoxib",
        "value": 84.0,
        "unit": "Percentage of participants",
        "ci_lower": 82.0,
        "ci_upper": 86.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo",
        "value": 83.0,
        "unit": "Percentage of participants",
        "ci_lower": 81.0,
        "ci_upper": 86.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Celecoxib"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT02442349",
    "brief_title": "Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2015-06-22",
    "completion_date": "2016-03-04",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT02442349",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "Documented sensitizing EGFR mutation (e.g., G719X, exon 19 deletion, L858R, L861Q) at any time since diagnosis"
      },
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "T790M mutation confirmed centrally on a biopsy taken after progression on the most recent regimen"
      }
    ],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": true,
    "prior_io": false,
    "prior_platinum": false,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "AZD9291",
        "value": 62.0,
        "unit": "% of participants",
        "ci_lower": 54.2,
        "ci_upper": 69.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "AZD9291",
        "value": 9.7,
        "unit": "Months",
        "ci_lower": 7.0,
        "ci_upper": 11.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "AZD9291",
        "value": 23.2,
        "unit": "Months",
        "ci_lower": 20.0,
        "ci_upper": 26.7,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "AZD9291"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT02432274",
    "brief_title": "Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma",
    "status": "COMPLETED",
    "start_date": "2014-12-29",
    "completion_date": "2019-07-18",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eisai Limited",
    "url": "https://clinicaltrials.gov/study/NCT02432274",
    "cancer_types": [
      "OTHER",
      "THCA"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Cohort 2A, Single-agent Expansion, DTC: Lenvatinib 14 mg/m^2",
        "value": 1.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort2B,Single-agentExpansion,Osteosarcoma:Lenvatinib14mg/m^2",
        "value": 32.1,
        "unit": "percentage of participants",
        "ci_lower": 15.9,
        "ci_upper": 52.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort 3B, Combination Expansion: Lenvatinib 14 mg/m^2",
        "value": 66.7,
        "unit": "percentage of participants",
        "ci_lower": 38.4,
        "ci_upper": 88.2,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Lenvatinib"
      ],
      "OG001": [
        "Lenvatinib",
        "Ifosfamide",
        "Etoposide"
      ],
      "OG002": [
        "Lenvatinib"
      ],
      "OG003": [
        "Lenvatinib"
      ],
      "OG004": [
        "Lenvatinib",
        "Ifosfamide",
        "Etoposide"
      ],
      "OG005": [
        "Lenvatinib",
        "Ifosfamide",
        "Etoposide"
      ],
      "OG006": [
        "Lenvatinib",
        "Ifosfamide",
        "Etoposide"
      ],
      "OG007": [
        "Lenvatinib",
        "Ifosfamide",
        "Etoposide"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI",
      "OG001": "Combo_TKI_Chemo",
      "OG002": "TKI",
      "OG003": "TKI",
      "OG004": "Combo_TKI_Chemo",
      "OG005": "Combo_TKI_Chemo",
      "OG006": "Combo_TKI_Chemo",
      "OG007": "Combo_TKI_Chemo"
    }
  },
  {
    "nct_id": "NCT02422615",
    "brief_title": "Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.",
    "status": "COMPLETED",
    "start_date": "2015-06-09",
    "completion_date": "2017-11-03",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT02422615",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "ER",
        "status": "POSITIVE",
        "details": "Estrogen receptor positive by local laboratory (eligibility requires ER and/or PR positivity)"
      },
      {
        "target": "PR",
        "status": "POSITIVE",
        "details": "Progesterone receptor positive by local laboratory (eligibility requires ER and/or PR positivity)"
      },
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "HER2-negative breast cancer determined by local laboratory"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Ribociclib + Fulvestrant",
        "value": 20.5,
        "unit": "Months",
        "ci_lower": 18.5,
        "ci_upper": 23.5,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Fulvestrant",
        "value": 12.8,
        "unit": "Months",
        "ci_lower": 10.9,
        "ci_upper": 16.3,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Ribociclib + Fulvestrant",
        "value": null,
        "unit": "Months",
        "ci_lower": 42.5,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Placebo + Fulvestrant",
        "value": 40.0,
        "unit": "Months",
        "ci_lower": 37.0,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Ribociclib",
        "Fulvestrant"
      ],
      "OG001": [
        "Fulvestrant"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER"
    }
  },
  {
    "nct_id": "NCT02407990",
    "brief_title": "Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors",
    "status": "COMPLETED",
    "start_date": "2015-06-02",
    "completion_date": "2020-08-12",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "BeiGene",
    "url": "https://clinicaltrials.gov/study/NCT02407990",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "NEGATIVE",
        "details": "Documented epidermal growth factor receptor (EGFR) mutation \u2014 excluded (Phase 1B)"
      },
      {
        "target": "ALK",
        "status": "NEGATIVE",
        "details": "Anaplastic lymphoma kinase (ALK) rearrangement \u2014 excluded (Phase 1B)"
      },
      {
        "target": "PD-L1",
        "status": "ANY",
        "details": "Archival tumor tissue or baseline biopsy required for analysis of programmed death-ligand 1; fresh biopsies recommended when feasible"
      },
      {
        "target": "MSI",
        "status": "HIGH",
        "details": "Microsatellite instability-high (MSI-H) status"
      },
      {
        "target": "MMR",
        "status": "POSITIVE",
        "details": "Mismatch repair deficient (dMMR)"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "BGB-A317 Phase 1B",
        "value": 11.6,
        "unit": "percentage of participants",
        "ci_lower": 8.41,
        "ci_upper": 15.57,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Tislelizumab (BGB-A317)"
      ],
      "OG001": [
        "Tislelizumab (BGB-A317)"
      ],
      "OG002": [
        "Tislelizumab (BGB-A317)"
      ],
      "OG003": [
        "Tislelizumab (BGB-A317)"
      ],
      "OG004": [
        "Tislelizumab (BGB-A317)"
      ],
      "OG005": [
        "Tislelizumab (BGB-A317)"
      ],
      "OG006": [
        "Tislelizumab (BGB-A317)"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO",
      "OG003": "IO",
      "OG004": "IO",
      "OG005": "IO",
      "OG006": "IO"
    }
  },
  {
    "nct_id": "NCT02426892",
    "brief_title": "Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2015-12-23",
    "completion_date": "2021-11-30",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "M.D. Anderson Cancer Center",
    "url": "https://clinicaltrials.gov/study/NCT02426892",
    "cancer_types": [
      "HNSC",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "HPV16",
        "status": "POSITIVE",
        "details": "HPV-16 serotype; assessed by Cervista assay"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT",
      "UNRESECTABLE"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "ISA101 Vaccine and Nivolumab (Complete Response - CR)",
        "value": 2.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "ISA101 Vaccine and Nivolumab (Partial Response - PR)",
        "value": 6.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "ISA101 Vaccine and Nivolumab",
        "value": 2.66,
        "unit": "months",
        "ci_lower": 2.5,
        "ci_upper": 9.44,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "ISA101 Vaccine and Nivolumab",
        "value": 15.3,
        "unit": "months",
        "ci_lower": 10.6,
        "ci_upper": 27.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "ISA 101",
        "Nivolumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO"
    }
  },
  {
    "nct_id": "NCT02411591",
    "brief_title": "A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC)",
    "status": "COMPLETED",
    "start_date": "2015-06-04",
    "completion_date": "2017-06-23",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eli Lilly and Company",
    "url": "https://clinicaltrials.gov/study/NCT02411591",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "If tumor has EGFR-activating mutation, prior EGFR-TKI treatment is mandatory."
      },
      {
        "target": "ALK",
        "status": "ANY",
        "details": "If tumor has ALK translocation, prior ALK inhibitor treatment is mandatory."
      }
    ],
    "cancer_stages": [
      "IV",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort 1 (Necitumumab 800 mg + Abemaciclib 100 mg)",
        "value": 66.7,
        "unit": "percentage of participants",
        "ci_lower": 5.4,
        "ci_upper": 94.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort 2 (Necitumumab 800 mg + Abemaciclib 150 mg)",
        "value": 32.3,
        "unit": "percentage of participants",
        "ci_lower": 20.4,
        "ci_upper": 44.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Cohort 3 (Necitumamab 800 mg + Abemaciclib 200 mg)",
        "value": 50.0,
        "unit": "percentage of participants",
        "ci_lower": 11.1,
        "ci_upper": 80.4,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Necitumumab",
        "Abemaciclib"
      ],
      "OG001": [
        "Necitumumab",
        "Abemaciclib"
      ],
      "OG002": [
        "Necitumumab",
        "Abemaciclib"
      ],
      "OG003": [
        "Necitumumab",
        "Abemaciclib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02431559",
    "brief_title": "Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer",
    "status": "COMPLETED",
    "start_date": "2015-12-02",
    "completion_date": "2018-12-11",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Ludwig Institute for Cancer Research",
    "url": "https://clinicaltrials.gov/study/NCT02431559",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Phase 1, Dose Level 0a",
        "value": 33.3,
        "unit": "percentage of participants",
        "ci_lower": 0.9,
        "ci_upper": 77.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Phase 1, Dose Level 0b",
        "value": 50.0,
        "unit": "percentage of participants",
        "ci_lower": 5.8,
        "ci_upper": 84.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Phase 1, Dose Level +1",
        "value": 33.3,
        "unit": "percentage of participants",
        "ci_lower": 4.6,
        "ci_upper": 67.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Phase 2",
        "value": 42.9,
        "unit": "percentage of participants",
        "ci_lower": 27.0,
        "ci_upper": 57.8,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Pegylated Liposomal Doxorubicin",
        "Durvalumab"
      ],
      "OG001": [
        "Pegylated Liposomal Doxorubicin",
        "Durvalumab"
      ],
      "OG002": [
        "Pegylated Liposomal Doxorubicin",
        "Durvalumab"
      ],
      "OG003": [
        "Pegylated Liposomal Doxorubicin",
        "Durvalumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_IO",
      "OG001": "Combo_Chemo_IO",
      "OG002": "Combo_Chemo_IO",
      "OG003": "Combo_Chemo_IO"
    }
  },
  {
    "nct_id": "NCT02437136",
    "brief_title": "Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)",
    "status": "COMPLETED",
    "start_date": "2015-08-26",
    "completion_date": "2022-09-29",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Syndax Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT02437136",
    "cancer_types": [
      "NSCLC",
      "SKCM",
      "CRC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "ANY",
        "details": "Required testing for EGFR mutations in adenocarcinoma; if EGFR-positive, must have been treated with prior EGFR therapy."
      },
      {
        "target": "ALK",
        "status": "ANY",
        "details": "Required testing for ALK rearrangements in adenocarcinoma; if ALK-positive, must have been treated with prior ALK therapy."
      },
      {
        "target": "BRAF",
        "status": "ANY",
        "details": "If BRAF V600 mutation-positive (melanoma cohort), must have experienced progression during treatment with a BRAF inhibitor."
      },
      {
        "target": "MSI",
        "status": "NEGATIVE",
        "details": "Must be mismatch repair-proficient / microsatellite-stable as determined by IHC for MMR proteins or PCR-based MSI testing (CRC expansion cohort)."
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT",
      "UNRESECTABLE",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 2, Cohort 1: Entinostat 5 mg Weekly + Pembrolizumab",
        "value": 22.2,
        "unit": "percentage of participants",
        "ci_lower": 6.4,
        "ci_upper": 47.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Phase 2, Cohort 2: Entinostat 5 mg Weekly + Pembrolizumab",
        "value": 9.2,
        "unit": "percentage of participants",
        "ci_lower": 3.8,
        "ci_upper": 18.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Phase 2, Cohort 3: Entinostat 5 mg Weekly + Pembrolizumab",
        "value": 18.9,
        "unit": "percentage of participants",
        "ci_lower": 9.4,
        "ci_upper": 32.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Phase 2, Cohort 4: Entinostat 5 mg Weekly + Pembrolizumab",
        "value": 5.4,
        "unit": "percentage of participants",
        "ci_lower": 0.7,
        "ci_upper": 18.2,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "entinostat",
        "pembrolizumab"
      ],
      "OG001": [
        "entinostat",
        "pembrolizumab"
      ],
      "OG002": [
        "entinostat",
        "pembrolizumab"
      ],
      "OG003": [
        "entinostat",
        "pembrolizumab"
      ],
      "OG004": [
        "entinostat",
        "pembrolizumab"
      ],
      "OG005": [
        "entinostat",
        "pembrolizumab"
      ],
      "OG006": [
        "entinostat",
        "pembrolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_IO_Targeted",
      "OG001": "Combo_IO_Targeted",
      "OG002": "Combo_IO_Targeted",
      "OG003": "Combo_IO_Targeted",
      "OG004": "Combo_IO_Targeted",
      "OG005": "Combo_IO_Targeted",
      "OG006": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT02489318",
    "brief_title": "A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2015-11-27",
    "completion_date": "2020-09-07",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Aragon Pharmaceuticals, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT02489318",
    "cancer_types": [
      "PRAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Placebo + Androgen Deprivation Therapy (ADT)",
        "value": 22.08,
        "unit": "months",
        "ci_lower": 18.46,
        "ci_upper": 32.92,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Apalutamide + ADT",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Placebo + Androgen Deprivation Therapy (ADT)",
        "value": 52.17,
        "unit": "months",
        "ci_lower": 41.86,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Apalutamide + ADT",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Androgen Deprivation Therapy (ADT)"
      ],
      "OG001": [
        "Apalutamide",
        "Androgen Deprivation Therapy (ADT)"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02452697",
    "brief_title": "Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2016-06-08",
    "completion_date": "2022-07-23",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Cristina Gasparetto",
    "url": "https://clinicaltrials.gov/study/NCT02452697",
    "cancer_types": [
      "LAML",
      "DLBC"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Cohort A - NK Cell Enriched-DLI Only",
        "value": 0.75,
        "unit": "proportion of participants",
        "ci_lower": 0.31,
        "ci_upper": 0.93,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Cohort A - NK-DLI + DUK-CPG-001",
        "value": 1.0,
        "unit": "proportion of participants",
        "ci_lower": 1.0,
        "ci_upper": 1.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Cohort B - NK Cell Enriched-DLI Only",
        "value": 0.5,
        "unit": "proportion of participants",
        "ci_lower": 0.06,
        "ci_upper": 0.84,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG003",
        "arm_title": "Cohort B - NK-DLI + DUK-CPG-001",
        "value": 0.8,
        "unit": "proportion of participants",
        "ci_lower": 0.2,
        "ci_upper": 0.97,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "NK Cell enriched-DLI"
      ],
      "OG001": [
        "NK Cell enriched-DLI",
        "DUK-CPG-001"
      ],
      "OG002": [
        "NK Cell enriched-DLI"
      ],
      "OG003": [
        "NK Cell enriched-DLI",
        "DUK-CPG-001"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER",
      "OG002": "OTHER",
      "OG003": "OTHER"
    }
  },
  {
    "nct_id": "NCT02481830",
    "brief_title": "Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer",
    "status": "COMPLETED",
    "start_date": "2015-09-14",
    "completion_date": "2018-08-17",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT02481830",
    "cancer_types": [
      "SCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "LOCALLY_ADVANCED",
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": "2L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Group A",
        "value": 7.46,
        "unit": "Months",
        "ci_lower": 5.65,
        "ci_upper": 9.2,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Group B",
        "value": 8.38,
        "unit": "Months",
        "ci_lower": 7.03,
        "ci_upper": 10.02,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Group A",
        "value": 1.45,
        "unit": "Months",
        "ci_lower": 1.41,
        "ci_upper": 1.51,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Group B",
        "value": 3.71,
        "unit": "Months",
        "ci_lower": 2.96,
        "ci_upper": 4.24,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab"
      ],
      "OG001": [
        "Topotecan",
        "Amrubicin"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "Chemo"
    }
  },
  {
    "nct_id": "NCT02472964",
    "brief_title": "Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin\u00a9+ Taxane for 1st Line, Met. Br. Ca.",
    "status": "COMPLETED",
    "start_date": "2012-07",
    "completion_date": "2016-03",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Mylan Inc.",
    "url": "https://clinicaltrials.gov/study/NCT02472964",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "HER2 amplification by FISH (ratio >2.0) OR HER2 overexpression by IHC (IHC3+ or IHC2+ with FISH confirmation); assessed by sponsor-identified central laboratory; archival tumor tissue acceptable"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Herceptin\u00a9 + Taxane",
        "value": 146.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "MYL-1401O Trastuzumab + Taxane",
        "value": 160.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Trastuzumab",
        "Paclitaxel",
        "Docetaxel"
      ],
      "OG001": [
        "MYL- 1401O",
        "Paclitaxel",
        "Docetaxel"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02490800",
    "brief_title": "Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma",
    "status": "COMPLETED",
    "start_date": "2015-05-20",
    "completion_date": "2022-09-30",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Basilea Pharmaceutica",
    "url": "https://clinicaltrials.gov/study/NCT02490800",
    "cancer_types": [
      "GBM",
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "EB1",
        "status": "POSITIVE",
        "details": "Tumor tissue positive for EB1 (required for Phase 2a dose expansion in recurrent glioblastoma)"
      }
    ],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 2a Dose Expansion Portion",
        "value": 11.1,
        "unit": "Percentage of participants",
        "ci_lower": 0.3,
        "ci_upper": 48.2,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Lisavanbulin"
      ],
      "OG001": [
        "Lisavanbulin"
      ],
      "OG002": [
        "Lisavanbulin"
      ],
      "OG003": [
        "Lisavanbulin"
      ],
      "OG004": [
        "Lisavanbulin"
      ],
      "OG005": [
        "Lisavanbulin"
      ],
      "OG006": [
        "Lisavanbulin"
      ],
      "OG007": [
        "Lisavanbulin"
      ],
      "OG008": [
        "Lisavanbulin"
      ],
      "OG009": [
        "Lisavanbulin"
      ],
      "OG010": [
        "Lisavanbulin"
      ],
      "OG011": [
        "Lisavanbulin"
      ],
      "OG012": [
        "Lisavanbulin"
      ],
      "OG013": [
        "Lisavanbulin"
      ],
      "OG014": [
        "Lisavanbulin"
      ],
      "OG015": [
        "Lisavanbulin"
      ],
      "OG016": [
        "Lisavanbulin"
      ],
      "OG017": [
        "Lisavanbulin"
      ],
      "OG018": [
        "Lisavanbulin"
      ],
      "OG019": [
        "Lisavanbulin"
      ],
      "OG020": [
        "Lisavanbulin"
      ],
      "OG021": [
        "Lisavanbulin"
      ],
      "OG022": [
        "Lisavanbulin"
      ],
      "OG023": [
        "Lisavanbulin"
      ]
    },
    "treatment_class_map": {
      "OG000": "OTHER",
      "OG001": "OTHER",
      "OG002": "OTHER",
      "OG003": "OTHER",
      "OG004": "OTHER",
      "OG005": "OTHER",
      "OG006": "OTHER",
      "OG007": "OTHER",
      "OG008": "OTHER",
      "OG009": "OTHER",
      "OG010": "OTHER",
      "OG011": "OTHER",
      "OG012": "OTHER",
      "OG013": "OTHER",
      "OG014": "OTHER",
      "OG015": "OTHER",
      "OG016": "OTHER",
      "OG017": "OTHER",
      "OG018": "OTHER",
      "OG019": "OTHER",
      "OG020": "OTHER",
      "OG021": "OTHER",
      "OG022": "OTHER",
      "OG023": "OTHER"
    }
  },
  {
    "nct_id": "NCT02471716",
    "brief_title": "Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor",
    "status": "COMPLETED",
    "start_date": "2015-06",
    "completion_date": "2020-04-30",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Five Prime Therapeutics, Inc.",
    "url": "https://clinicaltrials.gov/study/NCT02471716",
    "cancer_types": [
      "TGCT"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 2 FPA008 Dose Expansion Cohort 2A",
        "value": 8.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Phase 2 FPA008 Dose Expansion Cohort 2B",
        "value": 8.0,
        "unit": "Participants",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "COUNT_OF_PARTICIPANTS"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "FPA008 (cabiralizumab)"
      ],
      "OG001": [
        "FPA008 (cabiralizumab)"
      ],
      "OG002": [
        "FPA008 (cabiralizumab)"
      ],
      "OG003": [
        "FPA008 (cabiralizumab)"
      ],
      "OG004": [
        "FPA008 (cabiralizumab)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other",
      "OG004": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02481050",
    "brief_title": "Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2015-06-16",
    "completion_date": "2016-12-31",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Eisai Inc.",
    "url": "https://clinicaltrials.gov/study/NCT02481050",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "NEGATIVE",
        "details": "Determined by FISH; or 0 or 1+ by IHC staining"
      }
    ],
    "cancer_stages": [
      "METASTATIC"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Eribulin Mesylate 1.4 mg/m^2",
        "value": 12.3,
        "unit": "percentage of participants",
        "ci_lower": 5.08,
        "ci_upper": 23.68,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "DCR",
        "arm_id": "OG000",
        "arm_title": "Eribulin Mesylate 1.4 mg/m^2",
        "value": 64.9,
        "unit": "percentage of participants",
        "ci_lower": 51.13,
        "ci_upper": 77.09,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Eribulin Mesylate 1.4 mg/m^2",
        "value": 3.6,
        "unit": "months",
        "ci_lower": 2.86,
        "ci_upper": 4.07,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Eribulin Mesylate 1.4 mg/m^2",
        "value": 12.9,
        "unit": "months",
        "ci_lower": 9.76,
        "ci_upper": 16.56,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Eribulin Mesylate"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo"
    }
  },
  {
    "nct_id": "NCT02454972",
    "brief_title": "Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors",
    "status": "COMPLETED",
    "start_date": "2015-08-25",
    "completion_date": "2020-09-18",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "sponsor": "PharmaMar",
    "url": "https://clinicaltrials.gov/study/NCT02454972",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Biliary Tract Carcinoma Cohort",
        "value": 5.6,
        "unit": "percentage of participants",
        "ci_lower": 0.1,
        "ci_upper": 27.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Carcinoma of Unknown Primary Site Cohort",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 17.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Endometrial Carcinoma Cohort",
        "value": 11.3,
        "unit": "percentage of participants",
        "ci_lower": 5.0,
        "ci_upper": 21.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Ewing's Family of Tumors Cohort",
        "value": 14.3,
        "unit": "percentage of participants",
        "ci_lower": 4.0,
        "ci_upper": 32.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Germ Cell Tumors Cohort",
        "value": 4.3,
        "unit": "percentage of participants",
        "ci_lower": 0.1,
        "ci_upper": 21.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG005",
        "arm_title": "Head and Neck Carcinoma Cohort",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 24.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG006",
        "arm_title": "BRCA1/2-associated Metastatic Breast Carcinoma Cohort",
        "value": 28.6,
        "unit": "percentage of participants",
        "ci_lower": 11.3,
        "ci_upper": 55.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG007",
        "arm_title": "Neuroendocrine Tumors Cohort",
        "value": 6.5,
        "unit": "percentage of participants",
        "ci_lower": 0.8,
        "ci_upper": 21.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG008",
        "arm_title": "Small Cell Lung Cancer Cohort",
        "value": 36.2,
        "unit": "percentage of participants",
        "ci_lower": 27.0,
        "ci_upper": 46.1,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "lurbinectedin (PM01183)"
      ],
      "OG001": [
        "lurbinectedin (PM01183)"
      ],
      "OG002": [
        "lurbinectedin (PM01183)"
      ],
      "OG003": [
        "lurbinectedin (PM01183)"
      ],
      "OG004": [
        "lurbinectedin (PM01183)"
      ],
      "OG005": [
        "lurbinectedin (PM01183)"
      ],
      "OG006": [
        "lurbinectedin (PM01183)"
      ],
      "OG007": [
        "lurbinectedin (PM01183)"
      ],
      "OG008": [
        "lurbinectedin (PM01183)"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Chemo",
      "OG002": "Chemo",
      "OG003": "Chemo",
      "OG004": "Chemo",
      "OG005": "Chemo",
      "OG006": "Chemo",
      "OG007": "Chemo",
      "OG008": "Chemo"
    }
  },
  {
    "nct_id": "NCT02474355",
    "brief_title": "Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC",
    "status": "COMPLETED",
    "start_date": "2015-09-18",
    "completion_date": "2019-04-18",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT02474355",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [
      {
        "target": "EGFR",
        "status": "POSITIVE",
        "details": "T790M mutation"
      }
    ],
    "cancer_stages": [
      "IIIB",
      "IV",
      "LOCALLY_ADVANCED",
      "METASTATIC"
    ],
    "line_of_therapy": "2L",
    "prior_tki": true,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Osimertinib",
        "value": 22.8,
        "unit": "Months",
        "ci_lower": 21.6,
        "ci_upper": 23.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Osimertinib",
        "value": 11.1,
        "unit": "Months",
        "ci_lower": 11.0,
        "ci_upper": 12.0,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Osimertinib"
      ]
    },
    "treatment_class_map": {
      "OG000": "TKI"
    }
  },
  {
    "nct_id": "NCT02486718",
    "brief_title": "Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2015-10-31",
    "completion_date": "2024-01-26",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Hoffmann-La Roche",
    "url": "https://clinicaltrials.gov/study/NCT02486718",
    "cancer_types": [
      "NSCLC"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "IB",
      "IIA",
      "IIB",
      "IIIA"
    ],
    "line_of_therapy": "ADJUVANT",
    "prior_tki": false,
    "prior_io": false,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Atezolizumab",
        "value": 65.6,
        "unit": "months",
        "ci_lower": 52.4,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Best Supportive Care (BSC)",
        "value": 47.8,
        "unit": "months",
        "ci_lower": 37.0,
        "ci_upper": 65.8,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Atezolizumab",
        "value": 57.4,
        "unit": "months",
        "ci_lower": 42.2,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Best Supportive Care (BSC)",
        "value": 40.8,
        "unit": "months",
        "ci_lower": 31.4,
        "ci_upper": 57.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Atezolizumab",
        "value": 68.5,
        "unit": "months",
        "ci_lower": 51.8,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Best Supportive Care (BSC)",
        "value": 37.3,
        "unit": "months",
        "ci_lower": 30.1,
        "ci_upper": 57.8,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Atezolizumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "Placebo"
    }
  },
  {
    "nct_id": "NCT02466971",
    "brief_title": "Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2016-05-10",
    "completion_date": "2023-01-26",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "National Cancer Institute (NCI)",
    "url": "https://clinicaltrials.gov/study/NCT02466971",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [
      {
        "target": "G6PD",
        "status": "NEGATIVE",
        "details": "Known glucose-6-phosphate dehydrogenase (G6PD) deficiency excluded; G6PD testing optional"
      },
      {
        "target": "HIV",
        "status": "NEGATIVE",
        "details": "Known HIV infection excluded; known HIV-positive patients receiving combination antiretroviral therapy are ineligible (HIV testing optional)"
      }
    ],
    "cancer_stages": [
      "IB",
      "II",
      "IIIB",
      "IVA",
      "UNRESECTABLE"
    ],
    "line_of_therapy": "1L",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Arm I (Cisplatin, IMRT or RT, Brachytherapy)",
        "value": 78.1,
        "unit": "percentage of participants",
        "ci_lower": 70.0,
        "ci_upper": 84.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Arm II (Cisplatin, IMRT or RT, Brachytherapy, Triapine)",
        "value": 79.6,
        "unit": "percentage of participants",
        "ci_lower": 72.0,
        "ci_upper": 85.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Cisplatin"
      ],
      "OG001": [
        "Cisplatin",
        "Triapine"
      ]
    },
    "treatment_class_map": {
      "OG000": "Chemo",
      "OG001": "Combo_Chemo_Targeted"
    }
  },
  {
    "nct_id": "NCT02492711",
    "brief_title": "Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer",
    "status": "COMPLETED",
    "start_date": "2015-08-24",
    "completion_date": "2021-08-11",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "sponsor": "MacroGenics",
    "url": "https://clinicaltrials.gov/study/NCT02492711",
    "cancer_types": [
      "BRCA"
    ],
    "biomarkers": [
      {
        "target": "HER2",
        "status": "POSITIVE",
        "details": "Based on most recent tumor biopsy; HER2+ breast cancer"
      }
    ],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED",
      "RECURRENT"
    ],
    "line_of_therapy": "3L+",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Margetuximab Plus Chemotherapy",
        "value": 5.8,
        "unit": "months",
        "ci_lower": 5.52,
        "ci_upper": 6.97,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "Trastuzumab Plus Chemotherapy",
        "value": 4.9,
        "unit": "months",
        "ci_lower": 4.17,
        "ci_upper": 5.59,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG002",
        "arm_title": "Margetuximab Infusion Substudy",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG000",
        "arm_title": "Margetuximab Plus Chemotherapy",
        "value": 21.6,
        "unit": "months",
        "ci_lower": 0.66,
        "ci_upper": 61.44,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG001",
        "arm_title": "Trastuzumab Plus Chemotherapy",
        "value": 21.9,
        "unit": "months",
        "ci_lower": 0.07,
        "ci_upper": 64.53,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "OS",
        "arm_id": "OG002",
        "arm_title": "Margetuximab Infusion Substudy",
        "value": null,
        "unit": "months",
        "ci_lower": null,
        "ci_upper": null,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Margetuximab",
        "Physician's choice of chemotherapy",
        "Capecitabine",
        "Eribulin",
        "Gemcitabine"
      ],
      "OG001": [
        "Trastuzumab",
        "Physician's choice of chemotherapy",
        "Capecitabine",
        "Eribulin",
        "Gemcitabine"
      ],
      "OG002": [
        "Margetuximab"
      ],
      "OG003": [
        "Margetuximab"
      ],
      "OG004": [
        "Margetuximab"
      ]
    },
    "treatment_class_map": {
      "OG000": "Combo_Chemo_Targeted",
      "OG001": "Combo_Chemo_Targeted",
      "OG002": "Targeted_Other",
      "OG003": "Targeted_Other",
      "OG004": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02476968",
    "brief_title": "To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer",
    "status": "COMPLETED",
    "start_date": "2015-09-28",
    "completion_date": "2020-04-17",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "sponsor": "AstraZeneca",
    "url": "https://clinicaltrials.gov/study/NCT02476968",
    "cancer_types": [
      "OV"
    ],
    "biomarkers": [
      {
        "target": "BRCA1",
        "status": "POSITIVE",
        "details": "Germline or somatic mutation predicted to be deleterious or suspected deleterious (loss of function)"
      },
      {
        "target": "BRCA2",
        "status": "POSITIVE",
        "details": "Germline or somatic mutation predicted to be deleterious or suspected deleterious (loss of function)"
      },
      {
        "target": "ATM",
        "status": "POSITIVE",
        "details": "Qualifying mutation identified by the Lynparza HRR Assay in archival tumour tissue (BRCA-independent HRR mutation); applicable when tumour BRCA is wild-type"
      },
      {
        "target": "BARD1",
        "status": "POSITIVE",
        "details": "Qualifying mutation identified by the Lynparza HRR Assay in archival tumour tissue (BRCA-independent HRR mutation); applicable when tumour BRCA is wild-type"
      },
      {
        "target": "BRIP1",
        "status": "POSITIVE",
        "details": "Qualifying mutation identified by the Lynparza HRR Assay in archival tumour tissue (BRCA-independent HRR mutation); applicable when tumour BRCA is wild-type"
      },
      {
        "target": "CDK12",
        "status": "POSITIVE",
        "details": "Qualifying mutation identified by the Lynparza HRR Assay in archival tumour tissue (BRCA-independent HRR mutation); applicable when tumour BRCA is wild-type"
      },
      {
        "target": "CHEK1",
        "status": "POSITIVE",
        "details": "Qualifying mutation identified by the Lynparza HRR Assay in archival tumour tissue (BRCA-independent HRR mutation); applicable when tumour BRCA is wild-type"
      },
      {
        "target": "CHEK2",
        "status": "POSITIVE",
        "details": "Qualifying mutation identified by the Lynparza HRR Assay in archival tumour tissue (BRCA-independent HRR mutation); applicable when tumour BRCA is wild-type"
      },
      {
        "target": "FANCL",
        "status": "POSITIVE",
        "details": "Qualifying mutation identified by the Lynparza HRR Assay in archival tumour tissue (BRCA-independent HRR mutation); applicable when tumour BRCA is wild-type"
      },
      {
        "target": "PALB2",
        "status": "POSITIVE",
        "details": "Qualifying mutation identified by the Lynparza HRR Assay in archival tumour tissue (BRCA-independent HRR mutation); applicable when tumour BRCA is wild-type"
      },
      {
        "target": "PPP2R2A",
        "status": "POSITIVE",
        "details": "Qualifying mutation identified by the Lynparza HRR Assay in archival tumour tissue (BRCA-independent HRR mutation); applicable when tumour BRCA is wild-type"
      },
      {
        "target": "RAD51B",
        "status": "POSITIVE",
        "details": "Qualifying mutation identified by the Lynparza HRR Assay in archival tumour tissue (BRCA-independent HRR mutation); applicable when tumour BRCA is wild-type"
      },
      {
        "target": "RAD51C",
        "status": "POSITIVE",
        "details": "Qualifying mutation identified by the Lynparza HRR Assay in archival tumour tissue (BRCA-independent HRR mutation); applicable when tumour BRCA is wild-type"
      },
      {
        "target": "RAD51D",
        "status": "POSITIVE",
        "details": "Qualifying mutation identified by the Lynparza HRR Assay in archival tumour tissue (BRCA-independent HRR mutation); applicable when tumour BRCA is wild-type"
      },
      {
        "target": "RAD54L",
        "status": "POSITIVE",
        "details": "Qualifying mutation identified by the Lynparza HRR Assay in archival tumour tissue (BRCA-independent HRR mutation); applicable when tumour BRCA is wild-type"
      }
    ],
    "cancer_stages": [
      "RECURRENT"
    ],
    "line_of_therapy": "MAINTENANCE",
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": true,
    "outcomes": [
      {
        "outcome_type": "PFS",
        "arm_id": "OG000",
        "arm_title": "Overall BRCAm",
        "value": 18.0,
        "unit": "months",
        "ci_lower": 14.3,
        "ci_upper": 22.1,
        "dispersion_type": "MEDIAN"
      },
      {
        "outcome_type": "PFS",
        "arm_id": "OG001",
        "arm_title": "sBRCAm",
        "value": 16.6,
        "unit": "months",
        "ci_lower": 12.4,
        "ci_upper": 22.2,
        "dispersion_type": "MEDIAN"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Olaparib"
      ],
      "OG001": [
        "Olaparib"
      ]
    },
    "treatment_class_map": {
      "OG000": "Targeted_Other",
      "OG001": "Targeted_Other"
    }
  },
  {
    "nct_id": "NCT02488759",
    "brief_title": "An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors",
    "status": "COMPLETED",
    "start_date": "2015-10-13",
    "completion_date": "2021-03-19",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Bristol-Myers Squibb",
    "url": "https://clinicaltrials.gov/study/NCT02488759",
    "cancer_types": [
      "HNSC",
      "LIHC",
      "STAD"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "RECURRENT"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Metastatic Monotherapy",
        "value": 14.3,
        "unit": "Percentage of participants",
        "ci_lower": 1.8,
        "ci_upper": 42.8,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Metastatic Monotherapy",
        "value": 11.5,
        "unit": "Percentage of participants",
        "ci_lower": 2.4,
        "ci_upper": 30.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Metastatic Combo A",
        "value": 31.0,
        "unit": "Percentage of participants",
        "ci_lower": 17.6,
        "ci_upper": 47.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG003",
        "arm_title": "Metastatic Combo C",
        "value": 0.0,
        "unit": "Percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 36.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Metastatic Combo A",
        "value": 34.8,
        "unit": "Percentage of participants",
        "ci_lower": 16.4,
        "ci_upper": 57.3,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Metastatic Combo B",
        "value": 28.6,
        "unit": "Percentage of participants",
        "ci_lower": 11.3,
        "ci_upper": 52.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG004",
        "arm_title": "Metastatic Combo D",
        "value": 16.7,
        "unit": "Percentage of participants",
        "ci_lower": 0.4,
        "ci_upper": 64.1,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Metastatic Monotherapy",
        "value": 26.3,
        "unit": "Percentage of participants",
        "ci_lower": 9.1,
        "ci_upper": 51.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Metastatic Combo A",
        "value": 31.1,
        "unit": "Percentage of participants",
        "ci_lower": 18.2,
        "ci_upper": 46.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Metastatic Combo B",
        "value": 40.0,
        "unit": "Percentage of participants",
        "ci_lower": 25.7,
        "ci_upper": 55.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Metastatic Combo B",
        "value": 36.4,
        "unit": "Percentage of participants",
        "ci_lower": 22.4,
        "ci_upper": 52.2,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Metastatic Combo B",
        "value": 39.1,
        "unit": "Percentage of participants",
        "ci_lower": 19.7,
        "ci_upper": 61.5,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Metastatic Monotherapy",
        "value": 20.0,
        "unit": "Percentage of participants",
        "ci_lower": 0.5,
        "ci_upper": 71.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Metastatic Monotherapy",
        "value": 64.0,
        "unit": "Percentage of participants",
        "ci_lower": 42.5,
        "ci_upper": 82.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Metastatic Combo A",
        "value": 58.1,
        "unit": "Percentage of participants",
        "ci_lower": 42.1,
        "ci_upper": 73.0,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Metastatic Monotherapy",
        "value": 16.7,
        "unit": "Percentage of participants",
        "ci_lower": 4.7,
        "ci_upper": 37.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Metastatic Combo A",
        "value": 26.2,
        "unit": "Percentage of participants",
        "ci_lower": 13.9,
        "ci_upper": 42.0,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "Nivolumab"
      ],
      "OG001": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG002": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "OG003": [
        "Nivolumab",
        "Relatlimab"
      ],
      "OG004": [
        "Daratumumab",
        "Nivolumab"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO",
      "OG003": "IO",
      "OG004": "Combo_IO_Targeted"
    }
  },
  {
    "nct_id": "NCT02460224",
    "brief_title": "Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.",
    "status": "COMPLETED",
    "start_date": "2015-06-17",
    "completion_date": "2020-12-31",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "sponsor": "Novartis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/study/NCT02460224",
    "cancer_types": [
      "OTHER"
    ],
    "biomarkers": [],
    "cancer_stages": [
      "METASTATIC",
      "LOCALLY_ADVANCED"
    ],
    "line_of_therapy": null,
    "prior_tki": null,
    "prior_io": null,
    "prior_platinum": null,
    "outcomes": [
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 2: Naive - LAG525 400 mg Q3W + PDR001 300 mg Q3W",
        "value": 15.0,
        "unit": "percentage of participants",
        "ci_lower": 4.2,
        "ci_upper": 34.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Phase 2: Pre-treated - LAG525 400 mg Q3W + PDR001 300 mg Q3W",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 12.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 2: Naive - LAG525 400 mg Q3W + PDR001 300 mg Q3W",
        "value": 15.0,
        "unit": "percentage of participants",
        "ci_lower": 4.2,
        "ci_upper": 34.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Phase 2: Pre-treated - LAG525 400 mg Q3W + PDR001 300 mg Q3W",
        "value": 9.1,
        "unit": "percentage of participants",
        "ci_lower": 1.6,
        "ci_upper": 25.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 2: Naive - LAG525 400 mg Q3W + PDR001 300 mg Q3W",
        "value": 26.3,
        "unit": "percentage of participants",
        "ci_lower": 11.0,
        "ci_upper": 47.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Phase 2: Pre-treated - LAG525 400 mg Q3W + PDR001 300 mg Q3W",
        "value": 5.3,
        "unit": "percentage of participants",
        "ci_lower": 0.3,
        "ci_upper": 22.6,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 2: Naive - LAG525 400 mg Q3W + PDR001 300 mg Q3W",
        "value": 17.1,
        "unit": "percentage of participants",
        "ci_lower": 8.3,
        "ci_upper": 29.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Phase 2: Pre-treated - LAG525 400 mg Q3W + PDR001 300 mg Q3W",
        "value": 6.3,
        "unit": "percentage of participants",
        "ci_lower": 0.3,
        "ci_upper": 26.4,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG000",
        "arm_title": "Phase 2: Naive - LAG525 400 mg Q3W + PDR001 300 mg Q3W",
        "value": 14.3,
        "unit": "percentage of participants",
        "ci_lower": 4.0,
        "ci_upper": 32.9,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG001",
        "arm_title": "Phase 2: Naive - LAG525 600 mg Q4W + PDR001 400 mg Q4W",
        "value": 4.8,
        "unit": "percentage of participants",
        "ci_lower": 0.2,
        "ci_upper": 20.7,
        "dispersion_type": "NUMBER"
      },
      {
        "outcome_type": "ORR",
        "arm_id": "OG002",
        "arm_title": "Phase 2: Pre-treated - LAG525 400 mg Q3W + PDR001 300 mg Q3W",
        "value": 0.0,
        "unit": "percentage of participants",
        "ci_lower": 0.0,
        "ci_upper": 19.3,
        "dispersion_type": "NUMBER"
      }
    ],
    "arm_drugs": {
      "OG000": [
        "LAG525"
      ],
      "OG001": [
        "LAG525"
      ],
      "OG002": [
        "LAG525"
      ],
      "OG003": [
        "LAG525"
      ],
      "OG004": [
        "LAG525"
      ],
      "OG005": [
        "LAG525"
      ],
      "OG006": [
        "LAG525"
      ],
      "OG007": [
        "LAG525"
      ],
      "OG008": [
        "LAG525"
      ],
      "OG009": [
        "LAG525"
      ],
      "OG010": [
        "LAG525"
      ],
      "OG011": [
        "LAG525",
        "PDR001"
      ],
      "OG012": [
        "LAG525",
        "PDR001"
      ],
      "OG013": [
        "LAG525",
        "PDR001"
      ],
      "OG014": [
        "LAG525",
        "PDR001"
      ],
      "OG015": [
        "LAG525",
        "PDR001"
      ],
      "OG016": [
        "LAG525",
        "PDR001"
      ],
      "OG017": [
        "LAG525",
        "PDR001"
      ],
      "OG018": [
        "LAG525",
        "PDR001"
      ],
      "OG019": [
        "LAG525",
        "PDR001"
      ],
      "OG020": [
        "LAG525",
        "PDR001"
      ],
      "OG021": [
        "LAG525",
        "PDR001"
      ],
      "OG022": [
        "LAG525",
        "PDR001"
      ],
      "OG023": [
        "LAG525",
        "PDR001"
      ],
      "OG024": [
        "LAG525",
        "PDR001"
      ],
      "OG025": [
        "LAG525",
        "PDR001"
      ]
    },
    "treatment_class_map": {
      "OG000": "IO",
      "OG001": "IO",
      "OG002": "IO",
      "OG003": "IO",
      "OG004": "IO",
      "OG005": "IO",
      "OG006": "IO",
      "OG007": "IO",
      "OG008": "IO",
      "OG009": "IO",
      "OG010": "IO",
      "OG011": "IO",
      "OG012": "IO",
      "OG013": "IO",
      "OG014": "IO",
      "OG015": "IO",
      "OG016": "IO",
      "OG017": "IO",
      "OG018": "IO",
      "OG019": "IO",
      "OG020": "IO",
      "OG021": "IO",
      "OG022": "IO",
      "OG023": "IO",
      "OG024": "IO",
      "OG025": "IO"
    }
  }
]